###MEDLINE:90092414

Number	O
of	I-protein
glucocorticoid	B-protein
receptors	I-protein
in	I-protein
lymphocytes	O
and	I-protein
their	O
sensitivity	I-protein
to	I-protein
hormone	I-protein
action	O
.	O

The	O
study	O
demonstrated	O
a	I-protein
decreased	O
level	I-protein
of	I-protein
glucocorticoid	B-protein
receptors	I-protein
(	O
GR	B-protein
)	O
in	I-protein
peripheral	O
blood	O
lymphocytes	O
from	I-protein
hypercholesterolemic	O
subjects	O
,	O
and	I-protein
an	I-protein
elevated	I-protein
level	I-protein
in	I-protein
patients	O
with	I-protein
acute	O
myocardial	B-protein
infarction	I-protein
.	O

In	O
the	I-protein
lymphocytes	O
with	I-protein
a	I-protein
high	O
GR	B-protein
number	I-protein
,	O
dexamethasone	O
inhibited	O
[	O
3H	I-protein
]	O
-thymidine	O
and	I-protein
[	O
3H	I-protein
]	O
-acetate	O
incorporation	O
into	O
DNA	O
and	I-protein
cholesterol	O
,	O
respectively	O
,	O
in	I-protein
the	I-protein
same	O
manner	O
as	O
in	I-protein
the	I-protein
control	I-protein
cells	I-protein
.	O

On	O
the	I-protein
other	O
hand	O
,	O
a	I-protein
decreased	O
GR	B-protein
number	I-protein
resulted	O
in	I-protein
a	I-protein
less	O
efficient	O
dexamethasone	O
inhibition	O
of	I-protein
the	I-protein
incorporation	O
of	I-protein
labeled	O
compounds	O
.	O

These	O
data	O
showed	O
that	O
the	I-protein
sensitivity	I-protein
of	I-protein
lymphocytes	O
to	I-protein
glucocorticoids	O
changed	O
only	I-protein
with	I-protein
a	I-protein
decrease	O
of	I-protein
GR	B-protein
level	I-protein
.	O

###MEDLINE:90194790

[	O
1	I-protein
,	O
25-Dihydroxyvitamin	I-protein
D3	I-protein
receptors	I-protein
in	I-protein
lymphocytes	O
and	I-protein
T-	O
and	I-protein
B-lymphocyte	O
count	O
in	I-protein
patients	O
with	I-protein
glomerulonephritis	O
]	O

Content	O
of	I-protein
receptors	I-protein
to	I-protein
hormonal	O
form	I-protein
of	I-protein
vitamin	O
D3	I-protein
,	O
1.25	O
(	O
OH	O
)	O
2D3	O
,	O
constituted	O
27.3	O
fmole/mg	O
of	I-protein
protein	O
in	I-protein
lymphocytes	O
of	I-protein
peripheric	O
blood	O
of	I-protein
children	O
with	I-protein
glomerulonephritis	O
.	O

In	O
the	I-protein
patients	O
concentration	I-protein
of	I-protein
total	O
and	I-protein
ionized	O
form	I-protein
of	I-protein
Ca2+	I-protein
was	O
decreased	O
down	O
to	I-protein
2.04	O
mmole/L	O
and	I-protein
1.09	O
mmole/L	O
,	O
respectively	O
,	O
while	O
an	I-protein
increase	O
in	I-protein
parathormone	B-protein
(	O
PTH	B-protein
)	O
by	I-protein
36	I-protein
%	O
and	I-protein
a	I-protein
distinct	O
decrease	O
in	I-protein
25	I-protein
(	O
OH	O
)	O
D	O
concentration	I-protein
(	O
lower	I-protein
than	I-protein
1.25	O
ng/ml	O
)	O
was	O
found	O
in	I-protein
blood	O
;	O
content	O
of	I-protein
cAMP	O
was	O
also	O
decreased	O
in	I-protein
lymphocytes	O
by	I-protein
33	I-protein
%	O
.	O

At	O
the	I-protein
same	O
time	O
,	O
total	O
content	O
of	I-protein
T	O
lymphocytes	O
was	O
decreased	O
1.5-fold	O
in	I-protein
peripheric	O
blood	O
.	O

Treatment	O
with	I-protein
I-hydroxyvitamin	O
D3	I-protein
(	O
1-1.5	O
mg	O
daily	O
,	O
within	B-protein
4	I-protein
weeks	O
)	O
led	O
to	I-protein
normalization	O
of	I-protein
total	O
and	I-protein
ionized	O
form	I-protein
of	I-protein
Ca2+	I-protein
and	I-protein
of	I-protein
25	I-protein
(	O
OH	O
)	O
D	O
,	O
but	O
did	O
not	I-protein
affect	O
the	I-protein
PTH	B-protein
content	O
in	I-protein
blood	O
.	O

Concentration	O
of	I-protein
the	I-protein
receptors	I-protein
to	I-protein
1.25	O
(	O
OH	O
)	O
2D3	O
was	O
elevated	I-protein
up	O
to	I-protein
39.7	O
fmole/mg	O
after	O
I	I-protein
week	O
of	I-protein
the	I-protein
treatment	O
,	O
whereas	O
it	O
was	O
decreased	O
to	I-protein
the	I-protein
initial	O
level	I-protein
24.8	O
fmole/mg	O
within	B-protein
4	I-protein
weeks	O
;	O
simultaneous	O
alteration	O
in	I-protein
the	I-protein
cAMP	O
content	O
was	O
observed	O
in	I-protein
lymphocytes	O
.	O

Treatment	O
with	I-protein
1-	O
(	O
OH	O
)	O
D3	I-protein
normalized	O
also	O
the	I-protein
T	O
lymphocytes	O
content	O
in	I-protein
peripheric	O
blood	O
.	O

The	O
data	O
obtained	O
suggest	O
that	O
under	O
conditions	O
of	I-protein
glomerulonephritis	O
only	I-protein
high	O
content	O
of	I-protein
receptors	I-protein
to	I-protein
1.25	O
(	O
OH	O
)	O
2D3	O
in	I-protein
lymphocytes	O
enabled	B-protein
to	I-protein
perform	O
the	I-protein
cell	O
response	I-protein
to	I-protein
the	I-protein
hormone	I-protein
effect	O
.	O

###MEDLINE:89371608

Tumor	O
and	I-protein
serum	O
beta-2-microglobulin	B-protein
expression	I-protein
in	I-protein
women	O
with	I-protein
breast	O
cancer	O
.	O

To	O
investigate	O
whether	O
the	I-protein
tumor	O
expression	I-protein
of	I-protein
beta-2-microglobulin	B-protein
(	O
beta	I-protein
2-M	I-protein
)	O
could	O
serve	O
as	O
a	I-protein
marker	I-protein
of	I-protein
tumor	O
biologic	O
behavior	B-protein
,	O
the	I-protein
authors	O
studied	O
specimens	O
of	I-protein
breast	O
carcinomas	O
from	I-protein
60	I-protein
consecutive	O
female	I-protein
patients	O
.	O

Presence	O
of	I-protein
beta	B-protein
2-M	I-protein
was	O
analyzed	O
by	I-protein
immunohistochemistry	O
.	O

No	I-protein
significant	O
correlations	O
were	O
found	O
between	O
tumor	B-protein
beta	I-protein
2-M	I-protein
expression	I-protein
and	I-protein
several	I-protein
histologic	O
attributes	O
such	O
as	O
type	O
,	O
histologic	O
and	I-protein
nuclear	O
grades	O
,	O
mitotic	I-protein
index	I-protein
,	O
necrosis	I-protein
,	O
vascular	O
invasion	O
,	O
and	I-protein
lymphocytic	I-protein
infiltration	O
.	O

Likewise	O
,	O
beta	B-protein
2-M	I-protein
was	O
not	I-protein
associated	I-protein
with	I-protein
markers	O
of	I-protein
disease	I-protein
extension	O
such	O
as	O
TNM	B-protein
,	O
(	O
UICC	O
,	O
classification	O
of	I-protein
malignant	O
tumors	I-protein
)	O
staging	O
and	I-protein
axillary	O
lymph	O
node	I-protein
involvement	I-protein
or	I-protein
with	I-protein
estrogen	O
,	O
progesterone	B-protein
,	O
and	I-protein
glucocorticoid	B-protein
receptor	I-protein
levels	I-protein
.	O

However	O
,	O
there	O
was	O
a	I-protein
significantly	O
positive	I-protein
association	I-protein
between	O
tumor	B-protein
beta	I-protein
2-M	I-protein
expression	I-protein
and	I-protein
the	I-protein
degree	O
of	I-protein
lymphocytic	I-protein
infiltration	O
in	I-protein
the	I-protein
tumor	O
tissue	O
.	O

Beta	B-protein
2-M	I-protein
serum	O
levels	I-protein
were	O
determined	O
by	I-protein
an	I-protein
enzyme-linked	O
immunosorbent	O
assay	O
in	I-protein
samples	O
from	I-protein
22	I-protein
of	I-protein
the	I-protein
above	O
women	O
.	O

Although	O
some	O
of	I-protein
the	I-protein
highest	O
values	O
had	O
been	O
obtained	O
in	I-protein
women	O
with	I-protein
larger	O
(	O
T4	O
)	O
primary	O
tumors	I-protein
,	O
the	I-protein
authors	O
failed	O
to	I-protein
detect	O
any	O
statistical	O
relationship	O
between	O
beta	B-protein
2-M	I-protein
expression	I-protein
in	I-protein
the	I-protein
tumor	O
with	I-protein
serum	O
levels	I-protein
or	I-protein
between	O
serum	B-protein
beta	I-protein
2-M	I-protein
and	I-protein
the	I-protein
above	O
histologic	O
,	O
laboratory	O
,	O
and	I-protein
clinical	I-protein
factors	I-protein
.	O

###MEDLINE:90030612

[	O
Preliminary	O
observation	O
of	I-protein
level	I-protein
free-form	B-protein
E	I-protein
receptor	I-protein
levels	I-protein
in	I-protein
serum	O
of	I-protein
normal	O
childbearing-aged	O
and	I-protein
pregnant	O
women	O
]	O

In	O
137	I-protein
cases	O
of	I-protein
childbearing-aged	O
and	I-protein
pregnant	O
women	O
,	O
free	B-protein
form	I-protein
E	O
receptor	O
levels	I-protein
(	O
sE	O
)	O
in	I-protein
serum	O
were	O
measured	O
by	I-protein
ELISA	O
.	O

The	O
level	I-protein
of	I-protein
sE	B-protein
was	O
significantly	O
decreased	O
during	I-protein
the	I-protein
first	O
trimester	O
,	O
slightly	O
higher	O
in	I-protein
the	I-protein
second	O
trimester	O
,	O
and	I-protein
recovered	O
to	I-protein
normal	O
in	I-protein
the	I-protein
third	O
trimester	O
.	O

The	O
level	I-protein
remained	O
lower	I-protein
in	I-protein
29	I-protein
PIH	B-protein
women	O
but	O
appeared	O
higher	O
in	I-protein
overdue	O
pregnancies	O
as	O
compared	O
with	I-protein
the	I-protein
normal	O
3rd	O
trimester	O
range	O
.	O

The	O
results	O
indicate	O
that	O
there	O
is	O
a	I-protein
relationship	O
between	O
a	I-protein
change	O
in	I-protein
T	O
cell	O
function	I-protein
and	I-protein
pregnancy	O
.	O

###MEDLINE:89242103

Kappa	B-protein
B-specific	I-protein
DNA	I-protein
binding	I-protein
proteins	I-protein
:	O
role	O
in	I-protein
the	I-protein
regulation	I-protein
of	I-protein
human	O
interleukin-2	B-protein
gene	O
expression	I-protein
.	O

Transcriptional	I-protein
activation	I-protein
of	I-protein
the	I-protein
human	O
interleukin-2	B-protein
(	O
IL-2	B-protein
)	O
gene	O
,	O
like	I-protein
induction	I-protein
of	I-protein
the	I-protein
IL-2	B-protein
receptor	I-protein
alpha	I-protein
(	O
IL-2R	B-protein
alpha	I-protein
)	O
gene	O
and	I-protein
the	I-protein
type	O
1	I-protein
human	O
immunodeficiency	I-protein
virus	I-protein
(	O
HIV-1	O
)	O
,	O
is	O
shown	O
to	I-protein
be	O
modulated	I-protein
by	I-protein
a	I-protein
kappa	I-protein
B-like	I-protein
enhancer	I-protein
element	I-protein
.	O

Mutation	O
of	I-protein
a	I-protein
kappa	I-protein
B	O
core	O
sequence	I-protein
identified	I-protein
in	I-protein
the	I-protein
IL-2	B-protein
promoter	I-protein
(	O
-206	O
to	I-protein
-195	O
)	O
partially	O
inhibits	I-protein
both	O
mitogen-	O
and	I-protein
HTLV-I	O
Tax-mediated	O
activation	I-protein
of	I-protein
this	O
transcription	B-protein
unit	I-protein
and	I-protein
blocks	O
the	I-protein
specific	I-protein
binding	I-protein
of	I-protein
two	O
inducible	O
cellular	B-protein
factors	I-protein
.	O

These	O
kappa	I-protein
B-specific	I-protein
proteins	I-protein
(	O
80	I-protein
to	I-protein
90	I-protein
and	I-protein
50	I-protein
to	I-protein
55	I-protein
kilodaltons	O
)	O
similarly	O
interact	O
with	I-protein
the	I-protein
functional	O
kappa	I-protein
B	O
enhancer	O
present	O
in	I-protein
the	I-protein
IL-2R	O
alpha	O
promoter	I-protein
.	O

These	O
data	O
suggest	O
that	O
these	O
kappa	I-protein
B-specific	I-protein
proteins	I-protein
have	O
a	I-protein
role	O
in	I-protein
the	I-protein
coordinate	O
regulation	I-protein
of	I-protein
this	O
growth	O
factor-growth	O
factor	I-protein
receptor	O
gene	O
system	I-protein
that	O
controls	O
T	O
cell	O
proliferation	I-protein
.	O

###MEDLINE:89197277

Novel	I-protein
region	O
within	B-protein
the	I-protein
V	O
kappa	I-protein
gene	O
promoter	I-protein
is	O
responsible	O
for	I-protein
tissue	O
and	I-protein
stage-specific	O
expression	I-protein
of	I-protein
immunoglobulin	O
genes	I-protein
in	I-protein
human	O
lymphoid	O
neoplasms	O
.	O

Immunoglobulin	B-protein
gene-specific	I-protein
transacting	I-protein
factors	I-protein
have	O
been	O
shown	O
to	I-protein
play	O
a	I-protein
role	O
in	I-protein
lymphoid	O
tissue-specific	O
expression	I-protein
of	I-protein
immunoglobulin	O
genes	I-protein
.	O

The	O
role	O
of	I-protein
these	O
factors	I-protein
in	I-protein
B-cell	O
differentiation	I-protein
and	I-protein
stage-specific	O
expression	I-protein
of	I-protein
these	O
genes	I-protein
is	O
,	O
however	O
,	O
not	I-protein
fully	O
understood	O
.	O

We	O
have	O
used	O
a	I-protein
model	I-protein
of	I-protein
human	O
lymphoid	O
neoplasia	I-protein
to	I-protein
address	O
this	O
question	O
.	O

Different	O
fragments	I-protein
of	I-protein
unrearranged	O
human	O
variable	O
region	O
of	I-protein
immunoglobulin	O
kappa	I-protein
gene	O
(	O
V	O
kappa	I-protein
)	O
were	O
used	O
for	I-protein
cell-free	O
in	I-protein
vitro	O
transcription	O
and	I-protein
DNA	O
mobility	I-protein
shift	O
assays	O
.	O

Previously	O
described	O
enhancement	O
of	I-protein
in	I-protein
vitro	O
transcription	O
that	O
was	O
only	I-protein
seen	O
with	I-protein
nuclear	O
extracts	O
derived	I-protein
from	I-protein
B-cell	O
neoplasms	O
corresponding	O
to	I-protein
the	I-protein
late	O
stages	O
of	I-protein
B-cell	O
differentiation	I-protein
was	O
shown	O
to	I-protein
be	O
dependent	I-protein
on	I-protein
the	I-protein
actions	O
of	I-protein
these	O
factor	I-protein
(	O
s	I-protein
)	O
on	I-protein
the	I-protein
DNA	O
region	O
within	B-protein
the	I-protein
V	O
kappa	I-protein
gene	O
promoter	I-protein
.	O

This	O
region	O
is	O
located	O
within	B-protein
the	I-protein
920	O
bp	O
fragment	I-protein
located	O
210	I-protein
bp	O
upstream	O
from	I-protein
the	I-protein
coding	I-protein
region	O
and	I-protein
this	O
fragment	I-protein
represents	O
a	I-protein
possible	O
novel	O
DNA	O
region	O
,	O
which	O
plays	O
a	I-protein
role	O
in	I-protein
the	I-protein
stage-	O
and	I-protein
tissue-specific	O
expression	I-protein
of	I-protein
immunoglobulin	O
genes	I-protein
.	O

###MEDLINE:89179873

[	O
Determination	O
of	I-protein
the	I-protein
sensitivity	I-protein
to	I-protein
glucocorticoids	O
in	I-protein
vitro	O
]	O

A	O
modified	O
method	O
for	I-protein
the	I-protein
determination	I-protein
of	I-protein
glucocorticoid	B-protein
receptors	I-protein
in	I-protein
human	O
lymphocytes	O
is	O
suggested	O
.	O

The	O
principal	O
distinction	O
of	I-protein
the	I-protein
method	O
is	O
standardization	O
by	I-protein
the	I-protein
lymphocyte	O
count	O
in	I-protein
a	I-protein
sample	O
(	O
1	I-protein
mln	O
)	O
and	I-protein
the	I-protein
labeled	O
hormone	I-protein
concentration	I-protein
.	O

The	O
modification	I-protein
saves	O
time	O
and	I-protein
money	O
,	O
limits	O
the	I-protein
range	O
of	I-protein
the	I-protein
data	O
variations	O
,	O
and	I-protein
makes	O
use	O
of	I-protein
a	I-protein
lesser	O
volume	O
of	I-protein
blood	O
.	O

Examinations	O
of	I-protein
70	I-protein
children	O
aged	O
4	I-protein
to	I-protein
15	O
suffering	O
from	I-protein
the	I-protein
nephrotic	O
form	I-protein
of	I-protein
glomerulonephritis	O
have	O
made	O
it	O
possible	O
to	I-protein
distinguish	O
two	O
groups	O
of	I-protein
patients	O
:	O
with	I-protein
relatively	O
high	O
values	O
of	I-protein
specific	I-protein
binding	I-protein
X	O
=	O
6820.1	O
+/-	O
530.0	O
(	O
n	O
=	O
30	I-protein
,	O
p	O
=	O
0.95	O
,	O
t	I-protein
=	O
2.04	O
)	O
,	O
this	O
corresponding	O
to	I-protein
a	I-protein
clinical	I-protein
form	I-protein
of	I-protein
hormone	I-protein
-sensitive	O
glomerulonephritis	O
,	O
and	I-protein
with	I-protein
relatively	O
low	O
values	O
of	I-protein
specific	I-protein
binding	I-protein
X	O
=	O
1815.2	O
+/-	O
302.8	O
(	O
n	O
=	O
40	I-protein
,	O
p	O
=	O
0.95	O
,	O
t	I-protein
=	O
1.96	O
)	O
,	O
that	O
corresponds	O
to	I-protein
hormone	I-protein
-resistant	O
glomerulonephritis	O
.	O

Dynamic	O
studies	O
have	O
not	I-protein
shown	O
any	O
statistically	O
significant	O
changes	O
in	I-protein
the	I-protein
specific	I-protein
binding	I-protein
values	O
.	O

These	O
results	O
permit	O
regarding	O
the	I-protein
specific	I-protein
binding	I-protein
value	O
as	O
a	I-protein
prognostic	O
criterion	O
in	I-protein
the	I-protein
assessment	O
of	I-protein
corticosteroid	O
therapy	O
;	O
this	O
allows	O
a	I-protein
wide	O
employment	O
of	I-protein
the	I-protein
described	O
method	O
in	I-protein
practical	O
nephrology	O
.	O

###MEDLINE:89078997

Octamer-binding	B-protein
proteins	I-protein
from	I-protein
B	O
or	I-protein
HeLa	O
cells	I-protein
stimulate	O
transcription	O
of	I-protein
the	I-protein
immunoglobulin	O
heavy-chain	O
promoter	I-protein
in	I-protein
vitro	O
.	O

The	O
B-cell	O
-type	I-protein
specificity	I-protein
of	I-protein
the	I-protein
immunoglobulin	O
(	O
Ig	I-protein
)	O
heavy-chain	O
and	I-protein
light-chain	O
promoters	O
is	O
mediated	I-protein
by	I-protein
an	I-protein
octanucleotide	O
(	O
OCTA	O
)	O
element	I-protein
,	O
ATGCAAAT	O
,	O
that	O
is	O
also	O
a	I-protein
functional	O
component	O
of	I-protein
other	O
RNA	O
polymerase	O
II	I-protein
promoters	O
,	O
such	O
as	O
snRNA	O
and	I-protein
histone	O
H2B	O
promoters	O
.	O

Two	O
nuclear	B-protein
proteins	I-protein
that	O
bind	O
specifically	O
and	I-protein
with	I-protein
high	O
affinity	I-protein
to	I-protein
the	I-protein
OCTA	O
element	I-protein
have	O
been	O
identified	I-protein
.	O

NF-A1	B-protein
is	O
present	O
in	I-protein
a	I-protein
variety	O
of	I-protein
cell	O
types	I-protein
,	O
whereas	O
the	I-protein
presence	O
of	I-protein
NF-A2	B-protein
is	O
essentially	O
confined	O
to	I-protein
B	O
cells	I-protein
,	O
leading	O
to	I-protein
the	I-protein
hypothesis	O
that	O
NF-A2	B-protein
activates	O
cell-type-specific	O
transcription	O
of	I-protein
the	I-protein
Ig	I-protein
promoter	I-protein
and	I-protein
NF-A1	B-protein
mediates	O
the	I-protein
other	O
responses	O
of	I-protein
the	I-protein
OCTA	O
element	I-protein
.	O

Extracts	O
of	I-protein
the	I-protein
B-cell	O
line	I-protein
,	O
BJA-B	O
,	O
contain	O
high	O
levels	I-protein
of	I-protein
NF-A2	B-protein
and	I-protein
specifically	O
transcribe	O
Ig	I-protein
promoters	O
.	O

In	O
contrast	O
,	O
extracts	O
from	I-protein
HeLa	O
cells	I-protein
transcribed	I-protein
the	I-protein
Ig	I-protein
promoter	I-protein
poorly	O
.	O

Surprisingly	O
,	O
addition	O
of	I-protein
either	O
affinity-enriched	O
NF-A2	O
or	I-protein
NF-A1	O
to	I-protein
either	O
a	I-protein
HeLa	O
extract	O
or	I-protein
a	I-protein
partially	O
purified	O
reaction	I-protein
system	I-protein
specifically	O
stimulates	O
the	I-protein
Ig	I-protein
promoter	I-protein
.	O

This	O
suggests	O
that	O
the	I-protein
constitutive	I-protein
OCTA-binding	B-protein
factor	I-protein
NF-A1	I-protein
can	O
activate	O
transcription	O
of	I-protein
the	I-protein
Ig	I-protein
promoter	I-protein
and	I-protein
that	O
B-cell	O
-specific	I-protein
transcription	O
of	I-protein
this	O
promoter	I-protein
,	O
at	I-protein
least	O
in	I-protein
vitro	O
,	O
is	O
partially	O
due	I-protein
to	I-protein
a	I-protein
quantitative	I-protein
difference	O
in	I-protein
the	I-protein
amount	O
of	I-protein
OCTA-binding	B-protein
protein	I-protein
.	O

Because	O
NF-A1	B-protein
can	O
stimulate	O
Ig	I-protein
transcription	O
,	O
the	I-protein
inability	O
of	I-protein
this	O
factor	I-protein
to	I-protein
activate	O
in	I-protein
vivo	O
the	I-protein
Ig	I-protein
promoter	I-protein
to	I-protein
the	I-protein
same	O
degree	O
as	O
the	I-protein
snRNA	O
promoters	O
probably	O
reflects	O
a	I-protein
difference	O
in	I-protein
the	I-protein
context	O
of	I-protein
the	I-protein
OCTA	O
element	I-protein
in	I-protein
these	O
two	O
types	I-protein
of	I-protein
promoters	O
.	O

###MEDLINE:88264423

Identification	O
of	I-protein
a	I-protein
putative	O
regulator	O
of	I-protein
early	O
T	O
cell	O
activation	I-protein
genes	I-protein
.	O

Molecules	O
involved	I-protein
in	I-protein
the	I-protein
antigen	O
receptor-dependent	O
regulation	I-protein
of	I-protein
early	O
T	O
cell	O
activation	I-protein
genes	I-protein
were	O
investigated	O
with	I-protein
the	I-protein
use	O
of	I-protein
functional	O
sequences	I-protein
of	I-protein
the	I-protein
T	B-protein
cell	I-protein
activation-specific	I-protein
enhancer	I-protein
of	I-protein
interleukin-2	B-protein
(	O
IL-2	B-protein
)	O
.	O

One	I-protein
of	I-protein
these	O
sequences	I-protein
forms	I-protein
a	I-protein
protein	B-protein
complex	I-protein
,	O
NFAT-1	B-protein
,	O
specifically	O
with	I-protein
nuclear	O
extracts	O
of	I-protein
activated	O
T	O
cells	I-protein
.	O

This	O
complex	I-protein
appeared	O
10	I-protein
to	I-protein
25	I-protein
minutes	O
before	O
the	I-protein
activation	I-protein
of	I-protein
the	I-protein
IL-2	B-protein
gene	O
.	O

Studies	O
with	I-protein
inhibitors	I-protein
of	I-protein
protein	O
synthesis	I-protein
indicated	O
that	O
the	I-protein
time	O
of	I-protein
synthesis	I-protein
of	I-protein
the	I-protein
activator	O
of	I-protein
the	I-protein
IL-2	B-protein
gene	O
in	I-protein
Jurkat	O
T	O
cells	I-protein
corresponds	O
to	I-protein
the	I-protein
time	O
of	I-protein
appearance	O
of	I-protein
NFAT-1	B-protein
.	O

NFAT-1	B-protein
,	O
or	I-protein
a	I-protein
very	O
similar	O
protein	O
,	O
bound	I-protein
functional	O
sequences	I-protein
of	I-protein
the	I-protein
long	I-protein
terminal	O
repeat	I-protein
(	O
LTR	O
)	O
of	I-protein
the	I-protein
human	O
immunodeficiency	I-protein
virus	I-protein
type	O
1	I-protein
;	O
the	I-protein
LTR	O
of	I-protein
this	O
virus	I-protein
is	O
known	O
to	I-protein
be	O
stimulated	O
during	I-protein
early	O
T	O
cell	O
activation	I-protein
.	O

The	O
binding	I-protein
site	I-protein
for	I-protein
this	O
complex	I-protein
activated	O
a	I-protein
linked	I-protein
promoter	I-protein
after	O
transfection	O
into	O
antigen	O
receptor-activated	O
T	O
cells	I-protein
but	O
not	I-protein
other	O
cell	O
types	I-protein
.	O

These	O
characteristics	O
suggest	O
that	O
NFAT-1	B-protein
transmits	O
signals	I-protein
initiated	O
at	I-protein
the	I-protein
T	B-protein
cell	I-protein
antigen	I-protein
receptor	I-protein
.	O

###MEDLINE:88249842

Characterization	O
of	I-protein
thyroid	B-protein
hormone	I-protein
receptors	I-protein
in	I-protein
human	O
IM-9	O
lymphocytes	O
.	O

Although	O
putatively	O
identified	I-protein
more	O
than	I-protein
10	I-protein
years	O
ago	O
,	O
thyroid	B-protein
hormone	I-protein
receptors	I-protein
in	I-protein
human	O
tissues	O
remain	O
poorly	O
characterized	O
.	O

As	O
a	I-protein
first	O
step	O
towards	O
understanding	O
the	I-protein
mechanism	O
of	I-protein
thyroid	O
hormone	I-protein
action	O
in	I-protein
man	I-protein
we	O
have	O
characterized	O
T3	B-protein
binding	I-protein
sites	I-protein
in	I-protein
nuclei	O
of	I-protein
the	I-protein
human	O
lymphoblastoid	O
line	I-protein
,	O
IM-9	O
cells	I-protein
.	O

In	O
whole	O
cell	O
experiments	O
at	I-protein
37	I-protein
degrees	O
C	O
,	O
nuclear	O
binding	I-protein
of	I-protein
[	O
125I	I-protein
]	O
T3	I-protein
was	O
saturable	O
(	O
Kd	O
34	I-protein
+/-	O
6	I-protein
pmol/l	O
)	O
and	I-protein
of	I-protein
finite	O
capacity	O
(	O
approximately	O
equal	O
to	I-protein
350	I-protein
sites/cell	O
)	O
.	O

The	O
binding	I-protein
sites	I-protein
were	O
extracted	O
from	I-protein
a	I-protein
nuclear	O
pellet	O
by	I-protein
treatment	O
with	I-protein
0.4	O
mol/l	O
KCl	O
and	I-protein
sonication	O
.	O

Separation	O
of	I-protein
bound	I-protein
from	I-protein
free	B-protein
[	O
125I	I-protein
]	O
T3	I-protein
in	I-protein
the	I-protein
extracts	O
was	O
achieved	O
using	O
the	I-protein
calcium	O
phosphate	O
matrix	O
,	O
hydroxyapatite	O
at	I-protein
a	I-protein
concentration	I-protein
of	I-protein
0.3	O
ml	O
of	I-protein
a	I-protein
150	I-protein
g/l	O
slurry	O
.	O

Rectilinear	O
Scatchard	O
plots	O
were	O
obtained	O
only	I-protein
when	O
the	I-protein
hydroxyapatite	O
was	O
washed	O
with	I-protein
a	I-protein
buffer	O
containing	I-protein
0.5	O
%	O
Triton	O
X-100	O
.	O

Under	O
these	O
conditions	O
T3	B-protein
binding	I-protein
sites	I-protein
in	I-protein
the	I-protein
nuclear	O
extracts	O
were	O
present	O
at	I-protein
a	I-protein
concentration	I-protein
of	I-protein
22.4	O
+/-	O
8.6	O
fmol/mg	O
protein	O
and	I-protein
showed	O
an	I-protein
affinity	I-protein
of	I-protein
(	O
Kd	O
,	O
room	O
temperature	I-protein
)	O
140	I-protein
+/-	O
10	I-protein
pmol/l	O
.	O

The	O
same	O
assay	O
system	I-protein
was	O
used	O
to	I-protein
determine	O
the	I-protein
hierarchy	O
of	I-protein
affinities	O
for	I-protein
a	I-protein
range	O
of	I-protein
natural	O
and	I-protein
synthetic	I-protein
analogues	O
.	O

Calling	O
T3	O
100	I-protein
,	O
the	I-protein
order	O
of	I-protein
potencies	O
observed	O
was	O
:	O
Triac	O
,	O
500	I-protein
;	O
3	O
,	O
5-diiodo-3'-isopropylthyronine	O
,	O
89	I-protein
;	O
T4	O
,	O
32	I-protein
;	O
3	O
,	O
5-dimethyl-3'isopropylthyronine	O
2	I-protein
;	O
3	O
,	O
5-T2	O
,	O
0.7	O
,	O
rT3	O
,	O
0.4	O
;	O
3'5'-T2	O
,	O
less	O
than	I-protein
0.01	O
.	O

These	O
results	O
suggest	O
that	O
the	I-protein
T3	B-protein
binding	I-protein
sites	I-protein
present	O
in	I-protein
human	O
IM-9	O
lymphocyte	O
nuclei	O
and	I-protein
extracts	O
thereof	O
are	O
thyroid	B-protein
hormone	I-protein
receptors	I-protein
.	O

These	O
cells	I-protein
may	O
be	O
a	I-protein
useful	O
tool	O
to	I-protein
increase	O
our	O
understanding	O
of	I-protein
human	B-protein
T3	I-protein
receptors	I-protein

###MEDLINE:90185221

Definition	O
of	I-protein
T-cell	B-protein
specific	I-protein
DNA-binding	I-protein
factors	I-protein
that	O
interact	O
with	I-protein
a	I-protein
3'-silencer	O
in	I-protein
the	I-protein
CD4+	O
T-cell	O
gene	O
Rpt-1	O
.	O

Analysis	O
of	I-protein
the	I-protein
region	O
3	O
'	O
to	I-protein
the	I-protein
CD4+	O
T-cell	O
gene	O
Rpt-1	O
(	O
encoding	I-protein
regulatory	O
protein	O
T-lymphocyte	I-protein
1	I-protein
)	O
led	O
to	I-protein
the	I-protein
definition	O
of	I-protein
a	I-protein
silencer	O
element	I-protein
that	O
inhibits	I-protein
heterologous	O
gene	O
expression	I-protein
in	I-protein
certain	O
CD4+	O
T-cell	O
lines	B-protein
but	O
not	I-protein
in	I-protein
B-cell	O
or	I-protein
non-lymphoid	O
cell	O
lines	B-protein
.	O

Functional	O
silencer	O
activity	I-protein
in	I-protein
vivo	O
was	O
associated	I-protein
with	I-protein
the	I-protein
presence	O
of	I-protein
a	I-protein
specific	I-protein
silencer-DNA-protein	B-protein
complex	I-protein
in	I-protein
electrophoretic	O
mobility	I-protein
shift	O
assays	O
with	I-protein
T-cell	O
extracts	O
.	O

Formation	O
of	I-protein
this	O
complex	I-protein
was	O
selectively	O
inhibited	O
by	I-protein
the	I-protein
region	O
in	I-protein
HIV-1	O
containing	I-protein
a	I-protein
silencer	O
element	I-protein
.	O

We	O
discuss	O
the	I-protein
possibility	O
that	O
DNA-binding	B-protein
factors	I-protein
may	O
coregulate	O
HIV-1	O
and	I-protein
Rpt-1	O
gene	O
expression	I-protein
through	I-protein
a	I-protein
common	I-protein
transcriptional	O
silencer	O
element	I-protein
.	O

###MEDLINE:90061802

Congenital	O
immunodeficiencies	O
associated	I-protein
with	I-protein
absence	I-protein
of	I-protein
HLA	B-protein
class	I-protein
II	I-protein
antigens	I-protein
on	I-protein
lymphocytes	O
result	O
from	I-protein
distinct	O
mutations	I-protein
in	I-protein
trans-acting	B-protein
factors	I-protein
.	O

Coordinate	O
regulation	I-protein
of	I-protein
HLA	O
class	O
II	I-protein
gene	O
expression	I-protein
during	I-protein
development	O
and	I-protein
coinduction	O
of	I-protein
class	O
II	I-protein
genes	I-protein
by	I-protein
soluble	I-protein
factors	I-protein
suggests	O
that	O
common	I-protein
trans-acting	B-protein
factor	I-protein
(	O
s	I-protein
)	O
control	I-protein
expression	I-protein
of	I-protein
these	O
genes	I-protein
.	O

In	O
B-lymphoblastoid	O
cell	O
lines	B-protein
derived	I-protein
from	I-protein
two	O
independent	I-protein
class	O
II-deficient	O
bare	O
lymphocyte	O
syndrome	I-protein
patients	O
,	O
we	O
observed	O
a	I-protein
drastic	O
decrease	O
in	I-protein
transcription	O
rates	O
of	I-protein
the	I-protein
class	O
II	I-protein
genes	I-protein
.	O

When	O
these	O
cell	O
lines	B-protein
are	O
fused	O
,	O
class	O
II	I-protein
genes	I-protein
are	O
reexpressed	O
,	O
indicating	O
that	O
immunodeficiencies	O
in	I-protein
bare	O
lymphocyte	O
syndrome	I-protein
patients	O
are	O
the	I-protein
result	O
of	I-protein
two	O
distinct	O
mutations	I-protein
.	O

Further	O
studies	O
show	O
that	O
genes	I-protein
governing	O
the	I-protein
expression	I-protein
of	I-protein
class	B-protein
II	I-protein
antigens	I-protein
fall	O
into	O
at	I-protein
least	O
three	O
complementation	I-protein
groups	O
;	O
two	O
of	I-protein
these	O
were	O
previously	O
unidentified	O
in	I-protein
mutant	O
cell	O
lines	B-protein
generated	O
in	I-protein
vitro	O
.	O

In	O
addition	O
,	O
we	O
report	O
the	I-protein
identification	O
of	I-protein
two	O
discrete	O
complexes	O
,	O
NFX1.1	B-protein
and	I-protein
NFX1.2	B-protein
,	O
that	O
bind	O
to	I-protein
the	I-protein
DRA	B-protein
X	O
consensus	O
element	I-protein
.	O

Though	O
the	I-protein
mutation	I-protein
in	I-protein
at	I-protein
least	O
one	B-protein
mutant	O
line	I-protein
generated	O
in	I-protein
vitro	O
(	O
RJ2.2.5	O
)	O
affects	O
products	O
functioning	O
via	I-protein
interaction	I-protein
with	I-protein
the	I-protein
X	O
box	I-protein
,	O
clear	I-protein
alterations	O
in	I-protein
either	O
NFX1.1	B-protein
or	I-protein
NFX1.2	B-protein
are	O
not	I-protein
found	O
in	I-protein
any	O
of	I-protein
the	I-protein
mutant	O
cell	O
lines	B-protein
.	O

###MEDLINE:90022210

In	O
vivo	O
responsiveness	O
to	I-protein
glucocorticoid	O
correlated	O
with	I-protein
glucocorticoid	B-protein
receptor	I-protein
content	O
in	I-protein
peripheral	O
blood	O
leukocytes	O
in	I-protein
normal	O
humans	O
.	O

Dexamethasone	O
loading	O
tests	O
(	O
0.1	O
mg	O
dexamethasone/kg	O
,	O
iv	O
)	O
were	O
performed	O
in	I-protein
18	I-protein
normal	O
males	O
to	I-protein
evaluate	O
the	I-protein
individual	O
responsiveness	O
to	I-protein
glucocorticoid	O
.	O

There	O
were	O
inter-individual	O
differences	O
in	I-protein
increase	O
in	I-protein
peripheral	O
blood	O
polymorphonuclear	O
leukocyte	O
count	O
,	O
decrease	O
in	I-protein
peripheral	O
blood	O
lymphocyte	O
count	O
,	O
and	I-protein
increase	O
in	I-protein
plasma	O
free	B-protein
fatty	O
acids	I-protein
levels	I-protein
after	O
dexamethasone	O
injection	O
.	O

In	O
addition	O
,	O
there	O
was	O
a	I-protein
significant	O
correlation	O
between	O
the	I-protein
maximum	O
increase	O
in	I-protein
polymorphonuclear	O
leukocytes	O
and	I-protein
the	I-protein
maximum	O
decrease	O
in	I-protein
lymphocytes	O
(	O
r	I-protein
=	O
0.7514	O
,	O
p	O
less	O
than	I-protein
0.0003	O
)	O
.	O

Simultaneous	O
measurements	O
of	I-protein
glucocorticoid	B-protein
receptor	I-protein
content	O
by	I-protein
whole-cell	O
assay	O
revealed	O
that	O
glucocorticoid	B-protein
receptor	I-protein
content	O
in	I-protein
polymorphonuclear	O
leukocytes	O
linearly	O
correlated	O
with	I-protein
that	O
in	I-protein
the	I-protein
corresponding	O
lymphocytes	O
(	O
r	I-protein
=	O
0.9482	O
,	O
p	O
less	O
than	I-protein
0.0001	O
)	O
.	O

There	O
were	O
also	O
significant	O
correlations	O
between	O
the	I-protein
maximum	O
increase	O
in	I-protein
polymorphonuclear	O
leukocytes	O
and	I-protein
glucocorticoid	B-protein
receptor	I-protein
content	O
in	I-protein
polymorphonuclear	O
leukocytes	O
(	O
r	I-protein
=	O
0.7239	O
,	O
p	O
less	O
than	I-protein
0.0007	O
)	O
,	O
and	I-protein
between	O
the	I-protein
maximum	O
decrease	O
in	I-protein
lymphocytes	O
and	I-protein
glucocorticoid	B-protein
receptor	I-protein
content	O
in	I-protein
lymphocytes	O
(	O
r	I-protein
=	O
0.7703	O
,	O
p	O
less	O
than	I-protein
0.0002	O
)	O
.	O

These	O
results	O
suggest	O
that	O
individual	O
differences	O
are	O
preserved	O
both	O
in	I-protein
glucocorticoid	O
responsiveness	O
and	I-protein
in	I-protein
glucocorticoid	B-protein
receptor	I-protein
content	O
in	I-protein
peripheral	O
blood	O
leukocytes	O
in	I-protein
normal	O
humans	O
.	O

###MEDLINE:89378613

Estradiol	I-protein
receptors	I-protein
in	I-protein
the	I-protein
cytosol	I-protein
of	I-protein
peripheral	O
blood	O
mononuclear	O
cells	I-protein
in	I-protein
hepatitis	B-protein
B	O
virus	I-protein
carriers	O
treated	O
with	I-protein
interferon-alpha	B-protein
.	O

Estradiol	I-protein
receptors	I-protein
in	I-protein
the	I-protein
cytosol	I-protein
of	I-protein
peripheral	O
blood	O
mononuclear	O
cells	I-protein
and	I-protein
the	I-protein
effects	O
of	I-protein
interferon-alpha	B-protein
(	O
IFN-alpha	B-protein
)	O
on	I-protein
estradiol	B-protein
receptors	I-protein
were	O
studied	O
in	I-protein
asymptomatic	O
hepatitis	B-protein
B	O
virus	I-protein
(	O
HBV	B-protein
)	O
carriers	O
,	O
patients	O
with	I-protein
chronic	O
hepatitis	B-protein
B	O
and	I-protein
normal	O
controls	O
.	O

The	O
level	I-protein
of	I-protein
estradiol	B-protein
receptors	I-protein
in	I-protein
the	I-protein
cytosol	I-protein
of	I-protein
mononuclear	O
cells	I-protein
was	O
significantly	O
lower	I-protein
in	I-protein
asymptomatic	O
HBV	B-protein
carriers	O
and	I-protein
patients	O
with	I-protein
chronic	O
hepatitis	B-protein
B	O
,	O
compared	O
to	I-protein
normal	O
controls	O
.	O

This	O
low	O
level	I-protein
of	I-protein
cytosol	I-protein
estradiol	B-protein
receptors	I-protein
in	I-protein
patients	O
with	I-protein
chronic	O
hepatitis	B-protein
B	O
was	O
increased	I-protein
by	I-protein
the	I-protein
administration	O
of	I-protein
IFN-alpha	B-protein
.	O

In	O
addition	O
,	O
when	O
peripheral	O
blood	O
mononuclear	O
cells	I-protein
from	I-protein
patients	O
with	I-protein
chronic	O
hepatitis	B-protein
B	O
were	O
incubated	O
with	I-protein
IFN-alpha	B-protein
in	I-protein
vitro	O
,	O
the	I-protein
level	I-protein
of	I-protein
cytosol	I-protein
estradiol	B-protein
receptors	I-protein
also	O
increased	I-protein
by	I-protein
increasing	O
the	I-protein
concentration	I-protein
of	I-protein
IFN-alpha	B-protein
.	O

We	O
previously	O
reported	O
that	O
the	I-protein
response	I-protein
of	I-protein
mononuclear	O
cells	I-protein
to	I-protein
estrogen	O
is	O
impaired	O
in	I-protein
HBV	B-protein
carriers	O
,	O
and	I-protein
our	O
present	O
results	O
suggested	O
that	O
this	O
may	O
be	O
due	I-protein
to	I-protein
the	I-protein
low	O
level	I-protein
of	I-protein
estradiol	B-protein
receptors	I-protein
in	I-protein
the	I-protein
cytosol	I-protein
of	I-protein
mononuclear	O
cells	I-protein
.	O

###MEDLINE:89194996

Association	O
of	I-protein
increased	I-protein
lytic	O
effector	O
cell	O
function	I-protein
with	I-protein
high	O
estrogen	B-protein
receptor	I-protein
levels	I-protein
in	I-protein
tumor-bearing	O
patients	O
with	I-protein
breast	O
cancer	O
.	O

Tumor-bearing	O
patients	O
with	I-protein
breast	O
cancer	O
were	O
assayed	O
for	I-protein
their	O
natural	O
killer	O
(	O
NK	I-protein
)	O
cell	O
activity	I-protein
and	I-protein
for	I-protein
the	I-protein
function	I-protein
of	I-protein
activated	O
cytotoxic	O
T-cells	I-protein
,	O
as	O
assessed	O
by	I-protein
lectin-dependent	O
cellular	O
cytotoxicity	I-protein
(	O
LDCC	O
)	O
.	O

Tumor-bearing	O
patients	O
with	I-protein
breast	O
cancer	O
had	O
a	I-protein
significant	O
increase	O
in	I-protein
NK	I-protein
activity	I-protein
and	I-protein
in	I-protein
LDCC	O
,	O
as	O
compared	O
with	I-protein
healthy	O
control	I-protein
individuals	O
.	O

Although	O
the	I-protein
enhanced	I-protein
NK	I-protein
cell	O
activity	I-protein
and	I-protein
LDCC	O
were	O
closely	O
associated	I-protein
with	I-protein
high	O
levels	I-protein
(	O
greater	O
than	I-protein
31	I-protein
fmol/mg	O
)	O
of	I-protein
estrogen	B-protein
receptor	I-protein
(	O
ER	B-protein
)	O
content	O
in	I-protein
the	I-protein
primary	O
tumor	O
,	O
no	I-protein
other	O
clinical	I-protein
or	I-protein
histologic	O
correlation	O
between	O
the	I-protein
increase	O
in	I-protein
either	O
parameter	O
of	I-protein
cytotoxic	O
effector	O
cell	O
function	I-protein
could	O
be	O
found	O
.	O

Thus	O
,	O
ER	B-protein
levels	I-protein
greater	O
than	I-protein
31	I-protein
fmol/mg	O
might	O
be	O
associated	I-protein
with	I-protein
increased	I-protein
cytotoxic	O
effector	O
cell	O
function	I-protein
in	I-protein
tumor-bearing	O
patients	O
with	I-protein
breast	O
cancer	O
.	O

###MEDLINE:89195152

Properties	O
of	I-protein
glucocorticoid	B-protein
receptors	I-protein
in	I-protein
Epstein-Barr	B-protein
virus-transformed	O
lymphocytes	O
from	I-protein
patients	O
with	I-protein
familial	O
cortisol	O
resistance	O
.	O

In	O
a	I-protein
previous	O
report	O
of	I-protein
two	O
patients	O
with	I-protein
familial	O
glucocorticoid	O
resistance	O
due	I-protein
to	I-protein
reduced	O
numbers	O
of	I-protein
glucocorticoid	B-protein
receptors	I-protein
(	O
GR	B-protein
)	O
,	O
we	O
have	O
shown	O
decreased	O
numbers	O
of	I-protein
GR	B-protein
in	I-protein
peripheral	O
mononuclear	O
cells	I-protein
and	I-protein
cultured	O
fibroblasts	O
but	O
normal	O
affinity	I-protein
of	I-protein
GR	B-protein
in	I-protein
both	O
patients	O
.	O

In	O
this	O
study	O
,	O
peripheral	O
lymphocytes	O
from	I-protein
these	O
patients	O
,	O
one	B-protein
patient	O
's	I-protein
son	B-protein
and	I-protein
daughter	O
,	O
and	I-protein
normal	O
subjects	O
were	O
transformed	I-protein
with	I-protein
Epstein-Barr	B-protein
virus	I-protein
.	O

Reduced	O
numbers	O
and	I-protein
normal	O
affinity	I-protein
of	I-protein
GR	B-protein
were	O
found	O
in	I-protein
the	I-protein
Epstein-Barr	B-protein
virus-transformed	O
lymphocytes	O
from	I-protein
both	O
patients	O
while	O
the	I-protein
son	B-protein
and	I-protein
daughter	O
had	O
normal	O
numbers	O
and	I-protein
affinity	I-protein
of	I-protein
GR	B-protein
.	O

The	O
thermal	O
stability	O
of	I-protein
GR	B-protein
and	I-protein
thermal	O
activation	I-protein
of	I-protein
cytosolic	B-protein
receptors	I-protein
in	I-protein
both	O
patients	O
were	O
found	O
to	I-protein
be	O
normal	O
.	O

Although	O
the	I-protein
percentages	O
of	I-protein
nuclear	O
bound	I-protein
GR	B-protein
were	O
similar	O
in	I-protein
both	O
patients	O
and	I-protein
normal	O
controls	O
,	O
the	I-protein
absolute	O
amounts	O
of	I-protein
nuclear	O
bound	I-protein
GR	B-protein
of	I-protein
the	I-protein
patients	O
were	O
about	O
one-half	O
that	O
of	I-protein
normal	O
controls	O
.	O

These	O
abnormal	I-protein
properties	O
of	I-protein
GR	B-protein
(	O
reduced	O
numbers	O
of	I-protein
GR	B-protein
)	O
were	O
preserved	O
in	I-protein
the	I-protein
transformed	I-protein
cells	I-protein
from	I-protein
the	I-protein
patients	O
.	O

###MEDLINE:89219069

Octamer	B-protein
transcription	I-protein
factors	I-protein
1	I-protein
and	I-protein
2	I-protein
each	O
bind	O
to	I-protein
two	O
different	O
functional	O
elements	O
in	I-protein
the	I-protein
immunoglobulin	O
heavy-chain	O
promoter	I-protein
.	O

Immunoglobulin	O
heavy-chain	O
genes	I-protein
contain	O
two	O
conserved	O
sequence	I-protein
elements	O
5	O
'	O
to	I-protein
the	I-protein
site	I-protein
of	I-protein
transcription	O
initiation	I-protein
:	O
the	I-protein
octamer	O
ATGCAAAT	O
and	I-protein
the	I-protein
heptamer	O
CTCATGA	O
.	O

Both	O
of	I-protein
these	O
elements	O
are	O
required	O
for	I-protein
normal	O
cell-specific	I-protein
promoter	I-protein
function	I-protein
.	O

The	O
present	O
study	O
demonstrates	O
that	O
both	O
the	I-protein
ubiquitous	I-protein
and	I-protein
lymphoid-cell-specific	I-protein
octamer	I-protein
transcription	I-protein
factors	I-protein
(	O
OTF-1	B-protein
and	I-protein
OTF-2	B-protein
,	O
respectively	O
)	O
interact	O
specifically	O
with	I-protein
each	O
of	I-protein
the	I-protein
two	O
conserved	O
sequence	I-protein
elements	O
,	O
forming	I-protein
either	O
homo-	B-protein
or	I-protein
heterodimeric	I-protein
complexes	I-protein
.	O

This	O
was	O
surprising	O
,	O
since	O
the	I-protein
heptamer	O
and	I-protein
octamer	O
sequence	I-protein
motifs	I-protein
bear	O
no	I-protein
obvious	O
similarity	I-protein
to	I-protein
each	O
other	O
.	O

Binding	O
of	I-protein
either	O
factor	I-protein
to	I-protein
the	I-protein
octamer	O
element	I-protein
occurred	O
independently	O
.	O

However	O
,	O
OTF	B-protein
interaction	I-protein
with	I-protein
the	I-protein
heptamer	O
sequence	I-protein
appeared	O
to	I-protein
require	O
the	I-protein
presence	O
of	I-protein
an	I-protein
intact	O
octamer	O
motif	I-protein
and	I-protein
occurred	O
with	I-protein
a	I-protein
spacing	I-protein
of	I-protein
either	O
2	I-protein
or	I-protein
14	I-protein
base	I-protein
pairs	O
between	O
the	I-protein
two	O
elements	O
,	O
suggesting	O
coordinate	O
binding	I-protein
resulting	O
from	I-protein
protein-protein	O
interactions	O
.	O

The	O
degeneracy	O
in	I-protein
sequences	I-protein
recognized	I-protein
by	I-protein
the	I-protein
OTFs	B-protein
may	O
be	O
important	O
in	I-protein
widening	O
the	I-protein
range	O
over	O
which	O
gene	O
expression	I-protein
can	O
be	O
modulated	I-protein
and	I-protein
in	I-protein
establishing	O
cell	O
type	O
specificity	I-protein
.	O

###MEDLINE:89210808

Identification	O
of	I-protein
a	I-protein
novel	O
lymphoid	B-protein
specific	I-protein
octamer	I-protein
binding	I-protein
protein	I-protein
(	O
OTF-2B	B-protein
)	O
by	I-protein
proteolytic	I-protein
clipping	O
bandshift	O
assay	O
(	O
PCBA	O
)	O
.	O

The	O
octamer	O
sequence	I-protein
ATGCAAAT	O
is	O
found	O
in	I-protein
the	I-protein
promoters	O
of	I-protein
immunoglobulin	O
(	O
Ig	I-protein
)	O
heavy	I-protein
and	I-protein
light	I-protein
chain	I-protein
genes	I-protein
and	I-protein
in	I-protein
the	I-protein
heavy	I-protein
chain	I-protein
enhancer	O
and	I-protein
is	O
a	I-protein
major	O
determinant	I-protein
of	I-protein
the	I-protein
cell	O
type	O
specific	I-protein
expression	I-protein
of	I-protein
Ig	I-protein
genes	I-protein
in	I-protein
B	O
cells	I-protein
.	O

An	O
apparent	O
paradox	O
is	O
that	O
the	I-protein
same	O
sequence	I-protein
serves	O
as	O
an	I-protein
upstream	O
promoter	I-protein
or	I-protein
enhancer	O
element	I-protein
in	I-protein
a	I-protein
variety	O
of	I-protein
housekeeping	O
genes	I-protein
such	O
as	O
the	I-protein
histone	O
H2B	O
and	I-protein
U	I-protein
snRNA	O
genes	I-protein
.	O

The	O
differential	O
usage	O
of	I-protein
this	O
regulatory	O
sequence	I-protein
motif	I-protein
is	O
thought	O
to	I-protein
be	O
mediated	I-protein
by	I-protein
different	O
species	O
of	I-protein
octamer	B-protein
binding	I-protein
proteins	I-protein
.	O

One	I-protein
species	O
of	I-protein
100	I-protein
kd	O
,	O
designated	O
OTF-1	B-protein
,	O
is	O
present	O
in	I-protein
all	O
cell	O
types	I-protein
and	I-protein
may	O
exert	O
its	O
activating	O
function	I-protein
only	I-protein
when	O
it	O
can	O
interact	O
with	I-protein
additional	B-protein
adjacent	I-protein
transcription	B-protein
factors	I-protein
.	O

The	O
lymphoid	B-protein
cell	I-protein
specific	I-protein
octamer	I-protein
binding	I-protein
protein	I-protein
of	I-protein
60	I-protein
kd	O
(	O
OTF-2A	B-protein
)	O
specifically	O
stimulates	O
Ig	I-protein
promoters	O
which	O
consist	O
essentially	O
of	I-protein
a	I-protein
TATA-box	O
and	I-protein
an	I-protein
octamer	O
sequence	I-protein
upstream	O
of	I-protein
it	O
.	O

Here	O
we	O
present	O
evidence	O
for	I-protein
yet	O
another	O
B	B-protein
cell	I-protein
specific	I-protein
octamer	I-protein
binding	I-protein
protein	I-protein
of	I-protein
75	I-protein
kd	O
(	O
OTF-2B	B-protein
)	O
.	O

From	O
several	I-protein
findings	O
,	O
including	I-protein
the	I-protein
absence	I-protein
of	I-protein
OTF-2B	B-protein
(	O
but	O
not	I-protein
OTF-2A	B-protein
)	O
from	I-protein
a	I-protein
lymphocyte	O
line	I-protein
that	O
can	O
not	I-protein
respond	O
to	I-protein
the	I-protein
IgH	O
enhancer	O
,	O
we	O
propose	O
a	I-protein
role	O
of	I-protein
the	I-protein
novel	B-protein
octamer	I-protein
factor	I-protein
in	I-protein
the	I-protein
long	I-protein
range	O
activation	I-protein
by	I-protein
the	I-protein
IgH	O
enhancer	O
.	O

We	O
have	O
used	O
the	I-protein
proteolytic	I-protein
clipping	O
bandshift	O
assay	O
(	O
PCBA	O
)	O
technique	O
to	I-protein
distinguish	O
the	I-protein
three	O
different	O
forms	I-protein
found	O
in	I-protein
B	O
cells	I-protein
.	O

This	O
analysis	O
indicates	O
that	O
the	I-protein
75	I-protein
kd-species	O
OTF-2B	B-protein
is	O
closely	O
related	O
to	I-protein
the	I-protein
60	I-protein
kd	I-protein
species	I-protein
OTF-2A	I-protein
.	O

###MEDLINE:89052759

Inhibition	O
of	I-protein
interleukin	B-protein
2	I-protein
-induced	O
proliferation	I-protein
of	I-protein
cloned	O
murine	O
T	O
cells	I-protein
by	I-protein
glucocorticoids	O
.	O

Possible	O
involvement	I-protein
of	I-protein
an	I-protein
inhibitory	B-protein
protein	I-protein
.	O

The	O
ability	O
of	I-protein
glucocorticoids	O
to	I-protein
inhibit	O
interleukin	B-protein
2	I-protein
(	O
IL	B-protein
2	I-protein
)	O
-induced	O
T	O
cell	O
proliferation	I-protein
in	I-protein
two	O
cytotoxic	O
T	O
cell	O
(	O
CTL	O
)	O
clones	O
has	O
been	O
studied	O
.	O

A	O
complete	O
inhibition	O
of	I-protein
DNA	O
synthesis	I-protein
by	I-protein
dexamethasone	O
(	O
Dx	O
)	O
could	O
be	O
observed	O
when	O
IL	O
2-depleted	O
cultures	O
of	I-protein
CTL	O
were	O
either	O
incubated	O
for	I-protein
6	I-protein
h	I-protein
with	I-protein
the	I-protein
hormone	I-protein
prior	O
to	I-protein
the	I-protein
addition	O
of	I-protein
IL	B-protein
2	I-protein
or	I-protein
treated	O
simultaneously	O
with	I-protein
Dx	O
and	I-protein
a	I-protein
low	O
concentration	I-protein
of	I-protein
IL	B-protein
2	I-protein
.	O

No	I-protein
significant	O
reduction	I-protein
in	I-protein
the	I-protein
number	I-protein
and	I-protein
affinity	I-protein
of	I-protein
IL	B-protein
2	I-protein
receptors	I-protein
was	O
seen	O
after	O
6	I-protein
h	I-protein
incubation	O
with	I-protein
Dx	O
.	O

The	O
order	O
of	I-protein
potency	O
observed	O
with	I-protein
the	I-protein
different	O
steroids	O
indicated	O
that	O
this	O
inhibitory	O
effect	O
was	O
mediated	I-protein
through	I-protein
binding	I-protein
to	I-protein
a	I-protein
specific	I-protein
glucocorticoid	B-protein
receptor	I-protein
.	O

The	O
action	O
of	I-protein
these	O
hormones	I-protein
possibly	O
involves	O
the	I-protein
synthesis	I-protein
of	I-protein
an	I-protein
inhibitory	B-protein
protein	I-protein
(	O
s	I-protein
)	O
,	O
since	O
the	I-protein
presence	O
of	I-protein
cycloheximide	O
during	I-protein
the	I-protein
incubation	O
with	I-protein
Dx	O
prevented	O
the	I-protein
inhibition	O
of	I-protein
DNA	O
synthesis	I-protein
.	O

Furthermore	O
,	O
supernatant	O
from	I-protein
Dx-treated	O
CTL	O
contained	O
a	I-protein
nondialyzable	O
factor	I-protein
which	O
inhibited	O
DNA	O
synthesis	I-protein
and	I-protein
cell	O
growth	O
of	I-protein
CTL	O
clones	O
induced	I-protein
by	I-protein
IL	B-protein
2	I-protein
.	O

Blocking	O
of	I-protein
IL	B-protein
2	I-protein
synthesis	I-protein
and	I-protein
IL	B-protein
2	I-protein
receptor	I-protein
formation	O
have	O
been	O
proposed	O
as	O
one	B-protein
of	I-protein
the	I-protein
major	O
mechanisms	O
of	I-protein
glucocorticoid-induced	O
immunosuppression	O
.	O

Our	O
results	O
indicate	O
that	O
these	O
hormones	I-protein
may	O
also	O
affect	O
T	O
cell	O
proliferation	I-protein
by	I-protein
inhibiting	I-protein
IL	B-protein
2	I-protein
activity	I-protein
.	O

###MEDLINE:88263016

Identification	O
and	I-protein
purification	O
of	I-protein
a	I-protein
human	B-protein
immunoglobulin-enhancer-binding	I-protein
protein	I-protein
(	O
NF-kappa	B-protein
B	I-protein
)	O
that	O
activates	O
transcription	O
from	I-protein
a	I-protein
human	O
immunodeficiency	I-protein
virus	I-protein
type	O
1	I-protein
promoter	I-protein
in	I-protein
vitro	O
.	O

The	O
enhancer-binding	I-protein
factor	I-protein
NF-kappa	I-protein
B	I-protein
,	O
which	O
is	O
found	O
only	I-protein
in	I-protein
cells	I-protein
that	O
transcribe	O
immunoglobulin	O
light	I-protein
chain	I-protein
genes	I-protein
,	O
has	O
been	O
purified	O
from	I-protein
nuclear	O
extracts	O
of	I-protein
Namalwa	O
cells	I-protein
(	O
human	O
Burkitt	B-protein
lymphoma	I-protein
cells	I-protein
)	O
by	I-protein
sequence-specific	O
DNA	O
affinity	I-protein
chromatography	O
.	O

The	O
purified	O
NF-kappa	B-protein
B	I-protein
has	O
been	O
identified	I-protein
as	O
a	I-protein
51-kDa	B-protein
polypeptide	I-protein
by	I-protein
UV-crosslinking	O
analysis	O
.	O

``	O
Footprint	O
''	I-protein
and	I-protein
methylation-interference	O
analyses	O
have	O
shown	O
that	O
purified	O
NF-kappa	B-protein
B	I-protein
has	O
a	I-protein
binding	I-protein
activity	I-protein
specific	I-protein
for	I-protein
the	I-protein
kappa	I-protein
light	I-protein
chain	I-protein
enhancer	O
sequence	I-protein
.	O

The	O
purified	B-protein
factor	I-protein
activated	O
in	I-protein
vitro	O
transcription	O
of	I-protein
the	I-protein
human	O
immunodeficiency	I-protein
virus	I-protein
type	O
I	I-protein
promoter	I-protein
by	I-protein
binding	I-protein
to	I-protein
an	I-protein
upstream	O
NF-kappa	O
B-binding	O
site	I-protein

###MEDLINE:88213897

Lymphocyte	O
glucocorticoid	B-protein
receptor	I-protein
binding	I-protein
in	I-protein
depression	O
:	O
normal	O
values	O
following	O
recovery	O
.	O

The	O
number	I-protein
of	I-protein
glucocorticoid	B-protein
receptor	I-protein
sites	I-protein
in	I-protein
lymphocytes	O
and	I-protein
plasma	O
cortisol	O
concentrations	O
were	O
measured	O
in	I-protein
20	I-protein
patients	O
who	O
had	O
recovered	O
from	I-protein
major	O
depressive	I-protein
disorder	I-protein
and	I-protein
20	I-protein
healthy	O
control	I-protein
subjects	O
.	O

The	O
number	I-protein
of	I-protein
glucocorticoid	B-protein
receptor	I-protein
sites	I-protein
in	I-protein
lymphocytes	O
from	I-protein
the	I-protein
recovered	O
depressed	O
group	I-protein
was	O
not	I-protein
significantly	O
different	O
from	I-protein
that	O
of	I-protein
the	I-protein
control	I-protein
group	I-protein
.	O

Although	O
the	I-protein
mean	I-protein
plasma	O
cortisol	O
concentration	I-protein
in	I-protein
recovered	O
depressives	O
was	O
higher	O
than	I-protein
in	I-protein
control	I-protein
subjects	O
,	O
the	I-protein
difference	O
only	I-protein
just	O
reached	O
significance	O
.	O

This	O
study	O
shows	O
that	O
the	I-protein
reduction	I-protein
in	I-protein
glucocorticoid	B-protein
receptor	I-protein
numbers	O
which	O
occurs	O
during	I-protein
acute	O
depressive	I-protein
illness	O
does	O
not	I-protein
persist	O
on	I-protein
recovery	O
and	I-protein
is	O
,	O
therefore	O
,	O
state-dependent	O
.	O

###MEDLINE:88052881

Identification	O
and	I-protein
purification	O
of	I-protein
a	I-protein
human	B-protein
lymphoid-specific	I-protein
octamer-binding	I-protein
protein	I-protein
(	O
OTF-2	B-protein
)	O
that	O
activates	O
transcription	O
of	I-protein
an	I-protein
immunoglobulin	O
promoter	I-protein
in	I-protein
vitro	O
.	O

The	O
octamer	O
sequence	I-protein
5'-ATGCAAAT	O
,	O
in	I-protein
either	O
orientation	O
,	O
serves	O
as	O
an	I-protein
upstream	O
element	I-protein
in	I-protein
a	I-protein
variety	O
of	I-protein
promoters	O
and	I-protein
also	O
occurs	O
as	O
a	I-protein
modular	I-protein
enhancer	O
element	I-protein
.	O

It	O
is	O
of	I-protein
particular	O
interest	I-protein
in	I-protein
immunoglobulin	O
genes	I-protein
since	O
it	O
is	O
found	O
in	I-protein
the	I-protein
upstream	O
regions	O
of	I-protein
all	O
heavy	I-protein
and	I-protein
light	I-protein
chain	I-protein
promoters	O
and	I-protein
in	I-protein
the	I-protein
heavy	I-protein
chain	I-protein
enhancer	O
,	O
both	O
of	I-protein
which	O
are	O
known	O
to	I-protein
be	O
necessary	O
for	I-protein
cell-specific	I-protein
expression	I-protein
.	O

We	O
report	O
here	O
the	I-protein
chromatographic	O
separation	O
of	I-protein
ubiquitous	I-protein
and	I-protein
B	I-protein
cell-specific	I-protein
octamer-binding	I-protein
proteins	I-protein
.	O

The	O
B	B-protein
cell	I-protein
factor	I-protein
was	O
purified	O
to	I-protein
homogeneity	O
using	O
affinity	I-protein
chromatography	O
and	I-protein
consists	O
of	I-protein
three	O
peptides	O
of	I-protein
62	I-protein
,	O
61	I-protein
,	O
and	I-protein
58.5	O
+/-	O
1.5	I-protein
kd	O
.	O

Each	O
of	I-protein
the	I-protein
polypeptides	I-protein
was	O
renatured	O
after	O
SDS-PAGE	O
and	I-protein
shown	O
to	I-protein
bind	O
to	I-protein
the	I-protein
octamer	O
sequence	I-protein
.	O

The	O
specific	I-protein
DNA	O
binding	I-protein
activity	I-protein
of	I-protein
the	I-protein
pure	I-protein
B	B-protein
cell-specific	I-protein
factor	I-protein
was	O
indistinguishable	O
from	I-protein
that	O
of	I-protein
the	I-protein
affinity-purified	B-protein
ubiquitous	I-protein
factor	I-protein
.	O

This	O
B	B-protein
cell-specific	I-protein
octamer-binding	I-protein
factor	I-protein
,	O
in	I-protein
pure	I-protein
form	I-protein
,	O
activated	O
transcription	O
from	I-protein
a	I-protein
kappa	I-protein
light	I-protein
chain	I-protein
promoter	I-protein
in	I-protein
vitro	O
,	O
thus	O
demonstrating	O
that	O
it	O
is	O
indeed	O
a	I-protein
B	B-protein
cell-specific	I-protein
transcription	I-protein
factor	I-protein
for	I-protein
this	O
gene	O
.	O

In	O
addition	O
to	I-protein
the	I-protein
ubiquitous	I-protein
and	I-protein
B	I-protein
cell-specific	I-protein
octamer-binding	I-protein
factors	I-protein
,	O
we	O
identified	I-protein
several	I-protein
additional	B-protein
proteins	I-protein
,	O
one	B-protein
of	I-protein
which	O
is	O
B	O
cell	O
-specific	I-protein
,	O
that	O
interact	O
with	I-protein
the	I-protein
kappa	I-protein
promoter	I-protein
.	O

###MEDLINE:87251218

Decreased	O
deoxyribonucleic	O
acid	O
binding	I-protein
of	I-protein
glucocorticoid-receptor	B-protein
complex	I-protein
in	I-protein
cultured	O
skin	O
fibroblasts	O
from	I-protein
a	I-protein
patient	O
with	I-protein
the	I-protein
glucocorticoid	O
resistance	O
syndrome	I-protein
.	O

A	O
patient	O
with	I-protein
the	I-protein
syndrome	I-protein
of	I-protein
glucocorticoid	O
resistance	O
was	O
studied	O
.	O

A	O
27-yr-old	O
woman	O
initially	O
was	O
diagnosed	O
as	O
having	O
Cushing	O
's	I-protein
disease	I-protein
,	O
based	O
on	I-protein
the	I-protein
findings	O
of	I-protein
high	O
plasma	O
ACTH	B-protein
and	I-protein
serum	O
cortisol	O
levels	I-protein
,	O
increased	I-protein
urinary	O
cortisol	O
secretion	O
,	O
resistance	O
to	I-protein
adrenal	I-protein
suppression	O
with	I-protein
dexamethasone	O
,	O
and	I-protein
bilateral	I-protein
adrenal	I-protein
hyperplasia	I-protein
by	I-protein
computed	O
tomography	O
and	I-protein
scintigraphy	O
of	I-protein
the	I-protein
adrenal	I-protein
glands	O
.	O

However	O
,	O
she	O
had	O
no	I-protein
signs	O
or	I-protein
symptoms	O
of	I-protein
Cushing	O
's	I-protein
syndrome	I-protein
.	O

During	O
a	I-protein
5-yr	O
follow-up	O
,	O
no	I-protein
clinical	I-protein
abnormalities	I-protein
developed	O
,	O
although	O
hypercortisolism	O
persisted	O
.	O

End-organ	O
resistance	O
to	I-protein
cortisol	O
was	O
suspected	O
.	O

To	O
explain	O
the	I-protein
end-organ	O
resistance	O
to	I-protein
cortisol	O
,	O
the	I-protein
glucocorticoid	B-protein
receptors	I-protein
(	O
GR	B-protein
)	O
in	I-protein
peripheral	O
mononuclear	O
leukocytes	O
and	I-protein
cultured	O
skin	O
fibroblasts	O
from	I-protein
a	I-protein
forearm	O
skin	O
biopsy	O
were	O
characterized	O
and	I-protein
compared	O
with	I-protein
the	I-protein
results	O
of	I-protein
similar	O
studies	O
in	I-protein
normal	O
subjects	O
.	O

The	O
patient	O
's	I-protein
GR	B-protein
in	I-protein
whole	O
cell	O
assays	O
had	O
an	I-protein
increased	I-protein
dissociation	I-protein
constant	I-protein
(	O
Kd	O
)	O
.	O

In	O
the	I-protein
cytosol	I-protein
of	I-protein
cultured	O
skin	O
fibroblasts	O
from	I-protein
the	I-protein
patient	O
,	O
there	O
was	O
also	O
decreased	O
binding	I-protein
capacity	O
.	O

The	O
thermal	O
stability	O
and	I-protein
the	I-protein
sedimentation	O
coefficient	O
in	I-protein
a	I-protein
sucrose	O
density	I-protein
gradient	I-protein
of	I-protein
the	I-protein
receptors	I-protein
in	I-protein
the	I-protein
cytosol	I-protein
of	I-protein
cultured	O
skin	O
fibroblasts	O
from	I-protein
the	I-protein
patient	O
and	I-protein
normal	O
subjects	O
were	O
similar	O
.	O

GR	B-protein
complex	I-protein
activation	I-protein
,	O
analyzed	O
by	I-protein
DEAE-cellulose	O
chromatography	O
,	O
was	O
decreased	O
in	I-protein
the	I-protein
patient	O
.	O

DNA	O
binding	I-protein
of	I-protein
the	I-protein
GR	B-protein
complex	I-protein
after	O
temperature-induced	O
activation	I-protein
was	O
lower	I-protein
in	I-protein
the	I-protein
patient	O
than	I-protein
in	I-protein
normal	O
subjects	O
.	O

Nuclear	I-protein
translocation	O
of	I-protein
GR	B-protein
complexes	I-protein
from	I-protein
the	I-protein
patient	O
was	O
also	O
slightly	O
decreased	O
.	O

These	O
results	O
suggest	O
that	O
the	I-protein
patient	O
's	I-protein
glucocorticoid	O
resistance	O
was	O
due	I-protein
to	I-protein
a	I-protein
decrease	O
in	I-protein
the	I-protein
affinity	I-protein
of	I-protein
the	I-protein
receptor	O
for	I-protein
glucocorticoids	O
and	I-protein
a	I-protein
decrease	O
in	I-protein
the	I-protein
binding	I-protein
of	I-protein
the	I-protein
GR	B-protein
complex	I-protein
to	I-protein
DNA	O
.	O

###MEDLINE:87223096

Granulocyte-macrophage	B-protein
colony-stimulating	I-protein
factor	I-protein
.	O

Sensitive	O
and	I-protein
receptor-mediated	O
regulation	I-protein
by	I-protein
1	I-protein
,	O
25-dihydroxyvitamin	O
D3	I-protein
in	I-protein
normal	O
human	O
peripheral	O
blood	O
lymphocytes	O
.	O

We	O
show	O
that	O
1	I-protein
,	O
25-dihydroxyvitamin	O
D3	I-protein
(	O
1	I-protein
,	O
25	I-protein
[	O
OH	O
]	O
2D3	O
)	O
,	O
the	I-protein
most	O
hormonally	B-protein
active	O
metabolite	O
of	I-protein
vitamin	O
D3	I-protein
,	O
modulates	O
sensitively	O
and	I-protein
specifically	O
both	O
the	I-protein
protein	O
and	I-protein
messenger	O
RNA	O
accumulation	I-protein
of	I-protein
the	I-protein
multilineage	B-protein
growth	I-protein
factor	I-protein
granulocyte-macrophage	I-protein
colony-stimulating	I-protein
factor	I-protein
(	O
GM-CSF	B-protein
)	O
.	O

The	O
regulation	I-protein
of	I-protein
GM-CSF	B-protein
expression	I-protein
is	O
seen	O
in	I-protein
both	O
normal	O
human	O
mitogen-activated	O
T	O
lymphocytes	O
and	I-protein
T	O
lymphocytes	O
from	I-protein
a	I-protein
line	I-protein
(	O
S-LB1	O
)	O
transformed	I-protein
with	I-protein
human	O
T	O
cell	O
lymphotropic	O
virus	I-protein
1	I-protein
(	O
HTLV-1	B-protein
)	O
.	O

In	O
contrast	O
,	O
cells	I-protein
from	I-protein
a	I-protein
HTLV-1	B-protein
transformed	I-protein
T	O
lymphocyte	O
line	I-protein
(	O
Ab-VDR	O
)	O
established	O
from	I-protein
a	I-protein
patient	O
with	I-protein
vitamin	O
D-resistant	O
rickets	I-protein
type	O
II	I-protein
with	I-protein
undetectable	B-protein
1	I-protein
,	O
25	I-protein
(	O
OH	I-protein
)	O
2D3	I-protein
cellular	I-protein
receptors	I-protein
are	O
resistant	I-protein
to	I-protein
the	I-protein
action	O
of	I-protein
1	I-protein
,	O
25	I-protein
(	O
OH	O
)	O
2D3	O
.	O

Inhibition	O
of	I-protein
GM-CSF	B-protein
expression	I-protein
by	I-protein
1	I-protein
,	O
25	I-protein
(	O
OH	O
)	O
2D3	O
can	O
occur	O
independently	O
of	I-protein
interleukin	B-protein
2	I-protein
regulation	I-protein
and	I-protein
is	O
probably	O
mediated	I-protein
through	I-protein
cellular	B-protein
1	I-protein
,	O
25	I-protein
(	O
OH	I-protein
)	O
2D3	I-protein
receptors	I-protein
.	O

We	O
conclude	O
that	O
1	I-protein
,	O
25	I-protein
(	O
OH	O
)	O
2D3	O
may	O
be	O
important	O
in	I-protein
the	I-protein
physiology	O
of	I-protein
hematopoiesis	I-protein
.	O

###MEDLINE:87218708

Altered	O
interaction	I-protein
between	O
triiodothyronine	O
and	I-protein
its	O
nuclear	B-protein
receptors	I-protein
in	I-protein
absence	I-protein
of	I-protein
cortisol	O
:	O
a	I-protein
proposed	O
mechanism	O
for	I-protein
increased	I-protein
thyrotropin	O
secretion	O
in	I-protein
corticosteroid	O
deficiency	I-protein
states	O
.	O

Thyroid	O
hormones	I-protein
occasionally	O
appear	O
less	O
effective	O
when	O
administered	O
alone	O
to	I-protein
patients	O
with	I-protein
panhypopituitarism	B-protein
,	O
and	I-protein
manifestations	O
suggestive	O
of	I-protein
hypothyroidism	O
have	O
been	O
reported	O
in	I-protein
patients	O
suffering	O
from	I-protein
untreated	O
Addison	O
's	I-protein
disease	I-protein
.	O

In	O
the	I-protein
latter	O
condition	O
,	O
thyrotropin	O
secretion	O
is	O
increased	I-protein
:	O
this	O
occurs	O
already	O
after	O
as	O
little	O
as	O
2	I-protein
days	O
of	I-protein
temporary	O
withdrawal	O
of	I-protein
therapy	O
with	I-protein
substitution	O
doses	O
of	I-protein
corticosteroids	O
while	O
circulating	O
levels	I-protein
of	I-protein
thyroid	O
hormones	I-protein
remain	O
within	B-protein
normal	O
limits	O
.	O

Therefore	O
,	O
a	I-protein
possible	O
role	O
of	I-protein
cortisol	O
in	I-protein
interaction	I-protein
between	O
triiodothyronine	O
and	I-protein
its	O
nuclear	B-protein
receptors	I-protein
was	O
examined	O
at	I-protein
the	I-protein
level	I-protein
of	I-protein
circulating	O
lymphocytes	O
obtained	O
from	I-protein
patients	O
with	I-protein
primary	O
or	I-protein
secondary	O
adrenocortical	O
failure	I-protein
.	O

The	O
affinity	I-protein
of	I-protein
these	O
receptors	I-protein
was	O
found	O
to	I-protein
be	O
decreased	O
,	O
by	I-protein
more	O
than	I-protein
50	I-protein
%	O
on	I-protein
average	O
,	O
in	I-protein
the	I-protein
absence	I-protein
of	I-protein
cortisol	O
treatments	O
.	O

This	O
change	O
was	O
promptly	O
corrected	O
upon	O
resumption	O
of	I-protein
therapy	O
.	O

The	O
number	I-protein
of	I-protein
binding	I-protein
sites	I-protein
was	O
not	I-protein
significantly	O
modified	O
.	O

The	O
influence	O
of	I-protein
cortisol	O
on	I-protein
thyroid	B-protein
hormone	I-protein
receptors	I-protein
discussed	O
here	O
might	O
account	O
for	I-protein
the	I-protein
clinical	I-protein
observations	O
mentioned	O
above	O
.	O

###MEDLINE:87142820

Inhibition	O
by	I-protein
cortisol	O
of	I-protein
human	O
natural	O
killer	O
(	O
NK	I-protein
)	O
cell	O
activity	I-protein
.	O

The	O
effects	O
of	I-protein
cortisol	O
on	I-protein
the	I-protein
natural	O
killer	O
(	O
NK	I-protein
)	O
activity	I-protein
of	I-protein
human	O
peripheral	O
blood	O
mononuclear	O
(	O
PBM	O
)	O
cells	I-protein
were	O
studied	O
in	I-protein
vitro	O
using	O
a	I-protein
direct	O
4-h	O
51Cr-release	O
assay	O
and	I-protein
K	O
562	I-protein
cell	O
line	I-protein
as	O
a	I-protein
target	O
.	O

Preincubation	O
for	I-protein
20	I-protein
h	I-protein
of	I-protein
PBM	O
cells	I-protein
drawn	O
from	I-protein
healthy	O
donors	O
with	I-protein
1	I-protein
X	O
10	I-protein
(	O
-8	O
)	O
to	I-protein
1	I-protein
X	O
10	I-protein
(	O
-5	O
)	O
M	I-protein
cortisol	O
resulted	O
in	I-protein
a	I-protein
significant	O
decrease	O
of	I-protein
NK	I-protein
cell	O
activity	I-protein
.	O

The	O
magnitude	O
of	I-protein
the	I-protein
suppression	O
was	O
directly	O
related	O
to	I-protein
the	I-protein
steroid	O
concentration	I-protein
and	I-protein
inversely	O
related	O
to	I-protein
the	I-protein
number	I-protein
of	I-protein
effector	O
cells	I-protein
.	O

Cortisol	O
was	O
able	O
to	I-protein
minimize	O
the	I-protein
enhancement	O
of	I-protein
NK	I-protein
cytotoxicity	I-protein
obtainable	O
in	I-protein
the	I-protein
presence	O
of	I-protein
immune	O
interferon	O
(	O
IFN-gamma	B-protein
)	O
.	O

A	O
significantly	O
higher	O
suppression	O
was	O
achieved	O
after	O
sequential	O
exposure	O
of	I-protein
PBM	O
cells	I-protein
to	I-protein
cortisol	O
and	I-protein
equimolar	O
levels	I-protein
of	I-protein
prostaglandin	O
E2	O
(	O
PgE2	O
)	O
.	O

The	O
concomitant	O
incubation	O
with	I-protein
theophylline	O
and	I-protein
isobutyl-methylxanthine	O
failed	O
to	I-protein
enhance	O
the	I-protein
cortisol-induced	O
suppression	O
,	O
whereas	O
PgE2-dependent	O
inhibition	O
significantly	O
increased	I-protein
after	O
exposure	O
of	I-protein
PBM	O
cells	I-protein
to	I-protein
methyl-xanthines	O
.	O

The	O
inhibitory	O
effect	O
of	I-protein
cortisol	O
was	O
partially	O
or	I-protein
totally	O
prevented	O
by	I-protein
the	I-protein
concomitant	O
incubation	O
with	I-protein
equimolar	O
amounts	O
of	I-protein
11-deoxycortisol	O
and	I-protein
RU	O
486	I-protein
but	O
not	I-protein
of	I-protein
progesterone	B-protein
.	O

Treatment	O
of	I-protein
NK	I-protein
effectors	O
with	I-protein
a	I-protein
monoclonal	I-protein
anti-human	I-protein
corticosteroid-binding	I-protein
globulin	I-protein
(	O
CBG	B-protein
)	O
antibody	I-protein
produced	O
an	I-protein
enhancement	O
of	I-protein
the	I-protein
spontaneous	O
NK	I-protein
activity	I-protein
and	I-protein
a	I-protein
partial	I-protein
suppression	O
of	I-protein
cortisol-mediated	O
effects	O
.	O

Our	O
results	O
suggest	O
that	O
endogenous	O
glucocorticoids	O
play	O
a	I-protein
role	O
in	I-protein
the	I-protein
regulation	I-protein
of	I-protein
NK	I-protein
cell-mediated	O
cytotoxicity	I-protein
.	O

Since	O
the	I-protein
effect	O
of	I-protein
cortisol	O
was	O
additive	O
to	I-protein
that	O
of	I-protein
PgE2	O
and	I-protein
was	O
not	I-protein
changed	O
by	I-protein
phosphodiesterase	O
inhibitors	I-protein
,	O
it	O
is	O
conceivable	O
that	O
the	I-protein
hormone	I-protein
acts	O
at	I-protein
a	I-protein
level	I-protein
different	O
from	I-protein
the	I-protein
adenylate	B-protein
cyclase	I-protein
-	O
phosphodiesterase	O
system	I-protein
.	O

Data	O
obtained	O
with	I-protein
the	I-protein
use	O
of	I-protein
antiglucocorticoids	O
and	I-protein
the	I-protein
anti-CBG	B-protein
antibody	I-protein
are	O
compatible	O
with	I-protein
a	I-protein
role	O
both	O
of	I-protein
high-affinity	O
glucocorticoid	B-protein
receptors	I-protein
and	I-protein
of	I-protein
CBG	B-protein
in	I-protein
mediating	I-protein
cortisol	O
action	O
on	I-protein
the	I-protein
human	O
NK	I-protein
cell	O
activity	I-protein
.	O

###MEDLINE:87014826

Interaction	O
of	I-protein
cell-type-specific	B-protein
nuclear	I-protein
proteins	I-protein
with	I-protein
immunoglobulin	O
VH	I-protein
promoter	I-protein
region	O
sequences	I-protein
.	O

All	O
human	O
and	I-protein
murine	O
immunoglobulin	O
heavy	I-protein
chain	I-protein
variable	O
region	O
(	O
VH	I-protein
)	O
genes	I-protein
contain	O
the	I-protein
sequence	I-protein
ATGCAAAT	O
approximately	O
70	I-protein
nucleotides	O
5	O
'	O
from	I-protein
the	I-protein
site	I-protein
of	I-protein
transcription	O
initiation	I-protein
.	O

This	O
octanucleotide	O
,	O
in	I-protein
reverse	I-protein
orientation	O
,	O
is	O
also	O
found	O
in	I-protein
all	O
light	I-protein
chain	I-protein
variable	O
region	O
(	O
VL	O
)	O
genes	I-protein
,	O
and	I-protein
in	I-protein
the	I-protein
immunoglobulin	O
heavy	I-protein
chain	I-protein
transcriptional	O
enhancer	O
.	O

Transfection	O
studies	O
have	O
established	O
that	O
this	O
octamer	O
is	O
involved	I-protein
in	I-protein
the	I-protein
lymphoid-specific	I-protein
transcription	O
of	I-protein
immunoglobulin	O
genes	I-protein
.	O

Octamer-containing	O
fragments	I-protein
have	O
been	O
reported	O
to	I-protein
bind	O
a	I-protein
factor	I-protein
present	O
in	I-protein
nuclear	O
extracts	O
of	I-protein
human	O
cell	O
lines	B-protein
;	O
however	O
,	O
identical	O
binding	I-protein
activity	I-protein
was	O
detected	O
in	I-protein
both	O
B	O
lymphoid	O
and	I-protein
non-lymphoid	O
cells	I-protein
.	O

Here	O
we	O
establish	O
that	O
nuclear	O
extracts	O
from	I-protein
distinct	O
cell	O
types	I-protein
differ	O
in	I-protein
their	O
ability	O
to	I-protein
interact	O
with	I-protein
octamer-containing	O
fragments	I-protein
.	O

We	O
have	O
also	O
detected	O
a	I-protein
DNA-protein	O
interaction	I-protein
that	O
may	O
be	O
involved	I-protein
in	I-protein
the	I-protein
cell-type	O
specificity	I-protein
of	I-protein
immunoglobulin	O
expression	I-protein
,	O
and	I-protein
we	O
have	O
determined	O
that	O
a	I-protein
sequence	I-protein
upstream	O
of	I-protein
the	I-protein
octamer	O
participates	O
in	I-protein
an	I-protein
interaction	I-protein
with	I-protein
a	I-protein
nuclear	B-protein
protein	I-protein
(	O
s	I-protein
)	O
.	O

###MEDLINE:86259058

Preferential	O
transcription	O
of	I-protein
HTLV-I	O
LTR	O
in	I-protein
cell-free	O
extracts	O
of	I-protein
human	O
T	O
cells	I-protein
producing	O
HTLV-I	B-protein
viral	I-protein
proteins	I-protein
.	O

The	O
promoters	O
of	I-protein
the	I-protein
adenovirus	I-protein
2	I-protein
major	O
late	O
gene	O
,	O
the	I-protein
mouse	I-protein
beta-globin	O
gene	O
,	O
the	I-protein
mouse	I-protein
immunoglobulin	O
VH	I-protein
gene	O
and	I-protein
the	I-protein
LTR	O
of	I-protein
the	I-protein
human	O
T-lymphotropic	O
retrovirus	I-protein
type	O
I	I-protein
were	O
tested	O
for	I-protein
their	O
transcription	O
activities	O
in	I-protein
cell-free	O
extracts	O
of	I-protein
four	O
cell	O
lines	B-protein
;	O
HeLa	O
,	O
CESS	O
(	O
Epstein-Barr	B-protein
virus-transformed	O
human	O
B	O
cell	O
line	I-protein
)	O
,	O
MT-1	O
(	O
HTLV-I-infected	O
human	O
T	O
cell	O
line	I-protein
without	I-protein
viral	O
protein	O
synthesis	I-protein
)	O
,	O
and	I-protein
MT-2	O
(	O
HTLV-I-infected	O
human	O
T	O
cell	O
line	I-protein
producing	O
viral	B-protein
proteins	I-protein
)	O
.	O

LTR	O
was	O
preferentially	O
transcribed	I-protein
in	I-protein
the	I-protein
extracts	O
of	I-protein
MT-2	O
although	O
the	I-protein
other	O
three	O
genes	I-protein
were	O
transcribed	I-protein
with	I-protein
relatively	O
constant	I-protein
efficiencies	O
in	I-protein
different	O
extracts	O
.	O

The	O
results	O
agree	O
well	O
with	I-protein
the	I-protein
previous	O
in	I-protein
vivo	O
studies	O
on	I-protein
the	I-protein
promoter	I-protein
activity	I-protein
of	I-protein
HTLV-I	O
LTR	O
.	O

Mixing	O
of	I-protein
HeLa	O
and	I-protein
MT-2	O
extracts	O
revealed	O
the	I-protein
presence	O
of	I-protein
a	I-protein
LTR-specific	O
stimulating	I-protein
activity	I-protein
in	I-protein
MT-2	O
extracts	O
.	O

###MEDLINE:86092241

A	O
nuclear	B-protein
factor	I-protein
that	O
binds	O
to	I-protein
a	I-protein
conserved	O
sequence	I-protein
motif	I-protein
in	I-protein
transcriptional	O
control	I-protein
elements	O
of	I-protein
immunoglobulin	O
genes	I-protein
.	O

Trans-acting	B-protein
factors	I-protein
that	O
mediate	O
B-cell	O
specific	I-protein
transcription	O
of	I-protein
immunoglobulin	O
genes	I-protein
have	O
been	O
postulated	O
based	O
on	I-protein
an	I-protein
analysis	O
of	I-protein
the	I-protein
expression	I-protein
of	I-protein
exogenously	O
introduced	O
immunoglobulin	O
gene	O
recombinants	O
in	I-protein
lymphoid	O
and	I-protein
non-lymphoid	O
cells	I-protein
.	O

Two	O
B-cell-specific	O
,	O
cis-acting	O
transcriptional	O
regulatory	O
elements	O
have	O
been	O
identified	I-protein
.	O

One	I-protein
element	I-protein
is	O
located	O
in	I-protein
the	I-protein
intron	O
between	O
the	I-protein
variable	O
(	O
V	O
)	O
and	I-protein
constant	I-protein
(	O
C	O
)	O
regions	O
of	I-protein
both	O
heavy	I-protein
and	I-protein
kappa	I-protein
light-chain	O
genes	I-protein
and	I-protein
acts	O
as	O
a	I-protein
transcriptional	O
enhancer	O
.	O

The	O
second	O
element	I-protein
is	O
found	O
upstream	O
of	I-protein
both	O
heavy	I-protein
and	I-protein
kappa	I-protein
light-chain	O
gene	O
promoters	O
.	O

This	O
element	I-protein
directs	I-protein
lymphoid-specific	I-protein
transcription	O
even	O
in	I-protein
the	I-protein
presence	O
of	I-protein
viral	O
enhancers	O
.	O

We	O
have	O
sought	O
nuclear	O
factors	I-protein
that	O
might	O
bind	O
specifically	O
to	I-protein
these	O
two	O
regulatory	O
elements	O
by	I-protein
application	O
of	I-protein
a	I-protein
modified	O
gel	O
electrophoresis	O
DNA	O
binding	I-protein
assay	O
.	O

We	O
report	O
here	O
the	I-protein
identification	O
of	I-protein
a	I-protein
human	B-protein
B-cell	I-protein
nuclear	I-protein
factor	I-protein
(	O
IgNF-A	O
)	O
that	O
binds	O
to	I-protein
DNA	O
sequences	I-protein
in	I-protein
the	I-protein
upstream	O
regions	O
of	I-protein
both	O
the	I-protein
mouse	I-protein
heavy	I-protein
and	I-protein
kappa	I-protein
light-chain	O
gene	O
promoters	O
and	I-protein
also	O
to	I-protein
the	I-protein
mouse	I-protein
heavy-chain	O
gene	O
enhancer	O
.	O

This	O
sequence-specific	O
binding	I-protein
is	O
probably	O
mediated	I-protein
by	I-protein
a	I-protein
highly	O
conserved	O
sequence	I-protein
motif	I-protein
,	O
ATTTGCAT	O
,	O
present	O
in	I-protein
all	O
three	O
transcriptional	O
elements	O
.	O

Interestingly	O
,	O
a	I-protein
factor	I-protein
showing	O
similar	O
binding	I-protein
specificity	I-protein
to	I-protein
IgNF-A	B-protein
is	O
also	O
present	O
in	I-protein
human	O
HeLa	O
cells	I-protein
.	O

###MEDLINE:86238756

The	O
new	I-protein
world	O
primates	O
as	O
animal	O
models	O
of	I-protein
glucocorticoid	O
resistance	O
.	O

Many	O
New	I-protein
World	O
primate	O
species	O
have	O
greatly	O
increased	I-protein
plasma	O
cortisol	O
concentrations	O
,	O
decreased	O
plasma	O
cortisol	O
binding	I-protein
globulin	I-protein
capacity	O
and	I-protein
affinity	I-protein
,	O
marked	O
resistance	O
of	I-protein
the	I-protein
hypothalamic-pituitary-adrenal	O
axis	O
to	I-protein
suppression	O
by	I-protein
dexamethasone	O
,	O
and	I-protein
no	I-protein
biological	O
evidence	O
of	I-protein
glucocorticoid	O
excess	O
.	O

These	O
primates	O
also	O
have	O
high	O
levels	I-protein
of	I-protein
circulating	O
progesterone	B-protein
,	O
estrogen	O
,	O
mineralocorticoid	O
,	O
androgen	O
and	I-protein
vitamin	O
D	O
.	O

The	O
glucocorticoid	O
target	O
tissues	O
that	O
have	O
been	O
examined	O
(	O
circulating	O
mononuclear	O
lymphocytes	O
and	I-protein
cultured	O
skin	O
fibroblasts	O
)	O
have	O
normal	O
concentrations	O
of	I-protein
glucocorticoid	B-protein
receptors	I-protein
with	I-protein
decreased	O
affinity	I-protein
for	I-protein
dexamethasone	O
.	O

Transformation	I-protein
of	I-protein
B-lymphocytes	O
with	I-protein
the	I-protein
Epstein-Barr	B-protein
virus	I-protein
leads	O
to	I-protein
glucocorticoid	B-protein
receptor	I-protein
induction	I-protein
that	O
is	O
less	O
than	I-protein
that	O
observed	O
with	I-protein
cells	I-protein
from	I-protein
Old	O
World	O
primates	O
.	O

The	O
receptor	O
in	I-protein
these	O
cells	I-protein
has	O
a	I-protein
low	O
affinity	I-protein
for	I-protein
dexamethasone	O
.	O

The	O
low	O
affinity	I-protein
leads	O
to	I-protein
an	I-protein
increased	I-protein
loss	O
of	I-protein
specific	I-protein
bound	I-protein
ligand	O
during	I-protein
thermal	O
activation	I-protein
.	O

Meroreceptor	O
generation	O
is	O
normal	O
.	O

The	O
molecular	I-protein
weight	I-protein
of	I-protein
the	I-protein
receptor	O
,	O
determined	O
by	I-protein
SDS-PAGE	O
,	O
is	O
similar	O
to	I-protein
that	O
of	I-protein
Old	O
World	O
primates	O
(	O
approximately	O
92	I-protein
,	O
000	O
)	O
and	I-protein
the	I-protein
activation	I-protein
pattern	I-protein
per	O
se	O
,	O
examined	O
in	I-protein
vitro	O
by	I-protein
heating	O
cytosol	I-protein
and	I-protein
performing	O
phosphocellulose	O
chromatography	O
,	O
appears	O
similar	O
to	I-protein
that	O
of	I-protein
human	O
controls	O
.	O

The	O
ratios	O
of	I-protein
nuclear	O
to	I-protein
cytosolic	B-protein
hormone-receptor-complexes	I-protein
and	I-protein
of	I-protein
cytosolic	O
activated	O
to	I-protein
unactivated	B-protein
receptor	I-protein
complexes	I-protein
in	I-protein
intact	O
cells	I-protein
are	O
similar	O
to	I-protein
Old	O
World	O
primates	O
.	O

Results	O
from	I-protein
mixing	O
studies	O
do	O
not	I-protein
support	I-protein
the	I-protein
hypothesis	O
that	O
a	I-protein
binding	I-protein
inhibitor	O
(	O
s	I-protein
)	O
or	I-protein
a	I-protein
deficient	I-protein
cytosolic	O
positive	I-protein
modifier	I-protein
(	O
s	I-protein
)	O
of	I-protein
binding	I-protein
underlies	O
the	I-protein
findings	O
in	I-protein
these	O
primates	O
.	O

The	O
New	I-protein
World	O
primates	O
,	O
unlike	O
men	O
with	I-protein
the	I-protein
syndrome	I-protein
of	I-protein
primary	O
cortisol	O
resistance	O
,	O
have	O
compensated	O
for	I-protein
their	O
condition	O
with	I-protein
intra-adrenal	O
and	I-protein
mineralocorticoid	O
receptor	O
adaptations	O
.	O

Thus	O
,	O
unlike	O
Old	O
World	O
primates	O
,	O
cortisol	O
in	I-protein
New	I-protein
World	O
primates	O
has	O
only	I-protein
weak	I-protein
sodium-retaining	O
potency	O
because	O
the	I-protein
aldosterone	B-protein
receptor	I-protein
has	O
a	I-protein
low	O
affinity	I-protein
for	I-protein
cortisol	O
.	O

The	O
common	I-protein
element	I-protein
that	O
would	O
explain	O
the	I-protein
apparent	O
resistance	O
to	I-protein
six	O
steroid	O
hormones	I-protein
in	I-protein
New	I-protein
World	O
primates	O

###MEDLINE:98374270

Acetylation	O
and	I-protein
modulation	O
of	I-protein
erythroid	B-protein
Kruppel-like	I-protein
factor	I-protein
(	O
EKLF	B-protein
)	O
activity	I-protein
by	I-protein
interaction	I-protein
with	I-protein
histone	B-protein
acetyltransferases	I-protein
.	O

Erythroid	B-protein
Kruppel-like	I-protein
factor	I-protein
(	O
EKLF	B-protein
)	O
is	O
a	I-protein
red	I-protein
cell-specific	I-protein
transcriptional	I-protein
activator	I-protein
that	O
is	O
crucial	O
for	I-protein
consolidating	O
the	I-protein
switch	I-protein
to	I-protein
high	O
levels	I-protein
of	I-protein
adult	O
beta-globin	O
expression	I-protein
during	I-protein
erythroid	O
ontogeny	O
.	O

EKLF	B-protein
is	O
required	O
for	I-protein
integrity	O
of	I-protein
the	I-protein
chromatin	O
structure	O
at	I-protein
the	I-protein
beta-like	I-protein
globin	I-protein
locus	O
,	O
and	I-protein
it	O
interacts	I-protein
with	I-protein
a	I-protein
positive-acting	B-protein
factor	I-protein
in	I-protein
vivo	O
.	O

We	O
find	O
that	O
EKLF	B-protein
is	O
an	I-protein
acetylated	B-protein
transcription	I-protein
factor	I-protein
,	O
and	I-protein
that	O
it	O
interacts	I-protein
in	I-protein
vivo	O
with	I-protein
CBP	B-protein
,	O
p300	B-protein
,	O
and	I-protein
P/CAF	B-protein
.	O

However	O
,	O
its	O
interactions	O
with	I-protein
these	O
histone	B-protein
acetyltransferases	I-protein
are	O
not	I-protein
equivalent	O
,	O
as	O
CBP	B-protein
and	I-protein
p300	B-protein
,	O
but	O
not	I-protein
P/CAF	B-protein
,	O
utilize	O
EKLF	B-protein
as	O
a	I-protein
substrate	I-protein
for	I-protein
in	I-protein
vitro	O
acetylation	O
within	B-protein
its	O
trans-activation	O
region	O
.	O

The	O
functional	O
effects	O
of	I-protein
these	O
interactions	O
are	O
that	O
CBP	B-protein
and	I-protein
p300	B-protein
,	O
but	O
not	I-protein
P/CAF	B-protein
,	O
enhance	O
EKLF	B-protein
's	I-protein
transcriptional	O
activation	I-protein
of	I-protein
the	I-protein
beta-globin	O
promoter	I-protein
in	I-protein
erythroid	O
cells	I-protein
.	O

These	O
results	O
establish	O
EKLF	B-protein
as	O
a	I-protein
tissue-specific	B-protein
transcription	I-protein
factor	I-protein
that	O
undergoes	O
post-translational	O
acetylation	O
and	I-protein
suggest	O
a	I-protein
mechanism	O
by	I-protein
which	O
EKLF	B-protein
is	O
able	O
to	I-protein
alter	O
chromatin	O
structure	O
and	I-protein
induce	O
beta-globin	O
expression	I-protein
within	B-protein
the	I-protein
beta-like	I-protein
globin	I-protein
cluster	I-protein
.	O

###MEDLINE:98362153

Recognition	O
of	I-protein
herpes	B-protein
simplex	I-protein
virus	I-protein
type	I-protein
2	I-protein
tegument	I-protein
proteins	I-protein
by	I-protein
CD4	B-protein
T	O
cells	I-protein
infiltrating	O
human	O
genital	I-protein
herpes	O
lesions	O
.	O

The	O
local	O
cellular	O
immune	O
response	I-protein
to	I-protein
herpes	O
simplex	I-protein
virus	I-protein
(	O
HSV	O
)	O
is	O
important	O
in	I-protein
the	I-protein
control	I-protein
of	I-protein
recurrent	O
HSV	O
infection	I-protein
.	O

The	O
antiviral	I-protein
functions	O
of	I-protein
infiltrating	O
CD4-bearing	O
T	O
cells	I-protein
may	O
include	O
cytotoxicity	I-protein
,	O
inhibition	O
of	I-protein
viral	O
growth	O
,	O
lymphokine	B-protein
secretion	O
,	O
and	I-protein
support	I-protein
of	I-protein
humoral	O
and	I-protein
CD8	O
responses	O
.	O

The	O
antigens	I-protein
recognized	I-protein
by	I-protein
many	O
HSV-specific	O
CD4	B-protein
T	O
cells	I-protein
localizing	O
to	I-protein
genital	I-protein
HSV-2	O
lesions	O
are	O
unknown	O
.	O

T	O
cells	I-protein
recognizing	O
antigens	I-protein
encoded	O
within	B-protein
map	O
units	O
0.67	O
to	I-protein
0.73	O
of	I-protein
HSV	O
DNA	O
are	O
frequently	B-protein
recovered	O
from	I-protein
herpetic	O
lesions	O
.	O

Expression	O
cloning	O
with	I-protein
this	O
region	O
of	I-protein
DNA	O
now	O
shows	O
that	O
tegument	B-protein
protein	I-protein
VP22	B-protein
and	I-protein
the	I-protein
viral	B-protein
dUTPase	B-protein
,	O
encoded	O
by	I-protein
genes	I-protein
UL49	O
and	I-protein
UL50	O
,	O
respectively	O
,	O
are	O
T-cell	B-protein
antigens	I-protein
.	O

Separate	O
epitopes	B-protein
in	I-protein
VP22	B-protein
were	O
defined	I-protein
for	I-protein
T-cell	O
clones	O
from	I-protein
each	O
of	I-protein
three	O
patients	O
.	O

Reactivity	O
with	I-protein
the	I-protein
tegument	B-protein
protein	I-protein
encoded	O
by	I-protein
UL21	O
was	O
identified	I-protein
for	I-protein
an	I-protein
additional	B-protein
patient	O
.	O

Three	O
new	I-protein
epitopes	O
were	O
identified	I-protein
in	I-protein
VP16	O
,	O
a	I-protein
tegument	B-protein
protein	I-protein
associated	I-protein
with	I-protein
VP22	B-protein
.	O

Some	O
tegument-specific	O
CD4	B-protein
T-cell	O
clones	O
exhibited	O
cytotoxic	O
activity	I-protein
against	I-protein
HSV-infected	O
cells	I-protein
.	O

These	O
results	O
suggest	O
that	O
herpes	B-protein
simplex	I-protein
tegument	I-protein
proteins	I-protein
are	O
processed	O
for	I-protein
antigen	O
presentation	O
in	I-protein
vivo	O
and	I-protein
are	O
possible	O
candidate	O
compounds	O
for	I-protein
herpes	O
simplex	I-protein
vaccines	O
.	O

###MEDLINE:98349401

Fibrinogen	B-protein
activates	O
NF-kappa	B-protein
B	I-protein
transcription	I-protein
factors	I-protein
in	I-protein
mononuclear	O
phagocytes	O
.	O

Adhesion	O
to	I-protein
extracellular	O
matrices	O
is	O
known	O
to	I-protein
modulate	O
leukocyte	O
activation	I-protein
,	O
although	O
the	I-protein
mechanisms	O
are	O
not	I-protein
fully	O
understood	O
.	O

Mononuclear	O
phagocytes	O
are	O
exposed	O
to	I-protein
fibrinous	O
provisional	I-protein
matrix	O
throughout	O
migration	I-protein
into	O
inflammatory	O
foci	I-protein
,	O
so	O
this	O
study	O
was	O
undertaken	O
to	I-protein
determine	O
whether	O
fibrinogen	B-protein
triggers	O
activation	I-protein
of	I-protein
NF-kappa	B-protein
B	I-protein
transcription	I-protein
factors	I-protein
.	O

U937	O
cells	I-protein
differentiated	O
with	I-protein
PMA	O
in	I-protein
nonadherent	O
culture	O
were	O
shown	O
to	I-protein
express	O
two	O
fibrinogen-binding	B-protein
integrins	I-protein
,	O
predominately	O
CD11b/CD18	B-protein
,	O
and	I-protein
to	I-protein
a	I-protein
lesser	O
extent	O
,	O
CD11c/CD18	B-protein
.	O

Cells	O
stimulated	O
with	I-protein
fibrinogen	B-protein
(	O
10-100	O
microg/ml	O
)	O
/Mn2+	O
(	O
50	I-protein
microM	O
)	O
for	I-protein
2	I-protein
h	I-protein
were	O
examined	O
by	I-protein
electrophoretic	O
mobility	I-protein
shift	O
assay	O
.	O

NF-kappa	B-protein
B	I-protein
activation	I-protein
,	O
minimal	O
in	I-protein
unstimulated	O
cells	I-protein
,	O
was	O
substantially	O
up-regulated	O
by	I-protein
fibrinogen	B-protein
.	O

Fibrinogen	B-protein
also	O
caused	O
activation	I-protein
of	I-protein
AP-1	I-protein
,	O
but	O
not	I-protein
SP1	B-protein
or	I-protein
cAMP	B-protein
response	I-protein
element-binding	I-protein
protein	I-protein
(	O
CREB	B-protein
)	O
factors	I-protein
.	O

Blocking	O
mAbs	B-protein
against	I-protein
CD18	B-protein
and	I-protein
CD11b	B-protein
abrogated	O
fibrinogen	B-protein
-induced	O
NF-kappa	B-protein
B	I-protein
activation	I-protein
.	O

To	O
determine	O
the	I-protein
effects	O
on	I-protein
transcriptional	O
regulation	I-protein
,	O
U937	O
cells	I-protein
were	O
transfected	O
with	I-protein
a	I-protein
plasmid	O
containing	I-protein
the	I-protein
HIV-1	O
enhancer	O
(	O
bearing	O
two	O
NF-kappa	O
B	O
sites	I-protein
)	O
coupled	I-protein
to	I-protein
a	I-protein
chloramphenicol	B-protein
acetyltransferase	I-protein
(	O
CAT	B-protein
)	O
reporter	O
.	O

Cells	O
were	O
subsequently	O
stimulated	O
with	I-protein
1	I-protein
)	O
PMA	O
for	I-protein
24	I-protein
h	I-protein
,	O
inducing	I-protein
CAT	B-protein
activity	I-protein
by	I-protein
2.6-fold	O
,	O
2	I-protein
)	O
fibrinogen	B-protein
/Mn2+	O
for	I-protein
2	I-protein
h	I-protein
,	O
inducing	I-protein
CAT	B-protein
activity	I-protein
by	I-protein
3.2-fold	O
,	O
or	I-protein
3	O
)	O
costimulation	O
with	I-protein
fibrinogen	B-protein
and	I-protein
PMA	O
,	O
inducing	I-protein
5.7-fold	O
the	I-protein
CAT	B-protein
activity	I-protein
induced	I-protein
by	I-protein
PMA	O
alone	O
.	O

We	O
conclude	O
that	O
contact	O
with	I-protein
fibrinogen-derived	B-protein
proteins	I-protein
may	O
contribute	O
to	I-protein
mononuclear	O
phagocyte	O
activation	I-protein
by	I-protein
signaling	O
through	I-protein
CD11b/CD18	B-protein
,	O
resulting	O
in	I-protein
selective	O
activation	I-protein
of	I-protein
transcriptional	B-protein
regulatory	I-protein
factors	I-protein
,	O
including	I-protein
NF-kappa	B-protein
B	I-protein
.	O

###MEDLINE:98339383

Peripheral	O
blood	O
T	O
cells	I-protein
and	I-protein
monocytes	O
and	I-protein
B	O
cell	O
lines	B-protein
derived	I-protein
from	I-protein
patients	O
with	I-protein
lupus	O
express	O
estrogen	O
receptor	O
transcripts	I-protein
similar	O
to	I-protein
those	O
of	I-protein
normal	O
cells	I-protein
.	O

OBJECTIVE	O
:	O
To	O
identify	O
and	I-protein
characterize	O
estrogen	B-protein
receptor	I-protein
(	O
ER	B-protein
)	O
transcripts	I-protein
expressed	O
in	I-protein
immune	O
cells	I-protein
of	I-protein
patients	O
with	I-protein
systemic	B-protein
lupus	O
erythematosus	I-protein
(	O
SLE	O
)	O
and	I-protein
healthy	O
donors	O
.	O

METHODS	O
:	O
Peripheral	O
blood	O
monocytes	O
and	I-protein
T	O
cells	I-protein
were	O
prepared	O
from	I-protein
patients	O
with	I-protein
SLE	O
(	O
n	O
=	O
6	I-protein
)	O
and	I-protein
healthy	O
donors	O
(	O
n	O
=	O
8	I-protein
)	O
.	O

T	O
cells	I-protein
were	O
separated	O
into	O
CD4	B-protein
and	I-protein
CD8	O
.	O

Some	O
monocytes	O
and	I-protein
T	O
cells	I-protein
were	O
stimulated	O
with	I-protein
estradiol	O
,	O
PMA	O
,	O
and	I-protein
ionomycin	O
.	O

Epstein-Barr	B-protein
virus-transformed	O
B	O
cell	O
lines	B-protein
(	O
n	O
=	O
7	I-protein
)	O
and	I-protein
B	O
cell	O
hybridomas	O
(	O
n	O
=	O
2	I-protein
)	O
established	O
from	I-protein
patients	O
with	I-protein
SLE	O
and	I-protein
a	I-protein
healthy	O
individual	O
were	O
used	O
as	O
a	I-protein
B	O
cell	O
source	O
.	O

These	O
cells	I-protein
were	O
examined	O
for	I-protein
ER	O
mRNA	O
by	I-protein
reverse	I-protein
transcription	O
nested	O
polymerase	O
chain	I-protein
reaction	I-protein
.	O

Amplified	O
cDNA	I-protein
were	O
sequenced	O
by	I-protein
standard	O
methods	O
.	O

RESULTS	O
:	O
In	O
all	O
cells	I-protein
tested	O
,	O
ER	O
mRNA	O
was	O
expressed	O
without	I-protein
prior	O
in	I-protein
vitro	O
stimulation	I-protein
.	O

Partial	O
sequences	I-protein
from	I-protein
exons	I-protein
1-8	I-protein
were	O
nearly	O
identical	O
to	I-protein
the	I-protein
published	O
sequence	I-protein
of	I-protein
the	I-protein
human	O
ER	O
mRNA	O
.	O

There	O
were	O
no	I-protein
notable	O
differences	O
in	I-protein
the	I-protein
ER	O
transcripts	I-protein
between	O
patients	O
and	I-protein
healthy	O
controls	O
.	O

Variant	O
receptor	O
transcripts	I-protein
lacking	I-protein
exon	O
5	O
or	I-protein
exon	O
7	I-protein
,	O
which	O
encodes	O
the	I-protein
hormone	I-protein
binding	I-protein
domain	I-protein
,	O
were	O
identified	I-protein
in	I-protein
the	I-protein
majority	O
of	I-protein
the	I-protein
cells	I-protein
.	O

Precise	O
deletion	I-protein
of	I-protein
the	I-protein
exons	I-protein
suggests	O
that	O
they	O
are	O
alternatively	I-protein
spliced	I-protein
transcripts	I-protein
.	O

Whether	O
the	I-protein
detected	O
transcripts	I-protein
are	O
translated	O
into	O
functional	B-protein
receptor	I-protein
proteins	I-protein
remains	O
to	I-protein
be	O
determined	O
.	O

In	O
vitro	O
stimulation	I-protein
did	O
not	I-protein
affect	O
ER	O
mRNA	O
expression	I-protein
.	O

The	O
presence	O
of	I-protein
variants	O
did	O
not	I-protein
correlate	O
with	I-protein
disease	I-protein
activity	I-protein
or	I-protein
medication	O
.	O

CONCLUSION	O
:	O
Monocytes	O
,	O
T	O
cells	I-protein
,	O
and	I-protein
B	O
cells	I-protein
in	I-protein
patients	O
express	O
transcripts	I-protein
of	I-protein
the	I-protein
normal	O
wild	B-protein
type	I-protein
ER	I-protein
and	I-protein
the	I-protein
hormone	I-protein
binding	I-protein
domain	I-protein
variants	I-protein
in	I-protein
vivo	O
.	O

###MEDLINE:98325368

DNA	O
damaging	O
agents	O
induce	O
expression	I-protein
of	I-protein
Fas	B-protein
ligand	I-protein
and	I-protein
subsequent	O
apoptosis	O
in	I-protein
T	O
lymphocytes	O
via	I-protein
the	I-protein
activation	I-protein
of	I-protein
NF-kappa	B-protein
B	I-protein
and	I-protein
AP-1	I-protein
.	O

Apoptosis	I-protein
induced	I-protein
by	I-protein
DNA	O
damage	I-protein
and	I-protein
other	O
stresses	O
can	O
proceed	O
via	I-protein
expression	I-protein
of	I-protein
Fas	B-protein
ligand	I-protein
(	O
FasL	B-protein
)	O
and	I-protein
ligation	O
of	I-protein
its	O
receptor	O
,	O
Fas	B-protein
(	O
CD95	B-protein
)	O
.	O

We	O
report	O
that	O
activation	I-protein
of	I-protein
the	I-protein
two	O
transcription	B-protein
factors	I-protein
NF-kappa	B-protein
B	I-protein
and	I-protein
AP-1	I-protein
is	O
crucially	O
involved	I-protein
in	I-protein
FasL	O
expression	I-protein
induced	I-protein
by	I-protein
etoposide	B-protein
,	O
teniposide	O
,	O
and	I-protein
UV	O
irradiation	O
.	O

A	O
nondegradable	O
mutant	O
of	I-protein
I	I-protein
kappa	I-protein
B	I-protein
blocked	B-protein
both	O
FasL	O
expression	I-protein
and	I-protein
apoptosis	O
induced	I-protein
by	I-protein
DNA	O
damage	I-protein
but	O
not	I-protein
Fas	O
ligation	O
.	O

These	O
stimuli	O
also	O
induced	I-protein
the	I-protein
stress-activated	O
kinase	O
pathway	I-protein
(	O
SAPK/JNK	O
)	O
,	O
which	O
was	O
required	O
for	I-protein
the	I-protein
maximal	O
induction	I-protein
of	I-protein
apoptosis	O
.	O

A	O
1.2	I-protein
kb	O
FasL	O
promoter	I-protein
responded	O
to	I-protein
DNA	O
damage	I-protein
,	O
as	O
well	O
as	O
coexpression	O
with	I-protein
p65	B-protein
Rel	I-protein
or	I-protein
Fos/Jun	O
.	O

Mutations	O
in	I-protein
the	I-protein
relevant	I-protein
NF-kappa	O
B	O
and	I-protein
AP-1	I-protein
binding	I-protein
sites	I-protein
eliminated	I-protein
these	O
responses	O
.	O

Thus	O
,	O
activation	I-protein
of	I-protein
NF-kappa	B-protein
B	I-protein
and	I-protein
AP-1	I-protein
contributes	O
to	I-protein
stress-induced	O
apoptosis	O
via	I-protein
the	I-protein
expression	I-protein
of	I-protein
FasL	B-protein
.	O

###MEDLINE:98322350

A	O
small	O
,	O
nonpeptidyl	O
mimic	O
of	I-protein
granulocyte-colony-stimulating	B-protein
factor	I-protein
[	O
see	O
commetns	O
]	O

A	O
nonpeptidyl	O
small	O
molecule	I-protein
SB	O
247464	O
,	O
capable	O
of	I-protein
activating	O
granulocyte-colony-stimulating	B-protein
factor	I-protein
(	O
G-CSF	B-protein
)	O
signal	O
transduction	I-protein
pathways	O
,	O
was	O
identified	I-protein
in	I-protein
a	I-protein
high-throughput	O
assay	O
in	I-protein
cultured	O
cells	I-protein
.	O

Like	O
G-CSF	B-protein
,	O
SB	O
247464	O
induced	I-protein
tyrosine	O
phosphorylation	I-protein
of	I-protein
multiple	B-protein
signaling	I-protein
proteins	I-protein
and	I-protein
stimulated	O
primary	O
murine	O
bone	O
marrow	I-protein
cells	I-protein
to	I-protein
form	I-protein
granulocytic	O
colonies	O
in	I-protein
vitro	O
.	O

It	O
also	O
elevated	I-protein
peripheral	O
blood	O
neutrophil	O
counts	O
in	I-protein
mice	O
.	O

The	O
extracellular	B-protein
domain	I-protein
of	I-protein
the	I-protein
murine	B-protein
G-CSF	B-protein
receptor	I-protein
was	O
required	O
for	I-protein
the	I-protein
activity	I-protein
of	I-protein
SB	O
247464	O
,	O
suggesting	O
that	O
the	I-protein
compound	O
acts	O
by	I-protein
oligomerizing	B-protein
receptor	I-protein
chains	I-protein
.	O

The	O
results	O
indicate	O
that	O
a	I-protein
small	O
molecule	I-protein
can	O
activate	O
a	I-protein
receptor	O
that	O
normally	O
binds	O
a	I-protein
relatively	O
large	O
protein	O
ligand	O
.	O

###MEDLINE:98305722

Minimal	O
residual	O
disease	I-protein
in	I-protein
acute	O
myelogenous	O
leukemia	O
with	I-protein
PML/RAR	B-protein
alpha	I-protein
or	I-protein
AML1/ETO	O
mRNA	O
and	I-protein
phenotypic	O
analysis	O
of	I-protein
possible	O
T	O
and	I-protein
natural	O
killer	O
cells	I-protein
in	I-protein
bone	O
marrow	I-protein
.	O

Here	O
we	O
studied	O
minimal	O
residual	O
disease	I-protein
(	O
MRD	O
)	O
of	I-protein
patients	O
with	I-protein
acute	O
myeloid	O
leukemia	O
(	O
AML	O
)	O
who	O
have	O
PML/RAR	B-protein
alpha	I-protein
or	I-protein
AML1/ETO	B-protein
as	O
well	O
as	O
the	I-protein
phenotypic	O
analysis	O
of	I-protein
lymphocyte	O
subsets	O
involved	I-protein
in	I-protein
antitumor	O
immunity	O
.	O

Eight	O
patients	O
in	I-protein
long-term	O
(	O
LT	O
;	O
3	O
to	I-protein
15	O
years	O
)	O
and	I-protein
15	O
patients	O
in	I-protein
short-term	O
(	O
ST	O
;	O
up	O
to	I-protein
3	O
years	O
)	O
remission	O
were	O
studied	O
.	O

Using	O
the	I-protein
reverse	I-protein
transcription-polymerase	O
chain	I-protein
reaction	I-protein
(	O
RT	O
)	O
assay	O
,	O
the	I-protein
limit	O
of	I-protein
detection	O
was	O
10	I-protein
(	O
-5	O
)	O
to	I-protein
10	I-protein
(	O
-6	I-protein
)	O
for	I-protein
PML/RAR	O
alpha	O
transcript	O
and	I-protein
10	I-protein
(	O
-4	I-protein
)	O
to	I-protein
10	I-protein
(	O
-5	O
)	O
for	I-protein
the	I-protein
AML1/ETO	O
transcript	O
.	O

Simultaneously	O
,	O
T	O
lymphocyte	O
subsets	O
and	I-protein
NK	I-protein
cells	I-protein
from	I-protein
the	I-protein
peripheral	O
blood	O
(	O
PB	O
)	O
and	I-protein
bone	O
marrow	I-protein
(	O
BM	I-protein
)	O
were	O
investigated	O
by	I-protein
flow	O
cytometric	O
analysis	O
.	O

Four	O
of	I-protein
the	I-protein
eight	O
patients	O
in	I-protein
LT	O
and	I-protein
7	I-protein
of	I-protein
the	I-protein
15	O
patients	O
in	I-protein
ST	O
remission	O
were	O
MRD-positive	O
.	O

Although	O
all	O
MRD-positive	O
patients	O
in	I-protein
LT	O
remission	O
are	O
still	O
until	O
now	O
event-free	O
,	O
3	O
of	I-protein
the	I-protein
7	I-protein
MRD-positive	O
(	O
MRD+	O
)	O
patients	O
in	I-protein
ST	O
remission	O
soon	O
relapsed	O
.	O

The	O
total	O
populations	O
of	I-protein
CD4	B-protein
+	O
,	O
CD8	O
+	O
and	I-protein
CD56	B-protein
+	O
[	O
possible	O
T-cell	O
and	I-protein
natural	O
killer	O
(	O
T/NK	O
)	O
populations	O
]	O
in	I-protein
the	I-protein
BM	I-protein
of	I-protein
ST	O
patients	O
and	I-protein
MRD+/LT	O
patients	O
were	O
significantly	O
(	O
p	O
<	O
.01	O
)	O
low	O
.	O

The	O
CD8+	O
CD28+	O
population	O
showed	O
the	I-protein
same	O
tendency	O
(	O
p	O
<	O
.01-.02	O
)	O
.	O

The	O
T/NK	O
subsets	O
in	I-protein
the	I-protein
BM	I-protein
of	I-protein
MRD-negative	O
(	O
MRD-	O
)	O
LT	O
(	O
MRD-/LT	O
)	O
patients	O
showed	O
similar	O
numbers	O
of	I-protein
cells	I-protein
as	O
normal	O
volunteers	O
.	O

Basically	O
,	O
the	I-protein
total	O
percentage	O
of	I-protein
the	I-protein
CD4+	O
,	O
CD8+	O
and	I-protein
CD56+	O
cell	O
populations	O
in	I-protein
the	I-protein
BM	I-protein
was	O
increased	I-protein
and	I-protein
in	I-protein
the	I-protein
following	O
order	O
:	O
MRD-/LT	O
patients	O
,	O
normal	O
volunteers	O
,	O
MRD+/LT	O
patients	O
and	I-protein
MRD+	O
or	I-protein
-/ST	O
patients	O
.	O

The	O
percentages	O
of	I-protein
the	I-protein
T/NK-cell	O
subsets	O
in	I-protein
the	I-protein
PB	O
were	O
not	I-protein
significantly	O
different	O
among	O
these	O
groups	O
.	O

Thus	O
,	O
the	I-protein
difference	O
of	I-protein
the	I-protein
possible	O
T/NK-cell	O
phenotype	O
in	I-protein
the	I-protein
BM	I-protein
may	O
strongly	O
influence	O
clinical	I-protein
and	I-protein
molecular	I-protein
remission	O
.	O

These	O
results	O
still	O
remain	O
to	I-protein
be	O
confirmed	O
by	I-protein
further	O
studies	O
of	I-protein
the	I-protein
functional	O
anti-tumor	O
immunity	O
of	I-protein
T/NK	O
cells	I-protein
of	I-protein
AML	O
in	I-protein
remission	O
.	O

###MEDLINE:98295832

Mycobacterium	B-protein
tuberculosis	I-protein
mannose-capped	O
lipoarabinomannan	O
can	O
induce	O
NF-kappaB	B-protein
-dependent	I-protein
activation	I-protein
of	I-protein
human	O
immunodeficiency	I-protein
virus	I-protein
type	O
1	I-protein
long	I-protein
terminal	O
repeat	I-protein
in	I-protein
T	O
cells	I-protein
.	O

Tuberculosis	O
has	O
emerged	O
as	O
an	I-protein
epidemic	O
,	O
extended	O
by	I-protein
the	I-protein
large	O
number	I-protein
of	I-protein
individuals	O
infected	O
with	I-protein
human	O
immunodeficiency	I-protein
virus	I-protein
type	O
1	I-protein
(	O
HIV-1	O
)	O
.	O

The	O
major	O
goal	O
of	I-protein
this	O
study	O
was	O
to	I-protein
determine	O
whether	O
the	I-protein
mycobacterial	O
cell	O
wall	O
component	O
mannose-capped	O
lipoarabinomannan	O
(	O
ManLAM	O
)	O
of	I-protein
Mycobacterium	B-protein
tuberculosis	I-protein
(	O
M.	O
tuberculosis	I-protein
)	O
could	O
activate	O
transcription	O
of	I-protein
HIV-1	O
in	I-protein
T	O
cells	I-protein
with	I-protein
the	I-protein
use	O
of	I-protein
an	I-protein
in	I-protein
vitro	O
cell	O
culture	O
system	I-protein
.	O

These	O
experiments	O
are	O
of	I-protein
prime	I-protein
importance	O
considering	O
that	O
CD4	B-protein
-expressing	O
T	O
lymphocytes	O
represent	O
the	I-protein
major	O
virus	I-protein
reservoir	O
in	I-protein
the	I-protein
peripheral	O
blood	O
of	I-protein
infected	O
individuals	O
.	O

Using	O
the	I-protein
1G5	B-protein
cell	O
line	I-protein
harbouring	O
the	I-protein
luciferase	O
reporter	O
gene	O
under	O
the	I-protein
control	I-protein
of	I-protein
the	I-protein
HIV-1	O
LTR	O
,	O
it	O
was	O
first	O
found	O
that	O
culture	O
protein	O
filtrates	O
(	O
CFP	B-protein
)	O
from	I-protein
M.	O
tuberculosis	I-protein
or	I-protein
purified	O
ManLAM	O
could	O
activate	O
HIV-1	O
LTR-dependent	O
gene	O
expression	I-protein
unlike	O
similarly	O
prepared	O
CFP	B-protein
extracts	O
devoid	O
of	I-protein
ManLAM	O
.	O

The	O
implication	O
of	I-protein
protein	B-protein
tyrosine	I-protein
kinase	I-protein
(	O
s	I-protein
)	O
,	O
protein	I-protein
kinase	I-protein
A	I-protein
and/or	I-protein
protein	I-protein
kinase	I-protein
C	I-protein
was	O
highlighted	O
by	I-protein
the	I-protein
abrogation	O
of	I-protein
the	I-protein
ManLAM-mediated	O
activation	I-protein
of	I-protein
HIV-1	O
LTR-driven	O
gene	O
expression	I-protein
using	O
herbimycin	O
A	O
and	I-protein
H7	O
.	O

It	O
was	O
also	O
determined	O
,	O
using	O
electrophoresis	O
mobility	I-protein
shift	O
assays	O
,	O
that	O
M.	O
tuberculosis	I-protein
ManLAM	O
led	O
to	I-protein
the	I-protein
nuclear	O
translocation	O
of	I-protein
the	I-protein
transcription	B-protein
factor	I-protein
NF-kappaB	B-protein
.	O

M.	O
tuberculosis	I-protein
ManLAM	O
resulted	O
in	I-protein
clear	I-protein
induction	I-protein
of	I-protein
the	I-protein
luciferase	O
gene	O
placed	O
under	O
the	I-protein
control	I-protein
of	I-protein
the	I-protein
wild-type	I-protein
,	O
but	O
not	I-protein
the	I-protein
kappaB-mutated	O
,	O
HIV-1	O
LTR	O
region	O
.	O

Finally	O
,	O
the	I-protein
ManLAM-mediated	O
activation	I-protein
of	I-protein
HIV-1	O
LTR	O
transcription	O
was	O
found	O
to	I-protein
be	O
independent	I-protein
of	I-protein
the	I-protein
autocrine	B-protein
or	I-protein
paracrine	O
action	O
of	I-protein
endogenous	O
TNF-alpha	B-protein
.	O

The	O
results	O
suggest	O
that	O
M.	O
tuberculosis	I-protein
can	O
upregulate	O
HIV-1	O
expression	I-protein
in	I-protein
T	O
cells	I-protein
and	I-protein
could	O
thus	O
have	O
the	I-protein
potential	I-protein
to	I-protein
influence	O
the	I-protein
pathogenesis	O
of	I-protein
HIV-1	O
infection	I-protein
.	O

###MEDLINE:98230439

Human	O
immunodeficiency	I-protein
virus	I-protein
type	O
1	I-protein
long	I-protein
terminal	O
repeat	I-protein
quasispecies	O
differ	O
in	I-protein
basal	O
transcription	O
and	I-protein
nuclear	O
factor	I-protein
recruitment	I-protein
in	I-protein
human	O
glial	O
cells	I-protein
and	I-protein
lymphocytes	O
.	O

The	O
generation	O
of	I-protein
genomic	O
diversity	I-protein
during	I-protein
the	I-protein
course	O
of	I-protein
infection	I-protein
has	O
the	I-protein
potential	I-protein
to	I-protein
affect	O
all	O
aspects	O
of	I-protein
HIV-1	O
replication	O
,	O
including	I-protein
expression	I-protein
of	I-protein
the	I-protein
proviral	I-protein
genome	I-protein
.	O

To	O
gain	O
a	I-protein
better	O
understanding	O
of	I-protein
the	I-protein
impact	O
of	I-protein
long	I-protein
terminal	O
repeat	I-protein
(	O
LTR	O
)	O
sequence	I-protein
diversity	I-protein
on	I-protein
LTR-directed	O
gene	O
expression	I-protein
in	I-protein
cells	I-protein
of	I-protein
the	I-protein
central	O
nervous	O
system	I-protein
(	O
CNS	O
)	O
and	I-protein
immune	O
system	I-protein
,	O
we	O
amplified	O
and	I-protein
cloned	O
LTRs	O
from	I-protein
proviral	I-protein
DNA	O
in	I-protein
HIV-1-infected	O
peripheral	O
blood	O
.	O

Sequence	O
analysis	O
of	I-protein
nineteen	O
LTRs	O
cloned	O
from	I-protein
2	I-protein
adult	O
and	I-protein
3	O
pediatric	O
patients	O
revealed	O
an	I-protein
average	O
of	I-protein
33	I-protein
nucleotide	O
changes	O
(	O
with	I-protein
respect	O
to	I-protein
the	I-protein
sequence	I-protein
of	I-protein
the	I-protein
LAI	O
LTR	O
)	O
within	B-protein
the	I-protein
455-bp	O
U3	I-protein
region	O
.	O

Transient	I-protein
expression	I-protein
analyses	O
in	I-protein
cells	I-protein
of	I-protein
neuroglial	O
and	I-protein
lymphocytic	I-protein
origin	O
demonstrated	O
that	O
some	O
of	I-protein
these	O
LTRs	O
had	O
activities	O
which	O
varied	O
significantly	O
from	I-protein
the	I-protein
LAI	O
LTR	O
in	I-protein
U-373	O
MG	O
cells	I-protein
(	O
an	I-protein
astrocytoma	O
cell	O
line	I-protein
)	O
as	O
well	O
as	O
in	I-protein
Jurkat	O
cells	I-protein
(	O
a	I-protein
CD4-positive	O
lymphocyte	O
cell	O
line	I-protein
)	O
.	O

While	O
LTRs	O
which	O
demonstrated	O
the	I-protein
highest	O
activities	O
in	I-protein
U-373	O
MG	O
cells	I-protein
also	O
yielded	O
high	O
activities	O
in	I-protein
Jurkat	O
cells	I-protein
,	O
the	I-protein
LTRs	O
were	O
generally	O
more	O
active	O
in	I-protein
Jurkat	O
cells	I-protein
when	O
compared	O
to	I-protein
the	I-protein
LAI	O
LTR	O
.	O

Differences	O
in	I-protein
LTR	O
sequence	I-protein
also	O
resulted	O
in	I-protein
differences	O
in	I-protein
transcription	O
factor	I-protein
recruitment	I-protein
to	I-protein
cis-acting	O
sites	I-protein
within	B-protein
the	I-protein
U3	I-protein
region	O
of	I-protein
the	I-protein
LTR	O
,	O
as	O
demonstrated	O
by	I-protein
electrophoretic	O
mobility	I-protein
shift	O
assays	O
.	O

In	O
particular	O
,	O
naturally	O
occurring	O
sequence	I-protein
variation	I-protein
impacted	O
transcription	B-protein
factor	I-protein
binding	I-protein
to	I-protein
an	I-protein
activating	B-protein
transcription	I-protein
factor	I-protein
/	O
cAMP	O
response	I-protein
element	I-protein
binding	I-protein
(	O
ATF	B-protein
/	O
CREB	B-protein
)	O
binding	I-protein
site	I-protein
(	O
located	O
between	O
the	I-protein
LEF-1	I-protein
and	I-protein
distal	I-protein
NF-kappaB	B-protein
transcription	O
factor	I-protein
binding	I-protein
sites	I-protein
)	O
that	O
we	O
identified	I-protein
in	I-protein
previous	O
studies	O
of	I-protein
the	I-protein
HIV-1	O
LTR	O
.	O

These	O
findings	O
suggest	O
that	O
LTR	O
sequence	I-protein
changes	O
can	O
significantly	O
affect	O
basal	O
LTR	O
function	I-protein
and	I-protein
transcription	O
factor	I-protein
recruitment	I-protein
,	O
which	O
may	O
,	O
in	I-protein
turn	O
,	O
alter	O
the	I-protein
course	O
of	I-protein
viral	O
replication	O
in	I-protein
cells	I-protein
of	I-protein
CNS	O
and	I-protein
immune	O
system	I-protein
origin	O
.	O

###MEDLINE:98282480

HMG	B-protein
box	I-protein
containing	I-protein
transcription	I-protein
factors	I-protein
in	I-protein
lymphocyte	O
differentiation	I-protein
.	O

The	O
identification	O
of	I-protein
the	I-protein
mammalian	O
sex-determining	O
gene	O
Sry	O
has	O
led	O
to	I-protein
the	I-protein
discovery	O
of	I-protein
a	I-protein
large	O
family	O
of	I-protein
related	O
(	O
'	O
HMG	O
box	I-protein
'	O
)	O
transcription	B-protein
factors	I-protein
that	O
control	I-protein
developmental	O
events	O
in	I-protein
yeast	O
,	O
C.	I-protein
elegans	I-protein
,	O
Drosophila	I-protein
and	I-protein
vertebrates	O
.	O

In	O
lymphocyte	O
differentiation	I-protein
,	O
several	I-protein
HMG	B-protein
box	I-protein
proteins	I-protein
play	O
a	I-protein
decisive	O
role	O
.	O

Sox-4	B-protein
is	O
important	O
for	I-protein
very	O
early	O
B-cell	O
differentiation	I-protein
,	O
while	O
TCF-1	B-protein
/	O
LEF-1	I-protein
play	O
a	I-protein
crucial	O
role	O
in	I-protein
early	O
thymocyte	B-protein
development	O
.	O

TCF/LEF	B-protein
proteins	I-protein
have	O
recently	O
been	O
found	O
to	I-protein
constitute	O
a	I-protein
downstream	O
component	O
of	I-protein
the	I-protein
Wingless/Wnt	O
signal	O
transduction	I-protein
pathway	I-protein
.	O

In	O
flies	O
,	O
this	O
pathway	I-protein
controls	O
segment	I-protein
polarity	I-protein
;	O
in	I-protein
Xenopus	I-protein
it	O
controls	O
the	I-protein
definition	O
of	I-protein
the	I-protein
body	O
axis	O
.	O

Deregulation	O
of	I-protein
the	I-protein
pathway	I-protein
occurs	O
in	I-protein
several	I-protein
human	O
tumors	I-protein
.	O

These	O
insights	O
in	I-protein
the	I-protein
molecular	I-protein
events	O
that	O
are	O
involved	I-protein
in	I-protein
TCF/LEF	O
function	I-protein
in	I-protein
these	O
organisms	O
may	O
eventually	O
lead	O
to	I-protein
the	I-protein
understanding	O
of	I-protein
the	I-protein
function	I-protein
of	I-protein
these	O
HMG	B-protein
box	I-protein
proteins	I-protein
in	I-protein
lymphoid	O
development	O

###MEDLINE:98371688

Transcriptional	I-protein
regulation	I-protein
by	I-protein
C/EBP	I-protein
alpha	I-protein
and	I-protein
-beta	I-protein
in	I-protein
the	I-protein
expression	I-protein
of	I-protein
the	I-protein
gene	O
for	I-protein
the	I-protein
MRP14	B-protein
myeloid	I-protein
calcium	I-protein
binding	I-protein
protein	I-protein
.	O

Transcriptional	I-protein
regulation	I-protein
of	I-protein
the	I-protein
gene	O
for	I-protein
the	I-protein
myeloid	B-protein
calcium	I-protein
binding	I-protein
protein	I-protein
,	O
MRP14	B-protein
,	O
was	O
investigated	O
in	I-protein
human	O
monocytic	I-protein
leukemia	O
cell	O
lines	B-protein
.	O

The	O
MRP14	B-protein
gene	O
was	O
not	I-protein
expressed	O
in	I-protein
monoblastic	O
ML-1	B-protein
cells	I-protein
,	O
promonocytic	O
U-937	O
cells	I-protein
,	O
or	I-protein
promyelocytic	O
HL-60	O
cells	I-protein
.	O

On	O
the	I-protein
other	O
hand	O
,	O
the	I-protein
gene	O
was	O
expressed	O
in	I-protein
monocytic	I-protein
THP-1	O
cells	I-protein
and	I-protein
in	I-protein
the	I-protein
HL-60	O
cells	I-protein
treated	O
with	I-protein
1	I-protein
,	O
25-dihydroxyvitamin	O
D3	I-protein
(	O
VD3	O
)	O
.	O

The	O
level	I-protein
of	I-protein
MRP14	B-protein
in	I-protein
VD3-treated	O
HL-60	O
cells	I-protein
was	O
two-fold	O
higher	O
than	I-protein
that	O
in	I-protein
THP-1	O
cells	I-protein
.	O

Among	O
several	I-protein
known	O
transcription	B-protein
factor	I-protein
binding	I-protein
motifs	I-protein
,	O
nuclear	B-protein
protein	I-protein
(	O
s	I-protein
)	O
of	I-protein
VD3-treated	O
HL-60	O
cells	I-protein
and	I-protein
THP-1	O
cells	I-protein
bound	I-protein
to	I-protein
the	I-protein
CCAAT/enhancer	B-protein
binding	I-protein
protein	O
(	O
C/EBP	I-protein
)	O
-binding	I-protein
motif	I-protein
that	O
was	O
located	O
in	I-protein
the	I-protein
upstream	O
region	O
of	I-protein
the	I-protein
MRP14	B-protein
gene	O
(	O
-81	O
)	O
,	O
as	O
evidenced	O
by	I-protein
the	I-protein
competitive	O
gel	O
mobility-shift	O
assay	O
.	O

An	O
antibody	I-protein
for	I-protein
C/EBP	I-protein
alpha	I-protein
super-shifted	O
the	I-protein
nucleoprotein	I-protein
complex	I-protein
in	I-protein
THP-1	O
cells	I-protein
but	O
not	I-protein
in	I-protein
the	I-protein
VD3-treated	O
HL-60	O
cells	I-protein
,	O
whereas	O
an	I-protein
antibody	I-protein
for	I-protein
C/EBP	I-protein
beta	I-protein
blocked	B-protein
the	I-protein
formation	O
of	I-protein
the	I-protein
complex	I-protein
with	I-protein
the	I-protein
nuclear	B-protein
factor	I-protein
of	I-protein
the	I-protein
HL-60	O
cells	I-protein
but	O
not	I-protein
with	I-protein
that	O
of	I-protein
THP-1	O
cells	I-protein
.	O

An	O
anti-C/EBP	B-protein
delta	I-protein
antibody	I-protein
had	O
no	I-protein
effect	O
on	I-protein
the	I-protein
complex	I-protein
in	I-protein
either	O
cell	O
.	O

Thus	O
,	O
it	O
was	O
concluded	O
that	O
C/EBP	I-protein
alpha	I-protein
and	I-protein
-beta	I-protein
were	O
able	O
to	I-protein
bind	O
to	I-protein
the	I-protein
C/EBP	I-protein
motif	I-protein
,	O
and	I-protein
that	O
C/EBP	I-protein
alpha	I-protein
bound	I-protein
to	I-protein
the	I-protein
motif	I-protein
in	I-protein
THP-1	O
cells	I-protein
and	I-protein
C/EBP	I-protein
beta	I-protein
bound	I-protein
to	I-protein
that	O
in	I-protein
the	I-protein
VD3-treated	O
HL-60	O
cells	I-protein
.	O

Furthermore	O
,	O
to	I-protein
examine	O
the	I-protein
transcriptional	O
activity	I-protein
of	I-protein
the	I-protein
C/EBP	I-protein
motif	I-protein
,	O
we	O
transfected	O
several	I-protein
constructed	O
luciferase	O
reporter	O
DNAs	O
into	O
HL-60	O
cells	I-protein
and	I-protein
THP-1	O
cells	I-protein
.	O

The	O
luciferase	O
activity	I-protein
of	I-protein
the	I-protein
C/EBP	I-protein
motif	I-protein
in	I-protein
HL-60	O
cells	I-protein
was	O
increased	I-protein
by	I-protein
VD3	O
treatment	O
.	O

The	O
C/EBP	I-protein
motif	I-protein
in	I-protein
the	I-protein
MRP14	B-protein
gene	O
was	O
confirmed	O
to	I-protein
function	I-protein
as	O
a	I-protein
regulatory	O
region	O
in	I-protein
VD3-treated	O
HL-60	O
cells	I-protein
and	I-protein
THP-1	O
cells	I-protein
by	I-protein
the	I-protein
assay	O
.	O

Since	O
C/EBP	I-protein
beta	I-protein
was	O
also	O
detected	O
in	I-protein
VD3-untreated	O
HL-60	O
cells	I-protein
by	I-protein
immunoblotting	O
,	O
VD3	O
activated	O
C/EBP	I-protein
beta	I-protein
to	I-protein
bind	O
to	I-protein
the	I-protein
motif	I-protein
,	O
probably	O
through	I-protein
post-translational	O
modification	I-protein
.	O

###MEDLINE:98359134

Patients	O
with	I-protein
high-risk	O
myelodysplastic	B-protein
syndrome	I-protein
can	O
have	O
polyclonal	I-protein
or	I-protein
clonal	O
haemopoiesis	O
in	I-protein
complete	O
haematological	O
remission	O
.	O

The	O
clonality	O
of	I-protein
mature	B-protein
peripheral	O
blood-derived	O
myeloid	O
and	I-protein
lymphoid	O
cells	I-protein
and	I-protein
bone	O
marrow	I-protein
haemopoietic	O
progenitors	O
from	I-protein
18	I-protein
females	O
with	I-protein
myelodysplasia	B-protein
(	O
MDS	B-protein
)	O
(	O
five	I-protein
refractory	O
anaemia	O
,	O
RA	B-protein
;	O
one	B-protein
RA	B-protein
with	I-protein
ringed	O
sideroblasts	O
,	O
RARS	B-protein
;	O
three	O
chronic	O
myelomonocytic	O
leukaemia	O
,	O
CMML	O
;	O
four	O
RA	B-protein
with	I-protein
excess	O
of	I-protein
blasts	O
,	O
RAEB	O
;	O
five	I-protein
RAEB	O
in	I-protein
transformation	I-protein
,	O
RAEB-t	O
)	O
was	O
studied	O
by	I-protein
X-chromosome	O
inactivation	O
analysis	O
.	O

Using	O
the	I-protein
human	O
androgen-receptor	O
(	O
HUMARA	B-protein
)	O
assay	O
,	O
we	O
analysed	O
the	I-protein
clonal	O
patterns	O
of	I-protein
highly	O
purified	O
immature	B-protein
CD34+	O
38-	O
and	I-protein
committed	O
CD34+	O
38+	O
marrow-derived	O
progenitors	O
,	O
and	I-protein
CD16+	O
14-	O
granulocytes	O
,	O
CD14+	O
monocytes	O
,	O
CD3+	O
T	O
and	I-protein
CD19+	O
B	O
lymphocytes	O
from	I-protein
peripheral	O
blood	O
.	O

In	O
high-risk	O
patients	O
(	O
RAEB	O
,	O
RAEB-t	O
)	O
,	O
clonality	O
analysis	O
was	O
performed	O
before	O
and	I-protein
after	O
intensive	O
remission-induction	O
treatment	O
.	O

All	O
patients	O
,	O
except	O
one	B-protein
with	I-protein
RA	B-protein
,	O
had	O
predominance	O
of	I-protein
a	I-protein
single	O
clone	I-protein
in	I-protein
their	O
granulocytes	O
and	I-protein
monocytes	O
.	O

The	O
same	O
clonal	O
pattern	I-protein
was	O
found	O
in	I-protein
CD34+	O
progenitor	O
cells	I-protein
.	O

In	O
contrast	O
,	O
CD3+	O
T	O
lymphocytes	O
were	O
polyclonal	I-protein
or	I-protein
oligoclonal	O
in	I-protein
14/18	O
patients	O
.	O

X-chromosome	O
inactivation	O
patterns	O
of	I-protein
CD19+	O
B	O
cells	I-protein
were	O
highly	O
concordant	O
with	I-protein
CD3+	O
T	O
cells	I-protein
except	O
for	I-protein
two	O
patients	O
(	O
one	B-protein
RA	B-protein
,	O
one	B-protein
CMML	O
)	O
with	I-protein
monoclonal	I-protein
B	O
and	I-protein
polyclonal	I-protein
T	O
lymphocytes	O
,	O
therefore	O
suggesting	O
a	I-protein
clonal	O
mutation	I-protein
in	I-protein
a	I-protein
progenitor	O
common	I-protein
to	I-protein
the	I-protein
myeloid	O
and	I-protein
B-lymphoid	O
lineages	O
or	I-protein
the	I-protein
coexistence	O
of	I-protein
MDS	B-protein
and	I-protein
a	I-protein
B-cell	O
disorder	I-protein
in	I-protein
these	O
particular	O
patients	O
.	O

After	O
high-dose	O
non-myeloablative	O
chemotherapy	O
,	O
polyclonal	I-protein
haemopoiesis	O
was	O
reinstalled	O
in	I-protein
the	I-protein
mature	B-protein
myeloid	O
cells	I-protein
and	I-protein
immature	B-protein
and	I-protein
committed	O
marrow	I-protein
progenitors	O
in	I-protein
three	O
of	I-protein
four	O
patients	O
achieving	O
complete	O
haematological	O
remission	O
.	O

Therefore	O
we	O
conclude	O
that	O
most	O
haematological	O
remissions	O
in	I-protein
MDS	B-protein
are	O
associated	I-protein
with	I-protein
restoration	O
of	I-protein
polyclonal	I-protein
haemopoiesis	O
.	O

###MEDLINE:98348376

Prominent	O
sex	O
steroid	O
metabolism	I-protein
in	I-protein
human	O
lymphocytes	O
.	O

Steroid	I-protein
metabolism	I-protein
was	O
investigated	O
in	I-protein
cultured	O
human	O
B-lymphoblastoid	O
cells	I-protein
(	O
B-LCL	O
)	O
,	O
and	I-protein
peripheral	O
blood	O
T	O
and	I-protein
B	O
cells	I-protein
.	O

Gene	I-protein
expression	I-protein
was	O
examined	O
by	I-protein
reverse-transcription	O
polymerase	O
chain	I-protein
reaction	I-protein
amplification	O
(	O
RT-PCR	O
)	O
.	O

Appropriate	O
sized	O
transcripts	I-protein
were	O
detected	O
in	I-protein
both	O
cultured	O
and	I-protein
fresh	O
peripheral	O
lymphocytes	O
for	I-protein
CYP11A	B-protein
,	O
CYP17	B-protein
,	O
HSD11L	B-protein
(	O
11beta-hydroxysteroid	B-protein
dehydrogenase	I-protein
I	I-protein
)	O
,	O
HSD17B1	B-protein
(	O
17beta-hydroxysteroid	B-protein
dehydrogenase	I-protein
type	I-protein
I	I-protein
)	O
and	I-protein
SRD5A1	B-protein
(	O
5alpha-reductase	B-protein
I	I-protein
)	O
.	O

B-LCL	O
,	O
but	O
not	I-protein
T	O
and	I-protein
B	O
cells	I-protein
,	O
expressed	O
CYP11B	B-protein
.	O

There	O
was	O
minimal	O
expression	I-protein
of	I-protein
HSD3B1	B-protein
and	I-protein
HSD3B2	B-protein
(	O
3beta-hydroxysteroid	B-protein
dehydrogenase	I-protein
I	I-protein
and	I-protein
II	I-protein
)	O
in	I-protein
B-LCL	O
and	I-protein
T	O
cells	I-protein
.	O

Transcripts	O
for	I-protein
CYP19	B-protein
and	I-protein
HSD11K	B-protein
were	O
not	I-protein
detected	O
.	O

Corresponding	O
enzymatic	O
activity	I-protein
was	O
detectable	O
only	I-protein
for	I-protein
17-hydroxysteroid	B-protein
dehydrogenase	I-protein
and	I-protein
5alpha-reductase	O
,	O
respectively	O
producing	O
testosterone	O
and	I-protein
5alpha-dihydrotestosterone	O
.	O

Steroid	I-protein
identities	O
were	O
confirmed	O
by	I-protein
gas	O
chromatography/mass	O
spectrometry	O
(	O
GC/MS	O
)	O
.	O

One	I-protein
metabolite	O
thought	O
to	I-protein
be	O
deoxycorticosterone	O
was	O
identified	I-protein
by	I-protein
GC/MS	O
as	O
6alpha-hydroxypregnanolone	O
.	O

It	O
was	O
concluded	O
that	O
sex	O
hormone	I-protein
metabolism	I-protein
,	O
including	I-protein
androgen	O
synthesis	I-protein
,	O
occurs	O
in	I-protein
lymphocytes	O
,	O
and	I-protein
may	O
modulate	O
immune	O
response	I-protein
.	O

###MEDLINE:98342108

Human	O
white	I-protein
blood	O
cells	I-protein
and	I-protein
hair	O
follicles	O
are	O
good	O
sources	O
of	I-protein
mRNA	O
for	I-protein
the	I-protein
pterin	B-protein
carbinolamine	I-protein
dehydratase/dimerization	I-protein
cofactor	I-protein
of	I-protein
HNF1	B-protein
for	I-protein
mutation	I-protein
detection	O
.	O

Pterin	B-protein
carbinolamine	I-protein
dehydratase/dimerization	I-protein
cofactor	I-protein
of	I-protein
HNF1	B-protein
(	O
PCD/DCoH	B-protein
)	O
is	O
a	I-protein
protein	O
that	O
has	O
a	I-protein
dual	O
function	I-protein
.	O

It	O
is	O
a	I-protein
pterin	B-protein
4alpha-carbinolamine	I-protein
dehydratase	I-protein
that	O
is	O
involved	I-protein
in	I-protein
the	I-protein
regeneration	O
of	I-protein
the	I-protein
cofactor	B-protein
tetrahydrobiopterin	I-protein
during	I-protein
the	I-protein
phenylalanine	O
hydroxylase-	O
catalyzed	O
hydroxylation	O
of	I-protein
phenylalanine	O
.	O

In	O
addition	O
,	O
it	O
is	O
the	I-protein
dimerization	I-protein
cofactor	O
of	I-protein
HNF1	B-protein
that	O
is	O
able	O
to	I-protein
activate	O
the	I-protein
transcriptional	O
activity	I-protein
of	I-protein
HNF1	B-protein
.	O

Deficiencies	O
in	I-protein
the	I-protein
gene	O
for	I-protein
this	O
dual	B-protein
functional	I-protein
protein	I-protein
result	O
in	I-protein
hyperphenylalaninemia	O
.	O

Here	O
we	O
report	O
for	I-protein
the	I-protein
first	O
time	O
that	O
the	I-protein
PCD/DCoH	O
mRNA	O
is	O
present	O
in	I-protein
human	O
white	I-protein
blood	O
cells	I-protein
and	I-protein
hair	O
follicles	O
.	O

Taking	O
advantage	O
of	I-protein
this	O
finding	O
,	O
a	I-protein
sensitive	I-protein
,	O
rapid	O
and	I-protein
convenient	O
method	O
for	I-protein
screening	O
mutations	I-protein
occurring	O
in	I-protein
the	I-protein
coding	I-protein
region	O
of	I-protein
this	O
gene	O
has	O
been	O
described	O
.	O

Copyright	O
1998	O
Academic	O
Press	O
.	O

###MEDLINE:98325028

Biochemical	O
characterization	O
of	I-protein
the	I-protein
NF-Y	B-protein
transcription	I-protein
factor	I-protein
complex	I-protein
during	I-protein
B	O
lymphocyte	O
development	O
.	O

The	O
transcription	B-protein
factor	I-protein
,	O
NF-Y	B-protein
,	O
plays	O
a	I-protein
critical	I-protein
role	O
in	I-protein
tissue-specific	O
major	O
histocompatibility	O
complex	I-protein
class	O
II	I-protein
gene	O
transcription	O
.	O

In	O
this	O
report	O
the	I-protein
biochemical	O
properties	O
of	I-protein
the	I-protein
heterotrimeric	B-protein
NF-Y	I-protein
complex	I-protein
have	O
been	O
characterized	O
during	I-protein
stage-specific	O
B-cell	O
development	O
,	O
and	I-protein
in	I-protein
several	I-protein
class	O
II-	O
mutant	O
B-cell	O
lines	B-protein
,	O
which	O
represent	O
distinct	O
bare	O
lymphocyte	O
syndrome	I-protein
class	O
II	I-protein
genetic	O
complementation	I-protein
groups	O
.	O

The	O
NF-Y	B-protein
complex	I-protein
derived	I-protein
from	I-protein
class	O
II+	O
mature	B-protein
B-cells	I-protein
bound	I-protein
with	I-protein
high	O
affinity	I-protein
to	I-protein
anion	I-protein
exchangers	I-protein
,	O
and	I-protein
eluted	O
as	O
an	I-protein
intact	B-protein
trimeric	I-protein
complex	I-protein
,	O
whereas	O
,	O
NF-Y	B-protein
derived	I-protein
from	I-protein
class	O
II-	O
plasma	O
B-cells	I-protein
,	O
and	I-protein
from	I-protein
bare	O
lymphocyte	O
syndrome	I-protein
group	I-protein
II	I-protein
cell	O
lines	B-protein
,	O
RJ2.2.5	O
and	I-protein
RM3	O
,	O
dissociated	O
into	O
discrete	O
NF-YA	B-protein
and	I-protein
NF-YB	B-protein
:	O
C	I-protein
subunit	I-protein
fractions	I-protein
.	O

Recombination	O
of	I-protein
the	I-protein
MPC11	B-protein
plasma	I-protein
B-cell	I-protein
derived	I-protein
NF-Y	I-protein
A	I-protein
:	O
B	I-protein
:	O
C	I-protein
complex	I-protein
with	I-protein
the	I-protein
low	O
molecular	I-protein
mass	I-protein
protein	O
fraction	O
,	O
NF-Y-associated	B-protein
factors	I-protein
(	O
YAFs	O
)	O
,	O
derived	I-protein
from	I-protein
mature	B-protein
A20	O
B-cell	O
nuclei	O
,	O
conferred	O
high	O
affinity	I-protein
anion	I-protein
exchange	I-protein
binding	I-protein
to	I-protein
NF-Y	B-protein
as	O
an	I-protein
intact	B-protein
trimeric	I-protein
complex	I-protein
.	O

Recombination	O
of	I-protein
the	I-protein
native	B-protein
NF-YA	B-protein
:	O
B	I-protein
:	O
C	I-protein
complex	I-protein
with	I-protein
the	I-protein
transcriptional	B-protein
cofactor	I-protein
,	O
PC4	B-protein
,	O
likewise	O
conferred	O
high	B-protein
affinity	I-protein
NF-Y	I-protein
binding	I-protein
to	I-protein
anion	I-protein
exchangers	I-protein
,	O
and	I-protein
stabilized	O
NF-Y	B-protein
interaction	I-protein
with	I-protein
CCAAT-box	O
DNA	O
motifs	I-protein
in	I-protein
vitro	O
.	O

Interaction	O
between	O
PC4	B-protein
and	I-protein
NF-Y	B-protein
was	O
mapped	O
to	I-protein
the	I-protein
C-terminal	B-protein
region	I-protein
of	I-protein
PC4	B-protein
,	O
and	I-protein
the	I-protein
subunit	I-protein
interaction	I-protein
subdomain	I-protein
of	I-protein
the	I-protein
highly	B-protein
conserved	I-protein
DNA	I-protein
binding-subunit	I-protein
interaction	I-protein
domain	I-protein
(	O
DBD	B-protein
)	O
of	I-protein
NF-YA	B-protein
.	O

These	O
results	O
suggest	O
that	O
in	I-protein
class	O
II+	O
mature	B-protein
B-cells	I-protein
NF-Y	B-protein
is	O
associated	I-protein
with	I-protein
the	I-protein
protein	O
cofactor	O
,	O
PC4	B-protein
,	O
which	O
may	O
play	O
an	I-protein
important	O
role	O
in	I-protein
NF-Y-mediated	O
transcriptional	O
control	I-protein
of	I-protein
class	O
II	I-protein
genes	I-protein
.	O

###MEDLINE:98318219

Arrest	O
of	I-protein
B	O
lymphocyte	O
terminal	O
differentiation	I-protein
by	I-protein
CD40	B-protein
signaling	O
:	O
mechanism	O
for	I-protein
lack	O
of	I-protein
antibody-secreting	O
cells	I-protein
in	I-protein
germinal	B-protein
centers	O
.	O

Despite	O
extensive	O
research	O
,	O
the	I-protein
role	O
of	I-protein
CD40	B-protein
signaling	O
in	I-protein
B	O
cell	O
terminal	O
differentiation	I-protein
remains	O
controversial	O
.	O

Here	O
we	O
show	O
that	O
CD40	B-protein
engagement	O
arrests	O
B	O
cell	O
differentiation	I-protein
prior	O
to	I-protein
plasma	O
cell	O
formation	O
.	O

This	O
arrest	I-protein
is	O
manifested	O
at	I-protein
a	I-protein
molecular	I-protein
level	I-protein
as	O
a	I-protein
reduction	I-protein
in	I-protein
mRNA	O
levels	I-protein
of	I-protein
secretory	O
immunoglobulin	O
gene	O
products	O
such	O
as	O
mu	I-protein
(	O
s	I-protein
)	O
and	I-protein
J	I-protein
chain	I-protein
as	O
well	O
as	O
the	I-protein
loss	O
of	I-protein
the	I-protein
transcriptional	B-protein
regulator	I-protein
BLIMP-1	I-protein
.	O

Furthermore	O
,	O
the	I-protein
inhibition	O
of	I-protein
B	O
cell	O
differentiation	I-protein
by	I-protein
CD40	B-protein
engagement	O
could	O
not	I-protein
be	O
overcome	O
by	I-protein
either	O
mitogens	B-protein
or	I-protein
cytokines	B-protein
,	O
but	O
could	O
be	O
reversed	O
by	I-protein
antibodies	I-protein
that	O
interfere	O
with	I-protein
the	I-protein
CD40	B-protein
/	O
gp39	B-protein
interaction	I-protein
.	O

These	O
data	O
suggest	O
that	O
secretory	O
immunoglobulin	O
is	O
not	I-protein
produced	O
by	I-protein
B	O
cells	I-protein
that	O
are	O
actively	O
engaged	O
by	I-protein
gp39-expressing	O
T	O
cells	I-protein
.	O

###MEDLINE:98308097

A	O
positively	O
charged	O
alpha-lipoic	O
acid	O
analogue	O
with	I-protein
increased	I-protein
cellular	O
uptake	I-protein
and	I-protein
more	O
potent	O
immunomodulatory	O
activity	I-protein
.	O

alpha-Lipoic	O
acid	O
(	O
LA	O
)	O
is	O
taken	O
up	O
by	I-protein
cells	I-protein
and	I-protein
reduced	O
to	I-protein
its	O
potent	O
dithiol	O
form	I-protein
,	O
dihydrolipoate	O
(	O
DHLA	O
)	O
,	O
much	O
of	I-protein
which	O
is	O
rapidly	I-protein
effluxed	O
out	O
from	I-protein
cells	I-protein
.	O

To	O
improve	O
retention	I-protein
in	I-protein
cells	I-protein
,	O
the	I-protein
LA	O
molecule	I-protein
was	O
modified	O
to	I-protein
confer	O
a	I-protein
positive	I-protein
charge	I-protein
at	I-protein
physiological	O
pH	O
.	O

N	O
,	O
N-dimethyl	O
,	O
N'-2-amidoethyl-lipoate	O
was	O
synthesized	O
.	O

The	O
protonated	O
form	I-protein
of	I-protein
the	I-protein
new	I-protein
molecule	I-protein
is	O
referred	O
to	I-protein
as	O
LA-Plus	O
.	O

The	O
uptake	I-protein
of	I-protein
LA-Plus	O
by	I-protein
human	O
Wurzburg	O
T	O
cells	I-protein
was	O
higher	O
compared	O
to	I-protein
that	O
of	I-protein
LA	O
.	O

Several-fold	O
higher	O
amounts	O
of	I-protein
DHLA-Plus	O
,	O
the	I-protein
corresponding	O
reduced	O
form	I-protein
of	I-protein
LA-Plus	O
,	O
were	O
detected	O
in	I-protein
LA-Plus	O
treated	O
cells	I-protein
compared	O
to	I-protein
the	I-protein
amount	O
of	I-protein
DHLA	O
found	O
in	I-protein
cells	I-protein
treated	O
with	I-protein
LA	O
.	O

At	O
100	I-protein
microM	O
,	O
LA	O
did	O
not	I-protein
but	O
LA-Plus	O
inhibited	O
H2O2	O
induced	I-protein
NF-kappaB	B-protein
activation	I-protein
and	I-protein
NF-kappaB	B-protein
directed	I-protein
IL-2	B-protein
receptor	I-protein
expression	I-protein
.	O

Both	O
LA	O
and	I-protein
LA-Plus	O
synergised	O
with	I-protein
selenium	B-protein
in	I-protein
inhibiting	I-protein
H2O2	O
induced	I-protein
NF-kappaB	B-protein
activation	I-protein
.	O

At	O
150	I-protein
microM	O
LA-Plus	O
,	O
but	O
not	I-protein
LA	O
,	O
inhibited	O
TNFalpha	B-protein
induced	I-protein
NF-kappaB	B-protein
activation	I-protein
.	O

At	O
5	O
microM	O
LA-Plus	O
,	O
but	O
not	I-protein
LA	O
,	O
protected	O
against	I-protein
both	O
spontaneous	O
and	I-protein
etoposide	B-protein
induced	I-protein
apoptosis	O
in	I-protein
rat	I-protein
thymocytes	O
.	O

LA-Plus	O
is	O
thus	O
an	I-protein
improved	O
form	I-protein
of	I-protein
LA	O
with	I-protein
increased	I-protein
therapeutic	O
potential	I-protein
.	O

Copyright	O
1998	O
Academic	O
Press	O
.	O

###MEDLINE:98295734

Carrier	O
identification	O
in	I-protein
X-linked	O
immunodeficiency	I-protein
diseases	O
.	O

OBJECTIVE	O
:	O
Carrier	O
identification	O
in	I-protein
X-linked	O
immunodeficiency	I-protein
disorders	O
can	O
be	O
based	O
on	I-protein
the	I-protein
demonstration	O
of	I-protein
non-random	O
X	O
inactivation	O
(	O
NRXI	O
)	O
in	I-protein
affected	O
blood	O
cell	O
lineages	O
when	O
growth	O
is	O
impaired	O
in	I-protein
cells	I-protein
expressing	O
the	I-protein
abnormal	I-protein
gene	O
.	O

We	O
examined	O
the	I-protein
utility	O
of	I-protein
seeking	O
evidence	O
of	I-protein
NRXI	O
to	I-protein
test	O
the	I-protein
carrier	I-protein
status	I-protein
of	I-protein
women	O
in	I-protein
families	O
affected	O
by	I-protein
X-linked	O
severe	I-protein
combined	O
immunodeficiency	I-protein
(	O
XSCID	O
)	O
and	I-protein
X-linked	O
hypogammaglobulinaemia	O
(	O
XLH	B-protein
)	O
,	O
to	I-protein
identify	O
as	O
carriers	O
the	I-protein
mothers	O
of	I-protein
boys	O
with	I-protein
SCID	O
or	I-protein
hypogammaglobulinaemia	O
whose	O
phenotype	O
suggested	O
X-linkage	O
and	I-protein
to	I-protein
infer	O
X-linkage	O
in	I-protein
boys	O
with	I-protein
SCID	O
or	I-protein
hypogammaglobulinaemia	O
whose	O
disease	I-protein
was	O
not	I-protein
clearly	O
X-linked	O
on	I-protein
the	I-protein
basis	O
either	O
of	I-protein
family	O
history	O
or	I-protein
clinical	I-protein
and	I-protein
immunological	O
characteristics	O
.	O

METHODOLOGY	O
:	O
A	O
polymerase	O
chain	I-protein
reaction-based	O
method	O
was	O
used	O
to	I-protein
amplify	O
a	I-protein
polymorphic	I-protein
CAG	O
repeat	I-protein
in	I-protein
the	I-protein
first	O
exon	O
of	I-protein
the	I-protein
androgen	O
receptor	O
gene	O
after	O
selective	O
digestion	O
of	I-protein
the	I-protein
active	O
X	O
chromosome	O
with	I-protein
a	I-protein
methylation-sensitive	B-protein
enzyme	I-protein
,	O
HpaII	B-protein
to	I-protein
distinguish	O
between	O
the	I-protein
paternal	O
and	I-protein
maternal	B-protein
alleles	O
and	I-protein
to	I-protein
identify	O
their	O
methylation	O
status	I-protein
.	O

RESULTS	O
:	O
Heterozygosity	O
was	O
found	O
in	I-protein
24	I-protein
of	I-protein
31	I-protein
female	I-protein
subjects	O
(	O
77	I-protein
%	O
)	O
.	O

As	O
anticipated	O
,	O
NRXI	O
could	O
be	O
demonstrated	O
in	I-protein
all	O
lymphoid	O
cells	I-protein
studied	O
from	I-protein
obligate	O
carriers	O
of	I-protein
XSCID	O
and	I-protein
an	I-protein
obligate	O
carrier	I-protein
of	I-protein
XLH	B-protein
but	O
not	I-protein
on	I-protein
a	I-protein
carrier	I-protein
of	I-protein
X-linked	O
immunodeficiency	I-protein
with	I-protein
hyper-IgM	I-protein
.	O

The	O
finding	O
of	I-protein
NRXI	O
in	I-protein
the	I-protein
mother	O
of	I-protein
a	I-protein
boy	O
with	I-protein
a	I-protein
SCID	O
variant	I-protein
showed	O
her	O
to	I-protein
be	O
a	I-protein
carrier	I-protein
of	I-protein
XSCID	O
and	I-protein
establishes	O
that	O
her	O
son	B-protein
has	O
XSCID	O
,	O
not	I-protein
otherwise	O
evident	O
from	I-protein
available	O
data	O
.	O

CONCLUSIONS	O
:	O
This	O
PCR	O
assay	O
provides	O
a	I-protein
rapid	O
method	O
for	I-protein
carrier	I-protein
detection	O
of	I-protein
X-linked	O
immunodeficiencies	O
,	O
and	I-protein
has	O
allowed	O
us	O
to	I-protein
expand	O
the	I-protein
phenotype	O
of	I-protein
XSCID	O

###MEDLINE:98245000

Leukocyte-endothelial	O
interaction	I-protein
is	O
augmented	O
by	I-protein
high	O
glucose	O
concentrations	O
and	I-protein
hyperglycemia	O
in	I-protein
a	I-protein
NF-kB-dependent	O
fashion	O
.	O

We	O
addressed	O
the	I-protein
role	O
of	I-protein
hyperglycemia	O
in	I-protein
leukocyte-endothelium	O
interaction	I-protein
under	O
flow	O
conditions	O
by	I-protein
exposing	O
human	O
umbilical	O
vein	O
endothelial	O
cells	I-protein
for	I-protein
24	I-protein
h	I-protein
to	I-protein
normal	O
(	O
5	O
mM	O
)	O
,	O
high	O
concentration	I-protein
of	I-protein
glucose	O
(	O
30	I-protein
mM	O
)	O
,	O
advanced	O
glycosylation	O
end	I-protein
product-albumin	O
(	O
100	I-protein
microg/ml	O
)	O
,	O
or	I-protein
hyperglycemic	O
(	O
174-316	O
mg/dl	O
)	O
sera	O
from	I-protein
patients	O
with	I-protein
diabetes	O
and	I-protein
abnormal	I-protein
hemoglobin	O
A1c	O
(	O
8.1+/-1.4	O
%	O
)	O
.	O

At	O
the	I-protein
end	I-protein
of	I-protein
incubation	O
endothelial	O
cells	I-protein
were	O
perfused	O
with	I-protein
total	O
leukocyte	O
suspension	O
in	I-protein
a	I-protein
parallel	O
plate	O
flow	O
chamber	O
under	O
laminar	O
flow	O
(	O
1.5	I-protein
dyn/cm2	O
)	O
.	O

Rolling	O
and	I-protein
adherent	O
cells	I-protein
were	O
evaluated	O
by	I-protein
digital	I-protein
image	O
processing	O
.	O

Results	O
showed	O
that	O
30	I-protein
mM	O
glucose	O
significantly	O
(	O
P	O
<	O
0.01	O
)	O
increased	I-protein
the	I-protein
number	I-protein
of	I-protein
adherent	O
leukocytes	O
to	I-protein
endothelial	O
cells	I-protein
in	I-protein
respect	O
to	I-protein
control	I-protein
(	O
5	O
mM	O
glucose	O
;	O
151+/-19	O
versus	O
33+/-8	O
cells/mm2	O
)	O
.	O

A	O
similar	O
response	I-protein
was	O
induced	I-protein
by	I-protein
endothelial	O
stimulation	I-protein
with	I-protein
IL-1beta	B-protein
,	O
here	O
used	O
as	O
positive	I-protein
control	I-protein
(	O
195+/-20	O
cells/mm2	O
)	O
.	O

The	O
number	I-protein
of	I-protein
rolling	O
cells	I-protein
on	I-protein
endothelial	O
surface	O
was	O
not	I-protein
affected	O
by	I-protein
high	O
glucose	O
level	I-protein
.	O

Stable	O
adhesion	O
of	I-protein
leukocytes	O
to	I-protein
glucose-treated	O
as	O
well	O
as	O
to	I-protein
IL-1beta-stimulated	O
endothelial	O
cells	I-protein
was	O
preceded	O
by	I-protein
short	O
interaction	I-protein
of	I-protein
leukocytes	O
with	I-protein
the	I-protein
endothelial	O
surface	O
.	O

The	O
distance	O
travelled	O
by	I-protein
leukocytes	O
before	O
arrest	I-protein
on	I-protein
30	I-protein
mM	O
glucose	O
,	O
or	I-protein
on	I-protein
IL-1beta-treated	O
endothelial	O
cells	I-protein
,	O
was	O
significantly	O
(	O
P	O
<	O
0.01	O
)	O
higher	O
than	I-protein
that	O
observed	O
for	I-protein
leukocytes	O
adhering	O
on	I-protein
control	I-protein
endothelium	O
(	O
30	I-protein
mM	O
glucose	O
:	O
76.7+/-3.5	O
;	O
IL1beta	O
:	O
69.7+/-4	O
versus	O
5	O
mM	O
glucose	O
:	O
21.5+/-5	O
microm	O
)	O
.	O

Functional	O
blocking	O
of	I-protein
E-selectin	B-protein
,	O
intercellular	B-protein
cell	I-protein
adhesion	I-protein
molecule-1	I-protein
,	O
and	I-protein
vascular	B-protein
cell	I-protein
adhesion	I-protein
molecule-1	I-protein
on	I-protein
endothelial	O
cells	I-protein
with	I-protein
the	I-protein
corresponding	O
mouse	I-protein
mAb	I-protein
significantly	O
inhibited	O
glucose-induced	O
increase	O
in	I-protein
leukocyte	O
adhesion	O
(	O
67+/-16	O
,	O
83+/-12	O
,	O
62+/-8	O
versus	O
144+/-21	O
cells/	O
mm2	O
)	O
.	O

Confocal	O
fluorescence	O
microscopy	O
studies	O
showed	O
that	O
30	I-protein
mM	O
glucose	O
induced	I-protein
an	I-protein
increase	O
in	I-protein
endothelial	O
surface	O
expression	I-protein
of	I-protein
E-selectin	B-protein
,	O
intercellular	B-protein
cell	I-protein
adhesion	I-protein
molecule-1	I-protein
,	O
and	I-protein
vascular	B-protein
cell	I-protein
adhesion	I-protein
molecule-1	I-protein
.	O

Electrophoretic	O
mobility	I-protein
shift	O
assay	O
of	I-protein
nuclear	O
extracts	O
of	I-protein
human	O
umbilical	O
vein	O
endothelial	O
cells	I-protein
(	O
HUVEC	O
)	O
exposed	O
for	I-protein
1	I-protein
h	I-protein
to	I-protein
30	I-protein
mM	O
glucose	O
revealed	O
an	I-protein
intense	O
NF-kB	B-protein
activation	I-protein
.	O

Treatment	O
of	I-protein
HUVEC	O
exposed	O
to	I-protein
high	O
glucose	O
with	I-protein
the	I-protein
NF-kB	B-protein
inhibitors	I-protein
pyrrolidinedithiocarbamate	O
(	O
100	I-protein
microM	O
)	O
and	I-protein
tosyl-phe-chloromethylketone	O
(	O
25	I-protein
microM	O
)	O
significantly	O
reduced	O
(	O
P	O
<	O
0.05	O
)	O
leukocyte	O
adhesion	O
in	I-protein
respect	O
to	I-protein
HUVEC	O
treated	O
with	I-protein
glucose	O
alone	O
.	O

A	O
significant	O
(	O
P	O
<	O
0.01	O
)	O
inhibitory	O
effect	O
on	I-protein
glucose-induced	O
leukocyte	O
adhesion	O
was	O
observed	O
after	O
blocking	O
protein	B-protein
kinase	I-protein
C	I-protein
activity	I-protein
with	I-protein
staurosporine	O
(	O
5	O
nM	O
)	O
.	O

When	O
HUVEC	O
were	O
treated	O
with	I-protein
specific	I-protein
antisense	O
oligodesoxynucleotides	O
against	I-protein
PKCalpha	B-protein
and	I-protein
PKCepsilon	I-protein
isoforms	I-protein
before	O
the	I-protein
addition	O
of	I-protein
30	I-protein
mM	O
glucose	O
,	O
a	I-protein
significant	O
(	O
P	O
<	O
0.05	O
)	O
reduction	I-protein
in	I-protein
the	I-protein
adhesion	O
was	O
also	O
seen	O
.	O

Advanced	O
glycosylation	O
end	I-protein
product-albumin	B-protein
significantly	O
increased	I-protein
the	I-protein
number	I-protein
of	I-protein
adhering	O
leukocytes	O
in	I-protein
respect	O
to	I-protein
native	B-protein
albumin	I-protein
used	O
as	O
control	I-protein
(	O
110+/-16	O
versus	O
66+/-7	O
,	O
P	O
<	O
0.01	O
)	O
.	O

Sera	O
from	I-protein
diabetic	B-protein
patients	O
significantly	O
(	O
P	O
<	O
0.01	O
)	O
enhanced	I-protein
leukocyte	O
adhesion	O
as	O
compared	O
with	I-protein
controls	O
,	O
despite	O
normal	O
levels	I-protein
of	I-protein
IL-1beta	B-protein
and	I-protein
TNFalpha	B-protein
in	I-protein
these	O
sera	O
.	O

These	O
data	O
indicate	O
that	O
high	O
glucose	O
concentration	I-protein
and	I-protein
hyperglycemia	O
promote	O
leukocyte	O
adhesion	O
to	I-protein
the	I-protein
endothelium	O
through	I-protein
upregulation	O
of	I-protein
cell	O
surface	O
expression	I-protein
of	I-protein
adhesive	O
proteins	I-protein
,	O
possibly	O
depending	O
on	I-protein
NF-kB	B-protein
activation	I-protein
.	O

###MEDLINE:98282479

Ikaros	I-protein
in	I-protein
hemopoietic	B-protein
lineage	I-protein
determination	I-protein
and	I-protein
homeostasis	I-protein
.	O

Studies	O
on	I-protein
the	I-protein
molecular	I-protein
mechanisms	O
that	O
control	I-protein
hemopoietic	B-protein
differentiation	I-protein
have	O
focused	O
on	I-protein
signaling	O
cascades	O
and	I-protein
nuclear	O
effectors	O
that	O
drive	O
this	O
complex	I-protein
developmental	O
system	I-protein
in	I-protein
a	I-protein
regulated	O
fashion	O
.	O

Here	O
we	O
review	O
the	I-protein
role	O
of	I-protein
Ikaros	I-protein
,	O
the	I-protein
founding	O
member	I-protein
of	I-protein
a	I-protein
unique	I-protein
family	O
of	I-protein
zinc	B-protein
finger	I-protein
transcription	I-protein
factors	I-protein
in	I-protein
this	O
developmental	O
process	O
.	O

Studies	O
on	I-protein
an	I-protein
Ikaros	I-protein
null	O
mutation	I-protein
have	O
revealed	O
an	I-protein
essential	O
role	O
for	I-protein
this	O
factor	I-protein
in	I-protein
lymphoid	O
cell	O
fate	O
determination	I-protein
and	I-protein
at	I-protein
subsequent	O
branch	O
points	O
of	I-protein
the	I-protein
T	O
cell	O
differentiation	I-protein
pathway	I-protein
.	O

Differences	O
in	I-protein
the	I-protein
phenotypes	O
of	I-protein
a	I-protein
null	O
and	I-protein
a	I-protein
dominant	I-protein
negative	O
(	O
DN	O
)	O
Ikaros	I-protein
mutation	I-protein
provide	O
insight	O
into	O
a	I-protein
regulatory	O
network	I-protein
through	I-protein
which	O
Ikaros	I-protein
proteins	I-protein
exert	O
their	O
effects	O
in	I-protein
development	O
.	O

In	O
addition	O
a	I-protein
comparative	O
analysis	O
of	I-protein
the	I-protein
hemopoietic	B-protein
stem	I-protein
cell	O
and	I-protein
precursor	I-protein
compartment	I-protein
resulting	O
from	I-protein
the	I-protein
two	O
Ikaros	I-protein
mutations	I-protein
reveals	O
a	I-protein
profound	O
yet	O
not	I-protein
absolute	O
requirement	O
for	I-protein
Ikaros	I-protein

###MEDLINE:98372761

Induction	O
of	I-protein
early	B-protein
B	I-protein
cell	I-protein
factor	I-protein
(	O
EBF	B-protein
)	O
and	I-protein
multiple	O
B	O
lineage	I-protein
genes	I-protein
by	I-protein
the	I-protein
basic	B-protein
helix-loop-helix	I-protein
transcription	I-protein
factor	I-protein
E12	B-protein
.	O

The	O
transcription	B-protein
factors	I-protein
encoded	O
by	I-protein
the	I-protein
E2A	B-protein
and	I-protein
early	O
B	O
cell	O
factor	I-protein
(	O
EBF	B-protein
)	O
genes	I-protein
are	O
required	O
for	I-protein
the	I-protein
proper	O
development	O
of	I-protein
B	O
lymphocytes	O
.	O

However	O
,	O
the	I-protein
absence	I-protein
of	I-protein
B	O
lineage	I-protein
cells	I-protein
in	I-protein
E2A-	O
and	I-protein
EBF-deficient	O
mice	O
has	O
made	O
it	O
difficult	O
to	I-protein
determine	O
the	I-protein
function	I-protein
or	I-protein
relationship	O
between	O
these	O
proteins	I-protein
.	O

We	O
report	O
the	I-protein
identification	O
of	I-protein
a	I-protein
novel	O
model	I-protein
system	I-protein
in	I-protein
which	O
the	I-protein
role	O
of	I-protein
E2A	B-protein
and	I-protein
EBF	B-protein
in	I-protein
the	I-protein
regulation	I-protein
of	I-protein
multiple	O
B	O
lineage	I-protein
traits	O
can	O
be	O
studied	O
.	O

We	O
found	O
that	O
the	I-protein
conversion	I-protein
of	I-protein
70Z/3	O
pre-B	B-protein
lymphocytes	O
to	I-protein
cells	I-protein
with	I-protein
a	I-protein
macrophage-like	O
phenotype	O
is	O
associated	I-protein
with	I-protein
the	I-protein
loss	O
of	I-protein
E2A	B-protein
and	I-protein
EBF	B-protein
.	O

Moreover	O
,	O
we	O
show	O
that	O
ectopic	I-protein
expression	I-protein
of	I-protein
the	I-protein
E2A	O
protein	O
E12	B-protein
in	I-protein
this	O
macrophage	O
line	I-protein
results	O
in	I-protein
the	I-protein
induction	I-protein
of	I-protein
many	O
B	O
lineage	I-protein
genes	I-protein
,	O
including	I-protein
EBF	B-protein
,	O
IL7Ralpha	B-protein
,	O
lambda5	B-protein
,	O
and	I-protein
Rag-1	O
,	O
and	I-protein
the	I-protein
ability	O
to	I-protein
induce	O
kappa	I-protein
light	I-protein
chain	I-protein
in	I-protein
response	I-protein
to	I-protein
mitogen	O
.	O

Activation	O
of	I-protein
EBF	B-protein
may	O
be	O
one	B-protein
of	I-protein
the	I-protein
critical	I-protein
functions	O
of	I-protein
E12	B-protein
in	I-protein
regulating	O
the	I-protein
B	O
lineage	I-protein
phenotype	O
since	O
expression	I-protein
of	I-protein
EBF	B-protein
alone	O
leads	O
to	I-protein
the	I-protein
activation	I-protein
of	I-protein
a	I-protein
subset	I-protein
of	I-protein
E12	B-protein
-inducible	O
traits	O
.	O

Our	O
data	O
demonstrate	O
that	O
,	O
in	I-protein
the	I-protein
context	O
of	I-protein
this	O
macrophage	O
line	I-protein
,	O
E12	B-protein
induces	O
expression	I-protein
of	I-protein
EBF	B-protein
and	I-protein
together	O
these	O
transcription	B-protein
factors	I-protein
coordinately	O
regulate	O
numerous	O
B	O
lineage-associated	O
genes	I-protein
.	O

###MEDLINE:98361999

Activation-induced	O
down-regulation	O
of	I-protein
retinoid	B-protein
receptor	I-protein
RXRalpha	I-protein
expression	I-protein
in	I-protein
human	O
T	O
lymphocytes	O
.	O

Role	O
of	I-protein
cell	O
cycle	I-protein
regulation	I-protein
.	O

A	O
5.4-kilobase	O
mRNA	O
,	O
the	I-protein
expression	I-protein
of	I-protein
which	O
is	O
down-regulated	I-protein
after	O
treatment	O
of	I-protein
human	O
peripheral	O
blood	O
mononuclear	O
cells	I-protein
(	O
PBMCs	O
)	O
with	I-protein
various	O
T	O
cell-activating	O
agents	O
,	O
was	O
isolated	I-protein
using	O
an	I-protein
mRNA	O
differential	O
display	O
method	O
.	O

Nucleotide	O
sequence	I-protein
analysis	O
identified	I-protein
the	I-protein
5	O
'	O
end	I-protein
of	I-protein
this	O
RNA	O
as	O
human	O
retinoid	B-protein
receptor	O
RXRalpha	O
mRNA	O
.	O

Here	O
,	O
we	O
report	O
the	I-protein
nucleotide	O
sequence	I-protein
of	I-protein
3.6	O
kilobases	O
of	I-protein
this	O
RNA	O
,	O
which	O
represents	O
the	I-protein
3	O
'	O
end	I-protein
of	I-protein
RXRalpha	O
mRNA	O
,	O
the	I-protein
sequence	I-protein
of	I-protein
which	O
has	O
not	I-protein
been	O
previously	O
described	O
.	O

Activated	I-protein
PBMCs	O
also	O
expressed	O
lower	I-protein
levels	I-protein
of	I-protein
RXRalpha	B-protein
protein	I-protein
,	O
and	I-protein
a	I-protein
DNA	O
binding	I-protein
assay	O
showed	O
that	O
the	I-protein
activation-induced	B-protein
loss	O
of	I-protein
RXRalpha	O
mRNA	O
and	I-protein
protein	O
expression	I-protein
correlated	O
with	I-protein
the	I-protein
loss	O
of	I-protein
DNA	O
binding	I-protein
activity	I-protein
of	I-protein
this	O
protein	O
.	O

We	O
present	O
evidence	O
that	O
the	I-protein
transition	O
from	I-protein
G0/G1	I-protein
to	I-protein
S	I-protein
phase	I-protein
of	I-protein
the	I-protein
cell	O
cycle	I-protein
results	O
in	I-protein
the	I-protein
down-regulation	O
of	I-protein
RXRalpha	B-protein
expression	I-protein
and	I-protein
that	O
cell	O
cycle	I-protein
inhibitors	I-protein
,	O
which	O
block	O
the	I-protein
cells	I-protein
in	I-protein
G1	O
phase	I-protein
,	O
prevent	O
this	O
down-regulation	O
.	O

The	O
decrease	O
in	I-protein
the	I-protein
levels	I-protein
of	I-protein
RXRalpha	O
mRNA	O
was	O
found	O
to	I-protein
be	O
regulated	O
at	I-protein
the	I-protein
post-transcriptional	O
level	I-protein
and	I-protein
involved	I-protein
new	I-protein
protein	O
synthesis	I-protein
.	O

These	O
observations	O
indicate	O
that	O
the	I-protein
levels	I-protein
of	I-protein
RXRalpha	B-protein
expression	I-protein
in	I-protein
T	O
lymphocytes	O
are	O
coupled	I-protein
to	I-protein
cell	O
cycle	I-protein
progression	I-protein
,	O
and	I-protein
there	O
is	O
tight	O
regulatory	O
control	I-protein
of	I-protein
RXRalpha	B-protein
expression	I-protein
during	I-protein
the	I-protein
transition	O
from	I-protein
G0/G1	I-protein
to	I-protein
S	I-protein
phase	I-protein
of	I-protein
the	I-protein
cell	O
cycle	I-protein
.	O

###MEDLINE:98348903

Epidemiology	O
and	I-protein
pathogenesis	O
of	I-protein
AIDS-related	O
lymphomas	I-protein
.	O

Among	O
patients	O
with	I-protein
congenital	O
and	I-protein
acquired	O
immunodeficiencies	O
,	O
non-Hodgkin	O
's	I-protein
lymphoma	I-protein
(	O
NHLs	O
)	O
are	O
the	I-protein
most	O
common	I-protein
tumors	I-protein
of	I-protein
the	I-protein
immune	O
system	I-protein
.	O

In	O
the	I-protein
setting	O
of	I-protein
human	O
immunodeficiency	I-protein
virus	I-protein
(	O
HIV	I-protein
)	O
infection	I-protein
,	O
as	O
many	O
as	O
10	I-protein
%	O
to	I-protein
20	I-protein
%	O
of	I-protein
people	O
ultimately	O
developed	O
NHLs	O
.	O

These	O
tumors	I-protein
are	O
clinically	O
aggressive	I-protein
,	O
frequently	B-protein
involve	O
extranodal	O
sites	I-protein
,	O
and	I-protein
often	O
exhibit	O
unique	I-protein
features	I-protein
that	O
distinguish	O
them	O
from	I-protein
NHL	B-protein
arising	O
in	I-protein
individuals	O
with	I-protein
other	O
forms	I-protein
of	I-protein
immunosuppression	O
.	O

Important	O
in	I-protein
the	I-protein
development	O
of	I-protein
HIV-associated	O
NHL	B-protein
are	O
cytokines	B-protein
and	I-protein
other	O
factors	I-protein
that	O
induce	O
B-cell	O
proliferation	I-protein
and	I-protein
increase	O
the	I-protein
likelihood	O
of	I-protein
mutations	I-protein
of	I-protein
c-myc	B-protein
,	O
bcl-6	O
,	O
and	I-protein
other	O
tumor-suppressor	O
genes	I-protein
with	I-protein
carcinogenic	O
potential	I-protein
.	O

Specific	B-protein
forms	I-protein
of	I-protein
HIV-associated	O
NHL	B-protein
are	O
linked	I-protein
to	I-protein
expression	I-protein
of	I-protein
Epstein-Barr	B-protein
virus	I-protein
(	O
EBV	I-protein
)	O
-latent	I-protein
proteins	I-protein
;	O
the	I-protein
newly	O
described	O
DNA	O
virus	I-protein
,	O
Karposi	O
's	I-protein
sarcoma-associated	I-protein
herpesvirus/human	O
herpesvirus-8	O
(	O
KSHV/HHV-8	O
)	O
;	O
and	I-protein
perhaps	O
HIV	I-protein
.	O

Elucidation	O
of	I-protein
the	I-protein
factors	I-protein
that	O
contribute	O
to	I-protein
the	I-protein
high	O
incidence	O
of	I-protein
NHL	B-protein
among	O
patients	O
infected	O
with	I-protein
HIV	I-protein
provides	O
insights	O
into	O
important	O
elements	O
of	I-protein
lymphomagenesis	O
.	O

###MEDLINE:98338104

Matrix	I-protein
metalloproteinase	I-protein
expression	I-protein
in	I-protein
human	O
breast	O
cancer	O
:	O
an	I-protein
immunohistochemical	O
study	O
including	I-protein
correlation	O
with	I-protein
cathepsin	B-protein
D	I-protein
,	O
type	B-protein
IV	I-protein
collagen	I-protein
,	O
laminin	B-protein
,	O
fibronectin	B-protein
,	O
EGFR	B-protein
,	O
c-erbB-2	B-protein
oncoprotein	B-protein
,	O
p53	B-protein
,	O
steroid	O
receptors	I-protein
status	I-protein
and	I-protein
proliferative	O
indices	O
.	O

Matrix	I-protein
metalloproteinase	I-protein
s	I-protein
(	O
MMPs	B-protein
)	O
are	O
a	I-protein
group	I-protein
of	I-protein
enzymes	O
thought	O
to	I-protein
be	O
responsible	O
for	I-protein
both	O
normal	O
connective	O
tissue	O
matrix	O
remodelling	O
and	I-protein
accelerated	I-protein
breakdown	O
associated	I-protein
with	I-protein
tumour	I-protein
development	O
.	O

The	O
current	I-protein
study	O
aimed	O
to	I-protein
investigate	O
the	I-protein
immunohistochemical	O
expression	I-protein
of	I-protein
matrix	B-protein
metalloproteinase	I-protein
3	I-protein
(	O
MMP-3	B-protein
,	O
stromelysin-1	O
)	O
in	I-protein
correlation	O
with	I-protein
the	I-protein
expression	I-protein
of	I-protein
Basement	B-protein
Membrane	I-protein
(	O
BM	I-protein
)	O
antigen	I-protein
(	O
type	B-protein
IV	I-protein
collagen	I-protein
,	O
laminin	B-protein
)	O
,	O
fibronectin	O
,	O
cathepsin	B-protein
D	I-protein
,	O
p53	B-protein
,	O
c-erbB-2	B-protein
,	O
proliferative	O
activity	I-protein
(	O
Ki-67	B-protein
,	O
PCNA	B-protein
)	O
,	O
steroid	B-protein
receptor	I-protein
content	O
as	O
well	O
as	O
to	I-protein
the	I-protein
other	O
conventional	O
clinicopathological	O
parameters	O
in	I-protein
breast	O
cancer	O
.	O

This	O
study	O
was	O
performed	O
on	I-protein
a	I-protein
series	O
of	I-protein
frozen	O
and	I-protein
paraffin	O
sections	O
from	I-protein
84	I-protein
breast	O
cancer	O
specimens	O
by	I-protein
immunohistochemistry	O
using	O
the	I-protein
monoclonal	I-protein
antibody	I-protein
MMP-3	B-protein
(	O
Ab-1	O
)	O
.	O

Stromelysin-1	B-protein
(	O
ST1	B-protein
)	O
was	O
observed	O
in	I-protein
about	O
10	I-protein
%	O
of	I-protein
epithelial	O
cells	I-protein
in	I-protein
the	I-protein
control	I-protein
groups	O
(	O
cases	O
of	I-protein
fibrocystic	O
and	I-protein
benign	O
proliferative	O
breast	O
disease	I-protein
)	O
,	O
while	O
expression	I-protein
(	O
>	O
10	I-protein
%	O
of	I-protein
expression	I-protein
)	O
was	O
detected	O
in	I-protein
89.7	O
%	O
of	I-protein
tumours	O
.	O

The	O
expression	I-protein
of	I-protein
ST1	B-protein
in	I-protein
carcinoma	I-protein
cells	I-protein
was	O
strongly	O
associated	I-protein
with	I-protein
its	O
presence	O
in	I-protein
the	I-protein
stroma	O
(	O
p	O
<	O
0.001	O
)	O
.	O

A	O
significantly	O
positive	I-protein
correlation	O
was	O
found	O
between	O
ST1	B-protein
expression	I-protein
,	O
and	I-protein
p53	B-protein
tumour	I-protein
suppressor	O
gene	O
product	I-protein
(	O
p	O
=	O
0.004	O
)	O
,	O
and	I-protein
a	I-protein
relationship	O
with	I-protein
c-erbB-2	B-protein
protein	I-protein
and	I-protein
progesterone	B-protein
receptor	O
status	I-protein
was	O
also	O
indicated	O
.	O

These	O
findings	O
suggest	O
that	O
ST1	B-protein
expression	I-protein
in	I-protein
breast	O
cancer	O
tissue	O
is	O
irrespective	O
of	I-protein
the	I-protein
expression	I-protein
of	I-protein
the	I-protein
extracellular	O
matrix	O
component	O
,	O
the	I-protein
proteolytic	I-protein
enzyme	I-protein
cathepsin	I-protein
D	I-protein
and	I-protein
the	I-protein
growth	O
fraction	O
of	I-protein
the	I-protein
tumour	I-protein
,	O
and	I-protein
that	O
it	O
could	O
be	O
a	I-protein
potential	I-protein
new	I-protein
prognostic	O
marker	I-protein
in	I-protein
breast	O
cancer	O
.	O

###MEDLINE:98321739

Use	O
of	I-protein
transfected	O
liver	O
cells	I-protein
to	I-protein
evaluate	O
potential	I-protein
mechanisms	O
of	I-protein
alcohol-induced	O
liver	O
injury	O
[	O
see	O
comments	O
]	O

There	O
is	O
increased	I-protein
activity	I-protein
of	I-protein
the	I-protein
proinflammatory	B-protein
cytokine	I-protein
,	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
(	O
TNF	B-protein
)	O
in	I-protein
alcoholic	O
liver	O
disease	I-protein
(	O
ALD	O
)	O
.	O

Hepatic	B-protein
neutrophil	O
infiltration	O
is	O
a	I-protein
principal	O
injurious	O
manifestation	O
of	I-protein
ALD	O
.	O

TNF	B-protein
can	O
induce	O
cellular	O
oxidative	B-protein
injury	O
directly	O
,	O
and	I-protein
indirectly	O
by	I-protein
inducing	I-protein
neutrophil	O
chemotactic	I-protein
factor	I-protein
(	O
IL-8	B-protein
)	O
production	I-protein
by	I-protein
hepatocytes	I-protein
.	O

IL-8	B-protein
activates	O
and	I-protein
chemotactically	O
attracts	O
neutrophils	O
to	I-protein
the	I-protein
liver	O
where	O
they	O
release	I-protein
oxidizing	O
substances	O
.	O

Patients	O
with	I-protein
ALD	O
also	O
have	O
decreased	O
protective	B-protein
factors	I-protein
for	I-protein
cellular	O
oxidative	B-protein
injury	O
.	O

Manganous	B-protein
superoxide	I-protein
dismutase	I-protein
(	O
MnSOD	B-protein
)	O
is	O
an	I-protein
antioxidant	I-protein
protective	I-protein
factor	I-protein
.	O

The	O
objectives	O
of	I-protein
these	O
studies	O
were	O
to	I-protein
investigate	O
mechanisms	O
for	I-protein
induction	I-protein
of	I-protein
an	I-protein
injurious	B-protein
factor	I-protein
(	O
IL-8	B-protein
)	O
and	I-protein
a	I-protein
protective	B-protein
factor	I-protein
(	O
MnSOD	B-protein
)	O
in	I-protein
the	I-protein
HepG2	O
human	O
hepatoma	B-protein
cell	O
line	I-protein
.	O

In	O
the	I-protein
first	O
set	O
of	I-protein
experiments	O
,	O
IL-8	O
gene	O
reporter	O
constructs	O
were	O
used	O
to	I-protein
transiently	O
transfect	O
a	I-protein
derivative	O
(	O
MVh2E1-9	O
)	O
of	I-protein
the	I-protein
HepG2	O
cell	O
line	I-protein
which	O
expresses	O
P-4502E1	B-protein
and	I-protein
metabolizes	O
ethanol	O
.	O

Inactivation	O
of	I-protein
the	I-protein
NF-kappaB	B-protein
and	I-protein
3'NF-IL-6	O
DNA	O
binding	I-protein
sites	I-protein
decreased	O
IL-8	O
gene	O
transcriptional	O
activation	I-protein
in	I-protein
response	I-protein
to	I-protein
TNF	B-protein
while	O
inactivation	O
of	I-protein
the	I-protein
5'NF-IL-6	O
binding	I-protein
site	I-protein
increased	I-protein
IL-8	O
gene	O
transcriptional	O
activity	I-protein
in	I-protein
response	I-protein
to	I-protein
TNF	B-protein
.	O

This	O
system	I-protein
may	O
be	O
useful	O
to	I-protein
assess	O
the	I-protein
effects	O
of	I-protein
ethanol	O
on	I-protein
TNF	B-protein
-induced	O
hepatocyte	O
IL-8	B-protein
production	I-protein
.	O

In	O
the	I-protein
second	O
set	O
of	I-protein
experiments	O
,	O
HepG2	O
cells	I-protein
were	O
cultured	O
in	I-protein
25	I-protein
to	I-protein
100	I-protein
mmol	O
concentrations	O
of	I-protein
ethanol	O
.	O

Both	O
TNF	B-protein
and	I-protein
ethanol	O
increased	I-protein
HepG2	O
cell	O
MnSOD	B-protein
activity	I-protein
in	I-protein
short-term	O
(	O
72	I-protein
hr	O
)	O
cultures	O
with	I-protein
ethanol	O
.	O

However	O
,	O
after	O
long-term	O
(	O
10	I-protein
weeks	O
)	O
culture	O
with	I-protein
ethanol	O
,	O
there	O
was	O
no	I-protein
induction	I-protein
of	I-protein
MnSOD	B-protein
by	I-protein
ethanol	O
and	I-protein
there	O
was	O
a	I-protein
diminished	O
induction	I-protein
of	I-protein
MnSOD	B-protein
in	I-protein
response	I-protein
to	I-protein
TNF	B-protein
.	O

Further	O
studies	O
are	O
needed	O
to	I-protein
assess	O
the	I-protein
effect	O
of	I-protein
this	O
diminished	O
induction	I-protein
of	I-protein
MnSOD	B-protein
with	I-protein
chronic	O
ethanol	O
culture	O
on	I-protein
HepG2	O
cell	O
susceptibility	I-protein
to	I-protein
TNF	O
cytotoxicity	I-protein
.	O

We	O
conclude	O
that	O
transfected	O
liver	O
cell	O
lines	B-protein
can	O
be	O
used	O
to	I-protein
evaluate	O
mechanisms	O
for	I-protein
increased	I-protein
injurious	B-protein
factors	I-protein
and	I-protein
decreased	O
protective	B-protein
factors	I-protein
in	I-protein
alcoholic	O
liver	O
injury	O
.	O

###MEDLINE:98318652

Tissue	B-protein
factor	I-protein
transcription	O
driven	O
by	I-protein
Egr-1	B-protein
is	O
a	I-protein
critical	I-protein
mechanism	O
of	I-protein
murine	B-protein
pulmonary	I-protein
fibrin	I-protein
deposition	O
in	I-protein
hypoxia	B-protein
.	O

Local	O
hypoxemia	O
and	I-protein
stasis	O
trigger	O
thrombosis	O
.	O

We	O
have	O
demonstrated	O
previously	O
that	O
in	I-protein
a	I-protein
murine	O
model	I-protein
of	I-protein
normobaric	O
hypoxia	B-protein
pulmonary	I-protein
fibrin	B-protein
deposition	O
is	O
a	I-protein
result	O
of	I-protein
expression	I-protein
of	I-protein
tissue	B-protein
factor	I-protein
,	O
especially	O
in	I-protein
oxygen-deprived	B-protein
mononuclear	I-protein
phagocytes	I-protein
(	O
MPs	B-protein
)	O
.	O

We	O
now	O
show	O
that	O
transcription	B-protein
factor	I-protein
early-growth-response	I-protein
gene	I-protein
product	I-protein
(	O
Egr-1	O
)	O
is	O
rapidly	I-protein
activated	O
in	I-protein
hypoxia	B-protein
,	O
both	O
in	I-protein
vitro	O
and	I-protein
in	I-protein
vivo	O
,	O
and	I-protein
is	O
responsible	O
for	I-protein
transcription	O
and	I-protein
expression	I-protein
of	I-protein
tissue	B-protein
factor	I-protein
in	I-protein
hypoxic	O
lung	O
.	O

MPs	B-protein
and	I-protein
HeLa	O
cells	I-protein
subjected	O
to	I-protein
hypoxia	B-protein
(	O
pO2	O
approximately	O
13	I-protein
torr	O
)	O
had	O
increased	I-protein
levels	I-protein
of	I-protein
tissue	O
factor	I-protein
transcripts	I-protein
(	O
approximately	O
18-fold	O
)	O
and	I-protein
an	I-protein
increased	I-protein
rate	I-protein
of	I-protein
transcription	O
(	O
approximately	O
15-fold	O
)	O
,	O
based	O
on	I-protein
nuclear	O
run-on	O
analysis	O
.	O

Gel-shift	O
analysis	O
of	I-protein
nuclear	O
extracts	O
from	I-protein
hypoxic	B-protein
MPs	I-protein
and	I-protein
HeLa	O
cells	I-protein
demonstrated	O
increased	I-protein
DNA-binding	O
activity	I-protein
at	I-protein
the	I-protein
serum	O
response	I-protein
region	O
(	O
SRR	B-protein
;	O
-111/+14	O
bp	O
)	O
of	I-protein
the	I-protein
tissue	O
factor	I-protein
promoter	I-protein
at	I-protein
Egr-1	O
motifs	I-protein
.	O

Using	O
32P-labeled	O
Egr	O
consensus	O
oligonucleotide	O
,	O
we	O
observed	O
induction	I-protein
of	I-protein
DNA-binding	O
activity	I-protein
in	I-protein
nuclear	O
extracts	O
from	I-protein
hypoxic	O
lung	O
and	I-protein
HeLa	O
cells	I-protein
because	O
of	I-protein
activation	I-protein
of	I-protein
Egr-1	B-protein
,	O
by	I-protein
means	O
of	I-protein
supershift	O
analysis	O
.	O

Transient	I-protein
transfection	O
of	I-protein
HeLa	O
cells	I-protein
with	I-protein
chimeric	O
plasmids	O
containing	I-protein
wild-type	I-protein
or	I-protein
mutant	I-protein
SRR	B-protein
from	I-protein
the	I-protein
tissue	O
factor	I-protein
promoter	I-protein
showed	O
that	O
intact	O
Sp1	O
sites	I-protein
are	O
necessary	O
for	I-protein
basal	O
promoter	I-protein
activity	I-protein
,	O
whereas	O
the	I-protein
integrity	O
of	I-protein
Egr-1	O
sites	I-protein
was	O
required	O
for	I-protein
hypoxia-enhanced	O
expression	I-protein
.	O

A	O
central	O
role	O
for	I-protein
Egr-1	B-protein
in	I-protein
hypoxia-mediated	O
tissue	O
factor	I-protein
expression	I-protein
was	O
confirmed	O
by	I-protein
experiments	O
with	I-protein
homozygous	O
Egr-1	B-protein
null	O
mice	O
;	O
wild-type	I-protein
mice	O
subjected	O
to	I-protein
oxygen	B-protein
deprivation	I-protein
expressed	I-protein
tissue	I-protein
factor	I-protein
and	I-protein
showed	O
fibrin	B-protein
deposition	O
,	O
but	O
hypoxic	O
homozygous	O
Egr-1	B-protein
null	O
mice	O
displayed	O
neither	O
tissue	B-protein
factor	I-protein
nor	O
fibrin	B-protein
.	O

These	O
data	O
delineate	O
a	I-protein
novel	O
biology	O
for	I-protein
hypoxia-induced	O
fibrin	B-protein
deposition	O
,	O
in	I-protein
which	O
oxygen	O
deprivation-induced	O
activation	I-protein
of	I-protein
Egr-1	B-protein
,	O
resulting	O
in	I-protein
expression	I-protein
of	I-protein
tissue	B-protein
factor	I-protein
,	O
has	O
an	I-protein
unexpected	O
and	I-protein
central	O
role	O
.	O

###MEDLINE:98304427

Kinetics	O
of	I-protein
cytokine	B-protein
and	I-protein
NFAT	O
gene	O
expression	I-protein
in	I-protein
human	O
interleukin-2-dependent	O
T	O
lymphoblasts	O
stimulated	O
via	I-protein
T-cell	B-protein
receptor	I-protein
.	O

T	O
cells	I-protein
respond	O
to	I-protein
mitogenic	O
or	I-protein
antigenic	I-protein
stimulation	I-protein
by	I-protein
proliferation	I-protein
and	I-protein
by	I-protein
turning	O
on	I-protein
cytokine	O
gene	O
expression	I-protein
.	O

Here	O
we	O
have	O
analysed	O
the	I-protein
kinetics	O
and	I-protein
nature	O
of	I-protein
cytokine	O
production	I-protein
in	I-protein
human	O
peripheral	O
blood-derived	O
T	O
lymphoblasts	O
stimulated	O
with	I-protein
anti-CD3	B-protein
antibodies	I-protein
or	I-protein
Lens	B-protein
culinaris	I-protein
lectin	I-protein
(	O
LCL	B-protein
)	O
.	O

T	O
cells	I-protein
were	O
purified	O
from	I-protein
peripheral	O
blood	O
mononuclear	O
cells	I-protein
(	O
PBMC	O
)	O
and	I-protein
primarily	O
activated	O
with	I-protein
anti-CD3	B-protein
antibodies	I-protein
and	I-protein
cultured	O
in	I-protein
the	I-protein
presence	O
of	I-protein
interleukin-2	B-protein
(	O
IL-2	B-protein
)	O
.	O

Anti-CD3-restimulated	O
T	O
cells	I-protein
(	O
mainly	O
CD8+	O
)	O
produced	O
IL-2	B-protein
,	O
interferon-gamma	B-protein
(	O
IFN-gamma	B-protein
)	O
and	I-protein
tumour	I-protein
necrosis	I-protein
factor-alpha	I-protein
(	O
TNF-alpha	B-protein
)	O
and	I-protein
low	O
levels	I-protein
of	I-protein
IL-4	B-protein
and	I-protein
IL-10	B-protein
transcripts	I-protein
and	I-protein
proteins	I-protein
.	O

No	I-protein
IL-6	B-protein
gene	O
expression	I-protein
was	O
observed	O
.	O

In	O
LCL-stimulated	O
cells	I-protein
the	I-protein
cytokine	O
production	I-protein
pattern	I-protein
was	O
very	O
similar	O
.	O

Steady-state	O
mRNA	O
levels	I-protein
of	I-protein
IL-2	B-protein
,	O
IL-10	B-protein
and	I-protein
IFN-gamma	B-protein
peaked	O
at	I-protein
3	O
hr	O
after	O
anti-CD3	O
stimulation	I-protein
and	I-protein
declined	O
rapidly	I-protein
thereafter	O
.	O

The	O
kinetics	O
of	I-protein
TNF-alpha	B-protein
mRNA	O
expression	I-protein
was	O
faster	O
,	O
being	O
at	I-protein
its	O
peak	O
level	I-protein
1	I-protein
hr	O
after	O
stimulation	I-protein
.	O

Anti-CD3-stimulated	O
IL-2	B-protein
gene	O
expression	I-protein
was	O
down-regulated	I-protein
by	I-protein
protein	O
synthesis	I-protein
inhibitor	O
,	O
whereas	O
IL-10	B-protein
,	O
IFN-gamma	B-protein
and	I-protein
TNF-alpha	B-protein
genes	I-protein
were	O
readily	O
induced	I-protein
independent	I-protein
of	I-protein
ongoing	O
protein	O
synthesis	I-protein
.	O

T-cell	B-protein
receptor	I-protein
stimulation	I-protein
also	O
induced	I-protein
a	I-protein
very	O
rapid	O
expression	I-protein
of	I-protein
c-jun	B-protein
,	O
c-fos	B-protein
and	I-protein
NFATc1	B-protein
(	O
NFATc	B-protein
)	O
genes	I-protein
,	O
the	I-protein
gene	O
products	O
of	I-protein
which	O
are	O
involved	I-protein
in	I-protein
cytokine	O
gene	O
expression	I-protein
.	O

In	O
conclusion	O
,	O
the	I-protein
cytokines	B-protein
synthesized	O
by	I-protein
IL-2-dependent	O
T	O
cells	I-protein
were	O
predominantly	O
IL-2	B-protein
,	O
IFN-gamma	B-protein
and	I-protein
TNF-alpha	B-protein
.	O

###MEDLINE:98295684

An	O
animal	O
model	I-protein
to	I-protein
study	O
local	O
oxidation	O
of	I-protein
LDL	O
and	I-protein
its	O
biological	O
effects	O
in	I-protein
the	I-protein
arterial	I-protein
wall	O
.	O

Oxidized	O
LDL	O
(	O
oxLDL	O
)	O
is	O
present	O
in	I-protein
atherosclerotic	O
lesions	O
and	I-protein
is	O
believed	O
to	I-protein
play	O
a	I-protein
key	O
role	O
in	I-protein
atherogenesis	O
.	O

Mainly	O
on	I-protein
the	I-protein
basis	O
of	I-protein
cell	O
culture	O
studies	O
,	O
oxLDL	O
has	O
been	O
shown	O
to	I-protein
produce	O
many	O
biological	O
effects	O
that	O
influence	O
the	I-protein
atherosclerotic	O
process	O
.	O

To	O
study	O
LDL	O
oxidation	O
in	I-protein
vivo	O
,	O
we	O
have	O
established	O
a	I-protein
model	I-protein
in	I-protein
which	O
Sprague-Dawley	O
rats	O
are	O
given	O
a	I-protein
single	O
injection	O
of	I-protein
unmodified	O
human	O
LDL	O
(	O
>	O
or	I-protein
=	O
4	I-protein
mg/kg	O
body	O
weight	I-protein
)	O
.	O

Within	O
6	I-protein
hours	O
,	O
an	I-protein
accumulation	I-protein
of	I-protein
apolipoprotein	O
B	O
and	I-protein
epitopes	B-protein
present	O
on	I-protein
oxLDL	B-protein
are	O
detected	O
in	I-protein
the	I-protein
arterial	I-protein
endothelium	O
and	I-protein
media	I-protein
.	O

The	O
presence	O
of	I-protein
oxLDL	B-protein
is	O
associated	I-protein
with	I-protein
activation	I-protein
of	I-protein
the	I-protein
transcription	B-protein
factor	I-protein
nuclear	I-protein
factor-kappaB	I-protein
in	I-protein
the	I-protein
endothelium	O
as	O
well	O
as	O
endothelial	O
expression	I-protein
of	I-protein
intercellular	B-protein
adhesion	I-protein
molecule-1	I-protein
.	O

Injection	O
of	I-protein
LDL	O
enriched	I-protein
with	I-protein
the	I-protein
antioxidant	I-protein
probucol	O
resulted	O
in	I-protein
arterial	I-protein
accumulation	I-protein
of	I-protein
apolipoprotein	O
B	O
,	O
but	O
the	I-protein
expression	I-protein
of	I-protein
oxLDL-specific	O
epitopes	O
was	O
reduced	O
at	I-protein
24	I-protein
hours	O
.	O

Thus	O
,	O
this	O
simple	O
model	I-protein
has	O
the	I-protein
potential	I-protein
to	I-protein
analyze	O
the	I-protein
mechanisms	O
behind	O
and	I-protein
biological	O
effects	O
of	I-protein
LDL	O
oxidation	O
in	I-protein
vivo	O
.	O

###MEDLINE:98269066

Molecular	O
mechanisms	O
of	I-protein
promoter	I-protein
regulation	I-protein
of	I-protein
the	I-protein
gp34	O
gene	O
that	O
is	O
trans-activated	O
by	I-protein
an	I-protein
oncoprotein	B-protein
Tax	I-protein
of	I-protein
human	O
T	O
cell	O
leukemia	O
virus	I-protein
type	O
I	I-protein
.	O

We	O
investigated	O
the	I-protein
molecular	I-protein
mechanism	O
of	I-protein
transcriptional	O
activation	I-protein
of	I-protein
the	I-protein
gp34	O
gene	O
by	I-protein
the	I-protein
Tax	B-protein
oncoprotein	B-protein
of	I-protein
human	O
T	O
cell	O
leukemia	O
virus	I-protein
type	O
I	I-protein
(	O
HTLV-I	O
)	O
.	O

gp34	B-protein
is	O
a	I-protein
type	B-protein
II	I-protein
transmembrane	I-protein
molecule	I-protein
belonging	O
to	I-protein
the	I-protein
tumor	B-protein
necrosis	I-protein
factor	I-protein
family	I-protein
and	I-protein
is	O
constitutively	O
expressed	O
on	I-protein
HTLV-I-producing	O
cells	I-protein
but	O
not	I-protein
normal	O
resting	O
T	O
cells	I-protein
.	O

The	O
transcriptional	O
regulatory	O
region	O
of	I-protein
the	I-protein
gp34	O
gene	O
was	O
activated	O
by	I-protein
HTLV-I	O
Tax	B-protein
in	I-protein
the	I-protein
human	O
T	O
cell	O
line	I-protein
Jurkat	O
,	O
in	I-protein
which	O
endogenous	O
gp34	B-protein
is	O
induced	I-protein
by	I-protein
Tax	B-protein
.	O

Sequence	O
analysis	O
demonstrated	O
that	O
two	O
NF-kappaB-like	O
elements	O
(	O
1	I-protein
and	I-protein
2	I-protein
)	O
were	O
present	O
in	I-protein
the	I-protein
regulatory	O
region	O
.	O

Both	O
NF-kappaB-like	O
elements	O
were	O
able	O
to	I-protein
bind	O
to	I-protein
NF-kappaB	B-protein
or	I-protein
its	O
related	O
factor	I-protein
(	O
s	I-protein
)	O
in	I-protein
a	I-protein
Tax	B-protein
-dependent	I-protein
manner	O
.	O

Chloramphenicol	B-protein
acetyltransferase	I-protein
assays	O
indicated	O
that	O
NF-kappaB-like	O
element	I-protein
1	I-protein
was	O
Tax	B-protein
-responsive	O
,	O
although	O
the	I-protein
activity	I-protein
was	O
lower	I-protein
than	I-protein
that	O
the	I-protein
native	O
promoter	I-protein
.	O

NF-kappaB	B-protein
-like	I-protein
element	I-protein
2	I-protein
elevated	I-protein
promoter	I-protein
activity	I-protein
when	O
combined	O
with	I-protein
NF-kappaB-like	O
element	I-protein
1	I-protein
,	O
indicating	O
cooperative	O
function	I-protein
of	I-protein
the	I-protein
elements	O
for	I-protein
maximum	O
promoter	I-protein
function	I-protein
.	O

Unlike	O
typical	I-protein
NF-kappaB	B-protein
elements	O
,	O
the	I-protein
NF-kappaB-like	O
elements	O
in	I-protein
gp34	B-protein
were	O
not	I-protein
activated	O
by	I-protein
treatment	O
of	I-protein
Jurkat	O
cells	I-protein
with	I-protein
phorbol	O
ester	I-protein
despite	O
induction	I-protein
of	I-protein
the	I-protein
NF-kappaB	B-protein
-like	I-protein
binding	I-protein
activity	I-protein
.	O

Chloramphenicol	O
acetyltransferase	I-protein
reporter	O
assays	O
using	O
the	I-protein
region	O
upstream	O
of	I-protein
the	I-protein
NF-kappaB-like	O
elements	O
identified	I-protein
an	I-protein
upstream	O
region	O
that	O
reduced	O
transcription	O
from	I-protein
cognate	I-protein
and	I-protein
noncognate	O
core	O
promoters	O
in	I-protein
a	I-protein
Tax-independent	O
manner	O
.	O

Our	O
results	O
imply	O
complex	I-protein
regulation	I-protein
of	I-protein
expression	I-protein
of	I-protein
the	I-protein
gp34	O
gene	O
and	I-protein
suggest	O
implication	O
of	I-protein
gp34	B-protein
in	I-protein
proliferation	I-protein
of	I-protein
HTLV-I	O
infected	O
T	O
cells	I-protein
.	O

###MEDLINE:98279058

beta-Amyloid	B-protein
fibrils	I-protein
activate	O
parallel	O
mitogen-activated	O
protein	O
kinase	O
pathways	O
in	I-protein
microglia	O
and	I-protein
THP1	O
monocytes	O
.	O

The	O
senile	O
plaques	O
of	I-protein
Alzheimer	O
's	I-protein
disease	I-protein
are	O
foci	I-protein
of	I-protein
local	O
inflammatory	O
responses	O
,	O
as	O
evidenced	O
by	I-protein
the	I-protein
presence	O
of	I-protein
acute	B-protein
phase	I-protein
proteins	I-protein
and	I-protein
oxidative	B-protein
damage	I-protein
.	O

Fibrillar	B-protein
forms	I-protein
of	I-protein
beta-amyloid	O
(	O
Abeta	B-protein
)	O
,	O
which	O
are	O
the	I-protein
primary	O
constituents	O
of	I-protein
senile	O
plaques	O
,	O
have	O
been	O
shown	O
to	I-protein
activate	O
tyrosine	O
kinase-dependent	O
signal	O
transduction	I-protein
cascades	O
,	O
resulting	O
in	I-protein
inflammatory	O
responses	O
in	I-protein
microglia	O
.	O

However	O
,	O
the	I-protein
downstream	O
signaling	O
pathways	O
mediating	I-protein
Abeta	B-protein
-induced	O
inflammatory	O
events	O
are	O
not	I-protein
well	O
characterized	O
.	O

We	O
report	O
that	O
exposure	O
of	I-protein
primary	O
rat	I-protein
microglia	O
and	I-protein
human	O
THP1	O
monocytes	O
to	I-protein
fibrillar	B-protein
Abeta	I-protein
results	O
in	I-protein
the	I-protein
tyrosine	B-protein
kinase	I-protein
-dependent	I-protein
activation	I-protein
of	I-protein
two	O
parallel	O
signal	O
transduction	I-protein
cascades	O
involving	O
members	O
of	I-protein
the	I-protein
mitogen-activated	B-protein
protein	I-protein
kinase	I-protein
(	O
MAPK	I-protein
)	O
superfamily	I-protein
.	O

Abeta	B-protein
stimulated	O
the	I-protein
rapid	O
,	O
transient	O
activation	I-protein
of	I-protein
extracellular	B-protein
signal-regulated	I-protein
kinase	I-protein
1	I-protein
(	O
ERK1	B-protein
)	O
and	I-protein
ERK2	B-protein
in	I-protein
microglia	O
and	I-protein
ERK2	B-protein
in	I-protein
THP1	O
monocytes	O
.	O

A	O
second	O
superfamily	I-protein
member	I-protein
,	O
p38	B-protein
MAPK	I-protein
,	O
was	O
also	O
activated	O
with	I-protein
similar	O
kinetics	O
.	O

Scavenger	B-protein
receptor	I-protein
and	I-protein
receptor	I-protein
for	I-protein
advanced	I-protein
glycated	I-protein
end	I-protein
products	I-protein
(	O
RAGE	B-protein
)	O
ligands	O
failed	O
to	I-protein
activate	O
ERK	B-protein
and	I-protein
p38	B-protein
MAPK	I-protein
in	I-protein
the	I-protein
absence	I-protein
of	I-protein
significant	O
increases	O
in	I-protein
protein	O
tyrosine	O
phosphorylation	I-protein
,	O
demonstrating	O
that	O
scavenger	B-protein
receptors	I-protein
and	I-protein
RAGE	B-protein
are	O
not	I-protein
linked	I-protein
to	I-protein
these	O
pathways	O
.	O

Importantly	O
,	O
the	I-protein
stress-activated	B-protein
protein	I-protein
kinases	I-protein
(	O
SAPKs	O
)	O
were	O
not	I-protein
significantly	O
activated	O
in	I-protein
response	I-protein
to	I-protein
Abeta	B-protein
.	O

Downstream	O
effectors	O
of	I-protein
the	I-protein
MAPK	I-protein
signal	O
transduction	I-protein
cascades	O
include	O
MAPKAP	B-protein
kinases	I-protein
,	O
such	O
as	O
RSK1	B-protein
and	I-protein
RSK2	B-protein
,	O
as	O
well	O
as	O
transcription	B-protein
factors	I-protein
.	O

Exposure	O
of	I-protein
microglia	O
and	I-protein
THP1	O
monocytes	O
to	I-protein
Abeta	B-protein
resulted	O
in	I-protein
the	I-protein
activation	I-protein
of	I-protein
RSK1	B-protein
and	I-protein
RSK2	B-protein
and	I-protein
phosphorylation	I-protein
of	I-protein
cAMP	B-protein
response	I-protein
element-binding	I-protein
protein	I-protein
at	I-protein
Ser133	O
,	O
providing	O
a	I-protein
mechanism	O
for	I-protein
Abeta	B-protein
-induced	O
changes	O
in	I-protein
gene	O
expression	I-protein

###MEDLINE:98369636

Regulation	O
of	I-protein
cellular	B-protein
retinoic	I-protein
acid	I-protein
binding	I-protein
protein	I-protein
(	O
CRABP	B-protein
II	I-protein
)	O
during	I-protein
human	O
monocyte	B-protein
differentiation	I-protein
in	I-protein
vitro	O
.	O

Cellular	I-protein
retinoic	I-protein
acid	I-protein
binding	I-protein
proteins	I-protein
(	O
CRABP	B-protein
)	O
are	O
low	B-protein
molecular	I-protein
weight	I-protein
proteins	I-protein
whose	O
precise	O
function	I-protein
remains	O
unknown	O
.	O

They	O
bind	O
retinoids	O
and	I-protein
may	O
thereby	O
modulate	O
the	I-protein
intracellular	I-protein
steady-state	O
concentration	I-protein
of	I-protein
retinoids	O
.	O

Whereas	O
CRABP	B-protein
I	I-protein
is	O
ubiquitously	O
expressed	O
,	O
CRABP	B-protein
II	I-protein
is	O
mainly	O
detected	O
in	I-protein
various	O
cell	O
types	I-protein
of	I-protein
the	I-protein
skin	O
.	O

By	O
representative	O
difference	O
analysis	O
we	O
found	O
that	O
CRABP	B-protein
II	I-protein
is	O
also	O
strongly	O
expressed	O
in	I-protein
human	O
monocyte-derived	O
macrophages	O
(	O
MAC	O
)	O
but	O
not	I-protein
in	I-protein
freshly	O
isolated	I-protein
monocytes	O
(	O
MO	O
)	O
.	O

The	O
CRABP	B-protein
II	I-protein
mRNA	O
was	O
gradually	O
upregulated	O
during	I-protein
differentiation	I-protein
from	I-protein
MO	O
to	I-protein
MAC	O
in	I-protein
the	I-protein
presence	O
of	I-protein
2	I-protein
%	O
serum	O
.	O

Adherence	O
,	O
which	O
is	O
important	O
for	I-protein
MO	O
differentiation	I-protein
,	O
induced	I-protein
CRABP	B-protein
II	I-protein
expression	I-protein
,	O
but	O
the	I-protein
addition	O
of	I-protein
10	I-protein
(	O
-7	I-protein
)	O
M	I-protein
retinoic	O
acid	O
inhibited	O
the	I-protein
upregulation	O
of	I-protein
CRABP	B-protein
II	I-protein
expression	I-protein
during	I-protein
MO/MAC	O
differentiation	I-protein
.	O

As	O
MO	O
can	O
differentiate	O
along	O
the	I-protein
classical	O
pathway	I-protein
not	I-protein
only	I-protein
to	I-protein
MAC	O
but	O
also	O
to	I-protein
dendritic	B-protein
cells	I-protein
we	O
analyzed	O
the	I-protein
expression	I-protein
of	I-protein
CRABP	B-protein
II	I-protein
in	I-protein
MO-derived	O
dendritic	B-protein
cells	I-protein
cultured	O
with	I-protein
10	I-protein
%	O
FCS	B-protein
,	O
IL-4	B-protein
,	O
and	I-protein
GM-CSF	B-protein
.	O

In	O
contrast	O
to	I-protein
MAC	O
,	O
MO-derived	O
dendritic	B-protein
cells	I-protein
showed	O
an	I-protein
extremely	O
low	O
expression	I-protein
of	I-protein
CRABP	B-protein
II	I-protein
.	O

From	O
these	O
results	O
we	O
conclude	O
(	O
1	I-protein
)	O
that	O
the	I-protein
availability	O
and	I-protein
the	I-protein
metabolism	I-protein
of	I-protein
retinoids	O
may	O
be	O
different	O
in	I-protein
MAC	O
compared	O
to	I-protein
MO	O
and	I-protein
dendritic	B-protein
cells	I-protein
and	I-protein
(	O
2	I-protein
)	O
that	O
this	O
may	O
influence	O
differentiation	I-protein
and	I-protein
activation	I-protein
of	I-protein
those	O
cells	I-protein
.	O

###MEDLINE:98361776

Transcription	I-protein
factor	I-protein
B-cell-specific	I-protein
activator	I-protein
protein	I-protein
(	O
BSAP	B-protein
)	O
is	O
differentially	O
expressed	O
in	I-protein
B	O
cells	I-protein
and	I-protein
in	I-protein
subsets	O
of	I-protein
B-cell	O
lymphomas	I-protein
.	O

The	O
paired	O
box	I-protein
containing	I-protein
gene	O
PAX-5	O
encodes	O
the	I-protein
transcription	B-protein
factor	I-protein
BSAP	B-protein
(	O
B-cell-specific	B-protein
activator	I-protein
protein	I-protein
)	O
,	O
which	O
plays	O
a	I-protein
key	O
role	O
in	I-protein
B-lymphocyte	O
development	O
.	O

Despite	O
its	O
known	O
involvement	I-protein
in	I-protein
a	I-protein
rare	I-protein
subtype	I-protein
of	I-protein
non-Hodgkin	O
's	I-protein
lymphoma	I-protein
(	O
NHL	B-protein
)	O
,	O
a	I-protein
detailed	O
examination	O
of	I-protein
BSAP	B-protein
expression	I-protein
in	I-protein
NHL	B-protein
has	O
not	I-protein
been	O
previously	O
reported	O
.	O

In	O
this	O
study	O
,	O
we	O
analyzed	O
normal	O
and	I-protein
malignant	O
lymphoid	O
tissues	O
and	I-protein
cell	O
lines	B-protein
,	O
including	I-protein
102	I-protein
cases	O
of	I-protein
B-cell	O
NHL	B-protein
,	O
23	I-protein
cases	O
of	I-protein
T-	O
and	I-protein
null-cell	O
NHL	B-protein
,	O
and	I-protein
18	I-protein
cases	O
of	I-protein
Hodgkin	B-protein
's	I-protein
disease	I-protein
.	O

Normal	O
lymphoid	O
tissues	O
showed	O
strong	O
nuclear	O
BSAP	B-protein
expression	I-protein
in	I-protein
mantle	O
zone	I-protein
B	O
cells	I-protein
,	O
less	O
intense	O
reactivity	O
in	I-protein
follicular	B-protein
center	I-protein
B	O
cells	I-protein
,	O
and	I-protein
no	I-protein
expression	I-protein
in	I-protein
cells	I-protein
of	I-protein
the	I-protein
T-cell-rich	O
zones	O
.	O

Monocytoid	O
B	O
cells	I-protein
showed	O
weak	I-protein
expression	I-protein
,	O
whereas	O
plasma	O
cells	I-protein
and	I-protein
extrafollicular	O
large	O
transformed	I-protein
B	O
cells	I-protein
were	O
negative	O
.	O

Of	O
the	I-protein
102	I-protein
B-cell	O
NHLs	O
,	O
83	I-protein
(	O
81	I-protein
%	O
)	O
demonstrated	O
BSAP	B-protein
expression	I-protein
.	O

All	O
of	I-protein
the	I-protein
13	I-protein
(	O
100	I-protein
%	O
)	O
B-cell	O
chronic	O
lymphocytic	I-protein
leukemias	O
(	O
B-CLLs	O
)	O
,	O
21	I-protein
of	I-protein
(	O
100	I-protein
%	O
)	O
mantle	O
cells	I-protein
(	O
MCLs	O
)	O
,	O
and	I-protein
20	I-protein
of	I-protein
21	I-protein
(	O
95	I-protein
%	O
)	O
follicular	B-protein
lymphomas	I-protein
(	O
FLs	O
)	O
were	O
positive	I-protein
.	O

Moderate	O
staining	O
intensities	O
were	O
found	O
in	I-protein
most	O
B-CLL	O
and	I-protein
FL	O
cases	O
,	O
whereas	O
most	O
MCLs	O
showed	O
strong	O
reactions	O
,	O
paralleling	O
the	I-protein
strong	O
reactivity	O
of	I-protein
nonmalignant	O
mantle	O
cells	I-protein
.	O

Eight	O
of	I-protein
12	O
(	O
67	I-protein
%	O
)	O
marginal	O
zone	I-protein
lymphoma	I-protein
cases	O
showed	O
negative	O
or	I-protein
low	O
BSAP	B-protein
levels	I-protein
,	O
and	I-protein
17	I-protein
of	I-protein
24	I-protein
(	O
71	I-protein
%	O
)	O
large	O
B-cell	O
lymphomas	I-protein
displayed	O
moderate	O
to	I-protein
strong	O
expression	I-protein
.	O

None	O
of	I-protein
the	I-protein
23	I-protein
T-	O
and	I-protein
null-cell	O
lymphomas	I-protein
reacted	O
with	I-protein
the	I-protein
BSAP	B-protein
antisera	O
,	O
whereas	O
in	I-protein
Hodgkin	B-protein
's	I-protein
disease	I-protein
,	O
2	I-protein
of	I-protein
4	I-protein
(	O
50	I-protein
%	O
)	O
nodular	O
lymphocytic	I-protein
predominance	O
and	I-protein
5	O
of	I-protein
14	I-protein
(	O
36	I-protein
%	O
)	O
classical	O
cases	O
showed	O
weak	I-protein
nuclear	O
or	I-protein
nucleolar	O
BSAP	B-protein
reactions	O
in	I-protein
a	I-protein
fraction	O
of	I-protein
the	I-protein
tumor	O
cells	I-protein
.	O

Western	O
blot	O
analysis	O
showed	O
a	I-protein
52-kD	O
BSAP	B-protein
band	I-protein
in	I-protein
B-cell	O
lines	B-protein
,	O
but	O
not	I-protein
in	I-protein
non-B-cell	O
or	I-protein
plasma	O
cell	O
lines	B-protein
.	O

We	O
conclude	O
that	O
BSAP	B-protein
expression	I-protein
is	O
largely	O
restricted	I-protein
to	I-protein
lymphomas	I-protein
of	I-protein
B-cell	O
lineage	I-protein
and	I-protein
that	O
BSAP	B-protein
expression	I-protein
varies	O
in	I-protein
B-cell	O
subsets	O
and	I-protein
subtypes	O
of	I-protein
B-cell	O
NHL	B-protein
.	O

The	O
high	O
levels	I-protein
of	I-protein
BSAP	B-protein
,	O
especially	O
those	O
found	O
in	I-protein
large-cell	O
lymphomas	I-protein
and	I-protein
in	I-protein
some	O
follicular	B-protein
lymphomas	I-protein
,	O
may	O
be	O
a	I-protein
consequence	O
of	I-protein
deregulated	O
gene	O
expression	I-protein
and	I-protein
suggest	O
a	I-protein
possible	O
involvement	I-protein
of	I-protein
PAX-5	O
in	I-protein
certain	O
B-cell	O
malignancies	O
.	O

This	O
is	O
a	I-protein
US	I-protein
government	O
work	O
.	O

There	O
are	O
no	I-protein
restrictions	O
on	I-protein
its	O
use	O
.	O

###MEDLINE:98346788

Mitogen	O
and	I-protein
growth	O
factor-induced	O
activation	I-protein
of	I-protein
a	I-protein
STAT-like	B-protein
molecule	I-protein
in	I-protein
channel	I-protein
catfish	O
lymphoid	O
cells	I-protein
.	O

This	O
article	O
describes	O
the	I-protein
identification	O
of	I-protein
a	I-protein
putative	B-protein
STAT	I-protein
molecule	I-protein
in	I-protein
the	I-protein
channel	I-protein
catfish	O
(	O
Ictalurus	O
punctatus	O
)	O
,	O
the	I-protein
first	O
report	O
of	I-protein
such	O
a	I-protein
molecule	I-protein
in	I-protein
a	I-protein
'lower	O
'	O
vertebrate	O
.	O

A	O
monoclonal	I-protein
antibody	I-protein
against	I-protein
human	B-protein
STAT6	B-protein
recognizes	O
an	I-protein
approximately	O
100	I-protein
kDa	I-protein
molecule	I-protein
that	O
becomes	O
activated	O
and	I-protein
translocates	O
to	I-protein
the	I-protein
nucleus	I-protein
upon	O
both	O
growth	O
factor	I-protein
and	I-protein
mitogen	O
stimulation	I-protein
of	I-protein
catfish	O
leukocytes	O
.	O

This	O
presumed	O
catfish	B-protein
STAT	I-protein
binds	O
the	I-protein
mammalian	O
interferon-gamma	O
activation	I-protein
site	I-protein
,	O
a	I-protein
known	O
motif	I-protein
of	I-protein
mammalian	O
STAT	O
binding	I-protein
,	O
as	O
shown	O
by	I-protein
electromobility	O
shift	O
assays	O
.	O

Purification	O
of	I-protein
the	I-protein
proteins	I-protein
present	O
in	I-protein
these	O
DNA	B-protein
complexes	I-protein
confirms	O
that	O
the	I-protein
catfish	O
reactive	I-protein
molecule	I-protein
binds	O
to	I-protein
the	I-protein
interferon-gamma	O
activation	I-protein
site	I-protein
sequence	I-protein
.	O

These	O
results	O
suggest	O
that	O
STAT	B-protein
molecules	I-protein
have	O
been	O
highly	O
conserved	O
in	I-protein
vertebrate	O
evolution	O
.	O

###MEDLINE:98334015

Isolation	O
and	I-protein
analysis	O
of	I-protein
a	I-protein
T	O
cell	O
clone	I-protein
variant	I-protein
exhibiting	O
constitutively	O
phosphorylated	B-protein
Ser133	I-protein
cAMP	I-protein
response	I-protein
element-binding	I-protein
protein	I-protein
.	O

In	O
driving	O
T	O
cell	O
proliferation	I-protein
,	O
IL-2	B-protein
stimulates	O
a	I-protein
new	I-protein
program	O
of	I-protein
gene	O
expression	I-protein
that	O
includes	I-protein
proliferating	B-protein
cell	I-protein
nuclear	I-protein
antigen	I-protein
(	O
PCNA	B-protein
)	O
,	O
a	I-protein
requisite	O
processivity	O
factor	I-protein
for	I-protein
DNA	B-protein
polymerase	I-protein
delta	I-protein
.	O

PCNA	O
transcription	O
is	O
regulated	O
in	I-protein
part	I-protein
through	I-protein
tandem	I-protein
CRE	O
sequences	I-protein
in	I-protein
the	I-protein
promoter	I-protein
and	I-protein
CRE	I-protein
binding	I-protein
proteins	I-protein
;	O
IL-2	B-protein
stimulates	O
CREB	B-protein
phosphorylation	I-protein
in	I-protein
the	I-protein
resting	O
cloned	O
T	O
lymphocyte	O
,	O
L2	I-protein
.	O

After	O
culturing	O
L2	I-protein
cells	I-protein
for	I-protein
greater	O
than	I-protein
91	I-protein
days	O
,	O
we	O
consistently	O
isolate	O
a	I-protein
stable	I-protein
variant	I-protein
that	O
exhibits	O
constitutive	I-protein
CREB	B-protein
phosphorylation	I-protein
.	O

L2	I-protein
and	I-protein
L2	I-protein
variant	I-protein
cells	I-protein
were	O
tested	O
for	I-protein
IL-2	B-protein
responsiveness	O
and	I-protein
rapamycin	O
sensitivity	I-protein
with	I-protein
respect	O
to	I-protein
specific	I-protein
kinase	O
activity	I-protein
,	O
PCNA	B-protein
expression	I-protein
and	I-protein
proliferation	I-protein
.	O

In	O
L2	I-protein
cells	I-protein
,	O
IL-2	B-protein
stimulated	O
and	I-protein
rapamycin	O
inhibited	O
the	I-protein
following	O
:	O
cAMP-independent	O
CREB	B-protein
kinase	I-protein
activity	I-protein
,	O
PCNA	B-protein
expression	I-protein
and	I-protein
proliferation	I-protein
.	O

In	O
L2	I-protein
variant	I-protein
cells	I-protein
,	O
CREB	B-protein
kinase	I-protein
activity	I-protein
was	O
constitutively	O
high	O
;	O
IL-2	B-protein
stimulated	O
and	I-protein
rapamycin	O
blocked	B-protein
PCNA	O
expression	I-protein
and	I-protein
proliferation	I-protein
.	O

These	O
results	O
indicate	O
that	O
IL-2	B-protein
induces	O
a	I-protein
rapamycin-sensitive	O
,	O
cAMP-independent	O
CREB	B-protein
kinase	I-protein
activity	I-protein
in	I-protein
L2	I-protein
cells	I-protein
.	O

However	O
,	O
phosphorylation	I-protein
of	I-protein
CREB	B-protein
alone	O
is	O
not	I-protein
sufficient	O
to	I-protein
drive	O
PCNA	B-protein
expression	I-protein
and	I-protein
L2	I-protein
cell	O
proliferation	I-protein
in	I-protein
the	I-protein
absence	I-protein
of	I-protein
IL-2	B-protein
.	O

###MEDLINE:98321687

Serotonin	O
derivative	O
,	O
N-	O
(	O
p-coumaroyl	O
)	O
serotonin	I-protein
,	O
inhibits	I-protein
the	I-protein
production	I-protein
of	I-protein
TNF-alpha	B-protein
,	O
IL-1alpha	B-protein
,	O
IL-1beta	B-protein
,	O
and	I-protein
IL-6	B-protein
by	I-protein
endotoxin-stimulated	O
human	O
blood	O
monocytes	O
.	O

We	O
have	O
reported	O
that	O
N-	O
(	O
p-coumaroyl	O
)	O
serotonin	I-protein
(	O
CS	O
)	O
and	I-protein
its	O
derivatives	I-protein
with	I-protein
antioxidative	O
activity	I-protein
are	O
present	O
in	I-protein
safflower	O
seeds	O
.	O

As	O
reactive	I-protein
oxygen	O
species	O
(	O
ROS	B-protein
)	O
are	O
implicated	O
in	I-protein
the	I-protein
signaling	O
of	I-protein
lipopolysaccharide	B-protein
(	O
LPS	B-protein
)	O
,	O
we	O
examined	O
whether	O
CS	O
has	O
a	I-protein
suppressive	O
effect	O
on	I-protein
inflammatory	O
cytokine	O
generation	O
from	I-protein
human	O
monocyte	B-protein
s	I-protein
in	I-protein
vitro	O
.	O

CS	O
at	I-protein
50-200	O
microM	O
reduced	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
(	O
TNF	I-protein
)	O
,	O
interleukin-1	B-protein
(	O
IL-1	B-protein
)	O
,	O
and	I-protein
IL-6	B-protein
activities	O
in	I-protein
the	I-protein
culture	O
supernatants	O
from	I-protein
LPS-stimulated	O
human	O
blood	O
monocytes	O
without	I-protein
cytotoxicity	I-protein
.	O

ELISA	O
assay	O
revealed	O
that	O
the	I-protein
production	I-protein
of	I-protein
TNF-alpha	B-protein
,	O
IL-1alpha	B-protein
,	O
IL-1beta	B-protein
,	O
and	I-protein
IL-6	B-protein
was	O
inhibited	O
by	I-protein
CS	O
.	O

Northern	O
blot	O
analysis	O
showed	O
that	O
LPS-induced	O
expression	I-protein
of	I-protein
these	O
cytokine	O
mRNA	O
in	I-protein
monocytes	O
was	O
suppressed	I-protein
by	I-protein
CS	O
.	O

NF-kappaB	B-protein
activation	I-protein
was	O
also	O
inhibited	O
by	I-protein
CS	O
.	O

These	O
findings	O
indicate	O
that	O
CS	O
has	O
a	I-protein
suppressive	O
effect	O
on	I-protein
proinflammatory	O
cytokine	O
production	I-protein
from	I-protein
monocytes	O
,	O
and	I-protein
this	O
effect	O
is	O
based	O
in	I-protein
part	I-protein
on	I-protein
the	I-protein
suppression	O
of	I-protein
cytokine	O
mRNA	O
expression	I-protein
through	I-protein
inhibition	O
of	I-protein
NF-kappaB	B-protein
activation	I-protein
.	O

###MEDLINE:98314139

Elevated	O
expression	I-protein
of	I-protein
differentiation	I-protein
inhibitory	O
factor	I-protein
nm23	O
mRNA	O
in	I-protein
monoblastic	O
crisis	O
of	I-protein
a	I-protein
patient	O
with	I-protein
chronic	O
myelogenous	O
leukemia	O
.	O

Differentiation	O
inhibitory	O
factor	I-protein
nm23	O
gene	O
has	O
been	O
found	O
to	I-protein
be	O
expressed	O
in	I-protein
high	O
quantities	O
in	I-protein
acute	O
myelogenous	O
leukemia	O
(	O
AML	O
)	O
,	O
especially	O
in	I-protein
acute	O
monocytic	I-protein
leukemia	O
(	O
AML-M5	O
)	O
and	I-protein
is	O
suggested	O
as	O
a	I-protein
new	I-protein
prognostic	O
factor	I-protein
in	I-protein
AML-M5	O
.	O

We	O
report	O
an	I-protein
example	O
of	I-protein
elevated	I-protein
expression	I-protein
of	I-protein
nm23	O
mRNA	O
in	I-protein
a	I-protein
patient	O
with	I-protein
chronic	O
myelogenous	O
leukemia	O
(	O
CML	O
)	O
who	O
developed	O
monoblastic	O
crisis	O
.	O

Relative	O
levels	I-protein
of	I-protein
nm23-H1	O
and	I-protein
-H2	O
mRNA	O
extracted	O
from	I-protein
the	I-protein
patient	O
's	I-protein
peripheral	O
blood	O
mononuclear	O
cells	I-protein
and	I-protein
bone	O
marrow	I-protein
mononuclear	O
cells	I-protein
were	O
measured	O
by	I-protein
quantitative	I-protein
reverse	I-protein
transcriptase	I-protein
polymerase	O
chain	I-protein
reaction	I-protein
.	O

The	O
level	I-protein
of	I-protein
nm23-H1	O
mRNA	O
in	I-protein
CML	O
cells	I-protein
at	I-protein
the	I-protein
chronic	O
phase	I-protein
was	O
as	O
high	O
as	O
that	O
in	I-protein
bone	O
marrow	I-protein
cells	I-protein
from	I-protein
healthy	O
volunteers	O
.	O

The	O
mRNA	O
level	I-protein
of	I-protein
nm23-H2	O
was	O
slightly	O
below	O
the	I-protein
normal	O
level	I-protein
.	O

At	O
blastic	O
crisis	O
,	O
however	O
,	O
expression	I-protein
of	I-protein
both	O
nm23-H1	O
and	I-protein
-H2	O
mRNA	O
was	O
elevated	I-protein
to	I-protein
about	O
three	O
to	I-protein
nine	I-protein
times	O
of	I-protein
that	O
at	I-protein
the	I-protein
chronic	O
phase	I-protein
.	O

Proliferated	O
blastic	O
cells	I-protein
were	O
positive	I-protein
for	I-protein
non-specific	I-protein
esterase	I-protein
,	O
and	I-protein
the	I-protein
serum	O
lysozyme	B-protein
level	I-protein
was	O
elevated	I-protein
and	I-protein
diagnosed	O
as	O
monoblastic	O
crisis	O
.	O

The	O
patient	O
received	O
combined	O
chemotherapy	O
but	O
response	I-protein
was	O
partial	I-protein
.	O

These	O
findings	O
are	O
compatible	O
with	I-protein
our	O
previous	O
report	O
that	O
nm23	O
gene	O
is	O
overexpressed	O
in	I-protein
monocytic	I-protein
leukemia	O
.	O

###MEDLINE:98306174

Increased	O
transcription	O
decreases	O
the	I-protein
spontaneous	O
mutation	I-protein
rate	I-protein
at	I-protein
the	I-protein
thymidine	B-protein
kinase	O
locus	O
in	I-protein
human	O
cells	I-protein
.	O

Transcription	I-protein
increases	O
DNA	O
repair	I-protein
efficiency	O
and	I-protein
modulates	O
the	I-protein
distribution	I-protein
of	I-protein
certain	O
types	I-protein
of	I-protein
DNA	O
damage	I-protein
.	O

Furthermore	O
,	O
increased	I-protein
transcription	O
level	I-protein
stimulates	O
spontaneous	O
mutation	I-protein
rate	I-protein
in	I-protein
yeast	O
.	O

We	O
explored	O
whether	O
transcription	O
level	I-protein
affects	O
spontaneous	O
mutation	I-protein
rate	I-protein
in	I-protein
human	O
cells	I-protein
.	O

We	O
first	O
developed	O
two	O
thymidine	B-protein
kinase	O
(	O
tk	O
)	O
inducible	O
human	O
cell	O
lines	B-protein
using	O
the	I-protein
Gal4-Estrogen	O
receptor	O
system	I-protein
.	O

In	O
our	O
TK6i-G3	O
and	I-protein
G9	O
tk	O
heterozygous	O
cell	O
lines	B-protein
,	O
the	I-protein
active	O
tk	O
allele	I-protein
is	O
linked	I-protein
to	I-protein
an	I-protein
inducible	O
promoter	I-protein
element	I-protein
.	O

Tk	O
mRNA	O
is	O
induced	I-protein
following	O
treatment	O
with	I-protein
estrogen	O
.	O

Spontaneous	O
mutation	I-protein
rate	I-protein
was	O
significantly	O
decreased	O
in	I-protein
human	O
cell	O
lines	B-protein
after	O
induction	I-protein
in	I-protein
contrast	O
to	I-protein
the	I-protein
report	O
in	I-protein
yeast	O
.	O

Thus	O
,	O
humans	O
may	O
have	O
evolved	O
different	O
or	I-protein
additional	B-protein
mechanisms	O
to	I-protein
deal	O
with	I-protein
transcription	O
related	O
spontaneous	O
mutagenesis	O
.	O

Copyright	O
1998	O
Elsevier	O
Science	O
B.V	O
.	O

All	O
rights	O
reserved	O
.	O

###MEDLINE:98288355

Mutation	O
of	I-protein
BCL-6	O
gene	O
in	I-protein
normal	O
B	O
cells	I-protein
by	I-protein
the	I-protein
process	O
of	I-protein
somatic	I-protein
hypermutation	O
of	I-protein
Ig	I-protein
genes	I-protein
.	O

Immunoglobulin	O
(	O
Ig	I-protein
)	O
genes	I-protein
are	O
hypermutated	O
in	I-protein
B	O
lymphocytes	O
that	O
are	O
the	I-protein
precursors	O
to	I-protein
memory	O
B	O
cells	I-protein
.	O

The	O
mutations	I-protein
are	O
linked	I-protein
to	I-protein
transcription	O
initiation	I-protein
,	O
but	O
non-Ig	O
promoters	O
are	O
permissible	O
for	I-protein
the	I-protein
mutation	I-protein
process	O
;	O
thus	O
,	O
other	O
genes	I-protein
expressed	O
in	I-protein
mutating	O
B	O
cells	I-protein
may	O
also	O
be	O
subject	O
to	I-protein
somatic	I-protein
hypermutation	O
.	O

Significant	O
mutations	I-protein
were	O
not	I-protein
observed	O
in	I-protein
c-MYC	O
,	O
S14	O
,	O
or	I-protein
alpha-fetoprotein	B-protein
(	O
AFP	O
)	O
genes	I-protein
,	O
but	O
BCL-6	O
was	O
highly	O
mutated	O
in	I-protein
a	I-protein
large	O
proportion	O
of	I-protein
memory	O
B	O
cells	I-protein
of	I-protein
normal	O
individuals	O
.	O

The	O
mutation	I-protein
pattern	I-protein
was	O
similar	O
to	I-protein
that	O
of	I-protein
Ig	I-protein
genes	I-protein
.	O

###MEDLINE:98281994

CD28-mediated	O
activation	I-protein
in	I-protein
CD45RA+	O
and	I-protein
CD45RO+	O
T	O
cells	I-protein
:	O
enhanced	I-protein
levels	I-protein
of	I-protein
reactive	I-protein
oxygen	O
intermediates	O
and	I-protein
c-Rel	B-protein
nuclear	O
translocation	O
in	I-protein
CD45RA+	O
cells	I-protein
.	O

We	O
have	O
analyzed	O
the	I-protein
effect	O
of	I-protein
complete	O
T	O
cell	O
activation	I-protein
(	O
anti-CD3	B-protein
plus	O
anti-CD28	O
)	O
on	I-protein
the	I-protein
activation	I-protein
of	I-protein
NF-kappaB	B-protein
in	I-protein
CD45RA+	O
(	O
naive	O
)	O
and	I-protein
CD45RO+	O
(	O
memory/effector	O
)	O
T	O
cells	I-protein
.	O

Long	I-protein
exposure	O
(	O
24	I-protein
h	I-protein
)	O
induced	I-protein
stronger	O
NF-kappaB	B-protein
DNA	O
binding	I-protein
in	I-protein
CD45RA+	O
cells	I-protein
than	I-protein
in	I-protein
CD45RO+	O
cells	I-protein
.	O

Analysis	O
of	I-protein
the	I-protein
nuclear	B-protein
c-Rel	I-protein
protein	I-protein
indicated	O
that	O
after	O
anti-CD3+anti-CD28	O
stimulation	I-protein
the	I-protein
level	I-protein
of	I-protein
c-Rel	B-protein
was	O
higher	O
in	I-protein
CD45RA+	O
cells	I-protein
.	O

Analysis	O
of	I-protein
the	I-protein
cytoplasmic	O
inhibitor	O
IkappaBalpha	B-protein
indicated	O
that	O
anti-CD3+anti-CD28	O
stimulation	I-protein
induced	I-protein
a	I-protein
long-lasting	O
degradation	I-protein
in	I-protein
CD45RA+	O
cells	I-protein
but	O
in	I-protein
CD45RO+	O
cells	I-protein
the	I-protein
degradation	I-protein
process	O
was	O
more	O
rapid	O
.	O

Because	O
the	I-protein
CD28	B-protein
costimulus	O
is	O
known	O
to	I-protein
induce	O
the	I-protein
production	I-protein
of	I-protein
reactive	I-protein
oxygen	O
intermediates	O
(	O
ROIs	O
)	O
,	O
the	I-protein
intracellular	I-protein
ROI	O
levels	I-protein
in	I-protein
CD45RA+	O
and	I-protein
CD45RO+	O
cells	I-protein
were	O
compared	O
by	I-protein
flow	O
cytometry	O
.	O

ROIs	O
were	O
produced	O
in	I-protein
both	O
cell	O
types	I-protein
,	O
but	O
more	O
strongly	O
in	I-protein
CD45RA+	O
cells	I-protein
.	O

The	O
data	O
presented	O
in	I-protein
this	O
study	O
further	O
emphasize	O
the	I-protein
differences	O
between	O
CD45RA+	O
and	I-protein
CD45RO+	O
T	O
lymphocytes	O
in	I-protein
ROI-dependent	O
signaling	O
pathways	O
.	O

###MEDLINE:98278432

Non-Hodgkin	O
's	I-protein
lymphoma	I-protein
involving	O
bilateral	I-protein
breasts	O
[	O
see	O
comments	O
]	O

We	O
describe	O
here	O
two	O
cases	O
of	I-protein
diffuse	B-protein
large	O
cell	O
type	O
non-Hodgkin	O
's	I-protein
lymphoma	I-protein
affecting	O
the	I-protein
bilateral	I-protein
breasts	O
.	O

The	O
contralateral	O
tumor	O
in	I-protein
one	B-protein
case	O
appeared	O
17	I-protein
months	O
after	O
the	I-protein
first	O
mastectomy	O
,	O
whereas	O
the	I-protein
bilateral	I-protein
tumors	I-protein
occurred	O
concurrently	O
in	I-protein
the	I-protein
other	O
patient	O
who	O
was	O
pregnant	O
and	I-protein
showed	O
widespread	O
dissemination	O
at	I-protein
initial	O
presentation	O
.	O

Lymphoma	I-protein
cells	I-protein
from	I-protein
both	O
cases	O
showed	O
the	I-protein
mature	B-protein
B-cell	O
immunophenotype	O
and	I-protein
had	O
rearrangements	O
of	I-protein
the	I-protein
BCL6	B-protein
gene	O
.	O

Both	O
patients	O
developed	O
progressive	O
disease	I-protein
despite	O
chemo-radiotherapy	O
and	I-protein
died	O
of	I-protein
leukemic	O
manifestations	O
.	O

There	O
were	O
no	I-protein
apparent	O
pathological	O
features	I-protein
of	I-protein
lymphomas	I-protein
of	I-protein
mucosa-associated	O
lymphoid	O
tissue	O
origin	O

###MEDLINE:98369616

Biochemical	O
characterization	O
of	I-protein
MIP-1	B-protein
alpha	I-protein
nuclear	I-protein
protein	I-protein
.	O

A	O
family	O
of	I-protein
hematopoietic	B-protein
specific	I-protein
transcription	I-protein
factors	I-protein
,	O
MIP-1	B-protein
alpha	I-protein
nuclear	I-protein
protein	I-protein
(	O
MNP	I-protein
)	O
family	I-protein
,	O
has	O
recently	O
been	O
identified	I-protein
.	O

They	O
are	O
intimately	O
involved	I-protein
in	I-protein
regulating	O
the	I-protein
transcription	O
of	I-protein
the	I-protein
huMIP-1	O
alpha	O
gene	O
in	I-protein
monocytes	O
,	O
T-cells	I-protein
,	O
and	I-protein
transformed	I-protein
B-cells	I-protein
.	O

One	I-protein
member	I-protein
of	I-protein
the	I-protein
family	O
(	O
MNP-1	B-protein
)	O
is	O
essential	O
for	I-protein
promoter	I-protein
activity	I-protein
in	I-protein
monocytes	O
and	I-protein
B-cells	I-protein
,	O
while	O
another	O
(	O
MNP-2	B-protein
)	O
is	O
required	O
for	I-protein
full	O
promotor	O
activity	I-protein
in	I-protein
T-cells	I-protein
.	O

A	O
third	O
member	I-protein
of	I-protein
the	I-protein
family	O
(	O
MNP-3	B-protein
)	O
is	O
expressed	O
in	I-protein
PMA	O
induced	I-protein
HL60	O
cells	I-protein
and	I-protein
probably	O
has	O
a	I-protein
role	O
in	I-protein
monocyte	B-protein
differentiation	I-protein
.	O

In	O
this	O
communication	O
we	O
demonstrate	O
by	I-protein
two	O
techniques	O
that	O
MNP-1	B-protein
and	I-protein
MNP-2	B-protein
are	O
distinct	O
but	O
related	O
factors	I-protein
,	O
and	I-protein
we	O
present	O
further	O
evidence	O
to	I-protein
show	O
that	O
MNP-1	B-protein
acts	O
as	O
a	I-protein
heterodimer	O
.	O

###MEDLINE:98361768

Bcl-3	B-protein
expression	I-protein
and	I-protein
nuclear	O
translocation	O
are	O
induced	I-protein
by	I-protein
granulocyte-macrophage	I-protein
colony-stimulating	I-protein
factor	I-protein
and	I-protein
erythropoietin	B-protein
in	I-protein
proliferating	B-protein
human	O
erythroid	O
precursors	O
.	O

Bcl-3	B-protein
is	O
a	I-protein
proto-oncogene	I-protein
involved	I-protein
in	I-protein
the	I-protein
chromosomal	I-protein
translocation	O
t	I-protein
(	O
14	I-protein
;	O
19	I-protein
)	O
found	O
in	I-protein
some	O
patients	O
with	I-protein
chronic	O
lymphocytic	I-protein
leukemia	O
.	O

It	O
shares	O
structural	O
similarities	O
with	I-protein
and	I-protein
is	O
a	I-protein
member	I-protein
of	I-protein
the	I-protein
IkappaB	B-protein
family	I-protein
of	I-protein
proteins	I-protein
.	O

In	O
this	O
report	O
,	O
involvement	I-protein
of	I-protein
Bcl-3	B-protein
in	I-protein
hematopoietic	O
growth	O
factor-stimulated	O
erythroid	O
proliferation	I-protein
and	I-protein
differentiation	I-protein
was	O
examined	O
.	O

In	O
TF-1	O
cells	I-protein
,	O
an	I-protein
erythroleukemia	O
cell	O
line	I-protein
,	O
granulocyte-macrophage	I-protein
colony-stimulating	I-protein
factor	I-protein
(	O
GM-CSF	B-protein
)	O
and	I-protein
erythropoietin	B-protein
(	O
Epo	B-protein
)	O
greatly	O
enhanced	I-protein
Bcl-3	B-protein
expression	I-protein
at	I-protein
both	O
the	I-protein
protein	O
and	I-protein
mRNA	O
levels	I-protein
in	I-protein
association	I-protein
with	I-protein
stimulation	I-protein
of	I-protein
proliferation	I-protein
.	O

Bcl-3	B-protein
protein	I-protein
was	O
also	O
highly	O
expressed	O
in	I-protein
early	O
burst-forming	O
unit-erythroid	O
(	O
BFU-E	O
)	O
-derived	O
erythroid	O
precursors	O
(	O
day	O
7	I-protein
)	O
and	I-protein
decreased	O
during	I-protein
maturation	I-protein
(	O
days	O
10	I-protein
and	I-protein
14	I-protein
)	O
,	O
suggesting	O
that	O
Bcl-3	B-protein
is	O
involved	I-protein
in	I-protein
normal	O
erythroid	O
proliferation	I-protein
.	O

In	O
these	O
hematopoietic	O
cells	I-protein
,	O
Bcl-3	B-protein
was	O
hyperphosphorylated	O
.	O

GM-CSF	B-protein
and	I-protein
Epo	B-protein
modulated	I-protein
the	I-protein
subcellular	O
localization	I-protein
of	I-protein
Bcl-3	B-protein
.	O

Upon	O
stimulation	I-protein
of	I-protein
TF-1	O
cells	I-protein
with	I-protein
GM-CSF	B-protein
or	I-protein
Epo	B-protein
,	O
the	I-protein
nuclear	O
translocation	O
of	I-protein
Bcl-3	B-protein
was	O
dramatically	O
enhanced	I-protein
.	O

Overexpression	O
of	I-protein
Bcl-3	B-protein
in	I-protein
TF-1	O
cells	I-protein
by	I-protein
transient	O
transfection	O
along	O
with	I-protein
the	I-protein
NF-kappaB	B-protein
factors	I-protein
p50	B-protein
or	I-protein
p52	B-protein
resulted	O
in	I-protein
significant	O
induction	I-protein
of	I-protein
an	I-protein
human	O
immunodeficiency	I-protein
virus-type	O
1	I-protein
(	O
HIV-1	O
)	O
kappaB-TATA-luceriferase	O
reporter	O
plasmid	O
,	O
demonstrating	O
that	O
Bcl-3	B-protein
has	O
a	I-protein
positive	I-protein
role	O
in	I-protein
transactivation	O
of	I-protein
kappaB-containing	O
genes	I-protein
in	I-protein
erythroid	O
cells	I-protein
.	O

Stimulation	O
with	I-protein
GM-CSF	B-protein
enhanced	I-protein
c-myb	B-protein
mRNA	O
expression	I-protein
in	I-protein
these	O
cells	I-protein
.	O

Bcl-3	B-protein
in	I-protein
nuclear	O
extracts	O
of	I-protein
TF-1	O
cells	I-protein
bound	I-protein
to	I-protein
a	I-protein
kappaB	I-protein
enhancer	O
in	I-protein
the	I-protein
c-myb	B-protein
promoter	I-protein
together	O
with	I-protein
NF-kappaB2/p52	B-protein
and	I-protein
this	O
binding	I-protein
activity	I-protein
was	O
enhanced	I-protein
by	I-protein
GM-CSF	B-protein
stimulation	I-protein
.	O

Furthermore	O
,	O
cotransfection	O
of	I-protein
Bcl-3	B-protein
with	I-protein
p52	B-protein
or	I-protein
p50	B-protein
in	I-protein
TF-1	O
cells	I-protein
resulted	O
in	I-protein
significant	O
activation	I-protein
of	I-protein
a	I-protein
c-myb	B-protein
kappaB-TATA-luceriferase	O
reporter	O
plasmid	O
.	O

These	O
findings	O
suggest	O
that	O
Bcl-3	B-protein
may	O
participate	O
in	I-protein
the	I-protein
transcriptional	O
regulation	I-protein
of	I-protein
certain	O
kappaB-containing	O
genes	I-protein
involved	I-protein
in	I-protein
hematopoiesis	I-protein
,	O
including	I-protein
c-myb	B-protein
.	O

Copyright	O
1998	O
by	I-protein
The	O
American	O
Society	O
of	I-protein
Hematology	O
.	O

###MEDLINE:98348399

5-Lipoxygenase	B-protein
compartmentalization	O
in	I-protein
granulocytic	O
cells	I-protein
is	O
modulated	I-protein
by	I-protein
an	I-protein
internal	B-protein
bipartite	I-protein
nuclear	I-protein
localizing	I-protein
sequence	I-protein
and	I-protein
nuclear	B-protein
factor	I-protein
kappa	I-protein
B	I-protein
complex	I-protein
formation	O
.	O

A	O
region	O
of	I-protein
basic	O
amino	O
acids	I-protein
spanning	O
residues	B-protein
639-656	I-protein
in	I-protein
the	I-protein
human	O
5-lipoxygenase	I-protein
sequence	I-protein
resembles	O
a	I-protein
consensus	B-protein
bipartite	I-protein
nuclear	I-protein
localizing	I-protein
sequence	I-protein
.	O

A	O
synthetic	I-protein
peptide	O
consisting	O
of	I-protein
the	I-protein
Kaposi	I-protein
fibroblast	I-protein
growth	I-protein
factor	I-protein
signal	I-protein
sequence	I-protein
fused	O
to	I-protein
the	I-protein
5-lipoxygenase639-656	B-protein
bipartite	I-protein
nuclear	I-protein
localizing	I-protein
sequence	I-protein
has	O
a	I-protein
prominent	O
inhibitory	O
effect	O
on	I-protein
5-lipoxygenase	I-protein
catalysis	O
in	I-protein
granulocytic	O
HL-60	O
cells	I-protein
activated	O
by	I-protein
calcium	O
ionophor	O
A23187	O
.	O

Recombinant	B-protein
5-lipoxygenase	I-protein
was	O
not	I-protein
affected	O
by	I-protein
the	I-protein
peptide	O
.	O

The	O
peptide	O
also	O
inhibited	O
redistribution	O
of	I-protein
5-lipoxygenase	I-protein
from	I-protein
the	I-protein
cytosol	I-protein
to	I-protein
the	I-protein
nuclear	O
membrane	O
of	I-protein
HL-60	O
cells	I-protein
stimulated	O
by	I-protein
A23187	O
.	O

5-Lipoxygenase	B-protein
protein	I-protein
was	O
detected	O
in	I-protein
nuclear	B-protein
factor	I-protein
kappaB	I-protein
(	O
NF-kappaB	B-protein
)	O
p65	I-protein
subunit	I-protein
immunoprecipitate	O
fractions	O
prepared	O
from	I-protein
HL-60	O
cell	O
lysates	O
.	O

The	O
amount	O
of	I-protein
5-lipoxygenase	I-protein
protein	I-protein
coimmunoprecipitated	O
by	I-protein
NF-kappaB	B-protein
antiserum	O
was	O
increased	I-protein
following	O
A23187	O
stimulation	I-protein
.	O

In	O
cells	I-protein
treated	O
with	I-protein
agents	O
that	O
block	O
5-lipoxygenase	I-protein
translocation	O
to	I-protein
the	I-protein
nucleus	I-protein
,	O
5-lipoxygenase	I-protein
protein	O
appearing	O
in	I-protein
the	I-protein
NF-kappaB	B-protein
immunoprecipitate	O
was	O
diminished	O
.	O

Our	O
results	O
implicate	O
an	I-protein
internal	B-protein
bipartite	I-protein
nuclear	I-protein
localizing	I-protein
sequence	I-protein
as	O
a	I-protein
regulatory	O
domain	I-protein
that	O
modulates	O
5-lipoxygenase	I-protein
redistribution	O
and	I-protein
catalysis	O
in	I-protein
granulocytic	O
cells	I-protein
.	O

Additionally	O
,	O
our	O
results	O
suggest	O
that	O
molecular	I-protein
determinants	O
which	O
govern	O
5-lipoxygenase	I-protein
and	I-protein
NF-kappaB	B-protein
redistribution	O
to	I-protein
the	I-protein
nucleus	I-protein
may	O
be	O
coordinately	O
controlled	O
in	I-protein
granulocytic	O
cells	I-protein
.	O

Copyright	O
1998	O
Academic	O
Press	O
.	O

###MEDLINE:98334014

Inhibition	O
of	I-protein
CD28/CD3-mediated	O
costimulation	O
of	I-protein
naive	O
and	I-protein
memory	O
human	O
T	O
lymphocytes	O
by	I-protein
intracellular	I-protein
incorporation	O
of	I-protein
polyclonal	I-protein
antibodies	I-protein
specific	I-protein
for	I-protein
the	I-protein
activator	B-protein
protein-1	I-protein
transcriptional	I-protein
complex	I-protein
.	O

A	O
number	I-protein
of	I-protein
indirect	O
methods	O
have	O
been	O
utilized	O
in	I-protein
demonstrating	O
activator	B-protein
protein-1	I-protein
transcription	I-protein
factor	I-protein
function	I-protein
in	I-protein
IL-2	B-protein
promoter	I-protein
activity	I-protein
.	O

However	O
,	O
there	O
has	O
been	O
no	I-protein
direct	O
demonstration	O
that	O
activator	B-protein
protein-1	I-protein
is	O
involved	I-protein
in	I-protein
CD28-dependent	O
costimulation	O
of	I-protein
IL-2	B-protein
gene	O
transcription	O
in	I-protein
freshly	O
isolated	I-protein
naive	O
and	I-protein
memory	O
human	O
T	O
lymphocytes	O
.	O

To	O
address	O
this	O
issue	O
,	O
the	I-protein
method	O
of	I-protein
scrape	O
loading	O
was	O
applied	O
to	I-protein
purified	O
peripheral	O
blood	O
T	O
lymphocytes	O
.	O

Since	O
scrape	O
loading	O
relies	O
on	I-protein
adherent	O
cells	I-protein
,	O
peripheral	O
blood	O
human	O
T	O
(	O
PB-T	O
)	O
cells	I-protein
were	O
immobilized	O
on	I-protein
the	I-protein
nonspecific	O
cell	O
attachment	I-protein
factor	I-protein
poly-L-lysine	O
.	O

Cells	O
scraped	O
off	O
poly-L-lysine	O
in	I-protein
the	I-protein
presence	O
of	I-protein
Ig	I-protein
FITC	I-protein
efficiently	O
incorporated	O
Ig	I-protein
,	O
with	I-protein
relatively	O
uniform	O
fluorescence	O
.	O

T	O
cells	I-protein
retained	O
their	O
physical	O
parameters	O
as	O
measured	O
by	I-protein
forward	O
and	I-protein
side	O
light	I-protein
scatter	I-protein
,	O
and	I-protein
functional	O
activity	I-protein
as	O
measured	O
by	I-protein
costimulation	O
of	I-protein
proliferation	I-protein
and	I-protein
IL-2	B-protein
production	I-protein
after	O
being	O
scraped	O
off	O
this	O
substrate	I-protein
.	O

CD28/CD3-costimulated	O
T	O
cells	I-protein
produced	O
intracellular	I-protein
IL-2	B-protein
from	I-protein
all	O
subsets	O
measured	O
(	O
CD4+	O
,	O
CD4-	O
,	O
CD45RO+	O
,	O
and	I-protein
CD45RO-	O
)	O
.	O

IL-2	B-protein
production	I-protein
and	I-protein
intracellular	I-protein
accumulation	I-protein
in	I-protein
nonscraped	O
PB-T	O
cells	I-protein
activated	O
with	I-protein
CD28/CD3	O
coligation	O
were	O
skewed	I-protein
favoring	O
CD45RO+	O
and	I-protein
CD4+	O
subsets	O
,	O
as	O
was	O
IL-2	B-protein
production	I-protein
in	I-protein
scraped	O
PB-T	O
cells	I-protein
.	O

The	O
intracellular	I-protein
incorporation	O
of	I-protein
Abs	O
specific	I-protein
for	I-protein
c-Fos	B-protein
and	I-protein
c-Jun	B-protein
family	I-protein
members	I-protein
by	I-protein
scrape	O
loading	O
inhibited	O
the	I-protein
production	I-protein
and	I-protein
intracellular	I-protein
accumulation	I-protein
of	I-protein
IL-2	B-protein
within	B-protein
6	I-protein
h	I-protein
of	I-protein
costimulation	O
with	I-protein
PMA/ionomycin	O
,	O
or	I-protein
costimulation	O
by	I-protein
CD28	B-protein
and	I-protein
CD3	O
ligation	O
.	O

Scrape	O
loading	O
thus	O
provides	O
an	I-protein
efficient	O
mechanism	O
for	I-protein
intracellular	I-protein
incorporation	O
of	I-protein
macromolecules	O
,	O
and	I-protein
the	I-protein
first	O
direct	O
evidence	O
that	O
c-Fos	B-protein
and	I-protein
c-Jun	B-protein
are	O
involved	I-protein
in	I-protein
transcription	O
of	I-protein
the	I-protein
IL-2	B-protein
gene	O
within	B-protein
its	O
correct	O
chromosomal	I-protein
context	O
,	O
in	I-protein
resting	O
human	O
T	O
lymphocyte	O
subpopulations	O
.	O

###MEDLINE:98325215

Differential	O
expression	I-protein
of	I-protein
Nur77	I-protein
family	I-protein
members	I-protein
in	I-protein
human	O
T-lymphotropic	O
virus	I-protein
type	O
1-infected	O
cells	I-protein
:	O
transactivation	O
of	I-protein
the	I-protein
TR3/nur77	O
gene	O
by	I-protein
Tax	B-protein
protein	I-protein
.	O

We	O
analyzed	O
the	I-protein
differential	O
expression	I-protein
and	I-protein
regulation	I-protein
of	I-protein
three	O
members	O
of	I-protein
the	I-protein
Nur77	I-protein
transcription	I-protein
factor	I-protein
family	I-protein
by	I-protein
the	I-protein
human	O
T-lymphotropic	O
virus	I-protein
type	O
1	I-protein
(	O
HTLV-1	B-protein
)	O
Tax	B-protein
protein	I-protein
.	O

We	O
have	O
demonstrated	O
that	O
in	I-protein
both	O
HTLV-1-infected	O
cells	I-protein
and	I-protein
Tax-expressing	O
JPX-9	O
cells	I-protein
,	O
TR3/nur77	B-protein
is	O
highly	O
expressed	O
,	O
whereas	O
neither	O
NOR-1	O
nor	O
NOT	B-protein
expression	I-protein
is	O
detectable	O
.	O

Transient	I-protein
transfection	O
analysis	O
further	O
confirmed	O
the	I-protein
Tax	B-protein
transactivation	O
of	I-protein
the	I-protein
TR3/nur77	O
promoter	I-protein
but	O
not	I-protein
the	I-protein
NOR-1	O
promoter	I-protein
in	I-protein
different	O
cell	O
types	I-protein
.	O

Furthermore	O
,	O
expression	I-protein
of	I-protein
a	I-protein
luciferase	O
reporter	O
gene	O
driven	O
by	I-protein
the	I-protein
NGFI-B	O
(	O
rat	I-protein
homolog	O
of	I-protein
TR3/Nur77	B-protein
)	O
response	I-protein
element	I-protein
(	O
NBRE	O
)	O
provided	O
evidence	O
that	O
Tax	B-protein
-mediated	O
transactivation	O
resulted	O
in	I-protein
the	I-protein
induction	I-protein
of	I-protein
a	I-protein
functional	O
protein	O
.	O

Cotransfection	O
assays	O
with	I-protein
the	I-protein
TR3/nur77	O
promoter	I-protein
sequence	I-protein
or	I-protein
the	I-protein
NBRE	O
binding	I-protein
motif	I-protein
together	O
with	I-protein
a	I-protein
series	O
of	I-protein
Tax	B-protein
mutants	O
have	O
shown	O
that	O
Tax	B-protein
-induced	O
TR3/nur77	B-protein
expression	I-protein
is	O
mediated	I-protein
by	I-protein
CREB/ATF-related	B-protein
transcription	I-protein
factors	I-protein
.	O

###MEDLINE:98315075

Negative	O
regulation	I-protein
of	I-protein
the	I-protein
heat	O
shock	I-protein
transcriptional	O
response	I-protein
by	I-protein
HSBP1	B-protein
.	O

In	O
response	I-protein
to	I-protein
stress	O
,	O
heat	B-protein
shock	I-protein
factor	I-protein
1	I-protein
(	O
HSF1	B-protein
)	O
acquires	O
rapid	O
DNA	O
binding	I-protein
and	I-protein
transient	O
transcriptional	O
activity	I-protein
while	O
undergoing	O
conformational	O
transition	O
from	I-protein
an	I-protein
inert	O
non-DNA-binding	B-protein
monomer	I-protein
to	I-protein
active	O
functional	O
trimers	O
.	O

Attenuation	O
of	I-protein
the	I-protein
inducible	O
transcriptional	O
response	I-protein
occurs	O
during	I-protein
heat	O
shock	I-protein
or	I-protein
upon	O
recovery	O
at	I-protein
non-stress	O
conditions	O
and	I-protein
involves	O
dissociation	I-protein
of	I-protein
the	I-protein
HSF1	B-protein
trimer	I-protein
and	I-protein
loss	O
of	I-protein
activity	I-protein
.	O

We	O
have	O
used	O
the	I-protein
hydrophobic	I-protein
repeats	I-protein
of	I-protein
the	I-protein
HSF1	B-protein
trimerization	I-protein
domain	I-protein
in	I-protein
the	I-protein
yeast	O
two-hybrid	O
protein	O
interaction	I-protein
assay	O
to	I-protein
identify	O
heat	B-protein
shock	I-protein
factor	I-protein
binding	I-protein
protein	I-protein
1	I-protein
(	O
HSBP1	B-protein
)	O
,	O
a	I-protein
novel	O
,	O
conserved	O
,	O
76-amino-acid	B-protein
protein	I-protein
that	O
contains	I-protein
two	O
extended	O
arrays	O
of	I-protein
hydrophobic	I-protein
repeats	I-protein
that	O
interact	O
with	I-protein
the	I-protein
HSF1	B-protein
heptad	I-protein
repeats	I-protein
.	O

HSBP1	B-protein
is	O
nuclear-localized	O
and	I-protein
interacts	I-protein
in	I-protein
vivo	O
with	I-protein
the	I-protein
active	O
trimeric	O
state	I-protein
of	I-protein
HSF1	B-protein
that	O
appears	O
during	I-protein
heat	O
shock	I-protein
.	O

During	O
attenuation	O
of	I-protein
HSF1	B-protein
to	I-protein
the	I-protein
inert	O
monomer	O
,	O
HSBP1	B-protein
associates	O
with	I-protein
Hsp70	I-protein
.	O

HSBP1	B-protein
negatively	O
affects	O
HSF1	B-protein
DNA-binding	O
activity	I-protein
,	O
and	I-protein
overexpression	O
of	I-protein
HSBP1	B-protein
in	I-protein
mammalian	O
cells	I-protein
represses	O
the	I-protein
transactivation	O
activity	I-protein
of	I-protein
HSF1	B-protein
.	O

To	O
establish	O
a	I-protein
biological	O
role	O
for	I-protein
HSBP1	B-protein
,	O
the	I-protein
homologous	I-protein
Caenorhabditis	B-protein
elegans	I-protein
protein	I-protein
was	O
overexpressed	O
in	I-protein
body	O
wall	O
muscle	O
cells	I-protein
and	I-protein
was	O
shown	O
to	I-protein
block	O
activation	I-protein
of	I-protein
the	I-protein
heat	O
shock	I-protein
response	I-protein
from	I-protein
a	I-protein
heat	O
shock	I-protein
promoter-reporter	O
construct	O
.	O

Alteration	O
in	I-protein
the	I-protein
level	I-protein
of	I-protein
HSBP1	B-protein
expression	I-protein
in	I-protein
C.	I-protein
elegans	I-protein
has	O
severe	I-protein
effects	O
on	I-protein
survival	B-protein
of	I-protein
the	I-protein
animals	O
after	O
thermal	O
and	I-protein
chemical	O
stress	O
,	O
consistent	O
with	I-protein
a	I-protein
role	O
for	I-protein
HSBP1	B-protein
as	O
a	I-protein
negative	O
regulator	O
of	I-protein
the	I-protein
heat	O
shock	I-protein
response	I-protein
.	O

###MEDLINE:98302228

Long-range	O
transcriptional	O
regulation	I-protein
of	I-protein
cytokine	O
gene	O
expression	I-protein
.	O

Most	O
studies	O
on	I-protein
the	I-protein
control	I-protein
of	I-protein
cytokine	O
gene	O
expression	I-protein
have	O
involved	I-protein
the	I-protein
functional	O
analysis	O
of	I-protein
proximal	I-protein
promoters	O
.	O

Recent	O
work	O
has	O
identified	I-protein
distal	I-protein
elements	O
that	O
mediate	O
long-range	O
cytokine	O
gene	O
regulation	I-protein
and	I-protein
has	O
implicated	O
chromatin	O
reorganization	O
in	I-protein
regulation	I-protein
of	I-protein
cytokine	O
gene	O
loci	O
.	O

These	O
studies	O
have	O
begun	O
to	I-protein
elucidate	O
the	I-protein
basis	O
for	I-protein
cell-specificity	O
and	I-protein
high-level	O
expression	I-protein
of	I-protein
cytokine	O
genes	I-protein
.	O

###MEDLINE:98259083

A	O
signaling	O
complex	I-protein
of	I-protein
Ca2+-calmodulin-dependent	B-protein
protein	I-protein
kinase	I-protein
IV	I-protein
and	I-protein
protein	I-protein
phosphatase	I-protein
2A	I-protein
[	O
see	O
comments	O
]	O

Stimulation	O
of	I-protein
T	O
lymphocytes	O
results	O
in	I-protein
a	I-protein
rapid	O
increase	O
in	I-protein
intracellular	I-protein
calcium	O
concentration	I-protein
(	O
[	O
Ca2+	I-protein
]	O
i	I-protein
)	O
that	O
parallels	O
the	I-protein
activation	I-protein
of	I-protein
Ca2+-calmodulin-dependent	B-protein
protein	I-protein
kinase	I-protein
IV	I-protein
(	O
CaMKIV	B-protein
)	O
,	O
a	I-protein
nuclear	B-protein
enzyme	I-protein
that	O
can	O
phosphorylate	O
and	I-protein
activate	O
the	I-protein
cyclic	B-protein
adenosine	I-protein
monophosphate	I-protein
(	O
cAMP	I-protein
)	O
response	I-protein
element-binding	I-protein
protein	I-protein
(	O
CREB	B-protein
)	O
.	O

However	O
,	O
inactivation	O
of	I-protein
CaMKIV	B-protein
occurs	O
despite	O
the	I-protein
sustained	O
increase	O
in	I-protein
[	O
Ca2+	I-protein
]	O
i	I-protein
that	O
is	O
required	O
for	I-protein
T	O
cell	O
activation	I-protein
.	O

A	O
stable	I-protein
and	I-protein
stoichiometric	O
complex	I-protein
of	I-protein
CaMKIV	B-protein
with	I-protein
protein	B-protein
serine-threonine	I-protein
phosphatase	I-protein
2A	I-protein
(	O
PP2A	B-protein
)	O
was	O
identified	I-protein
in	I-protein
which	O
PP2A	B-protein
dephosphorylates	O
CaMKIV	B-protein
and	I-protein
functions	O
as	O
a	I-protein
negative	O
regulator	O
of	I-protein
CaMKIV	B-protein
signaling	O
.	O

In	O
Jurkat	O
T	O
cells	I-protein
,	O
inhibition	O
of	I-protein
PP2A	B-protein
activity	I-protein
by	I-protein
small	O
t	I-protein
antigen	O
enhanced	I-protein
activation	I-protein
of	I-protein
CREB	B-protein
-mediated	O
transcription	O
by	I-protein
CaMKIV	B-protein
.	O

These	O
findings	O
reveal	O
an	I-protein
intracellular	I-protein
signaling	O
mechanism	O
whereby	O
a	I-protein
protein	B-protein
serine-threonine	I-protein
kinase	I-protein
(	O
CaMKIV	B-protein
)	O
is	O
regulated	O
by	I-protein
a	I-protein
tightly	O
associated	I-protein
protein	B-protein
serine-threonine	I-protein
phosphatase	I-protein
(	O
PP2A	B-protein
)	O
.	O

###MEDLINE:98281992

Hypoxia	O
down-regulates	O
MCP-1	B-protein
expression	I-protein
:	O
implications	O
for	I-protein
macrophage	O
distribution	I-protein
in	I-protein
tumors	I-protein
.	O

Monocyte	I-protein
chemoattractant	I-protein
protein	I-protein
1	I-protein
(	O
MCP-1	B-protein
)	O
is	O
likely	B-protein
to	I-protein
contribute	O
to	I-protein
the	I-protein
macrophage	O
infiltrate	O
in	I-protein
human	O
ovarian	I-protein
carcinomas	O
.	O

Although	O
MCP-1	B-protein
is	O
predominantly	O
expressed	O
by	I-protein
the	I-protein
tumor	O
parenchyma	I-protein
,	O
macrophages	O
accumulate	O
at	I-protein
highest	O
density	I-protein
in	I-protein
necrotic	O
regions	O
,	O
which	O
are	O
associated	I-protein
with	I-protein
low	O
oxygen	O
tensions	O
.	O

Tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
(	O
TNF-alpha	B-protein
)	O
can	O
stimulate	O
MCP-1	B-protein
production	I-protein
and	I-protein
is	O
also	O
present	O
within	B-protein
ovarian	I-protein
carcinomas	O
.	O

We	O
have	O
investigated	O
the	I-protein
effect	O
of	I-protein
hypoxia	B-protein
both	O
on	I-protein
MCP-1	B-protein
expression	I-protein
in	I-protein
ovarian	I-protein
cancer	O
cell	O
lines	B-protein
and	I-protein
monocyte	B-protein
migration	I-protein
.	O

Hypoxia	O
down-regulated	I-protein
TNF-alpha-induced	O
MCP-1	B-protein
mRNA	O
and	I-protein
protein	O
production	I-protein
by	I-protein
ovarian	I-protein
cancer	O
cells	I-protein
.	O

The	O
effect	O
was	O
mimicked	O
by	I-protein
cobalt	O
chloride	O
and	I-protein
desferrioxamine	O
,	O
consistent	O
with	I-protein
a	I-protein
specific	I-protein
oxygen-sensing	O
mechanism	O
.	O

Unlike	O
antioxidants	O
,	O
hypoxia	B-protein
did	O
not	I-protein
inhibit	O
nuclear	O
factor	I-protein
KB	O
mobilization	O
.	O

Monocyte	I-protein
migration	I-protein
in	I-protein
response	I-protein
to	I-protein
MCP-1	B-protein
was	O
also	O
diminished	O
under	O
hypoxic	O
conditions	O
.	O

Down-regulation	O
of	I-protein
MCP-1	B-protein
expression	I-protein
and	I-protein
the	I-protein
inhibition	O
of	I-protein
monocyte	B-protein
migration	I-protein
are	O
independent	I-protein
effects	O
of	I-protein
hypoxia	B-protein
that	O
may	O
contribute	O
to	I-protein
the	I-protein
distribution	I-protein
of	I-protein
macrophages	O
within	B-protein
ovarian	I-protein
tumors	I-protein
.	O

###MEDLINE:98279279

Activation	O
of	I-protein
nuclear	O
factor	I-protein
kappa	I-protein
B	O
inflammatory	O
bowel	I-protein
disease	I-protein
[	O
see	O
comments	O
]	O

BACKGROUND	O
:	O
Expression	O
of	I-protein
pro-inflammatory	B-protein
cytokines	I-protein
is	O
increased	I-protein
in	I-protein
the	I-protein
intestinal	O
lamina	O
propria	O
of	I-protein
patients	O
with	I-protein
inflammatory	O
bowel	I-protein
disease	I-protein
(	O
IBD	O
)	O
.	O

Nuclear	I-protein
factor	I-protein
kappa	I-protein
B	I-protein
(	O
NF	B-protein
kappa	I-protein
B	I-protein
)	O
controls	O
transcription	O
of	I-protein
inflammation	O
genes	I-protein
.	O

On	O
activation	I-protein
,	O
NF	B-protein
kappa	I-protein
B	I-protein
is	O
rapidly	I-protein
released	O
from	I-protein
its	O
cytoplasmic	O
inhibitor	O
(	O
I	I-protein
kappa	I-protein
B	I-protein
)	O
,	O
transmigrates	O
into	O
the	I-protein
nucleus	I-protein
,	O
and	I-protein
binds	O
to	I-protein
DNA	O
response	I-protein
elements	O
in	I-protein
gene	O
promoter	I-protein
regions	O
.	O

AIMS	O
:	O
To	O
investigate	O
whether	O
increased	I-protein
activation	I-protein
of	I-protein
NF	B-protein
kappa	I-protein
B	I-protein
is	O
important	O
in	I-protein
IBD	O
and	I-protein
may	O
be	O
down-regulated	I-protein
by	I-protein
anti-inflammatory	O
treatment	O
.	O

METHODS	O
:	O
Activation	O
of	I-protein
NF	B-protein
kappa	I-protein
B	I-protein
was	O
determined	O
by	I-protein
western	O
blot	O
assessment	O
and	I-protein
electrophoretic	O
mobility	I-protein
shift	O
assay	O
in	I-protein
nuclear	O
extracts	O
of	I-protein
colonic	I-protein
biopsy	O
samples	O
as	O
well	O
as	O
lamina	O
propria	O
mononuclear	O
cells	I-protein
.	O

RESULTS	O
:	O
Nuclear	I-protein
levels	I-protein
of	I-protein
NF	B-protein
kappa	I-protein
B	I-protein
p65	I-protein
are	O
increased	I-protein
in	I-protein
lamina	O
propria	O
biopsy	O
specimens	O
from	I-protein
patients	O
with	I-protein
Crohn	O
's	I-protein
disease	I-protein
in	I-protein
comparison	O
with	I-protein
patients	O
with	I-protein
ulcerative	O
colitis	O
and	I-protein
controls	O
.	O

Increased	O
activation	I-protein
of	I-protein
NF	B-protein
kappa	I-protein
B	I-protein
was	O
detected	O
in	I-protein
lamina	O
propria	O
mononuclear	O
cells	I-protein
from	I-protein
patients	O
with	I-protein
active	O
IBD	O
.	O

Corticosteroids	O
strongly	O
inhibit	O
intestinal	O
NF	B-protein
kappa	I-protein
B	I-protein
activation	I-protein
in	I-protein
IBD	O
in	I-protein
vivo	O
and	I-protein
in	I-protein
vitro	O
by	I-protein
stabilising	O
the	I-protein
cytosolic	O
inhibitor	O
I	I-protein
kappa	I-protein
B	O
alpha	O
against	I-protein
activation	I-protein
induced	I-protein
degradation	I-protein
.	O

CONCLUSIONS	O
:	O
In	O
both	O
IBDs	O
,	O
but	O
particularly	O
Crohn	O
's	I-protein
disease	I-protein
,	O
increased	I-protein
activation	I-protein
of	I-protein
NF	B-protein
kappa	I-protein
B	I-protein
may	O
be	O
involved	I-protein
in	I-protein
the	I-protein
regulation	I-protein
of	I-protein
the	I-protein
inflammatory	O
response	I-protein
.	O

Inhibition	O
of	I-protein
NF	B-protein
kappa	I-protein
B	I-protein
activation	I-protein
may	O
represent	O
a	I-protein
mechanism	O
by	I-protein
which	O
steroids	O
exert	O
an	I-protein
anti-inflammatory	O
effect	O
in	I-protein
IBD	O

###MEDLINE:98367816

Insufficient	O
glycemic	O
control	I-protein
increases	O
nuclear	B-protein
factor-kappa	I-protein
B	I-protein
binding	I-protein
activity	I-protein
in	I-protein
peripheral	O
blood	O
mononuclear	O
cells	I-protein
isolated	I-protein
from	I-protein
patients	O
with	I-protein
type	O
1	I-protein
diabetes	O
.	O

OBJECTIVE	O
:	O
The	O
redox-sensitive	B-protein
transcription	I-protein
factor	I-protein
nuclear	B-protein
factor-kappa	I-protein
B	I-protein
(	O
NF-kappa	B-protein
B	I-protein
)	O
is	O
believed	O
to	I-protein
contribute	O
to	I-protein
late	O
diabetic	B-protein
complications	O
.	O

It	O
is	O
unknown	O
whether	O
NF-kappa	B-protein
B	I-protein
is	O
influenced	I-protein
by	I-protein
glycemic	O
control	I-protein
.	O

RESEARCH	O
DESIGN	O
AND	O
METHODS	O
:	O
To	O
determine	O
whether	O
NF-kappa	B-protein
B	I-protein
is	O
activated	O
in	I-protein
patients	O
with	I-protein
insufficient	O
glycemic	O
control	I-protein
(	O
HbA1c	O
>	O
10	I-protein
%	O
)	O
,	O
we	O
developed	O
a	I-protein
tissue	O
culture-independent	O
electrophoretic	O
mobility	I-protein
shift	O
assay	O
(	O
EMSA	O
)	O
-based	O
semiquantitative	O
detection	O
system	I-protein
that	O
allowed	O
us	O
to	I-protein
determine	O
NF-kappa	B-protein
B	I-protein
activation	I-protein
in	I-protein
ex	O
vivo-isolated	O
peripheral	O
blood	O
mononuclear	O
cells	I-protein
(	O
PBMCs	O
)	O
.	O

We	O
included	I-protein
43	I-protein
patients	O
with	I-protein
type	O
1	I-protein
diabetes	O
in	I-protein
this	O
cross-sectional	O
study	O
.	O

10	I-protein
of	I-protein
those	O
received	O
the	I-protein
antioxidant	I-protein
thioctic	O
acid	O
(	O
600	I-protein
mg/day	O
p.o.	O
)	O
for	I-protein
2	I-protein
weeks	O
.	O

RESULTS	O
:	O
Monocytes	O
of	I-protein
patients	O
with	I-protein
HbA1c	O
levels	I-protein
>	O
10	I-protein
%	O
demonstrated	O
significantly	O
higher	O
NF-kappa	B-protein
B	I-protein
binding	I-protein
activity	I-protein
in	I-protein
an	I-protein
EMSA	O
and	I-protein
a	I-protein
stronger	O
NF-kappa	B-protein
B	I-protein
staining	O
in	I-protein
immunohistochemistry	O
than	I-protein
monocytes	O
of	I-protein
patients	O
with	I-protein
HbA1c	O
levels	I-protein
of	I-protein
6-8	I-protein
%	O
.	O

The	O
increase	O
in	I-protein
NF-kappa	O
B	O
activation	I-protein
correlated	O
with	I-protein
an	I-protein
increase	O
in	I-protein
plasmatic	O
markers	O
of	I-protein
lipid	O
peroxidation	O
.	O

Treatment	O
with	I-protein
the	I-protein
antioxidant	I-protein
thioctic	O
acid	O
decreased	O
NF-kappa	B-protein
B	I-protein
binding	I-protein
activity	I-protein
.	O

CONCLUSIONS	O
:	O
Hyperglycemia	O
induces	O
activation	I-protein
of	I-protein
the	I-protein
transcription	B-protein
factor	I-protein
NF-kappa	I-protein
B	I-protein
in	I-protein
ex	O
vivo-isolated	O
PBMCs	O
of	I-protein
patients	O
with	I-protein
type	O
1	I-protein
diabetes	O
.	O

NF-kappa	B-protein
B	I-protein
activation	I-protein
is	O
at	I-protein
least	O
partially	O
dependent	I-protein
on	I-protein
oxidative	B-protein
stress	O
,	O
since	O
the	I-protein
antioxidant	I-protein
thioctic	O
acid	O
significantly	O
lowered	O
the	I-protein
extent	O
of	I-protein
NF-kappa	B-protein
B	I-protein
binding	I-protein
activity	I-protein
.	O

###MEDLINE:98361758

Synergistic	O
activation	I-protein
of	I-protein
MAP	B-protein
kinase	I-protein
(	O
ERK1/2	B-protein
)	O
by	I-protein
erythropoietin	B-protein
and	I-protein
stem	I-protein
cell	I-protein
factor	I-protein
is	O
essential	O
for	I-protein
expanded	B-protein
erythropoiesis	O
.	O

Stem	B-protein
cell	I-protein
factor	I-protein
(	O
SCF	B-protein
)	O
and	I-protein
erythropoietin	B-protein
(	O
EPO	B-protein
)	O
work	O
synergistically	O
to	I-protein
support	I-protein
erythropoiesis	O
,	O
but	O
the	I-protein
mechanism	O
for	I-protein
this	O
synergism	O
is	O
unknown	O
.	O

By	O
using	O
purified	O
human	O
erythroid	O
colony-forming	O
cells	I-protein
(	O
ECFC	O
)	O
,	O
we	O
have	O
found	O
that	O
SCF	B-protein
and	I-protein
EPO	B-protein
synergistically	O
activate	O
MAP	B-protein
kinase	I-protein
(	O
MAPK	I-protein
,	O
ERK1/2	B-protein
)	O
,	O
which	O
correlates	O
with	I-protein
the	I-protein
cell	O
growth	O
and	I-protein
thus	O
may	O
be	O
responsible	O
for	I-protein
the	I-protein
synergistic	O
effects	O
.	O

Treatment	O
of	I-protein
the	I-protein
cells	I-protein
with	I-protein
PD98059	O
and	I-protein
wortmannin	O
,	O
inhibitors	I-protein
of	I-protein
MEK	B-protein
and	I-protein
PI-3	B-protein
kinase	I-protein
,	O
respectively	O
,	O
inhibited	O
the	I-protein
synergistic	O
activation	I-protein
of	I-protein
MAPK	I-protein
and	I-protein
also	O
the	I-protein
cell	O
growth	O
,	O
further	O
supporting	O
this	O
conclusion	O
.	O

Wortmannin	O
only	I-protein
inhibits	I-protein
MAPK	I-protein
activation	I-protein
induced	I-protein
by	I-protein
EPO	B-protein
but	O
not	I-protein
that	O
by	I-protein
SCF	B-protein
,	O
suggesting	O
that	O
SCF	B-protein
and	I-protein
EPO	B-protein
may	O
activate	O
MAPK	I-protein
through	I-protein
different	O
pathways	O
,	O
which	O
would	O
facilitate	O
synergy	O
.	O

Furthermore	O
,	O
EPO	B-protein
,	O
but	O
not	I-protein
SCF	B-protein
,	O
led	O
to	I-protein
activation	I-protein
of	I-protein
STAT5	B-protein
,	O
whereas	O
SCF	B-protein
and	I-protein
wortmannin	O
had	O
no	I-protein
effect	O
on	I-protein
the	I-protein
EPO	B-protein
-induced	O
STAT5	B-protein
activation	I-protein
,	O
suggesting	O
that	O
STAT5	B-protein
is	O
not	I-protein
involved	I-protein
in	I-protein
the	I-protein
synergistic	O
action	O
of	I-protein
SCF	B-protein
and	I-protein
EPO	B-protein
.	O

Together	O
,	O
the	I-protein
data	O
suggest	O
that	O
synergistic	O
activation	I-protein
of	I-protein
MAPK	I-protein
by	I-protein
SCF	B-protein
and	I-protein
EPO	B-protein
is	O
essential	O
for	I-protein
expanded	B-protein
erythropoiesis	O
.	O

Copyright	O
1998	O
by	I-protein
The	O
American	O
Society	O
of	I-protein
Hematology	O
.	O

###MEDLINE:98345328

The	O
molecular	I-protein
and	I-protein
phenotypic	O
profile	O
of	I-protein
primary	O
central	O
nervous	O
system	I-protein
lymphoma	I-protein
identifies	O
distinct	O
categories	O
of	I-protein
the	I-protein
disease	I-protein
and	I-protein
is	O
consistent	O
with	I-protein
histogenetic	O
derivation	O
from	I-protein
germinal	B-protein
center-related	O
B	O
cells	I-protein
.	O

Primary	O
central	O
nervous	O
system	I-protein
lymphoma	I-protein
(	O
PCNSL	O
)	O
is	O
a	I-protein
major	O
cause	O
of	I-protein
morbidity	O
and	I-protein
mortality	B-protein
among	O
human	O
immunodeficiency	I-protein
virus	I-protein
(	O
HIV	I-protein
)	O
-infected	O
individuals	O
.	O

The	O
precise	O
histogenetic	O
derivation	O
and	I-protein
the	I-protein
molecular	I-protein
pathogenesis	O
of	I-protein
PCNSL	O
is	O
poorly	O
understood	O
.	O

In	O
an	I-protein
attempt	O
to	I-protein
clarify	O
the	I-protein
histogenesis	O
and	I-protein
pathogenesis	O
of	I-protein
these	O
lymphomas	I-protein
,	O
49	I-protein
PCNSL	O
(	O
26	O
acquired	O
immunodeficiency	I-protein
syndrome	I-protein
[	O
AIDS	O
]	O
-related	I-protein
and	I-protein
23	I-protein
AIDS-unrelated	O
)	O
were	O
analyzed	O
for	I-protein
multiple	O
biologic	O
markers	O
,	O
which	O
are	O
known	O
to	I-protein
bear	O
histogenetic	O
and	I-protein
pathogenetic	O
significance	O
for	I-protein
mature	B-protein
B-cell	O
neoplasms	O
.	O

PCNSL	O
associated	I-protein
frequently	B-protein
(	O
50.0	O
%	O
)	O
with	I-protein
mutations	I-protein
of	I-protein
BCL-6	O
5	O
'	O
noncoding	I-protein
regions	O
,	O
which	O
are	O
regarded	O
as	O
a	I-protein
marker	I-protein
of	I-protein
B-cell	O
transition	O
through	I-protein
the	I-protein
germinal	B-protein
center	I-protein
(	O
GC	O
)	O
.	O

Expression	O
of	I-protein
BCL-6	B-protein
protein	I-protein
,	O
which	O
is	O
restricted	I-protein
to	I-protein
GC	O
B	O
cells	I-protein
throughout	O
physiologic	O
B-cell	O
maturation	I-protein
,	O
was	O
detected	O
in	I-protein
100	I-protein
%	O
AIDS-unrelated	O
PCNSL	O
and	I-protein
in	I-protein
56.2	O
%	O
AIDS-related	O
cases	O
.	O

Notably	O
,	O
among	O
AIDS-related	O
PCNSL	O
,	O
expression	I-protein
of	I-protein
BCL-6	B-protein
was	O
mutually	O
exclusive	O
with	I-protein
expression	I-protein
of	I-protein
Epstein-Barr	B-protein
virus	I-protein
(	O
EBV	I-protein
)	O
-encoded	I-protein
latent	B-protein
membrane	I-protein
protein	I-protein
(	O
LMP	I-protein
)	O
-1	I-protein
and	I-protein
,	O
with	I-protein
few	O
exceptions	O
,	O
also	O
of	I-protein
BCL-2	B-protein
.	O

All	O
but	O
one	B-protein
PCNSL	O
expressed	O
hMSH2	O
,	O
which	O
among	O
mature	B-protein
B	O
cells	I-protein
selectively	O
stains	O
GC	O
B	O
cells	I-protein
.	O

These	O
data	O
suggest	O
that	O
PCNSL	O
may	O
be	O
frequently	B-protein
related	O
to	I-protein
GC	O
B	O
cells	I-protein
and	I-protein
may	O
be	O
segregated	O
into	O
two	O
major	O
biologic	O
categories	O
based	O
on	I-protein
the	I-protein
expression	I-protein
pattern	I-protein
of	I-protein
BCL-6	B-protein
,	O
LMP-1	B-protein
,	O
and	I-protein
BCL-2	B-protein
.	O

BCL-6	B-protein
(	O
+	O
)	O
/	O
LMP-1	B-protein
(	O
-	O
)	O
/	O
BCL-2	B-protein
(	O
-	O
)	O
PCNSL	O
occur	O
both	O
in	I-protein
the	I-protein
presence	O
and	I-protein
in	I-protein
the	I-protein
absence	I-protein
of	I-protein
HIV	I-protein
infection	I-protein
and	I-protein
consistently	O
display	O
a	I-protein
large	O
noncleaved	O
cell	O
morphology	O
.	O

Conversely	O
,	O
BCL-6	B-protein
(	O
-	O
)	O
/	O
LMP-1	B-protein
(	O
+	O
)	O
/	O
BCL-2	B-protein
(	O
+	O
)	O
PCNSL	O
are	O
restricted	I-protein
to	I-protein
HIV-infected	O
hosts	O
and	I-protein
are	O
represented	O
by	I-protein
lymphomas	I-protein
with	I-protein
immunoblastic	O
features	I-protein
.	O

These	O
data	O
are	O
relevant	I-protein
for	I-protein
the	I-protein
pathogenesis	O
and	I-protein
histogenesis	O
of	I-protein
PCNSL	O
and	I-protein
may	O
be	O
helpful	O
to	I-protein
segregate	O
distinct	O
biologic	O
and	I-protein
prognostic	O
categories	O
of	I-protein
these	O
lymphomas	I-protein
.	O

Copyright	O
1998	O
by	I-protein
The	O
American	O
Society	O
of	I-protein
Hematology	O
.	O

###MEDLINE:98330075

Antioxidant	I-protein
regulation	I-protein
of	I-protein
phorbol	O
ester-induced	O
adhesion	O
of	I-protein
human	O
Jurkat	O
T-cells	I-protein
to	I-protein
endothelial	O
cells	I-protein
.	O

Regulation	O
of	I-protein
adhesion	O
molecule	I-protein
expression	I-protein
and	I-protein
function	I-protein
by	I-protein
reactive	I-protein
oxygen	O
species	O
via	I-protein
specific	I-protein
redox	O
sensitive	I-protein
mechanisms	O
have	O
been	O
reported	O
.	O

The	O
effects	O
of	I-protein
clinically	O
safe	O
antioxidants	O
in	I-protein
the	I-protein
regulation	I-protein
of	I-protein
adhesion	O
molecule	I-protein
expression	I-protein
in	I-protein
human	O
endothelial	O
cells	I-protein
(	O
ECV	O
)	O
,	O
and	I-protein
adherence	O
of	I-protein
human	O
Jurkat	O
T	O
cells	I-protein
to	I-protein
ECV	O
cells	I-protein
were	O
investigated	O
.	O

The	O
thiol	O
antioxidant	I-protein
,	O
alpha-lipoate	O
,	O
at	I-protein
clinically	O
relevant	I-protein
doses	O
down-regulated	I-protein
phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
)	O
-induced	O
adhesion	O
molecule	I-protein
expression	I-protein
and	I-protein
cell-cell	O
adhesion	O
.	O

Inhibition	O
of	I-protein
PMA-induced	O
ICAM-1	O
and	I-protein
VCAM-1	B-protein
expression	I-protein
as	O
well	O
as	O
PMA-induced	O
adhesion	O
of	I-protein
Jurkat	O
T-cells	I-protein
to	I-protein
ECV	O
cells	I-protein
by	I-protein
alpha-lipoate	O
was	O
dose	O
dependent	I-protein
(	O
50-250	O
microM	O
)	O
.	O

The	O
effect	O
was	O
significant	O
for	I-protein
ICAM-1	B-protein
(	O
p	O
<	O
.01	O
)	O
and	I-protein
VCAM-1	B-protein
(	O
p	O
<	O
.01	O
)	O
expression	I-protein
in	I-protein
cells	I-protein
pretreated	O
with	I-protein
100	I-protein
microM	O
alpha-lipoate	O
compared	O
to	I-protein
PMA-activated	O
untreated	O
cells	I-protein
.	O

Inhibition	O
of	I-protein
PMA-induced	O
adhesion	O
molecule	I-protein
expression	I-protein
and	I-protein
cell-cell	O
adhesion	O
was	O
more	O
pronounced	O
when	O
a	I-protein
combination	O
of	I-protein
antioxidants	O
,	O
alpha-lipoate	O
and	I-protein
alpha-tocopherol	O
,	O
were	O
used	O
compared	O
to	I-protein
the	I-protein
use	O
of	I-protein
either	O
of	I-protein
these	O
antioxidant	I-protein
alone	O
.	O

The	O
regulation	I-protein
of	I-protein
adhesion	O
molecule	I-protein
expression	I-protein
and	I-protein
function	I-protein
by	I-protein
low	O
concentration	I-protein
of	I-protein
antioxidants	O
investigated	O
does	O
not	I-protein
appear	O
to	I-protein
be	O
NF-kappaB	B-protein
regulated	O
or	I-protein
transcription	O
dependent	I-protein
because	O
no	I-protein
change	O
in	I-protein
the	I-protein
mRNA	O
response	I-protein
was	O
observed	O
.	O

Protein	I-protein
kinase	I-protein
C	I-protein
(	O
PKC	B-protein
)	O
has	O
been	O
suggested	O
to	I-protein
regulate	O
PMA-induced	O
adhesion	O
molecule	I-protein
expression	I-protein
by	I-protein
post-transcriptional	O
stabilization	O
of	I-protein
adhesion	O
molecule	I-protein
mRNA	O
.	O

Alpha-lipoate	O
pretreatment	O
did	O
not	I-protein
influence	O
the	I-protein
response	I-protein
of	I-protein
PKC	B-protein
activity	I-protein
to	I-protein
PMA	O
.	O

Oxidants	O
are	O
known	O
to	I-protein
be	O
involved	I-protein
in	I-protein
the	I-protein
regulation	I-protein
of	I-protein
cell	O
adhesion	O
processes	O
.	O

Treatment	O
of	I-protein
ECV	O
cells	I-protein
with	I-protein
PMA	O
induced	I-protein
generation	O
of	I-protein
intracellular	I-protein
oxidants	O
.	O

Alpha-lipoate	O
(	O
100	I-protein
or	I-protein
250	I-protein
microM	O
)	O
treatment	O
decreased	O
PMA-induced	O
generation	O
of	I-protein
intracellular	I-protein
oxidants	O
.	O

The	O
inhibitory	O
effect	O
of	I-protein
low	O
concentration	I-protein
of	I-protein
alpha-lipaote	O
alone	O
or	I-protein
in	I-protein
combination	O
with	I-protein
alpha-tocopherol	O
on	I-protein
agonist-induced	O
adhesion	O
processes	O
observed	O
in	I-protein
this	O
study	O
may	O
be	O
of	I-protein
potential	I-protein
therapeutic	O
value	O
.	O

###MEDLINE:98325153

Binding	O
of	I-protein
human	O
immunodeficiency	I-protein
virus	I-protein
type	O
1	I-protein
to	I-protein
CD4	B-protein
and	I-protein
CXCR4	B-protein
receptors	I-protein
differentially	O
regulates	O
expression	I-protein
of	I-protein
inflammatory	O
genes	I-protein
and	I-protein
activates	O
the	I-protein
MEK	B-protein
/ERK	O
signaling	O
pathway	I-protein
.	O

We	O
have	O
previously	O
shown	O
that	O
binding	I-protein
of	I-protein
human	O
immunodeficiency	I-protein
virus	I-protein
type	O
1	I-protein
(	O
HIV-1	O
)	O
virions	O
to	I-protein
CD4	B-protein
receptors	I-protein
stimulates	O
association	I-protein
of	I-protein
Lck	B-protein
with	I-protein
Raf-1	B-protein
and	I-protein
results	O
in	I-protein
the	I-protein
activation	I-protein
of	I-protein
Raf-1	B-protein
kinase	I-protein
in	I-protein
a	I-protein
Ras-independent	O
manner	O
.	O

In	O
the	I-protein
present	O
study	O
,	O
we	O
demonstrate	O
that	O
HIV-1	B-protein
envelope	I-protein
glycoproteins	I-protein
of	I-protein
both	O
T-cell-tropic	O
and	I-protein
macrophagetropic	O
strains	O
rapidly	I-protein
activate	O
the	I-protein
ERK/mitogen-activated	O
protein	O
(	O
MAP	O
)	O
kinase	O
pathway	I-protein
and	I-protein
the	I-protein
binding	I-protein
of	I-protein
nuclear	B-protein
transcription	I-protein
factors	I-protein
(	O
AP-1	I-protein
,	O
NF-kappaB	B-protein
,	O
and	I-protein
C/EBP	I-protein
)	O
and	I-protein
stimulate	O
expression	I-protein
of	I-protein
cytokine	B-protein
and	I-protein
chemokine	O
genes	I-protein
.	O

The	O
activation	I-protein
of	I-protein
this	O
signaling	O
pathway	I-protein
requires	O
functional	O
CD4	B-protein
receptors	I-protein
and	I-protein
is	O
independent	I-protein
of	I-protein
binding	I-protein
to	I-protein
CXCR4	B-protein
.	O

Binding	O
of	I-protein
the	I-protein
natural	O
ligand	O
stromal	B-protein
cell-derived	I-protein
factor	I-protein
1	I-protein
(	O
SDF-1	B-protein
)	O
to	I-protein
CXCR4	B-protein
,	O
which	O
inhibits	I-protein
entry	I-protein
of	I-protein
T-cell-tropic	O
HIV-1	O
,	O
activates	O
also	O
the	I-protein
ERK/	O
MAP	O
kinase	O
pathway	I-protein
.	O

However	O
,	O
SDF-1	B-protein
did	O
not	I-protein
affect	O
the	I-protein
CD4-mediated	O
expression	I-protein
of	I-protein
cytokine	B-protein
and	I-protein
chemokine	O
genes	I-protein
.	O

These	O
results	O
provide	O
firm	O
molecular	I-protein
evidence	O
that	O
binding	I-protein
of	I-protein
HIV-1	B-protein
envelope	I-protein
glycoproteins	I-protein
to	I-protein
CD4	B-protein
receptor	I-protein
initiates	O
a	I-protein
signaling	O
pathway	I-protein
(	O
s	I-protein
)	O
independent	I-protein
of	I-protein
the	I-protein
binding	I-protein
to	I-protein
the	I-protein
chemokine	B-protein
receptor	I-protein
that	O
leads	O
to	I-protein
the	I-protein
aberrant	O
expression	I-protein
of	I-protein
inflammatory	O
genes	I-protein
and	I-protein
may	O
contribute	O
significantly	O
to	I-protein
HIV-1	O
replication	O
as	O
well	O
as	O
to	I-protein
deregulation	O
of	I-protein
the	I-protein
immune	O
system	I-protein
.	O

###MEDLINE:98315074

Antigen	I-protein
receptor	O
signaling	O
induces	O
MAP	O
kinase-mediated	O
phosphorylation	I-protein
and	I-protein
degradation	I-protein
of	I-protein
the	I-protein
BCL-6	B-protein
transcription	I-protein
factor	I-protein
.	O

The	O
bcl-6	O
proto-oncogene	I-protein
encodes	O
a	I-protein
POZ/zinc	B-protein
finger	I-protein
transcriptional	I-protein
repressor	I-protein
expressed	O
in	I-protein
germinal	B-protein
center	I-protein
(	O
GC	O
)	O
B	O
and	I-protein
T	O
cells	I-protein
and	I-protein
required	O
for	I-protein
GC	O
formation	O
and	I-protein
antibody	I-protein
affinity	I-protein
maturation	I-protein
.	O

Deregulation	O
of	I-protein
bcl-6	O
expression	I-protein
by	I-protein
chromosomal	I-protein
rearrangements	O
and	I-protein
point	O
mutations	I-protein
of	I-protein
the	I-protein
bcl-6	O
promoter	I-protein
region	O
are	O
implicated	O
in	I-protein
the	I-protein
pathogenesis	O
of	I-protein
B-cell	O
lymphoma	I-protein
.	O

The	O
signals	I-protein
regulating	O
bcl-6	O
expression	I-protein
are	O
not	I-protein
known	O
.	O

Here	O
we	O
show	O
that	O
antigen	O
receptor	O
activation	I-protein
leads	O
to	I-protein
BCL-6	O
phosphorylation	I-protein
by	I-protein
mitogen-activated	B-protein
protein	I-protein
kinase	I-protein
(	O
MAPK	I-protein
)	O
.	O

Phosphorylation	O
,	O
in	I-protein
turn	O
,	O
targets	O
BCL-6	B-protein
for	I-protein
rapid	O
degradation	I-protein
by	I-protein
the	I-protein
ubiquitin	O
/	O
proteasome	B-protein
pathway	I-protein
.	O

These	O
findings	O
indicate	O
that	O
BCL-6	B-protein
expression	I-protein
is	O
directly	O
controlled	O
by	I-protein
the	I-protein
antigen	O
receptor	O
via	I-protein
MAPK	I-protein
activation	I-protein
.	O

This	O
signaling	O
pathway	I-protein
may	O
be	O
crucial	O
for	I-protein
the	I-protein
control	I-protein
of	I-protein
B-cell	O
differentiation	I-protein
and	I-protein
antibody	I-protein
response	I-protein
and	I-protein
has	O
implications	O
for	I-protein
the	I-protein
regulation	I-protein
of	I-protein
other	O
POZ/zinc	B-protein
finger	I-protein
transcription	I-protein
factors	I-protein
in	I-protein
other	O
tissues	O
.	O

###MEDLINE:98310801

Glucocorticoid	B-protein
receptors	I-protein
are	O
differentially	O
expressed	O
in	I-protein
the	I-protein
cells	I-protein
and	I-protein
tissues	O
of	I-protein
the	I-protein
immune	O
system	I-protein
.	O

Cytosolic	I-protein
glucocorticoid	I-protein
receptor	I-protein
(	O
GR	B-protein
)	O
binding	I-protein
studies	O
on	I-protein
immune	O
tissues	O
demonstrate	O
that	O
the	I-protein
thymus	I-protein
exhibits	O
three	O
to	I-protein
four	O
times	O
higher	O
levels	I-protein
of	I-protein
GR	B-protein
protein	I-protein
than	I-protein
the	I-protein
spleen	B-protein
.	O

High	O
levels	I-protein
of	I-protein
GR	B-protein
are	O
consistent	O
with	I-protein
the	I-protein
exquisite	O
sensitivity	I-protein
of	I-protein
the	I-protein
thymus	I-protein
to	I-protein
glucocorticoid	O
exposure	O
.	O

Nevertheless	O
,	O
whole	O
cell	O
binding	I-protein
studies	O
reveal	O
similar	O
levels	I-protein
of	I-protein
GR	B-protein
in	I-protein
immature	B-protein
thymic	B-protein
T	O
lymphocytes	O
and	I-protein
more	O
mature	B-protein
,	O
splenic	O
T	O
lymphocytes	O
.	O

Moreover	O
,	O
whole	O
cell	O
binding	I-protein
techniques	O
indicate	O
that	O
neutrophils	O
(	O
which	O
represent	O
roughly	O
30	I-protein
%	O
of	I-protein
splenic	O
leukocytes	O
)	O
exhibit	O
higher	O
GR	B-protein
than	I-protein
both	O
T	O
and	I-protein
B	O
lymphocytes	O
,	O
further	O
contradicting	O
results	O
from	I-protein
cytosolic	O
binding	I-protein
studies	O
.	O

To	O
address	O
these	O
inconsistencies	O
,	O
GR	B-protein
protein	I-protein
was	O
assessed	O
in	I-protein
immune	O
cells	I-protein
and	I-protein
tissues	O
using	O
cytosolic	O
radioligand	O
binding	I-protein
.	O

Western	O
blot	O
analysis	O
,	O
and	I-protein
immunocytochemistry	O
.	O

Consistent	O
with	I-protein
previous	O
cytosolic	O
receptor	O
binding	I-protein
studies	O
on	I-protein
immune	O
tissue	O
homogenates	O
,	O
thymic	B-protein
T	O
cells	I-protein
were	O
found	O
to	I-protein
have	O
higher	O
levels	I-protein
of	I-protein
GR	B-protein
than	I-protein
T	O
cells	I-protein
isolated	I-protein
from	I-protein
the	I-protein
spleen	B-protein
.	O

In	O
addition	O
,	O
neutrophils	O
were	O
found	O
to	I-protein
have	O
fewer	O
GR	B-protein
than	I-protein
lymphocytes	O
and	I-protein
monocytes	O
.	O

These	O
results	O
indicate	O
a	I-protein
meaningful	O
relationship	O
between	O
receptor	O
expression	I-protein
and	I-protein
known	O
sensitivity	I-protein
to	I-protein
glucocorticoids	O
.	O

###MEDLINE:98252921

Functional	O
replacement	I-protein
of	I-protein
the	I-protein
mouse	I-protein
E2A	O
gene	O
with	I-protein
a	I-protein
human	O
HEB	B-protein
cDNA	I-protein
.	O

The	O
mammalian	O
E2A	O
,	O
HEB	B-protein
,	O
and	I-protein
E2-2	B-protein
genes	I-protein
encode	O
a	I-protein
unique	I-protein
class	O
of	I-protein
basic	B-protein
helix-loop-helix	I-protein
(	O
bHLH	I-protein
)	O
transcription	I-protein
factors	I-protein
that	O
are	O
evolutionarily	O
conserved	O
and	I-protein
essential	O
for	I-protein
embryonic	O
and	I-protein
postnatal	O
development	O
.	O

While	O
the	I-protein
structural	O
and	I-protein
functional	O
similarities	O
among	O
the	I-protein
gene	O
products	O
are	O
well	O
demonstrated	O
,	O
it	O
is	O
not	I-protein
clear	I-protein
why	O
deletion	I-protein
of	I-protein
E2A	B-protein
,	O
but	O
not	I-protein
HEB	B-protein
or	I-protein
E2-2	B-protein
,	O
leads	O
to	I-protein
a	I-protein
complete	O
arrest	I-protein
in	I-protein
B-lymphocyte	O
development	O
.	O

To	O
understand	O
the	I-protein
molecular	I-protein
basis	O
of	I-protein
the	I-protein
functional	O
specificity	I-protein
between	O
E2A	B-protein
and	I-protein
HEB	B-protein
/	O
E2-2	B-protein
in	I-protein
mammalian	O
development	O
,	O
we	O
generated	O
and	I-protein
tested	O
a	I-protein
panel	O
of	I-protein
E2A	O
knockin	O
mutations	I-protein
including	I-protein
subtle	O
mutations	I-protein
in	I-protein
the	I-protein
E12	B-protein
and	I-protein
E47	O
exons	I-protein
and	I-protein
substitution	O
of	I-protein
both	O
E12	B-protein
and	I-protein
E47	O
exons	I-protein
with	I-protein
a	I-protein
human	O
HEB	B-protein
cDNA	I-protein
.	O

We	O
find	O
that	O
the	I-protein
alternatively	I-protein
spliced	I-protein
E12	B-protein
and	I-protein
E47	I-protein
bHLH	I-protein
proteins	I-protein
of	I-protein
the	I-protein
E2A	O
gene	O
play	O
similar	O
and	I-protein
additive	O
roles	O
in	I-protein
supporting	O
B	O
lymphopoiesis	O
.	O

Further	O
,	O
we	O
find	O
that	O
HEB	B-protein
driven	O
by	I-protein
the	I-protein
endogenous	O
E2A	O
promoter	I-protein
can	O
functionally	O
replace	O
E2A	O
in	I-protein
supporting	O
B-cell	O
commitment	O
and	I-protein
differentiation	I-protein
toward	O
completion	O
.	O

Finally	O
,	O
the	I-protein
postnatal	O
lethality	O
associated	I-protein
with	I-protein
E2A	O
disruption	O
is	O
fully	O
rescued	O
by	I-protein
the	I-protein
addition	O
of	I-protein
HEB	B-protein
.	O

This	O
study	O
suggests	O
that	O
the	I-protein
functional	O
divergence	O
among	O
E12	B-protein
,	O
E47	B-protein
,	O
and	I-protein
HEB	B-protein
in	I-protein
different	O
cell	O
types	I-protein
is	O
partially	O
defined	I-protein
by	I-protein
the	I-protein
context	O
of	I-protein
gene	O
expression	I-protein
.	O

###MEDLINE:98281916

Biased	O
dependency	O
of	I-protein
CD80	B-protein
versus	O
CD86	B-protein
in	I-protein
the	I-protein
induction	I-protein
of	I-protein
transcription	B-protein
factors	I-protein
regulating	O
the	I-protein
human	O
IL-2	B-protein
promoter	I-protein
.	O

In	O
addition	O
to	I-protein
the	I-protein
signals	I-protein
obtained	O
by	I-protein
ligation	O
of	I-protein
the	I-protein
TCR	B-protein
,	O
T	O
cells	I-protein
need	O
additional	B-protein
,	O
co-stimulatory	O
signals	I-protein
to	I-protein
be	O
activated	O
.	O

One	I-protein
such	O
co-stimulatory	O
signal	O
is	O
delivered	O
when	O
CD28	B-protein
on	I-protein
T	O
cells	I-protein
binds	O
to	I-protein
CD80	B-protein
or	I-protein
CD86	B-protein
on	I-protein
antigen-presenting	O
cells	I-protein
(	O
APC	B-protein
)	O
.	O

In	O
the	I-protein
present	O
study	O
,	O
we	O
analyzed	O
the	I-protein
ability	O
of	I-protein
CD80	B-protein
and	I-protein
CD86	B-protein
to	I-protein
co-stimulate	O
human	O
T	O
cells	I-protein
activated	O
by	I-protein
superantigen	O
.	O

Using	O
the	I-protein
Raji	O
B	O
cell	O
lymphoma	I-protein
,	O
which	O
express	O
similar	O
levels	I-protein
of	I-protein
CD80	B-protein
and	I-protein
CD86	B-protein
,	O
it	O
was	O
found	O
that	O
T	O
cell	O
proliferation	I-protein
was	O
mainly	O
co-stimulated	O
by	I-protein
CD80	B-protein
.	O

To	O
further	O
characterize	O
the	I-protein
consequences	O
of	I-protein
this	O
biased	O
co-stimulatory	O
dependency	O
,	O
we	O
employed	O
a	I-protein
well-defined	O
system	I-protein
of	I-protein
transfected	O
CHO	O
cells	I-protein
expressing	O
human	B-protein
MHC	I-protein
class	I-protein
II	I-protein
together	O
with	I-protein
CD80	B-protein
,	O
CD86	B-protein
or	I-protein
CD80	B-protein
and	I-protein
CD86	B-protein
.	O

Proliferation	O
of	I-protein
freshly	O
prepared	O
CD4+	O
T	O
cells	I-protein
required	O
the	I-protein
presence	O
of	I-protein
either	O
CD80	B-protein
or	I-protein
CD86	B-protein
.	O

However	O
,	O
IL-2	B-protein
production	I-protein
reached	O
only	I-protein
suboptimal	O
levels	I-protein
in	I-protein
the	I-protein
presence	O
of	I-protein
CD86	B-protein
but	O
optimal	O
levels	I-protein
with	I-protein
CD80	B-protein
.	O

To	O
analyze	O
IL-2	B-protein
transcriptional	O
activity	I-protein
in	I-protein
CD80	B-protein
and	I-protein
CD86	B-protein
co-stimulated	O
T	O
cells	I-protein
we	O
used	O
Jurkat	O
T	O
cells	I-protein
transfected	O
with	I-protein
luciferase	O
reporter	O
gene	O
constructs	O
.	O

CD80	B-protein
induced	I-protein
higher	O
levels	I-protein
of	I-protein
IL-2	B-protein
promoter	I-protein
-enhancer	O
activity	I-protein
compared	O
to	I-protein
CD86	B-protein
.	O

Furthermore	O
,	O
the	I-protein
activity	I-protein
of	I-protein
transcription	B-protein
factors	I-protein
regulating	O
the	I-protein
IL-2	B-protein
promoter-enhancer	O
region	O
including	I-protein
activation	I-protein
protein-1	I-protein
,	O
CD28	B-protein
response	I-protein
element	I-protein
and	I-protein
nuclear	B-protein
factor	I-protein
kappaB	I-protein
were	O
4-8	I-protein
times	O
higher	O
after	O
CD80	B-protein
compared	O
to	I-protein
CD86	B-protein
ligation	O
.	O

Our	O
results	O
suggest	O
that	O
the	I-protein
eventual	O
appearance	O
of	I-protein
CD80	B-protein
on	I-protein
recently	O
activated	O
CD86+	O
APC	B-protein
is	O
important	O
for	I-protein
the	I-protein
superinduction	O
of	I-protein
IL-2	B-protein
production	I-protein
and	I-protein
to	I-protein
support	I-protein
vigorous	O
T	O
cell	O
proliferation	I-protein
.	O

###MEDLINE:98277450

Duplication	O
of	I-protein
the	I-protein
DR3	B-protein
gene	O
on	I-protein
human	O
chromosome	O
1p36	O
and	I-protein
its	O
deletion	I-protein
in	I-protein
human	O
neuroblastoma	O
.	O

The	O
human	O
DR3	B-protein
gene	O
,	O
whose	O
product	I-protein
is	O
also	O
known	O
as	O
Wsl-1/APO-3/TRAMP/LARD	B-protein
,	O
encodes	O
a	I-protein
tumor	B-protein
necrosis	I-protein
factor-related	I-protein
receptor	I-protein
that	O
is	O
expressed	O
primarily	O
on	I-protein
the	I-protein
surface	O
of	I-protein
thymocytes	O
and	I-protein
lymphocytes	O
.	O

DR3	B-protein
is	O
capable	O
of	I-protein
inducing	I-protein
both	O
NF-kappa	O
B	O
activation	I-protein
and	I-protein
apoptosis	O
when	O
overexpressed	O
in	I-protein
mammalian	O
cells	I-protein
,	O
although	O
its	O
ligand	O
has	O
not	I-protein
yet	O
been	O
identified	I-protein
.	O

We	O
report	O
here	O
that	O
the	I-protein
DR3	B-protein
gene	O
locus	O
is	O
tandemly	O
duplicated	I-protein
on	I-protein
human	O
chromosome	O
band	I-protein
1p36.2-p36.3	O
and	I-protein
that	O
these	O
genes	I-protein
are	O
hemizygously	O
deleted	O
and/or	O
translocated	O
to	I-protein
another	O
chromosome	O
in	I-protein
neuroblastoma	O
(	O
NB	O
)	O
cell	O
lines	B-protein
with	I-protein
amplified	O
MYCN	B-protein
.	O

Duplication	O
of	I-protein
at	I-protein
least	O
a	I-protein
portion	O
of	I-protein
the	I-protein
DR3	B-protein
gene	O
,	O
including	I-protein
the	I-protein
extracellular	B-protein
and	I-protein
transmembrane	I-protein
regions	I-protein
but	O
not	I-protein
the	I-protein
cytoplasmic	B-protein
domain	I-protein
,	O
was	O
demonstrated	O
by	I-protein
both	O
fluorescence	O
in	I-protein
situ	O
hybridization	O
and	I-protein
genomic	O
Southern	O
blotting	O
.	O

In	O
most	O
NB	O
cell	O
lines	B-protein
,	O
both	O
the	I-protein
DR3	B-protein
and	I-protein
the	I-protein
DR3L	O
sequences	I-protein
are	O
simultaneously	O
deleted	O
and/or	O
translocated	O
to	I-protein
another	O
chromosome	O
.	O

Finally	O
,	O
DR3/	B-protein
Wsl-1	I-protein
protein	I-protein
expression	I-protein
is	O
quite	O
variable	O
among	O
these	O
NB	O
cell	O
lines	B-protein
,	O
with	I-protein
very	O
low	O
or	I-protein
undetectable	O
levels	I-protein
in	I-protein
7	I-protein
of	I-protein
17	I-protein
NB	O
cell	O
lines	B-protein

###MEDLINE:86000980

Differential	O
protection	I-protein
of	I-protein
normal	O
and	I-protein
malignant	O
human	O
myeloid	O
progenitors	O
(	O
CFU-GM	O
)	O
from	I-protein
Ara-C	O
toxicity	O
using	O
cycloheximide	O
.	O

Cycloheximide	O
,	O
a	I-protein
reversible	O
protein	O
synthesis	I-protein
inhibitor	O
,	O
is	O
thought	O
to	I-protein
block	O
DNA	O
replication	O
in	I-protein
normal	O
cells	I-protein
by	I-protein
preventing	O
synthesis	I-protein
of	I-protein
a	I-protein
labile	I-protein
protein	I-protein
.	O

In	O
animal	O
systems	O
,	O
cycloheximide	O
protects	O
normal	O
cells	I-protein
from	I-protein
cytotoxic	O
S-phase	O
specific	I-protein
agents	O
,	O
such	O
as	O
cytosine	O
arabinoside	O
(	O
Ara-C	O
)	O
.	O

Malignant	B-protein
cells	I-protein
appear	O
not	I-protein
to	I-protein
be	O
susceptible	O
to	I-protein
cycloheximide-induced	O
cycle	I-protein
arrest	I-protein
and	I-protein
,	O
subsequently	O
,	O
may	O
not	I-protein
be	O
protected	O
from	I-protein
Ara-C	O
cytotoxicity	I-protein
.	O

The	O
effect	O
of	I-protein
cycloheximide	O
on	I-protein
granulocyte/macrophage	O
progenitors	O
(	O
CFU-GM	O
)	O
after	O
in	I-protein
vitro	O
Ara-C	O
exposure	O
was	O
examined	O
using	O
normal	O
human	O
bone	O
marrow	I-protein
,	O
malignant	O
progenitors	O
from	I-protein
patients	O
with	I-protein
chronic	O
myelogenous	O
leukemia	O
(	O
CML	O
)	O
,	O
and	I-protein
clonogenic	O
cells	I-protein
from	I-protein
the	I-protein
human	O
acute	O
nonlymphocytic	O
leukemia	O
cell	O
lines	B-protein
HL-60	O
and	I-protein
KG-1	O
.	O

Mononuclear	O
or	I-protein
clonogenic	O
cells	I-protein
were	O
incubated	O
for	I-protein
one	B-protein
hour	O
with	I-protein
cycloheximide	O
,	O
followed	O
by	I-protein
the	I-protein
addition	O
,	O
for	I-protein
three	O
or	I-protein
17	I-protein
hours	O
,	O
of	I-protein
Ara-C	O
before	O
being	O
plated	O
in	I-protein
a	I-protein
methylcellulose	O
culture	O
system	I-protein
.	O

CFU-GM	O
survival	B-protein
was	O
significantly	O
increase	O
if	O
normal	O
cells	I-protein
were	O
treated	O
with	I-protein
cycloheximide	O
before	O
Ara-C	O
exposure	O
.	O

Similar	B-protein
cycloheximide	O
pretreatment	O
of	I-protein
CML	O
progenitors	O
and	I-protein
clonogenic	O
HL-60	O
and	I-protein
KG-1	O
cells	I-protein
failed	O
to	I-protein
protect	O
CFU-GM	O
from	I-protein
Ara-C-induced	O
cytotoxicity	I-protein
.	O

###MEDLINE:85158098

Primary	O
cortisol	O
resistance	O
accompanied	O
by	I-protein
a	I-protein
reduction	I-protein
in	I-protein
glucocorticoid	B-protein
receptors	I-protein
in	I-protein
two	O
members	O
of	I-protein
the	I-protein
same	O
family	O
.	O

This	O
report	O
describes	O
studies	O
of	I-protein
a	I-protein
man	I-protein
suspected	O
of	I-protein
having	O
primary	O
cortisol	O
resistance	O
.	O

This	O
conclusion	O
is	O
based	O
on	I-protein
his	O
high	O
plasma	O
cortisol	O
levels	I-protein
and	I-protein
high	O
24-h	O
urinary	O
17-hydroxycorticosteroid	O
and	I-protein
cortisol	O
excretion	I-protein
,	O
plus	O
the	I-protein
fact	O
that	O
he	O
had	O
no	I-protein
manifestations	O
of	I-protein
Cushing	O
's	I-protein
syndrome	I-protein
.	O

Among	O
family	O
members	O
tested	O
,	O
his	O
mother	O
also	O
had	O
hypercortisolemia	O
.	O

Both	O
mother	O
and	I-protein
son	B-protein
had	O
high	O
levels	I-protein
of	I-protein
unbound	O
plasma	O
cortisol	O
,	O
but	O
their	O
plasma	O
ACTH	B-protein
concentrations	O
were	O
within	B-protein
the	I-protein
normal	O
range	O
.	O

Both	O
were	O
partially	O
resistant	I-protein
to	I-protein
dexamethasone	O
adrenal	I-protein
suppression	O
,	O
and	I-protein
both	O
had	O
mild	I-protein
hypertension	O
without	I-protein
hypokalemia	O
.	O

To	O
study	O
this	O
apparent	O
end-organ	O
resistance	O
to	I-protein
cortisol	O
,	O
we	O
examined	O
the	I-protein
glucocorticoid	B-protein
receptors	I-protein
in	I-protein
peripheral	O
mononuclear	O
cells	I-protein
.	O

Using	O
whole	O
cell	O
assays	O
,	O
glucocorticoid	B-protein
receptors	I-protein
in	I-protein
both	O
patients	O
were	O
found	O
to	I-protein
have	O
reduced	O
total	O
binding	I-protein
capacity	O
.	O

We	O
conclude	O
that	O
these	O
two	O
patients	O
,	O
members	O
of	I-protein
the	I-protein
same	O
family	O
,	O
have	O
primary	O
cortisol	O
resistance	O
accompanied	O
by	I-protein
a	I-protein
reduced	O
number	I-protein
of	I-protein
glucocorticoid	B-protein
receptors	I-protein
.	O

###MEDLINE:86151192

[	O
Glucocorticoid	B-protein
receptors	I-protein
and	I-protein
response	I-protein
to	I-protein
polychemotherapy	O
in	I-protein
acute	O
lymphatic	B-protein
leukemia	O
]	O

Glucocorticoid	B-protein
receptor	I-protein
(	O
GR	B-protein
)	O
levels	I-protein
were	O
quantified	O
in	I-protein
leukemic	O
blasts	O
from	I-protein
peripheral	O
blood	O
of	I-protein
86	I-protein
patients	O
with	I-protein
acute	O
lymphoblastic	O
leukemia	O
.	O

The	O
subsequent	O
achievement	O
of	I-protein
complete	O
remission	O
after	O
combination	O
chemotherapy	O
was	O
correlated	O
with	I-protein
high	O
receptor	O
levels	I-protein
.	O

Forty-seven	O
of	I-protein
50	I-protein
patients	O
with	I-protein
leukemic	O
cells	I-protein
containing	I-protein
more	O
than	I-protein
6	I-protein
,	O
000	O
receptor	O
sites	I-protein
and	I-protein
22	I-protein
of	I-protein
36	I-protein
patients	O
with	I-protein
cells	I-protein
containing	I-protein
less	O
than	I-protein
6	I-protein
,	O
000	O
receptor	O
sites	I-protein
achieved	O
remission	O
.	O

The	O
study	O
of	I-protein
glucocorticoid	B-protein
receptors	I-protein
in	I-protein
leukemic	O
cells	I-protein
may	O
predict	O
response	I-protein
to	I-protein
combination	O
chemotherapy	O
in	I-protein
patients	O
with	I-protein
acute	O
lymphoblastic	O
leukemia	O
.	O

###MEDLINE:84259095

Specific	B-protein
uptake	I-protein
of	I-protein
1	I-protein
,	O
25-dihydroxycholecalciferol	O
by	I-protein
human	O
chronic	O
myeloid	O
leukemia	O
cells	I-protein
.	O

We	O
have	O
examined	O
mononuclear	O
cell	O
preparations	O
from	I-protein
patients	O
with	I-protein
chronic	O
myeloid	O
leukemia	O
[	O
CML	O
]	O
for	I-protein
binding	I-protein
of	I-protein
and	I-protein
response	I-protein
to	I-protein
1	I-protein
,	O
25-dihydroxycholecalciferol	O
[	O
1	I-protein
,	O
25-	O
(	O
OH	O
)	O
2D3	O
]	O
.	O

Whole	O
cells	I-protein
specifically	O
took	O
up	O
[	O
3H	I-protein
]	O
-1	I-protein
,	O
25-	O
(	O
OH	O
)	O
2D3	O
with	I-protein
high	O
affinity	I-protein
(	O
Kd	O
3.6	O
X	O
10	I-protein
(	O
-11	O
)	O
M	I-protein
)	O
and	I-protein
low	O
capacity	O
.	O

Subcellular	O
fractionation	O
of	I-protein
labeled	O
cells	I-protein
showed	O
that	O
binding	I-protein
was	O
restricted	I-protein
to	I-protein
cytosols	O
and	I-protein
nuclei	O
.	O

Sucrose	O
gradient	I-protein
centrifugation	O
of	I-protein
cells	I-protein
preincubated	O
with	I-protein
[	O
3H	I-protein
]	O
-1	I-protein
,	O
25-	O
(	O
OH	O
)	O
2D3	O
revealed	O
a	I-protein
single	O
3.6S	O
peak	O
which	O
was	O
totally	O
displaced	O
with	I-protein
100-fold	O
excess	O
nonradioactive	O
hormone	I-protein
.	O

However	O
,	O
we	O
were	O
unable	O
to	I-protein
demonstrate	O
specific	I-protein
binding	I-protein
of	I-protein
1	I-protein
,	O
25-	O
(	O
OH	O
)	O
2D3	O
by	I-protein
postlabeling	O
standard	O
cytosol	I-protein
preparations	O
.	O

In	O
addition	O
,	O
cytosols	O
prepared	O
from	I-protein
a	I-protein
mixture	O
of	I-protein
CML	O
cells	I-protein
and	I-protein
1	I-protein
,	O
25-	O
(	O
OH	O
)	O
2D3	O
receptor-positive	O
T47D	O
(	O
human	O
breast	O
cancer	O
)	O
cells	I-protein
had	O
less	O
than	I-protein
10	I-protein
%	O
of	I-protein
the	I-protein
binding	I-protein
measured	O
in	I-protein
T47D	O
cytosol	I-protein
alone	O
.	O

However	O
,	O
the	I-protein
levels	I-protein
of	I-protein
binding	I-protein
in	I-protein
T47D	O
cytosols	O
were	O
not	I-protein
reduced	O
if	O
the	I-protein
receptors	I-protein
were	O
occupied	O
with	I-protein
[	O
3H	I-protein
]	O
-1	I-protein
,	O
25-	O
(	O
OH	O
)	O
2D3	O
prior	O
to	I-protein
the	I-protein
addition	O
of	I-protein
the	I-protein
CML	O
cytosols	O
.	O

Thus	O
,	O
CML	O
cells	I-protein
appear	O
to	I-protein
contain	O
both	O
the	I-protein
receptor	O
for	I-protein
1	I-protein
,	O
25-	O
(	O
OH	O
)	O
2D3	O
and	I-protein
an	I-protein
unknown	O
substance	I-protein
which	O
prevents	O
its	O
detection	O
following	O
the	I-protein
preparation	O
of	I-protein
cytosol	I-protein
.	O

Cells	O
from	I-protein
patients	O
with	I-protein
CML	O
in	I-protein
the	I-protein
chronic	O
phase	I-protein
specifically	O
bound	I-protein
more	O
1	I-protein
,	O
25-	O
(	O
OH	O
)	O
2D3	O
[	O
18.0	O
+/-	O
3.2	O
(	O
S.E.	O
)	O
fmol/10	O
(	O
7	I-protein
)	O
cells	I-protein
]	O
than	I-protein
did	O
those	O
in	I-protein
acute	O
myeloid	O
transformation	I-protein
[	O
7.2	I-protein
+/-	O
1.5	I-protein
]	O
or	I-protein
than	I-protein
did	O
cells	I-protein
from	I-protein
patients	O
with	I-protein
acute	O
myeloid	O
leukemia	O
[	O
2.6	O
+/-	O
0.8	O
]	O
.	O

Only	O
cells	I-protein
from	I-protein
the	I-protein
first	O
group	I-protein
of	I-protein
patients	O
responded	O
to	I-protein
the	I-protein
addition	O
of	I-protein
1	I-protein
,	O
25-	O
(	O
OH	O
)	O
2D3	O
by	I-protein
differentiating	O
along	O
the	I-protein
monocyte-macrophage	O
pathway	I-protein
.	O

We	O
conclude	O
that	O
the	I-protein
differentiation-induction	O
effect	O
of	I-protein
1	I-protein
,	O
25-	O
(	O
OH	O
)	O
2D3	O
is	O
likely	B-protein
to	I-protein
depend	O
on	I-protein
adequate	O
levels	I-protein
of	I-protein
receptor	O
and	I-protein
that	O
intact	O
cells	I-protein
rather	O
than	I-protein
cytosol	I-protein
preparations	O
should	O
be	O
studied	O
before	O
cells	I-protein
of	I-protein
a	I-protein
particular	O
tissue	O
are	O
designated	O
as	O
receptor	O
negative	O
.	O

###MEDLINE:84080809

Effect	O
of	I-protein
cell	O
cycle	I-protein
position	O
on	I-protein
dexamethasone	O
binding	I-protein
by	I-protein
mouse	I-protein
and	I-protein
human	O
lymphoid	O
cell	O
lines	B-protein
:	O
correlation	O
between	O
an	I-protein
increase	O
in	I-protein
dexamethasone	O
binding	I-protein
during	I-protein
S	I-protein
phase	I-protein
and	I-protein
dexamethasone	O
sensitivity	I-protein
.	O

We	O
determined	O
the	I-protein
effect	O
of	I-protein
cell	O
cycle	I-protein
position	O
on	I-protein
the	I-protein
amount	O
of	I-protein
dexamethasone	O
that	O
was	O
specifically	O
bound	I-protein
by	I-protein
mouse	I-protein
and	I-protein
human	O
lymphoid	O
cell	O
lines	B-protein
.	O

Cell	I-protein
lines	B-protein
that	O
were	O
either	O
sensitive	I-protein
or	I-protein
resistant	I-protein
to	I-protein
growth	O
inhibition	O
by	I-protein
dexamethasone	O
were	O
compared	O
.	O

Exponentially	O
growing	O
cells	I-protein
were	O
separated	O
by	I-protein
centrifugal	O
elutriation	O
into	O
fractions	O
that	O
corresponded	O
to	I-protein
different	O
positions	O
in	I-protein
the	I-protein
cell	O
cycle	I-protein
.	O

The	O
cell	O
cycle	I-protein
phase	I-protein
distribution	I-protein
of	I-protein
each	O
fraction	O
was	O
estimated	O
by	I-protein
flow	O
cytometry	O
and	I-protein
autoradiography	O
.	O

The	O
amount	O
of	I-protein
dexamethasone	O
bound	I-protein
per	O
cell	O
in	I-protein
each	O
fraction	O
was	O
measured	O
by	I-protein
a	I-protein
whole	O
cell	O
binding	I-protein
assay	O
.	O

In	O
three	O
dexamethasone-sensitive	O
cell	O
lines	B-protein
(	O
two	O
mouse	I-protein
and	I-protein
one	B-protein
human	O
)	O
,	O
we	O
found	O
that	O
the	I-protein
amount	O
of	I-protein
dexamethasone	O
bound	I-protein
per	O
cell	O
increased	I-protein
2-4-fold	O
between	O
G1	O
phase	I-protein
and	I-protein
S	I-protein
phase	I-protein
,	O
and	I-protein
then	O
decreased	O
during	I-protein
G2/M	O
phase	I-protein
.	O

Results	O
were	O
the	I-protein
same	O
when	O
the	I-protein
amount	O
of	I-protein
dexamethasone	O
bound	I-protein
per	O
milligram	O
of	I-protein
cell	B-protein
protein	I-protein
was	O
measured	O
.	O

Binding	O
affinity	I-protein
was	O
the	I-protein
same	O
during	I-protein
G1	O
phase	I-protein
and	I-protein
S	I-protein
phase	I-protein
,	O
but	O
the	I-protein
proportion	O
of	I-protein
bound	I-protein
dexamethasone	O
that	O
translocated	O
to	I-protein
the	I-protein
nucleus	I-protein
was	O
greater	O
during	I-protein
S	I-protein
phase	I-protein
.	O

In	O
contrast	O
,	O
we	O
found	O
that	O
the	I-protein
amount	O
of	I-protein
dexamethasone	O
bound	I-protein
per	O
cell	O
by	I-protein
three	O
dexamethasone-resistant	O
cell	O
lines	B-protein
(	O
two	O
mouse	I-protein
and	I-protein
one	B-protein
human	O
)	O
did	O
not	I-protein
increase	O
during	I-protein
S	I-protein
phase	I-protein
.	O

Our	O
results	O
indicate	O
that	O
cell	O
cycle	I-protein
changes	O
in	I-protein
dexamethasone	O
binding	I-protein
are	O
not	I-protein
simply	O
related	O
to	I-protein
changes	O
in	I-protein
cell	O
protein	O
or	I-protein
cell	O
volume	O
during	I-protein
the	I-protein
cell	O
cycle	I-protein
.	O

An	O
increase	O
in	I-protein
dexamethasone	O
binding	I-protein
during	I-protein
S	I-protein
phase	I-protein
may	O
be	O
required	O
for	I-protein
dexamethasone	O
to	I-protein
inhibit	O
cell	O
growth	O
,	O
and	I-protein
a	I-protein
failure	I-protein
of	I-protein
dexamethasone	O
binding	I-protein
to	I-protein
increase	O
during	I-protein
S	I-protein
phase	I-protein
might	O
represent	O
a	I-protein
new	I-protein
mechanism	O
of	I-protein
dexamethasone	O
resistance	O
in	I-protein
lymphoid	O
cells	I-protein
.	O

###MEDLINE:84066221

Presence	O
and	I-protein
steroid	O
inducibility	O
of	I-protein
glutamine	B-protein
synthetase	I-protein
in	I-protein
human	O
leukemic	O
cells	I-protein
.	O

Glutamine	I-protein
synthetase	I-protein
(	O
EC	I-protein
6.3.1.2	O
;	O
GS	O
)	O
is	O
present	O
in	I-protein
lymphoblasts	O
from	I-protein
patients	O
with	I-protein
acute	O
lymphoblastic	O
leukemia	O
(	O
ALL	B-protein
)	O
as	O
well	O
as	O
in	I-protein
normal	O
peripheral	O
blood	O
lymphocytes	O
.	O

In	O
16	I-protein
out	O
of	I-protein
20	I-protein
ALL	B-protein
patients	O
studied	O
exposure	O
of	I-protein
the	I-protein
cells	I-protein
to	I-protein
physiological	O
concentrations	O
of	I-protein
dexamethasone	O
in	I-protein
vitro	O
increased	I-protein
enzyme	I-protein
activity	I-protein
above	O
the	I-protein
control	I-protein
levels	I-protein
.	O

The	O
increase	O
was	O
specific	I-protein
for	I-protein
glucocorticoid	B-protein
receptor	I-protein
ligands	I-protein
.	O

A	O
direct	O
correlation	O
was	O
found	O
between	O
the	I-protein
magnitude	O
of	I-protein
glucocorticoid-mediated	O
increase	O
of	I-protein
GS	O
activity	I-protein
and	I-protein
the	I-protein
cellular	O
levels	I-protein
of	I-protein
specific	I-protein
glucocorticoid	B-protein
receptors	I-protein
assayed	O
in	I-protein
the	I-protein
same	O
cell	O
specimen	O
.	O

Moreover	O
,	O
the	I-protein
basal	O
levels	I-protein
of	I-protein
the	I-protein
enzyme	I-protein
measured	O
in	I-protein
cells	I-protein
prior	O
to	I-protein
exposure	O
to	I-protein
dexamethasone	O
correlated	O
negatively	O
with	I-protein
receptor	O
density	I-protein
.	O

It	O
is	O
suggested	O
that	O
the	I-protein
presence	O
of	I-protein
steroid-inducible	B-protein
GS	I-protein
in	I-protein
ALL	B-protein
cells	I-protein
may	O
prove	O
to	I-protein
be	O
a	I-protein
marker	I-protein
for	I-protein
functional	O
receptor	O
sites	I-protein
.	O

###MEDLINE:83230863

Binding	O
of	I-protein
progestins	O
to	I-protein
the	I-protein
glucocorticoid	B-protein
receptor	I-protein
.	O

Correlation	O
to	I-protein
their	O
glucocorticoid-like	O
effects	O
on	I-protein
in	I-protein
vitro	O
functions	O
of	I-protein
human	O
mononuclear	O
leukocytes	O
.	O

A	O
number	I-protein
of	I-protein
physiological	O
and	I-protein
synthetic	I-protein
progestins	O
were	O
tested	O
for	I-protein
their	O
ability	O
to	I-protein
compete	O
with	I-protein
[	O
3H	I-protein
]	O
dexamethasone	O
for	I-protein
the	I-protein
binding	I-protein
to	I-protein
the	I-protein
glucocorticoid	B-protein
receptor	I-protein
of	I-protein
human	O
mononuclear	O
leukocytes	O
and	I-protein
their	O
ability	O
to	I-protein
elicit	O
glucocorticoid-like	O
effects	O
on	I-protein
the	I-protein
same	O
cells	I-protein
.	O

As	O
compared	O
to	I-protein
the	I-protein
reference	O
compound	O
dexamethasone	O
(	O
relative	I-protein
receptor	O
binding	I-protein
affinity	I-protein
defined	I-protein
as	O
100	I-protein
%	O
)	O
,	O
two	O
potent	O
synthetic	I-protein
progestins	O
with	I-protein
a	I-protein
pregnane-type	O
structure	O
,	O
megestrol	O
acetate	O
and	I-protein
medroxyprogesterone	O
acetate	O
,	O
were	O
found	O
to	I-protein
display	O
a	I-protein
considerable	O
binding	I-protein
affinity	I-protein
towards	O
the	I-protein
receptor	O
(	O
46	I-protein
and	I-protein
42	I-protein
%	O
,	O
respectively	O
)	O
.	O

The	O
relative	I-protein
binding	I-protein
affinity	I-protein
of	I-protein
the	I-protein
naturally	O
occurring	O
ligand	O
,	O
cortisol	O
,	O
to	I-protein
the	I-protein
receptor	O
was	O
clearly	O
lower	I-protein
(	O
25	I-protein
%	O
)	O
.	O

The	O
effective	O
binding	I-protein
of	I-protein
medroxyprogesterone	O
acetate	O
to	I-protein
the	I-protein
glucocorticoid	B-protein
receptor	I-protein
was	O
confirmed	O
by	I-protein
direct	O
binding	I-protein
studies	O
utilizing	O
a	I-protein
tritiated	O
derivative	O
of	I-protein
this	O
steroid	O
.	O

No	I-protein
evidence	O
for	I-protein
the	I-protein
existence	O
of	I-protein
a	I-protein
specific	I-protein
progesterone	B-protein
receptor	I-protein
in	I-protein
human	O
mononuclear	O
leukocytes	O
was	O
obtained	O
as	O
judged	O
by	I-protein
the	I-protein
results	O
of	I-protein
competition	O
experiments	O
where	O
a	I-protein
progesterone	B-protein
receptor-specific	O
ligand	O
[	O
3H	I-protein
]	O
Org	O
2058	O
was	O
used	O
.	O

Medroxyprogesterone	O
acetate	O
and	I-protein
megestrol	O
acetate	O
also	O
induced	I-protein
glucocorticoid-like	O
effects	O
on	I-protein
the	I-protein
lymphocyte	O
functions	O
.	O

These	O
included	I-protein
inhibition	O
of	I-protein
the	I-protein
proliferative	O
responses	O
to	I-protein
the	I-protein
T-cell	B-protein
mitogens	I-protein
concanavalin	B-protein
A	I-protein
and	I-protein
phytohaemagglutinin	O
and	I-protein
an	I-protein
enhanced	I-protein
accumulation	I-protein
of	I-protein
immunoglobulin	O
secreting	O
cells	I-protein
in	I-protein
pokeweed	O
mitogen-stimulated	O
cultures	O
.	O

The	O
progestin	B-protein
effect	O
appears	O
to	I-protein
be	O
mediated	I-protein
through	I-protein
a	I-protein
radiosensitive	O
(	O
suppressor	O
)	O
subpopulation	O
of	I-protein
T	O
lymphocytes	O
.	O

In	O
contrast	O
,	O
the	I-protein
synthetic	I-protein
progestins	O
related	O
structurally	O
to	I-protein
19-nortestosterone	O
,	O
norethisterone	O
and	I-protein
d-norgestrel	O
,	O
were	O
virtually	O
devoid	O
of	I-protein
binding	I-protein
affinity	I-protein
towards	O
the	I-protein
glucocorticoid	B-protein
receptor	I-protein
nor	O
did	O
they	O
measurably	O
influence	O
the	I-protein
in	I-protein
vitro	O
lymphocyte	O
functions	O
.	O

These	O
studies	O
demonstrate	O
that	O
certain	O
progestins	O
in	I-protein
common	I-protein
clinical	I-protein
use	O
probably	O
possess	O
inherent	O
glucocorticoid	O
activity	I-protein
and	I-protein
suggest	O
that	O
side	O
effects	O
attributable	O
to	I-protein
this	O
character	O
(	O
e.g.	O
suppression	O
of	I-protein
the	I-protein
pituitary-adrenal	O
axis	O
)	O
might	O
be	O
expected	O
when	O
these	O
compounds	O
are	O
used	O
in	I-protein
pharmacological	O
doses	O
.	O

###MEDLINE:82136853

Metabolic	O
and	I-protein
ultrastructural	O
aspects	O
of	I-protein
the	I-protein
in	I-protein
vitro	O
lysis	O
of	I-protein
chronic	O
lymphocytic	I-protein
leukemia	O
cells	I-protein
by	I-protein
glucocorticoids	O
.	O

Human	O
chronic	O
lymphocytic	I-protein
leukemia	O
(	O
CLL	O
)	O
cells	I-protein
like	I-protein
prothymocytes	O
and	I-protein
immunoactivated	O
T-lymphocytes	O
are	O
readily	O
lysed	O
in	I-protein
vitro	O
by	I-protein
pharmacological	O
concentrations	O
of	I-protein
glucocorticoids	O
such	O
as	O
cortisol	O
,	O
whereas	O
peripheral	O
blood	O
lymphocytes	O
and	I-protein
thymocytes	O
are	O
unaffected	O
by	I-protein
the	I-protein
hormone	I-protein
.	O

In	O
this	O
study	O
,	O
metabolic	O
and	I-protein
ultrastructural	O
aspects	O
of	I-protein
the	I-protein
cortisol-induced	O
killing	O
process	O
of	I-protein
CLL	O
cells	I-protein
are	O
recorded	O
.	O

In	O
vitro	O
lysis	O
was	O
found	O
to	I-protein
be	O
temperature	I-protein
dependent	I-protein
and	I-protein
was	O
detected	O
only	I-protein
after	O
6	I-protein
to	I-protein
8	I-protein
hr	O
incubation	O
with	I-protein
cortisol	O
by	I-protein
means	O
of	I-protein
the	I-protein
trypan	O
blue	O
exclusion	O
test	O
.	O

However	O
,	O
30	I-protein
min	O
of	I-protein
incubation	O
with	I-protein
cortisol	O
at	I-protein
either	O
37	I-protein
degrees	O
or	I-protein
4	I-protein
degrees	O
followed	O
by	I-protein
the	I-protein
removal	O
of	I-protein
the	I-protein
hormone	I-protein
was	O
still	O
sufficient	O
to	I-protein
induce	O
the	I-protein
lytic	O
process	O
.	O

Ultrastructural	O
studies	O
demonstrated	O
sequential	O
changes	O
in	I-protein
the	I-protein
cytoplasm	O
,	O
including	I-protein
swelling	O
of	I-protein
mitochondria	O
and	I-protein
cytoplasmic	O
decompartmentalization	O
,	O
followed	O
by	I-protein
loss	O
of	I-protein
surface	O
microvilli	O
with	I-protein
the	I-protein
appearance	O
of	I-protein
``	O
holes	O
''	I-protein
in	I-protein
the	I-protein
cell	O
membrane	O
,	O
and	I-protein
subsequent	O
condensation	I-protein
of	I-protein
nuclear	O
chromatin	O
.	O

The	O
large	O
holes	O
in	I-protein
the	I-protein
membrane	O
appearing	O
after	O
6	I-protein
hr	O
of	I-protein
incubation	O
with	I-protein
the	I-protein
hormone	I-protein
may	O
be	O
the	I-protein
cause	O
for	I-protein
the	I-protein
penetration	O
of	I-protein
the	I-protein
viable	O
stain	O
into	O
the	I-protein
dead	O
cells	I-protein
,	O
as	O
seen	O
by	I-protein
light	I-protein
microscopy	O
.	O

Addition	O
of	I-protein
metabolic	O
inhibitors	I-protein
including	I-protein
actinomycin	O
D	O
,	O
puromycin	I-protein
,	O
and	I-protein
cycloheximide	O
following	O
administration	O
of	I-protein
cortisol	O
resulted	O
in	I-protein
inhibition	O
of	I-protein
the	I-protein
cell	O
lysis	O
.	O

An	O
excess	O
of	I-protein
an	I-protein
antagonist	O
such	O
as	O
cortexolone	O
was	O
found	O
to	I-protein
inhibit	O
the	I-protein
cortisol-induced	O
cytolysis	O
of	I-protein
the	I-protein
CLL	O
cells	I-protein
.	O

It	O
is	O
suggested	O
that	O
the	I-protein
glucocorticoid-induced	O
lysis	O
of	I-protein
human	O
CLL	O
cells	I-protein
is	O
similar	O
to	I-protein
the	I-protein
phenomenon	O
observed	O
in	I-protein
rat	I-protein
or	I-protein
murine	O
lymphocytes	O
and	I-protein
is	O
mediated	I-protein
by	I-protein
interaction	I-protein
of	I-protein
the	I-protein
steroid	O
molecule	I-protein
with	I-protein
the	I-protein
cytoplasmic	B-protein
receptor	I-protein
.	O

The	O
resulting	O
complex	I-protein
appears	O
to	I-protein
activate	O
specific	I-protein
gene	O
(	O
s	I-protein
)	O
the	I-protein
products	O
of	I-protein
which	O
eventually	O
cause	O
cytolysis	O
.	O

###MEDLINE:82048495

Glucocorticoid	B-protein
receptors	I-protein
in	I-protein
lymphoid	O
tumors	I-protein
.	O

There	O
is	O
a	I-protein
range	O
of	I-protein
levels	I-protein
of	I-protein
glucocorticoid	B-protein
receptor	I-protein
numbers	O
seen	O
in	I-protein
the	I-protein
various	O
subclasses	O
of	I-protein
acute	O
lymphatic	B-protein
leukemia	O
(	O
ALL	B-protein
)	O
.	O

This	O
variability	I-protein
can	O
not	I-protein
be	O
explained	O
by	I-protein
the	I-protein
known	O
correlation	O
between	O
active	O
cell	O
proliferation	I-protein
and	I-protein
an	I-protein
increase	O
in	I-protein
the	I-protein
number	I-protein
of	I-protein
receptors	I-protein
,	O
since	O
the	I-protein
tumors	I-protein
with	I-protein
the	I-protein
highest	O
growth	O
fraction	O
(	O
i.e.	O
,	O
Burkitt	B-protein
's	I-protein
lymphoma	I-protein
and	I-protein
T-cell	O
leukemia	O
)	O
tend	O
to	I-protein
have	O
lower	I-protein
average	O
receptor	O
numbers	O
than	I-protein
do	O
tumors	I-protein
with	I-protein
lower	I-protein
growth	O
fractions	O
such	O
as	O
common	I-protein
ALL	B-protein
.	O

All	O
clinical	I-protein
specimens	O
from	I-protein
patients	O
with	I-protein
lymphatic	B-protein
leukemia	O
have	O
some	O
measurable	O
level	I-protein
of	I-protein
glucocorticoid	B-protein
receptors	I-protein
;	O
therefore	O
,	O
the	I-protein
resistance	O
seen	O
in	I-protein
vivo	O
can	O
not	I-protein
be	O
explained	O
by	I-protein
the	I-protein
lack	O
of	I-protein
receptors	I-protein
.	O

However	O
,	O
there	O
has	O
been	O
a	I-protein
positive	I-protein
correlation	O
,	O
in	I-protein
our	O
hands	O
,	O
with	I-protein
receptor	O
level	I-protein
and	I-protein
prognosis	O
.	O

On	O
the	I-protein
basis	O
of	I-protein
in	I-protein
vitro	O
models	O
,	O
it	O
is	O
proposed	O
that	O
perhaps	O
the	I-protein
high	O
receptor	O
cell	O
lines	B-protein
(	O
i.e.	O
,	O
common	I-protein
ALL	B-protein
of	I-protein
childhood	I-protein
)	O
have	O
relative	I-protein
stability	O
of	I-protein
their	O
genetic	O
material	I-protein
making	O
glucocorticoid-resistant	O
mutations	I-protein
less	O
likely	B-protein
to	I-protein
occur	O
in	I-protein
patients	O
with	I-protein
these	O
cells	I-protein
than	I-protein
in	I-protein
low-receptor	O
cell	O
lines	B-protein
(	O
i.e.	O
,	O
T-cell	O
leukemia	O
)	O
.	O

This	O
greater	O
genetic	O
variability	I-protein
in	I-protein
the	I-protein
low-receptor	O
lines	B-protein
could	O
account	O
for	I-protein
the	I-protein
earlier	O
emergence	O
of	I-protein
clinical	I-protein
glucocorticoid	O
resistance	O
in	I-protein
these	O
patients	O
.	O

###MEDLINE:81271552

[	O
Tumor	O
histology	O
and	I-protein
steroid	B-protein
receptors	I-protein
in	I-protein
breast	O
carcinoma	I-protein
]	O

In	O
Specimens	O
of	I-protein
115	I-protein
patients	O
with	I-protein
breast	O
cancer	O
4	I-protein
tumorparameters	O
(	O
tumorsize	O
,	O
tumorboder	O
,	O
nucleargrade	O
,	O
lymphocytic	I-protein
stromal	O
reaction	I-protein
)	O
3	O
features	I-protein
of	I-protein
regional	O
lymphnodes	O
(	O
sinushistiocytosis	O
,	O
T-cellreaction	O
,	O
lymphnode	O
metastases	O
)	O
and	I-protein
estrogen	B-protein
and	I-protein
progesteron	I-protein
receptors	I-protein
were	O
determined	O
.	O

A	O
strong	O
sinushistiocytosis	O
and	I-protein
T-cellreaction	O
could	O
be	O
verified	O
mainly	O
in	I-protein
metastases	O
in	I-protein
free	B-protein
lymphnodes	O
.	O

The	O
steroid	B-protein
receptor	I-protein
content	O
does	O
not	I-protein
correlate	O
with	I-protein
histological	O
parameters	O

###MEDLINE:86040213

Aldosterone-receptor	B-protein
deficiency	I-protein
in	I-protein
pseudohypoaldosteronism	O
.	O

Pseudohypoaldosteronism	B-protein
,	O
a	I-protein
syndrome	I-protein
characterized	O
by	I-protein
salt	O
wasting	O
and	I-protein
failure	I-protein
to	I-protein
thrive	O
,	O
usually	O
presents	O
in	I-protein
infancy	O
as	O
high	O
urinary	O
levels	I-protein
of	I-protein
sodium	O
despite	O
hyponatremia	O
,	O
hyperkalemia	O
,	O
hyperreninemia	O
,	O
and	I-protein
elevated	I-protein
aldosterone	O
levels	I-protein
.	O

We	O
have	O
investigated	O
this	O
syndrome	I-protein
for	I-protein
the	I-protein
possibility	O
of	I-protein
abnormal	I-protein
Type	I-protein
I	I-protein
or	I-protein
``	B-protein
mineralocorticoid-like	I-protein
''	I-protein
receptors	I-protein
,	O
which	O
have	O
intrinsic	I-protein
steroid	O
specificity	I-protein
indistinguishable	O
from	I-protein
that	O
of	I-protein
renal	B-protein
mineralocorticoid	I-protein
receptors	I-protein
and	I-protein
are	O
found	O
in	I-protein
many	O
tissues	O
and	I-protein
cells	I-protein
,	O
including	I-protein
mononuclear	O
leukocytes	O
.	O

We	O
have	O
studied	O
three	O
patients	O
with	I-protein
pseudohypoaldosteronism	O
:	O
the	I-protein
28-year-old	O
index	I-protein
case	O
in	I-protein
Melbourne	O
(	O
Patient	O
1	I-protein
)	O
and	I-protein
two	O
siblings	O
in	I-protein
Munich	O
,	O
eight	O
and	I-protein
two	O
years	O
of	I-protein
age	I-protein
(	O
Patients	O
2	I-protein
and	I-protein
3	O
)	O
;	O
clinically	O
,	O
Patient	O
3	O
had	O
a	I-protein
less	O
severe	I-protein
case	O
than	I-protein
his	O
sister	I-protein
.	O

Percoll-separated	O
control	I-protein
monocytes	O
bound	I-protein
[	O
3H	I-protein
]	O
aldosterone	O
with	I-protein
high	O
affinity	I-protein
(	O
Kd	O
approximately	O
3	O
nM	O
)	O
and	I-protein
limited	O
capacity	O
(	O
150	I-protein
to	I-protein
600	I-protein
sites	I-protein
per	O
cell	O
)	O
.	O

On	O
repeated	O
examination	O
,	O
no	I-protein
[	O
3H	I-protein
]	O
aldosterone	O
binding	I-protein
was	O
found	O
in	I-protein
monocytes	O
from	I-protein
Patients	O
1	I-protein
and	I-protein
2	I-protein
;	O
in	I-protein
Patient	O
3	O
,	O
the	I-protein
levels	I-protein
were	O
62	I-protein
sites	I-protein
per	O
cell	O
,	O
more	O
than	I-protein
2	I-protein
S.D.	O
below	O
those	O
of	I-protein
the	I-protein
control	I-protein
.	O

Levels	O
in	I-protein
the	I-protein
parents	O
of	I-protein
the	I-protein
Munich	O
patients	O
(	O
first	O
cousins	O
)	O
were	O
normal	O
.	O

It	O
appears	O
that	O
pseudohypoaldosteronism	O
is	O
caused	O
by	I-protein
a	I-protein
Type	I-protein
I	I-protein
receptor	I-protein
defect	I-protein
,	O
that	O
the	I-protein
defect	I-protein
may	O
be	O
complete	O
or	I-protein
partial	I-protein
,	O
that	O
transmission	I-protein
may	O
be	O
autosomal	I-protein
recessive	I-protein
,	O
and	I-protein
that	O
the	I-protein
study	O
of	I-protein
patients	O
with	I-protein
pseudohypoaldosteronism	O
may	O
indicate	O
physiologic	O
roles	O
for	I-protein
Type	I-protein
I	I-protein
receptors	I-protein
in	I-protein
nonepithelial	O
tissues	O
.	O

###MEDLINE:85257187

Glucocorticoid	O
inhibition	O
of	I-protein
urokinase-like	B-protein
plasminogen	I-protein
activators	I-protein
in	I-protein
cultured	O
human	O
lymphoblasts	O
.	O

Two	O
human	O
lymphoblast	O
cell	O
lines	B-protein
,	O
LICR-LON-HMy2	O
(	O
HMy2	O
cells	I-protein
)	O
and	I-protein
GM4672A	O
cells	I-protein
,	O
are	O
moderately	O
growth	O
inhibited	O
by	I-protein
dexamethasone	O
(	O
1	I-protein
,	O
4-pregnadien-9-fluoro-16	O
alpha-methyl-11	O
beta	O
,	O
17	I-protein
alpha	O
,	O
21-triol-3	O
,	O
20-dione	O
)	O
(	O
Dex	O
)	O
.	O

Both	O
cell	O
types	I-protein
secrete	O
a	I-protein
urokinase	I-protein
(	O
UK	I-protein
)	O
-like	I-protein
plasminogen	I-protein
activator	I-protein
(	O
PA	I-protein
)	O
.	O

Treatment	O
of	I-protein
both	O
HMy2	O
and	I-protein
GM4672A	O
cells	I-protein
with	I-protein
Dex	O
for	I-protein
1-4	I-protein
days	O
inhibits	I-protein
extracellular	O
PA	I-protein
activity	I-protein
in	I-protein
a	I-protein
concentration-dependent	O
manner	O
,	O
being	O
half-maximal	O
at	I-protein
approximately	O
1	I-protein
X	O
10	I-protein
(	O
-9	O
)	O
M	I-protein
.	O

Inhibition	O
of	I-protein
PA	I-protein
in	I-protein
both	O
cell	O
types	I-protein
is	O
specific	I-protein
for	I-protein
active	O
glucocorticoids	O
,	O
and	I-protein
this	O
specificity	I-protein
parallels	O
the	I-protein
ability	O
of	I-protein
various	O
steroids	O
to	I-protein
bind	O
to	I-protein
glucocorticoid	B-protein
receptors	I-protein
.	O

HMy2	O
cell	O
PA	I-protein
is	O
fully	O
suppressible	O
by	I-protein
Dex	O
,	O
whereas	O
up	O
to	I-protein
one	B-protein
third	O
of	I-protein
the	I-protein
activator	O
expressed	O
by	I-protein
GM4672A	O
cells	I-protein
is	O
resistant	I-protein
to	I-protein
glucocorticoid	O
inhibition	O
.	O

Mixing	O
experiments	O
using	O
a	I-protein
UK	O
standard	O
and	I-protein
conditioned	O
media	I-protein
from	I-protein
Dex-treated	O
cells	I-protein
suggest	O
an	I-protein
absence	I-protein
of	I-protein
glucocorticoid-inducible	B-protein
inhibitors	I-protein
to	I-protein
UK	B-protein
or	I-protein
plasmin	B-protein
in	I-protein
both	O
cell	O
types	I-protein
.	O

However	O
,	O
conditioned	O
media	I-protein
from	I-protein
Dex-treated	O
GM4672A	O
cells	I-protein
inhibits	I-protein
a	I-protein
portion	O
of	I-protein
the	I-protein
homologous	I-protein
cellular	O
activator	O
in	I-protein
conditioned	O
media	I-protein
from	I-protein
control	I-protein
GM4672A	O
cells	I-protein
.	O

Thus	O
,	O
low	O
levels	I-protein
of	I-protein
glucocorticoid-inducible	B-protein
inhibitors	I-protein
may	O
contribute	O
to	I-protein
,	O
but	O
can	O
not	I-protein
fully	O
account	O
for	I-protein
,	O
Dex	O
inhibition	O
of	I-protein
GM4672A	B-protein
PA	I-protein
activity	I-protein
.	O

Glucocorticoid-inducible	B-protein
inhibitors	I-protein
in	I-protein
HMy2	O
cells	I-protein
are	O
either	O
totally	O
absent	O
or	I-protein
are	O
present	O
at	I-protein
undetectable	O
levels	I-protein
.	O

Thus	O
,	O
regulation	I-protein
of	I-protein
UK-like	B-protein
PAs	I-protein
in	I-protein
HMy2	O
and	I-protein
GM4672A	O
cells	I-protein
differs	O
with	I-protein
respect	O
to	I-protein
the	I-protein
extent	O
to	I-protein
which	O
glucocorticoids	O
inhibit	O
constitutively	O
expressed	O
activator	O
levels	I-protein
,	O
as	O
well	O
as	O
the	I-protein
possible	O
contribution	O
of	I-protein
glucocorticoid-inducible	B-protein
inhibitors	I-protein
to	I-protein
the	I-protein
regulatory	O
process	O
in	I-protein
GM4672A	O
cells	I-protein
.	O

###MEDLINE:85146267

Characterization	O
of	I-protein
aldosterone	O
binding	I-protein
sites	I-protein
in	I-protein
circulating	O
human	O
mononuclear	O
leukocytes	O
.	O

Aldosterone	O
binding	I-protein
sites	I-protein
in	I-protein
human	O
mononuclear	O
leukocytes	O
were	O
characterized	O
after	O
separation	O
of	I-protein
cells	I-protein
from	I-protein
blood	O
by	I-protein
a	I-protein
Percoll	O
gradient	I-protein
.	O

After	O
washing	O
and	I-protein
resuspension	O
in	I-protein
RPMI-1640	O
medium	I-protein
,	O
cells	I-protein
were	O
incubated	O
at	I-protein
37	I-protein
degrees	O
C	O
for	I-protein
1	I-protein
h	I-protein
with	I-protein
different	O
concentrations	O
of	I-protein
[	O
3H	I-protein
]	O
aldosterone	O
plus	O
a	I-protein
100-fold	O
concentration	I-protein
of	I-protein
RU-26988	O
(	O
11	I-protein
alpha	O
,	O
17	I-protein
alpha-dihydroxy-17	O
beta-propynylandrost-1	O
,	O
4	I-protein
,	O
6-trien-3-one	O
)	O
,	O
with	I-protein
or	I-protein
without	I-protein
an	I-protein
excess	O
of	I-protein
unlabeled	O
aldosterone	O
.	O

Aldosterone	O
binds	O
to	I-protein
a	I-protein
single	O
class	O
of	I-protein
receptors	I-protein
with	I-protein
an	I-protein
affinity	I-protein
of	I-protein
2.7	O
+/-	O
0.5	O
nM	O
(	O
means	O
+/-	O
SD	O
,	O
n	O
=	O
14	I-protein
)	O
and	I-protein
a	I-protein
capacity	O
of	I-protein
290	O
+/-	O
108	I-protein
sites/cell	O
(	O
n	O
=	O
14	I-protein
)	O
.	O

The	O
specificity	I-protein
data	O
show	O
a	I-protein
hierarchy	O
of	I-protein
affinity	I-protein
of	I-protein
desoxycorticosterone	O
=	O
corticosterone	O
=	O
aldosterone	O
greater	O
than	I-protein
hydrocortisone	O
greater	O
than	I-protein
dexamethasone	O
.	O

The	O
results	O
indicate	O
that	O
mononuclear	O
leukocytes	O
could	O
be	O
useful	O
for	I-protein
studying	O
the	I-protein
physiological	O
significance	O
of	I-protein
these	O
mineralocorticoid	B-protein
receptors	I-protein
and	I-protein
their	O
regulation	I-protein
in	I-protein
humans	O
.	O

###MEDLINE:86028039

Mineralocorticoid	B-protein
and	I-protein
glucocorticoid	I-protein
receptors	I-protein
in	I-protein
circulating	O
mononuclear	O
leukocytes	O
of	I-protein
patients	O
with	I-protein
primary	O
hyperaldosteronism	O
.	O

Mineralocorticoid	B-protein
and	I-protein
glucocorticoid	I-protein
receptors	I-protein
were	O
measured	O
in	I-protein
circulating	O
mononuclear	O
leukocytes	O
in	I-protein
5	O
patients	O
affected	O
by	I-protein
Conn	O
's	I-protein
syndrome	I-protein
(	O
3	O
cases	O
of	I-protein
bilateral	I-protein
adrenal	I-protein
hyperplasia	I-protein
and	I-protein
2	I-protein
cases	O
of	I-protein
adenoma	I-protein
plus	O
unilateral	O
hyperplasia	I-protein
)	O
.	O

The	O
number	I-protein
of	I-protein
the	I-protein
binding	I-protein
sites	I-protein
per	O
cell	O
resulted	O
significantly	O
lower	I-protein
(	O
189	I-protein
+/-	O
114	I-protein
,	O
mean	I-protein
+/-	O
SD	O
)	O
,	O
as	O
compared	O
with	I-protein
the	I-protein
normal	O
controls	O
(	O
298	O
+/-	O
105	I-protein
)	O
.	O

The	O
affinity	I-protein
of	I-protein
aldosterone	O
for	I-protein
the	I-protein
receptor	O
was	O
found	O
to	I-protein
be	O
not	I-protein
different	O
than	I-protein
that	O
of	I-protein
healthy	O
control	I-protein
subjects	O
.	O

The	O
capacity	O
and	I-protein
the	I-protein
affinity	I-protein
of	I-protein
dexamethasone	O
for	I-protein
glucocorticoid	B-protein
receptors	I-protein
ranged	O
in	I-protein
the	I-protein
normal	O
values	O
.	O

These	O
data	O
suggest	O
a	I-protein
possible	O
down-regulation	O
of	I-protein
mineralocorticoid	B-protein
receptors	I-protein
in	I-protein
humans	O
.	O

###MEDLINE:84306548

Short-term	O
and	I-protein
long-term	O
effects	O
of	I-protein
estrogen	O
on	I-protein
lymphoid	O
tissues	O
and	I-protein
lymphoid	O
cells	I-protein
with	I-protein
some	O
remarks	O
on	I-protein
the	I-protein
significance	O
for	I-protein
carcinogenesis	O
.	O

Estrogens	O
have	O
long	I-protein
been	O
thought	O
to	I-protein
play	O
a	I-protein
role	O
in	I-protein
regulating	O
the	I-protein
immune	O
system	I-protein
.	O

The	O
difference	O
in	I-protein
some	O
types	I-protein
of	I-protein
immune	O
responses	O
between	O
males	O
and	I-protein
females	O
is	O
well-known	O
,	O
as	O
is	O
the	I-protein
pronounced	O
thymic	B-protein
involution	O
induced	I-protein
by	I-protein
exogenous	O
estrogens	O
.	O

Estrogens	O
stimulate	O
some	O
aspects	O
of	I-protein
macrophage	O
activity	I-protein
and	I-protein
,	O
depending	O
on	I-protein
dose	O
and	I-protein
mitogen	O
,	O
inhibit	O
or	I-protein
stimulate	O
lymphocyte	O
proliferative	O
response	I-protein
in	I-protein
vitro	O
.	O

Another	I-protein
example	O
is	O
the	I-protein
estrogen	O
effect	O
on	I-protein
the	I-protein
delayed	O
type	O
hypersensitivity	O
response	I-protein
.	O

A	O
broad	O
review	O
is	O
given	O
of	I-protein
such	O
estrogen	O
effects	O
on	I-protein
lymphoid	O
tissue	O
and	I-protein
immune	O
response	I-protein
.	O

Most	O
of	I-protein
the	I-protein
studies	O
published	O
so	O
far	B-protein
are	O
phenomenological	O
.	O

However	O
,	O
the	I-protein
recent	O
description	O
of	I-protein
estrogen	B-protein
receptors	I-protein
in	I-protein
the	I-protein
thymus	I-protein
and	I-protein
in	I-protein
some	O
lymphocyte	O
subpopulations	O
,	O
as	O
well	O
as	O
a	I-protein
deeper	O
understanding	O
of	I-protein
regulating	O
factors	I-protein
in	I-protein
the	I-protein
immune	O
system	I-protein
,	O
open	I-protein
the	I-protein
possibility	O
of	I-protein
a	I-protein
more	O
detailed	O
understanding	O
of	I-protein
the	I-protein
estrogen	O
mechanism	O
of	I-protein
interference	O
.	O

Estrogen	O
effects	O
in	I-protein
adults	O
are	O
reversible	O
.	O

After	O
treating	O
neonatal	I-protein
mice	O
with	I-protein
the	I-protein
synthetic	I-protein
estrogen	O
diethylstilbestrol	O
(	O
DES	B-protein
)	O
,	O
disturbances	O
are	O
induced	I-protein
in	I-protein
lymphocyte	O
populations	O
and	I-protein
lymphocyte	O
functions	O
which	O
are	O
permanent	O
and	I-protein
irreversible	O
.	O

Lymphocytes	O
from	I-protein
adult	O
,	O
neonatally	O
DES-treated	O
female	I-protein
mice	O
have	O
a	I-protein
reduced	O
mitogen	O
response	I-protein
to	I-protein
ConA	B-protein
and	I-protein
LPS	B-protein
(	O
T	B-protein
and	I-protein
B	I-protein
cell	I-protein
mitogen	I-protein
)	O
and	I-protein
the	I-protein
delayed	O
type	O
hypersensitivity	O
response	I-protein
is	O
depressed	O
.	O

A	O
detailed	O
analysis	O
demonstrated	O
a	I-protein
decreased	O
T	O
helper	I-protein
cell	O
population	O
.	O

The	O
activity	I-protein
of	I-protein
Natural	O
Killer	I-protein
cells	I-protein
is	O
permanently	O
reduced	O
and	I-protein
this	O
functional	O
impairment	I-protein
is	O
related	O
to	I-protein
a	I-protein
decreased	O
number	I-protein
of	I-protein
these	O
cells	I-protein
,	O
in	I-protein
turn	O
determined	O
at	I-protein
the	I-protein
bone	O
marrow	I-protein
level	I-protein
.	O

The	O
same	O
animals	O
have	O
an	I-protein
increased	I-protein
sensitivity	I-protein
to	I-protein
chemical	O
carcinogens	O
(	O
methylcholanthrene	O
)	O
and	I-protein
they	O
spontaneously	O
develop	O
epithelial	O
changes	O
in	I-protein
the	I-protein
uterine	I-protein
cervix	O
which	O
morphologically	O
are	O
similar	O
to	I-protein
adenocarcinoma	I-protein
.	O

The	O
association	I-protein
between	O
estrogen-associated	O
malignancy	O
and	I-protein
estrogen	O
effects	O
in	I-protein
lymphocyte	O
functions	O
deserves	O
further	O
study	O
.	O

###MEDLINE:85104095

Drugs	O
affecting	O
the	I-protein
hormonal	O
receptors	I-protein
of	I-protein
normal	O
and	I-protein
leukaemic	O
peripheral	O
leucocytes	O
.	O

The	O
authors	O
investigated	O
the	I-protein
behaviour	O
of	I-protein
steroid	O
hormone	I-protein
uptake	I-protein
in	I-protein
leukaemic	O
cells	I-protein
(	O
CML	O
,	O
CLL	O
,	O
AML	O
,	O
ALL	B-protein
)	O
,	O
in	I-protein
basal	O
conditions	O
and	I-protein
after	O
incubation	O
with	I-protein
drugs	O
which	O
modify	O
the	I-protein
cellular	O
concentration	I-protein
of	I-protein
cAMP	O
,	O
PGE	I-protein
and	I-protein
PGF	B-protein
.	O

The	O
results	O
demonstrated	O
the	I-protein
presence	O
in	I-protein
leukaemic	O
cells	I-protein
of	I-protein
an	I-protein
alteration	O
in	I-protein
the	I-protein
incorporation	O
of	I-protein
steroid	O
hormones	I-protein
.	O

This	O
alteration	O
was	O
scarcely	O
modified	O
by	I-protein
incubation	O
with	I-protein
theophylline	O
,	O
which	O
increases	O
cellular	O
concentration	I-protein
of	I-protein
cAMP	O
.	O

On	O
the	I-protein
other	O
hand	O
,	O
it	O
was	O
moderately	O
counteracted	O
by	I-protein
thioproline	O
and	I-protein
was	O
evidently	O
inhibited	O
by	I-protein
flurbiprofen	O
,	O
which	O
also	O
reduced	O
cellular	O
concentrations	O
of	I-protein
prostaglandins	O
,	O
particularly	O
PGE2	O
,	O
with	I-protein
the	I-protein
exception	O
of	I-protein
PGF2	O
which	O
showed	O
a	I-protein
poor	O
response	I-protein
.	O

Differences	O
were	O
observed	O
in	I-protein
the	I-protein
behavior	B-protein
of	I-protein
hormonal	O
uptake	I-protein
of	I-protein
CML	O
,	O
in	I-protein
contrast	O
to	I-protein
that	O
of	I-protein
AML	O
,	O
CLL	O
and	I-protein
ALL	B-protein
peripheral	O
leucocytes	O
.	O

###MEDLINE:83295933

Human	O
breast	O
cancer	O
and	I-protein
impaired	O
NK	I-protein
cell	O
function	I-protein
.	O

Recent	O
advances	O
in	I-protein
tumor	O
immunology	O
have	O
led	O
to	I-protein
the	I-protein
discovery	O
of	I-protein
a	I-protein
new	I-protein
lymphoid	O
cell	O
with	I-protein
unique	I-protein
antitumor	O
activity	I-protein
.	O

Natural	O
killer	O
(	O
NK	I-protein
)	O
cells	I-protein
form	I-protein
an	I-protein
antitumor	O
surveillance	O
system	I-protein
and	I-protein
appear	O
to	I-protein
be	O
vital	O
in	I-protein
preventing	O
tumor	O
growth	O
and	I-protein
metastasis	O
in	I-protein
animal	O
models	O
.	O

We	O
studied	O
NK	I-protein
activity	I-protein
in	I-protein
patients	O
with	I-protein
benign	O
and	I-protein
malignant	O
breast	O
disease	I-protein
,	O
using	O
a	I-protein
chromium-51	O
release	I-protein
microtiter	O
cytotoxicity	I-protein
assay	O
with	I-protein
K562	O
cells	I-protein
as	O
targets	O
.	O

Compared	O
with	I-protein
benign	O
controls	O
,	O
patients	O
with	I-protein
malignancies	O
had	O
significantly	O
depressed	O
NK	I-protein
-mediated	O
lysis	O
(	O
P	O
less	O
than	I-protein
0.01	O
)	O
.	O

Furthermore	O
,	O
lysis	O
in	I-protein
those	O
with	I-protein
advanced	O
disease	I-protein
(	O
stages	O
II	I-protein
,	O
III	I-protein
,	O
and	I-protein
IV	I-protein
)	O
was	O
significantly	O
less	O
than	I-protein
in	I-protein
those	O
with	I-protein
limited	O
disease	I-protein
(	O
stage	I-protein
I	I-protein
)	O
(	O
P	O
less	O
than	I-protein
0.01	O
)	O
.	O

NK	I-protein
activity	I-protein
was	O
not	I-protein
correlated	O
to	I-protein
estrogen	O
or	I-protein
progesterone	B-protein
receptor	O
states	O
.	O

Positive	O
correlation	O
of	I-protein
a	I-protein
depressed	O
natural	O
killer	O
activity	I-protein
with	I-protein
the	I-protein
extent	O
of	I-protein
tumor	O
spread	O
supports	O
the	I-protein
concept	O
of	I-protein
an	I-protein
NK	I-protein
cell	O
immune	O
surveillance	O
system	I-protein
in	I-protein
breast	O
cancer	O
and	I-protein
emphasizes	O
its	O
importance	O
in	I-protein
this	O
malignancy	O
.	O

###MEDLINE:83188841

Immunosuppressive	O
effect	O
of	I-protein
serum	O
progesterone	B-protein
during	I-protein
pregnancy	O
depends	O
on	I-protein
the	I-protein
progesterone	B-protein
binding	I-protein
capacity	O
of	I-protein
the	I-protein
lymphocytes	O
.	O

Cytotoxic	O
activity	I-protein
and	I-protein
progesterone	B-protein
binding	I-protein
capacity	O
of	I-protein
the	I-protein
lymphocytes	O
,	O
together	O
with	I-protein
serum	O
progesterone	B-protein
concentrations	O
,	O
were	O
determined	O
in	I-protein
women	O
with	I-protein
normal	O
pregnancy	O
or	I-protein
with	I-protein
a	I-protein
clinical	I-protein
diagnosis	O
of	I-protein
threatened	O
abortion	O
or	I-protein
threatened	O
premature	O
labour	O
.	O

The	O
lymphocytes	O
of	I-protein
women	O
with	I-protein
threatened	O
abortion	O
or	I-protein
threatened	O
premature	O
labour	O
showed	O
significantly	O
higher	O
cytotoxic	O
activity	I-protein
(	O
P	O
less	O
than	I-protein
0.001	O
)	O
and	I-protein
significantly	O
lower	I-protein
progesterone	B-protein
binding	I-protein
capacity	O
(	O
P	O
less	O
than	I-protein
0.001	O
)	O
than	I-protein
did	O
lymphocytes	O
obtained	O
from	I-protein
the	I-protein
healthy	O
pregnant	O
women	O
.	O

Significant	O
inverse	O
correlation	O
was	O
found	O
between	O
progesterone	B-protein
binding	I-protein
capacity	O
and	I-protein
cytotoxic	O
activity	I-protein
of	I-protein
the	I-protein
lymphocytes	O
(	O
P	O
less	O
than	I-protein
0.001	O
)	O
,	O
but	O
the	I-protein
progesterone	B-protein
concentration	I-protein
of	I-protein
the	I-protein
pregnancy	O
serum	O
appeared	O
to	I-protein
have	O
no	I-protein
influence	O
on	I-protein
the	I-protein
other	O
two	O
parameters	O
.	O

The	O
findings	O
indicate	O
that	O
intact	O
progesterone	B-protein
binding	I-protein
capacity	O
of	I-protein
the	I-protein
lymphocytes	O
is	O
an	I-protein
essential	O
factor	I-protein
for	I-protein
the	I-protein
manifestation	O
of	I-protein
the	I-protein
blocking	O
effect	O
exerted	O
by	I-protein
pregnancy	O
serum	O
on	I-protein
lymphocyte	O
cytotoxicity	I-protein
in	I-protein
vitro	O
.	O

###MEDLINE:82166484

Serum	B-protein
sex	O
steroid	O
and	I-protein
peptide	O
hormone	I-protein
concentrations	O
,	O
and	I-protein
endometrial	I-protein
estrogen	O
and	I-protein
progestin	B-protein
receptor	O
levels	I-protein
during	I-protein
administration	O
of	I-protein
human	B-protein
leukocyte	I-protein
interferon	I-protein
.	O

Five	O
normally	O
cycling	O
healthy	O
women	O
were	O
given	O
daily	O
subcutaneous	O
injections	O
of	I-protein
human	B-protein
leukocyte	I-protein
interferon	I-protein
(	O
3	O
X	O
10	I-protein
(	O
6	I-protein
)	O
units/day	O
)	O
from	I-protein
the	I-protein
3rd	O
through	I-protein
23rd	O
day	O
of	I-protein
the	I-protein
menstrual	O
cycle	I-protein
,	O
and	I-protein
serum	O
steroid	O
and	I-protein
peptide	O
hormone	I-protein
concentrations	O
monitored	O
at	I-protein
3-day	O
intervals	O
during	I-protein
the	I-protein
treatment	O
and	I-protein
the	I-protein
preceding	O
control	I-protein
cycle	I-protein
.	O

Concentrations	O
of	I-protein
cytosol	I-protein
and	I-protein
nuclear	I-protein
estrogen	I-protein
receptors	I-protein
(	O
ERC	B-protein
and	I-protein
ERN	B-protein
,	O
respectively	O
)	O
and	I-protein
progestin	B-protein
receptors	I-protein
(	O
PRC	B-protein
and	I-protein
PRN	B-protein
)	O
were	O
also	O
measured	O
from	I-protein
endometrial	I-protein
biopsies	O
taken	O
on	I-protein
the	I-protein
24th	O
day	O
of	I-protein
the	I-protein
control	I-protein
and	I-protein
treatment	O
cycle	I-protein
.	O

In	O
addition	O
,	O
an	I-protein
extensive	O
monitoring	O
of	I-protein
clinical	I-protein
chemical	O
and	I-protein
hematological	B-protein
tests	O
from	I-protein
the	I-protein
blood	O
samples	O
were	O
performed	O
.	O

Serum	B-protein
estradiol	O
and	I-protein
progesterone	B-protein
concentrations	O
were	O
significantly	O
decreased	O
during	I-protein
the	I-protein
treatment	O
cycle	I-protein
,	O
suggesting	O
that	O
interferon	B-protein
interacts	I-protein
in	I-protein
vivo	O
with	I-protein
the	I-protein
function	I-protein
of	I-protein
both	O
FSH	O
and	I-protein
LH	O
.	O

No	I-protein
significant	O
changes	O
were	O
observed	O
in	I-protein
the	I-protein
serum	O
peptide	O
hormone	I-protein
concentrations	O
measured	O
(	O
FSH	O
,	O
LH	O
,	O
prolactin	B-protein
,	O
insulin	O
,	O
growth	O
hormone	I-protein
and	I-protein
TSH	O
)	O
;	O
neither	O
were	O
the	I-protein
levels	I-protein
of	I-protein
endometrial	I-protein
ERC	I-protein
,	O
ERN	I-protein
,	O
PRC	B-protein
and	I-protein
PRN	B-protein
affected	O
by	I-protein
interferon	B-protein
administration	O
.	O

As	O
expected	O
,	O
interferon	B-protein
administration	O
resulted	O
in	I-protein
decreased	O
leukocyte	O
counts	O
.	O

Moreover	O
,	O
an	I-protein
increasing	O
tendency	O
in	I-protein
the	I-protein
activities	O
of	I-protein
serum	B-protein
alkaline	I-protein
phosphatase	I-protein
and	I-protein
gamma-glutamyltransferase	O
during	I-protein
the	I-protein
interferon	B-protein
therapy	O
shows	O
that	O
interferon	B-protein
may	O
slightly	O
interfere	O
with	I-protein
the	I-protein
liver	O
function	I-protein
.	O

These	O
results	O
suggest	O
that	O
one	B-protein
of	I-protein
the	I-protein
mechanisms	O
by	I-protein
which	O
interferon	B-protein
treatment	O
may	O
affect	O
the	I-protein
growth	O
of	I-protein
hormone-dependent	O
neoplasms	O
could	O
be	O
the	I-protein
interaction	I-protein
with	I-protein
production	I-protein
and/or	O
function	I-protein
of	I-protein
circulating	O
hormonal	O
compounds	O
.	O

###MEDLINE:82086319

[	O
Glucocorticoid	B-protein
receptor	I-protein
level	I-protein
in	I-protein
the	I-protein
blood	O
leukocytes	O
in	I-protein
different	O
acute	O
diseases	O
]	O

Content	O
of	I-protein
glucocorticoid	B-protein
receptors	I-protein
in	I-protein
cytosol	I-protein
of	I-protein
blood	O
leukocytes	O
,	O
concentration	I-protein
of	I-protein
cortisol	O
and	I-protein
amount	O
of	I-protein
leukocytes	O
in	I-protein
blood	O
were	O
studied	O
in	I-protein
20	I-protein
patients	O
with	I-protein
acute	O
impairments	O
within	B-protein
the	I-protein
second	O
day	O
of	I-protein
the	I-protein
disease	I-protein
.	O

Content	O
of	I-protein
receptors	I-protein
in	I-protein
cytosol	I-protein
of	I-protein
blood	O
leukocytes	O
was	O
studied	O
using	O
3H-triamcinolone	O
acetonide	O
.	O

Distinct	O
increase	O
in	I-protein
amount	O
of	I-protein
the	I-protein
leukocyte	B-protein
glucocorticoid	I-protein
receptors	I-protein
was	O
found	O
in	I-protein
patients	O
with	I-protein
poisoning	O
by	I-protein
dichlorethane	O
and	I-protein
hypnotic	O
drugs	O
under	O
conditions	O
of	I-protein
acute	O
myocardial	B-protein
infarction	I-protein
.	O

In	O
acute	O
pancreatitis	O
content	O
of	I-protein
the	I-protein
leukocyte	B-protein
receptors	I-protein
was	O
not	I-protein
altered	I-protein
as	O
compared	O
with	I-protein
controls	O
.	O

Concentration	O
of	I-protein
endogenous	O
cortisol	O
was	O
increased	I-protein
in	I-protein
blood	O
of	I-protein
all	O
the	I-protein
patients	O
,	O
except	O
of	I-protein
the	I-protein
cases	O
of	I-protein
acetate	O
intoxication	O
.	O

Reverse	O
correlation	O
was	O
observed	O
between	O
concentration	I-protein
of	I-protein
cortisol	O
in	I-protein
blood	O
and	I-protein
content	O
of	I-protein
glucocorticoid	B-protein
receptors	I-protein
in	I-protein
leukocytes	O
.	O

But	O
in	I-protein
the	I-protein
patients	O
with	I-protein
acute	O
pancreatitis	O
the	I-protein
decrease	O
in	I-protein
content	O
of	I-protein
leukocyte	B-protein
glucocorticoid	I-protein
receptors	I-protein
was	O
not	I-protein
observed	O
although	O
there	O
was	O
an	I-protein
increase	O
in	I-protein
cortisol	O
concentration	I-protein
in	I-protein
blood	O
.	O

The	O
role	O
of	I-protein
glucocorticoid	B-protein
receptors	I-protein
in	I-protein
immunological	O
processes	O
under	O
conditions	O
of	I-protein
purulent	O
complications	O
and	I-protein
possibility	O
to	I-protein
regulate	O
the	I-protein
metabolism	I-protein
in	I-protein
leukocytes	O

###MEDLINE:86034627

Therapeutic	O
concentrations	O
of	I-protein
glucocorticoids	O
suppress	O
the	I-protein
antimicrobial	I-protein
activity	I-protein
of	I-protein
human	O
macrophages	O
without	I-protein
impairing	O
their	O
responsiveness	O
to	I-protein
gamma	B-protein
interferon	I-protein
.	O

By	O
exposing	O
human	O
blood-derived	O
macrophages	O
and	I-protein
alveolar	O
macrophages	O
in	I-protein
vitro	O
to	I-protein
dexamethasone	O
,	O
we	O
showed	O
in	I-protein
these	O
studies	O
that	O
glucocorticoids	O
markedly	O
suppress	O
the	I-protein
antimicrobial	I-protein
activity	I-protein
of	I-protein
macrophages	O
but	O
not	I-protein
macrophage	O
activation	I-protein
by	I-protein
lymphokines	O
.	O

As	O
little	O
as	O
2.5	O
X	O
10	I-protein
(	O
-8	O
)	O
mol/liter	O
of	I-protein
dexamethasone	O
prevented	O
macrophages	O
from	I-protein
inhibiting	I-protein
germination	O
of	I-protein
Aspergillus	O
spores	O
or	I-protein
from	I-protein
eliminating	O
ingested	O
bacteria	O
such	O
as	O
Listeria	O
,	O
Nocardia	O
,	O
or	I-protein
Salmonella	O
.	O

Damage	O
to	I-protein
macrophage	O
function	I-protein
was	O
inhibited	O
by	I-protein
progesterone	B-protein
and	I-protein
appeared	O
to	I-protein
be	O
receptor-mediated	O
.	O

In	O
accordance	O
with	I-protein
in	I-protein
vivo	O
observations	O
,	O
dexamethasone	O
required	O
24-36	O
h	I-protein
to	I-protein
suppress	O
antimicrobial	I-protein
activity	I-protein
.	O

While	O
glucocorticoids	O
interfered	O
with	I-protein
base-line	O
activity	I-protein
of	I-protein
macrophages	O
,	O
dexamethasone	O
concentrations	O
comparable	O
to	I-protein
drug	O
levels	I-protein
in	I-protein
patients	O
had	O
no	I-protein
effect	O
on	I-protein
macrophage	O
activation	I-protein
.	O

Proliferating	I-protein
lymphocytes	O
and	I-protein
gamma-interferon	B-protein
thus	O
increased	I-protein
the	I-protein
antimicrobial	I-protein
activity	I-protein
of	I-protein
phagocytes	O
exposed	O
to	I-protein
glucocorticoids	O
over	O
that	O
of	I-protein
control	I-protein
cells	I-protein
.	O

Macrophage	I-protein
activation	I-protein
and	I-protein
correction	O
of	I-protein
the	I-protein
dexamethasone	O
effect	O
by	I-protein
gamma-interferon	B-protein
,	O
however	O
,	O
was	O
dependent	I-protein
on	I-protein
the	I-protein
pathogen	O
.	O

The	O
lymphokine	B-protein
enhanced	I-protein
the	I-protein
antimicrobial	I-protein
activity	I-protein
of	I-protein
dexamethasone-treated	O
macrophages	O
against	I-protein
Listeria	O
and	I-protein
Salmonella	O
but	O
not	I-protein
against	I-protein
Aspergillus	O
or	I-protein
Nocardia	O
.	O

Dexamethasone-induced	O
damage	I-protein
to	I-protein
the	I-protein
antimicrobial	I-protein
activity	I-protein
of	I-protein
human	O
macrophages	O
in	I-protein
vitro	O
parallels	O
observations	O
that	O
glucocorticoids	O
render	O
laboratory	O
animals	O
susceptible	O
to	I-protein
listeriosis	O
and	I-protein
aspergillosis	O
by	I-protein
damaging	O
resident	O
macrophages	O
.	O

Suppression	O
of	I-protein
macrophage	O
antimicrobial	I-protein
activity	I-protein
should	O
thus	O
be	O
considered	O
when	O
treating	O
patients	O
with	I-protein
glucocorticoids	O
;	O
its	O
prevention	O
by	I-protein
gamma-interferon	B-protein
might	O
be	O
beneficial	O
for	I-protein
some	O
but	O
not	I-protein
all	O
pathogens	O
.	O

###MEDLINE:85254470

Interleukin	B-protein
2	I-protein
receptor	I-protein
(	O
Tac	B-protein
antigen	I-protein
)	O
expression	I-protein
in	I-protein
HTLV-I-associated	O
adult	O
T-cell	O
leukemia	O
.	O

Interleukin-2	B-protein
(	O
IL-2	B-protein
)	O
is	O
a	I-protein
lymphokine	B-protein
synthesized	O
by	I-protein
some	O
T-cells	I-protein
following	O
activation	I-protein
.	O

Resting	O
T-cells	I-protein
do	O
not	I-protein
express	O
IL-2	B-protein
receptors	I-protein
,	O
but	O
receptors	I-protein
are	O
rapidly	I-protein
expressed	O
on	I-protein
T-cells	I-protein
following	O
interaction	I-protein
of	I-protein
antigens	I-protein
,	O
mitogens	O
,	O
or	I-protein
monoclonal	I-protein
antibodies	I-protein
with	I-protein
the	I-protein
antigen-specific	B-protein
T-cell	I-protein
receptor	I-protein
complex	I-protein
.	O

Using	O
anti-Tac	B-protein
,	O
a	I-protein
monoclonal	I-protein
antibody	I-protein
that	O
recognizes	O
the	I-protein
IL-2	B-protein
receptor	I-protein
,	O
the	I-protein
receptor	O
has	O
been	O
purified	O
and	I-protein
shown	O
to	I-protein
be	O
a	I-protein
Mr	O
33	I-protein
,	O
000	O
peptide	O
that	O
is	O
posttranslationally	O
glycosylated	I-protein
to	I-protein
a	I-protein
Mr	O
55	I-protein
,	O
000	O
mature	B-protein
form	I-protein
.	O

Normal	O
resting	O
T-cells	I-protein
and	I-protein
most	O
leukemic	O
T-cell	O
populations	O
do	O
not	I-protein
express	O
IL-2	B-protein
receptors	I-protein
;	O
however	O
,	O
the	I-protein
leukemic	O
cells	I-protein
of	I-protein
the	I-protein
11	I-protein
patients	O
examined	O
who	O
had	O
human	O
T-cell	O
lymphotropic	O
virus-associated	I-protein
adult	O
T-cell	O
leukemia	O
expressed	O
the	I-protein
Tac	B-protein
antigen	I-protein
.	O

In	O
human	O
T-cell	O
lymphotropic	O
virus-I	O
infected	O
cells	I-protein
,	O
the	I-protein
Mr	O
42	I-protein
,	O
000	O
long	I-protein
open	I-protein
reading	I-protein
frame	I-protein
protein	I-protein
encoded	O
in	I-protein
part	I-protein
by	I-protein
the	I-protein
pX	O
region	O
of	I-protein
this	O
virus	I-protein
may	O
act	O
as	O
a	I-protein
transacting	B-protein
transcriptional	I-protein
activator	I-protein
that	O
induces	O
IL-2	B-protein
receptor	O
gene	O
transcription	O
,	O
thus	O
providing	O
an	I-protein
explanation	O
for	I-protein
the	I-protein
constant	I-protein
association	I-protein
of	I-protein
IL-2	B-protein
receptor	I-protein
expression	I-protein
with	I-protein
adult	O
T-cell	O
lymphotropic	O
virus-I	O
infection	I-protein
of	I-protein
lymphoid	O
cells	I-protein
.	O

The	O
constant	I-protein
expression	I-protein
of	I-protein
large	O
numbers	O
of	I-protein
IL-2	B-protein
receptors	I-protein
which	O
may	O
be	O
aberrant	O
may	O
play	O
a	I-protein
role	O
in	I-protein
the	I-protein
uncontrolled	O
growth	O
of	I-protein
adult	O
T-cell	O
leukemia	O
cells	I-protein
.	O

Two	O
patients	O
with	I-protein
Tac-positive	O
adult	O
T-cell	O
leukemia	O
have	O
been	O
treated	O
with	I-protein
the	I-protein
anti-Tac	O
.	O

One	I-protein
of	I-protein
the	I-protein
patients	O
had	O
6-	O
and	I-protein
3-mo	O
remissions	O
of	I-protein
his	O
leukemia	O
following	O
two	O
courses	O
of	I-protein
therapy	O
with	I-protein
this	O
monoclonal	I-protein
antibody	I-protein
directed	I-protein
toward	O
this	O
growth	B-protein
factor	I-protein
receptor	I-protein
.	O

###MEDLINE:86121439

Lymphocyte	O
glucocorticoid	B-protein
receptor	I-protein
binding	I-protein
in	I-protein
depressed	O
patients	O
with	I-protein
hypercortisolemia	O
.	O

Despite	O
elevated	I-protein
levels	I-protein
of	I-protein
serum	O
and	I-protein
urinary	O
cortisol	O
,	O
patients	O
with	I-protein
depressive	I-protein
illness	O
manifest	O
none	O
of	I-protein
the	I-protein
clinical	I-protein
stigmata	O
of	I-protein
glucocorticoid	O
excess	O
.	O

This	O
hypercortisolemia	O
in	I-protein
the	I-protein
absence	I-protein
of	I-protein
clinical	I-protein
effects	O
suggests	O
a	I-protein
state	I-protein
of	I-protein
hormone	I-protein
resistance	O
and	I-protein
could	O
be	O
mediated	I-protein
by	I-protein
alterations	O
in	I-protein
the	I-protein
glucocorticoid	B-protein
receptor	I-protein
.	O

Earlier	O
studies	O
have	O
shown	O
that	O
small	O
doses	O
of	I-protein
glucocorticoids	O
cause	O
a	I-protein
decrease	O
in	I-protein
glucocorticoid	B-protein
receptor	I-protein
binding	I-protein
in	I-protein
normal	O
human	O
lymphocytes	O
.	O

White	O
cells	I-protein
from	I-protein
depressed	O
patients	O
with	I-protein
significant	O
hypercortisolemia	O
would	O
be	O
expected	O
to	I-protein
show	O
a	I-protein
similar	O
change	O
in	I-protein
receptor	O
concentration	I-protein
if	O
peripheral	O
tissues	O
are	O
adequately	O
exposed	O
to	I-protein
and	I-protein
sensitive	I-protein
to	I-protein
the	I-protein
hormone	I-protein
.	O

In	O
this	O
study	O
we	O
compared	O
the	I-protein
binding	I-protein
of	I-protein
[	O
3H	I-protein
]	O
dexamethasone	O
to	I-protein
lymphocytes	O
from	I-protein
normal	O
subjects	O
and	I-protein
depressed	O
patients	O
with	I-protein
hypercortisolemia	O
.	O

Lymphocytes	O
from	I-protein
normal	O
subjects	O
had	O
a	I-protein
mean	I-protein
receptor	O
concentration	I-protein
of	I-protein
10.2	O
+/-	O
0.66	O
fm/10	O
(	O
6	I-protein
)	O
cells	I-protein
(	O
S.E.M.	O
)	O
and	I-protein
a	I-protein
dissociation	I-protein
constant	I-protein
of	I-protein
4.8	I-protein
+/-	O
0.47	O
nM	O
.	O

Lymphocytes	O
from	I-protein
depressed	O
patients	O
with	I-protein
abnormal	I-protein
0800	O
h	I-protein
serum	O
cortisol	O
after	O
dexamethasone	O
had	O
a	I-protein
mean	I-protein
receptor	O
concentration	I-protein
of	I-protein
8.8	O
+/-	O
0.75	O
fm/10	O
(	O
6	I-protein
)	O
cells	I-protein
,	O
which	O
was	O
not	I-protein
significantly	O
different	O
from	I-protein
that	O
in	I-protein
lymphocytes	O
from	I-protein
normal	O
subjects	O
or	I-protein
from	I-protein
depressed	O
subjects	O
with	I-protein
normal	O
post-dexamethasone	O
cortisol	O
levels	I-protein
(	O
9.4	O
+/-	O
0.95	O
fm/10	O
(	O
6	I-protein
)	O
cells	I-protein
)	O
.	O

Lymphocytes	O
from	I-protein
depressed	O
patients	O
with	I-protein
elevated	I-protein
urinary	O
free	B-protein
cortisol	O
excretion	I-protein
(	O
UFC	O
)	O
also	O
had	O
normal	O
receptor	O
concentration	I-protein
and	I-protein
binding	I-protein
affinity	I-protein
for	I-protein
dexamethasone	O
.	O

The	O
lack	O
of	I-protein
a	I-protein
change	O
in	I-protein
lymphocyte	O
glucocorticoid	B-protein
receptor	I-protein
concentration	I-protein
in	I-protein
the	I-protein
presence	O
of	I-protein
cortisol	O
excess	O
suggests	O
the	I-protein
possibility	O
that	O
hypercortisolemia	O
in	I-protein
depressive	I-protein
illness	O
represents	O
a	I-protein
state	I-protein
of	I-protein
peripheral	O
glucocorticoid	O
resistance	O
.	O

###MEDLINE:85102467

Structure	O
and	I-protein
regulation	I-protein
of	I-protein
the	I-protein
glucocorticoid	B-protein
hormone	I-protein
receptor	I-protein
.	O

The	O
glucocorticoid	B-protein
receptor	I-protein
is	O
an	I-protein
intracellular	I-protein
protein	I-protein
which	O
possesses	O
three	O
distinct	O
domains	I-protein
,	O
one	B-protein
that	O
binds	O
agonist	I-protein
and	I-protein
antagonist	O
steroids	O
,	O
one	B-protein
that	O
binds	O
DNA	O
,	O
and	I-protein
one	B-protein
that	O
binds	O
anti-receptor	B-protein
antibodies	I-protein
and	I-protein
is	O
required	O
for	I-protein
glucocorticoid	O
modulation	O
of	I-protein
gene	O
expression	I-protein
.	O

In	O
intact	O
cells	I-protein
,	O
receptor	O
number	I-protein
,	O
affinity	I-protein
and	I-protein
activity	I-protein
can	O
change	O
in	I-protein
response	I-protein
to	I-protein
factors	I-protein
that	O
bind	O
to	I-protein
the	I-protein
receptor	O
,	O
or	I-protein
that	O
act	O
indirectly	O
through	I-protein
ill-defined	O
mechanisms	O
which	O
may	O
include	O
resumption	O
or	I-protein
arrest	I-protein
of	I-protein
cell	O
cycling	O
and	I-protein
variations	O
in	I-protein
intracellular	I-protein
calcium	O
ion	I-protein
concentrations	O
.	O

Some	O
of	I-protein
these	O
factors	I-protein
appear	O
to	I-protein
exert	O
their	O
effect	O
by	I-protein
controlling	I-protein
critical	I-protein
receptor	O
properties	O
such	O
as	O
ATP-dependent	I-protein
phosphorylation	I-protein
,	O
integrity	O
of	I-protein
thiol	B-protein
groups	I-protein
,	O
and	I-protein
exposure	O
of	I-protein
key	B-protein
amino	I-protein
acid	I-protein
residues	I-protein
.	O

Glucocorticoid	O
agonists	O
promote	O
the	I-protein
'transformation	O
'	O
of	I-protein
the	I-protein
receptor	O
into	O
the	I-protein
DNA-binding	O
state	I-protein
,	O
which	O
is	O
competent	O
for	I-protein
modulating	I-protein
gene	O
expression	I-protein
.	O

Glucocorticoid	O
antagonists	O
are	O
steroids	O
that	O
interact	O
with	I-protein
the	I-protein
receptor	O
but	O
either	O
fail	O
to	I-protein
produce	O
a	I-protein
stable	I-protein
complex	I-protein
or	I-protein
produce	O
a	I-protein
stable	I-protein
but	I-protein
inefficient	I-protein
complex	I-protein
.	O

Although	O
substituent	O
groups	O
that	O
confer	O
agonist	I-protein
or	I-protein
antagonist	O
activity	I-protein
to	I-protein
the	I-protein
steroid	O
have	O
been	O
identified	I-protein
,	O
the	I-protein
molecular	I-protein
determinants	O
of	I-protein
this	O
difference	O
at	I-protein
the	I-protein
receptor	O
level	I-protein
remain	O
unknown	O
.	O

Most	O
in	I-protein
vitro	O
and	I-protein
in	I-protein
vivo	O
data	O
on	I-protein
receptor	O
regulation	I-protein
can	O
be	O
accommodated	O
by	I-protein
postulating	O
the	I-protein
existence	O
of	I-protein
an	I-protein
intracellular	I-protein
cycle	I-protein
that	O
involves	O
five	I-protein
states	O
of	I-protein
the	I-protein
receptor	O
.	O

The	O
active	O
free	B-protein
receptor	O
is	O
phosphorylated	O
,	O
reduced	O
,	O
and	I-protein
presumably	O
oligomeric	I-protein
(	O
state	I-protein
A	O
)	O
.	O

Following	O
binding	I-protein
of	I-protein
an	I-protein
agonist	I-protein
(	O
state	I-protein
B	O
)	O
,	O
it	O
can	O
become	O
transformed	I-protein
by	I-protein
dissociation	I-protein
into	O
its	O
subunits	I-protein
and	I-protein
dephosphorylation	O
(	O
state	I-protein
C	O
)	O
.	O

The	O
transformed	I-protein
receptor	I-protein
then	O
interacts	I-protein
with	I-protein
chromatin	O
(	O
state	I-protein
D	O
)	O
.	O

Dissociation	O
of	I-protein
the	I-protein
steroid	O
and	I-protein
oxidation	O
of	I-protein
receptor	B-protein
thiol	I-protein
group	I-protein
(	O
s	I-protein
)	O
lead	O
to	I-protein
the	I-protein
inactive	O
receptor	O
form	I-protein
(	O
state	I-protein
E	O
)	O
.	O

Reduction	O
and	I-protein
rephosphorylation	O
of	I-protein
the	I-protein
receptor	O
enable	O
it	O
to	I-protein
bind	O
steroids	O
again	O
so	O
that	O
the	I-protein
cycle	I-protein
is	O
closed	O
.	O

###MEDLINE:84178365

Thermodynamics	O
of	I-protein
steroid	O
binding	I-protein
to	I-protein
the	I-protein
human	B-protein
glucocorticoid	I-protein
receptor	I-protein
.	O

The	O
thermodynamics	O
of	I-protein
the	I-protein
interaction	I-protein
of	I-protein
glucocorticoids	O
with	I-protein
their	O
receptor	O
were	O
studied	O
in	I-protein
cytosol	I-protein
from	I-protein
human	O
lymphoblastoid	O
cells	I-protein
.	O

The	O
rate	I-protein
and	I-protein
affinity	I-protein
constants	O
of	I-protein
dexamethasone	O
and	I-protein
cortisol	O
between	O
0	I-protein
degree	O
and	I-protein
25	I-protein
degrees	O
C	O
were	O
calculated	O
by	I-protein
curve-fitting	O
from	I-protein
time-course	O
and	I-protein
equilibrium	O
kinetics	O
.	O

The	O
data	O
were	O
consistent	O
with	I-protein
a	I-protein
simple	O
reversible	O
bimolecular	O
interaction	I-protein
.	O

Arrhenius	O
and	I-protein
Va	I-protein
n't	O
Hoff	O
plots	O
were	O
curvilinear	O
for	I-protein
both	O
steroids	O
.	O

At	O
equilibrium	O
,	O
the	I-protein
solution	O
for	I-protein
the	I-protein
equation	O
delta	I-protein
G	O
=	O
delta	I-protein
H	I-protein
-	O
T	O
X	O
delta	I-protein
S	I-protein
(	O
eqn.	O
1	I-protein
)	O
was	O
(	O
in	I-protein
kJ	O
X	O
mol-1	O
)	O
-47	O
=	O
36	I-protein
-	O
83	I-protein
(	O
dexamethasone	O
)	O
and	I-protein
-42	I-protein
=	O
-9	O
-	O
33	I-protein
(	O
cortisol	O
)	O
at	I-protein
0	I-protein
degree	O
C	O
.	O

Enthalpy	O
and	I-protein
entropy	O
changes	O
decreased	O
quasi-linearly	O
with	I-protein
temperature	I-protein
such	O
that	O
,	O
at	I-protein
25	I-protein
degrees	O
C	O
,	O
the	I-protein
respective	O
values	O
were	O
-50	O
=	O
-75	O
+	O
25	I-protein
and	I-protein
-43	O
=	O
-48	O
+	O
5	O
.	O

Thus	O
,	O
for	I-protein
both	O
steroids	O
,	O
the	I-protein
interaction	I-protein
was	O
entropy-driven	O
at	I-protein
low	O
temperature	I-protein
and	I-protein
became	O
entirely	O
enthalpy-driven	O
at	I-protein
20	I-protein
degrees	O
C	O
.	O

Thermodynamic	O
values	O
for	I-protein
the	I-protein
transition	O
state	I-protein
were	O
calculated	O
from	I-protein
the	I-protein
rate	I-protein
constants	O
.	O

For	O
the	I-protein
forward	O
reaction	I-protein
,	O
eqn.	O
(	O
1	I-protein
)	O
gave	O
45	I-protein
=	O
84	I-protein
-	O
39	I-protein
(	O
dexamethasone	O
)	O
and	I-protein
46	I-protein
=	O
60	I-protein
-	O
14	I-protein
(	O
cortisol	O
)	O
at	I-protein
0	I-protein
degree	O
C	O
,	O
and	I-protein
44	I-protein
=	O
24	I-protein
+	O
20	I-protein
(	O
dexamethasone	O
)	O
and	I-protein
46	I-protein
=	O
28	I-protein
+	O
18	I-protein
(	O
cortisol	O
)	O
at	I-protein
25	I-protein
degrees	O
C	O
.	O

These	O
data	O
fit	O
quite	O
well	O
with	I-protein
a	I-protein
two-step	O
model	I-protein
[	O
Ross	O
&	O
Subramanian	O
(	O
1981	O
)	O
Biochemistry	O
20	I-protein
,	O
3096-3102	O
]	O
proposed	O
for	I-protein
ligand-protein	O
interactions	O
,	O
which	O
involves	O
a	I-protein
partial	I-protein
immobilization	O
of	I-protein
the	I-protein
reacting	I-protein
species	O
governed	O
by	I-protein
hydrophobic	I-protein
forces	O
,	O
followed	O
by	I-protein
stabilization	O
of	I-protein
the	I-protein
complex	I-protein
by	I-protein
short-range	O
interactions	O
.	O

On	O
the	I-protein
basis	O
of	I-protein
this	O
model	I-protein
,	O
an	I-protein
analysis	O
of	I-protein
the	I-protein
transition-state	O
thermodynamics	O
led	O
to	I-protein
the	I-protein
conclusion	O
that	O
no	I-protein
more	O
than	I-protein
half	I-protein
of	I-protein
the	I-protein
steroid	O
molecular	I-protein
area	O
is	O
engaged	O
in	I-protein
the	I-protein
binding	I-protein
process	O
.	O

###MEDLINE:84238528

Cell	I-protein
cycle-related	O
changes	O
in	I-protein
number	I-protein
of	I-protein
T-lymphocyte	I-protein
receptors	I-protein
for	I-protein
glucocorticoids	O
and	I-protein
insulin	O
.	O

Enriched	O
human	O
peripheral	O
T-lymphocytes	O
were	O
stimulated	O
with	I-protein
PHA	B-protein
and	I-protein
examined	O
for	I-protein
variations	O
in	I-protein
insulin	O
and	I-protein
glucocorticoid	O
(	O
dexamethasone	O
)	O
receptor	O
numbers	O
during	I-protein
the	I-protein
early	O
phases	O
of	I-protein
the	I-protein
cell	O
cycle	I-protein
.	O

Cells	O
in	I-protein
G0	O
,	O
G1a	O
and	I-protein
G1b	O
phases	O
,	O
where	O
the	I-protein
G1a	O
-	O
G1b	O
transition	O
is	O
an	I-protein
Interleukin	B-protein
2	I-protein
dependent	I-protein
event	O
,	O
were	O
quantitated	O
by	I-protein
flow	O
cytometry	O
.	O

Few	O
but	O
significant	O
numbers	O
of	I-protein
glucocorticoid	B-protein
receptors	I-protein
(	O
2700/cell	O
)	O
and	I-protein
no	I-protein
insulin	B-protein
receptors	I-protein
(	O
-1/cell	O
)	O
were	O
found	O
in	I-protein
the	I-protein
resting	O
(	O
G0	O
)	O
phase	I-protein
.	O

As	O
cells	I-protein
entered	O
the	I-protein
G1a	O
phase	I-protein
the	I-protein
specific	I-protein
binding	I-protein
of	I-protein
dexamethasone	O
increased	I-protein
and	I-protein
of	I-protein
insulin	O
took	O
place	O
.	O

Although	O
the	I-protein
specific	I-protein
binding	I-protein
further	O
increased	I-protein
as	O
T-cells	I-protein
entered	O
the	I-protein
G1b	O
phase	I-protein
(	O
as	O
measured	O
at	I-protein
44	I-protein
h	I-protein
of	I-protein
incubation	O
and	I-protein
using	O
hydroxyurea-treated	O
cells	I-protein
)	O
,	O
the	I-protein
major	O
changes	O
in	I-protein
the	I-protein
specific	I-protein
binding	I-protein
of	I-protein
dexamethasone	O
took	O
place	O
during	I-protein
the	I-protein
period	B-protein
16	I-protein
-	O
20	I-protein
h	I-protein
after	O
stimulation	I-protein
.	O

Based	O
on	I-protein
these	O
findings	O
,	O
it	O
is	O
concluded	O
that	O
both	O
receptor	O
types	I-protein
(	O
cell	B-protein
membrane	I-protein
and	I-protein
cytoplasmic	I-protein
receptors	I-protein
)	O
are	O
being	O
formed	O
and	I-protein
increased	I-protein
at	I-protein
G1	O
phase	I-protein
prior	O
to	I-protein
cell	O
proliferation	I-protein
,	O
indicating	O
the	I-protein
importance	O
of	I-protein
G1	O
phase	I-protein
in	I-protein
immunoregulation	O
.	O

###MEDLINE:83291326

Glucocorticoid	B-protein
receptors	I-protein
and	I-protein
cortico-sensitivity	O
in	I-protein
a	I-protein
human	O
clonal	O
monocytic	I-protein
cell	O
line	I-protein
,	O
CM-SM	O
.	O

CM-SM	O
is	O
a	I-protein
clonal	O
line	I-protein
of	I-protein
human	O
precursor	I-protein
mononuclear	O
phagocytes	O
inducible	O
to	I-protein
macrophage	O
differentiation	I-protein
in	I-protein
response	I-protein
to	I-protein
the	I-protein
tumor	O
promoter	I-protein
phorbol	O
ester	I-protein
12-O-tetradecanoyl-phorbol-13-acetate	O
(	O
TPA	B-protein
)	O
.	O

Untreated	O
CM-SM	O
cells	I-protein
contain	O
single	O
class	O
,	O
high-affinity	O
(	O
KD	O
=	O
4.0	O
X	O
10	I-protein
(	O
-9	O
)	O
M	I-protein
)	O
glucocorticoid-specific	O
receptor	O
sites	I-protein
(	O
approximately	O
60	I-protein
,	O
000	O
per	O
cell	O
)	O
,	O
as	O
measured	O
by	I-protein
a	I-protein
whole	O
cell	O
assay	O
,	O
at	I-protein
37	I-protein
degrees	O
C	O
,	O
using	O
[	O
3H	I-protein
]	O
triamcinolone	O
acetonide	O
(	O
TA	O
)	O
.	O

Exposure	O
of	I-protein
CM-SM	O
to	I-protein
dexamethasone	O
(	O
DEX	O
)	O
produced	O
a	I-protein
progressive	O
,	O
dose-	O
and	I-protein
time-related	O
series	O
of	I-protein
changes	O
in	I-protein
CM-SM	O
cell	O
growth	O
,	O
saturation	O
density	I-protein
,	O
morphology	O
,	O
and	I-protein
functional	O
properties	O
,	O
with	I-protein
half-maximal	O
effects	O
at	I-protein
about	O
10	I-protein
(	O
-9	O
)	O
M	I-protein
for	I-protein
DEX	O
.	O

TA-receptor	O
sites	I-protein
rapidly	I-protein
decreased	O
(	O
about	O
70	I-protein
%	O
)	O
after	O
DEX	O
treatment	O
,	O
without	I-protein
any	O
apparent	O
change	O
in	I-protein
steroid	O
specificity	I-protein
and	I-protein
affinity	I-protein
.	O

After	O
5	O
days	O
in	I-protein
culture	O
with	I-protein
a	I-protein
saturating	O
concentration	I-protein
(	O
3.6	O
X	O
10	I-protein
(	O
-8	O
)	O
M	I-protein
)	O
of	I-protein
hormone	I-protein
,	O
the	I-protein
cells	I-protein
reached	O
a	I-protein
saturation	O
density	I-protein
of	I-protein
about	O
9.0	O
X	O
10	I-protein
(	O
6	I-protein
)	O
viable	O
cells/ml	O
(	O
about	O
4.0	O
X	O
10	I-protein
(	O
6	I-protein
)	O
viable	O
cells/ml	O
in	I-protein
the	I-protein
controls	O
)	O
,	O
while	O
the	I-protein
modal	O
volume	O
of	I-protein
the	I-protein
resulting	O
cell	O
population	O
was	O
approximately	O
60	I-protein
%	O
,	O
as	O
compared	O
to	I-protein
the	I-protein
volume	O
of	I-protein
untreated	O
cells	I-protein
.	O

DEX-treated	O
cells	I-protein
appeared	O
less	O
differentiated	O
than	I-protein
controls	O
,	O
as	O
assessed	O
by	I-protein
combined	O
morphologic	O
,	O
antigenic	I-protein
,	O
and	I-protein
cytoenzymatic	O
analyses	O
.	O

DEX	O
almost	O
completely	O
inhibited	O
TPA	B-protein
activation	I-protein
of	I-protein
the	I-protein
following	O
macrophage	O
functions	O
:	O
adherency	O
to	I-protein
the	I-protein
culture	O
plate	O
,	O
expression	I-protein
of	I-protein
lysosomal	B-protein
enzymes	I-protein
,	O
Fc	B-protein
and	I-protein
C3	I-protein
receptors	I-protein
,	O
and	I-protein
stimulation	I-protein
of	I-protein
phagocytosis	O
.	O

After	O
removal	O
of	I-protein
DEX	O
,	O
the	I-protein
cells	I-protein
,	O
within	B-protein
a	I-protein
few	O
passages	O
,	O
returned	O
to	I-protein
a	I-protein
state	I-protein
apparently	O
identical	O
to	I-protein
the	I-protein
untreated	O
controls	O
and	I-protein
could	O
be	O
induced	I-protein
to	I-protein
macrophage	O
differentiation	I-protein
in	I-protein
response	I-protein
to	I-protein
TPA	B-protein
.	O

###MEDLINE:85152262

Acute	B-protein
lymphoblastic	O
leukemia	O
in	I-protein
children	O
:	O
current	I-protein
status	I-protein
,	O
controversies	O
,	O
and	I-protein
future	O
perspective	O
.	O

Disease-free	O
survival	B-protein
(	O
DFS	O
)	O
in	I-protein
childhood	I-protein
ALL	B-protein
is	O
60	I-protein
%	O
,	O
and	I-protein
survival	B-protein
in	I-protein
good	O
,	O
average	O
,	O
and	I-protein
poor	O
prognostic	O
groups	O
defined	I-protein
by	I-protein
initial	O
WBC	O
and	I-protein
age	I-protein
is	O
90	I-protein
,	O
60	I-protein
,	O
and	I-protein
45	I-protein
%	O
,	O
respectively	O
.	O

Additional	O
immunological	O
,	O
morphological	O
,	O
biochemical	O
,	O
cytokinetic	O
,	O
and	I-protein
cytogenetic	O
factors	I-protein
have	O
been	O
identified	I-protein
,	O
illustrating	O
the	I-protein
heterogeneity	O
of	I-protein
ALL	B-protein
and	I-protein
its	O
derivation	O
from	I-protein
malignant	O
clones	O
at	I-protein
various	O
stages	O
of	I-protein
differentiation	I-protein
and	I-protein
with	I-protein
varying	O
rates	O
of	I-protein
proliferation	I-protein
.	O

Of	O
biologic	O
importance	O
,	O
these	O
factors	I-protein
may	O
refine	O
further	O
the	I-protein
characteristic	O
features	I-protein
of	I-protein
clinically-determined	O
prognostic	O
groups	O
.	O

Multivariate	O
analysis	O
of	I-protein
large	O
prospective	O
trials	O
with	I-protein
homogeneous	O
therapy	O
will	O
be	O
required	O
to	I-protein
determine	O
the	I-protein
independent	I-protein
prognostic	O
importance	O
of	I-protein
these	O
factors	I-protein
.	O

Current	O
treatment	O
strategies	O
in	I-protein
ALL	B-protein
include	O
(	O
1	I-protein
)	O
tailoring	O
therapy	O
and	I-protein
its	O
intensity	O
to	I-protein
prognostic	O
groups	O
;	O
(	O
2	I-protein
)	O
multiple-drug	O
combinations	O
in	I-protein
induction	I-protein
;	O
(	O
3	O
)	O
early	O
use	O
of	I-protein
intrathecal	O
(	O
IT	O
)	O
methotrexate	O
(	O
MTX	B-protein
)	O
;	O
(	O
4	I-protein
)	O
CNS	O
prophylaxis	O
with	I-protein
IT	O
MTX	B-protein
alone	O
in	I-protein
good	O
prognosis	O
patients	O
and	I-protein
combined	O
cranial	I-protein
radiation	I-protein
(	O
CXRT	O
)	O
,	O
1800	O
rads	O
plus	O
IT	O
MTX	B-protein
,	O
in	I-protein
average	O
and	I-protein
poor	O
prognosis	O
patients	O
.	O

Current	O
studies	O
show	O
a	I-protein
CNS	O
relapse	O
rate	I-protein
of	I-protein
5	O
%	O
in	I-protein
all	O
prognostic	O
groups	O
.	O

Late	O
neuropsychological	O
defects	I-protein
caused	O
by	I-protein
cranial	I-protein
XRT	O
and	I-protein
IT	O
MTX	B-protein
have	O
prompted	O
programs	O
designed	O
to	I-protein
reduce	O
the	I-protein
potential	I-protein
late	O
toxicity	O
of	I-protein
CNS	O
prophylaxis	O
.	O

More	O
pronounced	O
in	I-protein
younger	O
children	O
,	O
these	O
abnormalities	I-protein
include	O
decreased	O
IQ	O
,	O
visual-motor	O
incoordination	O
,	O
poor	O
performance	O
in	I-protein
mathematics	O
,	O
and	I-protein
memory	O
dysfunction	O
.	O

Until	O
1980	O
,	O
more	O
intensive	O
induction	I-protein
,	O
consolidation	O
,	O
and	I-protein
maintenance	I-protein
therapy	O
had	O
failed	O
to	I-protein
prolong	O
DFS	O
in	I-protein
children	O
with	I-protein
a	I-protein
poor	O
prognosis	O
.	O

In	O
West	O
Germany	O
(	O
Berlin-Frankfurt-Muenster	O
protocol	O
)	O
a	I-protein
70	I-protein
to	I-protein
75	I-protein
%	O
DFS	O
is	O
seen	O
in	I-protein
all	O
patients	O
regardless	O
of	I-protein
initial	O
WBC	O
,	O
suggesting	O
that	O
effective	O
therapy	O
will	O
override	O
prognostic	O
factors	I-protein
.	O

Ultra-high-dose	O
MTX	B-protein
,	O
without	I-protein
cranial	I-protein
radiation	I-protein
,	O
is	O
also	O
showing	O
promise	O
in	I-protein
poor	O
prognosis	O
patients	O
.	O

Other	O
issues	O
include	O
the	I-protein
optimal	O
duration	O
of	I-protein
therapy	O
,	O
the	I-protein
role	O
of	I-protein
testicular	O
biopsies	O
,	O
and	I-protein
prophylactic	O
testicular	O
radiation	I-protein
.	O

Recent	O
studies	O
suggest	O
that	O
prognostic	O
factors	I-protein
lose	O
their	O
significance	O
after	O
2	I-protein
years	O
of	I-protein
continuous	O
complete	O
remission	O
and	I-protein
that	O
2	I-protein
years	O
of	I-protein
maintenance	I-protein
therapy	O
is	O
adequate	O
.	O

Bilateral	O
open-wedge	O
testicular	O
biopsies	O
have	O
identified	I-protein
occult	O
testicular	O
disease	I-protein
in	I-protein
8	I-protein
to	I-protein
10	I-protein
%	O
of	I-protein
males	O
.	O

A	O
unified	O
approach	O
to	I-protein
children	O
with	I-protein
leukemia/lymphoma	I-protein
,	O
a	I-protein
group	I-protein
with	I-protein
a	I-protein
particularly	O
poor	O
prognosis	O
,	O
utilizing	O
NHL-type	O
therapy	O
may	O
be	O
more	O
effective	O
than	I-protein
conventional	O
ALL	B-protein
therapy	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
400	O
WORDS	O
)	O

###MEDLINE:82114943

Glucocorticoid	B-protein
receptor	I-protein
and	I-protein
in	I-protein
vitro	O
sensitivity	I-protein
to	I-protein
steroid	O
hormones	I-protein
in	I-protein
human	O
lymphoproliferative	I-protein
diseases	O
and	I-protein
myeloid	O
leukemia	O
.	O

The	O
glucocorticoid	B-protein
receptor	I-protein
(	O
GR	B-protein
)	O
quantitation	O
by	I-protein
a	I-protein
whole-cell	O
assay	O
and/or	O
cytosol	I-protein
technique	O
and	I-protein
the	I-protein
in	I-protein
vitro	O
sensitivity	I-protein
to	I-protein
steroids	O
have	O
been	O
assessed	O
in	I-protein
peripheral	O
blood	O
cells	I-protein
from	I-protein
normal	O
donors	O
and	I-protein
patients	O
with	I-protein
chronic	O
lymphatic	B-protein
leukemia	O
(	O
CLL	O
)	O
,	O
acute	O
lymphoblastic	O
leukemia	O
(	O
ALL	B-protein
)	O
,	O
lymphosarcoma	O
cell	O
leukemia	O
(	O
LSCL	O
)	O
,	O
acute	O
nonlymphatic	O
leukemia	O
(	O
ANLL	O
)	O
,	O
and	I-protein
chronic	O
myeloid	O
leukemia	O
(	O
CML	O
)	O
.	O

Within	O
the	I-protein
lymphoproliferative	I-protein
diseases	O
,	O
ALL	B-protein
cells	I-protein
exhibited	O
the	I-protein
highest	O
GR	B-protein
concentration	I-protein
(	O
regardless	O
of	I-protein
the	I-protein
method	O
used	O
)	O
and	I-protein
the	I-protein
highest	O
in	I-protein
vitro	O
inhibition	O
of	I-protein
spontaneous	O
[	O
3H	I-protein
]	O
thymidine	B-protein
(	O
[	O
3H	I-protein
]	O
TdR	O
)	O
uptake	I-protein
by	I-protein
glucocorticoids	O
.	O

A	O
significant	O
relationship	O
between	O
GR	B-protein
concentration	I-protein
(	O
whole-cell	O
assay	O
)	O
and	I-protein
in	I-protein
vitro	O
sensitivity	I-protein
to	I-protein
dexamethasone	O
was	O
also	O
found	O
.	O

On	O
the	I-protein
contrary	O
,	O
CLL	O
cells	I-protein
presented	O
the	I-protein
highest	O
sensitivity	I-protein
to	I-protein
glucocorticoids	O
in	I-protein
PHA-stimulated	O
cell	O
cultures	O
.	O

Cells	O
from	I-protein
the	I-protein
only	I-protein
two	O
ALL	B-protein
patients	O
who	O
did	O
not	I-protein
undergo	O
a	I-protein
remission	O
after	O
glucocorticoid-inclusive	O
chemotherapy	O
had	O
both	O
the	I-protein
lowest	O
in	I-protein
vitro	O
sensitivity	I-protein
to	I-protein
dexamethasone	O
and	I-protein
the	I-protein
lowest	O
GR	O
concentration	I-protein
with	I-protein
whole-cell	O
assay	O
.	O

Concerning	O
myeloid	O
leukemia	O
,	O
ANLL	O
patients	O
had	O
GR	B-protein
concentrations	O
slightly	O
higher	O
than	I-protein
those	O
found	O
in	I-protein
the	I-protein
ALL	B-protein
group	I-protein
but	O
exhibited	O
the	I-protein
lowest	O
degree	O
of	I-protein
inhibition	O
of	I-protein
spontaneous	O
[	O
3H	I-protein
]	O
TdR	O
uptake	I-protein
by	I-protein
dexamethasone	O
(	O
stimulatory	I-protein
effects	O
occurred	O
in	I-protein
some	O
cases	O
)	O
.	O

CML	O
cells	I-protein
exhibited	O
an	I-protein
inhibition	O
degree	O
by	I-protein
in	I-protein
vitro	O
glucocorticoids	O
significantly	O
higher	O
than	I-protein
that	O
of	I-protein
ANLL	O
cells	I-protein
but	O
not	I-protein
different	O
from	I-protein
that	O
of	I-protein
lymphoproliferative	I-protein
diseases	O
.	O

No	I-protein
clear	I-protein
relationship	O
among	O
GR	O
pattern	I-protein
,	O
in	I-protein
vitro	O
cell	O
sensitivity	I-protein
to	I-protein
glucocorticoids	O
,	O
and	I-protein
clinicohematologic	O
parameters	O
was	O
observed	O
in	I-protein
myeloid	O
leukemia-bearing	O
patients	O
.	O

###MEDLINE:81265481

Glucocorticoid	B-protein
receptors	I-protein
and	I-protein
in	I-protein
vitro	O
corticosensitivity	O
of	I-protein
peanut-positive	O
and	I-protein
peanut-negative	O
human	O
thymocyte	B-protein
subpopulations	O
.	O

In	O
6	I-protein
human	O
thymus	I-protein
glands	O
,	O
the	I-protein
immature	B-protein
subset	I-protein
of	I-protein
thymocytes	O
was	O
separated	O
from	I-protein
the	I-protein
more	O
mature	B-protein
one	B-protein
,	O
by	I-protein
differential	O
peanut	O
lectin	O
agglutination	O
.	O

These	O
2	I-protein
cell	O
subpopulations	O
were	O
analyzed	O
for	I-protein
glucocorticoid	B-protein
receptor	I-protein
content	O
by	I-protein
using	O
a	I-protein
whole	O
cell	O
assay	O
,	O
with	I-protein
(	O
3H	I-protein
)	O
-triamcinolone	O
acetonide	O
as	O
tracer	O
.	O

The	O
unagglutinated	O
thymocytes	O
(	O
peanut	O
negative	O
)	O
contained	O
about	O
2	I-protein
times	O
more	O
receptor	O
sites	I-protein
per	O
cell	O
than	I-protein
agglutinated	O
(	O
peanut	O
positive	I-protein
)	O
ones	O
(	O
7650	O
+/-	O
1550	O
S.D.	O
verus	O
3195	O
+/-	O
896	O
S.D.	O
)	O
.	O

The	O
affinity	I-protein
for	I-protein
steroid	O
was	O
similar	O
in	I-protein
both	O
cell	O
subsets	O
,	O
as	O
was	O
the	I-protein
stereospecificity	O
for	I-protein
glucocorticoids	O
,	O
the	I-protein
time-course	O
of	I-protein
steroid-receptor	O
association	I-protein
,	O
and	I-protein
cytoplasmic	O
to	I-protein
nuclear	O
translocation	O
.	O

Despite	O
the	I-protein
greater	O
number	I-protein
of	I-protein
glucocorticoid	B-protein
receptor	I-protein
sites	I-protein
,	O
the	I-protein
peanut-negative	O
thymocyte	B-protein
subpopulation	O
did	O
not	I-protein
differ	O
from	I-protein
the	I-protein
peanut-positive	O
one	B-protein
in	I-protein
its	O
sensitivity	I-protein
to	I-protein
the	I-protein
inhibitory	O
effects	O
of	I-protein
triamcinolone	O
acetonide	O
,	O
as	O
determined	O
by	I-protein
measurements	O
of	I-protein
the	I-protein
incorporation	O
of	I-protein
radiolabeled	O
precursors	O
of	I-protein
protein	O
and	I-protein
DNA	O
.	O

Moreover	O
,	O
the	I-protein
peanut-negative	O
subset	I-protein
appeared	O
more	O
resistant	I-protein
in	I-protein
vitro	O
to	I-protein
the	I-protein
steroid-induced	O
cell	O
lysis	O
as	O
compared	O
to	I-protein
the	I-protein
peanut-positive	O
one	B-protein
.	O

Thus	O
,	O
our	O
data	O
suggest	O
that	O
glucocorticoid	B-protein
receptor	I-protein
density	I-protein
and	I-protein
corticosensitivity	O
are	O
not	I-protein
directly	O
correlated	O
and	I-protein
that	O
the	I-protein
number	I-protein
of	I-protein
glucocorticoid	B-protein
receptor	I-protein
sites	I-protein
may	O
be	O
dependent	I-protein
on	I-protein
the	I-protein
degree	O
of	I-protein
immunologic	O
maturation	I-protein

###MEDLINE:86034662

Defective	O
binding	I-protein
and	I-protein
function	I-protein
of	I-protein
1	I-protein
,	O
25-dihydroxyvitamin	I-protein
D3	I-protein
receptors	I-protein
in	I-protein
peripheral	O
mononuclear	O
cells	I-protein
of	I-protein
patients	O
with	I-protein
end-organ	O
resistance	O
to	I-protein
1	I-protein
,	O
25-dihydroxyvitamin	O
D	O
.	O

Lectin-induced	O
DNA	O
synthesis	I-protein
by	I-protein
peripheral	O
mononuclear	O
cells	I-protein
from	I-protein
17	I-protein
normal	O
donors	O
was	O
inhibited	O
(	O
40-60	O
%	O
)	O
by	I-protein
1	I-protein
,	O
25-dihydroxyvitamin	O
D3	I-protein
(	O
1	I-protein
,	O
25	I-protein
[	O
OH	O
]	O
2D3	O
)	O
at	I-protein
physiological	O
concentrations	O
(	O
10	I-protein
(	O
-10	O
)	O
-10	O
(	O
-9	O
)	O
M	I-protein
)	O
.	O

The	O
lymphocytes	O
acquire	O
specific	I-protein
receptors	I-protein
for	I-protein
1	I-protein
,	O
25	I-protein
(	O
OH	O
)	O
2D3	O
upon	O
activation	I-protein
by	I-protein
the	I-protein
lectins	O
.	O

This	O
process	O
precedes	O
the	I-protein
inhibitory	O
effect	O
of	I-protein
1	I-protein
,	O
25	I-protein
(	O
OH	O
)	O
2D3	O
.	O

We	O
studied	O
lymphocytes	O
from	I-protein
six	O
patients	O
from	I-protein
four	O
different	O
kindreds	O
with	I-protein
the	I-protein
syndrome	I-protein
of	I-protein
hereditary	O
end-organ	O
resistance	O
to	I-protein
1	I-protein
,	O
25	I-protein
(	O
OH	O
)	O
2D	I-protein
(	O
the	I-protein
so-called	O
vitamin	O
D-dependent	O
rickets	I-protein
type	O
II	I-protein
)	O
.	O

In	O
five	I-protein
patients	O
(	O
three	O
kindreds	O
)	O
peripheral	O
blood	O
mononuclear	O
cells	I-protein
did	O
not	I-protein
acquire	O
receptors	I-protein
for	I-protein
1	I-protein
,	O
25	I-protein
(	O
OH	O
)	O
2D3	O
upon	O
phytohemagglutinin-induced	O
activation	I-protein
.	O

Moreover	O
,	O
in	I-protein
contrast	O
to	I-protein
normal	O
lymphocytes	O
,	O
the	I-protein
mitogenic	O
stimulation	I-protein
of	I-protein
these	O
patients	O
'	O
lymphocytes	O
by	I-protein
phytohemagglutinin	B-protein
and	I-protein
concanavalin	B-protein
A	I-protein
was	O
not	I-protein
inhibited	O
by	I-protein
1	I-protein
,	O
25	I-protein
(	O
OH	O
)	O
2D3	O
.	O

Activated	I-protein
lymphocytes	O
of	I-protein
the	I-protein
sixth	O
patient	O
from	I-protein
a	I-protein
fourth	O
kindred	O
exhibited	O
normal	O
binding	I-protein
of	I-protein
[	O
3H	I-protein
]	O
1	I-protein
,	O
25	I-protein
(	O
OH	O
)	O
2D3	O
but	O
the	I-protein
hormone	I-protein
failed	O
to	I-protein
inhibit	O
the	I-protein
mitogenic	O
stimulation	I-protein
.	O

A	O
similar	O
pattern	I-protein
of	I-protein
the	I-protein
vitamin	O
D	O
effector	O
system	I-protein
was	O
previously	O
observed	O
in	I-protein
fibroblasts	O
cultured	O
from	I-protein
skin	O
biopsies	O
of	I-protein
the	I-protein
same	O
group	I-protein
of	I-protein
patients	O
.	O

The	O
conclusions	O
from	I-protein
these	O
findings	O
are	O
:	O
(	O
a	I-protein
)	O
the	I-protein
inhibition	O
of	I-protein
mitogenic	O
stimulation	I-protein
by	I-protein
1	I-protein
,	O
25	I-protein
(	O
OH	O
)	O
2D3	O
is	O
mediated	I-protein
by	I-protein
specific	I-protein
functional	I-protein
receptors	I-protein
to	I-protein
the	I-protein
hormone	I-protein
;	O
and	I-protein
(	O
b	O
)	O
the	I-protein
receptors	I-protein
for	I-protein
1	I-protein
,	O
25	I-protein
(	O
OH	O
)	O
2D3	O
in	I-protein
mononuclear	O
cells	I-protein
are	O
probably	O
controlled	O
genetically	O
by	I-protein
the	I-protein
same	O
mechanisms	O
as	O
the	I-protein
effector	O
system	I-protein
in	I-protein
well-characterized	O
target	O
organs	O
of	I-protein
the	I-protein
hormone	I-protein
,	O
such	O
as	O
intestine	I-protein
and	I-protein
kidney	O
.	O

###MEDLINE:86021813

Glucocorticoid	B-protein
receptors	I-protein
of	I-protein
mononuclear	O
leukocytes	O
from	I-protein
myasthenia	B-protein
gravis	I-protein
patients	O
.	O

The	O
present	O
study	O
was	O
performed	O
to	I-protein
analyse	O
glucocorticoid	B-protein
receptor	I-protein
(	O
GR	B-protein
)	O
binding	I-protein
in	I-protein
peripheral	O
blood	O
mononuclear	O
leukocytes	O
(	O
MNL	O
)	O
from	I-protein
39	I-protein
myasthenia	B-protein
gravis	I-protein
(	O
MG	O
)	O
patients	O
(	O
unoperated	O
patients	O
(	O
n	O
=	O
13	I-protein
)	O
,	O
thymectomized	O
patients	O
(	O
n	O
=	O
14	I-protein
)	O
and	I-protein
patients	O
receiving	O
glucocorticoids	O
:	O
thymectomized	O
(	O
n	O
=	O
11	I-protein
)	O
and	I-protein
unoperated	O
(	O
n	O
=	O
6	I-protein
]	O
.	O

A	O
whole	O
cell	O
binding	I-protein
assay	O
with	I-protein
3	O
(	O
H	I-protein
)	O
dexamethasone	O
was	O
used	O
.	O

GR	B-protein
mean	I-protein
values	O
were	O
significantly	O
higher	O
in	I-protein
the	I-protein
MNL	O
of	I-protein
MG	O
patients	O
(	O
thymectomized	O
or	I-protein
not	I-protein
)	O
not	I-protein
receiving	O
glucocorticoid	O
than	I-protein
in	I-protein
the	I-protein
MNL	O
of	I-protein
healthy	O
donors	O
.	O

Affinity	O
was	O
within	B-protein
the	I-protein
normal	O
range	O
.	O

Sex	O
,	O
age	I-protein
or	I-protein
clinical	I-protein
forms	I-protein
of	I-protein
illness	O
did	O
not	I-protein
influence	O
the	I-protein
results	O
.	O

In	O
patients	O
receiving	O
prednisone	O
(	O
Pd	O
)	O
the	I-protein
GR	B-protein
values	O
were	O
significantly	O
lower	I-protein
than	I-protein
in	I-protein
MG	O
patients	O
without	I-protein
Pd	O
therapy	O
,	O
independent	I-protein
of	I-protein
Pd	O
dose	O
or	I-protein
time	O
of	I-protein
administration	O
.	O

No	I-protein
differences	O
in	I-protein
receptor	O
binding	I-protein
between	O
normal	O
subjects	O
and	I-protein
MG	O
patients	O
receiving	O
Pd	O
have	O
been	O
found	O
.	O

###MEDLINE:86125840

Immunological	O
interference	O
of	I-protein
high	O
dose	O
corticosteroids	O
.	O

High-dose	O
corticosteroids	O
(	O
HDC	B-protein
)	O
will	O
influence	O
cellular	O
as	O
well	O
as	O
humoral	O
participants	O
of	I-protein
the	I-protein
immune	O
response	I-protein
.	O

The	O
lymphoid	O
tissue	O
will	O
decrease	O
in	I-protein
size	O
and	I-protein
weight	I-protein
after	O
prolonged	O
treatment	O
with	I-protein
HDC	B-protein
.	O

Lymphocyte	O
functions	O
will	O
be	O
impaired	O
.	O

Reduced	O
synthesis	I-protein
of	I-protein
B-	O
as	O
well	O
as	O
T-lymphocytes	O
will	O
be	O
seen	O
.	O

The	O
inhibitory	O
effect	O
on	I-protein
B-cell	O
function	I-protein
can	O
be	O
observed	O
both	O
as	O
decreased	O
serum	O
levels	I-protein
of	I-protein
immunoglobulins	O
and	I-protein
as	O
impaired	O
binding	I-protein
of	I-protein
antibodies	I-protein
and	I-protein
complement	O
to	I-protein
the	I-protein
cellular	O
surface	O
.	O

Reduced	O
T-cell	O
function	I-protein
indicated	O
by	I-protein
impaired	O
stimulation	I-protein
by	I-protein
PHA	B-protein
and	I-protein
porkweed	O
as	O
well	O
as	O
by	I-protein
impaired	O
lymphokinin	O
effects	O
on	I-protein
leukocyte	O
migration	I-protein
inhibition	O
has	O
been	O
reported	O
.	O

Reduced	O
lymphocyte	O
adherence	O
to	I-protein
antigen	O
and	I-protein
suppressed	I-protein
lymphocyte	O
reaction	I-protein
have	O
also	O
been	O
observed	O
.	O

Humoral	O
factors	I-protein
involved	I-protein
in	I-protein
chemotaxis	O
,	O
opsonisation	O
,	O
phagocytosis	O
,	O
vascular	O
permeability	I-protein
leading	O
to	I-protein
leakage	O
of	I-protein
fluid	I-protein
and	I-protein
cells	I-protein
and	I-protein
factors	I-protein
involved	I-protein
in	I-protein
lysis	O
of	I-protein
antigens	I-protein
are	O
impaired	O
.	O

This	O
can	O
be	O
explained	O
partly	O
by	I-protein
the	I-protein
observed	O
reduced	O
complement	O
activation	I-protein
via	I-protein
the	I-protein
alternative	O
as	O
well	O
as	O
the	I-protein
classical	O
pathway	I-protein
in	I-protein
association	I-protein
with	I-protein
HDC	B-protein
therapy	O
.	O

Acute	B-protein
processes	O
with	I-protein
increased	I-protein
vascular	O
permeability	I-protein
and	I-protein
accumulation	I-protein
of	I-protein
leukocytes	O
as	O
impairing	O
factors	I-protein
could	O
be	O
influenced	I-protein
beneficially	O
by	I-protein
HDC	B-protein
therapy	O
.	O

This	O
positive	I-protein
effect	O
can	O
be	O
seen	O
in	I-protein
treatment	O
of	I-protein
septic	O
shock	I-protein
or	I-protein
rejection	O
of	I-protein
a	I-protein
transplant	O
.	O

However	O
,	O
if	O
sepsis	O
or	I-protein
rejection	O
is	O
not	I-protein
rapidly	I-protein
reversed	O
,	O
complications	O
such	O
as	O
multisystem	O
organ	O
failure	I-protein
and	I-protein
bacteremia	O
are	O
prone	O
to	I-protein
appear	O
.	O

###MEDLINE:84282381

Identification	O
of	I-protein
human	B-protein
leukemic	I-protein
glucocorticoid	I-protein
receptors	I-protein
using	O
affinity	I-protein
labeling	O
and	I-protein
anti-human	B-protein
glucocorticoid	I-protein
receptor	I-protein
antibodies	I-protein
.	O

Antisera	O
raised	O
against	I-protein
human	B-protein
lymphoid	I-protein
glucocorticoid	I-protein
receptors	I-protein
were	O
used	O
in	I-protein
combination	O
with	I-protein
the	I-protein
glucocorticoid	B-protein
receptor	I-protein
affinity	I-protein
label	O
[	O
3H	I-protein
]	O
dexamethasone	O
21-mesylate	O
[	O
(	O
3H	I-protein
]	O
DM	I-protein
)	O
to	I-protein
identify	O
the	I-protein
glucocorticoid	B-protein
receptors	I-protein
of	I-protein
the	I-protein
human	O
B-lymphoblastoid	O
cell	O
line	I-protein
IM-9	O
and	I-protein
the	I-protein
human	O
T-cell	O
leukemic	O
cell	O
line	I-protein
CEM-C7	O
.	O

Antisera	O
were	O
obtained	O
following	O
immunization	O
of	I-protein
New	I-protein
Zealand	O
White	O
rabbits	O
with	I-protein
[	O
3H	I-protein
]	O
triamcinolone	I-protein
acetonide	I-protein
[	O
(	O
3H	I-protein
]	O
TA	I-protein
)	O
-glucocorticoid	I-protein
receptor	I-protein
complexes	I-protein
partially	O
purified	O
by	I-protein
two-stage	O
DNA-cellulose	O
chromatography	O
.	O

The	O
presence	O
of	I-protein
anti-human	B-protein
glucocorticoid	I-protein
receptor	I-protein
antibodies	I-protein
was	O
verified	O
by	I-protein
:	O
(	O
a	I-protein
)	O
adsorption	O
of	I-protein
[	O
3H	I-protein
]	O
TA-receptor-antibody	I-protein
complexes	I-protein
to	I-protein
Protein	I-protein
A	O
;	O
(	O
b	O
)	O
a	I-protein
shift	O
to	I-protein
higher	O
apparent	O
molecular	I-protein
weight	I-protein
in	I-protein
the	I-protein
elution	O
position	O
from	I-protein
Sephacryl	O
S300	O
of	I-protein
[	O
3H	I-protein
]	O
TA-receptor	I-protein
complexes	I-protein
incubated	O
with	I-protein
immune	O
serum	O
;	O
and	I-protein
(	O
c	I-protein
)	O
the	I-protein
ability	O
of	I-protein
immune	O
serum	O
to	I-protein
displace	O
[	O
3H	I-protein
]	O
TA-receptor	I-protein
complexes	I-protein
on	I-protein
sucrose	O
gradients	O
.	O

These	O
antibodies	I-protein
also	O
recognized	I-protein
rat	I-protein
liver	O
and	I-protein
murine	B-protein
S49	I-protein
cell	I-protein
glucocorticoid	I-protein
receptors	I-protein
.	O

Sodium	O
dodecyl	O
sulfate-polyacrylamide	O
gel	O
electrophoresis	O
of	I-protein
[	O
3H	I-protein
]	O
DM-labeled	O
IM-9	O
cytosol	I-protein
identified	I-protein
a	I-protein
major	O
competable	O
band	I-protein
with	I-protein
a	I-protein
molecular	I-protein
weight	I-protein
of	I-protein
approximately	O
90	I-protein
,	O
000	O
,	O
three	O
minor	I-protein
competable	O
components	O
with	I-protein
molecular	I-protein
weights	O
of	I-protein
approximately	O
78	I-protein
,	O
000	O
,	O
approximately	O
51	I-protein
,	O
000	O
,	O
and	I-protein
approximately	O
38	I-protein
,	O
500	I-protein
,	O
and	I-protein
at	I-protein
least	O
21	I-protein
other	O
noncompetable	O
components	O
.	O

Following	O
immunoprecipitation	O
of	I-protein
[	O
3H	I-protein
]	O
DM-labeled	O
cytosol	I-protein
with	I-protein
immune	O
serum	O
,	O
only	I-protein
the	I-protein
Mr	O
90	I-protein
,	O
000	O
and	I-protein
78	I-protein
,	O
000	O
components	O
were	O
seen	O
.	O

Sodium	O
dodecyl	O
sulfate-polyacrylamide	O
gel	O
electrophoresis	O
of	I-protein
[	O
3H	I-protein
]	O
DM-labeled	O
CEM-C7	O
cytosol	I-protein
revealed	O
a	I-protein
larger	O
number	I-protein
of	I-protein
[	O
3H	I-protein
]	O
DM-labeled	O
components	O
.	O

However	O
,	O
after	O
immunoprecipitation	O
of	I-protein
[	O
3H	I-protein
]	O
DM-labeled	O
CEM-C7	O
cytosol	I-protein
,	O
a	I-protein
predominant	O
competable	O
component	O
with	I-protein
a	I-protein
molecular	I-protein
weight	I-protein
of	I-protein
90	I-protein
,	O
000	O
was	O
easily	O
identified	I-protein
.	O

This	O
component	O
was	O
markedly	O
diminished	O
when	O
cytosols	O
from	I-protein
the	I-protein
glucocorticoid	O
receptor-deficient	O
cell	O
line	I-protein
ICR-27	O
were	O
used	O
.	O

Thus	O
,	O
the	I-protein
combination	O
of	I-protein
affinity	I-protein
labeling	O
and	I-protein
anti-human	B-protein
glucocorticoid	I-protein
receptor	I-protein
antibodies	I-protein
is	O
capable	O
of	I-protein
providing	O
direct	O
physical	O
identification	O
of	I-protein
human	B-protein
lymphoid	I-protein
glucocorticoid	I-protein
receptors	I-protein
.	O

###MEDLINE:84130660

Effect	O
of	I-protein
thymosin	B-protein
on	I-protein
glucocorticoid	B-protein
receptor	I-protein
activity	I-protein
and	I-protein
glucocorticoid	O
sensitivity	I-protein
of	I-protein
human	O
thymocytes	O
.	O

Incubation	O
with	I-protein
thymosin	B-protein
fraction	O
5	O
,	O
(	O
TMS	B-protein
F5	I-protein
at	I-protein
300	I-protein
micrograms/ml	O
)	O
a	I-protein
partially	O
purified	O
thymic	B-protein
factor	I-protein
,	O
reduced	O
the	I-protein
steroid	O
binding	I-protein
activity	I-protein
of	I-protein
human	O
infant	O
thymocytes	O
from	I-protein
9.6	O
+/-	O
2.1	O
fmole/ml	O
to	I-protein
5.0	O
+/-	O
2.0	O
fmole/ml	O
.	O

The	O
glucocorticoid	B-protein
receptor	I-protein
activity	I-protein
in	I-protein
normal	O
infant	O
thymocytes	O
was	O
found	O
to	I-protein
be	O
2	I-protein
,	O
146	I-protein
+/-	O
726	I-protein
(	O
s.d.	O
)	O
sites	I-protein
per	O
cell	O
with	I-protein
dissociation	I-protein
constant	I-protein
of	I-protein
1.4	I-protein
+/-	O
0.6	O
X	O
10	I-protein
(	O
-8	O
)	O
M	I-protein
.	O

TMS	B-protein
F5	I-protein
also	O
increased	I-protein
the	I-protein
resistance	O
of	I-protein
human	O
thymocytes	O
to	I-protein
the	I-protein
cytolytic	O
effect	O
of	I-protein
dexamethasone	O
(	O
2.5	O
X	O
10	I-protein
(	O
-8	O
)	O
M	I-protein
)	O
to	I-protein
168.6	O
+/-	O
30.2	O
%	O
of	I-protein
control	I-protein
(	O
P	O
less	O
than	I-protein
0.01	O
)	O
.	O

In	O
animals	O
,	O
medullary	O
and	I-protein
peripheral	O
blood	O
T	O
cells	I-protein
are	O
more	O
resistant	I-protein
to	I-protein
glucocorticoids	O
than	I-protein
immature	B-protein
thymic	B-protein
T	O
cells	I-protein
.	O

The	O
results	O
show	O
that	O
thymosin	B-protein
can	O
induce	O
changes	O
consistent	O
with	I-protein
differentiation	I-protein
in	I-protein
human	O
thymocytes	O
.	O

These	O
in	I-protein
vitro	O
results	O
are	O
consistent	O
with	I-protein
a	I-protein
physiological	O
role	O
of	I-protein
thymosin	B-protein
in	I-protein
intrathymic	O
T	O
cell	O
maturation	I-protein
in	I-protein
man	I-protein
.	O

Incubation	O
of	I-protein
a	I-protein
human	O
malignant	O
thymus	I-protein
derived	I-protein
T	O
cell	O
line	I-protein
(	O
MOLT	B-protein
3	O
)	O
with	I-protein
TMS	B-protein
F5	I-protein
also	O
resulted	O
in	I-protein
a	I-protein
significant	O
reduction	I-protein
of	I-protein
the	I-protein
number	I-protein
of	I-protein
steroid	O
binding	I-protein
sites	I-protein
to	I-protein
44.2	O
+/-	O
15.3	O
%	O
of	I-protein
control	I-protein
(	O
P	O
less	O
than	I-protein
0.05	O
)	O
,	O
but	O
TMS	B-protein
F5	I-protein
did	O
not	I-protein
significantly	O
reduce	O
the	I-protein
glucocorticoid	O
sensitivity	I-protein
of	I-protein
MOLT	B-protein
3	O
cells	I-protein
.	O

###MEDLINE:84032920

Specific	B-protein
high-affinity	I-protein
receptors	I-protein
for	I-protein
1	I-protein
,	O
25-dihydroxyvitamin	O
D3	I-protein
in	I-protein
human	O
peripheral	O
blood	O
mononuclear	O
cells	I-protein
:	O
presence	O
in	I-protein
monocytes	O
and	I-protein
induction	I-protein
in	I-protein
T	O
lymphocytes	O
following	O
activation	I-protein
.	O

Human	O
peripheral	O
blood	O
monocytes	O
have	O
high	O
affinity	I-protein
binding	I-protein
sites	I-protein
for	I-protein
1	I-protein
,	O
25-	O
(	O
OH	O
)	O
2D3	O
(	O
Kd	O
0.14	O
nM	O
,	O
sedimentation	O
coefficient	O
3.7S	O
)	O
.	O

Resting	O
human	O
peripheral	O
blood	O
T	O
lymphocytes	O
,	O
however	O
,	O
do	O
not	I-protein
have	O
a	I-protein
demonstrable	B-protein
1	I-protein
,	O
25-	I-protein
(	O
OH	I-protein
)	O
2D3	I-protein
receptor	I-protein
.	O

After	O
activation	I-protein
with	I-protein
phytohemagglutinin	O
the	I-protein
T	O
cells	I-protein
exhibit	O
the	I-protein
receptor	O
within	B-protein
24	I-protein
h	I-protein
,	O
and	I-protein
this	O
expression	I-protein
is	O
blocked	B-protein
by	I-protein
cycloheximide	O
.	O

The	O
receptor	O
in	I-protein
activated	O
T	O
lymphocytes	O
has	O
a	I-protein
sedimentation	O
coefficient	O
of	I-protein
3.7S	O
and	I-protein
a	I-protein
high	O
affinity	I-protein
(	O
Kd	O
0.10	O
nM	O
)	O
for	I-protein
the	I-protein
ligand	O
.	O

###MEDLINE:83186675

Effects	O
of	I-protein
chronic	O
glucocorticoid	O
excess	O
in	I-protein
man	I-protein
on	I-protein
insulin	O
binding	I-protein
to	I-protein
circulating	O
cells	I-protein
:	O
differences	O
between	O
endogenous	O
and	I-protein
exogenous	O
hypercorticism	O
.	O

We	O
measured	O
[	O
125I	O
]	O
insulin	O
binding	I-protein
to	I-protein
circulating	O
monocytes	O
or	I-protein
erythrocytes	O
from	I-protein
16	I-protein
patients	O
with	I-protein
chronic	O
glucocorticoid	O
excess	O
,	O
9	I-protein
chronically	O
treated	O
with	I-protein
prednisone	O
and	I-protein
7	I-protein
with	I-protein
adrenocortical	O
hyperfunction	O
.	O

With	O
monocytes	O
,	O
[	O
125I	O
]	O
insulin	O
binding	I-protein
was	O
iincreased	O
in	I-protein
all	O
patients	O
.	O

Analysis	O
of	I-protein
binding	I-protein
data	O
indicated	O
that	O
increased	I-protein
binding	I-protein
in	I-protein
patients	O
treated	O
with	I-protein
prednisone	O
was	O
due	I-protein
to	I-protein
an	I-protein
ncrease	O
in	I-protein
receptor	O
concentration	I-protein
,	O
whereas	O
in	I-protein
patients	O
with	I-protein
adrenocortical	O
hyperfunction	O
,	O
it	O
was	O
due	I-protein
to	I-protein
an	I-protein
increase	O
in	I-protein
receptor	O
affinity	I-protein
.	O

With	O
erythrocytes	O
from	I-protein
patients	O
with	I-protein
adrenocortical	O
hyperfunction	O
there	O
was	O
an	I-protein
increase	O
in	I-protein
receptor	O
affinity	I-protein
and	I-protein
a	I-protein
decrease	O
in	I-protein
receptor	O
concentration	I-protein
,	O
so	O
that	O
the	I-protein
binding	I-protein
of	I-protein
[	O
125I	O
]	O
insulin	O
was	O
normal	O
.	O

The	O
disparity	O
of	I-protein
results	O
between	O
endogenous	O
and	I-protein
exogenous	O
hypercorticism	O
,	O
between	O
the	I-protein
two	O
cell	O
types	I-protein
,	O
and	I-protein
between	O
the	I-protein
present	O
studies	O
and	I-protein
previous	O
studies	O
suggest	O
that	O
the	I-protein
effects	O
of	I-protein
glucocorticoid	O
excess	O
on	I-protein
the	I-protein
insulin	B-protein
receptor	I-protein
are	O
extremely	O
complex	I-protein
and	I-protein
wide-ranging	O
and	I-protein
that	O
in	I-protein
this	O
condition	O
,	O
extrapolations	O
in	I-protein
humans	O
from	I-protein
data	O
with	I-protein
circulating	O
cells	I-protein
to	I-protein
liver	O
and	I-protein
muscle	O
may	O
not	I-protein
be	O
appropriate	O
.	O

###MEDLINE:83106949

Reduced	O
level	I-protein
of	I-protein
cellular	B-protein
glucocorticoid	I-protein
receptors	I-protein
in	I-protein
patients	O
with	I-protein
anorexia	O
nervosa	I-protein
.	O

Specific	B-protein
glucocorticoid	B-protein
receptors	I-protein
were	O
measured	O
in	I-protein
circulating	O
mononuclear	O
leukocytes	O
from	I-protein
12	O
patients	O
with	I-protein
anorexia	O
nervosa	I-protein
and	I-protein
21	I-protein
healthy	O
control	I-protein
subjects	O
.	O

Cells	O
from	I-protein
patients	O
were	O
found	O
to	I-protein
contain	O
a	I-protein
significantly	O
(	O
p	O
less	O
than	I-protein
0.01	O
)	O
lower	I-protein
level	I-protein
of	I-protein
glucocorticoid	B-protein
receptor	I-protein
(	O
3830	O
+/-	O
210	I-protein
sites/cell	O
,	O
mean	I-protein
+/-	O
SE	O
)	O
than	I-protein
those	O
from	I-protein
controls	O
(	O
4930	O
+/-	O
250	I-protein
sites/cell	O
)	O
.	O

A	O
partial	I-protein
glucocorticoid	B-protein
receptor	I-protein
defect	I-protein
may	O
well	O
explain	O
the	I-protein
abnormal	I-protein
cortisol	O
metabolism	I-protein
and	I-protein
glucocorticoid	O
resistance	O
commonly	O
found	O
in	I-protein
patients	O
with	I-protein
anorexia	O
nervosa	I-protein
.	O

###MEDLINE:82147031

Regulation	O
of	I-protein
the	I-protein
glucocorticoid	B-protein
receptor	I-protein
in	I-protein
human	O
lymphocytes	O
.	O

The	O
presence	O
of	I-protein
a	I-protein
glucocorticoid	B-protein
receptor	I-protein
in	I-protein
human	O
lymphocytes	O
is	O
well	O
established	O
,	O
but	O
factors	I-protein
affecting	O
its	O
regulation	I-protein
have	O
not	I-protein
been	O
described	O
.	O

Using	O
a	I-protein
competitive	O
binding	I-protein
whole	O
cell	O
assay	O
,	O
we	O
have	O
examined	O
the	I-protein
binding	I-protein
of	I-protein
[	O
3H	I-protein
]	O
-dexamethasone	O
at	I-protein
24	I-protein
and	I-protein
37	I-protein
degrees	O
C	O
in	I-protein
untreated	O
normal	O
subjects	O
and	I-protein
in	I-protein
healthy	O
subjects	O
taking	O
various	O
glucocorticoid	O
preparations	O
.	O

At	O
24	I-protein
degrees	O
C	O
normal	O
human	O
lymphocytes	O
had	O
6000	O
binding	I-protein
sites/cell	O
and	I-protein
a	I-protein
dissociation	I-protein
constant	I-protein
of	I-protein
4	I-protein
x	I-protein
10	I-protein
(	O
-9	O
)	O
M	I-protein
.	O

The	O
administration	O
of	I-protein
1	I-protein
mg	O
of	I-protein
dexamethasone	O
,	O
5	O
mg	O
of	I-protein
prednisone	O
,	O
and	I-protein
37.5	O
mg	O
of	I-protein
cortisone	O
acetate	O
resulted	O
in	I-protein
a	I-protein
30	I-protein
%	O
decrease	O
in	I-protein
binding	I-protein
sites	I-protein
after	O
1	I-protein
week	O
with	I-protein
no	I-protein
change	O
in	I-protein
binding	I-protein
affinity	I-protein
.	O

No	I-protein
changes	O
in	I-protein
the	I-protein
number	I-protein
of	I-protein
binding	I-protein
sites	I-protein
was	O
noted	O
before	O
1	I-protein
week	O
and	I-protein
the	I-protein
diminished	O
number	I-protein
persisted	O
for	I-protein
1	I-protein
week	O
after	O
discontinuation	O
of	I-protein
glucocorticoid	O
treatment	O
.	O

Lymphocytes	O
from	I-protein
hospitalized	O
patients	O
taking	O
40-60	O
mg	O
of	I-protein
dexamethasone	O
daily	O
demonstrated	O
the	I-protein
same	O
change	O
in	I-protein
number	I-protein
of	I-protein
binding	I-protein
sites	I-protein
that	O
was	O
seen	O
in	I-protein
normal	O
subjects	O
taking	O
1	I-protein
mg	O
of	I-protein
dexamethasone	O
.	O

When	O
binding	I-protein
assays	O
were	O
carried	O
out	O
at	I-protein
physiologic	O
temperature	I-protein
there	O
was	O
the	I-protein
same	O
decrease	O
in	I-protein
number	I-protein
of	I-protein
binding	I-protein
sites	I-protein
after	O
dexamethasone	O
administration	O
,	O
and	I-protein
in	I-protein
addition	O
,	O
there	O
was	O
a	I-protein
two-fold	O
increase	O
in	I-protein
binding	I-protein
affinity	I-protein
.	O

Glucocorticoid	O
administration	O
results	O
in	I-protein
a	I-protein
time-dependent	O
decrease	O
in	I-protein
the	I-protein
number	I-protein
of	I-protein
lymphocyte	O
glucocorticoid	O
binding	I-protein
sites	I-protein
that	O
is	O
independent	I-protein
of	I-protein
the	I-protein
type	O
of	I-protein
glucocorticoid	O
administered	O
.	O

This	O
is	O
the	I-protein
first	O
in	I-protein
vivo	O
demonstration	O
that	O
glucocorticoids	O
modulate	O
their	O
own	O
receptors	I-protein
in	I-protein
man	I-protein
.	O

###MEDLINE:81209839

Immunoglobulin	O
localization	I-protein
in	I-protein
benign	O
and	I-protein
malignant	O
lesions	O
of	I-protein
the	I-protein
human	O
mammary	I-protein
gland	I-protein
.	O

Using	O
direct	O
imunofluorescence	O
,	O
lesions	O
from	I-protein
266	I-protein
human	O
breast	O
specimens	O
were	O
studied	O
for	I-protein
the	I-protein
presence	O
of	I-protein
IgA	O
,	O
IgM	I-protein
,	O
or	I-protein
IgG	I-protein
localization	I-protein
.	O

The	O
lesions	O
included	I-protein
benign	O
elements	O
from	I-protein
66	I-protein
subcutaneous	O
mastectomy	O
specimens	O
in	I-protein
which	O
the	I-protein
absence	I-protein
of	I-protein
simultaneous	O
breast	O
malignancy	O
was	O
documented	O
,	O
primary	O
breast	O
carcinomas	O
from	I-protein
153	I-protein
mastectomy	O
specimens	O
,	O
and	I-protein
47	I-protein
biopsies	O
containing	I-protein
metastatic	O
breast	O
cancer	O
.	O

A	O
statistically	O
significant	O
association	I-protein
of	I-protein
IgA	O
and	I-protein
IgM	I-protein
with	I-protein
benign	O
lesions	O
was	O
contrasted	O
to	I-protein
the	I-protein
association	I-protein
of	I-protein
IgG	I-protein
with	I-protein
malignant	O
lesions	O
.	O

In	O
both	O
primary	O
and	I-protein
metastatic	O
lesions	O
,	O
IgG	I-protein
localization	I-protein
was	O
associated	I-protein
with	I-protein
estrogen-receptor-poor	O
primary	O
cancers	I-protein
as	O
compared	O
with	I-protein
estrogen-receptor-rich	O
primary	O
cancers	I-protein
.	O

Among	O
primary	O
breast	O
cancer	O
patients	O
,	O
IgG	I-protein
localization	I-protein
in	I-protein
the	I-protein
tumor	O
correlated	O
with	I-protein
relative	I-protein
lymphopenia	O
.	O

A	O
shorter	I-protein
disease-free	O
interval	O
was	O
noted	O
in	I-protein
association	I-protein
with	I-protein
IgG	I-protein
localization	I-protein
among	O
the	I-protein
metastatic	O
breast	O
lesions	O
.	O

No	I-protein
statistically	O
significant	O
association	I-protein
between	O
stage	I-protein
of	I-protein
disease	I-protein
and	I-protein
immunoglobulin	O
presence	O
was	O
demonstrable	O
.	O

Moderate-to-severe	O
intraductal	O
epithelial	O
hyperplasias	O
were	O
more	O
often	O
associated	I-protein
with	I-protein
immunoglobulin	B-protein
G	I-protein
localization	I-protein
that	O
were	O
other	O
benign	O
lesions	O

###MEDLINE:86027718

Correlation	O
of	I-protein
steroid	B-protein
receptors	I-protein
with	I-protein
histologic	O
differentiation	I-protein
in	I-protein
mammary	I-protein
carcinoma	I-protein
.	O

A	O
Singapore	O
experience	O
.	O

Cancer	O
of	I-protein
the	I-protein
breast	O
is	O
the	I-protein
most	O
common	I-protein
tumor	O
in	I-protein
females	O
in	I-protein
Singapore	O
,	O
with	I-protein
the	I-protein
rate	I-protein
of	I-protein
20.7	O
per	O
100	I-protein
,	O
000	O
per	O
year	O
(	O
1977	O
estimate	O
)	O
,	O
which	O
is	O
predicted	I-protein
to	I-protein
increase	O
to	I-protein
29.8	O
per	O
100	I-protein
,	O
000	O
women	O
per	O
year	O
by	I-protein
1995	O
.	O

A	O
detailed	O
histopathologic	O
review	O
of	I-protein
50	I-protein
primary	O
breast	O
cancer	O
tumors	I-protein
analyzed	O
for	I-protein
estrogen	B-protein
receptor	I-protein
(	O
ER	B-protein
)	O
level	I-protein
was	O
carried	O
out	O
and	I-protein
a	I-protein
variety	O
of	I-protein
morphologic	O
features	I-protein
correlated	O
with	I-protein
ER	B-protein
results	O
to	I-protein
identify	O
any	O
factors	I-protein
that	O
will	O
improve	O
the	I-protein
management	O
and	I-protein
prognosis	O
for	I-protein
breast	O
cancer	O
.	O

Cytosol	O
was	O
incubated	O
with	I-protein
3H-estradiol	O
in	I-protein
the	I-protein
presence	O
and	I-protein
absence	I-protein
of	I-protein
cold	O
diethylstilbestrol	O
,	O
and	I-protein
bound	I-protein
and	I-protein
free	B-protein
hormone	I-protein
were	O
separated	O
by	I-protein
Dextran-coated	O
charcoal	O
method	O
.	O

Tumors	O
binding	I-protein
more	O
than	I-protein
5	O
fmol/mg	O
cytosol	I-protein
protein	I-protein
were	O
classified	O
as	O
ER	B-protein
-positive	O
.	O

Progesterone	B-protein
receptor	I-protein
(	O
PR	B-protein
)	O
level	I-protein
was	O
analyzed	O
in	I-protein
some	O
specimens	O
with	I-protein
the	I-protein
use	O
of	I-protein
a	I-protein
similar	O
method	O
.	O

Most	O
of	I-protein
the	I-protein
patients	O
were	O
Chinese	I-protein
(	O
90	I-protein
%	O
)	O
.	O

Three	O
patients	O
were	O
Malays	O
,	O
one	B-protein
was	O
Indian	O
,	O
and	I-protein
one	B-protein
was	O
European	O
in	I-protein
this	O
series	O
.	O

Results	O
indicated	O
that	O
there	O
was	O
strong	O
correlation	O
between	O
ER	B-protein
level	I-protein
,	O
age	I-protein
,	O
and	I-protein
histologic	O
grade	I-protein
of	I-protein
the	I-protein
tumors	I-protein
.	O

No	I-protein
correlation	O
existed	O
between	O
absence	I-protein
or	I-protein
presence	O
of	I-protein
lymph	O
node	I-protein
metastases	O
and	I-protein
ER	B-protein
.	O

Although	O
there	O
was	O
a	I-protein
trend	O
for	I-protein
ER	B-protein
-positive	O
tumors	I-protein
to	I-protein
have	O
a	I-protein
low-grade	O
lymphocytic	I-protein
infiltration	O
,	O
the	I-protein
difference	O
was	O
not	I-protein
statistically	O
significant	O
.	O

###MEDLINE:85233509

Mononuclear	O
cells	I-protein
infiltrating	O
human	O
mammary	I-protein
carcinomas	O
:	O
immunohistochemical	O
analysis	O
with	I-protein
monoclonal	I-protein
antibodies	I-protein
.	O

Breast	B-protein
carcinomas	O
were	O
examined	O
by	I-protein
the	I-protein
immunoperoxidase	O
technique	O
using	O
antisera	O
specific	I-protein
for	I-protein
lymphocyte	O
subsets	O
,	O
monocytes	O
,	O
NK	I-protein
cells	I-protein
and	I-protein
major	B-protein
histocompatibility	I-protein
antigens	I-protein
(	O
HLA-A	B-protein
,	O
-B	B-protein
,	O
-C	O
;	O
Ia-like	B-protein
)	O
.	O

Sixty-four	O
per	O
cent	O
of	I-protein
the	I-protein
patients	O
had	O
a	I-protein
moderate	O
or	I-protein
strong	O
mononuclear	O
cell	O
infiltration	O
,	O
77	I-protein
%	O
of	I-protein
the	I-protein
patients	O
without	I-protein
mononuclear	O
cell	O
infiltration	O
had	O
receptors	I-protein
for	I-protein
estrogens	O
as	O
compared	O
to	I-protein
51	I-protein
%	O
of	I-protein
the	I-protein
patients	O
with	I-protein
infiltration	O
.	O

The	O
majority	O
of	I-protein
the	I-protein
infiltrating	O
mononuclear	O
cells	I-protein
were	O
T	O
cells	I-protein
;	O
generally	O
the	I-protein
OKT8	O
cells	I-protein
were	O
predominant	O
.	O

The	O
Leu	O
3A/OKT8	O
cell	O
ratio	O
was	O
not	I-protein
related	O
to	I-protein
histological	O
type	O
,	O
tumor	O
size	O
,	O
age	I-protein
of	I-protein
the	I-protein
patient	O
or	I-protein
presence	O
of	I-protein
metastases	O
.	O

Some	O
of	I-protein
the	I-protein
T	O
cells	I-protein
had	O
the	I-protein
Ia	I-protein
antigen	I-protein
and	I-protein
were	O
thus	O
probably	O
activated	O
.	O

The	O
B	O
cells	I-protein
were	O
either	O
absent	O
or	I-protein
less	O
numerous	O
than	I-protein
the	I-protein
T	O
cells	I-protein
.	O

There	O
was	O
no	I-protein
relation	O
between	O
their	O
distribution	I-protein
and	I-protein
the	I-protein
various	O
parameters	O
studied	O
.	O

A	O
few	O
monocytes	O
were	O
heterogeneous	O
according	O
to	I-protein
their	O
markers	O
(	O
OKM	B-protein
I	I-protein
and	I-protein
acid	I-protein
phosphatase	I-protein
)	O
.	O

In	O
6	I-protein
cases	O
only	I-protein
there	O
was	O
a	I-protein
strong	O
infiltration	O
of	I-protein
mononuclear	O
cells	I-protein
positive	I-protein
for	I-protein
acid	B-protein
phosphatase	I-protein
.	O

The	O
number	I-protein
of	I-protein
the	I-protein
natural	O
killer	O
cells	I-protein
was	O
also	O
low	O
.	O

Only	O
a	I-protein
few	O
mononuclear	O
infiltrating	O
cells	I-protein
had	O
receptors	I-protein
for	I-protein
transferrin	B-protein
.	O

There	O
was	O
a	I-protein
positive	I-protein
correlation	O
between	O
the	I-protein
inflammatory	O
infiltration	O
and	I-protein
the	I-protein
presence	O
of	I-protein
HLA	B-protein
class-I	I-protein
antigens	I-protein
on	I-protein
tumor	O
cell	O
s	I-protein
.	O

Some	O
of	I-protein
the	I-protein
antisera	O
specific	I-protein
for	I-protein
lymphocyte	O
subsets	O
also	O
stained	O
the	I-protein
breast	O
carcinoma	I-protein
cells	I-protein
.	O

The	O
great	O
variations	O
in	I-protein
the	I-protein
subsets	O
of	I-protein
mononuclear	O
cells	I-protein
in	I-protein
breast	O
carcinomas	O
may	O
correspond	O
to	I-protein
various	O
systems	O
of	I-protein
defense	O
against	I-protein
neoplasm	O
.	O

###MEDLINE:85305500

A	O
case	O
of	I-protein
male	O
pseudohermaphroditism	O
with	I-protein
normal	O
androgen	O
receptor	O
binding	I-protein
and	I-protein
47	I-protein
,	O
XYY	O
karyotype	O
.	O

A	O
case	O
of	I-protein
male	O
pseudohermaphroditism	O
with	I-protein
47	I-protein
,	O
XYY	O
karyotype	O
in	I-protein
blood	O
and	I-protein
cutaneous	O
fibroblasts	O
is	O
described	O
.	O

The	O
plasma	O
testosterone	O
response	I-protein
to	I-protein
HCG	B-protein
stimulation	I-protein
was	O
slightly	O
below	O
the	I-protein
normal	O
range	O
on	I-protein
two	O
occasions	O
suggesting	O
a	I-protein
deficit	I-protein
of	I-protein
gonadal	B-protein
function	I-protein
.	O

A	O
study	O
of	I-protein
the	I-protein
receptors	I-protein
for	I-protein
dihydrotestosterone	I-protein
in	I-protein
fibroblasts	O
of	I-protein
genital	I-protein
and	I-protein
nongenital	O
skin	O
showed	O
a	I-protein
normal	O
concentration	I-protein
of	I-protein
receptors	I-protein
in	I-protein
genital	I-protein
skin	O
;	O
5-alpha-reductase	O
activity	I-protein
in	I-protein
fibroblasts	O
of	I-protein
the	I-protein
genital	I-protein
skin	O
was	O
low	O
,	O
but	O
the	I-protein
plasma	O
relationship	O
testosterone/dihydrotestosterone	O
under	O
HCG	B-protein
stimulation	I-protein
was	O
normal	O
.	O

The	O
diagnostic	O
possibility	O
of	I-protein
a	I-protein
complete	O
testicular	O
feminization	I-protein
syndrome	I-protein
with	I-protein
normal	O
receptors	I-protein
for	I-protein
dihydrotestosterone	I-protein
is	O
commented	O
on	I-protein
.	O

###MEDLINE:84290642

1	I-protein
,	O
25-Dihydroxyvitamin	O
D3	I-protein
inhibits	I-protein
antigen-induced	O
T	O
cell	O
activation	I-protein
.	O

The	O
proliferative	O
response	I-protein
of	I-protein
murine	O
spleen	B-protein
and	I-protein
thymus	I-protein
cells	I-protein
to	I-protein
antigen	O
but	O
not	I-protein
to	I-protein
lectin	B-protein
was	O
inhibited	O
by	I-protein
the	I-protein
active	O
metabolite	O
of	I-protein
vitamin	O
D3	I-protein
,	O
1	I-protein
,	O
25-	O
(	O
OH	O
)	O
2D3	O
.	O

To	O
directly	O
examine	O
the	I-protein
effect	O
of	I-protein
1	I-protein
,	O
25-	O
(	O
OH	O
)	O
2D3	O
on	I-protein
T	O
cell	O
activation	I-protein
in	I-protein
the	I-protein
absence	I-protein
of	I-protein
other	O
complicating	O
interactions	O
,	O
we	O
utilized	O
a	I-protein
panel	O
of	I-protein
cloned	O
Ia-restricted	O
T	O
cell	O
hybridomas	O
that	O
secrete	O
IL	B-protein
2	I-protein
on	I-protein
activation	I-protein
by	I-protein
cloned	O
Ia-bearing	O
stimulator	I-protein
cells	I-protein
(	O
TA3	B-protein
)	O
or	I-protein
when	O
stimulated	O
by	I-protein
mitogen	O
.	O

Physiologic	O
concentrations	O
of	I-protein
1	I-protein
,	O
25-	O
(	O
OH	O
)	O
2D3	O
(	O
0.01	O
to	I-protein
0.1	O
nm	O
)	O
inhibited	O
the	I-protein
antigen-induced	O
secretion	O
of	I-protein
IL	B-protein
2	I-protein
by	I-protein
several	I-protein
of	I-protein
these	O
T	O
cell	O
hybridomas	O
.	O

This	O
inhibition	O
was	O
dependent	I-protein
on	I-protein
the	I-protein
concentration	I-protein
of	I-protein
the	I-protein
free	B-protein
hormone	I-protein
and	I-protein
could	O
be	O
overcome	O
by	I-protein
increasing	O
the	I-protein
number	I-protein
of	I-protein
Ia-bearing	O
stimulator	I-protein
cells	I-protein
used	O
.	O

Pretreatment	O
of	I-protein
the	I-protein
T	O
hybridoma	O
but	O
not	I-protein
the	I-protein
TA3	B-protein
stimulator	I-protein
cell	O
with	I-protein
1	I-protein
,	O
25-	O
(	O
OH	O
)	O
2D3	O
resulted	O
in	I-protein
inhibition	O
of	I-protein
activation	I-protein
.	O

These	O
results	O
are	O
consistent	O
with	I-protein
the	I-protein
finding	O
that	O
specific	I-protein
1	I-protein
,	O
25-	I-protein
(	O
OH	I-protein
)	O
2D3	I-protein
receptors	I-protein
are	O
present	O
on	I-protein
the	I-protein
T	O
cell	O
hybridomas	O
but	O
are	O
lacking	I-protein
in	I-protein
TA3	B-protein
cells	I-protein
.	O

1	I-protein
,	O
25-	O
(	O
OH	O
)	O
2D3	O
failed	O
,	O
however	O
,	O
to	I-protein
inhibit	O
the	I-protein
activation	I-protein
of	I-protein
the	I-protein
T	O
cell	O
hybridomas	O
by	I-protein
lectin	B-protein
or	I-protein
by	I-protein
an	I-protein
anti-Thy-1	B-protein
antibody	I-protein
.	O

These	O
findings	O
suggest	O
that	O
1	I-protein
,	O
25-	O
(	O
OH	O
)	O
2D3	O
may	O
be	O
interfering	I-protein
with	I-protein
early	O
events	O
of	I-protein
antigen-induced	O
T	O
cell	O
activation	I-protein
,	O
perhaps	O
by	I-protein
hindering	O
T	O
cell	O
recognition	I-protein
of	I-protein
the	I-protein
relevant	I-protein
antigen	O
on	I-protein
stimulator	I-protein
cell	O
surfaces	O
.	O

This	O
system	I-protein
should	O
prove	O
useful	O
in	I-protein
studying	O
the	I-protein
molecular	I-protein
mechanisms	O
by	I-protein
which	O
1	I-protein
,	O
25-	O
(	O
OH	O
)	O
2D3	O
acts	O
to	I-protein
inhibit	O
T	O
cell	O
activation	I-protein
and	I-protein
subsequent	O
IL	B-protein
2	I-protein
production	I-protein
.	O

###MEDLINE:84106471

Glucocorticoid	B-protein
receptors	I-protein
and	I-protein
steroid	O
sensitivity	I-protein
in	I-protein
normal	O
and	I-protein
neoplastic	I-protein
human	O
lymphoid	O
tissues	O
:	O
a	I-protein
review	O
.	O

The	O
determination	I-protein
of	I-protein
estrogen	B-protein
and	I-protein
progesterone	B-protein
receptors	I-protein
in	I-protein
breast	O
cancer	O
has	O
been	O
shown	O
to	I-protein
be	O
useful	O
in	I-protein
predicting	O
the	I-protein
response	I-protein
to	I-protein
endocrine	I-protein
therapy	O
.	O

Given	O
their	O
well-known	O
inhibitory	O
effects	O
on	I-protein
lymphoid	O
tissue	O
,	O
glucocorticoids	O
have	O
been	O
used	O
widely	B-protein
in	I-protein
the	I-protein
treatment	O
of	I-protein
leukemia	O
.	O

Given	O
these	O
facts	O
,	O
over	O
the	I-protein
last	O
10	I-protein
years	O
,	O
several	I-protein
investigators	O
have	O
measured	O
the	I-protein
number	I-protein
of	I-protein
glucocorticoid	B-protein
receptors	I-protein
in	I-protein
normal	O
and	I-protein
neoplastic	I-protein
lymphoid	O
tissue	O
to	I-protein
see	O
whether	O
their	O
number	I-protein
correlated	O
with	I-protein
glucocorticoid	O
responsiveness	O
in	I-protein
vitro	O
or	I-protein
in	I-protein
vivo	O
.	O

No	I-protein
clear	I-protein
correlation	O
could	O
be	O
established	O
between	O
the	I-protein
level	I-protein
of	I-protein
glucocorticoid	B-protein
receptor	I-protein
and	I-protein
the	I-protein
in	I-protein
vitro	O
action	O
of	I-protein
steroids	O
in	I-protein
normal	O
and	I-protein
neoplastic	I-protein
lymphoid	O
tissue	O
.	O

In	O
contrast	O
,	O
attempts	O
to	I-protein
correlate	O
glucocorticoid	B-protein
receptor	I-protein
levels	I-protein
in	I-protein
acute	O
lymphocytic	I-protein
leukemia	O
to	I-protein
in	I-protein
vivo	O
steroid	O
responsiveness	O
and	I-protein
immunological	O
type	O
using	O
the	I-protein
whole-cell-binding	O
assay	O
for	I-protein
receptor	O
determination	I-protein
and	I-protein
selecting	O
the	I-protein
patients	O
according	O
to	I-protein
age	I-protein
and	I-protein
immunological	O
criteria	O
have	O
been	O
more	O
successful	O
.	O

###MEDLINE:84053675

[	O
Glucocorticoid	B-protein
receptors	I-protein
in	I-protein
normal	O
human	O
lymphocytes	O
]	O

Glucocorticoid	O
(	O
GC	B-protein
)	O
receptors	I-protein
were	O
studied	O
in	I-protein
intact	O
lymphocytes	O
from	I-protein
11	I-protein
donors	O
.	O

GC	O
binding	I-protein
parameters	O
were	O
found	O
to	I-protein
be	O
highly	O
reproducible	O
in	I-protein
repeated	O
experiments	O
with	I-protein
lymphocytes	O
.	O

It	O
was	O
shown	O
that	O
GC	B-protein
receptors	I-protein
in	I-protein
donors	O
'	O
lymphocytes	O
could	O
be	O
distributed	O
into	O
two	O
different	O
classes	O
similarly	O
to	I-protein
the	I-protein
pattern	I-protein
seen	O
in	I-protein
skin	O
fibroblasts	O
.	O

Human	O
lymphocytes	O
are	O
an	I-protein
adequate	O
object	O
for	I-protein
studying	O
genetically	O
determined	O
variability	I-protein
of	I-protein
GC	B-protein
receptors	I-protein
and	I-protein
its	O
clinical	I-protein
importance	O
.	O

###MEDLINE:83217486

Specific	B-protein
estrogen	O
binding	I-protein
sites	I-protein
in	I-protein
human	O
lymphoid	O
cells	I-protein
and	I-protein
thymic	B-protein
cells	I-protein
.	O

The	O
binding	I-protein
of	I-protein
estrogen	O
in	I-protein
preparations	O
of	I-protein
human	O
peripheral	O
blood	O
mononuclear	O
cells	I-protein
,	O
as	O
well	O
as	O
by	I-protein
splenic	O
and	I-protein
thymic	B-protein
cells	I-protein
is	O
demonstrated	O
by	I-protein
three	O
different	O
approaches	O
(	O
Dextran-coated	O
charcoal	O
method	O
,	O
whole	O
cell	O
assay	O
,	O
and	I-protein
gel	O
filtration	O
on	I-protein
a	I-protein
sepharose	O
4B	I-protein
column	O
)	O
.	O

Scatchard	O
's	I-protein
analysis	O
of	I-protein
[	O
3H	I-protein
]	O
-moxestrol	O
(	O
R2858	O
)	O
and	I-protein
[	O
3H	I-protein
]	O
-estradiol	O
binding	I-protein
proves	O
the	I-protein
existence	O
of	I-protein
a	I-protein
single	O
class	O
of	I-protein
receptor	O
sites	I-protein
having	O
a	I-protein
dissociation	I-protein
constant	I-protein
of	I-protein
0.18-2.4	O
X	O
10	I-protein
(	O
-9	O
)	O
M	I-protein
.	O

Physicochemical	O
properties	O
of	I-protein
the	I-protein
binder	I-protein
,	O
including	I-protein
binding	I-protein
capacity	O
and	I-protein
steroid	O
specificity	I-protein
,	O
are	O
quite	O
similar	O
to	I-protein
those	O
reported	O
for	I-protein
the	I-protein
thymus	I-protein
of	I-protein
small	O
mammalian	O
species	O
or	I-protein
human	O
thymoma	O
.	O

###MEDLINE:83131778

Administration	O
of	I-protein
fibroblast	B-protein
interferon	I-protein
to	I-protein
patients	O
with	I-protein
advanced	O
breast	O
cancer	O
:	O
possible	O
effects	O
on	I-protein
skin	O
metastasis	O
and	I-protein
on	I-protein
hormone	I-protein
receptors	I-protein
.	O

Eleven	O
patients	O
with	I-protein
metastasized	O
breast	O
cancer	O
received	O
8	I-protein
intramuscular	O
injections	O
of	I-protein
6	I-protein
x	I-protein
10	I-protein
(	O
6	I-protein
)	O
units	O
of	I-protein
human	B-protein
fibroblast	I-protein
interferon	I-protein
over	O
a	I-protein
period	B-protein
of	I-protein
40	I-protein
days	O
.	O

The	O
injections	O
did	O
not	I-protein
cause	O
local	O
irritation	O
or	I-protein
inflammation	O
.	O

Fever	O
occurred	O
in	I-protein
only	I-protein
1	I-protein
of	I-protein
the	I-protein
11	I-protein
patients	O
.	O

Although	O
several	I-protein
types	I-protein
of	I-protein
metastases	O
were	O
monitored	O
,	O
only	I-protein
skin	O
nodules	O
consistently	O
(	O
10	I-protein
out	O
of	I-protein
11	I-protein
patients	O
)	O
exhibited	O
changes	O
that	O
were	O
suggestive	O
of	I-protein
a	I-protein
therapeutic	O
effect	O
of	I-protein
the	I-protein
treatment	O
regimen	O
:	O
either	O
a	I-protein
simple	O
decrease	O
in	I-protein
size	O
of	I-protein
some	O
nodules	O
or	I-protein
central	O
necrosis	I-protein
accompanied	O
by	I-protein
an	I-protein
inflammatory	O
reaction	I-protein
.	O

NK-activity	O
of	I-protein
peripheral	O
blood	O
leukocytes	O
was	O
significantly	O
increased	I-protein
after	O
administration	O
of	I-protein
the	I-protein
first	O
dose	O
;	O
the	I-protein
effect	O
of	I-protein
subsequent	O
injections	O
was	O
less	O
clear	I-protein
.	O

Receptors	O
for	I-protein
estrogens	O
and	I-protein
progestogens	O
were	O
increased	I-protein
in	I-protein
the	I-protein
tumor	O
biopsies	O
of	I-protein
2	I-protein
out	O
of	I-protein
2	I-protein
and	I-protein
5	O
out	O
of	I-protein
6	I-protein
patients	O
tested	O
respectively	O
.	O

###MEDLINE:82098485

Decreased	O
glucocorticoid	B-protein
receptor	I-protein
binding	I-protein
in	I-protein
adrenal	I-protein
insufficiency	I-protein
.	O

To	O
examine	O
the	I-protein
effect	O
of	I-protein
glucocorticoid	O
deficiency	I-protein
on	I-protein
the	I-protein
glucocorticoid	B-protein
receptor	I-protein
,	O
we	O
examine	O
the	I-protein
binding	I-protein
of	I-protein
[	O
3H	I-protein
]	O
dexamethasone	O
to	I-protein
lymphocytes	O
in	I-protein
normal	O
subjects	O
and	I-protein
patients	O
with	I-protein
adrenal	I-protein
insufficiency	I-protein
before	O
and	I-protein
after	O
glucocorticoid	O
replacement	I-protein
therapy	O
.	O

Using	O
a	I-protein
whole	O
cell	O
competitive	O
binding	I-protein
assay	O
,	O
normal	O
human	O
lymphocytes	O
had	O
5977	O
+/-	O
1487	O
(	O
mean	I-protein
+/-	O
SD	O
)	O
binding	I-protein
sites/cell	O
and	I-protein
a	I-protein
dissociation	I-protein
constant	I-protein
of	I-protein
10	I-protein
+/-	O
2	I-protein
nM	O
.	O

Lymphocytes	O
from	I-protein
patients	O
with	I-protein
untreated	O
adrenal	I-protein
insufficiency	I-protein
had	O
fewer	O
binding	I-protein
sites	I-protein
(	O
3364	O
+/-322	O
)	O
and	I-protein
a	I-protein
2-fold	O
increase	O
in	I-protein
binding	I-protein
affinity	I-protein
(	O
5.4	I-protein
+/-	O
0.9	O
mM	O
)	O
.	O

The	O
administration	O
of	I-protein
conventional	O
replacement	I-protein
doses	O
of	I-protein
cortisone	O
acetate	O
for	I-protein
6	I-protein
months	O
caused	O
no	I-protein
change	O
in	I-protein
receptor	O
number	I-protein
,	O
but	O
was	O
associated	I-protein
with	I-protein
a	I-protein
decrease	O
in	I-protein
binding	I-protein
affinity	I-protein
toward	O
normal	O
.	O

After	O
long	I-protein
term	O
glucocorticoid	O
replacement	I-protein
therapy	O
,	O
binding	I-protein
parameters	O
were	O
similar	O
to	I-protein
those	O
in	I-protein
patients	O
before	O
treatment	O
.	O

The	O
physiological	O
implications	O
of	I-protein
the	I-protein
decreased	O
receptor	O
number	I-protein
and	I-protein
increased	I-protein
binding	I-protein
affinity	I-protein
in	I-protein
adrenal	I-protein
insufficiency	I-protein
remain	O
to	I-protein
be	O
elucidated	O
.	O

###MEDLINE:81209206

Glucocorticoid	B-protein
receptor	I-protein
concentrations	O
and	I-protein
terminal	O
transferase	I-protein
activity	I-protein
as	O
indicators	O
of	I-protein
prognosis	O
in	I-protein
acute	O
non-lymphocytic	O
leukaemia	O
.	O

Activity	O
of	I-protein
terminal	B-protein
deoxynucleotidyl	I-protein
transferase	I-protein
(	O
TdT	O
)	O
,	O
adenosine	B-protein
deaminase	I-protein
,	O
and	I-protein
5'nucleotidase	B-protein
and	I-protein
the	I-protein
cellular	O
concentration	I-protein
of	I-protein
glucocorticoid	B-protein
(	O
dexamethasone	I-protein
)	O
receptor	I-protein
were	O
determined	O
in	I-protein
25	I-protein
patients	O
with	I-protein
acute	O
non-lymphocytic	O
leukaemia	O
.	O

All	O
patients	O
were	O
treated	O
according	O
to	I-protein
a	I-protein
common	I-protein
protocol	O
.	O

Increased	O
activity	I-protein
of	I-protein
TdT	O
(	O
greater	O
than	I-protein
0.1	O
unit/microgram	O
DNA	O
)	O
was	O
found	O
in	I-protein
11	I-protein
patients	O
.	O

This	O
group	I-protein
of	I-protein
patients	O
was	O
shown	O
to	I-protein
have	O
higher	O
remission	O
and	I-protein
survival	B-protein
rates	O
(	O
p	O
=	O
0.06	O
)	O
compared	O
with	I-protein
patients	O
with	I-protein
low	O
activity	I-protein
of	I-protein
TdT	B-protein
.	O

The	O
glucocorticoid	B-protein
receptor	I-protein
concentration	I-protein
of	I-protein
the	I-protein
leukaemic	O
blast	O
cells	I-protein
ranged	O
from	I-protein
0	I-protein
to	I-protein
0.94	O
fmol/microgram	O
DNA	O
.	O

Thirteen	O
patients	O
had	O
blast	O
cells	I-protein
with	I-protein
a	I-protein
glucocorticoid	B-protein
receptor	I-protein
concentration	I-protein
over	O
0.22	O
fmol/microgram	O
DNA	O
.	O

These	O
patients	O
had	O
significantly	O
increased	I-protein
remission	O
and	I-protein
survival	B-protein
rates	O
(	O
p	O
=	O
0.006	O
)	O
compared	O
with	I-protein
those	O
with	I-protein
a	I-protein
low	O
receptor	O
concentration	I-protein
.	O

This	O
finding	O
can	O
not	I-protein
be	O
explained	O
by	I-protein
a	I-protein
difference	O
in	I-protein
sensitivity	I-protein
to	I-protein
glucocorticoids	O
since	O
these	O
were	O
not	I-protein
used	O
as	O
therapeutic	O
agents	O
.	O

Adenosine	I-protein
deaminase	I-protein
and	I-protein
5'nucleotidase	O
activities	O
both	O
varied	O
within	B-protein
two	O
orders	O
of	I-protein
magnitude	O
.	O

No	I-protein
correlation	O
could	O
be	O
found	O
between	O
activities	O
of	I-protein
these	O
enzymes	O
and	I-protein
remission	O
or	I-protein
survival	B-protein
rate	I-protein
.	O

These	O
results	O
show	O
that	O
measurements	O
of	I-protein
TdT	B-protein
activity	I-protein
and	I-protein
the	I-protein
glucocorticoid	B-protein
receptor	I-protein
concentration	I-protein
yield	O
valuable	O
prognostic	O
information	I-protein
in	I-protein
acute	O
non-lymphocytic	O
leukaemia	O

###MEDLINE:85284782

[	O
3H	I-protein
]	O
cortivazol	O
:	O
a	I-protein
unique	I-protein
high	O
affinity	I-protein
ligand	O
for	I-protein
the	I-protein
glucocorticoid	B-protein
receptor	I-protein
.	O

Cortivazol	O
(	O
CVZ	O
)	O
and	I-protein
deacylcortivazol	O
(	O
DAC	B-protein
)	O
are	O
pyrazolosteroids	O
with	I-protein
potent	O
glucocorticoid	O
activity	I-protein
.	O

In	O
previous	O
work	O
we	O
showed	O
that	O
DAC	B-protein
is	O
40-fold	O
more	O
potent	O
than	I-protein
dexamethasone	O
(	O
DEX	O
)	O
in	I-protein
lysing	O
leukemic	O
lymphoblasts	O
.	O

To	O
assess	O
the	I-protein
interaction	I-protein
between	O
these	O
atypical	I-protein
steroids	O
and	I-protein
the	I-protein
glucocorticoid	B-protein
receptor	I-protein
,	O
we	O
examined	O
the	I-protein
binding	I-protein
of	I-protein
[	O
3H	I-protein
]	O
CVZ	O
to	I-protein
cytosol	I-protein
from	I-protein
glucocorticoid-sensitive	O
and	I-protein
-resistant	O
variants	O
of	I-protein
the	I-protein
human	O
leukemic	O
cell	O
line	I-protein
CEM	O
C7	I-protein
.	O

In	O
glucocorticoid-sensitive	O
cells	I-protein
[	O
3H	I-protein
]	O
CVZ	O
causes	O
a	I-protein
2-fold	O
induction	I-protein
of	I-protein
glutamine	B-protein
synthetase	I-protein
and	I-protein
binds	O
to	I-protein
a	I-protein
protein	O
in	I-protein
the	I-protein
4.6	O
S	I-protein
region	O
of	I-protein
high	O
salt	O
sucrose	O
gradients	O
.	O

On	O
DEAE-cellulose	O
chromatography	O
,	O
[	O
3H	I-protein
]	O
CVZ-receptor	I-protein
complexes	I-protein
show	O
a	I-protein
shift	O
from	I-protein
high	O
(	O
0.25	O
M	I-protein
KP	O
)	O
to	I-protein
low	O
salt	O
(	O
0.09	O
M	I-protein
KP	O
)	O
eluting	O
forms	I-protein
upon	O
activation	I-protein
.	O

CVZ	O
competes	O
for	I-protein
a	I-protein
97	I-protein
,	O
000-dalton	O
protein	O
labeled	O
by	I-protein
[	O
3H	I-protein
]	O
dexamethasone	O
mesylate	O
.	O

Scatchard	O
analysis	O
of	I-protein
the	I-protein
binding	I-protein
of	I-protein
[	O
3H	I-protein
]	O
CVZ	O
in	I-protein
glucocorticoid-sensitive	O
cells	I-protein
revealed	O
a	I-protein
curvilinear	O
plot	O
which	O
resolved	O
into	O
high	O
(	O
0.4	O
nM	O
)	O
and	I-protein
low	O
(	O
11	I-protein
nM	O
)	O
affinity	I-protein
components	O
.	O

The	O
receptor	O
concentration	I-protein
of	I-protein
the	I-protein
low	O
affinity	I-protein
site	I-protein
(	O
0.30	O
pmol/mg	O
protein	O
)	O
was	O
approximately	O
twice	O
that	O
of	I-protein
the	I-protein
high	O
affinity	I-protein
site	I-protein
(	O
0.14	O
pmol/mg	O
protein	O
)	O
.	O

Dissociation	O
experiments	O
with	I-protein
dilution	I-protein
and/or	O
excess	O
unlabeled	O
CVZ	O
supported	I-protein
the	I-protein
presence	O
of	I-protein
independent	I-protein
sites	I-protein
.	O

In	O
contrast	O
,	O
the	I-protein
binding	I-protein
of	I-protein
[	O
3H	I-protein
]	O
DEX	O
to	I-protein
C7	I-protein
cytosol	I-protein
revealed	O
a	I-protein
single	O
class	O
of	I-protein
binding	I-protein
sites	I-protein
(	O
Kd	O
=	O
1.9	O
nM	O
;	O
receptor	O
concentration	I-protein
,	O
0.46	O
pmol/mg	O
protein	O
)	O
.	O

Examination	O
of	I-protein
the	I-protein
binding	I-protein
of	I-protein
[	O
3H	I-protein
]	O
CVZ	O
using	O
10	I-protein
(	O
-5	O
)	O
M	I-protein
DEX	O
as	O
the	I-protein
competing	O
ligand	O
showed	O
that	O
DEX	O
binds	O
only	I-protein
to	I-protein
the	I-protein
low	O
affinity	I-protein
site	I-protein
detected	O
by	I-protein
[	O
3H	I-protein
]	O
CVZ	O
.	O

In	O
cytosol	I-protein
from	I-protein
a	I-protein
glucocorticoid-resistant	O
cell	O
line	I-protein
with	I-protein
virtually	O
no	I-protein
[	O
3H	I-protein
]	O
DEX	O
binding	I-protein
,	O
[	O
3H	I-protein
]	O
CVZ	O
detected	O
a	I-protein
single	O
high	B-protein
affinity	I-protein
binding	I-protein
site	I-protein
that	O
was	O
similar	O
in	I-protein
dissociation	I-protein
constant	I-protein
(	O
0.8	O
nM	O
)	O
and	I-protein
receptor	O
concentration	I-protein
(	O
0.13	O
pmol/mg	O
protein	O
)	O
to	I-protein
the	I-protein
high	O
affinity	I-protein
site	I-protein
detected	O
in	I-protein
the	I-protein
glucocorticoid-sensitive	O
cell	O
line	I-protein
C7	I-protein
.	O

###MEDLINE:85266114

A	O
controlled	O
pore	I-protein
glass	O
bead	O
assay	O
for	I-protein
the	I-protein
measurement	O
of	I-protein
cytoplasmic	B-protein
and	I-protein
nuclear	I-protein
glucocorticoid	I-protein
receptors	I-protein
.	O

An	O
assay	O
for	I-protein
the	I-protein
quantitation	O
of	I-protein
cytoplasmic	B-protein
and	I-protein
nuclear	I-protein
glucocorticoid	I-protein
receptors	I-protein
in	I-protein
lymphoid	O
tissue	O
has	O
been	O
developed	O
using	O
controlled	O
pore	I-protein
glass	O
(	O
CPG	O
)	O
beads	O
.	O

Soluble	B-protein
receptor	I-protein
--	I-protein
3H-steroid	I-protein
complex	I-protein
(	O
cytosol	I-protein
or	I-protein
nuclear	O
extract	O
)	O
is	O
adsorbed	O
quantitatively	O
within	B-protein
the	I-protein
crevasses	O
of	I-protein
porous	O
glass	O
beads	O
.	O

Excess	O
labeled	O
steroid	O
as	O
well	O
as	O
most	O
non-specifically	O
bound	I-protein
steroid	O
is	O
easily	O
washed	O
away	O
,	O
leaving	O
the	I-protein
hormone-receptor	B-protein
complex	I-protein
retained	O
by	I-protein
the	I-protein
beads	O
.	O

Bound	O
3H-steroid	O
is	O
eluted	O
with	I-protein
ethanol	O
and	I-protein
measured	O
for	I-protein
radioactivity	O
.	O

This	O
procedure	O
which	O
is	O
simple	O
,	O
rapid	O
,	O
and	I-protein
highly	O
reproducible	O
is	O
carried	O
out	O
using	O
frozen	O
samples	O
(	O
stable	I-protein
for	I-protein
many	O
months	O
)	O
containing	I-protein
as	O
few	O
as	O
1	I-protein
X	O
10	I-protein
(	O
7	I-protein
)	O
cells	I-protein
.	O

A	O
comparison	O
of	I-protein
the	I-protein
CPG	O
assay	O
to	I-protein
dextran	O
coated	O
charcoal	O
and	I-protein
a	I-protein
whole	O
cell	O
assay	O
demonstrates	O
that	O
CPG	O
and	I-protein
dextran	O
coated	O
charcoal	O
give	O
equivalent	O
measurements	O
of	I-protein
cytosolic	B-protein
receptor	I-protein
concentration	I-protein
,	O
while	O
the	I-protein
CPG	O
and	I-protein
whole	O
cell	O
assays	O
provide	O
equivalent	O
values	O
for	I-protein
total	O
receptor	O
content	O
.	O

###MEDLINE:85186850

Plasmacytoid	O
blast	O
crisis	O
in	I-protein
B-cell	O
chronic	O
lymphocytic	I-protein
leukemia	O
:	O
effect	O
of	I-protein
estradiol	O
on	I-protein
growth	O
and	I-protein
differentiation	I-protein
in	I-protein
vitro	O
.	O

Evolution	O
of	I-protein
a	I-protein
case	O
of	I-protein
chronic	O
lymphocytic	I-protein
leukemia	O
(	O
CLL	O
)	O
into	O
blast	O
crisis	O
was	O
found	O
to	I-protein
be	O
characterized	O
by	I-protein
three	O
unusual	I-protein
features	I-protein
(	O
1	I-protein
)	O
the	I-protein
phenotype	O
of	I-protein
the	I-protein
emerging	O
blast	O
cells	I-protein
was	O
that	O
of	I-protein
pre-plasmacytoid	O
cells	I-protein
as	O
shown	O
by	I-protein
plasma	O
cell	O
morphology	O
and	I-protein
an	I-protein
immunological	O
phenotype	O
corresponding	O
partially	O
with	I-protein
CLL-	O
or	I-protein
intermediate	O
B-cells	I-protein
,	O
partially	O
with	I-protein
plasma	O
cells	I-protein
(	O
terminal	B-protein
transferase	I-protein
-	O
,	O
common	I-protein
acute	B-protein
lymphocytic	I-protein
leukemia	I-protein
antigen	I-protein
-	O
,	O
Ia+	B-protein
,	O
surface	B-protein
immunoglobulin	I-protein
heavy	I-protein
chains	I-protein
-	O
,	O
surface	B-protein
kappa	I-protein
light	I-protein
chains	I-protein
+	O
,	O
intracytoplasmic	B-protein
immunoglobulin	I-protein
A+	I-protein
and	I-protein
G+	I-protein
,	O
BA-1+	B-protein
,	O
polyclonal	I-protein
gammaglobulin	O
production	I-protein
)	O
;	O
(	O
2	I-protein
)	O
cytogenetic	O
analysis	O
of	I-protein
spontaneous	O
metaphases	O
revealed	O
that	O
in	I-protein
addition	O
to	I-protein
the	I-protein
typical	I-protein
CLL	O
abnormality	O
,	O
trisomy	O
12	O
,	O
in	I-protein
all	O
of	I-protein
the	I-protein
cells	I-protein
,	O
an	I-protein
additional	B-protein
translocation	O
between	O
chromosomes	O
14	I-protein
and	I-protein
17	I-protein
was	O
present	O
in	I-protein
40	I-protein
%	O
with	I-protein
a	I-protein
presumptive	O
breakpoint	O
on	I-protein
chromosome	O
14	I-protein
(	O
q12-3	O
)	O
never	I-protein
described	O
before	O
(	O
commonly	O
q32	I-protein
)	O
and	I-protein
(	O
3	O
)	O
the	I-protein
progression	I-protein
of	I-protein
the	I-protein
disease	I-protein
was	O
associated	I-protein
with	I-protein
a	I-protein
striking	O
increase	O
in	I-protein
the	I-protein
expression	I-protein
by	I-protein
the	I-protein
transformed	I-protein
cells	I-protein
of	I-protein
specific	I-protein
binding	I-protein
sites	I-protein
for	I-protein
estradiol	O
(	O
E2	O
)	O
due	I-protein
to	I-protein
an	I-protein
actual	O
increase	O
in	I-protein
total	O
cellular	B-protein
receptor	I-protein
proteins	I-protein
and	I-protein
not	I-protein
to	I-protein
a	I-protein
change	O
in	I-protein
receptor	O
affinity	I-protein
for	I-protein
E2	O
.	O

The	O
functional	O
status	I-protein
of	I-protein
the	I-protein
steroid	B-protein
receptors	I-protein
was	O
confirmed	O
by	I-protein
nuclear	O
transfer	O
of	I-protein
the	I-protein
cytoplasmic	B-protein
hormone-receptor	I-protein
complex	I-protein
upon	O
temperature	I-protein
activation	I-protein
.	O

Since	O
the	I-protein
rise	O
in	I-protein
E2-receptor	B-protein
display	O
paralleled	O
a	I-protein
large	O
increase	O
in	I-protein
the	I-protein
proliferative	O
activity	I-protein
of	I-protein
the	I-protein
cells	I-protein
as	O
well	O
as	O
a	I-protein
change	O
in	I-protein
their	O
maturation	I-protein
status	I-protein
the	I-protein
question	O
was	O
raised	O
as	O
to	I-protein
whether	O
the	I-protein
E2-receptor	B-protein
should	O
be	O
considered	O
as	O
a	I-protein
physiological	O
marker	I-protein
of	I-protein
growth	O
rate	I-protein
or	I-protein
of	I-protein
cellular	O
differentiation	I-protein
.	O

Exposure	O
of	I-protein
the	I-protein
patient	O
's	I-protein
blast	O
cells	I-protein
to	I-protein
E2	O
in	I-protein
vitro	O
resulted	O
in	I-protein
cessation	O
of	I-protein
cell	O
growth	O
following	O
at	I-protein
least	O
one	B-protein
mitosis	I-protein
after	O
addition	O
of	I-protein
the	I-protein
inducer	I-protein
as	O
seen	O
from	I-protein
the	I-protein
replacement	I-protein
of	I-protein
the	I-protein
large	O
blasts	O
by	I-protein
small	O
CLL-like	O
cells	I-protein
without	I-protein
definite	O
signs	O
of	I-protein
alteration	O
of	I-protein
the	I-protein
differentiation	I-protein
status	I-protein
.	O

This	O
suggests	O
the	I-protein
association	I-protein
of	I-protein
E2-receptor	B-protein
expression	I-protein
with	I-protein
control	I-protein
of	I-protein
growth	O
rather	O
than	I-protein
cell	O
maturation	I-protein
.	O

###MEDLINE:84259121

Multiple	B-protein
forms	I-protein
and	I-protein
fragments	I-protein
of	I-protein
cytosolic	B-protein
glucocorticoid	I-protein
receptors	I-protein
from	I-protein
human	O
leukemic	O
cells	I-protein
and	I-protein
normal	O
lymphocytes	O
.	O

Therapy	O
with	I-protein
glucocorticoids	O
is	O
generally	O
more	O
effective	O
in	I-protein
acute	O
lymphoblastic	O
leukemia	O
than	I-protein
in	I-protein
other	O
types	I-protein
of	I-protein
human	O
leukemia	O
.	O

Previous	O
studies	O
,	O
however	O
,	O
have	O
not	I-protein
revealed	O
any	O
consistent	O
relationship	O
between	O
clinical	I-protein
responsiveness	O
and	I-protein
the	I-protein
cellular	O
or	I-protein
cytosolic	O
concentration	I-protein
of	I-protein
glucocorticoid-binding	B-protein
sites	I-protein
.	O

The	O
objectives	O
of	I-protein
this	O
study	O
were	O
to	I-protein
determine	O
whether	O
there	O
are	O
intrinsic	I-protein
structural	O
differences	O
among	O
the	I-protein
glucocorticoid	B-protein
receptors	I-protein
in	I-protein
various	O
types	I-protein
of	I-protein
leukemic	O
cells	I-protein
and	I-protein
normal	O
lymphocytes	O
and	I-protein
to	I-protein
investigate	O
the	I-protein
role	O
of	I-protein
endogenous	B-protein
peptidases	I-protein
in	I-protein
receptor	O
degradation	I-protein
.	O

Cytosols	O
were	O
prepared	O
from	I-protein
fresh	O
or	I-protein
rapidly	I-protein
frozen	O
leukocytes	O
from	I-protein
6	I-protein
healthy	O
adults	O
and	I-protein
35	I-protein
high-risk	O
leukemia	O
patients	O
(	O
median	O
white	I-protein
blood	O
cell	O
count	O
,	O
150	I-protein
,	O
000	O
cells/microliter	O
;	O
median	O
age	I-protein
,	O
13	I-protein
years	O
)	O
.	O

Receptors	O
were	O
labeled	O
with	I-protein
[	O
3H	I-protein
]	O
triamcinolone	O
acetonide	O
and	I-protein
quantitated	O
by	I-protein
charcoal-dextran	O
treatment	O
or	I-protein
Sephadex	O
LH-20	O
chromatography	O
.	O

Mean	O
and	I-protein
median	O
cytosolic	O
receptor	O
concentrations	O
in	I-protein
12	O
acute	O
lymphoblastic	O
leukemia	O
specimens	O
lacking	I-protein
the	I-protein
standard	O
B-cell	O
or	I-protein
T-cell	O
markers	O
(	O
``	O
null	O
cells	I-protein
''	I-protein
)	O
were	O
approximately	O
4-fold	O
higher	O
than	I-protein
in	I-protein
23	I-protein
other	O
leukemic	O
cell	O
specimens	O
.	O

No	I-protein
other	O
consistent	O
differences	O
in	I-protein
receptor	O
content	O
were	O
observed	O
.	O

Agarose	O
filtration	O
and	I-protein
ultracentrifugation	O
in	I-protein
hypotonic	O
buffers	O
containing	I-protein
20	I-protein
mM	O
Na2MoO4	O
revealed	O
complexes	O
of	I-protein
similar	O
size	O
and	I-protein
shape	O
in	I-protein
all	O
clinical	I-protein
specimens	O
tested	O
and	I-protein
two	O
established	O
leukemic	O
cell	O
lines	B-protein
.	O

They	O
had	O
Stokes	O
radii	O
(	O
Rs	O
)	O
of	I-protein
8.1	I-protein
+/-	O
0.5	O
(	O
S.D.	O
)	O
nm	O
(	O
n	O
=	O
50	I-protein
)	O
,	O
sedimentation	O
coefficients	O
of	I-protein
9.5	I-protein
+/-	O
0.3S	O
(	O
n	O
=	O
40	I-protein
)	O
,	O
molecular	I-protein
weights	O
of	I-protein
approximately	O
330	I-protein
,	O
000	O
,	O
and	I-protein
axial	O
ratios	O
(	O
a/b	O
)	O
of	I-protein
approximately	O
12	O
.	O

In	O
hypertonic	O
,	O
molybdate-free	O
buffer	O
,	O
these	O
oligomeric	I-protein
complexes	I-protein
were	O
dissociated	O
into	O
subunits	I-protein
with	I-protein
Rs	O
of	I-protein
5.9	O
+/-	O
0.3	O
nm	O
(	O
n	O
=	O
12	O
)	O
and	I-protein
a/b	O
of	I-protein
11	I-protein
to	I-protein
12	O
,	O
as	O
observed	O
previously	O
for	I-protein
other	O
receptors	I-protein
.	O

Fragmentation	O
of	I-protein
the	I-protein
oligomer	B-protein
and	I-protein
the	I-protein
subunit	I-protein
was	O
evident	O
in	I-protein
some	O
cytosols	O
.	O

High	O
activities	O
of	I-protein
peptidases	O
of	I-protein
various	O
specificities	O
were	O
detected	O
in	I-protein
leukemic	O
cell	O
cytosols	O
,	O
as	O
in	I-protein
other	O
cytosols	O
,	O
by	I-protein
fluorometric	O
assays	O
with	I-protein
derivatives	I-protein
of	I-protein
7-amino-4-methylcoumarin	O
.	O

Receptor	I-protein
cleavage	O
by	I-protein
these	O
and	I-protein
other	O
endogenous	B-protein
enzymes	I-protein
may	O
account	O
for	I-protein
previous	O
observations	O
of	I-protein
``	O
abnormal	I-protein
''	I-protein
receptors	I-protein
in	I-protein
cytosols	O
from	I-protein
some	O
leukemic	O
specimens	O
.	O

We	O
conclude	O
that	O
intrinsic	I-protein
structural	O
defects	I-protein
in	I-protein
the	I-protein
receptors	I-protein
are	O
unlikely	O
explanations	O
for	I-protein
the	I-protein
unresponsiveness	O
of	I-protein
some	O
types	I-protein
of	I-protein
leukemia	O
to	I-protein
steroid	O
therapy	O
.	O

###MEDLINE:84140373

Glucocorticoid	B-protein
receptor	I-protein
number	I-protein
and	I-protein
intracellular	I-protein
water	O
space	I-protein
.	O

In	O
order	O
to	I-protein
elucidate	O
the	I-protein
relationship	O
between	O
cell	O
water	O
content	O
and	I-protein
number	I-protein
of	I-protein
glucocorticoid	B-protein
receptors	I-protein
,	O
eleven	O
normal	O
and	I-protein
malignant	O
lymphoid	O
or	I-protein
myelomonocytic	O
cell	O
types	I-protein
originating	O
from	I-protein
mouse	I-protein
,	O
rat	I-protein
and	I-protein
man	I-protein
were	O
investigated	O
.	O

The	O
cellular	O
water	O
space	I-protein
was	O
measured	O
with	I-protein
3H2O	O
,	O
and	I-protein
glucocorticoid	B-protein
receptor	I-protein
number	I-protein
was	O
measured	O
in	I-protein
a	I-protein
whole-cell	O
binding	I-protein
assay	O
with	I-protein
[	O
3H	I-protein
]	O
dexamethasone	O
at	I-protein
30	I-protein
and	I-protein
37	I-protein
degrees	O
C	O
.	O

The	O
intracellular	I-protein
water	O
phase	I-protein
concentration	I-protein
of	I-protein
glucocorticoid	B-protein
receptors	I-protein
(	O
around	O
40	I-protein
nmol/l	O
cell	O
water	O
)	O
,	O
and	I-protein
the	I-protein
dependence	O
of	I-protein
receptor	O
affinity	I-protein
on	I-protein
temperature	I-protein
were	O
similar	O
in	I-protein
normal	O
and	I-protein
malignant	O
rodent	I-protein
and	I-protein
human	O
cells	I-protein
.	O

It	O
is	O
concluded	O
that	O
comparisons	O
of	I-protein
glucocorticoid	B-protein
receptor	I-protein
levels	I-protein
are	O
best	O
made	O
on	I-protein
the	I-protein
basis	O
of	I-protein
intracellular	I-protein
receptor	I-protein
concentrations	O
.	O

###MEDLINE:84001945

Covalent	O
labeling	O
of	I-protein
rat	I-protein
thymocyte	B-protein
and	I-protein
human	B-protein
lymphoid	I-protein
glucocorticoid	I-protein
receptor	I-protein
.	O

Lymphoid	O
cells	I-protein
contain	O
specific	I-protein
receptors	I-protein
for	I-protein
glucocorticoids	O
.	O

We	O
have	O
used	O
[	O
3H	I-protein
]	O
dexamethasone-21-mesylate	O
to	I-protein
label	O
covalently	I-protein
glucocorticoid	B-protein
receptors	I-protein
in	I-protein
rat	I-protein
thymic	B-protein
lymphocytes	O
and	I-protein
in	I-protein
neoplastic	I-protein
cells	I-protein
obtained	O
from	I-protein
patients	O
with	I-protein
acute	O
lymphoblastic	O
leukemia	O
and	I-protein
malignant	O
lymphoma	I-protein
.	O

The	O
covalently	I-protein
labeled	O
glucocorticoid	B-protein
receptors	I-protein
were	O
identified	I-protein
by	I-protein
polyacrylamide	O
gel	O
electrophoresis	O
(	O
in	I-protein
the	I-protein
presence	O
of	I-protein
0.1	O
%	O
sodium	O
dodecyl	O
sulfate	I-protein
)	O
.	O

In	O
cytosolic	O
fractions	O
prepared	O
from	I-protein
rat	I-protein
thymic	B-protein
lymphocytes	O
,	O
[	O
3H	I-protein
]	O
-dexamethasone-21-mesylate	O
labels	O
a	I-protein
protein	O
(	O
Mr	O
approximately	O
equal	O
to	I-protein
95	I-protein
,	O
000	O
)	O
which	O
was	O
identified	I-protein
as	O
the	I-protein
glucocorticoid	B-protein
receptor	I-protein
by	I-protein
the	I-protein
following	O
criteria	O
:	O
(	O
a	I-protein
)	O
labeling	O
of	I-protein
this	O
moiety	I-protein
is	O
inhibited	O
by	I-protein
treatment	O
with	I-protein
a	I-protein
100-fold	O
molar	O
excess	O
of	I-protein
glucocorticoids	O
,	O
such	O
as	O
dexamethasone	O
and	I-protein
triamcinolone	O
acetonide	O
;	O
and	I-protein
(	O
b	O
)	O
the	I-protein
covalently	I-protein
labeled	O
Mr	O
approximately	O
equal	O
to	I-protein
95	I-protein
,	O
000	O
protein	O
is	O
activated	O
(	O
by	I-protein
heating	O
at	I-protein
20	I-protein
degrees	O
for	I-protein
30	I-protein
min	O
)	O
to	I-protein
a	I-protein
form	I-protein
that	O
binds	O
to	I-protein
DNA-cellulose	O
.	O

When	O
intact	O
thymocytes	O
are	O
treated	O
with	I-protein
[	O
3H	I-protein
]	O
dexamethasone-21-mesylate	O
,	O
an	I-protein
Mr	O
approximately	O
equal	O
to	I-protein
95	I-protein
,	O
000	O
moiety	I-protein
is	O
also	O
labeled	O
covalently	I-protein
.	O

Approximately	O
35	I-protein
%	O
of	I-protein
the	I-protein
glucocorticoid	B-protein
receptors	I-protein
can	O
be	O
labeled	O
covalently	I-protein
when	O
intact	O
thymocytes	O
are	O
treated	O
with	I-protein
100	I-protein
nM	O
[	O
3H	I-protein
]	O
dexamethasone-21-mesylate	O
for	I-protein
30	I-protein
min	O
at	I-protein
4	I-protein
degrees	O
.	O

Neoplastic	O
cells	I-protein
from	I-protein
acute	O
lymphoblastic	O
leukemia	O
and	I-protein
malignant	O
lymphoma	I-protein
were	O
treated	O
with	I-protein
[	O
3H	I-protein
]	O
dexamethasone-21-mesylate	O
.	O

In	O
all	O
samples	O
,	O
an	I-protein
Mr	O
approximately	O
equal	O
to	I-protein
95	I-protein
,	O
000	O
moiety	I-protein
was	O
labeled	O
covalently	I-protein
;	O
labeling	O
was	O
inhibited	O
by	I-protein
excess	O
glucocorticoid	O
.	O

Smaller	B-protein
moieties	I-protein
were	O
also	O
identified	I-protein
by	I-protein
competition	O
experiments	O
;	O
these	O
may	O
represent	O
proteolytic	I-protein
fragments	I-protein
of	I-protein
the	I-protein
Mr	O
approximately	O
equal	O
to	I-protein
95	I-protein
,	O
000	O
receptor	O
.	O

Thus	O
,	O
in	I-protein
rat	I-protein
and	I-protein
human	O
lymphoid	O
cells	I-protein
,	O
[	O
3H	I-protein
]	O
dexamethasone-21-mesylate	O
can	O
be	O
used	O
to	I-protein
label	O
covalently	I-protein
the	I-protein
glucocorticoid	B-protein
receptor	I-protein
.	O

###MEDLINE:83204609

The	O
association	I-protein
of	I-protein
cytosol	I-protein
oestrogen	B-protein
and	I-protein
progesterone	B-protein
receptors	I-protein
with	I-protein
histological	O
features	I-protein
of	I-protein
breast	O
cancer	O
and	I-protein
early	O
recurrence	O
of	I-protein
disease	I-protein
.	O

Two	O
hundred	O
and	I-protein
eighty-eight	O
primary	O
breast	O
tumours	O
were	O
examined	O
for	I-protein
the	I-protein
presence	O
or	I-protein
absence	I-protein
of	I-protein
oestrogen	B-protein
(	O
REc	I-protein
)	O
and	I-protein
progesterone	B-protein
(	O
RPc	I-protein
)	O
receptors	I-protein
.	O

Analysis	O
has	O
shown	O
a	I-protein
relative	I-protein
interdependence	O
between	O
the	I-protein
steroid	O
receptor	O
status	I-protein
of	I-protein
primary	O
breast	O
cancer	O
and	I-protein
other	O
prognostic	O
variables	O
such	O
as	O
histological	O
grade	I-protein
,	O
lymphocytic	I-protein
infiltration	O
and	I-protein
tumour	I-protein
elastosis	O
.	O

There	O
were	O
significant	O
associations	O
between	O
epithelial	O
cellularity	O
,	O
stromal	O
fibrosis	O
and	I-protein
the	I-protein
value	O
of	I-protein
REc	B-protein
in	I-protein
those	O
tumours	O
in	I-protein
which	O
the	I-protein
receptor	O
was	O
present	O
.	O

Cellularity	O
and	I-protein
fibrosis	O
were	O
unrelated	O
to	I-protein
the	I-protein
presence	O
or	I-protein
absence	I-protein
of	I-protein
oestrogen	B-protein
receptor	I-protein
.	O

By	O
contrast	O
,	O
neither	O
the	I-protein
presence	O
or	I-protein
absence	I-protein
nor	O
the	I-protein
value	O
of	I-protein
RPc	B-protein
could	O
be	O
related	O
to	I-protein
cellularity	O
or	I-protein
fibrosis	O
.	O

The	O
value	O
of	I-protein
REc	B-protein
and	I-protein
RPc	O
analysis	O
as	O
an	I-protein
indicator	O
of	I-protein
prognosis	O
was	O
examined	O
in	I-protein
a	I-protein
sub-group	O
of	I-protein
175	I-protein
patients	O
receiving	O
no	I-protein
additional	B-protein
treatment	O
following	O
mastectomy	O
.	O

Overall	O
relapse-free	O
survival	B-protein
(	O
RFS	B-protein
)	O
was	O
no	I-protein
different	O
for	I-protein
those	O
patients	O
with	I-protein
receptors	I-protein
compared	O
to	I-protein
those	O
without	I-protein
them	O
(	O
REc	O
P	O
=	O
0.11	O
,	O
RPc	O
P	O
=	O
0.7	O
)	O
.	O

There	O
was	O
no	I-protein
difference	O
in	I-protein
RFS	B-protein
of	I-protein
receptor	O
positive	I-protein
and	I-protein
negative	O
tumours	O
when	O
the	I-protein
axillary	O
node	I-protein
status	I-protein
was	O
taken	O
into	O
account	O
.	O

###MEDLINE:82281646

Clinical	O
implications	O
of	I-protein
glucocorticoid	B-protein
receptors	I-protein
in	I-protein
human	O
leukemia	O
.	O

Normal	O
lymphoid	O
cells	I-protein
contain	O
glucocorticoid	B-protein
receptor	I-protein
.	O

A	O
variety	O
of	I-protein
stimuli	O
that	O
activate	O
these	O
cells	I-protein
also	O
induce	O
increases	O
in	I-protein
receptor	O
concentration	I-protein
.	O

Similar	B-protein
glucocorticoid	B-protein
receptors	I-protein
can	O
be	O
detected	O
in	I-protein
lymphoid	O
cells	I-protein
from	I-protein
patients	O
with	I-protein
acute	O
lymphoblastic	O
leukemia	O
(	O
ALL	B-protein
)	O
.	O

Absence	O
of	I-protein
the	I-protein
glucocorticoid	B-protein
receptor	I-protein
(	O
usually	O
found	O
in	I-protein
treated	O
patients	O
)	O
predicts	O
lack	O
of	I-protein
glucocorticoid	O
responsiveness	O
.	O

Furthermore	O
,	O
in	I-protein
our	O
hands	O
,	O
glucocorticoid	B-protein
receptor	I-protein
levels	I-protein
correlate	O
with	I-protein
the	I-protein
duration	O
of	I-protein
complete	O
remission	O
in	I-protein
ALL	B-protein
(	O
though	O
not	I-protein
in	I-protein
other	O
forms	I-protein
of	I-protein
leukemia	O
)	O
.	O

This	O
association	I-protein
is	O
independent	I-protein
of	I-protein
cell	O
type	O
,	O
age	I-protein
,	O
sex	O
,	O
or	I-protein
initial	O
leukocyte	O
count	O
.	O

The	O
level	I-protein
of	I-protein
receptor	O
shows	O
a	I-protein
negative	O
correlation	O
with	I-protein
increasing	O
aggressiveness	I-protein
of	I-protein
the	I-protein
tumor	O
(	O
null-cell	O
leukemia	O
greater	O
than	I-protein
T-cell	O
leukemia	O
greater	O
than	I-protein
Burkitt	B-protein
's	I-protein
lymphoma	I-protein
)	O
.	O

###MEDLINE:83005500

Corticosteroid-mediated	O
immunoregulation	O
in	I-protein
man	I-protein
.	O

Glucocorticoids	O
have	O
profound	O
and	I-protein
complex	I-protein
effects	O
on	I-protein
the	I-protein
human	O
immune	O
response	I-protein
.	O

However	O
,	O
the	I-protein
precise	O
mechanisms	O
of	I-protein
the	I-protein
corticosteroid-induced	O
immunoregulation	O
in	I-protein
man	I-protein
have	O
not	I-protein
been	O
precisely	O
defined	I-protein
.	O

Intracytoplasmic	B-protein
corticosteroid-specific	I-protein
receptors	I-protein
appear	O
to	I-protein
be	O
an	I-protein
important	O
common	I-protein
pathway	I-protein
for	I-protein
steroid-induced	O
changes	O
,	O
but	O
variations	O
of	I-protein
receptor	O
parameters	O
do	O
not	I-protein
account	O
for	I-protein
the	I-protein
multifaceted	O
effects	O
on	I-protein
the	I-protein
immune	O
system	I-protein
.	O

Human	O
circulating	O
mononuclear	O
cells	I-protein
redistribute	O
out	O
of	I-protein
the	I-protein
intravascular	O
compartment	I-protein
following	O
treatment	O
with	I-protein
corticosteroids	O
.	O

Although	O
certain	O
components	O
at	I-protein
this	O
redistribution	O
phenomenon	O
have	O
been	O
well-characterized	O
,	O
the	I-protein
importance	O
of	I-protein
this	O
compartmental	O
cellular	O
shift	O
with	I-protein
respect	O
to	I-protein
the	I-protein
mechanisms	O
of	I-protein
corticosteroid-induced	O
immunoregulation	O
are	O
less	O
well-defined	O
.	O

Recent	O
observations	O
that	O
activated	O
lymphocytes	O
may	O
be	O
sensitive	I-protein
to	I-protein
the	I-protein
lytic	O
effects	O
of	I-protein
glucocorticoids	O
suggest	O
that	O
under	O
certain	O
situations	O
the	I-protein
elimination	O
of	I-protein
selected	O
subsets	O
of	I-protein
cells	I-protein
may	O
be	O
a	I-protein
relevant	I-protein
mechanism	O
of	I-protein
corticosteroid-mediated	O
immunoregulation	O
in	I-protein
man	I-protein
.	O

Corticosteroid-mediated	O
effects	O
on	I-protein
monocyte	B-protein
function	I-protein
may	O
be	O
an	I-protein
important	O
mechanism	O
of	I-protein
drug-induced	O
immunoregulation	O
in	I-protein
monocyte-dependent	O
responses	O
.	O

In	O
some	O
experimental	O
conditions	O
,	O
corticosteroids	O
inhibit	O
Interleukin	B-protein
1	I-protein
production	I-protein
by	I-protein
monocytes	O
.	O

The	O
immunoregulatory	O
effects	O
of	I-protein
corticosteroids	O
on	I-protein
lymphocyte	O
immune	O
responses	O
are	O
complex	I-protein
.	O

In	O
vitro	O
corticosteroids	O
appear	O
to	I-protein
selectively	O
affect	O
early	O
immunoregulatory	O
events	O
as	O
opposed	O
to	I-protein
altering	O
an	I-protein
established	O
response	I-protein
.	O

Multiple	B-protein
sites	I-protein
of	I-protein
steroid-induced	O
modulations	O
of	I-protein
human	O
B	O
cell	O
responses	O
have	O
been	O
defined	I-protein
.	O

###MEDLINE:81260241

Human	O
lymphoid	O
cell	O
lines	B-protein
and	I-protein
glucocorticoids	O
:	O
II	I-protein
.	O

Whole	O
cell	O
and	I-protein
cytoplasmic	O
binding	I-protein
properties	O
of	I-protein
lymphoblastoid	O
,	O
leukaemia	O
and	I-protein
lymphoma	I-protein
lines	B-protein
.	O

The	O
glucocorticoid	O
binding	I-protein
properties	O
of	I-protein
18	I-protein
human	O
lymphoid	O
cell	O
lines	B-protein
(	O
HLCL	O
)	O
have	O
been	O
investigated	O
.	O

The	O
specificity	I-protein
of	I-protein
steroid	O
binding	I-protein
was	O
confirmed	O
with	I-protein
various	O
glucocorticoid	O
agonists	O
and	I-protein
antagonists	O
.	O

A	O
gradation	O
in	I-protein
whole	O
cell	O
and	I-protein
cytoplasmic	O
glucocorticoid	O
binding	I-protein
capacity	O
was	O
observed	O
in	I-protein
the	I-protein
different	O
cell	O
line	I-protein
types	I-protein
:	O
lymphoblastoid	O
greater	O
than	I-protein
lymphoma	I-protein
greater	O
than	I-protein
leukaemia	O
.	O

The	O
cytoplasmic	B-protein
receptors	I-protein
of	I-protein
leukaemia	O
and	I-protein
lymphoblastoid	O
lines	B-protein
appeared	O
to	I-protein
contain	O
both	O
proteinaceous	O
and	I-protein
phospholipid	O
components	O
.	O

Cytoplasmic	I-protein
steroid-receptor	I-protein
complexes	I-protein
exhibited	O
a	I-protein
wide	O
range	O
of	I-protein
sedimentation	O
coefficients	O
(	O
8.5-11.3S	O
)	O
in	I-protein
low	O
ionic	O
strength	O
buffer	O
but	O
there	O
was	O
no	I-protein
correlation	O
with	I-protein
cell	O
line	I-protein
type	O
or	I-protein
glucocorticoid	O
sensitivity	I-protein
.	O

Activation	O
of	I-protein
these	O
complexes	O
by	I-protein
heat	O
(	O
37	I-protein
degrees	O
C	O
)	O
or	I-protein
exposure	O
to	I-protein
high	O
ionic	O
strength	O
buffer	O
(	O
0.3	O
M	I-protein
NaCl	O
)	O
induced	I-protein
nuclear	O
binding	I-protein
of	I-protein
steroid	O
but	O
only	I-protein
complexes	O
in	I-protein
high	O
ionic	O
strength	O
buffer	O
manifested	O
changes	O
in	I-protein
sedimentation	O
coefficient	O
.	O

No	I-protein
correlation	O
was	O
observed	O
between	O
the	I-protein
level	I-protein
or	I-protein
nature	O
of	I-protein
glucocorticoid	O
binding	I-protein
and	I-protein
the	I-protein
cytolethal	O
or	I-protein
cytostatic	O
responsiveness	O
of	I-protein
HLCL	O
to	I-protein
glucocorticoid	O
treatment	O
in	I-protein
vitro	O
.	O

The	O
resistance	O
to	I-protein
cytolethal	O
effects	O
can	O
not	I-protein
be	O
ascribed	O
to	I-protein
a	I-protein
failure	I-protein
of	I-protein
cells	I-protein
to	I-protein
take	O
up	O
and	I-protein
bind	O
steroid	O
or	I-protein
to	I-protein
significant	O
differences	O
in	I-protein
the	I-protein
molecular	I-protein
species	O
of	I-protein
cytoplasmic	B-protein
receptors	I-protein
present	O
.	O

The	O
molecular	I-protein
mechanisms	O
by	I-protein
which	O
glucocorticoids	O
achieve	O
cytolethal	O
responses	O
in	I-protein
human	O
lymphoid	O
cells	I-protein

###MEDLINE:98281994

CD28	B-protein
-mediated	O
activation	I-protein
in	I-protein
CD45RA+	O
and	I-protein
CD45RO+	O
T	O
cells	I-protein
:	O
enhanced	I-protein
levels	I-protein
of	I-protein
reactive	I-protein
oxygen	O
intermediates	O
and	I-protein
c-Rel	B-protein
nuclear	O
translocation	O
in	I-protein
CD45RA+	O
cells	I-protein
.	O

We	O
have	O
analyzed	O
the	I-protein
effect	O
of	I-protein
complete	O
T	O
cell	O
activation	I-protein
(	O
anti-CD3	B-protein
plus	O
anti-CD28	O
)	O
on	I-protein
the	I-protein
activation	I-protein
of	I-protein
NF-kappaB	B-protein
in	I-protein
CD45RA+	O
(	O
naive	O
)	O
and	I-protein
CD45RO+	O
(	O
memory/effector	O
)	O
T	O
cells	I-protein
.	O

Long	I-protein
exposure	O
(	O
24	I-protein
h	I-protein
)	O
induced	I-protein
stronger	O
NF-kappaB	B-protein
DNA	O
binding	I-protein
in	I-protein
CD45RA+	O
cells	I-protein
than	I-protein
in	I-protein
CD45RO+	O
cells	I-protein
.	O

Analysis	O
of	I-protein
the	I-protein
nuclear	B-protein
c-Rel	I-protein
protein	I-protein
indicated	O
that	O
after	O
anti-CD3+anti-CD28	O
stimulation	I-protein
the	I-protein
level	I-protein
of	I-protein
c-Rel	B-protein
was	O
higher	O
in	I-protein
CD45RA+	O
cells	I-protein
.	O

Analysis	O
of	I-protein
the	I-protein
cytoplasmic	O
inhibitor	O
IkappaBalpha	B-protein
indicated	O
that	O
anti-CD3+anti-CD28	O
stimulation	I-protein
induced	I-protein
a	I-protein
long-lasting	O
degradation	I-protein
in	I-protein
CD45RA+	O
cells	I-protein
but	O
in	I-protein
CD45RO+	O
cells	I-protein
the	I-protein
degradation	I-protein
process	O
was	O
more	O
rapid	O
.	O

Because	O
the	I-protein
CD28	B-protein
costimulus	O
is	O
known	O
to	I-protein
induce	O
the	I-protein
production	I-protein
of	I-protein
reactive	I-protein
oxygen	O
intermediates	O
(	O
ROIs	O
)	O
,	O
the	I-protein
intracellular	I-protein
ROI	O
levels	I-protein
in	I-protein
CD45RA+	O
and	I-protein
CD45RO+	O
cells	I-protein
were	O
compared	O
by	I-protein
flow	O
cytometry	O
.	O

ROIs	O
were	O
produced	O
in	I-protein
both	O
cell	O
types	I-protein
,	O
but	O
more	O
strongly	O
in	I-protein
CD45RA+	O
cells	I-protein
.	O

The	O
data	O
presented	O
in	I-protein
this	O
study	O
further	O
emphasize	O
the	I-protein
differences	O
between	O
CD45RA+	O
and	I-protein
CD45RO+	O
T	O
lymphocytes	O
in	I-protein
ROI-dependent	O
signaling	O
pathways	O
.	O

###MEDLINE:98282479

Ikaros	I-protein
in	I-protein
hemopoietic	B-protein
lineage	I-protein
determination	I-protein
and	I-protein
homeostasis	I-protein
.	O

Studies	O
on	I-protein
the	I-protein
molecular	I-protein
mechanisms	O
that	O
control	I-protein
hemopoietic	B-protein
differentiation	I-protein
have	O
focused	O
on	I-protein
signaling	O
cascades	O
and	I-protein
nuclear	O
effectors	O
that	O
drive	O
this	O
complex	I-protein
developmental	O
system	I-protein
in	I-protein
a	I-protein
regulated	O
fashion	O
.	O

Here	O
we	O
review	O
the	I-protein
role	O
of	I-protein
Ikaros	I-protein
,	O
the	I-protein
founding	O
member	I-protein
of	I-protein
a	I-protein
unique	I-protein
family	O
of	I-protein
zinc	B-protein
finger	I-protein
transcription	I-protein
factors	I-protein
in	I-protein
this	O
developmental	O
process	O
.	O

Studies	O
on	I-protein
an	I-protein
Ikaros	I-protein
null	O
mutation	I-protein
have	O
revealed	O
an	I-protein
essential	O
role	O
for	I-protein
this	O
factor	I-protein
in	I-protein
lymphoid	O
cell	O
fate	O
determination	I-protein
and	I-protein
at	I-protein
subsequent	O
branch	O
points	O
of	I-protein
the	I-protein
T	O
cell	O
differentiation	I-protein
pathway	I-protein
.	O

Differences	O
in	I-protein
the	I-protein
phenotypes	O
of	I-protein
a	I-protein
null	O
and	I-protein
a	I-protein
dominant	I-protein
negative	O
(	O
DN	O
)	O
Ikaros	I-protein
mutation	I-protein
provide	O
insight	O
into	O
a	I-protein
regulatory	O
network	I-protein
through	I-protein
which	O
Ikaros	I-protein
proteins	I-protein
exert	O
their	O
effects	O
in	I-protein
development	O
.	O

In	O
addition	O
a	I-protein
comparative	O
analysis	O
of	I-protein
the	I-protein
hemopoietic	B-protein
stem	I-protein
cell	O
and	I-protein
precursor	I-protein
compartment	I-protein
resulting	O
from	I-protein
the	I-protein
two	O
Ikaros	I-protein
mutations	I-protein
reveals	O
a	I-protein
profound	O
yet	O
not	I-protein
absolute	O
requirement	O
for	I-protein
Ikaros	I-protein
in	I-protein
the	I-protein
production	I-protein
and	I-protein
differentiation	I-protein
of	I-protein
these	O
populations	O
.	O

###MEDLINE:98266173

Overexpression	O
of	I-protein
p65	B-protein
and	I-protein
c-Jun	B-protein
substitutes	O
for	I-protein
B7-1	O
costimulation	O
by	I-protein
targeting	I-protein
the	I-protein
CD28RE	O
within	B-protein
the	I-protein
IL-2	B-protein
promoter	I-protein
.	O

The	O
role	O
of	I-protein
Rel	B-protein
and	I-protein
activation	I-protein
protein-1	I-protein
(	O
AP-1	I-protein
)	O
in	I-protein
IL-2	B-protein
promoter	I-protein
activity	I-protein
in	I-protein
B7-1-	O
and	I-protein
leukocyte	O
function-associated	I-protein
Ag-3	O
(	O
LFA.	O
3	O
)	O
-costimulated	O
T	O
cells	I-protein
has	O
been	O
evaluated	O
.	O

We	O
demonstrate	O
that	O
overexpression	O
of	I-protein
c-Jun	B-protein
but	O
not	I-protein
c-Fos	B-protein
increases	O
IL-2	B-protein
promoter	I-protein
activity	I-protein
in	I-protein
both	O
B7-1-	O
and	I-protein
LFA-3-costimulated	O
Jurkat	O
T	O
cells	I-protein
.	O

Cotransfection	O
of	I-protein
both	O
c-Jun	B-protein
and	I-protein
c-Fos	O
substitutes	O
for	I-protein
B7-1	O
costimulation	O
in	I-protein
driving	O
an	I-protein
activation	I-protein
protein-1	I-protein
response	I-protein
element	I-protein
but	O
not	I-protein
for	I-protein
the	I-protein
IL-2	B-protein
promoter	I-protein
.	O

Overexpression	O
of	I-protein
Rel	B-protein
proteins	I-protein
demonstrated	O
that	O
p65-expressing	O
Jurkat	O
cells	I-protein
transcribed	I-protein
equally	O
well	O
a	I-protein
nuclear	O
factor	I-protein
kappabeta	O
reporter	O
construct	O
when	O
costimulated	O
with	I-protein
B7-1	B-protein
or	I-protein
LFA-3	B-protein
,	O
but	O
transcription	O
of	I-protein
IL-2	B-protein
promoter	I-protein
or	I-protein
CD28	B-protein
response	I-protein
element	I-protein
(	O
CD28RE	O
)	O
-driven	O
reporters	O
was	O
superior	I-protein
in	I-protein
B7-1-costimulated	O
cells	I-protein
.	O

Combined	O
expression	I-protein
of	I-protein
c-Jun	B-protein
and	I-protein
p65	B-protein
induced	I-protein
vigorous	O
transcription	O
of	I-protein
IL-2	B-protein
promoter-	O
and	I-protein
CD28RE-driven	O
reporter	O
constructs	O
in	I-protein
both	O
LFA-3-	O
and	I-protein
B7-1-costimulated	O
Jurkat	O
cells	I-protein
.	O

Mutating	O
the	I-protein
CD28RE	O
but	O
not	I-protein
the	I-protein
upstream	O
nuclear	O
factor	I-protein
kappabeta-binding	O
site	I-protein
in	I-protein
the	I-protein
IL-2	B-protein
promoter	I-protein
reduced	O
B7-1	B-protein
-driven	O
transcription	O
>	O
90	I-protein
%	O
.	O

The	O
results	O
implicates	O
a	I-protein
major	O
role	O
of	I-protein
the	I-protein
CD28RE	O
in	I-protein
the	I-protein
integration	I-protein
of	I-protein
p65	B-protein
/	O
c-Jun	B-protein
-mediated	O
transcription	O
within	B-protein
the	I-protein
IL-2	B-protein
promoter	I-protein
.	O

We	O
suggest	O
that	O
the	I-protein
transition	O
from	I-protein
an	I-protein
autocrine	B-protein
LFA-3	B-protein
-driven	O
immune	O
response	I-protein
to	I-protein
a	I-protein
B7	I-protein
--	I-protein
induced	I-protein
paracrine	O
immune	O
response	I-protein
involves	O
the	I-protein
activation	I-protein
of	I-protein
c-Jun	B-protein
and	I-protein
p65	B-protein
,	O
which	O
target	O
the	I-protein
CD28RE	O
region	O
of	I-protein
the	I-protein
IL-2	B-protein
promoter	I-protein
.	O

###MEDLINE:98263946

Defects	O
in	I-protein
actin-cap	O
formation	O
in	I-protein
Vav-deficient	O
mice	O
implicate	O
an	I-protein
actin	O
requirement	O
for	I-protein
lymphocyte	O
signal	O
transduction	I-protein
.	O

BACKGROUND	O
:	O
Antigen-receptor	O
interactions	O
on	I-protein
lymphocytes	O
result	O
in	I-protein
local	O
clustering	O
of	I-protein
actin	O
,	O
receptors	I-protein
and	I-protein
signaling	B-protein
molecules	I-protein
into	O
an	I-protein
asymmetric	I-protein
membrane	O
structure	O
termed	O
a	I-protein
cap	I-protein
.	O

Although	O
actin	O
polymerization	I-protein
is	O
known	O
to	I-protein
be	O
required	O
,	O
the	I-protein
mechanisms	O
underlying	O
cap	I-protein
formation	O
are	O
unclear	O
.	O

We	O
have	O
studied	O
the	I-protein
events	O
underlying	O
cap	I-protein
formation	O
using	O
mice	O
bearing	O
a	I-protein
null	O
mutation	I-protein
in	I-protein
vav	B-protein
(	O
vav	B-protein
-/-	O
)	O
,	O
a	I-protein
gene	O
that	O
encodes	O
a	I-protein
guanine-nucleotide	B-protein
exchange	I-protein
factor	I-protein
for	I-protein
the	I-protein
GTPase	B-protein
Rac	I-protein
.	O

RESULTS	O
:	O
Lymphocytes	O
from	I-protein
vav	B-protein
-/-	O
mice	O
failed	O
to	I-protein
form	I-protein
T-cell	O
receptor	O
caps	O
following	O
activation	I-protein
and	I-protein
had	O
a	I-protein
defective	O
actin	O
cytoskeleton	O
.	O

The	O
vav-/-	O
T	O
cells	I-protein
were	O
deficient	I-protein
in	I-protein
interleukin-2	B-protein
(	O
IL-2	B-protein
)	O
production	I-protein
and	I-protein
proliferation	I-protein
,	O
and	I-protein
the	I-protein
peak	O
of	I-protein
Ca2+	I-protein
mobilization	O
was	O
reduced	O
although	O
of	I-protein
normal	O
duration	O
.	O

Activation	O
of	I-protein
Jun	B-protein
N-terminal	I-protein
kinase	I-protein
or	I-protein
stress-activated	B-protein
kinase	I-protein
(	O
JNK	B-protein
or	I-protein
SAPK	B-protein
)	O
and	I-protein
mitogen-activated	B-protein
protein	I-protein
kinase	I-protein
(	O
MAPK	I-protein
)	O
and	I-protein
the	I-protein
induction	I-protein
of	I-protein
the	I-protein
transcription	B-protein
factor	I-protein
NF-ATc1	O
and	I-protein
egr-1	O
genes	I-protein
was	O
normal	O
.	O

Despite	O
the	I-protein
reduced	O
Ca2+	I-protein
mobilization	O
,	O
translocation	O
of	I-protein
cytoplasmic	B-protein
NF-ATc	I-protein
to	I-protein
the	I-protein
nucleus	I-protein
was	O
normal	O
,	O
reflecting	O
that	O
the	I-protein
lower	I-protein
levels	I-protein
of	I-protein
Ca2+	I-protein
in	I-protein
vav-/-	O
cells	I-protein
were	O
still	O
sufficient	O
to	I-protein
activate	O
calcineurin	B-protein
.	O

Treatment	O
of	I-protein
lymphocytes	O
with	I-protein
cytochalasin	O
D	O
,	O
which	O
blocks	O
actin	O
polymerization	I-protein
,	O
inhibited	O
cap	I-protein
formation	O
and	I-protein
produced	O
defects	I-protein
in	I-protein
signaling	O
and	I-protein
IL-2	B-protein
transcriptional	O
induction	I-protein
in	I-protein
response	I-protein
to	I-protein
antigen-receptor	O
signaling	O
that	O
were	O
nearly	O
identical	O
to	I-protein
those	O
seen	O
in	I-protein
vav-/-	O
cells	I-protein
.	O

In	O
transfection	O
studies	O
,	O
either	O
constitutively	O
active	O
Vav	B-protein
or	I-protein
Rac	B-protein
could	O
complement	O
constitutively	O
active	O
calcineurin	B-protein
to	I-protein
activate	O
NF-AT-dependent	O
transcription	O
.	O

CONCLUSIONS	O
:	O
These	O
results	O
indicate	O
that	O
Vav	B-protein
is	O
required	O
for	I-protein
cap	I-protein
formation	O
in	I-protein
lymphocytes	O
.	O

Furthermore	O
,	O
the	I-protein
correlation	O
between	O
cap	I-protein
formation	O
,	O
IL-2	B-protein
production	I-protein
and	I-protein
proliferation	I-protein
supports	O
the	I-protein
hypothesis	O
that	O
an	I-protein
actin-dependent	I-protein
pathway	I-protein
is	O
a	I-protein
source	O
of	I-protein
specialized	O
growth	O
regulatory	O
signals	I-protein
.	O

###MEDLINE:98248918

CD14	B-protein
-dependent	I-protein
activation	I-protein
of	I-protein
human	O
endothelial	O
cells	I-protein
by	I-protein
Bacteroides	O
fragilis	O
outer	O
membrane	O
.	O

We	O
studied	O
the	I-protein
capacity	O
of	I-protein
isolated	I-protein
Bacteriodes	O
fragilis	O
outer	O
membrane	O
,	O
B.	O
fragilis	O
NCTC9343	O
lipopolysaccharide	B-protein
(	O
LPS	B-protein
;	O
endotoxin	O
)	O
,	O
and	I-protein
B.	O
fragilis	O
NCTC9343	O
capsular	O
polysaccharides	O
to	I-protein
activate	O
human	O
umbilical	O
vein	O
endothelial	O
cell	O
(	O
HUVEC	O
)	O
monolayers	O
.	O

To	O
assess	O
HUVEC	O
activation	I-protein
,	O
E-selectin	O
expression	I-protein
was	O
measured	O
by	I-protein
enzyme-linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
,	O
Northern	O
blot	O
analysis	O
for	I-protein
E-selectin-specific	O
mRNA	O
,	O
and	I-protein
electrophoretic	O
gel	O
mobility	I-protein
shift	O
assay	O
(	O
EMSA	O
)	O
for	I-protein
NF-kappa	B-protein
B	I-protein
,	O
a	I-protein
transcription	B-protein
factor	I-protein
necessary	O
for	I-protein
E-selectin	O
gene	O
activation	I-protein
.	O

Exposure	O
of	I-protein
HUVECs	O
to	I-protein
B.	O
fragilis	O
outer	O
membrane	O
fractions	O
,	O
separated	O
from	I-protein
other	O
components	O
of	I-protein
the	I-protein
B.	O
fragilis	O
cell	O
wall	O
by	I-protein
isopycnic	O
,	O
sucrose	O
gradient	I-protein
centrifugation	O
,	O
significantly	O
increased	I-protein
surface	O
expression	I-protein
of	I-protein
E-selectin	B-protein
and	I-protein
induced	I-protein
functional	O
endothelial	O
cell	O
-dependent	I-protein
leukocyte	O
adhesion	O
.	O

B.	O
fragilis	O
outer	O
membranes	O
induced	I-protein
translocation	O
of	I-protein
NF-kappa	B-protein
B	I-protein
to	I-protein
HUVEC	O
nuclei	O
and	I-protein
accumulation	I-protein
of	I-protein
E-selectin	O
mRNA	O
in	I-protein
HUVEC	O
cytoplasm	O
.	O

E-selectin	O
expression	I-protein
induced	I-protein
by	I-protein
B.	O
fragilis	O
outer	O
membranes	O
was	O
not	I-protein
blocked	B-protein
by	I-protein
polymixin	O
B	O
.	O

In	O
contrast	O
,	O
E-selectin	O
expression	I-protein
induced	I-protein
by	I-protein
outer	O
membrane	O
fractions	O
purified	O
from	I-protein
E.	I-protein
coli	I-protein
was	O
competitively	O
inhibited	O
by	I-protein
polymixin	O
B	O
.	O

Neither	O
purified	O
B.	O
fragilis	O
LPS	B-protein
,	O
a	I-protein
prominent	O
constituent	O
of	I-protein
the	I-protein
outer	O
membrane	O
,	O
nor	O
purified	O
B.	O
fragilis	O
capsular	O
polysaccharides	O
induced	I-protein
HUVEC	O
activation	I-protein
.	O

Two	O
different	O
monoclonal	I-protein
antibodies	I-protein
directed	I-protein
against	I-protein
human	B-protein
CD14	B-protein
completely	O
inhibited	O
B.	O
fragilis	O
outer	O
membrane-induced	O
NF-kappa	B-protein
B	I-protein
activation	I-protein
,	O
E-selectin	O
transcription	O
,	O
and	I-protein
E-selectin	O
surface	O
expression	I-protein
.	O

We	O
conclude	O
that	O
the	I-protein
outer	O
membrane	O
component	O
of	I-protein
the	I-protein
B.	O
fragilis	O
cell	O
wall	O
contains	I-protein
a	I-protein
proinflammatory	B-protein
factor	I-protein
(	O
s	I-protein
)	O
,	O
that	O
is	O
not	I-protein
LPS	B-protein
,	O
which	O
induces	O
human	O
endothelial	O
cell	O
activation	I-protein
by	I-protein
a	I-protein
soluble	I-protein
CD14	B-protein
-dependent	I-protein
mechanism	O
.	O

###MEDLINE:98240931

NF-kappaB	B-protein
protects	O
HIV-1-infected	O
myeloid	O
cells	I-protein
from	I-protein
apoptosis	O
.	O

HIV-1	O
infection	I-protein
of	I-protein
primary	O
monocytic	I-protein
cells	I-protein
and	I-protein
myeloid	O
cell	O
lines	B-protein
results	O
in	I-protein
sustained	O
NF-kappaB	B-protein
activation	I-protein
.	O

Recently	O
,	O
NF-kappaB	B-protein
induction	I-protein
has	O
been	O
shown	O
to	I-protein
play	O
a	I-protein
role	O
in	I-protein
protecting	O
cells	I-protein
from	I-protein
programmed	O
cell	O
death	O
.	O

In	O
the	I-protein
present	O
study	O
,	O
we	O
sought	O
to	I-protein
investigate	O
whether	O
constitutive	I-protein
NF-kappaB	B-protein
activity	I-protein
in	I-protein
chronically	O
HIV-1-infected	O
promonocytic	O
U937	O
(	O
U9-IIIB	O
)	O
and	I-protein
myeloblastic	O
PLB-985	O
(	O
PLB-IIIB	O
)	O
cells	I-protein
affects	O
apoptotic	O
signaling	O
.	O

TNFalpha	B-protein
and	I-protein
cycloheximide	O
caused	O
infected	O
cells	I-protein
to	I-protein
undergo	O
apoptosis	O
more	O
rapidly	I-protein
than	I-protein
parental	O
U937	O
and	I-protein
PLB-985	O
cells	I-protein
.	O

Inhibition	O
of	I-protein
TNFalpha	B-protein
-induced	O
NF-kappaB	B-protein
activation	I-protein
using	O
the	I-protein
antioxidant	I-protein
N-acetylcysteine	O
(	O
NAC	B-protein
)	O
resulted	O
in	I-protein
increased	I-protein
apoptosis	O
in	I-protein
both	O
U937	O
and	I-protein
U9-IIIB	O
cells	I-protein
,	O
while	O
preactivation	O
of	I-protein
NF-kappaB	B-protein
with	I-protein
the	I-protein
non-apoptotic	B-protein
inducer	I-protein
IL-1beta	I-protein
caused	O
a	I-protein
relative	I-protein
decrease	O
in	I-protein
apoptosis	O
.	O

Inhibition	O
of	I-protein
constitutive	I-protein
NF-kappaB	B-protein
activity	I-protein
in	I-protein
U9-IIIB	O
and	I-protein
PLB-IIIB	O
cells	I-protein
also	O
induced	I-protein
apoptosis	O
,	O
suggesting	O
that	O
NF-kappaB	B-protein
protects	O
cells	I-protein
from	I-protein
a	I-protein
persistent	I-protein
apoptotic	O
signal	O
.	O

TNFalpha	B-protein
plus	O
NAC	B-protein
treatment	O
resulted	O
in	I-protein
a	I-protein
marked	O
decrease	O
in	I-protein
Bcl-2	B-protein
protein	I-protein
levels	I-protein
in	I-protein
HIV-1-infected	O
cells	I-protein
,	O
coupled	I-protein
with	I-protein
an	I-protein
increase	O
in	I-protein
Bax	B-protein
protein	I-protein
compared	O
to	I-protein
uninfected	O
cells	I-protein
,	O
suggesting	O
that	O
the	I-protein
difference	O
in	I-protein
susceptibility	I-protein
to	I-protein
TNFalpha	B-protein
-induced	O
apoptosis	O
may	O
relate	O
to	I-protein
the	I-protein
differences	O
in	I-protein
relative	I-protein
levels	I-protein
of	I-protein
Bcl-2	B-protein
and	I-protein
Bax	B-protein
.	O

The	O
protective	O
role	O
of	I-protein
NF-kappaB	B-protein
in	I-protein
blocking	O
TNFalpha-	O
and	I-protein
HIV-1-induced	O
apoptosis	O
was	O
supported	I-protein
by	I-protein
studies	O
in	I-protein
Jurkat	O
T	O
cells	I-protein
engineered	O
to	I-protein
express	O
IkappaB	B-protein
alpha	I-protein
repressor	I-protein
mutants	I-protein
(	O
TD-IkappaB	B-protein
)	O
under	O
the	I-protein
control	I-protein
of	I-protein
a	I-protein
tetracycline-responsive	O
promoter	I-protein
.	O

Cells	O
underwent	O
apoptosis	O
in	I-protein
response	I-protein
to	I-protein
TNFalpha	B-protein
only	I-protein
when	O
NF-kappaB	B-protein
activation	I-protein
was	O
inhibited	O
by	I-protein
TD-IkappaB	B-protein
expression	I-protein
.	O

As	O
was	O
observed	O
for	I-protein
the	I-protein
U9-IIIB	O
cells	I-protein
,	O
TNFalpha	B-protein
treatment	O
also	O
induced	I-protein
a	I-protein
marked	O
decrease	O
in	I-protein
Bcl-2	B-protein
protein	I-protein
levels	I-protein
in	I-protein
TD-IkappaB	O
expressing	O
cells	I-protein
.	O

These	O
experiments	O
demonstrate	O
that	O
apoptotic	O
signaling	O
is	O
perturbed	O
in	I-protein
HIV-1-infected	O
U9-IIIB	O
cells	I-protein
and	I-protein
indicate	O
that	O
NF-kappaB	B-protein
activation	I-protein
may	O
play	O
an	I-protein
additional	B-protein
protective	O
role	O
against	I-protein
HIV-1-induced	O
apoptosis	O
in	I-protein
myeloid	O
cells	I-protein
.	O

###MEDLINE:98227977

Human	O
normal	O
peripheral	O
blood	O
B-lymphocytes	O
are	O
deficient	I-protein
in	I-protein
DNA-dependent	O
protein	O
kinase	O
activity	I-protein
due	I-protein
to	I-protein
the	I-protein
expression	I-protein
of	I-protein
a	I-protein
variant	I-protein
form	I-protein
of	I-protein
the	I-protein
Ku86	B-protein
protein	I-protein
.	O

The	O
heterodimeric	O
Ku	I-protein
protein	I-protein
,	O
which	O
comprises	O
a	I-protein
86	I-protein
kDa	I-protein
(	O
Ku86	B-protein
)	O
amd	O
a	I-protein
70	I-protein
kDa	I-protein
(	O
Ku70	I-protein
)	O
subunits	I-protein
,	O
is	O
an	I-protein
abundant	I-protein
nuclear	B-protein
DNA-binding	I-protein
protein	I-protein
which	O
binds	O
in	I-protein
vitro	O
to	I-protein
DNA	O
termini	O
without	I-protein
sequence	I-protein
specificity	I-protein
.	O

Ku	I-protein
is	O
the	I-protein
DNA-targeting	B-protein
component	I-protein
of	I-protein
the	I-protein
large	O
catalytic	I-protein
sub-unit	I-protein
of	I-protein
the	I-protein
DNA-dependent	B-protein
protein	I-protein
kinase	I-protein
complex	I-protein
(	O
DNA-PK	B-protein
[	O
CS	I-protein
]	O
)	O
,	O
that	O
plays	O
a	I-protein
critical	I-protein
role	O
in	I-protein
mammalian	O
double-strand	O
break	O
repair	I-protein
and	I-protein
lymphoid	O
V	O
(	O
D	O
)	O
J	I-protein
recombination	O
.	O

By	O
using	O
electrophoretic	O
mobility	I-protein
shift	O
assays	O
,	O
we	O
demonstrated	O
that	O
in	I-protein
addition	O
to	I-protein
the	I-protein
major	B-protein
Ku	I-protein
x	I-protein
DNA	I-protein
complex	I-protein
usually	O
detected	O
in	I-protein
cell	O
line	I-protein
extracts	O
,	O
a	I-protein
second	O
complex	I-protein
with	I-protein
faster	O
electrophoretic	O
mobility	I-protein
was	O
observed	O
in	I-protein
normal	O
peripheral	O
blood	O
lymphocytes	O
(	O
PBL	O
)	O
extracts	O
.	O

The	O
presence	O
of	I-protein
this	O
faster	B-protein
migrating	I-protein
complex	I-protein
was	O
restricted	I-protein
to	I-protein
B	O
cells	I-protein
among	O
the	I-protein
circulating	O
lymphocyte	O
population	O
.	O

Western	O
blot	O
analysis	O
revealed	O
that	O
B	O
cells	I-protein
express	O
a	I-protein
variant	I-protein
form	I-protein
of	I-protein
the	I-protein
Ku86	B-protein
protein	I-protein
with	I-protein
an	I-protein
apparent	O
molecular	I-protein
weight	I-protein
of	I-protein
69	I-protein
kDa	I-protein
,	O
and	I-protein
not	I-protein
the	I-protein
86	I-protein
kDa-	I-protein
full-length	I-protein
protein	I-protein
.	O

Although	O
the	I-protein
heterodimer	B-protein
Ku70/variant-Ku86	I-protein
binds	O
to	I-protein
DNA-ends	O
,	O
this	O
altered	I-protein
form	I-protein
of	I-protein
the	I-protein
Ku	I-protein
heterodimer	I-protein
has	O
a	I-protein
decreased	O
ability	O
to	I-protein
recruit	O
the	I-protein
catalytic	I-protein
component	I-protein
of	I-protein
the	I-protein
complex	I-protein
,	O
DNA-PK	B-protein
(	O
CS	I-protein
)	O
,	O
which	O
contributes	O
to	I-protein
an	I-protein
absence	I-protein
of	I-protein
detectable	O
DNA-PK	O
activity	I-protein
in	I-protein
B	O
cells	I-protein
.	O

These	O
data	O
provide	O
a	I-protein
molecular	I-protein
basis	O
for	I-protein
the	I-protein
increased	I-protein
sensitivity	I-protein
of	I-protein
B	O
cells	I-protein
to	I-protein
ionizing	O
radiation	I-protein
and	I-protein
identify	O
a	I-protein
new	I-protein
mechanism	O
of	I-protein
regulation	I-protein
of	I-protein
DNA-PK	O
activity	I-protein
that	O
operates	O
in	I-protein
vivo	O
.	O

###MEDLINE:98220845

Co-stimulation	O
of	I-protein
human	O
peripheral	O
blood	O
mononuclear	O
cells	I-protein
with	I-protein
IL-2	B-protein
and	I-protein
anti-CD3	B-protein
monoclonal	I-protein
antibodies	I-protein
induces	O
phosphorylation	I-protein
of	I-protein
CREB	B-protein
.	O

Phosphorylation	O
of	I-protein
the	I-protein
cAMP-response	B-protein
element	I-protein
binding	I-protein
protein	I-protein
CREB	B-protein
within	B-protein
1	I-protein
h	I-protein
of	I-protein
CD2	B-protein
but	O
not	I-protein
CD3	O
cross-linking	O
of	I-protein
human	O
PBMC	O
was	O
recently	O
demonstrated	O
.	O

The	O
absence	I-protein
of	I-protein
P-CREB	B-protein
following	O
CD3	O
cross-linking	O
was	O
unexpected	O
,	O
as	O
other	O
laboratories	O
reported	O
increased	I-protein
phosphorylation	I-protein
of	I-protein
CREB	B-protein
following	O
CD3	O
cross-linking	O
of	I-protein
the	I-protein
Jurkat	O
lymphocyte	O
cell	O
line	I-protein
.	O

Due	O
to	I-protein
Jurkat	O
T-cells	I-protein
being	O
IL-2-independent	O
,	O
it	O
was	O
postulated	O
that	O
IL-2	B-protein
might	O
provide	O
a	I-protein
necessary	O
co-stimulus	O
for	I-protein
phosphorylation	I-protein
of	I-protein
CREB	B-protein
in	I-protein
primary	O
lymphocytes	O
.	O

Therefore	O
,	O
P-CREB	B-protein
was	O
evaluated	O
following	O
co-stimulation	O
of	I-protein
human	O
PBMC	O
through	I-protein
the	I-protein
IL-2	B-protein
and	I-protein
CD2	B-protein
or	I-protein
CD3	I-protein
receptors	I-protein
.	O

IL-2	B-protein
did	O
not	I-protein
further	O
augment	O
phosphorylation	I-protein
of	I-protein
CREB	B-protein
following	O
CD2	B-protein
cross-linking	O
.	O

However	O
,	O
while	O
neither	O
IL-2	B-protein
nor	O
CD3	O
cross-linking	O
alone	O
induced	I-protein
P-CREB	B-protein
,	O
a	I-protein
4.5-fold	O
increase	O
in	I-protein
phosphorylation	I-protein
of	I-protein
CREB	B-protein
within	B-protein
1	I-protein
h	I-protein
of	I-protein
IL-2/CD3	O
co-stimulation	O
was	O
observed	O
.	O

Phosphorylation	O
was	O
not	I-protein
associated	I-protein
with	I-protein
the	I-protein
induction	I-protein
of	I-protein
cAMP	O
,	O
and	I-protein
inhibition	O
of	I-protein
PKA	O
signaling	O
had	O
no	I-protein
effect	O
on	I-protein
P-CREB	B-protein
.	O

Consistent	O
with	I-protein
signal	O
transduction	I-protein
through	I-protein
p56lck	B-protein
or	I-protein
p59fyn	O
,	O
inhibition	O
of	I-protein
PTK	B-protein
signaling	O
reduced	O
phosphorylation	I-protein
50	I-protein
%	O
.	O

Interestingly	O
,	O
inhibiting	I-protein
PKC	B-protein
signaling	O
with	I-protein
calphostin	O
C	O
further	O
increased	I-protein
P-CREB	O
levels	I-protein
3-fold	O
over	O
that	O
observed	O
in	I-protein
IL-2/CD3	O
co-stimulated	O
cells	I-protein
not	I-protein
pretreated	O
with	I-protein
a	I-protein
PKC	B-protein
inhibitor	O
.	O

In	O
contrast	O
to	I-protein
previous	O
studies	O
performed	O
in	I-protein
the	I-protein
absence	I-protein
of	I-protein
exogenous	B-protein
IL-2	B-protein
,	O
no	I-protein
increase	O
in	I-protein
binding	I-protein
of	I-protein
CREB	B-protein
to	I-protein
a	I-protein
32P-labeled	O
oligonucleotide	O
probe	O
was	O
observed	O
by	I-protein
electrophoretic	O
mobility	I-protein
shift	O
assay	O
.	O

These	O
data	O
suggest	O
that	O
the	I-protein
IL-2	B-protein
and	I-protein
CD3	B-protein
signaling	O
pathways	O
provide	O
a	I-protein
necessary	O
and	I-protein
co-operative	O
stimulus	O
promoting	I-protein
phosphorylation	I-protein
of	I-protein
CREB	B-protein
following	O
receptor	O
cross-linking	O
.	O

###MEDLINE:98211678

HIV-1	O
infection	I-protein
induces	O
a	I-protein
selective	O
reduction	I-protein
in	I-protein
STAT5	B-protein
protein	O
expression	I-protein
.	O

HIV-1	O
infection	I-protein
is	O
accompanied	O
by	I-protein
qualitative	O
and	I-protein
quantitative	I-protein
defects	I-protein
in	I-protein
CD4+	O
T	O
lymphocytes	O
.	O

Loss	O
of	I-protein
immune	O
function	I-protein
in	I-protein
HIV	I-protein
patients	O
is	O
usually	O
associated	I-protein
with	I-protein
a	I-protein
profound	O
dysregulation	O
of	I-protein
cytokine	O
production	I-protein
.	O

To	O
investigate	O
whether	O
cytokine	O
signaling	O
defects	I-protein
occur	O
during	I-protein
HIV	I-protein
infection	I-protein
,	O
PHA	B-protein
blasts	O
from	I-protein
healthy	O
human	O
donors	O
were	O
infected	O
with	I-protein
two	O
strains	O
of	I-protein
HIV-1	O
and	I-protein
screened	O
for	I-protein
the	I-protein
expression	I-protein
of	I-protein
STAT	B-protein
proteins	I-protein
used	O
in	I-protein
cytokine	O
signaling	O
.	O

A	O
selective	O
decrease	O
in	I-protein
STAT5B	B-protein
was	O
seen	O
8	I-protein
days	O
after	O
infection	I-protein
with	I-protein
the	I-protein
BZ167	O
dual-tropic	O
HIV	I-protein
isolate	O
,	O
but	O
not	I-protein
with	I-protein
the	I-protein
Ba-L	O
,	O
M-tropic	O
strain	O
.	O

Based	O
on	I-protein
these	O
findings	O
,	O
purified	O
T	O
cells	I-protein
from	I-protein
HIV-infected	O
patients	O
in	I-protein
different	O
stages	O
of	I-protein
disease	I-protein
were	O
also	O
tested	O
for	I-protein
STAT	B-protein
expression	I-protein
;	O
decreases	O
in	I-protein
STAT5A	B-protein
,	O
STAT5B	B-protein
,	O
and	I-protein
STAT1alpha	B-protein
were	O
observed	O
in	I-protein
all	O
patients	O
.	O

The	O
reduction	I-protein
in	I-protein
STATs	B-protein
seen	O
in	I-protein
vivo	O
and	I-protein
in	I-protein
vitro	O
after	O
HIV	I-protein
infection	I-protein
may	O
contribute	O
to	I-protein
the	I-protein
loss	O
of	I-protein
T	O
cell	O
function	I-protein
in	I-protein
HIV	I-protein
disease	I-protein
.	O

###MEDLINE:98204128

Transcription	I-protein
factors	I-protein
that	O
regulate	O
monocyte	B-protein
/	O
macrophage	O
differentiation	I-protein
.	O

Although	O
all	O
the	I-protein
cells	I-protein
in	I-protein
an	I-protein
organism	O
contain	O
the	I-protein
same	O
genetic	O
information	I-protein
,	O
differences	O
in	I-protein
the	I-protein
cell	O
phenotype	O
arise	O
from	I-protein
the	I-protein
expression	I-protein
of	I-protein
lineage-specific	O
genes	I-protein
.	O

During	O
myelopoiesis	O
,	O
external	I-protein
differentiating	O
signals	I-protein
regulate	O
the	I-protein
expression	I-protein
of	I-protein
a	I-protein
set	O
of	I-protein
transcription	B-protein
factors	I-protein
.	O

The	O
combined	O
action	O
of	I-protein
these	O
transcription	B-protein
factors	I-protein
subsequently	O
determines	O
the	I-protein
expression	I-protein
of	I-protein
myeloid-specific	I-protein
genes	I-protein
and	I-protein
the	I-protein
generation	O
of	I-protein
monocytes	O
and	I-protein
macrophages	O
.	O

In	O
particular	O
,	O
the	I-protein
transcription	B-protein
factor	I-protein
PU.1	B-protein
has	O
a	I-protein
critical	I-protein
role	O
in	I-protein
this	O
process	O
.	O

We	O
review	O
the	I-protein
contribution	O
of	I-protein
several	I-protein
transcription	B-protein
factors	I-protein
to	I-protein
the	I-protein
control	I-protein
of	I-protein
macrophage	O
development	O

###MEDLINE:21370255

Transcription	I-protein
factor	I-protein
LKLF	B-protein
is	O
sufficient	O
to	I-protein
program	O
T	O
cell	O
quiescence	O
via	I-protein
a	I-protein
c-Myc	B-protein
--	I-protein
dependent	I-protein
pathway	I-protein
.	O

T	O
lymphocytes	O
circulate	O
in	I-protein
a	I-protein
quiescent	O
state	I-protein
until	O
they	O
encounter	O
cognate	I-protein
antigen	I-protein
bound	I-protein
to	I-protein
the	I-protein
surface	O
of	I-protein
an	I-protein
antigen-presenting	O
cell	O
.	O

The	O
molecular	I-protein
pathways	O
that	O
regulate	O
T	O
cell	O
quiescence	O
remain	O
largely	O
unknown	O
.	O

Here	O
we	O
show	O
that	O
forced	O
expression	I-protein
of	I-protein
the	I-protein
lung	B-protein
Kruppel-like	I-protein
transcription	I-protein
factor	I-protein
(	O
LKLF	B-protein
)	O
in	I-protein
Jurkat	O
T	O
cells	I-protein
is	O
sufficient	O
to	I-protein
program	O
a	I-protein
quiescent	O
phenotype	O
characterized	O
by	I-protein
decreased	O
proliferation	I-protein
,	O
reduced	O
cell	O
size	O
and	I-protein
protein	O
synthesis	I-protein
and	I-protein
decreased	O
surface	O
expression	I-protein
of	I-protein
activation	I-protein
markers	O
.	O

Conversely	O
,	O
LKLF-deficient	O
peripheral	O
T	O
cells	I-protein
produced	O
by	I-protein
gene	O
targeting	I-protein
showed	O
increased	I-protein
proliferation	I-protein
,	O
increased	I-protein
cell	O
size	O
and	I-protein
enhanced	I-protein
expression	I-protein
of	I-protein
surface	O
activation	I-protein
markers	O
in	I-protein
vivo	O
.	O

LKLF	B-protein
appeared	O
to	I-protein
function	I-protein
,	O
at	I-protein
least	O
in	I-protein
part	I-protein
,	O
by	I-protein
decreasing	O
expression	I-protein
of	I-protein
the	I-protein
proto-oncogene	I-protein
encoding	I-protein
c-Myc	B-protein
.	O

Forced	O
expression	I-protein
of	I-protein
LKLF	B-protein
was	O
associated	I-protein
with	I-protein
markedly	O
decreased	O
c-Myc	B-protein
expression	I-protein
.	O

In	O
addition	O
,	O
many	O
effects	O
of	I-protein
LKLF	B-protein
expression	I-protein
were	O
mimicked	O
by	I-protein
expression	I-protein
of	I-protein
the	I-protein
dominant-negative	I-protein
MadMyc	I-protein
protein	I-protein
and	I-protein
rescued	O
by	I-protein
overexpression	O
of	I-protein
c-Myc	B-protein
.	O

Thus	O
,	O
LKLF	B-protein
is	O
both	O
necessary	O
and	I-protein
sufficient	O
to	I-protein
program	O
quiescence	O
in	I-protein
T	O
cells	I-protein
and	I-protein
functions	O
,	O
in	I-protein
part	I-protein
,	O
by	I-protein
negatively	O
regulating	O
a	I-protein
c-Myc	B-protein
--	I-protein
dependent	I-protein
pathway	I-protein
.	O

###MEDLINE:21361184

HTLV-1	B-protein
p12	I-protein
(	O
I	I-protein
)	O
protein	I-protein
enhances	O
STAT5	B-protein
activation	I-protein
and	I-protein
decreases	O
the	I-protein
interleukin-2	B-protein
requirement	O
for	I-protein
proliferation	I-protein
of	I-protein
primary	O
human	O
peripheral	O
blood	O
mononuclear	O
cells	I-protein
.	O

The	O
p12	B-protein
(	O
I	I-protein
)	O
protein	I-protein
,	O
encoded	O
by	I-protein
the	I-protein
pX	O
open	I-protein
reading	I-protein
frame	I-protein
I	I-protein
of	I-protein
the	I-protein
human	O
T-lymphotropic	O
virus	I-protein
type	O
1	I-protein
(	O
HTLV-1	B-protein
)	O
,	O
is	O
a	I-protein
hydrophobic	I-protein
protein	I-protein
that	O
localizes	O
to	I-protein
the	I-protein
endoplasmic	O
reticulum	I-protein
and	I-protein
the	I-protein
Golgi	I-protein
.	O

Although	O
p12	B-protein
(	O
I	I-protein
)	O
contains	I-protein
4	I-protein
minimal	I-protein
proline-rich	I-protein
,	O
src	B-protein
homology	I-protein
3-binding	I-protein
motifs	I-protein
(	O
PXXP	B-protein
)	O
,	O
a	I-protein
characteristic	O
commonly	O
found	O
in	I-protein
proteins	I-protein
involved	I-protein
in	I-protein
signaling	O
pathways	O
,	O
it	O
has	O
not	I-protein
been	O
known	O
whether	O
p12	B-protein
(	O
I	I-protein
)	O
has	O
a	I-protein
role	O
in	I-protein
modulating	I-protein
intracellular	I-protein
signaling	O
pathways	O
.	O

This	O
study	O
demonstrated	O
that	O
p12	B-protein
(	O
I	I-protein
)	O
binds	O
to	I-protein
the	I-protein
cytoplasmic	B-protein
domain	I-protein
of	I-protein
the	I-protein
interleukin-2	B-protein
receptor	I-protein
(	O
IL-2R	I-protein
)	O
beta	I-protein
chain	I-protein
that	O
is	O
involved	I-protein
in	I-protein
the	I-protein
recruitment	I-protein
of	I-protein
the	I-protein
Jak1	B-protein
and	I-protein
Jak3	I-protein
kinases	I-protein
.	O

As	O
a	I-protein
result	O
of	I-protein
this	O
interaction	I-protein
,	O
p12	B-protein
(	O
I	I-protein
)	O
increases	O
signal	B-protein
transducers	I-protein
and	I-protein
activators	I-protein
of	I-protein
transcription	I-protein
5	I-protein
(	O
STAT5	B-protein
)	O
DNA	O
binding	I-protein
and	I-protein
transcriptional	O
activity	I-protein
and	I-protein
this	O
effect	O
depends	O
on	I-protein
the	I-protein
presence	O
of	I-protein
both	O
IL-2R	B-protein
beta	I-protein
and	I-protein
gamma	I-protein
(	O
c	I-protein
)	O
chains	I-protein
and	I-protein
Jak3	B-protein
.	O

Transduction	O
of	I-protein
primary	O
human	O
peripheral	O
blood	O
mononuclear	O
cells	I-protein
(	O
PBMCs	O
)	O
with	I-protein
a	I-protein
human	O
immunodeficiency	I-protein
virus	I-protein
type	O
1-based	O
retroviral	O
vector	O
expressing	O
p12	B-protein
(	O
I	I-protein
)	O
also	O
resulted	O
in	I-protein
increased	I-protein
STAT5	B-protein
phosphorylation	I-protein
and	I-protein
DNA	O
binding	I-protein
.	O

However	O
,	O
p12	B-protein
(	O
I	I-protein
)	O
could	O
increase	O
proliferation	I-protein
of	I-protein
human	O
PBMCs	O
only	I-protein
after	O
stimulation	I-protein
of	I-protein
T-cell	B-protein
receptors	I-protein
by	I-protein
treatment	O
of	I-protein
cells	I-protein
with	I-protein
low	O
concentrations	O
of	I-protein
alphaCD3	B-protein
and	I-protein
alphaCD28	I-protein
antibodies	I-protein
.	O

In	O
addition	O
,	O
the	I-protein
proliferative	O
advantage	O
of	I-protein
p12	B-protein
(	O
I	I-protein
)	O
-transduced	O
PBMCs	O
was	O
evident	O
mainly	O
at	I-protein
low	O
concentrations	O
of	I-protein
IL-2	B-protein
.	O

Together	O
,	O
these	O
data	O
indicate	O
that	O
p12	B-protein
(	O
I	I-protein
)	O
may	O
confer	O
a	I-protein
proliferative	O
advantage	O
on	I-protein
HTLV-1-infected	O
cells	I-protein
in	I-protein
the	I-protein
presence	O
of	I-protein
suboptimal	O
antigen	O
stimulation	I-protein
and	I-protein
that	O
this	O
event	O
may	O
account	O
for	I-protein
the	I-protein
clonal	O
proliferation	I-protein
of	I-protein
infected	O
T	O
cells	I-protein
in	I-protein
vivo	O
.	O

(	O
Blood.	O
2001	O
;	O
98	I-protein
:	O
823-829	O
)	O

###MEDLINE:21359034

Single	O
dose	O
intranasal	O
administration	O
of	I-protein
retinal	B-protein
autoantigen	I-protein
generates	O
a	I-protein
rapid	O
accumulation	I-protein
and	I-protein
cell	O
activation	I-protein
in	I-protein
draining	O
lymph	O
node	I-protein
and	I-protein
spleen	B-protein
:	O
implications	O
for	I-protein
tolerance	I-protein
therapy	O
.	O

BACKGROUND/AIMS	O
:	O
A	O
single	O
intranasal	O
delivery	O
of	I-protein
retinal	B-protein
autoantigen	I-protein
suppresses	O
effectively	O
experimental	O
autoimmune	B-protein
uveoretinitis	O
(	O
EAU	O
)	O
.	O

To	O
further	O
unravel	O
underlying	O
mechanisms	O
the	I-protein
authors	O
wished	O
to	I-protein
determine	O
,	O
firstly	O
,	O
the	I-protein
kinetics	O
of	I-protein
antigen	O
delivery	O
and	I-protein
,	O
secondly	O
,	O
the	I-protein
early	O
cellular	O
responses	O
involved	I-protein
in	I-protein
the	I-protein
initial	O
stages	O
of	I-protein
nasal	O
mucosal	O
tolerance	I-protein
induction	I-protein
.	O

METHODS	O
:	O
Flow	O
cytometry	O
,	O
cell	O
proliferation	I-protein
assays	O
,	O
and	I-protein
microscopy	O
were	O
used	O
to	I-protein
track	O
antigen	B-protein
following	O
a	I-protein
single	O
,	O
intranasal	O
dose	O
of	I-protein
Alexa-488	B-protein
labelled	I-protein
retinal	I-protein
antigen	I-protein
.	O

RESULTS	O
:	O
A	O
rapid	O
accumulation	I-protein
of	I-protein
antigen	O
within	B-protein
both	O
superficial	I-protein
cervical	I-protein
lymph	O
nodes	O
(	O
SCLN	O
)	O
and	I-protein
spleen	B-protein
was	O
observed	O
after	O
30	I-protein
minutes	O
.	O

Significant	O
proliferative	O
responses	O
to	I-protein
IRBP	B-protein
were	O
elicited	O
by	I-protein
48	I-protein
hours	O
indicating	O
that	O
systemic	B-protein
priming	O
of	I-protein
naive	O
T	O
cells	I-protein
to	I-protein
retinal	B-protein
antigen	I-protein
had	O
occurred	O
.	O

Cell	I-protein
activation	I-protein
was	O
further	O
confirmed	O
by	I-protein
immunoprecipitation	O
studies	O
,	O
which	O
demonstrated	O
phosphorylation	I-protein
of	I-protein
STAT4	B-protein
but	O
not	I-protein
STAT6	B-protein
in	I-protein
both	O
lymph	O
nodes	O
and	I-protein
spleen	B-protein
.	O

However	O
,	O
at	I-protein
24	I-protein
hours	O
,	O
STAT4	B-protein
heterodimerisation	O
with	I-protein
STAT	B-protein
3	I-protein
was	O
only	I-protein
observed	O
in	I-protein
spleen	B-protein
.	O

CONCLUSIONS	O
:	O
The	O
results	O
provide	O
novel	O
evidence	O
that	O
following	O
a	I-protein
single	O
intranasal	O
application	O
rapid	O
transfer	O
of	I-protein
antigen	B-protein
occurs	O
.	O

Resulting	O
T	O
cell	O
proliferation	I-protein
develops	O
consequent	O
to	I-protein
differential	O
cell	O
signalling	I-protein
in	I-protein
SCLN	O
and	I-protein
spleen	B-protein
.	O

Further	O
understanding	O
of	I-protein
these	O
underlying	O
cellular	O
mechanisms	O
,	O
in	I-protein
particular	O
as	O
is	O
inferred	O
by	I-protein
the	I-protein
results	O
the	I-protein
contribution	O
of	I-protein
local	O
versus	O
systemic	B-protein
tolerance	I-protein
induction	I-protein
,	O
may	O
assist	O
in	I-protein
strategies	O
to	I-protein
clinically	O
apply	O
mucosal	O
tolerance	I-protein
therapy	O
successfully	O
.	O

###MEDLINE:21351024

Regulation	O
of	I-protein
interleukin	B-protein
(	O
IL	I-protein
)	O
-18	I-protein
receptor	I-protein
alpha	I-protein
chain	I-protein
expression	I-protein
on	I-protein
CD4	B-protein
(	O
+	O
)	O
T	O
cells	I-protein
during	I-protein
T	O
helper	I-protein
(	O
Th	O
)	O
1/Th2	O
differentiation	I-protein
.	O

Critical	O
downregulatory	O
role	O
of	I-protein
IL-4	B-protein
.	O

Interleukin	B-protein
(	O
IL	I-protein
)	O
-18	I-protein
has	O
been	O
well	O
characterized	O
as	O
a	I-protein
costimulatory	O
factor	I-protein
for	I-protein
the	I-protein
induction	I-protein
of	I-protein
IL-12-mediated	B-protein
interferon	I-protein
(	O
IFN	B-protein
)	O
-gamma	I-protein
production	I-protein
by	I-protein
T	O
helper	I-protein
(	O
Th	O
)	O
1	I-protein
cells	I-protein
,	O
but	O
also	O
can	O
induce	O
IL-4	B-protein
production	I-protein
and	I-protein
thus	O
facilitate	O
the	I-protein
differentiation	I-protein
of	I-protein
Th2	O
cells	I-protein
.	O

To	O
determine	O
the	I-protein
mechanisms	O
by	I-protein
which	O
IL-18	B-protein
might	O
regulate	O
these	O
diametrically	O
distinct	O
immune	O
responses	O
,	O
we	O
have	O
analyzed	O
the	I-protein
role	O
of	I-protein
cytokines	B-protein
in	I-protein
the	I-protein
regulation	I-protein
of	I-protein
IL-18	B-protein
receptor	I-protein
alpha	I-protein
chain	I-protein
(	O
IL-18Ralpha	B-protein
)	O
expression	I-protein
.	O

The	O
majority	O
of	I-protein
peripheral	O
CD4	B-protein
(	O
+	O
)	O
T	O
cells	I-protein
constitutively	O
expressed	O
the	I-protein
IL-18Ralpha	B-protein
.	O

Upon	O
antigen	O
stimulation	I-protein
in	I-protein
the	I-protein
presence	O
of	I-protein
IL-12	B-protein
,	O
marked	O
enhancement	O
of	I-protein
IL-18Ralpha	B-protein
expression	I-protein
was	O
observed	O
.	O

IL-12	B-protein
-mediated	O
upregulation	O
of	I-protein
IL-18Ralpha	B-protein
required	O
IFN-gamma	B-protein
.	O

Activated	I-protein
CD4	B-protein
(	O
+	O
)	O
T	O
cells	I-protein
that	O
expressed	O
low	O
levels	I-protein
of	I-protein
IL-18Ralpha	B-protein
could	O
produce	O
IFN-gamma	B-protein
when	O
stimulated	O
with	I-protein
the	I-protein
combination	O
of	I-protein
IL-12	B-protein
and	I-protein
IL-18	B-protein
,	O
while	O
CD4	B-protein
(	O
+	O
)	O
cells	I-protein
which	O
expressed	O
high	O
levels	I-protein
of	I-protein
IL-18Ralpha	B-protein
could	O
respond	O
to	I-protein
IL-18	B-protein
alone	O
.	O

In	O
contrast	O
,	O
T	O
cell	O
stimulation	I-protein
in	I-protein
the	I-protein
presence	O
of	I-protein
IL-4	B-protein
resulted	O
in	I-protein
a	I-protein
downregulation	O
of	I-protein
IL-18Ralpha	B-protein
expression	I-protein
.	O

Both	O
IL-4	B-protein
(	O
-/	O
)	O
-	O
and	I-protein
signal	O
transducer	O
and	I-protein
activator	O
of	I-protein
transcription	O
(	O
Stat	O
)	O
6	I-protein
(	O
-/	O
)	O
-	O
T	O
cells	I-protein
expressed	O
higher	O
levels	I-protein
of	I-protein
IL-18Ralpha	B-protein
after	O
TCR	O
stimulation	I-protein
.	O

Furthermore	O
,	O
activated	O
T	O
cells	I-protein
from	I-protein
Stat6	O
(	O
-/	O
)	O
-	O
mice	O
produced	O
more	O
IFN-gamma	B-protein
in	I-protein
response	I-protein
to	I-protein
IL-18	B-protein
than	I-protein
wild-type	I-protein
controls	O
.	O

Thus	O
,	O
positive/negative	O
regulation	I-protein
of	I-protein
the	I-protein
IL-18Ralpha	B-protein
by	I-protein
the	I-protein
major	O
inductive	O
cytokines	B-protein
(	O
IL-12	B-protein
and	I-protein
IL-4	B-protein
)	O
determines	O
the	I-protein
capacity	O
of	I-protein
IL-18	B-protein
to	I-protein
polarize	O
an	I-protein
immune	O
response	I-protein
.	O

###MEDLINE:21342532

Glucocorticoid-regulated	B-protein
transcription	I-protein
factors	I-protein
.	O

Glucocorticoids	O
are	O
the	I-protein
most	O
effective	O
antiinflammatory	O
drugs	O
used	O
in	I-protein
the	I-protein
treatment	O
of	I-protein
asthma	I-protein
.	O

They	O
act	O
by	I-protein
binding	I-protein
to	I-protein
a	I-protein
specific	I-protein
receptor	O
(	O
GR	B-protein
)	O
that	O
,	O
upon	O
activation	I-protein
,	O
translocates	O
to	I-protein
the	I-protein
nucleus	I-protein
and	I-protein
either	O
increases	O
(	O
transactivates	O
)	O
or	I-protein
decreases	O
(	O
transrepresses	O
)	O
gene	O
expression	I-protein
.	O

Inhibition	O
of	I-protein
pro-inflammatory	B-protein
transcription	I-protein
factors	I-protein
such	O
as	O
activator	B-protein
protein	I-protein
(	O
AP	I-protein
)	O
-1	I-protein
,	O
signal	B-protein
transducers	I-protein
and	I-protein
activators	I-protein
of	I-protein
transcription	I-protein
(	O
STATs	B-protein
)	O
,	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	O
T	O
cells	I-protein
(	O
NFAT	B-protein
)	O
and	I-protein
nuclear	B-protein
factor	I-protein
(	O
NF	I-protein
)	O
-kappa	I-protein
B	I-protein
is	O
thought	O
to	I-protein
be	O
a	I-protein
major	O
action	O
of	I-protein
glucocorticoids	O
.	O

Acetylation	O
of	I-protein
histones	O
allows	O
unwinding	O
of	I-protein
the	I-protein
local	O
DNA	O
structure	O
and	I-protein
enables	O
RNA	B-protein
polymerase	I-protein
II	I-protein
to	I-protein
enhance	O
gene	O
transcription	O
.	O

Histone	I-protein
acetylation	O
is	O
regulated	O
by	I-protein
a	I-protein
balance	O
between	O
the	I-protein
activity	I-protein
of	I-protein
histone	B-protein
acetyltransferases	I-protein
(	O
HATs	O
)	O
and	I-protein
histone	B-protein
deacetylases	I-protein
(	O
HDACs	O
)	O
.	O

GR	B-protein
acts	O
as	O
a	I-protein
direct	O
inhibitor	O
of	I-protein
NF-kappa	O
B-induced	O
HAT	B-protein
activity	I-protein
and	I-protein
also	O
by	I-protein
recruiting	O
HDAC2	B-protein
to	I-protein
the	I-protein
NF-kappa	B-protein
B/HAT	I-protein
complex	I-protein
.	O

A	O
sub-group	O
of	I-protein
patients	O
with	I-protein
glucocorticoid-insensitive	O
asthma	I-protein
have	O
an	I-protein
inability	O
to	I-protein
induce	O
histone	O
acetylation	O
in	I-protein
response	I-protein
to	I-protein
dexamethasone	O
suggesting	O
reduced	O
expression	I-protein
of	I-protein
a	I-protein
GR-specific	B-protein
HAT	B-protein
.	O

This	O
suggests	O
that	O
pharmacological	O
manipulation	O
of	I-protein
specific	I-protein
histone	O
acetylation	O
status	I-protein
is	O
a	I-protein
potentially	O
useful	O
approach	O
for	I-protein
the	I-protein
treatment	O
of	I-protein
inflammatory	O
diseases	O
.	O

Identification	O
of	I-protein
the	I-protein
precise	O
mechanism	O
by	I-protein
which	O
activated	O
GR	B-protein
recruits	O
HDAC2	B-protein
may	O
reveal	O
new	I-protein
targets	O
for	I-protein
the	I-protein
development	O
of	I-protein
drugs	O
that	O
may	O
dissociate	O
the	I-protein
antiinflammatory	O
actions	O
of	I-protein
glucocorticoids	O
from	I-protein
their	O
side	O
effects	O
that	O
are	O
largely	O
due	I-protein
to	I-protein
gene	O
induction	I-protein
.	O

Copyright	O
Academic	O
Press	O
.	O

###MEDLINE:21336830

Differential	O
ultraviolet-B-induced	O
immunomodulation	O
in	I-protein
XPA	B-protein
,	O
XPC	B-protein
,	O
and	I-protein
CSB	B-protein
DNA	O
repair-deficient	O
mice	O
.	O

Ultraviolet	B-protein
B	O
irradiation	O
has	O
serious	O
consequences	O
for	I-protein
cellular	O
immunity	O
and	I-protein
can	O
suppress	O
the	I-protein
rejection	O
of	I-protein
skin	O
tumors	I-protein
and	I-protein
the	I-protein
resistance	O
to	I-protein
infectious	O
diseases	O
.	O

DNA	O
damage	I-protein
plays	O
a	I-protein
crucial	O
role	O
in	I-protein
these	O
immunomodulatory	O
effects	O
of	I-protein
ultraviolet	O
B	O
,	O
as	O
impaired	O
repair	I-protein
of	I-protein
ultraviolet-B-induced	O
DNA	O
damage	I-protein
has	O
been	O
shown	O
to	I-protein
cause	O
suppression	O
of	I-protein
cellular	O
immunity	O
.	O

Ultraviolet-B-induced	O
DNA	O
damage	I-protein
is	O
repaired	O
by	I-protein
the	I-protein
nucleotide	O
excision	O
repair	I-protein
mechanism	O
very	O
efficiently	O
.	O

Nucleotide	O
excision	O
repair	I-protein
comprises	O
two	O
subpathways	O
:	O
transcription-coupled	O
and	I-protein
global	O
genome	I-protein
repair	I-protein
.	O

In	O
this	O
study	O
the	I-protein
immunologic	O
consequences	O
of	I-protein
specific	I-protein
nucleotide	O
excision	O
repair	I-protein
defects	I-protein
in	I-protein
three	O
mouse	I-protein
models	O
,	O
XPA	B-protein
,	O
XPC	B-protein
,	O
and	I-protein
CSB	B-protein
mutant	O
mice	O
,	O
were	O
investigated	O
.	O

XPA	B-protein
mice	O
carry	O
a	I-protein
total	O
nucleotide	O
excision	O
repair	I-protein
defect	I-protein
,	O
whereas	O
XPC	B-protein
and	I-protein
CSB	B-protein
mice	O
only	I-protein
lack	O
global	O
genome	I-protein
and	I-protein
transcription-coupled	O
nucleotide	O
excision	O
repair	I-protein
,	O
respectively	O
.	O

Our	O
data	O
demonstrate	O
that	O
cellular	O
immune	O
parameters	O
in	I-protein
XPA	B-protein
,	O
XPC	B-protein
,	O
and	I-protein
CSB	B-protein
mice	O
are	O
normal	O
compared	O
with	I-protein
their	O
wild-type	I-protein
(	O
control	I-protein
)	O
littermates	O
.	O

This	O
may	O
indicate	O
that	O
the	I-protein
reported	O
altered	I-protein
cellular	O
responses	O
in	I-protein
xeroderma	O
pigmentosum	I-protein
patients	O
are	O
not	I-protein
constitutive	I-protein
but	O
could	O
be	O
due	I-protein
to	I-protein
external	I-protein
factors	I-protein
,	O
such	O
as	O
ultraviolet	O
B	O
.	O

Upon	O
exposure	O
to	I-protein
ultraviolet	O
B	O
,	O
only	I-protein
XPA	B-protein
mice	O
are	O
very	O
sensitive	I-protein
to	I-protein
ultraviolet-B-induced	O
inhibition	O
of	I-protein
Th1-mediated	O
contact	O
hypersensitivity	O
responses	O
and	I-protein
interferon-gamma	B-protein
production	I-protein
in	I-protein
skin	O
draining	O
lymph	O
nodes	O
.	O

Lipopolysaccharide-stimulated	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
and	I-protein
interleukin-10	B-protein
production	I-protein
are	O
significantly	O
augmented	O
in	I-protein
both	O
XPA	B-protein
and	I-protein
CSB	B-protein
mice	O
after	O
ultraviolet	O
B	O
exposure	O
.	O

Lymph	O
node	I-protein
cell	O
numbers	O
were	O
increased	I-protein
very	O
significantly	O
in	I-protein
XPA	B-protein
,	O
mildly	O
increased	I-protein
in	I-protein
CSB	B-protein
,	O
and	I-protein
not	I-protein
in	I-protein
XPC	B-protein
mice	O
.	O

In	O
general	O
XPC	B-protein
mice	O
do	O
not	I-protein
exhibit	O
any	O
indication	O
of	I-protein
enhanced	I-protein
ultraviolet	O
B	O
susceptibility	I-protein
with	I-protein
regard	O
to	I-protein
the	I-protein
immune	O
parameters	O
analyzed	O
.	O

These	O
data	O
suggest	O
that	O
both	O
global	O
genome	I-protein
repair	I-protein
and	I-protein
transcription-coupled	O
repair	I-protein
are	O
needed	O
to	I-protein
prevent	O
immunomodulation	O
by	I-protein
ultraviolet	O
B	O
,	O
whereas	O
transcription-coupled	O
repair	I-protein
is	O
the	I-protein
major	O
DNA	O
repair	I-protein
subpathway	O
of	I-protein
nucleotide	O
excision	O
repair	I-protein
that	O
prevents	O
the	I-protein
acute	O
ultraviolet-B-induced	O
effects	O
such	O
as	O
erythema	I-protein
.	O

###MEDLINE:21328827

Biomechanical	O
strain	O
induces	O
class	O
a	I-protein
scavenger	B-protein
receptor	I-protein
expression	I-protein
in	I-protein
human	O
monocyte/macrophages	O
and	I-protein
THP-1	O
cells	I-protein
:	O
a	I-protein
potential	I-protein
mechanism	O
of	I-protein
increased	I-protein
atherosclerosis	B-protein
in	I-protein
hypertension	O
.	O

BACKGROUND	O
:	O
Although	O
hypertension	O
is	O
an	I-protein
important	O
risk	O
factor	I-protein
for	I-protein
the	I-protein
development	O
of	I-protein
atherosclerosis	B-protein
,	O
the	I-protein
mechanisms	O
for	I-protein
this	O
interaction	I-protein
are	O
incompletely	O
described	O
.	O

Previous	O
studies	O
have	O
suggested	O
that	O
biomechanical	O
strain	O
regulates	O
macrophage	O
phenotype	O
.	O

We	O
tested	O
the	I-protein
hypothesis	O
that	O
biomechanical	O
strain	O
can	O
induce	O
expression	I-protein
of	I-protein
the	I-protein
class	B-protein
A	I-protein
scavenger	I-protein
receptor	I-protein
(	O
SRA	B-protein
)	O
,	O
an	I-protein
important	O
lipoprotein	B-protein
receptor	I-protein
in	I-protein
atherogenesis	O
.	O

METHODS	O
AND	O
RESULTS	O
:	O
Human	O
monocyte/macrophages	O
or	I-protein
THP-1	O
cells	I-protein
were	O
cultured	O
in	I-protein
a	I-protein
device	O
that	O
imposes	O
uniform	O
biaxial	O
cyclic	O
1-Hz	O
strains	O
of	I-protein
0	I-protein
%	O
,	O
1	I-protein
%	O
,	O
2	I-protein
%	O
,	O
or	I-protein
3	O
%	O
,	O
and	I-protein
SRA	B-protein
expression	I-protein
was	O
analyzed	O
.	O

Mechanical	O
strains	O
induced	I-protein
SRA	B-protein
mRNA	O
(	O
3.5+/-0.6-fold	O
at	I-protein
3	O
%	O
strain	O
for	I-protein
48	I-protein
hours	O
,	O
P	O
<	O
0.01	O
)	O
and	I-protein
SRA	B-protein
protein	I-protein
in	I-protein
THP-1	O
cells	I-protein
in	I-protein
an	I-protein
amplitude-dependent	O
manner	O
.	O

This	O
induction	I-protein
was	O
accompanied	O
by	I-protein
augmented	O
expression	I-protein
of	I-protein
the	I-protein
class	B-protein
B	I-protein
scavenger	I-protein
receptor	I-protein
CD36	B-protein
(	O
2.8+/-0.3-fold	O
,	O
P	O
<	O
0.001	O
)	O
but	O
not	I-protein
by	I-protein
increased	I-protein
peroxisome	B-protein
proliferator-activated	I-protein
receptor-gamma	I-protein
expression	I-protein
.	O

To	O
evaluate	O
this	O
effect	O
in	I-protein
vivo	O
,	O
apolipoprotein	O
E	O
(	O
-/-	O
)	O
mice	O
were	O
randomly	O
assigned	O
to	I-protein
receive	O
standard	O
chow	O
,	O
a	I-protein
high-cholesterol	O
diet	O
,	O
or	I-protein
a	I-protein
high-cholesterol	O
diet	O
with	I-protein
hypertension	O
induced	I-protein
by	I-protein
angiotensin	B-protein
II	I-protein
infusion	O
for	I-protein
8	I-protein
weeks	O
.	O

Immunohistochemistry	O
revealed	O
that	O
among	O
macrophages	O
in	I-protein
atherosclerotic	O
lesions	O
of	I-protein
the	I-protein
aorta	I-protein
,	O
the	I-protein
proportion	O
of	I-protein
macrophages	O
with	I-protein
SRA	B-protein
expression	I-protein
was	O
highest	O
in	I-protein
hypertensive	O
animals	O
on	I-protein
a	I-protein
high-cholesterol	O
diet	O
(	O
43.9+/-0.7	O
%	O
,	O
versus	O
12.0+/-2.0	O
%	O
for	I-protein
normotensive	O
animals	O
on	I-protein
a	I-protein
high-cholesterol	O
diet	O
and	I-protein
4.7+/-4.7	O
%	O
for	I-protein
animals	O
on	I-protein
standard	O
chow	O
;	O
P	O
<	O
0.001	O
)	O
.	O

CONCLUSIONS	O
:	O
Biomechanical	O
strain	O
induces	O
SRA	B-protein
expression	I-protein
by	I-protein
monocyte/macrophages	O
,	O
suggesting	O
a	I-protein
novel	O
mechanism	O
for	I-protein
promotion	O
of	I-protein
atherosclerosis	B-protein
in	I-protein
hypertensive	O
patients	O
.	O

###MEDLINE:21316949

High	O
glucose	O
induces	O
MCP-1	B-protein
expression	I-protein
partly	O
via	I-protein
tyrosine	O
kinase-AP-1	O
pathway	I-protein
in	I-protein
peritoneal	O
mesothelial	O
cells	I-protein
.	O

BACKGROUND	O
:	O
High	O
glucose	O
in	I-protein
peritoneal	O
dialysis	O
solutions	O
has	O
been	O
implicated	O
in	I-protein
the	I-protein
pathogenesis	O
of	I-protein
peritoneal	O
fibrosis	O
in	I-protein
chronic	O
ambulatory	O
peritoneal	O
dialysis	O
(	O
CAPD	O
)	O
patients	O
.	O

However	O
,	O
the	I-protein
mechanisms	O
are	O
not	I-protein
very	O
clear	I-protein
.	O

Peritoneal	O
macrophages	O
seem	O
to	I-protein
participate	O
in	I-protein
the	I-protein
process	O
of	I-protein
peritoneal	O
fibrosis	O
and	I-protein
monocyte	B-protein
chemoattractant	I-protein
protein-1	I-protein
(	O
MCP-1	B-protein
)	O
plays	O
a	I-protein
key	O
role	O
in	I-protein
the	I-protein
recruitment	I-protein
of	I-protein
monocytes	O
toward	O
the	I-protein
peritoneal	O
cavity	O
.	O

However	O
,	O
little	O
is	O
known	O
about	O
the	I-protein
effect	O
of	I-protein
high	O
glucose	O
on	I-protein
MCP-1	B-protein
expression	I-protein
and	I-protein
its	O
signal	O
transduction	I-protein
pathway	I-protein
in	I-protein
human	O
peritoneal	O
mesothelial	O
cells	I-protein
.	O

METHODS	O
:	O
Mesothelial	O
cells	I-protein
were	O
cultured	O
with	I-protein
glucose	O
(	O
5	O
to	I-protein
100	I-protein
mmol/L	O
)	O
or	I-protein
mannitol	O
chronically	O
for	I-protein
up	O
to	I-protein
seven	O
days	O
.	O

MCP-1	B-protein
expression	I-protein
of	I-protein
mRNA	O
and	I-protein
protein	O
was	O
measured	O
by	I-protein
Northern	O
blot	O
analysis	O
and	I-protein
enzyme-linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
.	O

Chemotactic	O
activity	I-protein
of	I-protein
high-glucose-conditioned	O
culture	O
supernatant	O
was	O
measured	O
by	I-protein
chemotactic	I-protein
assay	O
.	O

To	O
examine	O
the	I-protein
roles	O
of	I-protein
the	I-protein
transcription	B-protein
factors	I-protein
activator	B-protein
protein-1	I-protein
(	O
AP-1	I-protein
)	O
and	I-protein
nuclear	B-protein
factor-kappaB	I-protein
(	O
NF-kappaB	B-protein
)	O
,	O
electrophoretic	O
mobility	I-protein
shift	O
assay	O
(	O
EMSA	O
)	O
was	O
performed	O
.	O

RESULTS	O
:	O
Glucose	O
induced	I-protein
MCP-1	B-protein
mRNA	O
expression	I-protein
in	I-protein
a	I-protein
time-	O
and	I-protein
dose-dependent	O
manner	O
.	O

MCP-1	B-protein
protein	I-protein
in	I-protein
cell	O
culture	O
supernant	O
was	O
also	O
increased	I-protein
.	O

Equivalent	O
concentrations	O
of	I-protein
mannitol	O
had	O
no	I-protein
significant	O
effect	O
.	O

High-glucose-conditioned	O
supernatant	O
possessed	O
an	I-protein
increased	I-protein
chemotactic	I-protein
activity	I-protein
for	I-protein
monocytes	O
,	O
which	O
was	O
neutralized	O
by	I-protein
anti-MCP-1	B-protein
antibody	I-protein
.	O

EMSA	O
revealed	O
that	O
glucose	O
increased	I-protein
the	I-protein
AP-1	I-protein
binding	I-protein
activity	I-protein
in	I-protein
a	I-protein
time-	O
and	I-protein
dose-dependent	O
manner	O
,	O
but	O
not	I-protein
NF-kappaB	B-protein
.	O

Curcumin	O
,	O
an	I-protein
inhibitor	O
of	I-protein
AP-1	I-protein
,	O
dose-dependently	O
suppressed	I-protein
the	I-protein
induction	I-protein
of	I-protein
MCP-1	B-protein
mRNA	O
by	I-protein
high	O
glucose	O
.	O

Tyrosine	O
kinase	O
inhibitors	I-protein
such	O
as	O
genistein	O
(	O
12.5	O
to	I-protein
50	I-protein
micromol/L	O
)	O
and	I-protein
herbimycin	O
A	O
(	O
0.1	O
to	I-protein
1	I-protein
micromol/L	O
)	O
inhibited	O
the	I-protein
high-glucose-induced	O
MCP-1	B-protein
mRNA	O
expression	I-protein
in	I-protein
a	I-protein
dose-dependent	O
manner	O
,	O
and	I-protein
also	O
suppressed	I-protein
the	I-protein
high-glucose-induced	O
AP-1	I-protein
binding	I-protein
activity	I-protein
.	O

CONCLUSIONS	O
:	O
:	O
High	O
glucose	O
induced	I-protein
mesothelial	O
MCP-1	B-protein
expression	I-protein
partly	O
via	I-protein
the	I-protein
tyrosine	O
kinase-	O
AP-1	I-protein
pathway	I-protein
.	O

###MEDLINE:21311861

Signal	I-protein
thresholds	O
and	I-protein
modular	I-protein
synergy	O
during	I-protein
expression	I-protein
of	I-protein
costimulatory	B-protein
molecules	I-protein
in	I-protein
B	O
lymphocytes	O
.	O

We	O
analyzed	O
intracellular	I-protein
pathways	O
modulating	I-protein
surface	O
densities	O
of	I-protein
CD80	B-protein
and	I-protein
CD86	B-protein
in	I-protein
B	O
cells	I-protein
activated	O
through	I-protein
ligation	O
of	I-protein
the	I-protein
Ag	I-protein
receptor	I-protein
,	O
and	I-protein
the	I-protein
adhesion	B-protein
molecule	I-protein
CD54	B-protein
.	O

Whereas	O
B	B-protein
cell	I-protein
Ag	I-protein
receptor	I-protein
(	O
BCR	B-protein
)	O
cross-linking	O
alone	O
stimulated	O
increased	I-protein
expression	I-protein
of	I-protein
CD86	B-protein
,	O
up-regulation	O
of	I-protein
CD80	B-protein
required	O
dual	O
stimulation	I-protein
with	I-protein
anti-IgM	O
and	I-protein
anti-CD54	O
.	O

The	O
principal	O
downstream	O
component	O
contributed	O
by	I-protein
BCR	B-protein
signaling	O
,	O
toward	O
both	O
CD80	B-protein
and	I-protein
CD86	B-protein
induction	I-protein
,	O
was	O
the	I-protein
elevated	I-protein
concentration	I-protein
of	I-protein
free	B-protein
cytoplasmic	O
Ca	O
(	O
2+	I-protein
)	O
,	O
recruited	O
by	I-protein
way	O
of	I-protein
capacitative	O
influx	O
.	O

This	O
alone	O
was	O
sufficient	O
to	I-protein
generate	O
an	I-protein
increase	O
in	I-protein
CD86	B-protein
levels	I-protein
.	O

However	O
,	O
CD80	B-protein
enhancement	O
required	O
the	I-protein
concerted	O
action	O
of	I-protein
both	O
intracellular	I-protein
Ca	O
(	O
2+	I-protein
)	O
concentration	I-protein
and	I-protein
CD54-initiated	O
pathways	O
.	O

The	O
nexus	O
between	O
anti-IgM	O
and	I-protein
anti-CD54	O
stimulation	I-protein
,	O
in	I-protein
the	I-protein
context	O
of	I-protein
CD80	B-protein
regulation	I-protein
,	O
was	O
identified	I-protein
to	I-protein
involve	O
a	I-protein
self-propagating	O
process	O
of	I-protein
sequential	O
synergy	O
.	O

The	O
first	O
step	O
involved	I-protein
amplified	O
accumulation	I-protein
of	I-protein
intracellular	I-protein
cAMP	O
,	O
as	O
a	I-protein
result	O
of	I-protein
cross-talk	O
between	O
BCR	B-protein
-mobilized	O
Ca	O
(	O
2+	I-protein
)	O
and	I-protein
CD54-derived	O
signals	I-protein
.	O

This	O
then	O
facilitated	I-protein
a	I-protein
second	O
synergistic	O
interaction	I-protein
between	O
Ca	O
(	O
2+	I-protein
)	O
and	I-protein
cAMP	O
,	O
culminating	O
in	I-protein
CD80	B-protein
expression	I-protein
.	O

Our	O
findings	O
of	I-protein
distinct	O
signal	O
transducer	O
requirements	O
,	O
with	I-protein
the	I-protein
added	O
consequences	O
of	I-protein
cross-talk	O
,	O
offers	O
an	I-protein
explanation	O
for	I-protein
variable	O
modulation	O
of	I-protein
costimulatory	O
molecule	I-protein
expression	I-protein
in	I-protein
response	I-protein
to	I-protein
diverse	O
physiological	O
stimuli	O
.	O

Importantly	O
,	O
these	O
results	O
also	O
reveal	O
how	O
concentration	I-protein
threshold	I-protein
barriers	O
for	I-protein
recruitment	I-protein
of	I-protein
individual	O
second	O
messengers	O
can	O
be	O
overcome	O
by	I-protein
constructive	O
convergence	O
of	I-protein
signaling	O
modules	O
.	O

###MEDLINE:21301916

The	O
role	O
of	I-protein
Epstein-Barr	B-protein
virus	I-protein
in	I-protein
neoplastic	I-protein
transformation	I-protein
.	O

In	O
this	O
review	O
,	O
we	O
focus	I-protein
on	I-protein
new	I-protein
data	O
from	I-protein
basic	O
,	O
translational	I-protein
and	I-protein
clinical	I-protein
research	O
relating	O
to	I-protein
the	I-protein
Epstein-Barr	B-protein
virus	I-protein
(	O
EBV	O
)	O
.	O

Beside	O
its	O
well-known	O
tropism	O
for	I-protein
B	O
lymphocytes	O
and	I-protein
epithelial	O
cells	I-protein
,	O
EBV	O
also	O
infects	O
T	O
lymphocytes	O
,	O
monocytes	O
and	I-protein
granulocytes	O
.	O

After	O
primary	O
infection	I-protein
,	O
EBV	O
persists	O
throughout	O
the	I-protein
life	O
span	O
in	I-protein
resting	O
memory	O
B	O
cells	I-protein
,	O
from	I-protein
where	O
it	O
is	O
reactivated	O
upon	O
breakdown	O
of	I-protein
cellular	O
immunity	O
.	O

In	O
the	I-protein
process	O
of	I-protein
neoplastic	I-protein
transformation	I-protein
,	O
the	I-protein
EBV-encoded	O
latent	B-protein
membrane	O
protein	O
1	I-protein
(	O
LMP1	B-protein
)	O
oncogene	I-protein
represents	O
the	I-protein
major	O
driving	O
force	O
.	O

LMP1	O
acts	O
like	I-protein
a	I-protein
constitutively	B-protein
activated	I-protein
receptor	I-protein
of	I-protein
the	I-protein
tumor	B-protein
necrosis	I-protein
factor	I-protein
receptor	I-protein
family	I-protein
and	I-protein
allows	O
the	I-protein
amplification	O
or	I-protein
bypassing	O
of	I-protein
physiological	O
regulatory	O
signals	I-protein
through	I-protein
direct	O
and	I-protein
indirect	O
interactions	O
with	I-protein
proteins	I-protein
of	I-protein
the	I-protein
tumor	B-protein
necrosis	I-protein
factor	I-protein
receptor-associated	I-protein
factor	I-protein
(	O
TRAF	B-protein
)	O
family	I-protein
.	O

TRAF2	B-protein
-mediated	O
NF-kappaB	B-protein
activation	I-protein
,	O
AP-1	I-protein
induction	I-protein
and	I-protein
JAK3	B-protein
/	O
STAT	B-protein
activation	I-protein
may	O
result	O
in	I-protein
sustained	O
proliferation	I-protein
leading	O
to	I-protein
lymphoma	I-protein
.	O

The	O
ability	O
of	I-protein
LMP1	B-protein
to	I-protein
suppress	O
germinal	B-protein
center	I-protein
formation	O
and	I-protein
its	O
capacity	O
to	I-protein
mediate	O
its	O
own	O
transcriptional	O
activation	I-protein
shed	O
new	I-protein
light	I-protein
on	I-protein
the	I-protein
pathogenesis	O
of	I-protein
EBV-associated	O
latency	O
type	O
II	I-protein
lymphoproliferations	O
like	I-protein
Hodgkin	B-protein
's	I-protein
disease	I-protein
and	I-protein
angioimmunoblastic	O
lymphadenopathy	O
.	O

The	O
carboxy	B-protein
terminus	I-protein
of	I-protein
LMP1	B-protein
is	O
also	O
a	I-protein
reliable	O
marker	I-protein
for	I-protein
individual	O
EBV	O
strain	O
identification	O
and	I-protein
thus	O
offers	O
new	I-protein
possibilities	O
in	I-protein
tracing	O
the	I-protein
molecular	I-protein
events	O
leading	O
to	I-protein
posttransplant	O
lymphoproliferative	I-protein
disorders	O
(	O
PTLDs	O
)	O
.	O

Cytotoxic	O
T	O
lymphocytes	O
directed	I-protein
against	I-protein
well-characterized	O
epitopes	O
of	I-protein
EBV	O
latency	O
genes	I-protein
represent	O
an	I-protein
already	O
successful	O
and	I-protein
promising	O
therapeutic	O
approach	O
to	I-protein
EBV-associated	O
lymphomas	I-protein
,	O
in	I-protein
particular	O
PTLDs	O

###MEDLINE:21369576

Interferon-alpha	B-protein
drives	O
T	O
cell-mediated	O
immunopathology	O
in	I-protein
the	I-protein
intestine	I-protein
.	O

The	O
ability	O
of	I-protein
interferon	B-protein
(	O
IFN	B-protein
)	O
-alpha	I-protein
to	I-protein
induce	O
autoimmunity	O
and	I-protein
exacerbate	O
Th1	O
diseases	O
is	O
well	O
known	O
.	O

We	O
have	O
recently	O
described	O
enhanced	I-protein
expression	I-protein
of	I-protein
IFN-alpha	B-protein
in	I-protein
the	I-protein
mucosa	B-protein
of	I-protein
patients	O
with	I-protein
celiac	B-protein
disease	I-protein
(	O
CD	O
)	O
,	O
a	I-protein
gluten-sensitive	O
Th1-mediated	O
enteropathy	O
,	O
characterized	O
by	I-protein
villous	O
atrophy	I-protein
and	I-protein
crypt	O
cell	O
hyperplasia	I-protein
.	O

Previous	O
studies	O
from	I-protein
this	O
laboratory	O
have	O
shown	O
that	O
T	O
cell	O
activation	I-protein
in	I-protein
explant	O
cultures	O
of	I-protein
human	O
fetal	O
gut	I-protein
can	O
also	O
result	O
in	I-protein
villous	O
atrophy	I-protein
and	I-protein
crypt	O
cell	O
hyperplasia	I-protein
.	O

We	O
have	O
,	O
therefore	O
,	O
examined	O
changes	O
that	O
take	O
place	O
in	I-protein
explant	O
cultures	O
of	I-protein
human	O
fetal	O
gut	I-protein
after	O
activation	I-protein
of	I-protein
T	O
cells	I-protein
with	I-protein
anti-CD3	B-protein
and/or	O
IFN-alpha	B-protein
.	O

We	O
show	O
that	O
activation	I-protein
of	I-protein
T	O
cells	I-protein
with	I-protein
anti-CD3	B-protein
alone	O
elicits	O
a	I-protein
small	O
IFN-gamma	B-protein
and	I-protein
TNF-alpha	B-protein
response	I-protein
with	I-protein
no	I-protein
tissue	O
injury	O
.	O

Similarly	O
,	O
no	I-protein
changes	O
are	O
seen	O
in	I-protein
explants	O
cultured	O
with	I-protein
IFN-alpha	B-protein
alone	O
.	O

However	O
,	O
addition	O
of	I-protein
IFN-alpha	B-protein
with	I-protein
anti-CD3	B-protein
results	O
in	I-protein
enhanced	I-protein
Th1	O
response	I-protein
and	I-protein
crypt	O
cell	O
hyperplasia	I-protein
.	O

This	O
is	O
associated	I-protein
with	I-protein
enhanced	I-protein
phosphorylation	I-protein
of	I-protein
STAT1	B-protein
,	O
STAT3	B-protein
,	O
and	I-protein
Fyn	B-protein
,	O
a	I-protein
Src	B-protein
homology	I-protein
tyrosine	I-protein
kinase	I-protein
,	O
which	O
interacts	I-protein
with	I-protein
both	O
TCR	B-protein
and	I-protein
IFN-alpha	O
signal	O
components	O
.	O

Together	O
these	O
data	O
indicate	O
that	O
IFN-alpha	B-protein
can	O
facilitate	O
activation	I-protein
of	I-protein
Th1-reactive	O
cells	I-protein
in	I-protein
the	I-protein
gut	I-protein
and	I-protein
drive	O
immunopathology	O
.	O

###MEDLINE:21363766

Suppression	O
of	I-protein
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	O
production	I-protein
by	I-protein
cAMP	O
in	I-protein
human	O
monocytes	O
:	O
dissociation	I-protein
with	I-protein
mRNA	O
level	I-protein
and	I-protein
independent	I-protein
of	I-protein
interleukin-10	B-protein
.	O

BACKGROUND	O
:	O
Elevation	O
of	I-protein
cellular	O
cAMP	O
inhibits	I-protein
lipopolysaccharide	B-protein
(	O
LPS	B-protein
)	O
-stimulated	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
(	O
TNF-alpha	B-protein
)	O
production	I-protein
and	I-protein
increases	O
the	I-protein
expression	I-protein
of	I-protein
interleukin	B-protein
(	O
IL	I-protein
)	O
-10	I-protein
in	I-protein
mononuclear	O
cells	I-protein
.	O

TNF-alpha	B-protein
gene	O
expression	I-protein
obligates	O
activation	I-protein
of	I-protein
the	I-protein
transcription	B-protein
factor	I-protein
nuclear	I-protein
factor	I-protein
kappaB	I-protein
(	O
NF-kappaB	B-protein
)	O
.	O

Exogenous	O
IL-10	B-protein
inhibits	I-protein
NF-kappaB	B-protein
in	I-protein
monocytes	O
and	I-protein
thus	O
attenuates	O
TNF-alpha	B-protein
production	I-protein
.	O

We	O
examined	O
the	I-protein
role	O
of	I-protein
endogenous	O
IL-10	B-protein
in	I-protein
the	I-protein
regulation	I-protein
of	I-protein
NF-kappaB	B-protein
activation	I-protein
and	I-protein
TNF-alpha	B-protein
production	I-protein
in	I-protein
human	O
monocytes	O
by	I-protein
cAMP	O
.	O

METHODS	O
:	O
Human	O
monocytes	O
were	O
stimulated	O
with	I-protein
Escherichia	O
coli	I-protein
LPS	B-protein
(	O
100	I-protein
ng/ml	O
)	O
with	I-protein
and	I-protein
without	I-protein
forskolin	O
(	O
FSK	O
,	O
50	I-protein
microM	O
)	O
or	I-protein
dibutyryl	O
cyclic	O
AMP	O
(	O
dbcAMP	O
,	O
100	I-protein
microM	O
)	O
.	O

Cytokine	B-protein
(	O
TNF-alpha	B-protein
and	I-protein
IL-10	B-protein
)	O
release	I-protein
was	O
measured	O
by	I-protein
immunoassay	O
.	O

TNF-alpha	B-protein
mRNA	O
was	O
measured	O
by	I-protein
reverse	I-protein
transcription	O
polymerase	O
chain	I-protein
reaction	I-protein
,	O
and	I-protein
NF-kappaB	B-protein
DNA	O
binding	I-protein
activity	I-protein
was	O
assessed	O
by	I-protein
gel	O
mobility	I-protein
shift	O
assay	O
.	O

RESULTS	O
:	O
cAMP-elevating	O
agents	O
inhibited	O
LPS-stimulated	O
TNF-alpha	B-protein
release	I-protein
(	O
0.77	O
+/-	O
0.13	O
ng/10	O
(	O
6	I-protein
)	O
cells	I-protein
in	I-protein
LPS	B-protein
+	O
dbcAMP	O
and	I-protein
0.68	O
+/-	O
0.19	O
ng/10	O
(	O
6	I-protein
)	O
cells	I-protein
in	I-protein
LPS	B-protein
+	O
FSK	O
,	O
both	O
P	O
<	O
0.05	O
vs	O
1.61	O
+/-	O
0.34	O
ng/10	O
(	O
6	I-protein
)	O
cells	I-protein
in	I-protein
LPS	B-protein
alone	O
)	O
.	O

Conversely	O
,	O
cAMP	O
enhanced	I-protein
LPS-stimulated	O
IL-10	B-protein
release	I-protein
(	O
100	I-protein
+/-	O
21.5	O
pg/10	O
(	O
6	I-protein
)	O
cells	I-protein
in	I-protein
LPS	B-protein
+	O
dbcAMP	O
and	I-protein
110	I-protein
+/-	O
25.2	O
pg/10	O
(	O
6	I-protein
)	O
cells	I-protein
in	I-protein
LPS	B-protein
+	O
FSK	O
,	O
both	O
P	O
<	O
0.05	O
vs	O
53.3	O
+/-	O
12.8	O
pg/10	O
(	O
6	I-protein
)	O
cells	I-protein
in	I-protein
LPS	B-protein
alone	O
)	O
.	O

Neither	O
TNF-alpha	B-protein
mRNA	O
expression	I-protein
nor	O
NF-kappaB	B-protein
activation	I-protein
stimulated	O
by	I-protein
LPS	B-protein
was	O
inhibited	O
by	I-protein
the	I-protein
cAMP-elevating	O
agents	O
.	O

Neutralization	O
of	I-protein
IL-10	B-protein
with	I-protein
a	I-protein
specific	I-protein
antibody	I-protein
did	O
not	I-protein
attenuate	O
the	I-protein
effect	O
of	I-protein
cAMP-elevating	O
agents	O
on	I-protein
TNF-alpha	B-protein
production	I-protein
.	O

CONCLUSION	O
:	O
The	O
results	O
indicate	O
that	O
cAMP	O
inhibits	I-protein
LPS-stimulated	O
TNF-alpha	B-protein
production	I-protein
through	I-protein
a	I-protein
posttranscriptional	O
mechanism	O
that	O
is	O
independent	I-protein
of	I-protein
endogenous	O
IL-10	B-protein
.	O

Copyright	O
2001	O
Academic	O
Press	O
.	O

###MEDLINE:21359858

Activation	O
of	I-protein
the	I-protein
p21	O
(	O
CIP1/WAF1	O
)	O
promoter	I-protein
by	I-protein
bone	B-protein
morphogenetic	I-protein
protein-2	I-protein
in	I-protein
mouse	I-protein
B	O
lineage	I-protein
cells	I-protein
.	O

BMPs	B-protein
exert	O
a	I-protein
negative	O
growth	O
effect	O
on	I-protein
various	O
types	I-protein
of	I-protein
cells	I-protein
.	O

We	O
have	O
previously	O
reported	O
that	O
BMP-2	B-protein
inhibited	O
the	I-protein
growth	O
of	I-protein
HS-72	O
mouse	I-protein
hybridoma	O
cells	I-protein
by	I-protein
inducing	I-protein
p21	O
(	O
CIP1/WAF1	O
)	O
expression	I-protein
.	O

In	O
the	I-protein
present	O
study	O
,	O
we	O
demonstrated	O
that	O
BMP-2	B-protein
activated	O
the	I-protein
mouse	I-protein
p21	O
(	O
CIP1/WAF1	O
)	O
promoter	I-protein
in	I-protein
HS-72	O
cells	I-protein
,	O
and	I-protein
that	O
a	I-protein
29-base	O
pair	O
(	O
b	O
)	O
region	O
of	I-protein
the	I-protein
promoter	I-protein
(	O
-1928/-1900	O
relative	I-protein
to	I-protein
the	I-protein
TATA	O
box	I-protein
)	O
,	O
conserved	O
between	O
mice	O
and	I-protein
humans	O
,	O
was	O
responsive	I-protein
to	I-protein
BMP-2	B-protein
as	O
well	O
as	O
expression	I-protein
of	I-protein
Smad1	B-protein
,	O
Smad4	B-protein
,	O
and	I-protein
constitutively	O
active	O
mutants	O
of	I-protein
BMP	B-protein
type	I-protein
I	I-protein
receptors	I-protein
.	O

Furthermore	O
,	O
an	I-protein
oligonucleotide	O
containing	I-protein
the	I-protein
29-b	O
region	O
was	O
found	O
to	I-protein
be	O
associated	I-protein
with	I-protein
Smad4	B-protein
and	I-protein
phosphorylated	B-protein
Smad1	I-protein
in	I-protein
the	I-protein
nuclear	O
extract	O
of	I-protein
BMP-2	B-protein
-stimulated	O
HS-72	O
cells	I-protein
.	O

These	O
results	O
suggested	O
that	O
BMP-2	B-protein
might	O
activate	O
p21	O
(	O
CIP1/WAF1	O
)	O
transcription	O
by	I-protein
inducing	I-protein
a	I-protein
binding	I-protein
of	I-protein
Smad4	B-protein
and	I-protein
Smad1	B-protein
to	I-protein
the	I-protein
29-b	O
region	O
in	I-protein
HS-72	O
cells	I-protein
.	O

###MEDLINE:21352151

Dendritic	O
cell	O
development	O
from	I-protein
common	I-protein
myeloid	O
progenitors	O
.	O

Dendritic	O
cells	I-protein
(	O
DCs	O
)	O
are	O
professional	O
antigen-presenting	O
cells	I-protein
which	O
both	O
initiate	O
adaptive	O
immune	O
responses	O
and	I-protein
control	I-protein
tolerance	I-protein
to	I-protein
self-antigens	B-protein
.	O

It	O
has	O
been	O
suggested	O
that	O
these	O
different	O
effects	O
on	I-protein
responder	I-protein
cells	I-protein
depend	O
on	I-protein
subsets	O
of	I-protein
DCs	O
arising	O
from	I-protein
either	O
myeloid	O
or	I-protein
lymphoid	O
hematopoietic	O
origins	O
.	O

In	O
this	O
model	I-protein
,	O
CD8	O
alpha+	O
Mac-1-	O
DCs	O
are	O
supposed	O
to	I-protein
be	O
of	I-protein
lymphoid	O
while	O
CD8	O
alpha-	O
Mac-1+	O
DCs	O
are	O
supposed	O
to	I-protein
be	O
of	I-protein
myeloid	O
origin	O
.	O

Here	O
we	O
summarize	O
our	O
findings	O
that	O
both	O
CD8	O
alpha+	O
and	I-protein
CD8	O
alpha-	O
DCs	O
can	O
arise	O
from	I-protein
clonogenic	O
common	I-protein
myeloid	O
progenitors	O
(	O
CMPs	O
)	O
in	I-protein
both	O
thymus	I-protein
and	I-protein
spleen	B-protein
.	O

Therefore	O
CD8	B-protein
alpha	I-protein
expression	I-protein
DCs	O
does	O
not	I-protein
indicate	O
a	I-protein
lymphoid	O
origin	O
and	I-protein
differences	O
among	O
CD8	O
alpha+	O
and	I-protein
CD8	O
alpha-	O
DCs	O
might	O
rather	O
reflect	O
maturation	I-protein
status	I-protein
than	I-protein
ontogeny	O
.	O

On	O
the	I-protein
basis	O
of	I-protein
transplantation	I-protein
studies	O
,	O
it	O
seems	O
likely	B-protein
that	O
most	O
of	I-protein
the	I-protein
DCs	O
in	I-protein
secondary	O
lymphoid	O
organs	O
and	I-protein
a	I-protein
substantial	O
fraction	O
of	I-protein
thymic	B-protein
DCs	O
are	O
myeloid-derived	O
.	O

###MEDLINE:21341822

Macrophage	I-protein
stimulation	I-protein
with	I-protein
Murabutide	O
,	O
an	I-protein
HIV-suppressive	O
muramyl	O
peptide	O
derivative	O
,	O
selectively	O
activates	O
extracellular	B-protein
signal-regulated	I-protein
kinases	I-protein
1	I-protein
and	I-protein
2	I-protein
,	O
C/EBPbeta	B-protein
and	I-protein
STAT1	B-protein
:	O
role	O
of	I-protein
CD14	B-protein
and	I-protein
Toll-like	B-protein
receptors	I-protein
2	I-protein
and	I-protein
4	I-protein
.	O

The	O
smallest	O
unit	I-protein
of	I-protein
bacterial	I-protein
peptidoglycans	O
known	O
to	I-protein
be	O
endowed	O
with	I-protein
biological	O
activities	O
is	O
muramyl	O
dipeptide	I-protein
(	O
MDP	B-protein
)	O
.	O

A	O
clinically	O
acceptable	O
synthetic	I-protein
derivative	O
of	I-protein
MDP	B-protein
,	O
namely	O
murabutide	O
(	O
MB	O
)	O
,	O
has	O
been	O
found	O
to	I-protein
present	O
interesting	O
pharmacological	O
properties	O
and	I-protein
to	I-protein
suppress	O
HIV-1	O
replication	O
in	I-protein
monocyte-derived	O
macrophages	O
(	O
MDM	B-protein
)	O
.	O

We	O
have	O
addressed	O
the	I-protein
signaling	O
events	O
activated	O
in	I-protein
MDM	B-protein
following	O
stimulation	I-protein
with	I-protein
either	O
MB	O
or	I-protein
the	I-protein
potent	O
immunostimulant	O
LPS	B-protein
.	O

We	O
also	O
examined	O
whether	O
signaling	O
by	I-protein
muramyl	O
peptides	O
involves	O
the	I-protein
use	O
of	I-protein
cell	B-protein
surface	I-protein
receptors	I-protein
,	O
including	I-protein
CD14	B-protein
and	I-protein
Toll-like	B-protein
receptor	I-protein
2	I-protein
(	O
TLR2	B-protein
)	O
or	I-protein
TLR4	B-protein
that	O
are	O
known	O
to	I-protein
be	O
signal-transducing	B-protein
receptors	I-protein
for	I-protein
other	O
bacterial	I-protein
cell	O
wall	O
components	O
.	O

We	O
demonstrate	O
that	O
,	O
unlike	O
LPS	B-protein
,	O
the	I-protein
safe	O
immunomodulator	O
MB	O
selectively	O
activates	O
extracellular	B-protein
signal-regulated	I-protein
kinases	I-protein
(	O
Erk	B-protein
)	O
1/2	I-protein
,	O
in	I-protein
the	I-protein
absence	I-protein
of	I-protein
detectable	O
Jun	B-protein
N-terminal	I-protein
kinase	I-protein
(	O
JNK	B-protein
)	O
or	I-protein
p38	B-protein
mitogen-activated	I-protein
kinase	I-protein
activation	I-protein
.	O

Furthermore	O
,	O
STAT1	B-protein
activation	I-protein
but	O
weak	I-protein
or	I-protein
no	I-protein
activation	I-protein
of	I-protein
STAT3	B-protein
or	I-protein
STAT5	B-protein
respectively	O
,	O
could	O
be	O
detected	O
in	I-protein
MB-stimulated	O
MDM	B-protein
.	O

Using	O
MonoMac6	O
cells	I-protein
,	O
we	O
observed	O
high	O
C/EBPbeta	B-protein
and	I-protein
AP-1	I-protein
but	O
weaker	O
and	I-protein
transient	O
NF-kappaB	B-protein
activation	I-protein
by	I-protein
MB	O
.	O

Moreover	O
,	O
the	I-protein
truncated	I-protein
form	I-protein
of	I-protein
C/EBPbeta	B-protein
,	O
known	O
to	I-protein
repress	O
HIV-1	O
transcription	O
,	O
was	O
detected	O
in	I-protein
extracts	O
from	I-protein
MB-treated	O
THP-1	O
cells	I-protein
.	O

Surprisingly	O
,	O
neither	O
MB	O
nor	O
MDP	B-protein
were	O
able	O
to	I-protein
transduce	O
signals	I-protein
via	I-protein
CD14	B-protein
and	I-protein
TLR2	B-protein
or	I-protein
4	I-protein
.	O

These	O
findings	O
present	O
major	O
differences	O
in	I-protein
the	I-protein
early	O
cell	O
activation	I-protein
process	O
between	O
LPS	B-protein
and	I-protein
muramyl	O
peptides	O
,	O
and	I-protein
strongly	O
argue	O
for	I-protein
the	I-protein
implication	O
of	I-protein
co-receptors	O
other	O
than	I-protein
TLR2	B-protein
and	I-protein
TLR4	B-protein
in	I-protein
mediating	I-protein
the	I-protein
signaling	O
events	O
induced	I-protein
by	I-protein
defined	I-protein
subunits	I-protein
of	I-protein
bacterial	I-protein
peptidoglycans	O
.	O

###MEDLINE:21336700

Nuclear	I-protein
peroxisome	B-protein
proliferator-activated	I-protein
receptors	I-protein
alpha	I-protein
and	I-protein
gamma	I-protein
have	O
opposing	O
effects	O
on	I-protein
monocyte	B-protein
chemotaxis	O
in	I-protein
endometriosis	O
.	O

The	O
peroxisome	B-protein
proliferator-activated	I-protein
receptors	I-protein
(	O
PPARs	I-protein
)	O
alpha	I-protein
and	I-protein
gamma	I-protein
are	O
nuclear	B-protein
receptors	I-protein
that	O
play	O
important	O
roles	O
in	I-protein
inflammatory	O
diseases	O
like	I-protein
ulcerative	O
colitis	O
and	I-protein
arthritis	I-protein
.	O

In	O
this	O
study	O
,	O
we	O
examined	O
the	I-protein
possible	O
role	O
of	I-protein
PPARs	B-protein
in	I-protein
macrophage	O
attraction	O
into	O
the	I-protein
peritoneal	O
cavity	O
of	I-protein
patients	O
with	I-protein
endometriosis	O
.	O

We	O
identified	I-protein
PPAR-alpha	O
and	I-protein
-gamma	O
messenger	O
RNA	O
by	I-protein
RT-PCR	O
and	I-protein
protein	O
by	I-protein
immunoblotting	O
of	I-protein
lysates	O
of	I-protein
peritoneal	O
macrophages	O
and	I-protein
monocytic	I-protein
U937	O
cells	I-protein
.	O

Using	O
immunocytochemistry	O
,	O
we	O
localized	I-protein
PPAR-alpha	B-protein
and	I-protein
-gamma	I-protein
within	B-protein
the	I-protein
nuclei	O
of	I-protein
both	O
cell	O
types	I-protein
.	O

Monocyte	I-protein
chemotactic	I-protein
activity	I-protein
of	I-protein
peritoneal	O
fluid	I-protein
from	I-protein
patients	O
with	I-protein
endometriosis	O
was	O
quantified	O
in	I-protein
Boyden	O
chambers	O
.	O

Migration	O
of	I-protein
U937	O
cells	I-protein
was	O
increased	I-protein
by	I-protein
WY	O
14643	O
and	I-protein
reduced	O
by	I-protein
rosiglitazone	O
.	O

Peritoneal	O
fluid	I-protein
from	I-protein
patients	O
with	I-protein
endometriosis	O
activated	O
U937	O
cells	I-protein
transiently	O
transfected	O
with	I-protein
a	I-protein
PPAR-alpha/GAL4	O
luciferase	O
reporter	O
.	O

By	O
contrast	O
,	O
peritoneal	O
fluid	I-protein
did	O
not	I-protein
cause	O
significant	O
activation	I-protein
of	I-protein
PPAR-gamma/GAL4	O
constructs	O
.	O

The	O
U937	O
cells	I-protein
transiently	O
transfected	O
with	I-protein
a	I-protein
PPAR	B-protein
response	I-protein
element	I-protein
luciferase	O
reporter	O
showed	O
disease	I-protein
stage-dependent	O
up-regulation	O
when	O
treated	O
with	I-protein
peritoneal	O
fluid	I-protein
from	I-protein
patients	O
with	I-protein
endometriosis	O
.	O

Treatment	O
with	I-protein
peritoneal	O
fluid	I-protein
from	I-protein
healthy	O
controls	O
down-regulated	I-protein
PPAR	B-protein
response	I-protein
element	I-protein
transactivation	O
.	O

We	O
conclude	O
that	O
peritoneal	O
fluid	I-protein
of	I-protein
endometriosis	O
patients	O
contains	I-protein
activators	I-protein
of	I-protein
PPAR-alpha	B-protein
that	O
stimulate	O
macrophage	O
chemotaxis	O
.	O

Inhibitors	O
of	I-protein
PPAR-alpha	B-protein
or	I-protein
activators	I-protein
of	I-protein
PPAR-gamma	B-protein
could	O
be	O
developed	O
for	I-protein
the	I-protein
treatment	O
of	I-protein
inflammation	O
associated	I-protein
with	I-protein
endometriosis	O
.	O

###MEDLINE:21329192

Long-term-impaired	O
expression	I-protein
of	I-protein
nuclear	B-protein
factor-kappa	I-protein
B	I-protein
and	I-protein
I	I-protein
kappa	I-protein
B	I-protein
alpha	I-protein
in	I-protein
peripheral	O
blood	O
mononuclear	O
cells	I-protein
of	I-protein
trauma	O
patients	O
.	O

Nuclear	I-protein
factor	I-protein
(	O
NF	I-protein
)	O
-kappa	I-protein
B	I-protein
expression	I-protein
and	I-protein
dimer	O
characteristics	O
were	O
studied	O
in	I-protein
peripheral	O
blood	O
mononuclear	O
cells	I-protein
(	O
PBMCs	O
)	O
of	I-protein
major-trauma	O
patients	O
and	I-protein
healthy	O
controls	O
.	O

Analysis	O
of	I-protein
PBMCs	O
on	I-protein
days	O
1	I-protein
,	O
3	O
,	O
5	O
,	O
and	I-protein
10	I-protein
after	O
trauma	O
revealed	O
that	O
expression	I-protein
of	I-protein
both	O
p65p50	B-protein
heterodimers	I-protein
and	I-protein
p50p50	B-protein
homodimers	I-protein
was	O
significantly	O
reduced	O
compared	O
with	I-protein
that	O
in	I-protein
controls	O
.	O

In	O
vitro	O
lipopolysaccharide	B-protein
(	O
LPS	B-protein
)	O
stimulation	I-protein
of	I-protein
PBMCs	O
induced	I-protein
NF-kappa	B-protein
B	I-protein
translocation	O
.	O

However	O
,	O
throughout	O
the	I-protein
survey	O
,	O
p65p50	O
activation	I-protein
remained	O
significantly	O
lower	I-protein
in	I-protein
trauma	O
patients	O
than	I-protein
in	I-protein
controls	O
.	O

After	O
LPS	B-protein
stimulation	I-protein
in	I-protein
vitro	O
,	O
the	I-protein
p65p50/p50p50	O
ratio	O
was	O
significantly	O
lower	I-protein
in	I-protein
PBMCs	O
from	I-protein
trauma	O
patients	O
than	I-protein
from	I-protein
healthy	O
controls	O
.	O

The	O
ex	O
vivo	O
expression	I-protein
of	I-protein
I	I-protein
kappa	I-protein
B	I-protein
alpha	I-protein
was	O
higher	O
in	I-protein
PBMCs	O
of	I-protein
controls	O
than	I-protein
of	I-protein
trauma	O
patients	O
.	O

LPS	B-protein
did	O
not	I-protein
induce	O
I	I-protein
kappa	I-protein
B	O
expression	I-protein
in	I-protein
PBMCs	O
from	I-protein
trauma	O
patients	O
,	O
but	O
strong	O
induction	I-protein
was	O
obtained	O
with	I-protein
staphylococci	O
,	O
suggesting	O
that	O
this	O
defect	I-protein
is	O
not	I-protein
universal	O
and	I-protein
depends	O
on	I-protein
the	I-protein
nature	O
of	I-protein
the	I-protein
activating	O
signal	O
.	O

Although	O
no	I-protein
direct	O
correlation	O
was	O
found	O
between	O
levels	I-protein
of	I-protein
interleukin-10	B-protein
or	I-protein
transforming	B-protein
growth	I-protein
factor-beta	I-protein
and	I-protein
NF-kappa	B-protein
B	I-protein
,	O
these	O
immunosuppressive	B-protein
cytokines	I-protein
were	O
significantly	O
elevated	I-protein
in	I-protein
trauma	O
patients	O
by	I-protein
10	I-protein
days	O
after	O
admission	O
.	O

The	O
long-term	O
low-basal	O
and	I-protein
LPS-induced	O
nuclear	O
translocation	O
of	I-protein
NF-kappa	B-protein
B	I-protein
recalled	O
long-term	O
immunoparalysis	O
observed	O
in	I-protein
patients	O
with	I-protein
severe	I-protein
inflammatory	O
stress	O
such	O
as	O
trauma	O
.	O

###MEDLINE:21317758

Hepatic	B-protein
ischemia-reperfusion	O
injury	O
.	O

BACKGROUND	O
:	O
The	O
morbidity	O
associated	I-protein
with	I-protein
liver	O
transplantation	I-protein
and	I-protein
major	O
hepatic	O
resections	O
is	O
partly	O
a	I-protein
result	O
of	I-protein
ischemia-reperfusion	O
injury	O
.	O

DATA	O
SOURCES	O
:	O
The	O
entire	O
world	O
literature	O
on	I-protein
the	I-protein
subject	O
was	O
searched	O
via	I-protein
Medline	O
.	O

Keywords	O
included	I-protein
reperfusion	O
injury	O
,	O
transplantation	I-protein
,	O
liver	O
resection	O
,	O
nitric	B-protein
oxide	I-protein
,	O
endothelin	O
,	O
cytokines	B-protein
,	O
Kupffer	O
cells	I-protein
,	O
ischemic/ischaemic	O
preconditioning	O
,	O
and	I-protein
nuclear	B-protein
factor-kappa	I-protein
B	I-protein
.	O

CONCLUSIONS	O
:	O
An	O
imbalance	O
between	O
endothelin	O
and	I-protein
nitric	B-protein
oxide	I-protein
levels	I-protein
results	O
in	I-protein
failure	I-protein
of	I-protein
the	I-protein
hepatic	O
microcirculation	O
at	I-protein
the	I-protein
onset	I-protein
of	I-protein
reperfusion	O
.	O

Activation	O
of	I-protein
nuclear	B-protein
factor-kappa	I-protein
B	I-protein
in	I-protein
the	I-protein
liver	O
promotes	O
proinflammatory	B-protein
cytokine	I-protein
and	I-protein
adhesion	O
molecule	I-protein
synthesis	I-protein
.	O

These	O
result	O
in	I-protein
oxygen-derived	O
free	B-protein
radical	O
production	I-protein
and	I-protein
neutrophil	O
recruitment	I-protein
,	O
further	O
contributing	O
to	I-protein
cellular	O
injury	O
.	O

Various	O
therapeutic	O
modalities	O
acting	O
on	I-protein
the	I-protein
above	O
mediators	O
have	O
been	O
successfully	O
used	O
to	I-protein
attenuate	O
reperfusion	O
injury	O
in	I-protein
animal	O
models	O
of	I-protein
hepatic	O
transplantation	I-protein
and	I-protein
resection	O
.	O

Application	O
of	I-protein
the	I-protein
knowledge	O
gained	O
from	I-protein
animal	O
models	O
of	I-protein
hepatic	O
ischemia-reperfusion	O
to	I-protein
the	I-protein
clinical	I-protein
setting	O
will	O
improve	O
the	I-protein
outcome	O
of	I-protein
hepatic	O
surgery	O
.	O

###MEDLINE:21311876

Down-regulation	O
of	I-protein
IL-12	O
p40	O
gene	O
in	I-protein
Plasmodium	B-protein
berghei-infected	O
mice	O
.	O

We	O
analyzed	O
the	I-protein
mechanism	O
that	O
causes	O
suppression	O
of	I-protein
IL-12	O
p40	O
gene	O
induction	I-protein
during	I-protein
Plasmodium	B-protein
berghei	O
infection	I-protein
.	O

Although	O
IL-12	B-protein
together	O
with	I-protein
IFN-gamma	B-protein
plays	O
an	I-protein
important	O
role	O
in	I-protein
protection	I-protein
against	I-protein
pathogenic	O
infection	I-protein
,	O
the	I-protein
IL-12	B-protein
p70	I-protein
protein	I-protein
production	I-protein
of	I-protein
infected	O
macrophages	O
is	O
lower	I-protein
than	I-protein
that	O
by	I-protein
the	I-protein
uninfected	O
macrophages	O
.	O

We	O
showed	O
in	I-protein
the	I-protein
present	O
study	O
that	O
the	I-protein
induction	I-protein
of	I-protein
IL-12	O
p40	O
gene	O
but	O
not	I-protein
IL-12	O
p35	O
gene	O
in	I-protein
macrophages	O
of	I-protein
P.	O
berghei-infected	O
mice	O
was	O
profoundly	O
inhibited	O
.	O

The	O
inhibition	O
was	O
induced	I-protein
by	I-protein
interaction	I-protein
with	I-protein
macrophages	O
that	O
had	O
contacted	O
with	I-protein
P.	O
berghei-infected	O
erythrocytes	O
and	I-protein
was	O
mediated	I-protein
by	I-protein
a	I-protein
soluble	I-protein
factor	I-protein
,	O
IL-10	B-protein
.	O

There	O
was	O
comparable	O
activation	I-protein
of	I-protein
NF-kappaB	B-protein
in	I-protein
uninfected	O
and	I-protein
infected	O
cells	I-protein
.	O

The	O
induction	I-protein
of	I-protein
IFN-regulatory	O
factor-1	I-protein
gene	O
was	O
comparable	O
in	I-protein
transcription	O
level	I-protein
in	I-protein
uninfected	O
and	I-protein
infected	O
cells	I-protein
,	O
while	O
the	I-protein
unidentified	O
complex	I-protein
formation	O
of	I-protein
IFN-regulatory	B-protein
factor-1	I-protein
was	O
observed	O
in	I-protein
infected	O
cells	I-protein
.	O

Therefore	O
,	O
the	I-protein
inhibition	O
of	I-protein
the	I-protein
IL-12	O
p40	O
gene	O
induction	I-protein
appeared	O
to	I-protein
be	O
regulated	O
at	I-protein
transcriptional	O
regulation	I-protein
level	I-protein
of	I-protein
the	I-protein
gene	O
.	O

###MEDLINE:21309954

The	O
Friend	B-protein
of	I-protein
GATA	B-protein
proteins	I-protein
U-shaped	O
,	O
FOG-1	B-protein
,	O
and	I-protein
FOG-2	B-protein
function	I-protein
as	O
negative	O
regulators	O
of	I-protein
blood	O
,	O
heart	O
,	O
and	I-protein
eye	O
development	O
in	I-protein
Drosophila	I-protein
.	O

Friend	B-protein
of	I-protein
GATA	B-protein
(	O
FOG	B-protein
)	O
proteins	I-protein
regulate	O
GATA	B-protein
factor-activated	O
gene	O
transcription	O
.	O

During	O
vertebrate	O
hematopoiesis	I-protein
,	O
FOG	B-protein
and	I-protein
GATA	B-protein
proteins	I-protein
cooperate	O
to	I-protein
promote	O
erythrocyte	O
and	I-protein
megakaryocyte	I-protein
differentiation	I-protein
.	O

The	O
Drosophila	I-protein
FOG	B-protein
homologue	I-protein
U-shaped	I-protein
(	O
Ush	B-protein
)	O
is	O
expressed	O
similarly	O
in	I-protein
the	I-protein
blood	O
cell	O
anlage	O
during	I-protein
embryogenesis	O
.	O

During	O
hematopoiesis	I-protein
,	O
the	I-protein
acute	O
myeloid	O
leukemia	O
1	I-protein
homologue	O
Lozenge	O
and	I-protein
Glial	O
cells	I-protein
missing	I-protein
are	O
required	O
for	I-protein
the	I-protein
production	I-protein
of	I-protein
crystal	I-protein
cells	I-protein
and	I-protein
plasmatocytes	O
,	O
respectively	O
.	O

However	O
,	O
additional	B-protein
factors	I-protein
have	O
been	O
predicted	I-protein
to	I-protein
control	I-protein
crystal	I-protein
cell	O
proliferation	I-protein
.	O

In	O
this	O
report	O
,	O
we	O
show	O
that	O
Ush	B-protein
is	O
expressed	O
in	I-protein
hemocyte	O
precursors	O
and	I-protein
plasmatocytes	O
throughout	O
embryogenesis	O
and	I-protein
larval	O
development	O
,	O
and	I-protein
the	I-protein
GATA	B-protein
factor	I-protein
Serpent	I-protein
is	O
essential	O
for	I-protein
Ush	B-protein
embryonic	O
expression	I-protein
.	O

Furthermore	O
,	O
loss	O
of	I-protein
ush	O
function	I-protein
results	O
in	I-protein
an	I-protein
overproduction	O
of	I-protein
crystal	I-protein
cells	I-protein
,	O
whereas	O
forced	O
expression	I-protein
of	I-protein
Ush	B-protein
reduces	O
this	O
cell	O
population	O
.	O

Murine	B-protein
FOG-1	I-protein
and	I-protein
FOG-2	I-protein
also	O
can	O
repress	O
crystal	I-protein
cell	O
production	I-protein
,	O
but	O
a	I-protein
mutant	O
version	O
of	I-protein
FOG-2	B-protein
lacking	I-protein
a	I-protein
conserved	O
motif	I-protein
that	O
binds	O
the	I-protein
corepressor	I-protein
C-terminal	I-protein
binding	I-protein
protein	I-protein
fails	O
to	I-protein
affect	O
the	I-protein
cell	O
lineage	I-protein
.	O

The	O
GATA	B-protein
factor	I-protein
Pannier	I-protein
(	O
Pnr	B-protein
)	O
is	O
required	O
for	I-protein
eye	O
and	I-protein
heart	O
development	O
in	I-protein
Drosophila	I-protein
.	O

When	O
Ush	B-protein
,	O
FOG-1	B-protein
,	O
FOG-2	B-protein
,	O
or	I-protein
mutant	B-protein
FOG-2	I-protein
is	O
coexpressed	O
with	I-protein
Pnr	B-protein
during	I-protein
these	O
developmental	O
processes	O
,	O
severe	I-protein
eye	O
and	I-protein
heart	O
phenotypes	O
result	O
,	O
consistent	O
with	I-protein
a	I-protein
conserved	O
negative	O
regulation	I-protein
of	I-protein
Pnr	B-protein
function	I-protein
.	O

These	O
results	O
indicate	O
that	O
the	I-protein
fly	O
and	I-protein
mouse	I-protein
FOG	B-protein
proteins	I-protein
function	I-protein
similarly	O
in	I-protein
three	O
distinct	O
cellular	O
contexts	O
in	I-protein
Drosophila	I-protein
,	O
but	O
may	O
use	O
different	O
mechanisms	O
to	I-protein
regulate	O
genetic	O
events	O
in	I-protein
blood	O
vs	O
.	O
cardial	O
or	I-protein
eye	O
cell	O
lineages	O

###MEDLINE:21376061

The	O
RING	I-protein
finger	I-protein
protein	I-protein
Siah-1	B-protein
regulates	O
the	I-protein
level	I-protein
of	I-protein
the	I-protein
transcriptional	B-protein
coactivator	I-protein
OBF-1	B-protein
.	O

The	O
transcriptional	B-protein
coactivator	I-protein
OBF-1	B-protein
,	O
which	O
interacts	I-protein
with	I-protein
Oct-1	B-protein
and	I-protein
Oct-2	B-protein
and	I-protein
the	I-protein
octamer	O
site	I-protein
DNA	O
,	O
has	O
been	O
shown	O
to	I-protein
be	O
critical	I-protein
for	I-protein
development	O
of	I-protein
a	I-protein
normal	O
immune	O
response	I-protein
and	I-protein
the	I-protein
formation	O
of	I-protein
germinal	B-protein
centers	O
in	I-protein
secondary	O
lymphoid	O
organs	O
.	O

Here	O
we	O
have	O
identified	I-protein
the	I-protein
RING	I-protein
finger	I-protein
protein	I-protein
Siah-1	B-protein
as	O
a	I-protein
protein	O
interacting	I-protein
specifically	O
with	I-protein
OBF-1	B-protein
.	O

This	O
interaction	I-protein
is	O
mediated	I-protein
by	I-protein
the	I-protein
C-terminal	O
part	I-protein
of	I-protein
Siah-1	B-protein
and	I-protein
by	I-protein
residues	O
in	I-protein
the	I-protein
N-terminus	O
of	I-protein
OBF-1	B-protein
,	O
partly	O
distinct	O
from	I-protein
the	I-protein
residues	O
required	O
for	I-protein
formation	O
of	I-protein
a	I-protein
complex	I-protein
with	I-protein
the	I-protein
Oct	B-protein
POU	B-protein
domains	I-protein
and	I-protein
the	I-protein
DNA	O
.	O

Interaction	O
between	O
Siah-1	B-protein
and	I-protein
OBF-1	B-protein
leads	O
to	I-protein
downregulation	O
of	I-protein
OBF-1	B-protein
protein	I-protein
level	I-protein
but	O
not	I-protein
mRNA	O
,	O
and	I-protein
to	I-protein
a	I-protein
corresponding	O
reduction	I-protein
in	I-protein
octamer	O
site-dependent	O
transcription	O
activation	I-protein
.	O

Inhibition	O
of	I-protein
the	I-protein
ubiquitin-proteasome	O
pathway	I-protein
in	I-protein
B	O
cells	I-protein
leads	O
to	I-protein
elevated	I-protein
levels	I-protein
of	I-protein
OBF-1	B-protein
protein	I-protein
.	O

Furthermore	O
,	O
in	I-protein
immunized	O
mice	O
,	O
OBF-1	B-protein
protein	I-protein
amounts	O
are	O
dramatically	O
increased	I-protein
in	I-protein
primary	O
activated	O
B	O
cells	I-protein
,	O
without	I-protein
concomitant	O
increase	O
in	I-protein
OBF-1	B-protein
mRNA	O
.	O

These	O
data	O
suggest	O
that	O
Siah-1	B-protein
is	O
part	I-protein
of	I-protein
a	I-protein
novel	O
regulatory	O
loop	I-protein
controlling	I-protein
the	I-protein
level	I-protein
of	I-protein
OBF-1	B-protein
protein	I-protein
in	I-protein
B	O
cells	I-protein
.	O

###MEDLINE:21370254

The	O
beta-catenin	I-protein
--	I-protein
TCF-1	B-protein
pathway	I-protein
ensures	O
CD4	B-protein
(	O
+	O
)	O
CD8	O
(	O
+	O
)	O
thymocyte	B-protein
survival	B-protein
.	O

The	O
association	I-protein
of	I-protein
trans-acting	B-protein
T	I-protein
cell	I-protein
factors	I-protein
(	O
TCFs	O
)	O
or	I-protein
lymphoid	B-protein
enhancer	I-protein
factor	I-protein
1	I-protein
(	O
LEF-1	I-protein
)	O
with	I-protein
their	O
coactivator	O
beta-catenin	I-protein
mediates	O
transient	O
transcriptional	O
responses	O
to	I-protein
extracellular	O
Wnt	O
signals	I-protein
.	O

We	O
show	O
here	O
that	O
T	O
cell	O
maturation	I-protein
depends	O
on	I-protein
the	I-protein
presence	O
of	I-protein
the	I-protein
beta-catenin	I-protein
--	I-protein
binding	I-protein
domain	I-protein
in	I-protein
TCF-1	B-protein
.	O

This	O
domain	I-protein
is	O
necessary	O
to	I-protein
mediate	O
the	I-protein
survival	B-protein
of	I-protein
immature	B-protein
CD4	B-protein
(	O
+	O
)	O
CD8	O
(	O
+	O
)	O
double-positive	O
(	O
DP	I-protein
)	O
thymocytes	O
.	O

Accelerated	O
spontaneous	O
thymocyte	B-protein
death	O
in	I-protein
the	I-protein
absence	I-protein
of	I-protein
TCF-1	B-protein
correlates	O
with	I-protein
aberrantly	O
low	O
expression	I-protein
of	I-protein
the	I-protein
anti-apoptotic	I-protein
protein	I-protein
Bcl-x	I-protein
(	O
L	I-protein
)	O
.	O

Increasing	O
anti-apoptotic	I-protein
effectors	O
in	I-protein
thymocytes	O
by	I-protein
the	I-protein
use	O
of	I-protein
a	I-protein
Bcl-2	B-protein
transgene	O
rescued	O
TCF-1-deficient	O
DP	I-protein
thymocytes	O
from	I-protein
apoptosis	O
.	O

Thus	O
,	O
TCF-1	B-protein
,	O
upon	O
association	I-protein
with	I-protein
beta-catenin	I-protein
,	O
transiently	O
ensures	O
the	I-protein
survival	B-protein
of	I-protein
immature	B-protein
T	O
cells	I-protein
,	O
which	O
enables	O
them	O
to	I-protein
generate	O
and	I-protein
edit	O
T	B-protein
cell	I-protein
receptor	I-protein
(	O
TCR	B-protein
)	O
alpha	I-protein
chains	I-protein
and	I-protein
attempt	O
TCR	B-protein
-mediated	O
positive	I-protein
selection	O
.	O

###MEDLINE:21361181

TRAIL/Apo2L	B-protein
ligand	I-protein
selectively	O
induces	O
apoptosis	O
and	I-protein
overcomes	O
drug	O
resistance	O
in	I-protein
multiple	O
myeloma	O
:	O
therapeutic	O
applications	O
.	O

Multiple	B-protein
myeloma	O
(	O
MM	O
)	O
remains	O
incurable	O
and	I-protein
novel	O
treatments	O
are	O
urgently	O
needed	O
.	O

Preclinical	O
in	I-protein
vitro	O
and	I-protein
in	I-protein
vivo	O
evaluations	O
were	O
performed	O
to	I-protein
assess	O
the	I-protein
potential	I-protein
therapeutic	O
applications	O
of	I-protein
human	B-protein
recombinant	I-protein
tumor	I-protein
necrosis	I-protein
factor	I-protein
(	O
TNF	I-protein
)	O
-related	I-protein
apoptosis-inducing	I-protein
ligand/Apo2	I-protein
ligand	I-protein
(	O
TRAIL/Apo2L	B-protein
)	O
in	I-protein
MM	O
.	O

TRAIL/Apo2L	B-protein
potently	O
induced	I-protein
apoptosis	O
of	I-protein
MM	O
cells	I-protein
from	I-protein
patients	O
and	I-protein
the	I-protein
majority	O
of	I-protein
MM	O
cell	O
lines	B-protein
,	O
including	I-protein
cells	I-protein
sensitive	I-protein
or	I-protein
resistant	I-protein
to	I-protein
dexamethasone	O
(	O
Dex	O
)	O
,	O
doxorubicin	O
(	O
Dox	O
)	O
,	O
melphalan	O
,	O
and	I-protein
mitoxantrone	O
.	O

TRAIL/Apo2L	B-protein
also	O
overcame	O
the	I-protein
survival	B-protein
effect	O
of	I-protein
interleukin	B-protein
6	I-protein
on	I-protein
MM	O
cells	I-protein
and	I-protein
did	O
not	I-protein
affect	O
the	I-protein
survival	B-protein
of	I-protein
peripheral	O
blood	O
and	I-protein
bone	O
marrow	I-protein
mononuclear	O
cells	I-protein
and	I-protein
purified	O
B	O
cells	I-protein
from	I-protein
healthy	O
donors	O
.	O

The	O
status	I-protein
of	I-protein
the	I-protein
TRAIL	B-protein
receptors	I-protein
(	O
assessed	O
by	I-protein
immunoblotting	O
and	I-protein
flow	O
cytometry	O
)	O
could	O
not	I-protein
predict	O
TRAIL	B-protein
sensitivity	I-protein
of	I-protein
MM	O
cells	I-protein
.	O

The	O
anti-MM	O
activity	I-protein
of	I-protein
TRAIL/Apo2L	B-protein
was	O
confirmed	O
in	I-protein
nu/xid/bg	O
mice	O
xenografted	O
with	I-protein
human	O
MM	O
cells	I-protein
;	O
TRAIL	B-protein
(	O
500	I-protein
microg	O
intraperitoneally	O
daily	O
for	I-protein
14	I-protein
days	O
)	O
was	O
well	O
tolerated	O
and	I-protein
significantly	O
suppressed	I-protein
the	I-protein
growth	O
of	I-protein
plasmacytomas	O
.	O

Dox	O
up-regulated	O
the	I-protein
expression	I-protein
of	I-protein
the	I-protein
TRAIL	B-protein
receptor	I-protein
death	I-protein
receptor	I-protein
5	I-protein
(	O
DR5	B-protein
)	O
and	I-protein
synergistically	O
enhanced	I-protein
the	I-protein
effect	O
of	I-protein
TRAIL	B-protein
not	I-protein
only	I-protein
against	I-protein
MM	O
cells	I-protein
sensitive	I-protein
to	I-protein
,	O
but	O
also	O
against	I-protein
those	O
resistant	I-protein
to	I-protein
,	O
Dex-	O
or	I-protein
Dox-induced	O
apoptosis	O
.	O

Nuclear	I-protein
factor	I-protein
(	O
NF	O
)	O
-kappaB	O
inhibitors	I-protein
,	O
such	O
as	O
SN50	O
(	O
a	I-protein
cell-permeable	O
inhibitor	O
of	I-protein
the	I-protein
nuclear	O
translocation	O
and	I-protein
transcriptional	O
activity	I-protein
of	I-protein
NF-kappaB	B-protein
)	O
or	I-protein
the	I-protein
proteasome	O
inhibitor	O
PS-341	O
,	O
enhanced	I-protein
the	I-protein
proapoptotic	O
activity	I-protein
of	I-protein
TRAIL/Apo2L	B-protein
against	I-protein
TRAIL-sensitive	O
MM	O
cells	I-protein
,	O
whereas	O
SN50	O
reversed	O
the	I-protein
TRAIL	B-protein
resistance	O
of	I-protein
ARH-77	I-protein
and	I-protein
IM-9	O
MM	O
cells	I-protein
.	O

Importantly	O
,	O
normal	O
B	O
lymphocytes	O
were	O
not	I-protein
sensitized	O
to	I-protein
TRAIL	B-protein
by	I-protein
either	O
Dox	O
,	O
SN50	O
,	O
or	I-protein
PS-341	O
.	O

These	O
preclinical	O
studies	O
suggest	O
that	O
TRAIL/Apo2L	B-protein
can	O
overcome	O
conventional	O
drug	O
resistance	O
and	I-protein
provide	O
the	I-protein
basis	O
for	I-protein
clinical	I-protein
trials	O
of	I-protein
TRAIL	B-protein
-based	O
treatment	O
regimens	O
to	I-protein
improve	O
outcome	O
in	I-protein
patients	O
with	I-protein
MM	O
.	O

(	O
Blood.	O
2001	O
;	O
98	I-protein
:	O
795-804	O
)	O

###MEDLINE:21357628

CD28	B-protein
costimulation	O
is	O
required	O
not	I-protein
only	I-protein
to	I-protein
induce	O
IL-12	B-protein
receptor	I-protein
but	O
also	O
to	I-protein
render	O
janus	B-protein
kinases/STAT4	I-protein
responsive	I-protein
to	I-protein
IL-12	B-protein
stimulation	I-protein
in	I-protein
TCR-triggered	O
T	O
cells	I-protein
.	O

The	O
activation	I-protein
of	I-protein
resting	O
T	O
cells	I-protein
for	I-protein
the	I-protein
acquisition	O
of	I-protein
various	O
functions	O
depends	O
on	I-protein
whether	O
CD28	B-protein
costimulatory	O
signals	I-protein
are	O
provided	O
upon	O
T	O
cell	O
receptor	O
stimulation	I-protein
.	O

Here	O
,	O
we	O
investigated	O
how	O
CD28	B-protein
costimulation	O
functions	O
to	I-protein
allow	O
TCR	B-protein
-triggered	O
resting	O
T	O
cells	I-protein
to	I-protein
acquire	O
IL-12	B-protein
responsiveness	O
.	O

When	O
T	O
cells	I-protein
are	O
stimulated	O
with	I-protein
low	O
doses	O
of	I-protein
anti-CD3	B-protein
mAb	I-protein
,	O
CD28	B-protein
costimulation	O
was	O
required	O
for	I-protein
the	I-protein
optimal	O
levels	I-protein
of	I-protein
IL-12	B-protein
receptor	I-protein
(	O
IL-12R	B-protein
)	O
expression	I-protein
.	O

However	O
,	O
stimulation	I-protein
of	I-protein
T	O
cells	I-protein
with	I-protein
high	O
doses	O
of	I-protein
anti-CD3	B-protein
alone	O
induced	I-protein
comparable	O
levels	I-protein
of	I-protein
IL-12R	B-protein
expression	I-protein
to	I-protein
those	O
induced	I-protein
upon	O
CD28	B-protein
costimulation	O
.	O

Nevertheless	O
,	O
there	O
was	O
a	I-protein
substantial	O
difference	O
in	I-protein
IL-12	B-protein
responsiveness	O
between	O
these	O
two	O
groups	O
of	I-protein
T	O
cells	I-protein
:	O
compared	O
to	I-protein
anti-CD28-costimulated	O
T	O
cells	I-protein
,	O
T	O
cells	I-protein
that	O
were	O
not	I-protein
costimulated	O
with	I-protein
anti-CD28	B-protein
exhibited	O
decreased	O
levels	I-protein
of	I-protein
Janus	B-protein
kinases	I-protein
(	O
JAK	O
)	O
JAK2/TYK2	B-protein
and	I-protein
STAT4	B-protein
phosphorylation	I-protein
and	I-protein
IFN-y	O
production	I-protein
following	O
IL-12	O
stimulation	I-protein
.	O

Importantly	O
,	O
STAT6	B-protein
phosphorylation	I-protein
following	O
IL-4	B-protein
stimulation	I-protein
was	O
not	I-protein
decreased	O
in	I-protein
anti-CD28-uncostimulated	O
T	O
cells	I-protein
.	O

These	O
resutls	O
indicate	O
that	O
CD28	B-protein
costimulation	O
not	I-protein
only	I-protein
contributes	O
to	I-protein
up-regulating	O
IL-12R	O
expression	I-protein
but	O
is	O
also	O
required	O
to	I-protein
render	O
JAKs/STAT4	B-protein
responsive	I-protein
to	I-protein
IL-12	O
stimulation	I-protein
.	O

###MEDLINE:21351021

Constitutively	O
activated	O
Akt-1	B-protein
is	O
vital	O
for	I-protein
the	I-protein
survival	B-protein
of	I-protein
human	O
monocyte-differentiated	O
macrophages	O
.	O

Role	O
of	I-protein
Mcl-1	B-protein
,	O
independent	I-protein
of	I-protein
nuclear	B-protein
factor	I-protein
(	O
NF	I-protein
)	O
-kappaB	I-protein
,	O
Bad	B-protein
,	O
or	I-protein
caspase	O
activation	I-protein
.	O

Recent	O
data	O
from	I-protein
mice	O
deficient	I-protein
for	I-protein
phosphatase	B-protein
and	I-protein
tensin	O
homologue	O
deleted	O
from	I-protein
chromosome	O
10	I-protein
or	I-protein
src	B-protein
homology	I-protein
2	I-protein
domain-containing	I-protein
5	I-protein
'	O
inositol	I-protein
phosphatase	I-protein
,	O
phosphatases	O
that	O
negatively	O
regulate	O
the	I-protein
phosphatidylinositol	B-protein
3-kinase	I-protein
(	O
PI3K	B-protein
)	O
pathway	I-protein
,	O
revealed	O
an	I-protein
increased	I-protein
number	I-protein
of	I-protein
macrophages	O
in	I-protein
these	O
animals	O
,	O
suggesting	O
an	I-protein
essential	O
role	O
for	I-protein
the	I-protein
PI3K	B-protein
pathway	I-protein
for	I-protein
macro-phage	O
survival	B-protein
.	O

Here	O
,	O
we	O
focused	O
on	I-protein
the	I-protein
role	O
of	I-protein
the	I-protein
PI3K-regulated	B-protein
serine/threonine	I-protein
kinase	I-protein
Akt-1	B-protein
in	I-protein
modulating	I-protein
macrophage	O
survival	B-protein
.	O

Akt-1	B-protein
was	O
constitutively	O
activated	O
in	I-protein
human	O
macrophages	O
and	I-protein
addition	O
of	I-protein
the	I-protein
PI3K	B-protein
inhibitor	O
,	O
LY294002	O
,	O
suppressed	I-protein
the	I-protein
activation	I-protein
of	I-protein
Akt-1	B-protein
and	I-protein
induced	I-protein
cell	O
death	O
.	O

Furthermore	O
,	O
suppression	O
of	I-protein
Akt-1	B-protein
by	I-protein
inhibition	O
of	I-protein
PI3K	B-protein
or	I-protein
a	I-protein
dominant	I-protein
negative	I-protein
(	O
DN	I-protein
)	O
Akt-1	I-protein
resulted	O
in	I-protein
loss	O
of	I-protein
mitochondrial	O
transmembrane	O
potential	I-protein
,	O
activation	I-protein
of	I-protein
caspases-9	B-protein
and	I-protein
-3	I-protein
,	O
and	I-protein
DNA	O
fragmentation	I-protein
.	O

The	O
effects	O
of	I-protein
PI3K	B-protein
inhibition	O
were	O
reversed	O
by	I-protein
the	I-protein
ectopic	I-protein
expression	I-protein
of	I-protein
constitutively	O
activated	O
Akt-1	B-protein
or	I-protein
Bcl-x	B-protein
(	O
L	I-protein
)	O
.	O

Inhibition	O
of	I-protein
PI3K	B-protein
/Akt-1	O
pathway	I-protein
either	O
by	I-protein
LY294002	O
or	I-protein
DN	B-protein
Akt-1	I-protein
had	O
no	I-protein
effect	O
on	I-protein
the	I-protein
constitutive	I-protein
or	I-protein
inducible	O
activation	I-protein
of	I-protein
nuclear	B-protein
factor	I-protein
(	O
NF	I-protein
)	O
-kappaB	I-protein
in	I-protein
human	O
macrophages	O
.	O

However	O
,	O
after	O
inhibition	O
of	I-protein
the	I-protein
PI3K	B-protein
/	O
Akt-1	B-protein
pathway	I-protein
,	O
a	I-protein
marked	O
decrease	O
in	I-protein
the	I-protein
expression	I-protein
of	I-protein
the	I-protein
antiapoptotic	B-protein
molecule	I-protein
Mcl-1	B-protein
,	O
but	O
not	I-protein
other	O
Bcl-2	B-protein
family	I-protein
members	I-protein
was	O
observed	O
,	O
and	I-protein
Mcl-1	B-protein
rescued	O
macrophages	O
from	I-protein
LY294002-induced	O
cell	O
death	O
.	O

Further	O
,	O
inhibition	O
of	I-protein
Mcl-1	B-protein
by	I-protein
antisense	O
oligonucleotides	O
,	O
also	O
resulted	O
in	I-protein
macrophage	O
apoptosis	O
.	O

Thus	O
,	O
our	O
findings	O
demonstrate	O
that	O
the	I-protein
constitutive	I-protein
activation	I-protein
of	I-protein
Akt-1	B-protein
regulates	O
macrophage	O
survival	B-protein
through	I-protein
Mcl-1	B-protein
,	O
which	O
is	O
independent	I-protein
of	I-protein
caspases	B-protein
,	O
NF-kappaB	B-protein
,	O
or	I-protein
Bad	B-protein
.	O

###MEDLINE:21340428

GRbeta	B-protein
expression	I-protein
in	I-protein
nasal	O
polyp	O
inflammatory	O
cells	I-protein
and	I-protein
its	O
relationship	O
to	I-protein
the	I-protein
anti-inflammatory	O
effects	O
of	I-protein
intranasal	O
fluticasone	O
.	O

BACKGROUND	O
:	O
Nasal	O
polyposis	I-protein
disease	I-protein
is	O
an	I-protein
inflammatory	O
disorder	I-protein
with	I-protein
intense	O
eosinophilic	O
infiltration	O
of	I-protein
respiratory	I-protein
mucosa	B-protein
that	O
is	O
often	O
difficult	O
to	I-protein
control	I-protein
with	I-protein
topical	O
steroids	O
.	O

Recent	O
evidence	O
suggests	O
that	O
overexpression	O
of	I-protein
the	I-protein
glucocorticoid	B-protein
receptor	I-protein
splice	I-protein
variant	I-protein
GRbeta	B-protein
in	I-protein
inflammatory	O
cells	I-protein
might	O
contribute	O
to	I-protein
steroid	O
insensitivity	O
in	I-protein
diseases	O
such	O
as	O
asthma	I-protein
.	O

OBJECTIVE	O
:	O
The	O
purposes	O
of	I-protein
this	O
investigation	O
were	O
to	I-protein
determine	O
whether	O
nasal	O
polyp	O
(	O
NP	O
)	O
inflammatory	O
cells	I-protein
overexpress	O
GRbeta	B-protein
and	I-protein
to	I-protein
examine	O
whether	O
GRbeta	B-protein
overexpression	O
is	O
associated	I-protein
with	I-protein
insensitivity	O
to	I-protein
the	I-protein
potent	O
topical	O
steroid	O
fluticasone	O
propionate	O
(	O
FP	I-protein
)	O
.	O

METHODS	O
:	O
Biopsies	O
were	O
obtained	O
from	I-protein
10	I-protein
subjects	O
with	I-protein
NPs	O
before	O
and	I-protein
4	I-protein
weeks	O
after	O
treatment	O
with	I-protein
intranasal	O
FP	I-protein
.	O

Middle	O
turbinates	O
biopsies	O
from	I-protein
6	I-protein
healthy	O
,	O
nonallergic	O
subjects	O
served	O
as	O
normal	O
controls	O
.	O

Biopsies	O
were	O
immunostained	O
for	I-protein
inflammatory	O
cell	O
markers	O
as	O
well	O
as	O
GRbeta	B-protein
and	I-protein
probed	O
for	I-protein
various	O
cytokine	O
mRNA	O
.	O

The	O
anti-inflammatory	O
response	I-protein
to	I-protein
FP	I-protein
was	O
examined	O
in	I-protein
relation	O
to	I-protein
pretreatment	O
levels	I-protein
of	I-protein
GRbeta	B-protein
expression	I-protein
.	O

RESULTS	O
:	O
The	O
total	O
numbers	O
of	I-protein
inflammatory	O
cells	I-protein
were	O
increased	I-protein
in	I-protein
NPs	O
.	O

The	O
percentage	O
of	I-protein
inflammatory	O
cells	I-protein
expressing	O
GRbeta	B-protein
was	O
also	O
increased	I-protein
(	O
40.5	O
%	O
+/-	O
19.2	O
%	O
vs	O
16.1	O
%	O
+/-	O
4.0	O
%	O
,	O
P	O
=.009	O
)	O
.	O

GRbeta	B-protein
expression	I-protein
in	I-protein
NPs	O
was	O
almost	O
exclusive	O
to	I-protein
T	O
lymphocytes	O
,	O
eosinophils	O
,	O
and	I-protein
macrophages	O
.	O

An	O
inverse	O
correlation	O
was	O
observed	O
between	O
the	I-protein
baseline	O
inflammatory	O
cell	O
GRbeta	O
expression	I-protein
and	I-protein
the	I-protein
reduction	I-protein
after	O
FP	I-protein
treatment	O
in	I-protein
EG2-positive	O
eosinophils	O
,	O
CD4-positive	O
T	O
lymphocytes	O
,	O
endothelial	O
VCAM-1	O
expression	I-protein
,	O
and	I-protein
IL-4	B-protein
mRNA-positive	O
cells	I-protein
.	O

NPs	O
that	O
were	O
``	O
FP-insensitive	O
''	I-protein
in	I-protein
terms	O
of	I-protein
suppression	O
of	I-protein
eosinophil	O
numbers	O
(	O
major	B-protein
basic	I-protein
protein	I-protein
-positive	O
)	O
had	O
a	I-protein
significantly	O
greater	O
percentage	O
of	I-protein
GRbeta-positive	O
inflammatory	O
cells	I-protein
,	O
a	I-protein
higher	O
ratio	O
of	I-protein
GRbeta-positive/GRalpha-positive	O
cells	I-protein
,	O
and	I-protein
increased	I-protein
numbers	O
of	I-protein
GRbeta-positive	O
eosinophils	O
and	I-protein
macrophages	O
in	I-protein
comparison	O
with	I-protein
those	O
that	O
were	O
``	O
FP-sensitive.	O
''	I-protein

``	O
FP-insensitive	O
''	I-protein
NPs	O
also	O
demonstrated	O
a	I-protein
higher	O
percentage	O
of	I-protein
IL-5-positive	O
inflammatory	O
cells	I-protein
expressing	O
GRbeta	B-protein
before	O
and	I-protein
after	O
FP	I-protein
treatment	O
.	O

CONCLUSION	O
:	O
GRbeta	B-protein
expression	I-protein
appears	O
to	I-protein
be	O
a	I-protein
marker	I-protein
of	I-protein
steroid	O
insensitivity	O
in	I-protein
NPs	O
.	O

Expression	O
of	I-protein
GRbeta	B-protein
by	I-protein
NP	O
inflammatory	O
cells	I-protein
,	O
particularly	O
T	O
cells	I-protein
and	I-protein
eosinophils	O
,	O
might	O
render	O
them	O
resistant	I-protein
to	I-protein
suppression	O
by	I-protein
topical	O
steroids	O
and	I-protein
thereby	O
contribute	O
to	I-protein
persistent	I-protein
NP	O
inflammation	O
.	O

###MEDLINE:21334898

Transcriptional	I-protein
regulation	I-protein
of	I-protein
galectin-10	O
(	O
eosinophil	B-protein
Charcot-Leyden	I-protein
crystal	I-protein
protein	I-protein
)	O
:	O
a	I-protein
GC	O
box	I-protein
(	O
-44	I-protein
to	I-protein
-50	O
)	O
controls	O
butyric	O
acid	O
induction	I-protein
of	I-protein
gene	O
expression	I-protein
.	O

Galectin-10	B-protein
(	O
gal-10	O
,	O
also	O
known	O
as	O
Charcot-Leyden	B-protein
crystal	I-protein
protein	I-protein
)	O
is	O
a	I-protein
member	I-protein
of	I-protein
the	I-protein
galectin	B-protein
family	I-protein
of	I-protein
beta-galactoside	I-protein
binding	I-protein
proteins	I-protein
that	O
is	O
expressed	O
uniquely	O
in	I-protein
eosinophilic	O
and	I-protein
basophilic	O
leukocytes	O
.	O

To	O
gain	O
a	I-protein
better	O
understanding	O
of	I-protein
galectin	O
gene	O
expression	I-protein
,	O
we	O
present	O
an	I-protein
analysis	O
of	I-protein
the	I-protein
transcriptional	O
regulation	I-protein
of	I-protein
the	I-protein
gene	O
encoding	I-protein
gal-10	B-protein
.	O

Analysis	O
of	I-protein
the	I-protein
minimal	O
promoter	I-protein
revealed	O
nine	I-protein
consensus-binding	O
sites	I-protein
for	I-protein
transcription	B-protein
factors	I-protein
,	O
including	I-protein
several	I-protein
that	O
are	O
also	O
found	O
in	I-protein
the	I-protein
minimal	O
promoters	O
of	I-protein
galectins	O
-1	I-protein
,	O
-2	O
,	O
and	I-protein
-3	O
.	O

The	O
decrease	O
in	I-protein
gal-10	O
promoter	I-protein
activity	I-protein
after	O
disruption	O
of	I-protein
either	O
the	I-protein
GC	O
box	I-protein
(	O
-44	I-protein
to	I-protein
-50	O
)	O
or	I-protein
the	I-protein
Oct	O
site	I-protein
(	O
-255	O
to	I-protein
-261	O
)	O
suggests	O
that	O
these	O
sites	I-protein
,	O
along	O
with	I-protein
the	I-protein
previously	O
characterized	O
GATA	B-protein
and	I-protein
EoTF	O
sites	I-protein
,	O
are	O
necessary	O
for	I-protein
full	O
promoter	I-protein
activity	I-protein
.	O

By	O
supershift	O
analysis	O
,	O
we	O
demonstrate	O
binding	I-protein
of	I-protein
the	I-protein
transcription	B-protein
factors	I-protein
Sp1	B-protein
and	I-protein
Oct1	B-protein
to	I-protein
the	I-protein
consensus	O
GC	O
box	I-protein
and	I-protein
the	I-protein
Oct	O
site	I-protein
,	O
respectively	O
.	O

Similar	B-protein
to	I-protein
gal-1	O
,	O
gal-10	O
expression	I-protein
is	O
induced	I-protein
by	I-protein
butyric	O
acid	O
,	O
an	I-protein
effect	O
that	O
is	O
lost	O
upon	O
ablation	O
of	I-protein
the	I-protein
GC	O
box	I-protein
.	O

Additionally	O
,	O
we	O
demonstrate	O
AML3	B-protein
binding	I-protein
to	I-protein
the	I-protein
consensus	O
AML	O
site	I-protein
and	I-protein
YY1	O
binding	I-protein
to	I-protein
the	I-protein
Inr	O
sequence	I-protein
,	O
both	O
elements	O
functioning	O
as	O
silencers	O
in	I-protein
the	I-protein
gal-10	O
promoter	I-protein
.	O

###MEDLINE:21328787

Tumour-stromal	O
interactions	O
.	O

Role	O
of	I-protein
the	I-protein
stroma	O
in	I-protein
mammary	I-protein
development	O
.	O

Mammary	I-protein
development	O
depends	O
on	I-protein
branching	I-protein
morphogenesis	I-protein
,	O
namely	O
the	I-protein
bifurcation	O
and	I-protein
extension	O
of	I-protein
ductal	I-protein
growth	O
points	O
(	O
end	I-protein
buds	O
)	O
and	I-protein
secretory	O
lobules	O
into	O
a	I-protein
more	O
or	I-protein
less	O
fatty	O
stroma	O
.	O

Because	O
breast	O
carcinomas	O
are	O
overwhelmingly	O
ductal	I-protein
in	I-protein
origin	O
,	O
this	O
review	O
focuses	O
on	I-protein
stromal	O
influences	I-protein
guiding	O
postnatal	O
ductal	I-protein
development	O
and	I-protein
there	O
is	O
only	I-protein
the	I-protein
briefest	O
account	O
of	I-protein
the	I-protein
role	O
of	I-protein
embryonic	O
stroma	O
(	O
mesenchyme	O
)	O
.	O

The	O
stroma	O
as	O
the	I-protein
necessary	O
target	O
for	I-protein
endocrine	I-protein
mammogens	O
and	I-protein
the	I-protein
source	O
of	I-protein
stimulatory	I-protein
growth	O
factors	I-protein
is	O
described	O
and	I-protein
the	I-protein
importance	O
of	I-protein
mammary	I-protein
epithelium-induced	O
modifications	O
of	I-protein
the	I-protein
periductal	O
stroma	O
is	O
emphasized	O
.	O

Evidence	O
is	O
presented	O
that	O
if	O
they	O
are	O
to	I-protein
grow	O
,	O
end	I-protein
buds	O
must	O
condition	O
proximal	I-protein
fatty	O
stroma	O
by	I-protein
recruiting	O
white	I-protein
blood	O
cells	I-protein
as	O
well	O
as	O
inducing	I-protein
stromal	O
cell	O
division	I-protein
and	I-protein
,	O
possibly	O
,	O
estrogen	B-protein
receptors	I-protein
.	O

The	O
induction	I-protein
of	I-protein
a	I-protein
fibrous	O
stromal	O
tunic	O
around	O
the	I-protein
end	I-protein
bud	I-protein
is	O
described	O
and	I-protein
its	O
likely	B-protein
role	O
as	O
a	I-protein
complex	I-protein
ductal	I-protein
morphogen	O
is	O
discussed	O
;	O
a	I-protein
possible	O
role	O
in	I-protein
growth	O
inhibition	O
is	O
also	O
considered	O
.	O

Although	O
the	I-protein
signals	I-protein
governing	O
fibrotic	O
induction	I-protein
,	O
ductal	I-protein
morphogenesis	I-protein
,	O
and	I-protein
growth	O
inhibition	O
are	O
unknown	O
,	O
a	I-protein
role	O
for	I-protein
transforming	B-protein
growth	I-protein
factor-beta	I-protein
is	O
highly	O
likely	B-protein
and	I-protein
is	O
discussed	O
.	O

Finally	O
,	O
a	I-protein
need	O
for	I-protein
new	I-protein
conceptual	O
and	I-protein
experimental	O
approaches	O
to	I-protein
understanding	O
stromal-epithelial	O
signaling	O
is	O
discussed	O
.	O

###MEDLINE:21313314

Adipophilin	I-protein
is	O
a	I-protein
sensitive	I-protein
marker	I-protein
for	I-protein
lipid	O
loading	O
in	I-protein
human	O
blood	O
monocytes	O
.	O

Adipophilin	I-protein
,	O
a	I-protein
marker	I-protein
of	I-protein
lipid	O
accumulation	I-protein
initially	O
described	O
in	I-protein
adipocytes	O
,	O
was	O
recently	O
shown	O
to	I-protein
be	O
induced	I-protein
in	I-protein
macrophage	O
foam	O
cells	I-protein
.	O

We	O
found	O
that	O
even	O
freshly	O
isolated	I-protein
blood	O
monocytes	O
express	O
adipophilin	B-protein
and	I-protein
that	O
the	I-protein
amount	O
of	I-protein
adipophilin	B-protein
protein	I-protein
is	O
variable	O
in	I-protein
monocytes	O
from	I-protein
different	O
healthy	O
individuals	O
.	O

However	O
,	O
the	I-protein
physiological	O
expression	I-protein
of	I-protein
adipophilin	B-protein
does	O
not	I-protein
correlate	O
with	I-protein
the	I-protein
levels	I-protein
of	I-protein
free	B-protein
fatty	O
acids	I-protein
,	O
cholesterylesters	O
or	I-protein
free	B-protein
cholesterol	O
.	O

Enzymatically	B-protein
modified	I-protein
low-density	I-protein
lipoprotein	I-protein
(	O
E-LDL	B-protein
)	O
induces	O
rapid	O
foam	O
cell	O
formation	O
in	I-protein
monocytes	O
and	I-protein
upregulates	O
adipophilin	B-protein
mRNA	O
and	I-protein
protein	O
within	B-protein
2	I-protein
h	I-protein
of	I-protein
incubation	O
.	O

This	O
rapid	O
induction	I-protein
of	I-protein
adipophilin	B-protein
is	O
accompanied	O
by	I-protein
a	I-protein
significant	O
increase	O
of	I-protein
free	B-protein
fatty	O
acids	I-protein
in	I-protein
monocytes	O
incubated	O
with	I-protein
E-LDL	B-protein
.	O

Adipophilin	I-protein
facilitates	O
the	I-protein
uptake	I-protein
of	I-protein
free	B-protein
fatty	O
acids	I-protein
,	O
and	I-protein
here	O
we	O
demonstrate	O
that	O
free	B-protein
fatty	O
acids	I-protein
increase	O
is	O
related	O
to	I-protein
the	I-protein
early	O
upregulation	O
of	I-protein
adipophilin	B-protein
expression	I-protein
in	I-protein
blood	O
monocytes	O
.	O

Fatty	I-protein
acids	I-protein
are	O
ligands	O
for	I-protein
peroxisome	B-protein
proliferator-activated	I-protein
receptor-gamma	I-protein
(	O
PPARgamma	B-protein
)	O
,	O
and	I-protein
the	I-protein
upregulation	O
of	I-protein
adipophilin	B-protein
mRNA	O
by	I-protein
PPARgamma	O
agonists	O
like	I-protein
15d-PGJ	O
(	O
2	I-protein
)	O
and	I-protein
ciglitazone	O
indicates	O
that	O
PPARgamma	B-protein
may	O
mediate	O
the	I-protein
induction	I-protein
of	I-protein
adipophilin	B-protein
expression	I-protein
in	I-protein
human	O
blood	O
monocytes	O
.	O

###MEDLINE:21311859

Constitutive	O
expression	I-protein
of	I-protein
MHC	O
class	O
II	I-protein
genes	I-protein
in	I-protein
melanoma	O
cell	O
lines	B-protein
results	O
from	I-protein
the	I-protein
transcription	O
of	I-protein
class	O
II	I-protein
transactivator	I-protein
abnormally	O
initiated	O
from	I-protein
its	O
B	O
cell-specific	I-protein
promoter	I-protein
.	O

In	O
melanoma	O
cell	O
lines	B-protein
,	O
two	O
different	O
patterns	O
of	I-protein
MHC	O
class	O
II	I-protein
expression	I-protein
have	O
been	O
described	O
,	O
either	O
an	I-protein
IFN	B-protein
gamma-inducible	I-protein
expression	I-protein
of	I-protein
HLA-DR	I-protein
and	I-protein
HLA-DP	O
,	O
with	I-protein
a	I-protein
faint	O
or	I-protein
null	O
expression	I-protein
of	I-protein
HLA-DQ	O
,	O
resembling	O
that	O
described	O
for	I-protein
melanocytes	O
,	O
or	I-protein
a	I-protein
constitutive	I-protein
expression	I-protein
,	O
i.e.	O
,	O
IFN-gamma	B-protein
independent	I-protein
,	O
of	I-protein
all	O
three	O
HLA-D	O
isotypes	O
.	O

As	O
this	O
latter	O
phenotype	O
has	O
been	O
associated	I-protein
with	I-protein
a	I-protein
more	O
rapid	O
progression	I-protein
of	I-protein
melanoma	O
tumors	I-protein
,	O
we	O
have	O
analyzed	O
in	I-protein
different	O
melanoma	O
cell	O
lines	B-protein
the	I-protein
molecular	I-protein
mechanisms	O
leading	O
to	I-protein
this	O
abnormal	I-protein
pattern	I-protein
of	I-protein
MHC	O
class	O
II	I-protein
expression	I-protein
.	O

In	O
agreement	O
with	I-protein
the	I-protein
evidence	O
of	I-protein
a	I-protein
coordinate	O
transcription	O
of	I-protein
the	I-protein
HLA-D	O
genes	I-protein
in	I-protein
these	O
cell	O
lines	B-protein
,	O
we	O
have	O
shown	O
the	I-protein
constitutive	I-protein
expression	I-protein
of	I-protein
CIITA	B-protein
(	O
class	O
II	I-protein
transactivator	I-protein
)	O
transcripts	I-protein
,	O
CIITA	B-protein
being	O
known	O
as	O
the	I-protein
master	O
switch	I-protein
of	I-protein
MHC	O
class	O
II	I-protein
expression	I-protein
.	O

Unexpectedly	O
,	O
these	O
transcripts	I-protein
initiate	O
from	I-protein
promoter	I-protein
III	I-protein
of	I-protein
the	I-protein
CIITA	B-protein
gene	O
,	O
a	I-protein
promoter	I-protein
that	O
is	O
mainly	O
used	O
constitutively	O
in	I-protein
B	O
lymphocytes	O
.	O

This	O
expression	I-protein
was	O
further	O
shown	O
to	I-protein
occur	O
through	I-protein
factor	I-protein
(	O
s	I-protein
)	O
acting	O
on	I-protein
the	I-protein
enhancer	O
located	O
upstream	O
of	I-protein
CIITA	B-protein
promoter	I-protein
III	I-protein
,	O
which	O
was	O
previously	O
described	O
in	I-protein
epithelioid	O
cells	I-protein
as	O
an	I-protein
IFN-gamma-response	O
sequence	I-protein
.	O

The	O
hypothesis	O
of	I-protein
a	I-protein
general	O
abnormality	O
of	I-protein
the	I-protein
IFN-gamma	O
transduction	I-protein
pathway	I-protein
was	O
dismissed	O
.	O

Constitutive	O
transcription	O
of	I-protein
CIITA	B-protein
from	I-protein
promoter	I-protein
III	I-protein
having	O
been	O
observed	O
in	I-protein
unrelated	O
melanoma	O
cell	O
lines	B-protein
,	O
we	O
propose	O
the	I-protein
hypothesis	O
that	O
this	O
phenomenon	O
might	O
not	I-protein
be	O
a	I-protein
random	O
event	O
,	O
but	O
could	O
be	O
linked	I-protein
to	I-protein
the	I-protein
neoplasic	O
state	I-protein
of	I-protein
the	I-protein
melanoma	O
cells	I-protein

###MEDLINE:21371733

Caspase	I-protein
-mediated	O
calcineurin	O
activation	I-protein
contributes	O
to	I-protein
IL-2	B-protein
release	I-protein
during	I-protein
T	O
cell	O
activation	I-protein
.	O

Calcineurin	B-protein
,	O
a	I-protein
Ca	B-protein
(	O
2+	I-protein
)	O
/calmodulin-dependent	I-protein
Ser/Thr	I-protein
phosphatase	I-protein
(	O
protein	I-protein
phosphatase	I-protein
2B	I-protein
)	O
,	O
plays	O
a	I-protein
critical	I-protein
role	O
in	I-protein
IL-2	B-protein
production	I-protein
during	I-protein
T	O
cell	O
activation	I-protein
.	O

It	O
has	O
been	O
previously	O
reported	O
that	O
IL-2	B-protein
release	I-protein
in	I-protein
activated	O
Jurkat	O
T	O
requires	O
caspase-like	O
activity	I-protein
(	O
Posmantur	O
et	I-protein
al.	O
(	O
1998	O
)	O
Exp.	O
Cell.	O
Res.	O
244	I-protein
,	O
302-309	O
)	O
.	O

We	O
report	O
here	O
that	O
the	I-protein
60-kDa	B-protein
catalytic	I-protein
subunit	I-protein
of	I-protein
calcineurin	B-protein
A	I-protein
(	O
Cn	B-protein
A	I-protein
)	O
was	O
partially	O
cleaved	O
to	I-protein
a	I-protein
45-kDa	O
form	I-protein
in	I-protein
phytohemagglutinin	O
A	O
(	O
PHA	B-protein
)	O
or	I-protein
phorbol	O
ester	I-protein
+	O
ionomycin	O
(	O
P	O
+	O
I	I-protein
)	O
-activated	I-protein
Jurkat	O
cells	I-protein
.	O

In	O
parallel	O
,	O
proteolytic	I-protein
activation	I-protein
of	I-protein
upstream	O
caspases	O
(	O
caspase-8	O
and	I-protein
-9	O
)	O
as	O
well	O
as	O
effector	B-protein
caspase-3	I-protein
was	O
also	O
observed	O
.	O

Cn	B-protein
A	I-protein
cleavage	O
was	O
caspase	O
mediated	I-protein
,	O
since	O
it	O
was	O
inhibitable	O
by	I-protein
pan-caspase	O
inhibitor	O
Cbz-Asp-CH	O
(	O
2	I-protein
)	O
OC	O
(	O
O	I-protein
)	O
-2	O
,	O
6-dichlorobenzene	O
(	O
Z-D-DCB	O
)	O
.	O

Cn	B-protein
A	I-protein
cleavage	O
was	O
also	O
observed	O
when	O
purified	O
calcineurin	B-protein
was	O
digested	O
in	I-protein
vitro	O
with	I-protein
caspase-3	O
.	O

Truncated	B-protein
Cn	I-protein
A	I-protein
was	O
associated	I-protein
with	I-protein
enhanced	I-protein
phosphatase	O
activity	I-protein
and	I-protein
reduced	O
calmodulin	O
sensitivity	I-protein
.	O

Furthermore	O
,	O
in	I-protein
PHA	B-protein
or	I-protein
P	O
+	O
I-activated	O
Jurkat	O
cells	I-protein
,	O
dephosphorylation	O
of	I-protein
calcineurin	B-protein
substrate	I-protein
NFATc	B-protein
(	O
a	I-protein
transcription	B-protein
factor	I-protein
known	O
to	I-protein
be	O
involved	I-protein
in	I-protein
transactivation	O
of	I-protein
the	I-protein
IL-2	B-protein
gene	O
)	O
,	O
was	O
also	O
suppressed	I-protein
by	I-protein
Z-D-DCB	O
.	O

Taken	O
together	O
,	O
our	O
results	O
suggest	O
that	O
caspase-mediated	O
cleavage	O
of	I-protein
Cn	B-protein
A	I-protein
contributes	O
to	I-protein
IL-2	B-protein
production	I-protein
during	I-protein
T	O
cell	O
activation	I-protein
.	O

Copyright	O
2001	O
Academic	O
Press	O
.	O

###MEDLINE:21363219

Maturation	O
of	I-protein
human	O
dendritic	B-protein
cells	I-protein
as	O
sulfasalazine	O
target	O
.	O

AIM	O
:	O
Sulfasalazine	O
,	O
a	I-protein
nonsteroidal	O
anti-inflammatory	O
drug	O
,	O
is	O
effective	O
in	I-protein
treating	O
some	O
autoimmune	B-protein
diseases	O
,	O
but	O
its	O
mechanism	O
of	I-protein
action	O
is	O
unclear	O
.	O

To	O
determine	O
whether	O
dendritic	B-protein
cells	I-protein
could	O
be	O
a	I-protein
possible	O
target	O
of	I-protein
the	I-protein
drug	O
,	O
we	O
studied	O
the	I-protein
effects	O
of	I-protein
sulfasalazine	O
and	I-protein
its	O
metabolites	O
,	O
aminosalicylate	O
and	I-protein
sulfapyridine	O
,	O
on	I-protein
in	I-protein
vitro	O
maturation	I-protein
(	O
terminal	O
differentiation	I-protein
)	O
of	I-protein
human	O
myeloid	O
dendritic	B-protein
cells	I-protein
.	O

METHODS	O
:	O
We	O
prepared	O
immature	B-protein
dendritic	B-protein
cells	I-protein
by	I-protein
incubating	O
CD14-positive	O
cells	I-protein
in	I-protein
the	I-protein
presence	O
of	I-protein
granulocyte-	B-protein
macrophage	I-protein
colony-stimulating	I-protein
factor	I-protein
and	I-protein
interleukin	B-protein
(	O
IL	I-protein
)	O
-4	I-protein
.	O

The	O
cells	I-protein
were	O
matured	O
by	I-protein
addition	O
of	I-protein
tumor	B-protein
necrosis	I-protein
factor	I-protein
(	O
TNF	I-protein
)	O
-a	I-protein
,	O
IL-1	B-protein
beta	I-protein
,	O
and	I-protein
prostaglandin	O
E2	O
in	I-protein
the	I-protein
presence	O
of	I-protein
sulfasalazine	O
or	I-protein
its	O
metabolites	O
--	I-protein
aminosalicylate	O
and	I-protein
sulfapyridine	O
,	O
or	I-protein
their	O
combinations	O
.	O

We	O
quantified	O
the	I-protein
effect	O
of	I-protein
drugs	O
on	I-protein
the	I-protein
dendritic	B-protein
cell	O
characteristics	O
,	O
such	O
as	O
stimulation	I-protein
of	I-protein
autologous	O
and	I-protein
allogeneic	O
pan-T	O
cell	O
proliferation	I-protein
,	O
surface	O
marker	I-protein
phenotype	O
,	O
IL-12	O
p40	O
subunit	I-protein
secretion	O
,	O
and	I-protein
activation	I-protein
of	I-protein
nuclear	B-protein
transcription	I-protein
factor	I-protein
(	O
NF	I-protein
)	O
-kappa	I-protein
B	I-protein
.	O

RESULTS	O
:	O
Dendritic	O
cells	I-protein
treated	O
with	I-protein
sulfasalazine	O
(	O
1.25	O
micromol/L	O
or	I-protein
2.5	O
micromol/L	O
)	O
could	O
not	I-protein
stimulate	O
T	O
cells	I-protein
(	O
p	O
<	O
0.028	O
,	O
two-sided	O
paired	O
t-test	O
)	O
.	O

In	O
distinction	O
to	I-protein
drug-free	O
maturing	O
dendritic	B-protein
cells	I-protein
,	O
2.5	O
micromol/L	O
sulfasalazine	O
upregulated	O
the	I-protein
levels	I-protein
of	I-protein
CD14	B-protein
and	I-protein
CD68	B-protein
and	I-protein
downregulated	O
the	I-protein
levels	I-protein
of	I-protein
CD40	B-protein
,	O
CD80	B-protein
,	O
and	I-protein
CD83	B-protein
(	O
for	I-protein
all	O
CD	O
markers	O
,	O
p	O
<	O
0.03	O
for	I-protein
difference	O
between	O
measurements	O
in	I-protein
the	I-protein
absence	I-protein
and	I-protein
the	I-protein
presence	O
of	I-protein
sulfasalazine	O
)	O
.	O

From	O
concentration-dependent	O
changes	O
in	I-protein
CD83	B-protein
expression	I-protein
,	O
we	O
found	O
an	I-protein
apparent	O
ID50	O
>	O
>	O
1.5	I-protein
micromol/L	O
sulfasalazine	O
.	O

The	O
apparent	O
ID50	O
value	O
for	I-protein
aminosalicylate-inhibited	O
maturation	I-protein
was	O
4	I-protein
micromol/L	O
.	O

Sulfapyridine	O
had	O
no	I-protein
effect	O
.	O

At	O
1.25	O
micromol/L	O
,	O
sulfasalazine	O
largely	O
inhibited	O
NF-kB	O
activation	I-protein
in	I-protein
dendritic	B-protein
cells	I-protein
.	O

CONCLUSION	O
:	O
Maturing	O
human	O
dendritic	B-protein
cells	I-protein
are	O
hundred-fold	O
more	O
sensitive	I-protein
to	I-protein
sulfasalazine	O
than	I-protein
T	O
cells	I-protein
and	I-protein
NK	I-protein
cells	I-protein
and	I-protein
the	I-protein
most	O
sensitive	I-protein
human	O
cells	I-protein
described	O
so	O
far	B-protein
.	O

Thus	O
,	O
dendritic	B-protein
cell	O
maturation	I-protein
is	O
an	I-protein
important	O
target	O
of	I-protein
sulfasalazine	O
.	O

Because	O
of	I-protein
the	I-protein
role	O
of	I-protein
dendritic	B-protein
cells	I-protein
in	I-protein
(	O
auto	O
)	O
immunity	O
,	O
inhibition	O
of	I-protein
their	O
maturation	I-protein
might	O
provide	O
a	I-protein
target	O
for	I-protein
further	O
optimization	I-protein
of	I-protein
sulfasalazine	O
therapy	O
.	O

###MEDLINE:21359969

Defective	O
function	I-protein
of	I-protein
the	I-protein
proteasome	B-protein
in	I-protein
autoimmunity	O
:	O
involvement	I-protein
of	I-protein
impaired	O
NF-kappaB	B-protein
activation	I-protein
.	O

Type	I-protein
1	I-protein
diabetes	O
(	O
also	O
known	O
as	O
insulin-dependent	O
diabetes	O
mellitus	I-protein
or	I-protein
juvenile-onset	I-protein
diabetes	O
)	O
is	O
usually	O
caused	O
by	I-protein
T	O
cell-mediated	O
autoimmunity	O
,	O
with	I-protein
a	I-protein
prediabetic	O
state	I-protein
characterized	O
by	I-protein
the	I-protein
production	I-protein
of	I-protein
autoantibodies	O
specific	I-protein
for	I-protein
proteins	I-protein
expressed	O
by	I-protein
pancreatic	O
beta	O
cells	I-protein
.	O

The	O
nonobese	O
patient	O
with	I-protein
diabetes	O
(	O
NOD	B-protein
)	O
mouse	I-protein
is	O
a	I-protein
spontaneous	O
model	I-protein
of	I-protein
type	O
1	I-protein
diabetes	O
with	I-protein
a	I-protein
strong	O
genetic	O
component	O
that	O
maps	O
to	I-protein
the	I-protein
major	B-protein
histocompatibility	I-protein
complex	I-protein
(	O
MHC	O
)	O
region	O
of	I-protein
the	I-protein
genome	I-protein
.	O

A	O
specific	I-protein
proteasome	B-protein
defect	I-protein
has	O
been	O
identified	I-protein
in	I-protein
NOD	B-protein
mouse	I-protein
in	I-protein
select	O
lymphocytic	I-protein
and	I-protein
monocytic	I-protein
lineages	O
that	O
results	O
from	I-protein
down-regulation	O
of	I-protein
expression	I-protein
of	I-protein
the	I-protein
proteasome	B-protein
subunit	I-protein
LMP2	B-protein
,	O
which	O
is	O
encoded	O
by	I-protein
a	I-protein
gene	O
in	I-protein
the	I-protein
MHC	O
genomic	O
region	O
.	O

This	O
defect	I-protein
prevents	O
the	I-protein
proteolytic	I-protein
processing	O
required	O
for	I-protein
the	I-protein
production	I-protein
and	I-protein
activation	I-protein
of	I-protein
the	I-protein
transcription	B-protein
factor	I-protein
nuclear	I-protein
factor-kappaB	I-protein
(	O
NF-kappaB	B-protein
)	O
,	O
which	O
plays	O
important	O
roles	O
in	I-protein
immune	O
and	I-protein
inflammatory	O
responses	O
,	O
as	O
well	O
as	O
increases	O
the	I-protein
susceptibility	I-protein
of	I-protein
the	I-protein
affected	O
cells	I-protein
to	I-protein
apoptosis	O
induced	I-protein
by	I-protein
tumor	B-protein
necrosis	I-protein
factor-alpha	I-protein
(	O
TNF-alpha	B-protein
)	O
.	O

The	O
novel	O
role	O
of	I-protein
the	I-protein
proteasome	B-protein
in	I-protein
dysfunction	O
in	I-protein
autoimmunity	O
is	O
presented	O
and	I-protein
documented	O
to	I-protein
be	O
both	O
tissue	O
and	I-protein
developmental	O
stage	I-protein
specific	I-protein
.	O

We	O
propose	O
a	I-protein
role	O
of	I-protein
the	I-protein
proteasome	B-protein
as	O
a	I-protein
step	O
in	I-protein
disease	I-protein
pathogenesis	O
and	I-protein
tissue	O
targeting	I-protein
.	O

###MEDLINE:21352808

Down-regulation	O
of	I-protein
TDT	B-protein
transcription	O
in	I-protein
CD4	B-protein
(	O
+	O
)	O
CD8	O
(	O
+	O
)	O
thymocytes	O
by	I-protein
Ikaros	I-protein
proteins	I-protein
in	I-protein
direct	O
competition	O
with	I-protein
an	I-protein
Ets	B-protein
activator	I-protein
.	O

Ikaros	I-protein
is	O
a	I-protein
unique	I-protein
regulator	O
of	I-protein
lymphopoiesis	O
that	O
associates	O
with	I-protein
pericentromeric	O
heterochromatin	B-protein
and	I-protein
has	O
been	O
implicated	O
in	I-protein
heritable	O
gene	O
inactivation	O
.	O

Binding	O
and	I-protein
competition	O
experiments	O
demonstrate	O
that	O
Ikaros	I-protein
dimers	I-protein
compete	O
with	I-protein
an	I-protein
Ets	B-protein
activator	I-protein
for	I-protein
occupancy	O
of	I-protein
the	I-protein
lymphocyte-specific	O
TdT	O
promoter	I-protein
.	O

Mutations	O
that	O
selectively	O
disrupt	O
Ikaros	I-protein
binding	I-protein
to	I-protein
an	I-protein
integrated	O
TdT	O
promoter	I-protein
had	O
no	I-protein
effect	O
on	I-protein
promoter	I-protein
function	I-protein
in	I-protein
a	I-protein
CD4	B-protein
(	O
+	O
)	O
CD8	O
(	O
+	O
)	O
thymocyte	B-protein
line	I-protein
.	O

However	O
,	O
these	O
mutations	I-protein
abolished	O
down-regulation	O
on	I-protein
differentiation	I-protein
,	O
providing	O
evidence	O
that	O
Ikaros	I-protein
plays	O
a	I-protein
direct	O
role	O
in	I-protein
repression	I-protein
.	O

Reduced	O
access	O
to	I-protein
restriction	O
enzyme	I-protein
cleavage	O
suggested	O
that	O
chromatin	O
alterations	O
accompany	O
down-regulation	O
.	O

The	O
Ikaros-dependent	O
down-regulation	O
event	O
and	I-protein
the	I-protein
observed	O
chromatin	O
alterations	O
appear	O
to	I-protein
precede	O
pericentromeric	O
repositioning	O
.	O

Current	O
models	O
propose	O
that	O
the	I-protein
functions	O
of	I-protein
Ikaros	I-protein
should	O
be	O
disrupted	O
by	I-protein
a	I-protein
small	O
isoform	I-protein
that	O
retains	O
the	I-protein
dimerization	I-protein
domain	I-protein
and	I-protein
lacks	O
the	I-protein
DNA-binding	B-protein
domain	I-protein
.	O

Surprisingly	O
,	O
in	I-protein
the	I-protein
CD4	B-protein
(	O
+	O
)	O
CD8	O
(	O
+	O
)	O
thymocyte	B-protein
line	I-protein
,	O
overexpression	O
of	I-protein
a	I-protein
small	B-protein
Ikaros	I-protein
isoform	I-protein
had	O
no	I-protein
effect	O
on	I-protein
differentiation	I-protein
or	I-protein
on	I-protein
the	I-protein
pericentromeric	O
targeting	I-protein
and	I-protein
DNA-binding	O
properties	O
of	I-protein
Ikaros	I-protein
.	O

Rather	O
,	O
the	I-protein
small	O
isoform	I-protein
assembled	O
into	O
multimeric	B-protein
complexes	I-protein
with	I-protein
DNA-bound	B-protein
Ikaros	I-protein
at	I-protein
the	I-protein
pericentromeric	O
foci	I-protein
.	O

The	O
capacity	O
for	I-protein
in	I-protein
vivo	O
multimer	O
formation	O
suggests	O
that	O
interactions	O
between	O
Ikaros	I-protein
dimers	I-protein
bound	I-protein
to	I-protein
the	I-protein
TdT	O
promoter	I-protein
and	I-protein
those	O
bound	I-protein
to	I-protein
pericentromeric	O
repeat	I-protein
sequences	I-protein
may	O
contribute	O
to	I-protein
the	I-protein
pericentromeric	O
repositioning	O
of	I-protein
the	I-protein
inactive	O
gene	O
.	O

###MEDLINE:21341829

Type	I-protein
I	I-protein
interferons	I-protein
and	I-protein
IL-12	O
:	O
convergence	O
and	I-protein
cross-regulation	O
among	O
mediators	O
of	I-protein
cellular	O
immunity	O
.	O

Therapeutic	O
use	O
of	I-protein
type	B-protein
I	I-protein
IFN	B-protein
(	O
IFN-alpha/beta	B-protein
)	O
has	O
become	O
common	I-protein
.	O

Many	O
of	I-protein
the	I-protein
diverse	O
diseases	O
targeted	O
are	O
marked	O
by	I-protein
pathogenetic	O
abnormalities	I-protein
in	I-protein
cell-mediated	O
immunity	O
(	O
CMI	O
)	O
,	O
these	O
cellular	O
immune	O
responses	O
either	O
causing	O
injury	O
to	I-protein
the	I-protein
host	O
,	O
lacking	I-protein
sufficient	O
vigor	O
for	I-protein
virus	I-protein
or	I-protein
tumor	O
clearance	I-protein
,	O
or	I-protein
both	O
.	O

In	O
general	O
,	O
therapeutic	O
efficacy	O
is	O
limited	O
.	O

It	O
is	O
thus	O
notable	O
that	O
the	I-protein
pleiotropic	B-protein
effects	O
of	I-protein
type	B-protein
I	I-protein
IFN	B-protein
on	I-protein
CMI	O
remain	O
poorly	O
understood	O
.	O

We	O
characterized	O
the	I-protein
effects	O
of	I-protein
type	B-protein
I	I-protein
IFN	B-protein
on	I-protein
the	I-protein
production	I-protein
of	I-protein
IL-12	B-protein
,	O
the	I-protein
central	B-protein
immunoregulatory	I-protein
cytokine	I-protein
of	I-protein
the	I-protein
CD4	B-protein
(	O
+	O
)	O
T	O
cell	O
arm	O
of	I-protein
CMI	O
.	O

We	O
show	O
that	O
type	B-protein
I	I-protein
IFN	B-protein
are	O
potent	O
inhibitors	I-protein
of	I-protein
IL-12	B-protein
production	I-protein
by	I-protein
human	O
monocytes/macrophages	O
.	O

The	O
underlying	O
mechanism	O
involves	O
transcriptional	O
inhibition	O
of	I-protein
the	I-protein
IL-12p40	O
gene	O
,	O
marked	O
by	I-protein
down-regulation	O
of	I-protein
PU.1	B-protein
binding	I-protein
activity	I-protein
at	I-protein
the	I-protein
upstream	O
Ets	O
site	I-protein
of	I-protein
the	I-protein
IL-12p40	O
promoter	I-protein
.	O

Type	I-protein
I	I-protein
IFN	B-protein
have	O
previously	O
been	O
shown	O
to	I-protein
be	O
able	O
to	I-protein
substitute	O
for	I-protein
IL-12	B-protein
in	I-protein
driving	O
IFN-gamma	O
production	I-protein
from	I-protein
T	O
and	I-protein
NK	I-protein
cells	I-protein
.	O

The	O
ability	O
of	I-protein
IFN-alpha/beta	B-protein
to	I-protein
suppress	O
IL-12	O
production	I-protein
while	O
up-regulating	O
IFN-gamma	O
production	I-protein
suggests	O
a	I-protein
possible	O
mechanistic	O
basis	O
for	I-protein
the	I-protein
difficulties	O
of	I-protein
employing	O
these	O
cytokines	B-protein
in	I-protein
diseases	O
involving	O
abnormalities	I-protein
of	I-protein
CMI	O
.	O

###MEDLINE:21336723

Nuclear	I-protein
factor-kappaB	I-protein
suppressive	O
and	I-protein
inhibitor-kappaB	B-protein
stimulatory	I-protein
effects	O
of	I-protein
troglitazone	O
in	I-protein
obese	O
patients	O
with	I-protein
type	O
2	I-protein
diabetes	O
:	O
evidence	O
of	I-protein
an	I-protein
antiinflammatory	O
action	O
?	O

It	O
has	O
been	O
shown	O
recently	O
that	O
troglitazone	O
exerts	O
an	I-protein
anti-inflammatory	O
effect	O
,	O
in	I-protein
vitro	O
,	O
and	I-protein
in	I-protein
experimental	O
animals	O
.	O

To	O
test	O
these	O
properties	O
in	I-protein
humans	O
,	O
we	O
investigated	O
the	I-protein
effect	O
of	I-protein
troglitazone	O
on	I-protein
the	I-protein
proinflammatory	B-protein
transcription	I-protein
factor	I-protein
nuclear	I-protein
factor-kappaB	I-protein
and	I-protein
its	O
inhibitory	B-protein
protein	I-protein
IkappaB	I-protein
in	I-protein
mononuclear	O
cells	I-protein
(	O
MNC	O
)	O
and	I-protein
plasma	B-protein
soluble	I-protein
intracellular	I-protein
adhesion	I-protein
molecule-1	I-protein
,	O
monocyte	B-protein
chemoattractant	I-protein
protein-1	I-protein
,	O
plasminogen	B-protein
activator	I-protein
inhibitor-1	B-protein
,	O
and	I-protein
C-reactive	B-protein
protein	I-protein
.	O

We	O
also	O
examined	O
the	I-protein
effect	O
of	I-protein
troglitazone	O
on	I-protein
reactive	I-protein
oxygen	O
species	O
generation	O
,	O
p47	B-protein
(	O
phox	I-protein
)	O
subunit	I-protein
expression	I-protein
,	O
9-hydroxyoctadecadienoic	O
acid	O
(	O
9-HODE	O
)	O
,	O
13-HODE	O
,	O
o-tyrosine	O
,	O
and	I-protein
m-tyrosine	O
in	I-protein
obese	O
patients	O
with	I-protein
type	O
2	I-protein
diabetes	O
.	O

Seven	O
obese	O
patients	O
with	I-protein
type	O
2	I-protein
diabetes	O
were	O
treated	O
with	I-protein
troglitazone	O
(	O
400	O
mg/day	O
)	O
for	I-protein
4	I-protein
weeks	O
.	O

Blood	B-protein
samples	O
were	O
obtained	O
at	I-protein
weekly	O
intervals	O
.	O

Nuclear	I-protein
factor-kappaB	I-protein
binding	I-protein
activity	I-protein
in	I-protein
MNC	O
nuclear	O
extracts	O
was	O
significantly	O
inhibited	O
after	O
troglitazone	O
treatment	O
at	I-protein
week	O
1	I-protein
and	I-protein
continued	O
to	I-protein
be	O
inhibited	O
up	O
to	I-protein
week	O
4	I-protein
.	O

On	O
the	I-protein
other	O
hand	O
,	O
IkappaB	O
protein	O
levels	I-protein
increased	I-protein
significantly	O
after	O
troglitazone	O
treatment	O
at	I-protein
week	O
1	I-protein
,	O
and	I-protein
this	O
increase	O
persisted	O
throughout	O
the	I-protein
study	O
.	O

Plasma	I-protein
monocyte	B-protein
chemoattractant	I-protein
protein-1	I-protein
and	I-protein
soluble	I-protein
intracellular	I-protein
adhesion	I-protein
molecule-1	I-protein
concentrations	O
did	O
not	I-protein
decrease	O
significantly	O
after	O
troglitazone	O
treatment	O
,	O
although	O
there	O
was	O
a	I-protein
trend	O
toward	O
inhibition	O
.	O

Reactive	O
oxygen	O
species	O
generation	O
by	I-protein
polymorphonuclear	O
cells	I-protein
and	I-protein
MNC	O
,	O
p47	B-protein
(	O
phox	I-protein
)	O
subunit	I-protein
protein	I-protein
quantities	O
,	O
plasminogen	B-protein
activator	I-protein
inhibitor-1	B-protein
,	O
and	I-protein
C-reactive	B-protein
protein	I-protein
levels	I-protein
decreased	O
significantly	O
after	O
troglitazone	O
intake	O
.	O

13-HODE/linoleic	O
acid	O
and	I-protein
9-HODE/linoleic	O
acid	O
ratios	O
also	O
decreased	O
after	O
troglitazone	O
intake	O
.	O

However	O
,	O
o-tyrosine/phenylalanine	O
and	I-protein
m-tyrosine/phenylalanine	O
ratios	O
did	O
not	I-protein
change	O
significantly	O
.	O

These	O
data	O
show	O
that	O
troglitazone	O
has	O
profound	O
antiinflammatory	O
effects	O
in	I-protein
addition	O
to	I-protein
antioxidant	I-protein
effects	O
in	I-protein
obese	O
type	O
2	I-protein
diabetics	O
;	O
these	O
effects	O
may	O
be	O
relevant	I-protein
to	I-protein
the	I-protein
recently	O
described	O
beneficial	O
antiatherosclerotic	O
effects	O
of	I-protein
troglitazone	O
at	I-protein
the	I-protein
vascular	O
level	I-protein
.	O

###MEDLINE:21329455

OX40	B-protein
stimulation	I-protein
by	I-protein
gp34/OX40	B-protein
ligand	I-protein
enhances	O
productive	O
human	O
immunodeficiency	I-protein
virus	I-protein
type	O
1	I-protein
infection	I-protein
.	O

OX40	B-protein
is	O
a	I-protein
member	I-protein
of	I-protein
the	I-protein
tumor	B-protein
necrosis	I-protein
factor	I-protein
(	O
TNF	I-protein
)	O
receptor	I-protein
superfamily	I-protein
and	I-protein
known	O
to	I-protein
be	O
an	I-protein
important	O
costimulatory	B-protein
molecule	I-protein
expressed	O
on	I-protein
activated	O
T	O
cells	I-protein
.	O

To	O
investigate	O
the	I-protein
role	O
of	I-protein
costimulation	O
of	I-protein
OX40	B-protein
in	I-protein
human	O
immunodeficiency	I-protein
virus	I-protein
type	O
1	I-protein
(	O
HIV-1	O
)	O
infection	I-protein
by	I-protein
its	O
natural	O
ligand	O
,	O
gp34	B-protein
,	O
the	I-protein
OX40-transfected	O
ACH-2	O
cell	O
line	I-protein
,	O
ACH-2/OX40	O
,	O
chronically	O
infected	O
with	I-protein
HIV-1	O
,	O
was	O
cocultured	O
with	I-protein
paraformaldehyde	O
(	O
PFA	O
)	O
-fixed	O
gp34-transfected	O
mouse	I-protein
cell	O
line	I-protein
,	O
SV-T2/gp34	O
.	O

The	O
results	O
showed	O
that	O
HIV-1	O
production	I-protein
was	O
strongly	O
induced	I-protein
.	O

This	O
was	O
followed	O
by	I-protein
apparent	O
apoptosis	O
,	O
and	I-protein
both	O
processes	O
were	O
specifically	O
inhibited	O
by	I-protein
the	I-protein
gp34	B-protein
-specific	I-protein
neutralizing	B-protein
monoclonal	I-protein
antibody	I-protein
5A8	I-protein
.	O

Endogenous	O
TNF	B-protein
alpha	I-protein
(	O
TNF-alpha	B-protein
)	O
and	I-protein
TNF-beta	O
production	I-protein
were	O
not	I-protein
involved	I-protein
in	I-protein
the	I-protein
enhanced	I-protein
HIV-1	O
production	I-protein
.	O

Furthermore	O
,	O
enhanced	I-protein
HIV-1	O
transcription	O
in	I-protein
gp34	B-protein
-stimulated	O
ACH-2/OX40	O
cells	I-protein
was	O
dependent	I-protein
on	I-protein
the	I-protein
kappa	I-protein
B	O
site	I-protein
of	I-protein
the	I-protein
HIV-1	O
long	I-protein
terminal	O
repeat	I-protein
,	O
and	I-protein
the	I-protein
OX40-gp34	O
interaction	I-protein
activated	O
NF-kappa	B-protein
B	I-protein
consisting	O
of	I-protein
p50	B-protein
and	I-protein
p65	I-protein
subunits	I-protein
.	O

When	O
primary	O
activated	O
CD4	B-protein
(	O
+	O
)	O
T	O
cells	I-protein
acutely	O
infected	O
with	I-protein
HIV-1	O
(	O
NL4-3	O
)	O
(	O
CXCR4-using	O
T-cell-line-tropic	O
)	O
were	O
cocultured	O
with	I-protein
PFA-fixed	O
gp34	O
(	O
+	O
)	O
human	O
T-cell	O
leukemia	O
virus	I-protein
type	O
1-bearing	O
MT-2	O
cells	I-protein
or	I-protein
SV-T2/gp34	O
cells	I-protein
,	O
HIV-1	O
production	I-protein
was	O
also	O
markedly	O
enhanced	I-protein
.	O

The	O
enhancement	O
was	O
again	O
significantly	O
inhibited	O
by	I-protein
5A8	O
.	O

The	O
present	O
study	O
first	O
shows	O
that	O
OX40-gp34	O
interaction	I-protein
stimulates	O
HIV-1	O
expression	I-protein
and	I-protein
suggests	O
that	O
OX40	B-protein
triggering	O
by	I-protein
gp34	B-protein
may	O
play	O
an	I-protein
important	O
role	O
in	I-protein
enhancing	I-protein
HIV-1	O
production	I-protein
in	I-protein
both	O
acutely	O
and	I-protein
latently	O
infected	O
CD4	B-protein
(	O
+	O
)	O
T	O
cells	I-protein
in	I-protein
vivo	O
.	O

###MEDLINE:21319877

Troglitazone	O
,	O
a	I-protein
PPARgamma	B-protein
ligand	I-protein
,	O
inhibits	I-protein
osteopontin	O
gene	O
expression	I-protein
in	I-protein
human	O
monocytes/macrophage	O
THP-1	O
cells	I-protein
.	O

Peroxizome	B-protein
proliferator-activated	I-protein
receptor-gamma	I-protein
(	O
PPARgamma	B-protein
)	O
is	O
a	I-protein
member	I-protein
of	I-protein
the	I-protein
nuclear	B-protein
receptor	I-protein
family	I-protein
of	I-protein
transcription	B-protein
factors	I-protein
that	O
regulate	O
adipocyte	I-protein
differentiation	I-protein
.	O

Recent	O
studies	O
indicate	O
that	O
liganded	B-protein
PPARgamma	I-protein
not	I-protein
only	I-protein
promotes	O
differentiation	I-protein
but	O
also	O
inhibits	I-protein
the	I-protein
activation	I-protein
of	I-protein
macrophages	O
.	O

Osteopontin	B-protein
,	O
a	I-protein
component	O
of	I-protein
extracellular	O
matrix	O
,	O
is	O
synthesized	O
by	I-protein
macrophages	O
in	I-protein
atherosclerotic	O
plaques	O
.	O

In	O
this	O
study	O
,	O
we	O
examined	O
whether	O
PPARgamma	B-protein
ligand	O
regulates	O
osteopontin	O
gene	O
expression	I-protein
in	I-protein
THP-1	O
cells	I-protein
,	O
a	I-protein
cell	O
line	I-protein
derived	I-protein
from	I-protein
human	O
monocytic	I-protein
leukemia	O
cells	I-protein
which	O
can	O
differentiate	O
to	I-protein
macrophage	O
upon	O
stimulation	I-protein
with	I-protein
phorbol	O
ester	I-protein
PMA	O
.	O

Northern	O
blot	O
analysis	O
showed	O
that	O
osteopontin	O
expression	I-protein
is	O
markedly	O
induced	I-protein
in	I-protein
response	I-protein
to	I-protein
PMA	O
.	O

Troglitazone	O
,	O
a	I-protein
PPARgamma	B-protein
ligand	I-protein
,	O
dramatically	O
attenuated	O
the	I-protein
PMA-induced	O
osteopontin	O
expression	I-protein
.	O

Transient	I-protein
transfection	O
assays	O
of	I-protein
the	I-protein
human	O
osteopontin	O
promoter/luciferase	O
construct	O
which	O
contains	I-protein
a	I-protein
5'-flanking	O
region	O
between	O
-1500	O
and	I-protein
+87	O
relative	I-protein
to	I-protein
the	I-protein
transcription	O
start	O
site	I-protein
demonstrate	O
that	O
either	O
treatment	O
with	I-protein
troglitazone	O
or	I-protein
cotransfection	O
of	I-protein
PPARgamma	B-protein
expression	I-protein
vector	O
inhibits	I-protein
osteopontin	O
promoter	I-protein
activity	I-protein
.	O

These	O
data	O
indicate	O
that	O
troglitazone	O
reduces	O
osteopontin	O
gene	O
expression	I-protein
at	I-protein
transcriptional	O
level	I-protein
through	I-protein
PPARgamma	B-protein
activation	I-protein
,	O
and	I-protein
suggest	O
the	I-protein
role	O
of	I-protein
troglitazone	O
in	I-protein
inhibiting	I-protein
the	I-protein
ability	O
of	I-protein
macrophages	O
to	I-protein
produce	O
extracellular	O
matrix	O
,	O
which	O
is	O
particularly	O
relevant	I-protein
to	I-protein
atherosclerotic	O
plaque	O
formation	O
.	O

###MEDLINE:21311880

Transcription	I-protein
factor	I-protein
NF-kappa	I-protein
B	I-protein
regulates	O
Ig	I-protein
lambda	I-protein
light	I-protein
chain	I-protein
gene	O
rearrangement	O
.	O

The	O
tissue-	O
and	I-protein
stage-specific	O
assembly	I-protein
of	I-protein
Ig	I-protein
and	I-protein
TCR	O
genes	I-protein
is	O
mediated	I-protein
by	I-protein
a	I-protein
common	I-protein
V	B-protein
(	O
D	I-protein
)	O
J	I-protein
recombinase	I-protein
complex	I-protein
in	I-protein
precursor	I-protein
lymphocytes	O
.	O

Directed	O
alterations	O
in	I-protein
the	I-protein
accessibility	I-protein
of	I-protein
V	O
,	O
D	O
,	O
and	I-protein
J	I-protein
gene	O
segments	O
target	O
the	I-protein
recombinase	O
to	I-protein
specific	I-protein
Ag	I-protein
receptor	O
loci	O
.	O

Accessibility	O
within	B-protein
a	I-protein
given	O
locus	O
is	O
regulated	O
by	I-protein
the	I-protein
functional	O
interaction	I-protein
of	I-protein
transcription	B-protein
factors	I-protein
with	I-protein
cognate	I-protein
enhancer	O
elements	O
and	I-protein
correlates	O
with	I-protein
the	I-protein
transcriptional	O
activity	I-protein
of	I-protein
unrearranged	O
gene	O
segments	O
.	O

As	O
demonstrated	O
in	I-protein
our	O
prior	O
studies	O
,	O
rearrangement	O
of	I-protein
the	I-protein
Igkappa	O
locus	O
is	O
regulated	O
by	I-protein
the	I-protein
inducible	B-protein
transcription	I-protein
factor	I-protein
NF-kappaB	B-protein
.	O

In	O
contrast	O
to	I-protein
the	I-protein
Igkappa	O
locus	O
,	O
known	O
transcriptional	O
control	I-protein
elements	O
in	I-protein
the	I-protein
Iglambda	O
locus	O
lack	O
functional	O
NF-kappaB	B-protein
binding	I-protein
sites	I-protein
.	O

Consistent	O
with	I-protein
this	O
observation	O
,	O
the	I-protein
expression	I-protein
of	I-protein
assembled	O
Iglambda	O
genes	I-protein
in	I-protein
mature	B-protein
B	O
cells	I-protein
has	O
been	O
shown	O
to	I-protein
be	O
NF-kappaB	B-protein
independent	I-protein
.	O

Nonetheless	O
,	O
we	O
now	O
show	O
that	O
specific	I-protein
repression	I-protein
of	I-protein
NF-kappaB	B-protein
inhibits	I-protein
germline	O
transcription	O
and	I-protein
recombination	O
of	I-protein
Iglambda	O
gene	O
segments	O
in	I-protein
precursor	I-protein
B	O
cells	I-protein
.	O

Molecular	O
analyses	O
indicate	O
that	O
the	I-protein
block	O
in	I-protein
NF-kappaB	B-protein
impairs	O
Iglambda	O
rearrangement	O
at	I-protein
the	I-protein
level	I-protein
of	I-protein
recombinase	B-protein
accessibility	I-protein
.	O

In	O
contrast	O
,	O
the	I-protein
activities	O
of	I-protein
known	O
Iglambda	O
promoter	I-protein
and	I-protein
enhancer	O
elements	O
are	O
unaffected	O
in	I-protein
the	I-protein
same	O
cellular	O
background	O
.	O

These	O
findings	O
expand	O
the	I-protein
range	O
of	I-protein
NF-kappaB	B-protein
action	O
in	I-protein
precursor	I-protein
B	O
cells	I-protein
beyond	O
Igkappa	B-protein
to	I-protein
include	O
the	I-protein
control	I-protein
of	I-protein
recombinational	O
accessibility	I-protein
at	I-protein
both	O
L	O
chain	I-protein
loci	O
.	O

Moreover	O
,	O
our	O
results	O
strongly	O
suggest	O
the	I-protein
existence	O
of	I-protein
a	I-protein
novel	O
Iglambda	O
regulatory	O
element	I-protein
that	O
is	O
either	O
directly	O
or	I-protein
indirectly	O
activated	O
by	I-protein
NF-kappaB	B-protein
during	I-protein
the	I-protein
early	O
stages	O
of	I-protein
B	O
cell	O
development	O
.	O

###MEDLINE:21391971

Transcription	I-protein
factor	I-protein
STAT5A	B-protein
is	O
a	I-protein
substrate	I-protein
of	I-protein
Bruton	B-protein
's	I-protein
tyrosine	I-protein
kinase	I-protein
in	I-protein
B	O
cells	I-protein
.	O

STAT5A	B-protein
is	O
a	I-protein
molecular	I-protein
regulator	O
of	I-protein
proliferation	I-protein
,	O
differentiation	I-protein
,	O
and	I-protein
apoptosis	O
in	I-protein
lymphohematopoietic	O
cells	I-protein
.	O

Here	O
we	O
show	O
that	O
STAT5A	B-protein
can	O
serve	O
as	O
a	I-protein
functional	O
substrate	I-protein
of	I-protein
Bruton	B-protein
's	I-protein
tyrosine	I-protein
kinase	I-protein
(	O
BTK	B-protein
)	O
.	O

Purified	O
recombinant	B-protein
BTK	B-protein
was	O
capable	O
of	I-protein
directly	O
binding	I-protein
purified	B-protein
recombinant	I-protein
STAT5A	B-protein
with	I-protein
high	O
affinity	I-protein
(	O
K	O
(	O
d	I-protein
)	O
=	O
44	I-protein
nm	O
)	O
,	O
as	O
determined	O
by	I-protein
surface	O
plasmon	O
resonance	O
using	O
a	I-protein
BIAcore	O
biosensor	O
system	I-protein
.	O

BTK	B-protein
was	O
also	O
capable	O
of	I-protein
tyrosine-phosphorylating	O
ectopically	O
expressed	O
recombinant	B-protein
STAT5A	B-protein
on	I-protein
Tyr	O
(	O
694	O
)	O
both	O
in	I-protein
vitro	O
and	I-protein
in	I-protein
vivo	O
in	I-protein
a	I-protein
Janus	B-protein
kinase	I-protein
3	I-protein
-independent	O
fashion	O
.	O

BTK	B-protein
phosphorylated	O
the	I-protein
Y665F	B-protein
,	O
Y668F	I-protein
,	O
and	I-protein
Y682F	I-protein
,	O
Y683F	I-protein
mutants	I-protein
but	O
not	I-protein
the	I-protein
Y694F	B-protein
mutant	I-protein
of	I-protein
STAT5A	B-protein
.	O

STAT5A	B-protein
mutations	I-protein
in	I-protein
the	I-protein
Src	B-protein
homology	I-protein
2	I-protein
(	O
SH2	I-protein
)	O
and	I-protein
SH3	I-protein
domains	I-protein
did	O
not	I-protein
alter	O
the	I-protein
BTK	B-protein
-mediated	O
tyrosine	O
phosphorylation	I-protein
.	O

Recombinant	B-protein
BTK	B-protein
proteins	I-protein
with	I-protein
mutant	O
pleckstrin	O
homology	I-protein
,	O
SH2	B-protein
,	O
or	I-protein
SH3	I-protein
domains	I-protein
were	O
capable	O
of	I-protein
phosphorylating	O
STAT5A	B-protein
,	O
whereas	O
recombinant	B-protein
BTK	B-protein
proteins	I-protein
with	I-protein
SH1/kinase	O
domain	I-protein
mutations	I-protein
were	O
not	I-protein
.	O

In	O
pull-down	O
experiments	O
,	O
only	I-protein
full-length	B-protein
BTK	B-protein
and	I-protein
its	O
SH1/kinase	B-protein
domain	I-protein
(	O
but	O
not	I-protein
the	I-protein
pleckstrin	O
homology	I-protein
,	O
SH2	B-protein
,	O
or	I-protein
SH3	I-protein
domains	I-protein
)	O
were	O
capable	O
of	I-protein
binding	I-protein
STAT5A	B-protein
.	O

Ectopically	O
expressed	O
BTK	B-protein
kinase	I-protein
domain	I-protein
was	O
capable	O
of	I-protein
tyrosine-phosphorylating	O
STAT5A	B-protein
both	O
in	I-protein
vitro	O
and	I-protein
in	I-protein
vivo	O
.	O

BTK	B-protein
-mediated	O
tyrosine	O
phosphorylation	I-protein
of	I-protein
ectopically	O
expressed	O
wild	O
type	O
(	O
but	O
not	I-protein
Tyr	B-protein
(	O
694	I-protein
)	O
mutant	I-protein
)	O
STAT5A	B-protein
enhanced	I-protein
its	O
DNA	O
binding	I-protein
activity	I-protein
.	O

In	O
BTK	B-protein
-competent	O
chicken	I-protein
B	O
cells	I-protein
,	O
anti-IgM-stimulated	O
tyrosine	O
phosphorylation	I-protein
of	I-protein
STAT5	B-protein
protein	I-protein
was	O
prevented	O
by	I-protein
pretreatment	O
with	I-protein
the	I-protein
BTK	B-protein
inhibitor	O
LFM-A13	O
but	O
not	I-protein
by	I-protein
pretreatment	O
with	I-protein
the	I-protein
JAK3	B-protein
inhibitor	O
HI-P131	O
.	O

B	O
cell	O
antigen	O
receptor	O
ligation	O
resulted	O
in	I-protein
enhanced	I-protein
tyrosine	O
phosphorylation	I-protein
of	I-protein
STAT5	B-protein
in	I-protein
BTK	B-protein
-deficient	O
chicken	I-protein
B	O
cells	I-protein
reconstituted	O
with	I-protein
wild	B-protein
type	I-protein
human	I-protein
BTK	B-protein
but	O
not	I-protein
in	I-protein
BTK	B-protein
-deficient	O
chicken	I-protein
B	O
cells	I-protein
reconstituted	O
with	I-protein
kinase-inactive	B-protein
mutant	I-protein
BTK	B-protein
.	O

Similarly	O
,	O
anti-IgM	O
stimulation	I-protein
resulted	O
in	I-protein
enhanced	I-protein
tyrosine	O
phosphorylation	I-protein
of	I-protein
STAT5A	B-protein
in	I-protein
BTK	B-protein
-competent	O
B	O
cells	I-protein
from	I-protein
wild	O
type	O
mice	O
but	O
not	I-protein
in	I-protein
BTK	B-protein
-deficient	O
B	O
cells	I-protein
from	I-protein
XID	O
mice	O
.	O

In	O
contrast	O
to	I-protein
B	O
cells	I-protein
from	I-protein
XID	O
mice	O
,	O
B	O
cells	I-protein
from	I-protein
JAK3	B-protein
knockout	O
mice	O
showed	O
a	I-protein
normal	O
STAT5A	B-protein
phosphorylation	I-protein
response	I-protein
to	I-protein
anti-IgM	O
stimulation	I-protein
.	O

These	O
findings	O
provide	O
unprecedented	O
experimental	O
evidence	O
that	O
BTK	B-protein
plays	O
a	I-protein
nonredundant	O
and	I-protein
pivotal	O
role	O
in	I-protein
B	O
cell	O
antigen	O
receptor-mediated	O
STAT5A	B-protein
activation	I-protein
in	I-protein
B	O
cells	I-protein

###MEDLINE:21291437

Role	O
of	I-protein
T-bet	B-protein
in	I-protein
commitment	O
of	I-protein
TH1	B-protein
cells	I-protein
before	O
IL-12	B-protein
-dependent	I-protein
selection	O
.	O

How	O
cytokines	B-protein
control	I-protein
differentiation	I-protein
of	I-protein
helper	I-protein
T	O
(	O
TH	O
)	O
cells	I-protein
is	O
controversial	O
.	O

We	O
show	O
that	O
T-bet	B-protein
,	O
without	I-protein
apparent	O
assistance	O
from	I-protein
interleukin	B-protein
12	I-protein
(	O
IL-12	B-protein
)	O
/	O
STAT4	B-protein
,	O
specifies	O
TH1	B-protein
effector	O
fate	O
by	I-protein
targeting	I-protein
chromatin	O
remodeling	B-protein
to	I-protein
individual	O
interferon-gamma	O
(	O
IFN-gamma	B-protein
)	O
alleles	O
and	I-protein
by	I-protein
inducing	I-protein
IL-12	O
receptor	O
beta2	O
expression	I-protein
.	O

Subsequently	O
,	O
it	O
appears	O
that	O
IL-12	B-protein
/	O
STAT4	B-protein
serves	O
two	O
essential	O
functions	O
in	I-protein
the	I-protein
development	O
of	I-protein
TH1	B-protein
cells	I-protein
:	O
as	O
growth	O
signal	O
,	O
inducing	I-protein
survival	B-protein
and	I-protein
cell	O
division	I-protein
;	O
and	I-protein
as	O
trans-activator	O
,	O
prolonging	O
IFN-gamma	B-protein
synthesis	I-protein
through	I-protein
a	I-protein
genetic	O
interaction	I-protein
with	I-protein
the	I-protein
coactivator	B-protein
,	O
CREB-binding	B-protein
protein	I-protein
.	O

These	O
results	O
suggest	O
that	O
a	I-protein
cytokine	B-protein
does	O
not	I-protein
simply	O
induce	O
TH	O
fate	O
choice	O
but	O
instead	I-protein
may	O
act	O
as	O
an	I-protein
essential	O
secondary	O
stimulus	O
that	O
mediates	O
selective	O
survival	B-protein
of	I-protein
a	I-protein
lineage	I-protein
.	O

###MEDLINE:21286476

Stat6	B-protein
is	O
necessary	O
and	I-protein
sufficient	O
for	I-protein
IL-4	B-protein
's	I-protein
role	O
in	I-protein
Th2	O
differentiation	I-protein
and	I-protein
cell	O
expansion	O
.	O

IL-4	B-protein
plays	O
a	I-protein
critical	I-protein
role	O
in	I-protein
the	I-protein
differentiation	I-protein
of	I-protein
T	O
CR-stimulated	O
naive	O
CD4	B-protein
T	O
cells	I-protein
to	I-protein
the	I-protein
Th2	O
phenotype	O
.	O

In	O
response	I-protein
to	I-protein
IL-4	B-protein
,	O
the	I-protein
IL-4R	B-protein
activates	O
a	I-protein
set	O
of	I-protein
phosphotyrosine	B-protein
binding	I-protein
domain-containing	I-protein
proteins	I-protein
,	O
including	I-protein
insulin	B-protein
receptor	I-protein
substrate	I-protein
1/2	I-protein
,	O
Shc	B-protein
,	O
and	I-protein
IL-4R	B-protein
interacting	I-protein
protein	I-protein
,	O
as	O
well	O
as	O
Stat6	B-protein
.	O

Stat6	O
has	O
been	O
shown	O
to	I-protein
be	O
required	O
for	I-protein
Th2	O
differentiation	I-protein
.	O

To	O
determine	O
the	I-protein
roles	O
of	I-protein
the	I-protein
phosphotyrosine	B-protein
binding	I-protein
adaptors	I-protein
in	I-protein
Th2	O
differentiation	I-protein
,	O
we	O
prepared	O
a	I-protein
retrovirus	I-protein
containing	I-protein
a	I-protein
mutant	O
of	I-protein
the	I-protein
human	B-protein
(	O
h	I-protein
)	O
IL-4R	I-protein
alpha-chain	B-protein
,	O
Y497F	B-protein
,	O
which	O
is	O
unable	O
to	I-protein
recruit	O
these	O
adaptors	O
.	O

The	O
mutant	B-protein
hIL-4Ralpha	I-protein
,	O
as	O
well	O
as	O
the	I-protein
wild-type	I-protein
(	O
WT	I-protein
)	O
hIL-4Ralpha	I-protein
,	O
was	O
introduced	O
into	O
naive	O
CD4	B-protein
T	O
cells	I-protein
.	O

Upon	O
hIL-4	O
stimulation	I-protein
,	O
Y497F	B-protein
worked	O
as	O
well	O
as	O
the	I-protein
WT	B-protein
hIL-4Ralpha	I-protein
in	I-protein
driving	O
Th2	O
differentiation	I-protein
,	O
as	O
measured	O
by	I-protein
Gata3	O
up-regulation	O
and	I-protein
IL-4	B-protein
production	I-protein
.	O

Furthermore	O
,	O
IL-4-driven	O
cell	O
expansion	O
was	O
also	O
normal	O
in	I-protein
the	I-protein
cells	I-protein
infected	O
with	I-protein
Y497F	B-protein
,	O
although	O
cells	I-protein
infected	O
with	I-protein
Y497F	B-protein
were	O
not	I-protein
capable	O
of	I-protein
phosphorylating	O
insulin	B-protein
receptor	I-protein
substrate	I-protein
2	I-protein
.	O

These	O
results	O
suggest	O
that	O
the	I-protein
signal	O
pathway	I-protein
mediated	I-protein
by	I-protein
Y497	B-protein
is	O
dispensable	O
for	I-protein
both	O
IL-4	B-protein
-driven	O
Th2	O
differentiation	I-protein
and	I-protein
cell	O
expansion	O
.	O

Both	O
WT	B-protein
and	I-protein
Y497F	I-protein
hIL-4Ralpha	I-protein
lose	O
the	I-protein
ability	O
to	I-protein
drive	O
Th2	O
differentiation	I-protein
and	I-protein
cell	O
expansion	O
in	I-protein
Stat6-knockout	O
CD4	B-protein
T	O
cells	I-protein
.	O

A	O
constitutively	O
activated	O
form	I-protein
of	I-protein
Stat6	B-protein
introduced	O
into	O
CD4	B-protein
T	O
cells	I-protein
resulted	O
in	I-protein
both	O
Th2	O
differentiation	I-protein
and	I-protein
enhanced	I-protein
cell	O
expansion	O
.	O

Thus	O
,	O
activated	B-protein
Stat6	I-protein
is	O
necessary	O
and	I-protein
sufficient	O
to	I-protein
mediate	O
both	O
IL-4	B-protein
-driven	O
Th2	O
differentiation	I-protein
and	I-protein
cell	O
expansion	O
in	I-protein
CD4	B-protein
T	O
cells	I-protein
.	O

###MEDLINE:21278505

The	O
effect	O
of	I-protein
HIV-1	B-protein
regulatory	I-protein
proteins	I-protein
on	I-protein
cellular	O
genes	I-protein
:	O
derepression	O
of	I-protein
the	I-protein
IL-2	B-protein
promoter	I-protein
by	I-protein
Tat	I-protein
.	O

In	O
HIV-infected	O
individuals	O
dysregulation	O
of	I-protein
the	I-protein
immune	O
system	I-protein
is	O
characterized	O
by	I-protein
severe	I-protein
disorders	O
of	I-protein
the	I-protein
cytokine	O
network	I-protein
.	O

Increase	O
secretion	O
of	I-protein
IL-2	B-protein
,	O
the	I-protein
major	O
T	O
cell	O
growth	O
and	I-protein
differentiation	I-protein
cytokine	B-protein
,	O
may	O
play	O
a	I-protein
decisive	O
role	O
in	I-protein
sensitization	O
of	I-protein
T	O
cells	I-protein
for	I-protein
activation	I-protein
induced	I-protein
apoptosis	O
and	I-protein
indirect	O
death	O
of	I-protein
activated	O
T	O
cells	I-protein
through	I-protein
augmented	O
virus	I-protein
replication	O
.	O

We	O
investigated	O
the	I-protein
cause	O
of	I-protein
enhanced	I-protein
IL-2	B-protein
secretion	O
and	I-protein
found	O
that	O
the	I-protein
HIV	I-protein
Tat	I-protein
induces	O
this	O
effect	O
.	O

We	O
demonstrate	O
that	O
increased	I-protein
IL-2	B-protein
secretion	O
is	O
due	I-protein
to	I-protein
Tat	I-protein
-enhanced	O
IL-2	B-protein
promoter	I-protein
activation	I-protein
.	O

Tat	I-protein
derepresses	O
and	I-protein
activates	O
the	I-protein
distal	I-protein
AP-1	I-protein
site	I-protein
(	O
position	O
-185	O
to	I-protein
-177	O
)	O
in	I-protein
the	I-protein
IL-2	B-protein
promoter	I-protein
.	O

In	O
nonstimulated	O
T	O
cells	I-protein
a	I-protein
repressor	O
complex	I-protein
containing	I-protein
NF-IL6	B-protein
,	O
JunB	B-protein
,	O
c-Fos	B-protein
and	I-protein
Fra-1	B-protein
is	O
formed	O
on	I-protein
the	I-protein
AP-1	I-protein
(	O
IL-2/d	O
)	O
site	I-protein
and	I-protein
represses	O
IL-2	B-protein
promoter	I-protein
activity	I-protein
.	O

After	O
T	O
cell	O
activation	I-protein
,	O
a	I-protein
heterodimeric	B-protein
activator	I-protein
containing	I-protein
p65	I-protein
and	I-protein
c-Jun	B-protein
binds	O
to	I-protein
the	I-protein
AP-1	I-protein
(	O
IL-2/d	O
)	O
site	I-protein
.	O

HIV	I-protein
Tat	I-protein
enhances	O
activation	I-protein
of	I-protein
NF-kappaB	B-protein
and	I-protein
consequently	O
,	O
activates	O
the	I-protein
AP-1	I-protein
(	O
IL-2/d	O
)	O
site	I-protein
.	O

Our	O
data	O
provide	O
evidence	O
for	I-protein
a	I-protein
novel	O
mechanism	O
by	I-protein
which	O
HIV	I-protein
Tat	I-protein
dysregulates	O
IL-2	B-protein
production	I-protein
and	I-protein
therefore	O
may	O
contribute	O
to	I-protein
the	I-protein
HIV-1	O
infection	I-protein
in	I-protein
a	I-protein
way	O
yet	O
to	I-protein
be	O
clarified	O
.	O

###MEDLINE:21272363

Transforming	B-protein
growth	I-protein
factor-beta1	I-protein
interferes	O
with	I-protein
thrombopoietin-induced	O
signal	O
transduction	I-protein
in	I-protein
megakaryoblastic	B-protein
and	I-protein
erythroleukemic	O
cells	I-protein
.	O

OBJECTIVE	O
:	O
Thrombopoietin	B-protein
(	O
TPO	B-protein
)	O
and	I-protein
transforming	B-protein
growth	I-protein
factor-beta	I-protein
(	O
1	I-protein
)	O
(	O
TGF-beta	I-protein
(	O
1	I-protein
)	O
)	O
have	O
been	O
shown	O
to	I-protein
exert	O
opposite	O
effects	O
on	I-protein
proliferation	I-protein
and	I-protein
megakaryocytic	O
differentiation	I-protein
of	I-protein
hematopoietic	O
cells	I-protein
.	O

To	O
determine	O
whether	O
TGF-beta	I-protein
(	O
1	I-protein
)	O
interferes	O
directly	O
with	I-protein
TPO	B-protein
-induced	O
signal	O
transduction	I-protein
in	I-protein
hematopoietic	O
cells	I-protein
,	O
we	O
compared	O
the	I-protein
regulatory	O
effects	O
in	I-protein
the	I-protein
TPO	B-protein
-responsive	O
cell	O
lines	B-protein
Mo-7e	O
and	I-protein
HEL	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
The	O
cells	I-protein
were	O
stimulated	O
by	I-protein
100	I-protein
ng/mL	O
TPO	B-protein
and/or	O
100	I-protein
ng/mL	O
TGF-beta1	B-protein
and	I-protein
analyzed	O
for	I-protein
proliferation	I-protein
(	O
3H	I-protein
thymidine	B-protein
incorporation	O
)	O
,	O
viability	O
(	O
trypan	O
blue	O
exclusion	O
)	O
,	O
and	I-protein
protein	O
expression	I-protein
and	I-protein
phosphorylation	I-protein
(	O
Western	O
blot	O
)	O
.	O

RESULTS	O
:	O
TPO	B-protein
enhanced	I-protein
the	I-protein
proliferation	I-protein
of	I-protein
Mo-7e	O
cells	I-protein
as	O
determined	O
by	I-protein
3H-thymidine	O
incorporation	O
,	O
whereas	O
TGF-beta1	B-protein
suppressed	I-protein
baseline	O
cell	O
growth	O
and	I-protein
antagonized	O
the	I-protein
proliferative	O
effect	O
of	I-protein
TPO	B-protein
.	O

TPO	B-protein
-induced	O
proliferation	I-protein
also	O
was	O
reduced	O
by	I-protein
a	I-protein
specific	I-protein
inhibitor	O
of	I-protein
the	I-protein
mitogen-activated	B-protein
protein	I-protein
kinase	I-protein
(	O
MAPK	I-protein
)	O
pathway	I-protein
(	O
PD098059	O
)	O
,	O
which	O
inhibits	I-protein
activation	I-protein
of	I-protein
the	I-protein
MAPK	I-protein
extracellular	I-protein
signal-regulated	I-protein
kinases	I-protein
(	O
ERK	B-protein
)	O
ERK1	B-protein
and	I-protein
ERK2	B-protein
,	O
and	I-protein
AG490	O
,	O
an	I-protein
inhibitor	O
of	I-protein
Janus	B-protein
kinase-2	I-protein
,	O
which	O
completely	O
blocked	B-protein
TPO	B-protein
-induced	O
proliferation	I-protein
.	O

As	O
demonstrated	O
by	I-protein
Western	O
blotting	O
,	O
TGF-beta1	B-protein
reduced	O
the	I-protein
TPO	B-protein
-stimulated	O
ERK1	B-protein
/	O
ERK2	B-protein
and	I-protein
STAT5	B-protein
phosphorylation	I-protein
in	I-protein
Mo-7e	O
and	I-protein
HEL	O
cells	I-protein
.	O

This	O
effect	O
was	O
completely	O
reversed	O
by	I-protein
preincubation	O
with	I-protein
a	I-protein
tyrosine	O
phosphatase	O
inhibitor	O
(	O
Na3VO4	O
)	O
,	O
which	O
suggests	O
that	O
TGF-beta1	B-protein
activated	O
a	I-protein
phosphatase	B-protein
.	O

Although	O
STAT3	B-protein
also	O
was	O
activated	O
by	I-protein
TPO	B-protein
,	O
STAT3	B-protein
activation	I-protein
remained	O
unaltered	O
by	I-protein
TGF-beta1	B-protein
.	O

CONCLUSION	O
:	O
Taken	O
together	O
,	O
these	O
data	O
suggest	O
that	O
TGF-beta1	B-protein
modulates	O
TPO	B-protein
-mediated	O
effects	O
on	I-protein
megakaryocytic	O
proliferation	I-protein
by	I-protein
interfering	I-protein
with	I-protein
TPO	B-protein
-induced	O
signal	O
transduction	I-protein
,	O
particularly	O
by	I-protein
reducing	O
the	I-protein
activities	O
of	I-protein
MAPK	I-protein
ERK1/ERK2	I-protein
and	I-protein
STAT5	B-protein
.	O

###MEDLINE:21347972

Invariant	B-protein
chain	I-protein
induces	O
B	O
cell	O
maturation	I-protein
by	I-protein
activating	O
a	I-protein
TAF	B-protein
(	O
II	I-protein
)	O
105-NF-kappaB	I-protein
-dependent	I-protein
transcription	O
program	O
.	O

Early	O
stages	O
of	I-protein
B	O
cell	O
development	O
occur	O
in	I-protein
the	I-protein
bone	O
marrow	I-protein
,	O
resulting	O
in	I-protein
formation	O
of	I-protein
immature	B-protein
B	O
cells	I-protein
.	O

From	O
there	O
these	O
immature	B-protein
cells	I-protein
migrate	O
to	I-protein
the	I-protein
spleen	B-protein
where	O
they	O
differentiate	O
to	I-protein
mature	B-protein
cells	I-protein
.	O

This	O
final	O
maturation	I-protein
step	O
is	O
crucial	O
for	I-protein
the	I-protein
B	O
cells	I-protein
to	I-protein
become	O
responsive	I-protein
to	I-protein
antigens	I-protein
and	I-protein
to	I-protein
participate	O
in	I-protein
the	I-protein
immune	O
response	I-protein
.	O

Recently	O
,	O
invariant	I-protein
chain	I-protein
(	O
Ii	O
)	O
,	O
a	I-protein
major	B-protein
histocompatibility	I-protein
complex	I-protein
class	I-protein
II	I-protein
chaperone	I-protein
,	O
as	O
well	O
as	O
the	I-protein
transcription	B-protein
factors	I-protein
c-Rel	B-protein
and	I-protein
p65/RelA	O
,	O
were	O
found	O
to	I-protein
play	O
a	I-protein
role	O
in	I-protein
the	I-protein
final	O
antigen-independent	O
differentiation	I-protein
stage	I-protein
of	I-protein
B	O
cells	I-protein
in	I-protein
the	I-protein
spleen	B-protein
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
a	I-protein
possible	O
link	I-protein
between	O
Ii	B-protein
-dependent	I-protein
B	O
cell	O
maturation	I-protein
and	I-protein
the	I-protein
NF-kappaB	B-protein
pathway	I-protein
.	O

Our	O
studies	O
indicate	O
that	O
Ii	B-protein
-induced	O
B	O
cell	O
maturation	I-protein
involves	O
activation	I-protein
of	I-protein
transcription	O
mediated	I-protein
by	I-protein
the	I-protein
NF-kappaB	B-protein
p65/RelA	I-protein
homodimer	B-protein
and	I-protein
requires	O
the	I-protein
B	B-protein
cell-enriched	I-protein
coactivator	I-protein
TBP-associated	I-protein
factor	I-protein
(	O
II	I-protein
)	O
105	I-protein
.	O

###MEDLINE:21258442

Androgens	O
indirectly	O
accelerate	O
thymocyte	B-protein
apoptosis	O
.	O

Apoptotic	O
processes	O
,	O
or	I-protein
the	I-protein
disturbance	O
of	I-protein
the	I-protein
natural	O
regulation	I-protein
of	I-protein
these	O
processes	O
,	O
may	O
be	O
involved	I-protein
in	I-protein
the	I-protein
pathogenesis	O
of	I-protein
autoimmune	B-protein
diseases	O
(	O
AID	B-protein
)	O
.	O

Women	O
are	O
,	O
in	I-protein
general	O
,	O
more	O
susceptible	O
than	I-protein
men	O
to	I-protein
develop	O
AID	B-protein
like	I-protein
rheumatoid	O
arthritis	I-protein
.	O

Androgens	O
and	I-protein
glucocorticoids	O
,	O
in	I-protein
contrast	O
to	I-protein
oestrogens	O
,	O
have	O
favourable	O
effects	O
in	I-protein
AID	B-protein
models	O
as	O
well	O
as	O
in	I-protein
human	O
AID	B-protein
.	O

It	O
is	O
known	O
that	O
glucocorticoids	O
(	O
GC	O
)	O
,	O
used	O
for	I-protein
treatment	O
of	I-protein
AID	B-protein
,	O
increase	O
apoptosis	O
in	I-protein
the	I-protein
thymus	I-protein
resulting	O
in	I-protein
decreased	O
numbers	O
of	I-protein
CD4+	O
CD8+	O
thymocytes	O
.	O

It	O
was	O
asked	O
whether	O
androgens	O
,	O
in	I-protein
contrast	O
to	I-protein
oestrogens	O
,	O
exert	O
their	O
favourable	O
effects	O
in	I-protein
the	I-protein
treatment	O
of	I-protein
AID	B-protein
by	I-protein
a	I-protein
mechanism	O
comparable	O
to	I-protein
that	O
described	O
for	I-protein
GC	O
by	I-protein
eliminating	O
the	I-protein
apoptosis	O
prone	O
CD4+	O
CD8+	O
population	O
in	I-protein
the	I-protein
thymus	I-protein
.	O

Although	O
both	O
androgens	O
and	I-protein
oestrogens	O
proved	O
thymolytic	O
,	O
a	I-protein
significantly	O
decreased	O
percentage	O
of	I-protein
CD4+	O
CD8+	O
thymocytes	O
was	O
observed	O
by	I-protein
flow	O
cytometry	O
after	O
treatment	O
of	I-protein
mice	O
with	I-protein
the	I-protein
androgen	O
methyltestosterone	O
,	O
but	O
not	I-protein
with	I-protein
the	I-protein
oestrogen	O
ethinylestradiol	O
.	O

To	O
investigate	O
whether	O
the	I-protein
observed	O
thymolytic	O
effects	O
were	O
due	I-protein
to	I-protein
the	I-protein
presence	O
of	I-protein
hormone	I-protein
receptors	I-protein
on	I-protein
thymocytes	O
,	O
cells	I-protein
were	O
isolated	I-protein
from	I-protein
the	I-protein
thymus	I-protein
and	I-protein
incubated	O
with	I-protein
androgens	O
or	I-protein
oestrogens	O
to	I-protein
measure	O
apoptosis	O
.	O

Several	O
techniques	O
were	O
used	O
to	I-protein
determine	O
thymocyte	B-protein
apoptosis	O
in	I-protein
vitro	O
,	O
but	O
no	I-protein
enhanced	I-protein
apoptotic	O
signal	O
was	O
observed	O
.	O

Using	O
the	I-protein
very	O
sensitive	I-protein
TUNEL	O
assay	O
,	O
no	I-protein
direct	O
effect	O
of	I-protein
androgens	O
on	I-protein
thymocytes	O
in	I-protein
vitro	O
could	O
be	O
observed	O
.	O

This	O
is	O
in	I-protein
sharp	O
contrast	O
to	I-protein
the	I-protein
high	O
signal	O
observed	O
with	I-protein
GC	O
.	O

Therefore	O
,	O
upon	O
in	I-protein
vivo	O
androgen	O
treatment	O
,	O
other	O
cells	I-protein
containing	I-protein
androgen	B-protein
receptors	I-protein
than	I-protein
thymocytes	O
are	O
probably	O
involved	I-protein
in	I-protein
inducing	I-protein
the	I-protein
increase	O
in	I-protein
thymic	B-protein
apoptosis	O
.	O

To	O
study	O
the	I-protein
role	O
of	I-protein
the	I-protein
androgen	B-protein
receptor	I-protein
on	I-protein
thymocyte	B-protein
apoptosis	O
,	O
androgen	B-protein
receptor	I-protein
mutant	O
(	O
Tfm/Y	O
)	O
mice	O
were	O
treated	O
with	I-protein
androgens	O
.	O

No	I-protein
alterations	O
of	I-protein
thymocyte	B-protein
subpopulations	O
were	O
seen	O
,	O
suggesting	O
that	O
changes	O
in	I-protein
the	I-protein
percentage	O
of	I-protein
CD4+	O
CD8+	O
thymocytes	O
after	O
administration	O
of	I-protein
androgens	O
depend	O
on	I-protein
the	I-protein
presence	O
of	I-protein
functional	O
androgen	B-protein
receptors	I-protein
.	O

Thus	O
,	O
it	O
is	O
concluded	O
that	O
androgens	O
indirectly	O
accelerate	O
thymocyte	B-protein
apoptosis	O
in	I-protein
vivo	O
.	O

###MEDLINE:21256403

Inhibition	O
of	I-protein
the	I-protein
transcription	B-protein
factors	I-protein
AP-1	I-protein
and	I-protein
NF-kappaB	B-protein
in	I-protein
CD4	B-protein
T	O
cells	I-protein
by	I-protein
peroxisome	B-protein
proliferator-activated	I-protein
receptor	I-protein
gamma	I-protein
ligands	I-protein
.	O

The	O
peroxisome	B-protein
proliferator-activated	I-protein
receptor	I-protein
gamma	I-protein
(	O
PPARgamma	B-protein
)	O
,	O
a	I-protein
member	I-protein
of	I-protein
the	I-protein
nuclear	B-protein
hormone	I-protein
receptor	I-protein
superfamily	I-protein
,	O
is	O
essential	O
for	I-protein
adipocyte	I-protein
differentiation	I-protein
and	I-protein
glucose	O
homeostasis	I-protein
.	O

PPARgamma	B-protein
has	O
been	O
found	O
recently	O
to	I-protein
regulate	O
macrophage	O
activation	I-protein
in	I-protein
response	I-protein
to	I-protein
mitogens	B-protein
and	I-protein
inflammation	O
.	O

Our	O
study	O
shows	O
PPARgamma	B-protein
to	I-protein
be	O
preferentially	O
expressed	O
in	I-protein
the	I-protein
nuclei	O
of	I-protein
resting	O
T	O
cells	I-protein
and	I-protein
to	I-protein
increase	O
upon	O
activation	I-protein
of	I-protein
T	O
cells	I-protein
by	I-protein
either	O
anti-CD3	B-protein
and	I-protein
anti-CD28	B-protein
or	I-protein
phorbol	O
myristyl	O
acetate	O
(	O
PMA	O
)	O
.	O

We	O
also	O
found	O
the	I-protein
PPARgamma	B-protein
ligand	I-protein
ciglitizone	O
to	I-protein
attenuate	O
the	I-protein
activation	I-protein
of	I-protein
T	O
cells	I-protein
by	I-protein
inhibiting	I-protein
cytokine	O
gene	O
expression	I-protein
and	I-protein
anti-CD3	B-protein
and	I-protein
anti-CD28	B-protein
or	I-protein
PMA-induced	O
proliferative	O
responses	O
.	O

Inhibition	O
of	I-protein
both	O
the	I-protein
proliferative	O
response	I-protein
and	I-protein
inflammatory	O
cytokine	O
expression	I-protein
in	I-protein
CD4	B-protein
T	O
cells	I-protein
was	O
correlated	O
with	I-protein
suppression	O
of	I-protein
the	I-protein
activated	B-protein
transcription	I-protein
factors	I-protein
AP1	B-protein
and	I-protein
NF-kappaB	B-protein
.	O

PPARgamma	B-protein
ligands	I-protein
also	O
strongly	O
inhibited	O
SEA-induced	O
Vbeta3	O
T	O
cell	O
activation	I-protein
in	I-protein
vivo	O
.	O

These	O
results	O
,	O
together	O
with	I-protein
previous	O
findings	O
of	I-protein
the	I-protein
inhibitory	O
effect	O
of	I-protein
PPARgamma	B-protein
ligands	O
on	I-protein
activated	O
macrophages	O
,	O
provide	O
clear	I-protein
evidence	O
for	I-protein
PPARgamma	B-protein
as	O
a	I-protein
negative	O
regulator	O
of	I-protein
the	I-protein
inflammatory	O
activation	I-protein
of	I-protein
both	O
macrophage	O
and	I-protein
T	O
cells	I-protein
.	O

PPARgamma	B-protein
may	O
thus	O
be	O
a	I-protein
potential	I-protein
therapeutic	O
target	O
for	I-protein
the	I-protein
treatment	O
of	I-protein
autoimmunity	O
.	O

###MEDLINE:21240684

A	O
prominent	O
role	O
for	I-protein
activator	B-protein
protein-1	I-protein
in	I-protein
the	I-protein
transcription	O
of	I-protein
the	I-protein
human	O
2B4	O
(	O
CD244	B-protein
)	O
gene	O
in	I-protein
NK	I-protein
cells	I-protein
.	O

The	O
cell	B-protein
surface	I-protein
glycoprotein	I-protein
2B4	I-protein
(	O
CD244	B-protein
)	O
of	I-protein
the	I-protein
Ig	I-protein
superfamily	I-protein
is	O
involved	I-protein
in	I-protein
the	I-protein
regulation	I-protein
of	I-protein
NK	I-protein
and	I-protein
T	O
lymphocyte	O
functions	O
.	O

We	O
have	O
recently	O
identified	I-protein
CD48	B-protein
as	O
the	I-protein
high	B-protein
affinity	I-protein
counterreceptor	I-protein
for	I-protein
2B4	B-protein
in	I-protein
both	O
mice	O
and	I-protein
humans	O
.	O

The	O
cytoplasmic	B-protein
domain	I-protein
of	I-protein
2B4	B-protein
associates	O
with	I-protein
src	B-protein
homology	I-protein
2	I-protein
domain-containing	I-protein
protein	I-protein
or	I-protein
signaling	B-protein
lymphocyte	I-protein
activation	I-protein
molecule-associated	I-protein
protein	I-protein
,	O
whose	O
mutation	I-protein
is	O
the	I-protein
underlying	O
genetic	O
defect	I-protein
in	I-protein
the	I-protein
X-linked	O
lymphoproliferative	I-protein
syndrome	I-protein
.	O

In	O
this	O
study	O
,	O
we	O
report	O
the	I-protein
molecular	I-protein
cloning	O
and	I-protein
characterization	O
of	I-protein
the	I-protein
human	O
2B4	O
(	O
h2B4	O
)	O
promoter	I-protein
.	O

Through	O
primer	O
extension	O
analysis	O
,	O
we	O
found	O
that	O
the	I-protein
transcription	O
of	I-protein
the	I-protein
h2B4	O
gene	O
initiates	O
at	I-protein
multiple	O
start	O
sites	I-protein
.	O

We	O
isolated	I-protein
h2B4	O
genomic	O
clones	O
and	I-protein
PCR	O
amplified	O
the	I-protein
5	O
'	O
untranslated	I-protein
region	O
containing	I-protein
the	I-protein
promoter	I-protein
elements	O
.	O

We	O
have	O
identified	I-protein
a	I-protein
functional	O
AP-1	I-protein
site	I-protein
that	O
lies	O
between	O
(	O
-106	O
to	I-protein
-100	O
)	O
through	I-protein
transient	O
transfection	O
analysis	O
in	I-protein
YT	O
cells	I-protein
,	O
a	I-protein
human	O
NK	I-protein
cell	O
line	I-protein
.	O

EMSAs	O
with	I-protein
Abs	O
specific	I-protein
for	I-protein
various	O
protein	B-protein
factors	I-protein
of	I-protein
the	I-protein
AP-1	I-protein
family	I-protein
revealed	O
that	O
multiple	O
members	O
of	I-protein
the	I-protein
Jun	B-protein
family	I-protein
are	O
involved	I-protein
in	I-protein
the	I-protein
regulation	I-protein
of	I-protein
the	I-protein
h2B4	O
gene	O
.	O

Mutation	O
of	I-protein
the	I-protein
AP-1	I-protein
site	I-protein
not	I-protein
only	I-protein
abolishes	O
protein/DNA	O
interactions	O
but	O
also	O
promoter	I-protein
activity	I-protein
.	O

These	O
results	O
demonstrate	O
a	I-protein
significant	O
role	O
for	I-protein
AP-1	I-protein
in	I-protein
the	I-protein
transcriptional	O
regulation	I-protein
of	I-protein
the	I-protein
h2B4	O
gene	O
.	O

###MEDLINE:21240402

Functional	O
correction	O
of	I-protein
FA-C	O
cells	I-protein
with	I-protein
FANCC	B-protein
suppresses	O
the	I-protein
expression	I-protein
of	I-protein
interferon	O
gamma-inducible	I-protein
genes	I-protein
.	O

Because	O
hematopoietic	O
cells	I-protein
derived	I-protein
from	I-protein
Fanconi	B-protein
anemia	I-protein
(	O
FA	O
)	O
patients	O
of	I-protein
the	I-protein
C-complementation	O
group	I-protein
(	O
FA-C	O
)	O
are	O
hypersensitive	O
to	I-protein
the	I-protein
inhibitory	O
effects	O
of	I-protein
interferon	B-protein
gamma	I-protein
(	O
IFNgamma	B-protein
)	O
,	O
the	I-protein
products	O
of	I-protein
certain	O
IFNgamma-inducible	O
genes	I-protein
known	O
to	I-protein
influence	O
hematopoietic	O
cell	O
survival	B-protein
were	O
quantified	O
.	O

High	O
constitutive	I-protein
expression	I-protein
of	I-protein
the	I-protein
IFNgamma-inducible	O
genes	I-protein
,	O
IFN-stimulated	B-protein
gene	I-protein
factor	I-protein
3	I-protein
gamma	I-protein
subunit	I-protein
(	O
ISGF3gamma	B-protein
)	O
,	O
IFN	B-protein
regulatory	I-protein
factor-1	I-protein
(	O
IRF-1	B-protein
)	O
,	O
and	I-protein
the	I-protein
cyclin-dependent	B-protein
kinase	I-protein
inhibitor	I-protein
p21	I-protein
(	O
WAF1	B-protein
)	O
was	O
found	O
in	I-protein
FANCC	B-protein
mutant	O
B	O
lymphoblasts	O
,	O
low-density	O
bone	O
marrow	I-protein
cells	I-protein
,	O
and	I-protein
murine	O
embryonic	O
fibroblasts	O
.	O

Paradoxically	O
,	O
these	O
cells	I-protein
do	O
not	I-protein
activate	B-protein
signal	I-protein
transducer	I-protein
and	I-protein
activator	I-protein
of	I-protein
transcription	I-protein
(	O
STAT	I-protein
)	O
1	I-protein
properly	O
.	O

In	O
an	I-protein
attempt	O
to	I-protein
clarify	O
mechanisms	O
by	I-protein
which	O
FA-C	O
cells	I-protein
overexpress	O
IFNgamma-inducible	O
genes	I-protein
in	I-protein
the	I-protein
face	O
of	I-protein
defective	O
STAT1	B-protein
phosphorylation	I-protein
,	O
it	O
was	O
reasoned	O
that	O
decreased	O
levels	I-protein
of	I-protein
activated	B-protein
STAT1	B-protein
might	O
result	O
in	I-protein
reduced	O
expression	I-protein
of	I-protein
a	I-protein
hematopoietic	B-protein
IFNgamma-responsive	I-protein
protein	I-protein
that	O
normally	O
modulates	O
expression	I-protein
of	I-protein
other	O
IFNgamma-responsive	O
genes	I-protein
.	O

Levels	O
of	I-protein
the	I-protein
IFNgamma	B-protein
-inducible	I-protein
factor	I-protein
IFN	B-protein
consensus	I-protein
sequence	I-protein
binding	I-protein
protein	I-protein
(	O
ICSBP	B-protein
)	O
,	O
a	I-protein
negative	B-protein
trans-acting	I-protein
regulator	I-protein
of	I-protein
some	O
IFNgamma-inducible	O
genes	I-protein
,	O
were	O
quantified	O
.	O

ICSBP	B-protein
levels	I-protein
were	O
reduced	O
in	I-protein
FA-C	O
B	O
lymphoblasts	O
and	I-protein
MEFs	O
.	O

However	O
,	O
enforced	O
expression	I-protein
of	I-protein
ICSBP	B-protein
failed	O
to	I-protein
down-regulate	O
IRF-1	B-protein
,	O
ISGF3gamma	B-protein
,	O
and	I-protein
p21	O
(	O
WAF1	B-protein
)	O
.	O

Thus	O
,	O
the	I-protein
FANCC	B-protein
protein	I-protein
functions	O
to	I-protein
modulate	O
expression	I-protein
of	I-protein
a	I-protein
family	O
of	I-protein
genes	I-protein
that	O
in	I-protein
normal	O
cells	I-protein
are	O
inducible	O
only	I-protein
by	I-protein
specific	I-protein
environmental	O
cues	O
for	I-protein
apoptosis	O
or	I-protein
mitogenic	O
inhibition	O
,	O
but	O
it	O
does	O
so	O
independently	O
of	I-protein
the	I-protein
classic	O
IFN-STAT1	O
pathway	I-protein
and	I-protein
is	O
not	I-protein
the	I-protein
direct	O
result	O
of	I-protein
reduced	O
ICSBP	B-protein
expression	I-protein
.	O

###MEDLINE:21235950

A	O
genetic	O
investigation	O
of	I-protein
E2A	O
function	I-protein
in	I-protein
lymphocyte	O
development	O
.	O

Lymphocytes	O
are	O
derived	I-protein
from	I-protein
hematopoietic	O
stem	I-protein
cells	I-protein
(	O
HSC	B-protein
)	O
following	O
a	I-protein
series	O
of	I-protein
regulated	O
differentiation	I-protein
events	O
.	O

Multipotent	O
HSCs	O
become	O
committed	O
to	I-protein
the	I-protein
B	O
cell	O
lineage	I-protein
in	I-protein
bone	O
marrow	I-protein
and	I-protein
the	I-protein
T	O
cell	O
lineage	I-protein
in	I-protein
the	I-protein
thymus	I-protein
after	O
receiving	O
appropriate	O
signals	I-protein
from	I-protein
the	I-protein
corresponding	O
microenvironment	O
.	O

These	O
committed	O
lymphoid	O
cells	I-protein
must	O
then	O
undergo	O
V	O
(	O
D	O
)	O
J	I-protein
recombination	O
at	I-protein
the	I-protein
immunoglobulin	O
gene	O
or	I-protein
T	O
cell	O
receptor	O
gene	O
locus	O
resulting	O
in	I-protein
clonal	O
production	I-protein
of	I-protein
functional	O
B	O
or	I-protein
T	O
lymphocytes	O
,	O
respectively	O
.	O

Lymphocyte	O
commitment	O
and	I-protein
differentiation	I-protein
are	O
accompanied	O
by	I-protein
programmed	O
gene	O
expression	I-protein
or	I-protein
repression	I-protein
events	O
which	O
are	O
driven	O
by	I-protein
lineage	I-protein
and	I-protein
stage	I-protein
specific	I-protein
transcription	I-protein
factors	I-protein
.	O

The	O
basic-helix-loop-helix	B-protein
(	O
bHLH	I-protein
)	O
transcription	I-protein
factors	I-protein
encoded	O
by	I-protein
the	I-protein
E2A	O
gene	O
are	O
involved	I-protein
in	I-protein
several	I-protein
differentiation	I-protein
events	O
during	I-protein
B	O
and	I-protein
T	O
cell	O
development	O
,	O
including	I-protein
lineage	I-protein
commitment	O
,	O
initiation	I-protein
of	I-protein
V	O
(	O
D	O
)	O
J	I-protein
recombination	O
,	O
and	I-protein
antigen	O
receptor	O
mediated	I-protein
proliferation	I-protein
and	I-protein
differentiation	I-protein
.	O

Several	O
recent	O
reviews	O
have	O
provided	O
a	I-protein
comprehensive	O
discussion	O
of	I-protein
biochemical	O
,	O
cellular	O
,	O
and	I-protein
genetic	O
research	O
on	I-protein
E2A	O
function	I-protein
in	I-protein
lymphocyte	O
development	O
(	O
1	I-protein
,	O
2	I-protein
)	O
.	O

Here	O
,	O
we	O
only	I-protein
discuss	O
some	O
of	I-protein
the	I-protein
genetic	O
approaches	O
our	O
laboratory	O
(	O
except	O
where	O
it	O
is	O
noted	O
)	O
has	O
undertaken	O
to	I-protein
investigate	O
the	I-protein
molecular	I-protein
pathways	O
mediated	I-protein
by	I-protein
E2A	B-protein
transcription	I-protein
factors	I-protein
in	I-protein
lymphocyte	O
development	O

###MEDLINE:21301738

D609	O
inhibits	I-protein
ionizing	O
radiation-induced	I-protein
oxidative	B-protein
damage	I-protein
by	I-protein
acting	O
as	O
a	I-protein
potent	O
antioxidant	I-protein
.	O

Tricyclodecan-9-yl-xanthogenate	O
(	O
D609	O
)	O
has	O
been	O
extensively	O
studied	O
in	I-protein
biological	O
systems	O
and	I-protein
exhibits	O
a	I-protein
variety	O
of	I-protein
biological	O
functions	O
,	O
including	I-protein
antiviral	I-protein
,	O
antitumor	O
,	O
and	I-protein
anti-inflammatory	O
activities	O
.	O

Most	O
of	I-protein
these	O
activities	O
have	O
been	O
largely	O
attributed	O
to	I-protein
the	I-protein
inhibitory	O
effect	O
of	I-protein
D609	O
on	I-protein
phosphatidylcholine-specific	I-protein
phospholipase	B-protein
C	I-protein
.	O

However	O
,	O
as	O
a	I-protein
xanthate	O
derivative	O
,	O
D609	O
is	O
a	I-protein
strong	O
electrolyte	O
and	I-protein
readily	O
dissociates	O
to	I-protein
xanthate	O
anions	O
and	I-protein
cations	O
of	I-protein
alkali	I-protein
metals	O
in	I-protein
solution	O
.	O

Xanthate	O
anions	O
and	I-protein
protonated	O
xanthic	O
acid	O
contain	O
a	I-protein
free	B-protein
thiol	O
moiety	I-protein
and	I-protein
are	O
highly	O
reductive	O
.	O

This	O
implies	O
that	O
D609	O
and	I-protein
other	O
xanthate	O
derivatives	I-protein
may	O
function	I-protein
as	O
potent	O
antioxidants	O
.	O

Indeed	O
,	O
we	O
found	O
that	O
D609	O
inhibited	O
the	I-protein
Fenton	O
reaction-induced	O
oxidation	O
of	I-protein
dihydrorhodamine	O
123	I-protein
in	I-protein
a	I-protein
dose-dependent	O
manner	O
similar	O
to	I-protein
that	O
of	I-protein
pyrrolidinedithiocarbamate	O
,	O
a	I-protein
well	O
known	O
antioxidant	I-protein
.	O

In	O
addition	O
,	O
D609	O
inhibited	O
the	I-protein
formation	O
of	I-protein
the	I-protein
alpha-phenyl-tert-butylnitrone-free	O
radical	O
spin	O
adducts	O
and	I-protein
lipid	O
peroxidation	O
of	I-protein
synaptosomal	O
membranes	O
by	I-protein
the	I-protein
Fenton	O
reagents	O
.	O

Furthermore	O
,	O
preincubation	O
of	I-protein
lymphocytes	O
with	I-protein
D609	O
resulted	O
in	I-protein
a	I-protein
significant	O
diminution	O
of	I-protein
ionizing	O
radiation	I-protein
(	O
IR	O
)	O
-induced	O
1	I-protein
)	O
production	I-protein
of	I-protein
reactive	I-protein
oxygen	O
species	O
;	O
2	I-protein
)	O
decrease	O
in	I-protein
intracellular	I-protein
reduced	O
glutathione	O
;	O
3	O
)	O
oxidative	B-protein
damage	I-protein
to	I-protein
proteins	I-protein
and	I-protein
lipids	O
;	O
and	I-protein
4	I-protein
)	O
activation	I-protein
of	I-protein
nuclear	B-protein
factor-kappaB	I-protein
.	O

Moreover	O
,	O
when	O
D609	O
(	O
50	I-protein
mg/kg	O
i.v.	O
)	O
was	O
administered	O
to	I-protein
mice	O
10	I-protein
min	O
prior	O
to	I-protein
total	O
body	O
IR	O
(	O
6.5	O
and	I-protein
8.5	O
Gy	O
)	O
,	O
it	O
protected	O
the	I-protein
mice	O
from	I-protein
IR-induced	O
lethality	O
.	O

Thus	O
,	O
these	O
results	O
indicate	O
that	O
D609	O
is	O
a	I-protein
potent	O
antioxidant	I-protein
and	I-protein
has	O
the	I-protein
ability	O
to	I-protein
inhibit	O
IR-induced	O
cellular	O
oxidative	B-protein
stress	O
.	O

###MEDLINE:21369994

Inhibition	O
of	I-protein
AP-1	I-protein
by	I-protein
the	I-protein
glucocorticoid-inducible	B-protein
protein	I-protein
GILZ	B-protein
.	O

The	O
immunosuppressive	O
effects	O
of	I-protein
glucocorticoids	O
arise	O
largely	O
by	I-protein
inhibition	O
of	I-protein
cytokine	O
gene	O
expression	I-protein
,	O
which	O
has	O
been	O
ascribed	O
to	I-protein
interference	O
between	O
the	I-protein
glucocorticoid	B-protein
receptor	I-protein
and	I-protein
transcription	B-protein
factors	I-protein
such	O
as	O
AP-1	I-protein
and	I-protein
NF-kappa	B-protein
B	I-protein
as	O
well	O
as	O
by	I-protein
competition	O
for	I-protein
common	I-protein
coactivators	O
.	O

Here	O
we	O
show	O
that	O
glucocorticoid-induced	O
inhibition	O
of	I-protein
interleukin-2	B-protein
mRNA	O
expression	I-protein
in	I-protein
activated	O
normal	O
T	O
cells	I-protein
required	O
new	I-protein
protein	O
synthesis	I-protein
,	O
suggesting	O
that	O
this	O
phenomenon	O
is	O
secondary	O
to	I-protein
expression	I-protein
of	I-protein
glucocorticoid-regulated	O
genes	I-protein
.	O

One	I-protein
of	I-protein
the	I-protein
most	O
prominent	O
glucocorticoid-induced	O
genes	I-protein
is	O
glucocorticoid-induced	O
leucine	O
zipper	I-protein
(	O
GILZ	B-protein
)	O
,	O
which	O
has	O
been	O
reported	O
to	I-protein
inhibit	O
activation-induced	B-protein
up-regulation	O
of	I-protein
Fas	B-protein
ligand	I-protein
(	O
FasL	B-protein
)	O
mRNA	O
.	O

Indeed	O
,	O
transient	O
expression	I-protein
of	I-protein
GILZ	B-protein
in	I-protein
Jurkat	O
T	O
cells	I-protein
blocked	B-protein
induction	I-protein
of	I-protein
a	I-protein
reporter	O
construct	O
driven	O
by	I-protein
the	I-protein
FasL	O
promoter	I-protein
.	O

This	O
could	O
be	O
accounted	O
for	I-protein
by	I-protein
GILZ	B-protein
-mediated	O
inhibition	O
of	I-protein
Egr-2	B-protein
and	I-protein
Egr-3	B-protein
,	O
NFAT/AP-1	B-protein
-inducible	O
transcription	B-protein
factors	I-protein
that	O
bind	O
a	I-protein
regulatory	O
element	I-protein
in	I-protein
the	I-protein
FasL	O
promoter	I-protein
and	I-protein
up-regulate	O
FasL	O
expression	I-protein
.	O

GILZ	B-protein
also	O
potently	O
inhibited	O
AP-1-driven	O
and	I-protein
IL-2	B-protein
promoter-driven	O
reporter	O
constructs	O
,	O
and	I-protein
recombinant	O
GILZ	B-protein
specifically	O
interacted	O
with	I-protein
c-Fos	B-protein
and	I-protein
c-Jun	B-protein
in	I-protein
vitro	O
and	I-protein
inhibited	O
the	I-protein
binding	I-protein
of	I-protein
active	O
AP-1	I-protein
to	I-protein
its	O
target	O
DNA	O
.	O

Whereas	O
homodimerization	O
of	I-protein
GILZ	B-protein
required	O
the	I-protein
presence	O
of	I-protein
its	O
leucine	B-protein
zipper	I-protein
,	O
the	I-protein
interaction	I-protein
with	I-protein
c-Fos	B-protein
and	I-protein
c-Jun	B-protein
occurred	O
through	I-protein
the	I-protein
N-terminal	B-protein
60-amino	I-protein
acid	I-protein
region	I-protein
of	I-protein
GILZ	B-protein
.	O

Thus	O
,	O
GILZ	B-protein
represents	O
a	I-protein
glucocorticoid-induced	O
gene	O
product	I-protein
that	O
can	O
inhibit	O
a	I-protein
variety	O
of	I-protein
activation-induced	B-protein
events	O
,	O
at	I-protein
least	O
in	I-protein
part	I-protein
by	I-protein
direct	O
interference	O
with	I-protein
AP-1	I-protein
,	O
and	I-protein
is	O
therefore	O
a	I-protein
candidate	O
for	I-protein
a	I-protein
mediator	O
of	I-protein
glucocorticoid-induced	O
immunosuppression	O
.	O

###MEDLINE:21286460

Pharmacokinetic	O
differences	O
between	O
a	I-protein
T	O
cell-tolerizing	O
and	I-protein
a	I-protein
T	O
cell-activating	O
peptide	O
.	O

Vaccination	O
with	I-protein
a	I-protein
peptide	O
representing	O
a	I-protein
CTL	O
epitope	I-protein
from	I-protein
the	I-protein
human	O
papillomavirus	I-protein
(	O
HPV	O
)	O
16	I-protein
E7	B-protein
protein	I-protein
induces	O
a	I-protein
specific	I-protein
CTL	O
response	I-protein
that	O
prevents	O
the	I-protein
outgrowth	I-protein
of	I-protein
HPV16	O
E7-expressing	O
tumors	I-protein
.	O

In	O
contrast	O
,	O
vaccination	O
with	I-protein
a	I-protein
peptide	O
encoding	I-protein
an	I-protein
adenovirus	I-protein
type	O
5	O
(	O
Ad5	O
)	O
E1A	O
CTL	O
epitope	I-protein
results	O
in	I-protein
CTL	O
tolerance	I-protein
and	I-protein
enhanced	I-protein
growth	O
of	I-protein
an	I-protein
Ad5	O
E1A-expressing	O
tumor	O
.	O

It	O
is	O
unclear	O
why	O
these	O
peptides	O
induce	O
such	O
opposite	O
effects	O
.	O

To	O
determine	O
whether	O
a	I-protein
difference	O
in	I-protein
pharmacokinetics	O
can	O
explain	O
the	I-protein
functional	O
contrasts	O
,	O
tritiated	O
Ad5	O
E1A	O
and	I-protein
HPV16	O
E7	O
peptides	O
were	O
injected	O
into	O
mice	O
.	O

Results	O
show	O
that	O
the	I-protein
tolerizing	O
peptide	O
spread	O
through	I-protein
the	I-protein
body	O
16	I-protein
times	O
faster	O
than	I-protein
the	I-protein
activating	O
peptide	O
and	I-protein
was	O
cleared	O
at	I-protein
least	O
2	I-protein
times	O
faster	O
.	O

The	O
HPV16	O
E7	O
peptide	O
kinetics	O
correlated	O
with	I-protein
the	I-protein
kinetics	O
of	I-protein
HPV16	B-protein
E7	I-protein
-specific	I-protein
CTL	O
induction	I-protein
.	O

In	O
contrast	O
,	O
Ad5	O
E1A	O
peptide	O
injection	O
resulted	O
in	I-protein
physical	O
deletion	I-protein
of	I-protein
preexisting	O
Ad5	B-protein
E1A	I-protein
-specific	I-protein
CTLs	B-protein
within	B-protein
24	I-protein
h	I-protein
after	O
injection	O
.	O

This	O
tolerization	O
occurred	O
at	I-protein
the	I-protein
time	O
when	O
the	I-protein
peptide	O
reached	O
its	O
maximum	O
peptide	O
concentration	I-protein
in	I-protein
the	I-protein
organs	O
.	O

These	O
data	O
suggest	O
that	O
ubiquitous	I-protein
expression	I-protein
of	I-protein
the	I-protein
tolerizing	O
Ad5	O
E1A	O
peptide	O
within	B-protein
a	I-protein
short	O
period	B-protein
of	I-protein
time	O
causes	O
activation-induced	B-protein
cell	O
death	O
of	I-protein
Ad5	B-protein
E1A	I-protein
-specific	I-protein
CTLs	B-protein
.	O

Therefore	O
,	O
information	I-protein
on	I-protein
the	I-protein
pharmacokinetics	O
of	I-protein
peptides	O
is	O
vital	O
for	I-protein
the	I-protein
safety	O
and	I-protein
efficacy	O
of	I-protein
peptide-based	O
vaccines	O
.	O

###MEDLINE:21278495

Smad3	B-protein
and	I-protein
Smad4	B-protein
mediate	O
transforming	B-protein
growth	I-protein
factor-beta1	I-protein
-induced	O
IgA	O
expression	I-protein
in	I-protein
murine	O
B	O
lymphocytes	O
.	O

Transforming	B-protein
growth	I-protein
factor	I-protein
(	O
TGF	B-protein
)	O
-beta1	I-protein
is	O
well	O
established	O
as	O
a	I-protein
critical	I-protein
IgA	B-protein
isotype	I-protein
switching	I-protein
factor	I-protein
and	I-protein
Smad	B-protein
molecules	I-protein
have	O
been	O
reported	O
to	I-protein
act	O
as	O
transducers	O
and	I-protein
transcriptional	B-protein
factors	I-protein
in	I-protein
the	I-protein
expression	I-protein
of	I-protein
TGF-beta1	B-protein
-targeted	O
genes	I-protein
.	O

We	O
examined	O
the	I-protein
involvement	I-protein
of	I-protein
Smad	B-protein
proteins	I-protein
in	I-protein
TGF-beta1	B-protein
-induced	O
IgA	O
expression	I-protein
.	O

First	O
,	O
we	O
found	O
that	O
TGF-beta1	B-protein
significantly	O
increases	O
endogenous	O
germ-line	O
(	O
GL	O
)	O
alpha	O
transcripts	I-protein
by	I-protein
LPS-stimulated	O
CH12.LX.4933	O
(	O
mu	I-protein
(	O
+	O
)	O
)	O
B	O
lymphoma	I-protein
cells	I-protein
.	O

To	O
investigate	O
its	O
signaling	O
mechanisms	O
,	O
the	I-protein
lymphoma	I-protein
cell	O
line	I-protein
was	O
transfected	O
with	I-protein
pFL3	O
that	O
contains	I-protein
the	I-protein
TGF-beta-responsive	O
element	I-protein
of	I-protein
the	I-protein
GLalpha	O
promoter	I-protein
,	O
and	I-protein
stimulated	O
with	I-protein
TGF-beta1	B-protein
.	O

Similar	B-protein
to	I-protein
endogenous	O
GLalpha	O
transcripts	I-protein
,	O
TGF-beta1	B-protein
induces	O
GLalpha	O
promoter	I-protein
activity	I-protein
and	I-protein
overexpression	O
of	I-protein
Smad3	B-protein
markedly	O
enhances	O
the	I-protein
promoter	I-protein
activity	I-protein
.	O

This	O
activity	I-protein
is	O
further	O
augmented	O
by	I-protein
cotransfected	B-protein
Smad4	I-protein
.	O

On	O
the	I-protein
other	O
hand	O
,	O
Smad7	B-protein
substantially	O
abrogates	O
the	I-protein
synergistic	O
effect	O
of	I-protein
Smad3/4	B-protein
on	I-protein
GLalpha	O
promoter	I-protein
activity	I-protein
.	O

In	O
addition	O
,	O
overexpression	O
of	I-protein
Smad3/4	B-protein
enhances	O
TGF-beta1	B-protein
-induced	O
endogenous	O
GLalpha	O
transcripts	I-protein
in	I-protein
normal	O
spleen	B-protein
B	O
cell	O
s	I-protein
.	O

Finally	O
,	O
in	I-protein
the	I-protein
presence	O
of	I-protein
TGF-beta1	B-protein
,	O
overexpression	O
of	I-protein
Smad3/4	B-protein
selectively	O
increases	O
both	O
surface	O
IgA	O
expression	I-protein
and	I-protein
IgA	O
production	I-protein
.	O

The	O
results	O
from	I-protein
the	I-protein
present	O
study	O
indicate	O
that	O
Smad3	B-protein
,	O
Smad4	B-protein
,	O
and	I-protein
Smad7	B-protein
,	O
at	I-protein
least	O
in	I-protein
part	I-protein
,	O
serve	O
as	O
mediators	O
linking	I-protein
TGF-beta1	B-protein
to	I-protein
transcriptional	O
regulation	I-protein
of	I-protein
IgA	O
switching	O
related	O
gene	O
and	I-protein
regulation	I-protein
of	I-protein
IgA	O
class	O
switching	O
.	O

###MEDLINE:21264350

The	O
translesion	B-protein
DNA	I-protein
polymerase	I-protein
zeta	I-protein
plays	O
a	I-protein
major	O
role	O
in	I-protein
Ig	I-protein
and	I-protein
bcl-6	O
somatic	I-protein
hypermutation	O
.	O

Ig	I-protein
somatic	I-protein
mutations	I-protein
would	O
be	O
introduced	O
by	I-protein
a	I-protein
polymerase	O
(	O
pol	I-protein
)	O
while	O
repairing	O
DNA	O
outside	O
main	O
DNA	O
replication	O
.	O

We	O
show	O
that	O
human	O
B	O
cells	I-protein
constitutively	O
express	O
the	I-protein
translesion	B-protein
pol	I-protein
zeta	I-protein
,	O
which	O
effectively	O
extends	O
DNA	O
past	O
mismatched	O
bases	O
(	O
mispair	O
extender	O
)	O
,	O
and	I-protein
pol	I-protein
eta	I-protein
,	O
which	O
bypasses	O
DNA	O
lesions	O
in	I-protein
an	I-protein
error-free	O
fashion	O
.	O

Upon	O
B	B-protein
cell	I-protein
receptor	I-protein
(	O
BCR	B-protein
)	O
engagement	O
and	I-protein
coculture	O
with	I-protein
activated	O
CD4+	O
T	O
cells	I-protein
,	O
these	O
lymphocytes	O
upregulated	O
pol	I-protein
zeta	I-protein
,	O
downregulated	O
pol	I-protein
eta	I-protein
,	O
and	I-protein
mutated	O
the	I-protein
Ig	I-protein
and	I-protein
bcl-6	O
genes	I-protein
.	O

Inhibition	O
of	I-protein
the	I-protein
pol	I-protein
zeta	I-protein
REV3	B-protein
catalytic	I-protein
subunit	I-protein
by	I-protein
specific	I-protein
phosphorothioate-modified	O
oligonucleotides	O
impaired	O
Ig	I-protein
and	I-protein
bcl-6	O
hypermutation	O
and	I-protein
UV	O
damage-induced	O
DNA	O
mutagenesis	O
,	O
without	I-protein
affecting	O
cell	O
cycle	I-protein
or	I-protein
viability	O
.	O

Thus	O
,	O
pol	I-protein
zeta	I-protein
plays	O
a	I-protein
critical	I-protein
role	O
in	I-protein
Ig	I-protein
and	I-protein
bcl-6	O
hypermutation	O
,	O
perhaps	O
facilitated	I-protein
by	I-protein
the	I-protein
downregulation	O
of	I-protein
pol	I-protein
eta	I-protein
.	O

###MEDLINE:21260138

Molecular	O
mechanism	O
of	I-protein
cell	O
cycle	I-protein
progression	I-protein
induced	I-protein
by	I-protein
the	I-protein
oncogene	I-protein
product	I-protein
Tax	I-protein
of	I-protein
human	O
T-cell	O
leukemia	O
virus	I-protein
type	O
I	I-protein
.	O

The	O
trans-activator	B-protein
protein	I-protein
Tax	I-protein
of	I-protein
human	O
T-cell	O
leukemia	O
virus	I-protein
type	O
I	I-protein
(	O
HTLV-I	O
)	O
plays	O
an	I-protein
important	O
role	O
in	I-protein
the	I-protein
development	O
of	I-protein
adult	O
T-cell	O
leukemia	O
through	I-protein
,	O
at	I-protein
least	O
in	I-protein
part	I-protein
,	O
its	O
ability	O
to	I-protein
stimulate	O
cell	O
growth	O
.	O

We	O
previously	O
reported	O
that	O
Tax	B-protein
induced	I-protein
cell	O
cycle	I-protein
progression	I-protein
from	I-protein
G0/G1	I-protein
phase	I-protein
to	I-protein
S	I-protein
and	I-protein
G2/M	O
phases	O
in	I-protein
human	O
T-cell	O
line	I-protein
Kit	I-protein
225	I-protein
cells	I-protein
.	O

To	O
elucidate	O
molecular	I-protein
mechanism	O
of	I-protein
Tax	B-protein
-induced	O
cell	O
cycle	I-protein
progression	I-protein
,	O
we	O
systematically	O
examined	O
the	I-protein
effects	O
of	I-protein
Tax	B-protein
on	I-protein
biochemical	O
events	O
associated	I-protein
with	I-protein
cell	O
cycle	I-protein
progression	I-protein
.	O

Introduction	O
of	I-protein
Tax	B-protein
into	O
resting	O
Kit	I-protein
225	I-protein
cells	I-protein
induced	I-protein
activation	I-protein
of	I-protein
the	I-protein
G1/S	O
transition	O
regulation	I-protein
cascade	O
consisting	O
of	I-protein
activation	I-protein
of	I-protein
cyclin	B-protein
dependent	I-protein
kinase	I-protein
2	I-protein
(	O
CDK2	B-protein
)	O
and	I-protein
CDK4	B-protein
,	O
phosphorylation	I-protein
of	I-protein
the	I-protein
Rb	B-protein
family	I-protein
proteins	I-protein
and	I-protein
an	I-protein
increase	O
in	I-protein
free	B-protein
E2F	B-protein
.	O

The	O
kinase	O
activation	I-protein
was	O
found	O
to	I-protein
result	O
from	I-protein
Tax	B-protein
-induced	O
expression	I-protein
of	I-protein
genes	I-protein
for	I-protein
cell	B-protein
cycle	I-protein
regulatory	I-protein
molecules	I-protein
including	I-protein
cyclin	B-protein
D2	I-protein
,	O
cyclin	B-protein
E	I-protein
,	O
E2F1	B-protein
,	O
CDK2	B-protein
,	O
CDK4	B-protein
and	I-protein
CDK6	B-protein
,	O
and	I-protein
Tax	B-protein
-induced	O
reduction	I-protein
of	I-protein
CDK	I-protein
inhibitors	I-protein
p19	I-protein
(	O
INK4d	O
)	O
and	I-protein
p27	B-protein
(	O
Kip1	I-protein
)	O
.	O

These	O
modulations	O
by	I-protein
Tax	B-protein
always	O
paralleled	O
the	I-protein
ability	O
of	I-protein
Tax	B-protein
to	I-protein
activate	O
the	I-protein
NF-kappaB	B-protein
transcription	O
pathway	I-protein
.	O

These	O
results	O
indicate	O
the	I-protein
important	O
role	O
of	I-protein
Tax	B-protein
-mediated	O
trans-activation	O
of	I-protein
the	I-protein
genes	I-protein
for	I-protein
cell	B-protein
cycle	I-protein
regulatory	I-protein
molecules	I-protein
in	I-protein
Tax	B-protein
-induced	O
cell	O
cycle	I-protein
progression	I-protein
.	O

###MEDLINE:21347936

Cot	B-protein
kinase	I-protein
induces	O
cyclooxygenase-2	O
expression	I-protein
in	I-protein
T	O
cells	I-protein
through	I-protein
activation	I-protein
of	I-protein
the	I-protein
nuclear	B-protein
factor	I-protein
of	I-protein
activated	O
T	O
cells	I-protein
.	O

Cyclooxygenase-2	B-protein
(	O
COX-2	B-protein
)	O
is	O
induced	I-protein
in	I-protein
human	O
T	O
lymphocytes	O
upon	O
T	B-protein
cell	I-protein
receptor	I-protein
triggering	O
.	O

Here	O
we	O
report	O
that	O
Cot	B-protein
kinase	I-protein
,	O
a	I-protein
mitogen-activated	B-protein
protein	I-protein
kinase	I-protein
kinase	I-protein
kinase	I-protein
involved	I-protein
in	I-protein
T	O
cell	O
activation	I-protein
,	O
up-regulates	O
COX-2	B-protein
gene	O
expression	I-protein
in	I-protein
Jurkat	O
T	O
cells	I-protein
.	O

Induction	O
of	I-protein
COX-2	B-protein
promoter	I-protein
activity	I-protein
by	I-protein
Cot	B-protein
kinase	I-protein
occurred	O
mainly	O
through	I-protein
activation	I-protein
of	I-protein
the	I-protein
nuclear	B-protein
factor	I-protein
of	I-protein
activated	O
T	O
cells	I-protein
(	O
NFAT	B-protein
)	O
.	O

Mutation	O
of	I-protein
the	I-protein
distal	I-protein
(	O
-105/-97	O
)	O
and	I-protein
proximal	I-protein
(	O
-76/-61	O
)	O
NFAT	O
response	I-protein
elements	O
in	I-protein
the	I-protein
COX-2	B-protein
promoter	I-protein
abolished	O
the	I-protein
activation	I-protein
induced	I-protein
by	I-protein
Cot	B-protein
kinase	I-protein
.	O

Even	O
more	O
,	O
coexpression	O
of	I-protein
a	I-protein
dominant	I-protein
negative	O
version	O
of	I-protein
NFAT	B-protein
inhibited	O
Cot	B-protein
kinase	I-protein
-mediated	O
COX-2	B-protein
promoter	I-protein
activation	I-protein
,	O
whereas	O
cotransfection	O
of	I-protein
a	I-protein
constitutively	O
active	O
version	O
of	I-protein
the	I-protein
calcium-dependent	I-protein
phosphatase	I-protein
calcineurin	I-protein
synergizes	O
with	I-protein
Cot	B-protein
kinase	I-protein
in	I-protein
the	I-protein
up-regulation	O
of	I-protein
COX-2	B-protein
promoter	I-protein
-driven	O
transcription	O
.	O

Strikingly	O
,	O
Cot	B-protein
kinase	I-protein
increased	I-protein
transactivation	O
mediated	I-protein
by	I-protein
a	I-protein
GAL4-NFAT	B-protein
fusion	I-protein
protein	I-protein
containing	I-protein
the	I-protein
N-terminal	B-protein
transactivation	I-protein
domain	I-protein
of	I-protein
NFATp	B-protein
.	O

In	O
contrast	O
to	I-protein
phorbol	O
ester	I-protein
plus	O
calcium	O
ionophore	O
A23187	O
,	O
Cot	B-protein
kinase	I-protein
increases	O
both	O
COX-2	B-protein
promoter	I-protein
activity	I-protein
and	I-protein
NFAT	B-protein
-mediated	O
transactivation	O
in	I-protein
a	I-protein
cyclosporin	O
A-independent	O
manner	O
.	O

These	O
data	O
indicate	O
that	O
Cot	B-protein
kinase	I-protein
up-regulates	O
COX-2	B-protein
promoter	I-protein
-driven	O
transcription	O
through	I-protein
the	I-protein
NFAT	O
response	I-protein
elements	O
,	O
being	O
the	I-protein
Cot	B-protein
kinase	I-protein
-induced	O
NFAT	B-protein
-dependent	I-protein
transactivation	O
presumably	O
implicated	O
in	I-protein
this	O
up-regulation	O
.	O

###MEDLINE:21240683

Positive	O
and	I-protein
negative	O
roles	O
of	I-protein
the	I-protein
trans-acting	B-protein
T	I-protein
cell	I-protein
factor-1	I-protein
for	I-protein
the	I-protein
acquisition	O
of	I-protein
distinct	O
Ly-49	B-protein
MHC	I-protein
class	I-protein
I	I-protein
receptors	I-protein
by	I-protein
NK	I-protein
cells	I-protein
.	O

Members	O
of	I-protein
the	I-protein
Ly-49	O
gene	O
family	O
code	O
for	I-protein
class	B-protein
I	I-protein
MHC-specific	I-protein
receptors	I-protein
that	O
regulate	O
NK	I-protein
cell	O
function	I-protein
.	O

Due	O
to	I-protein
a	I-protein
combinatorial	O
distribution	I-protein
of	I-protein
Ly-49	B-protein
receptors	I-protein
,	O
NK	I-protein
cells	I-protein
display	O
considerable	O
clonal	O
heterogeneity	O
.	O

The	O
acquisition	O
of	I-protein
one	B-protein
Ly-49	B-protein
receptor	I-protein
,	O
Ly-49A	B-protein
is	O
strictly	O
dependent	I-protein
on	I-protein
the	I-protein
transcriptional	B-protein
trans-acting	I-protein
factor	I-protein
T	I-protein
cell-specific	I-protein
factor-1	I-protein
(	O
TCF-1	B-protein
)	O
.	O

Indeed	O
,	O
TCF-1	B-protein
binds	O
to	I-protein
two	O
sites	I-protein
in	I-protein
the	I-protein
Ly-49a	O
promoter	I-protein
and	I-protein
regulates	O
its	O
activity	I-protein
,	O
suggesting	O
that	O
the	I-protein
Ly-49a	O
gene	O
is	O
a	I-protein
direct	O
TCF-1	B-protein
target	O
.	O

TCF-1	B-protein
deficiency	I-protein
resulted	O
in	I-protein
the	I-protein
altered	I-protein
usage	O
of	I-protein
additional	B-protein
Ly-49	B-protein
receptors	I-protein
.	O

We	O
show	O
in	I-protein
this	O
study	O
,	O
using	O
TCF-1	B-protein
beta	I-protein
(	O
2	I-protein
)	O
-microglobulin	I-protein
double-deficient	O
mice	O
,	O
that	O
these	O
repertoire	O
alterations	O
are	O
not	I-protein
due	I-protein
to	I-protein
Ly-49/MHC	O
class	O
I	I-protein
interactions	O
.	O

Our	O
findings	O
rather	O
suggest	O
a	I-protein
TCF-1	B-protein
-dependent	I-protein
,	O
cell	O
autonomous	O
effect	O
on	I-protein
the	I-protein
acquisition	O
of	I-protein
multiple	O
Ly-49	B-protein
receptors	I-protein
.	O

Besides	O
reduced	O
receptor	O
usage	O
(	O
Ly-49A	B-protein
and	I-protein
D	I-protein
)	O
,	O
we	O
also	O
observed	O
no	I-protein
effect	O
(	O
Ly-49C	O
)	O
and	I-protein
significantly	O
expanded	B-protein
(	O
Ly-49G	B-protein
and	I-protein
I	I-protein
)	O
receptor	I-protein
usage	O
in	I-protein
the	I-protein
absence	I-protein
of	I-protein
TCF-1	B-protein
.	O

These	O
effects	O
did	O
not	I-protein
in	I-protein
all	O
cases	O
correlate	O
with	I-protein
the	I-protein
presence	O
of	I-protein
TCF	B-protein
binding	I-protein
sites	I-protein
in	I-protein
the	I-protein
respective	O
proximal	I-protein
promoter	I-protein
.	O

Therefore	O
,	O
besides	O
TCF-1	B-protein
binding	I-protein
to	I-protein
the	I-protein
proximal	I-protein
promoter	I-protein
,	O
Ly-49	O
acquisition	O
may	O
also	O
be	O
regulated	O
by	I-protein
TCF-1	B-protein
binding	I-protein
to	I-protein
more	O
distant	O
cis-acting	O
elements	O
and/or	O
by	I-protein
regulating	O
the	I-protein
expression	I-protein
of	I-protein
additional	B-protein
trans-acting	O
factors	I-protein
.	O

Consistent	O
with	I-protein
the	I-protein
observed	O
differential	O
,	O
positive	I-protein
or	I-protein
negative	O
role	O
of	I-protein
TCF-1	B-protein
for	I-protein
Ly-49	B-protein
receptor	I-protein
acquisition	O
,	O
reporter	O
gene	O
assays	O
revealed	O
the	I-protein
presence	O
of	I-protein
an	I-protein
inducing	I-protein
as	O
well	O
as	O
a	I-protein
repressing	I-protein
TCF	B-protein
site	I-protein
in	I-protein
certain	O
proximal	I-protein
Ly-49	O
promoters	O
.	O

These	O
findings	O
reveal	O
an	I-protein
important	O
role	O
of	I-protein
TCF-1	B-protein
for	I-protein
the	I-protein
formation	O
of	I-protein
the	I-protein
NK	I-protein
cell	I-protein
receptor	I-protein
repertoire	O
.	O

###MEDLINE:21240390

Ligation	O
of	I-protein
CD11b	B-protein
and	I-protein
CD11c	B-protein
beta	I-protein
(	O
2	I-protein
)	O
integrins	I-protein
by	I-protein
antibodies	I-protein
or	I-protein
soluble	I-protein
CD23	I-protein
induces	O
macrophage	B-protein
inflammatory	I-protein
protein	I-protein
1alpha	I-protein
(	O
MIP-1alpha	B-protein
)	O
and	I-protein
MIP-1beta	O
production	I-protein
in	I-protein
primary	O
human	O
monocytes	O
through	I-protein
a	I-protein
pathway	I-protein
dependent	I-protein
on	I-protein
nuclear	B-protein
factor-kappaB	I-protein
.	O

Chemokines	B-protein
and	I-protein
adhesion	B-protein
molecules	I-protein
such	O
as	O
integrins	B-protein
play	O
a	I-protein
major	O
part	I-protein
in	I-protein
the	I-protein
trafficking	O
,	O
extravasation	O
,	O
and	I-protein
recruitment	I-protein
of	I-protein
leukocytes	O
to	I-protein
inflammatory	O
sites	I-protein
.	O

This	O
study	O
investigated	O
the	I-protein
effects	O
of	I-protein
beta	O
(	O
2	I-protein
)	O
integrin	O
engagement	O
on	I-protein
chemokine	O
production	I-protein
by	I-protein
freshly	O
isolated	I-protein
human	O
monocytes	O
.	O

We	O
found	O
that	O
ligation	O
of	I-protein
CD11b	B-protein
or	I-protein
CD11c	B-protein
but	O
not	I-protein
CD11a	B-protein
alpha	I-protein
chains	I-protein
of	I-protein
beta	B-protein
(	O
2	I-protein
)	O
integrins	I-protein
by	I-protein
antibodies	I-protein
or	I-protein
soluble	I-protein
CD23	I-protein
(	O
sCD23	I-protein
)	O
fusion	I-protein
proteins	I-protein
rapidly	I-protein
induced	I-protein
transcription	O
and	I-protein
secretion	O
of	I-protein
interleukin	B-protein
8	I-protein
,	O
macrophage	B-protein
inflammatory	I-protein
protein	I-protein
(	O
MIP	B-protein
)	O
1alpha	I-protein
,	O
and	I-protein
MIP-1beta	B-protein
.	O

Because	O
the	I-protein
promoters	O
of	I-protein
these	O
chemokine	O
genes	I-protein
contain	O
kappaB	I-protein
binding	I-protein
sites	I-protein
,	O
we	O
assessed	O
the	I-protein
possible	O
role	O
of	I-protein
nuclear	B-protein
factor-kappaB	I-protein
(	O
NF-kappaB	B-protein
)	O
in	I-protein
controlling	I-protein
induction	I-protein
of	I-protein
the	I-protein
genes	I-protein
through	I-protein
beta	O
(	O
2	I-protein
)	O
integrin	O
engagement	O
.	O

Electrophoretic	O
mobility	I-protein
shift	O
assays	O
showed	O
that	O
sCD23	O
or	I-protein
antibodies	I-protein
to	I-protein
CD11b	B-protein
or	I-protein
to	I-protein
CD11c	O
up-regulated	O
DNA-binding	O
activity	I-protein
of	I-protein
NF-kappaB	B-protein
.	O

Activation	O
of	I-protein
NF-kappaB	B-protein
was	O
accompanied	O
by	I-protein
degradation	I-protein
of	I-protein
its	O
cytosolic	O
inhibitor	O
IkappaB-alpha	O
.	O

Blockade	O
of	I-protein
depletion	O
of	I-protein
IkappaB-alpha	B-protein
by	I-protein
proteasome	O
inhibitors	I-protein
(	O
proteasome	O
inhibitor	O
I	I-protein
or	I-protein
acetyl-leucinyl-leucinyl-norleucinal	O
)	O
led	O
to	I-protein
concomitant	O
inhibition	O
of	I-protein
NF-kappaB	B-protein
DNA-binding	O
activity	I-protein
and	I-protein
expression	I-protein
of	I-protein
MIP-1alpha	B-protein
and	I-protein
MIP-1beta	O
messenger	O
RNA	O
induced	I-protein
by	I-protein
beta	O
(	O
2	I-protein
)	O
integrin	O
ligation	O
.	O

These	O
results	O
suggest	O
that	O
triggering	O
of	I-protein
CD11b	B-protein
or	I-protein
CD11c	B-protein
beta	I-protein
(	O
2	I-protein
)	O
integrin	I-protein
on	I-protein
primary	O
human	O
monocytes	O
provides	O
activation	I-protein
signals	I-protein
leading	O
to	I-protein
nuclear	O
translocation	O
of	I-protein
NF-kappaB	B-protein
and	I-protein
subsequent	O
secretion	O
of	I-protein
MIP-1alpha	B-protein
and	I-protein
MIP-1beta	B-protein
that	O
may	O
have	O
an	I-protein
important	O
role	O
in	I-protein
recruitment	I-protein
of	I-protein
other	O
inflammatory	O
cells	I-protein
during	I-protein
initiation	I-protein
of	I-protein
an	I-protein
inflammatory	O
response	I-protein

###MEDLINE:21293129

Synergistic	O
transcriptional	O
activation	I-protein
of	I-protein
human	O
Acyl-coenzyme	O
A	O
:	O
cholesterol	O
acyltransterase-1	O
gene	O
by	I-protein
interferon-gamma	B-protein
and	I-protein
all-trans-retinoic	O
acid	O
THP-1	O
cells	I-protein
.	O

Acyl-coenzyme	O
A	O
:	O
cholesterol	O
acyltransferase	O
(	O
ACAT	B-protein
)	O
is	O
an	I-protein
intracellular	I-protein
enzyme	I-protein
involved	I-protein
in	I-protein
cellular	O
cholesterol	O
homeostasis	I-protein
and	I-protein
in	I-protein
atherosclerotic	O
foam	O
cell	O
formation	O
.	O

Human	O
ACAT-1	O
gene	O
contains	I-protein
two	O
promoters	O
(	O
P1	I-protein
and	I-protein
P7	O
)	O
,	O
each	O
located	O
in	I-protein
a	I-protein
different	O
chromosome	O
(	O
1	I-protein
and	I-protein
7	I-protein
)	O
(	O
Li	O
,	O
B.	O
L.	O
,	O
Li	O
,	O
X.	O
L.	O
,	O
Duan	O
,	O
Z.	O
J.	O
,	O
Lee	O
,	O
O.	O
,	O
Lin	O
,	O
S.	I-protein
,	O
Ma	O
,	O
Z.	O
M.	O
,	O
Chang	O
,	O
C.	I-protein
C.	I-protein
,	O
Yang	O
,	O
X.	O
Y.	O
,	O
Park	O
,	O
J.	O
P.	O
,	O
Mohandas	O
,	O
T.	I-protein
K.	O
,	O
Noll	O
,	O
W.	O
,	O
Chan	O
,	O
L.	O
,	O
and	I-protein
Chang	O
,	O
T.	I-protein
Y.	O
(	O
1999	O
)	O
J.	O
Biol	O
Chem.	O
274	I-protein
,	O
11060-11071	O
)	O
.	O

Interferon-gamma	B-protein
(	O
IFN-gamma	B-protein
)	O
,	O
a	I-protein
cytokine	B-protein
that	O
exerts	O
many	O
pro-atherosclerotic	O
effects	O
in	I-protein
vivo	O
,	O
causes	O
up-regulation	O
of	I-protein
ACAT-1	O
mRNA	O
in	I-protein
human	O
blood	O
monocyte-derived	O
macrophages	O
and	I-protein
macrophage-like	O
cells	I-protein
but	O
not	I-protein
in	I-protein
other	O
cell	O
types	I-protein
.	O

To	O
examine	O
the	I-protein
molecular	I-protein
nature	O
of	I-protein
this	O
observation	O
,	O
we	O
identified	I-protein
within	B-protein
the	I-protein
ACAT-1	O
P1	I-protein
promoter	I-protein
a	I-protein
159-base	O
pair	O
core	O
region	O
.	O

This	O
region	O
contains	I-protein
4	I-protein
Sp1	O
elements	O
and	I-protein
an	I-protein
IFN-gamma	B-protein
activated	O
sequence	I-protein
(	O
GAS	B-protein
)	O
that	O
overlaps	O
with	I-protein
the	I-protein
second	O
Sp1	O
element	I-protein
.	O

In	O
the	I-protein
monocytic	I-protein
cell	O
line	I-protein
THP-1	O
cell	O
,	O
the	I-protein
combination	O
of	I-protein
IFN-gamma	B-protein
and	I-protein
all-trans-retinoic	O
acid	O
(	O
a	I-protein
known	O
differentiation	I-protein
agent	O
)	O
enhances	O
the	I-protein
ACAT-1	O
P1	I-protein
promoter	I-protein
but	O
not	I-protein
the	I-protein
P7	O
promoter	I-protein
.	O

Additional	O
experiments	O
showed	O
that	O
all-trans-retinoic	O
acid	O
causes	O
large	O
induction	I-protein
of	I-protein
the	I-protein
transcription	B-protein
factor	I-protein
STAT1	B-protein
,	O
while	O
IFN-gamma	O
causes	O
activation	I-protein
of	I-protein
STAT1	B-protein
such	O
that	O
it	O
binds	O
to	I-protein
the	I-protein
GAS/Sp1	O
site	I-protein
in	I-protein
the	I-protein
ACAT-1	O
P1	I-protein
promoter	I-protein
.	O

Our	O
work	O
provides	O
a	I-protein
molecular	I-protein
mechanism	O
to	I-protein
account	O
for	I-protein
the	I-protein
effect	O
of	I-protein
IFN-gamma	B-protein
in	I-protein
causing	O
transcriptional	O
activation	I-protein
of	I-protein
ACAT-1	B-protein
in	I-protein
macrophage-like	O
cells	I-protein
.	O

###MEDLINE:21288911

Inhaled	O
nitric	B-protein
oxide	I-protein
down-regulates	O
intrapulmonary	O
nitric	B-protein
oxide	I-protein
production	I-protein
in	I-protein
lipopolysaccharide-induced	B-protein
acute	O
lung	O
injury	O
.	O

OBJECTIVE	O
:	O
To	O
examine	O
whether	O
inhaled	O
nitric	B-protein
oxide	I-protein
(	O
NO	I-protein
)	O
affected	O
the	I-protein
intrapulmonary	O
production	I-protein
of	I-protein
NO	I-protein
,	O
reactive	I-protein
oxygen	O
species	O
,	O
and	I-protein
nuclear	B-protein
factor-kappaB	I-protein
in	I-protein
a	I-protein
lipopolysaccharide	B-protein
(	O
LPS	B-protein
)	O
-induced	O
model	I-protein
of	I-protein
acute	O
lung	O
injury	O
.	O

DESIGN	O
:	O
Prospective	O
,	O
randomized	O
,	O
laboratory	O
study	O
.	O

SETTING	O
:	O
Experimental	O
laboratory	O
at	I-protein
a	I-protein
biomedical	O
institute	O
.	O

SUBJECTS	O
:	O
Twenty	O
male	O
rabbits	O
weighing	O
2.5-3.5	O
kg	O
.	O

INTERVENTIONS	O
:	O
Saline	O
or	I-protein
LPS	B-protein
(	O
5	O
mg/kg	O
of	I-protein
body	O
weight	I-protein
)	O
was	O
administered	O
intravenously	O
with	I-protein
or	I-protein
without	I-protein
NO	I-protein
inhalation	O
(	O
10	I-protein
ppm	O
)	O
in	I-protein
each	O
group	I-protein
of	I-protein
five	I-protein
rabbits	O
.	O

MEASUREMENTS	O
AND	O
MAIN	O
RESULTS	O
:	O
LPS	B-protein
increased	I-protein
the	I-protein
lung	O
leak	I-protein
index	I-protein
,	O
the	I-protein
neutrophils	O
and	I-protein
NO	I-protein
levels	I-protein
in	I-protein
bronchoalveolar	O
lavage	O
fluid	I-protein
,	O
and	I-protein
NO	I-protein
levels	I-protein
produced	O
by	I-protein
resting	O
and	I-protein
stimulated	O
alveolar	O
macrophages	O
.	O

Inhaled	O
NO	I-protein
decreased	O
the	I-protein
lung	O
leak	I-protein
index	I-protein
,	O
the	I-protein
neutrophils	O
and	I-protein
NO	I-protein
levels	I-protein
as	O
measured	O
by	I-protein
nitrite	O
levels	I-protein
in	I-protein
the	I-protein
lavage	O
fluid	I-protein
,	O
and	I-protein
NO	I-protein
produced	O
by	I-protein
the	I-protein
resting	O
and	I-protein
stimulated	O
alveolar	O
macrophages	O
.	O

Inhaled	O
NO	I-protein
also	O
blocked	B-protein
the	I-protein
activities	O
of	I-protein
reactive	I-protein
oxygen	O
species	O
and	I-protein
nuclear	B-protein
factor-kappaB	I-protein
binding	I-protein
to	I-protein
DNA	O
in	I-protein
lavage	O
cells	I-protein
and	I-protein
in	I-protein
alveolar	O
macrophages	O
.	O

CONCLUSION	O
:	O
Inhaled	O
NO	I-protein
attenuates	O
LPS-induced	O
acute	O
lung	O
injury	O
,	O
possibly	O
by	I-protein
decreasing	O
NO	I-protein
production	I-protein
in	I-protein
the	I-protein
lungs	O
.	O

The	O
mechanism	O
of	I-protein
reducing	O
NO	I-protein
production	I-protein
resulting	O
from	I-protein
inhaled	O
NO	I-protein
may	O
involve	O
,	O
in	I-protein
part	I-protein
,	O
the	I-protein
activities	O
of	I-protein
reactive	I-protein
oxygen	O
species	O
and/or	O
nuclear	B-protein
factor-kappaB	I-protein
.	O

###MEDLINE:21286431

Treatment	O
of	I-protein
allergic	O
airway	I-protein
inflammation	O
and	I-protein
hyperresponsiveness	O
by	I-protein
antisense-induced	O
local	O
blockade	O
of	I-protein
GATA-3	B-protein
expression	I-protein
.	O

Recent	O
studies	O
in	I-protein
transgenic	O
mice	O
have	O
revealed	O
that	O
expression	I-protein
of	I-protein
a	I-protein
dominant	I-protein
negative	O
form	I-protein
of	I-protein
the	I-protein
transcription	B-protein
factor	I-protein
GATA-3	I-protein
in	I-protein
T	O
cells	I-protein
can	O
prevent	O
T	O
helper	I-protein
cell	O
type	O
2	I-protein
(	O
Th2	O
)	O
-mediated	O
allergic	O
airway	I-protein
inflammation	O
in	I-protein
mice	O
.	O

However	O
,	O
it	O
remains	O
unclear	O
whether	O
GATA-3	B-protein
plays	O
a	I-protein
role	O
in	I-protein
the	I-protein
effector	O
phase	I-protein
of	I-protein
allergic	O
airway	I-protein
inflammation	O
and	I-protein
whether	O
antagonizing	I-protein
the	I-protein
expression	I-protein
and/or	O
function	I-protein
of	I-protein
GATA-3	B-protein
can	O
be	O
used	O
for	I-protein
the	I-protein
therapy	O
of	I-protein
allergic	O
airway	I-protein
inflammation	O
and	I-protein
hyperresponsiveness	O
.	O

Here	O
,	O
we	O
analyzed	O
the	I-protein
effects	O
of	I-protein
locally	O
antagonizing	I-protein
GATA-3	B-protein
function	I-protein
in	I-protein
a	I-protein
murine	O
model	I-protein
of	I-protein
asthma	I-protein
.	O

We	O
could	O
suppress	O
GATA-3	O
expression	I-protein
in	I-protein
interleukin	B-protein
(	O
IL	I-protein
)	O
-4	I-protein
-producing	O
T	O
cells	I-protein
in	I-protein
vitro	O
and	I-protein
in	I-protein
vivo	O
by	I-protein
an	I-protein
antisense	O
phosphorothioate	O
oligonucleotide	O
overlapping	I-protein
the	I-protein
translation	I-protein
start	O
site	I-protein
of	I-protein
GATA-3	B-protein
,	O
whereas	O
nonsense	I-protein
control	I-protein
oligonucleotides	O
were	O
virtually	O
inactive	O
.	O

In	O
a	I-protein
murine	O
model	I-protein
of	I-protein
asthma	I-protein
associated	I-protein
with	I-protein
allergic	O
pulmonary	I-protein
inflammation	O
and	I-protein
hyperresponsiveness	O
in	I-protein
ovalbumin	I-protein
(	O
OVA	O
)	O
-sensitized	O
mice	O
,	O
local	O
intranasal	O
administration	O
of	I-protein
fluorescein	O
isothiocyanate-labeled	O
GATA-3	O
antisense	O
oligonucleotides	O
led	O
to	I-protein
DNA	O
uptake	I-protein
in	I-protein
lung	O
cells	I-protein
associated	I-protein
with	I-protein
a	I-protein
reduction	I-protein
of	I-protein
intracellular	I-protein
GATA-3	O
expression	I-protein
.	O

Such	O
intrapulmonary	O
blockade	O
of	I-protein
GATA-3	B-protein
expression	I-protein
caused	O
an	I-protein
abrogation	O
of	I-protein
signs	O
of	I-protein
lung	O
inflammation	O
including	I-protein
infiltration	O
of	I-protein
eosinophils	O
and	I-protein
Th2	B-protein
cytokine	I-protein
production	I-protein
.	O

Furthermore	O
,	O
treatment	O
with	I-protein
antisense	O
but	O
not	I-protein
nonsense	I-protein
oligonucleotides	O
induced	I-protein
a	I-protein
significant	O
reduction	I-protein
of	I-protein
airway	I-protein
hyperresponsiveness	O
in	I-protein
OVA-sensitized	O
mice	O
to	I-protein
levels	I-protein
comparable	O
to	I-protein
saline-treated	O
control	I-protein
mice	O
,	O
as	O
assessed	O
by	I-protein
both	O
enhanced	I-protein
pause	O
(	O
PenH	O
)	O
responses	O
and	I-protein
pulmonary	I-protein
resistance	O
determined	O
by	I-protein
body	O
plethysmography	O
.	O

These	O
data	O
indicate	O
a	I-protein
critical	I-protein
role	O
for	I-protein
GATA-3	B-protein
in	I-protein
the	I-protein
effector	O
phase	I-protein
of	I-protein
a	I-protein
murine	O
asthma	I-protein
model	I-protein
and	I-protein
suggest	O
that	O
local	O
delivery	O
of	I-protein
GATA-3	O
antisense	O
oligonucleotides	O
may	O
be	O
a	I-protein
novel	O
approach	O
for	I-protein
the	I-protein
treatment	O
of	I-protein
airway	I-protein
hyperresponsiveness	O
such	O
as	O
in	I-protein
asthma	I-protein
.	O

This	O
approach	O
has	O
the	I-protein
potential	I-protein
advantage	O
of	I-protein
suppressing	I-protein
the	I-protein
expression	I-protein
of	I-protein
various	O
proinflammatory	B-protein
Th2	I-protein
cytokines	I-protein
simultaneously	O
rather	O
than	I-protein
suppressing	I-protein
the	I-protein
activity	I-protein
of	I-protein
a	I-protein
single	O
cytokine	B-protein
.	O

###MEDLINE:21276281

T	O
helper-cell	O
phenotype	O
regulates	O
atherosclerosis	B-protein
in	I-protein
mice	O
under	O
conditions	O
of	I-protein
mild	I-protein
hypercholesterolemia	O
.	O

BACKGROUND	O
:	O
T	O
cells	I-protein
are	O
implicated	O
in	I-protein
atherosclerosis	B-protein
,	O
but	O
little	O
is	O
known	O
about	O
the	I-protein
genetic	O
control	I-protein
or	I-protein
molecular	I-protein
pathways	O
,	O
especially	O
under	O
conditions	O
of	I-protein
mild	I-protein
hypercholesterolemia	O
.	O

METHODS	O
AND	O
RESULTS	O
:	O
BALB/c	O
mice	O
,	O
making	O
a	I-protein
CD4+	O
Th2	O
(	O
IL-4+	O
)	O
cell	O
response	I-protein
,	O
express	O
both	O
MHC	B-protein
class	I-protein
II	I-protein
antigens	I-protein
(	O
IA	I-protein
(	O
d	I-protein
)	O
,	O
IE	I-protein
(	O
d	I-protein
)	O
)	O
and	I-protein
are	O
atherosclerosis-resistant	O
.	O

C57Bl/6	O
mice	O
produce	O
a	I-protein
CD4+	O
Th1	O
(	O
interferon	B-protein
[	O
IFN	B-protein
]	O
gamma+	O
)	O
response	I-protein
,	O
express	O
IA	I-protein
(	O
b	O
)	O
but	O
no	I-protein
IE	I-protein
,	O
and	I-protein
are	O
atherosclerosis-prone	O
.	O

To	O
evaluate	O
T	O
helper-cell	O
phenotype	O
in	I-protein
fatty	O
streak	O
formation	O
,	O
wild-type	I-protein
C57Bl/6	O
mice	O
(	O
IA	I-protein
(	O
b	O
)	O
+IE-	O
)	O
and	I-protein
transgenic	O
mice	O
,	O
either	O
AB	I-protein
(	O
o	O
)	O
,	O
IA	I-protein
(	O
b	O
)	O
-IE-	O
;	O
ABEalpha	O
,	O
IA-IE	O
(	O
k	O
)	O
+	O
;	O
or	I-protein
BL	I-protein
:	O
TG	O
:	O
Ealpha	O
,	O
IA	I-protein
(	O
b	O
)	O
+IE	O
(	O
k	O
)	O
+	O
,	O
were	O
fed	O
a	I-protein
high-cholesterol	O
diet	O
for	I-protein
16	I-protein
weeks	O
and	I-protein
evaluated	O
histomorphometrically	O
for	I-protein
aortic	I-protein
lesions	O
.	O

Lesion	O
size	O
in	I-protein
AB	I-protein
(	O
o	O
)	O
,	O
ABEalpha	O
,	O
and	I-protein
BL	I-protein
:	O
TG	O
:	O
Ealpha	O
strains	O
was	O
decreased	O
by	I-protein
54	I-protein
%	O
,	O
79	I-protein
%	O
,	O
and	I-protein
82	I-protein
%	O
,	O
respectively	O
,	O
compared	O
with	I-protein
wild-type	I-protein
,	O
correlating	O
with	I-protein
decreased	O
Th1	O
and	I-protein
increased	I-protein
Th2	O
expression	I-protein
and	I-protein
suggesting	O
that	O
T	O
helper-cell	O
phenotype	O
is	O
important	O
in	I-protein
fatty	O
lesion	O
development	O
.	O

Decreasing	O
Th1	O
cells	I-protein
by	I-protein
antibodies	I-protein
(	O
alpha-CD4	O
)	O
or	I-protein
cytokines	B-protein
(	O
IL-4	B-protein
)	O
also	O
caused	O
>	O
/=80	O
%	O
reductions	O
in	I-protein
lesion	O
size	O
.	O

Immunohistology	O
revealed	O
IFN-gamma	B-protein
,	O
but	O
not	I-protein
IL-4	B-protein
,	O
colocalized	O
with	I-protein
activated	O
macrophages	O
.	O

Confirming	O
these	O
findings	O
in	I-protein
a	I-protein
different	O
mouse	I-protein
strain	O
,	O
BALB/c	O
Stat	O
6	I-protein
knockout	O
mice	O
(	O
Th2	O
cell-deficient	O
)	O
developed	O
aortic	I-protein
lesions	O
comparable	O
to	I-protein
C57Bl/6	O
mice	O
on	I-protein
the	I-protein
same	O
diet	O
.	O

CONCLUSIONS	O
:	O
In	O
mildly	O
hypercholesterolemic	O
C57Bl/6	O
mice	O
,	O
presence	O
of	I-protein
IA	I-protein
(	O
b	O
)	O
and	I-protein
absence	I-protein
of	I-protein
IE	I-protein
regulated	O
CD4+	O
T	O
helper-cell	O
phenotype	O
;	O
fatty	O
lesions	O
were	O
proportional	O
to	I-protein
IFNgamma+	O
Th1	O
cells	I-protein
in	I-protein
both	O
C57Bl/6	O
and	I-protein
BALB/c	O
strains	O
.	O

IFN-gamma	B-protein
may	O
participate	O
through	I-protein
macrophage	O
activation	I-protein
,	O
whereas	O
IL-4	B-protein
may	O
act	O
to	I-protein
limit	O
Th1-cell	O
response	I-protein
.	O

###MEDLINE:21269099

Requirement	O
for	I-protein
p38	B-protein
and	I-protein
p44/p42	B-protein
mitogen-activated	I-protein
protein	I-protein
kinases	I-protein
in	I-protein
RAGE	B-protein
-mediated	O
nuclear	B-protein
factor-kappaB	I-protein
transcriptional	O
activation	I-protein
and	I-protein
cytokine	O
secretion	O
.	O

Advanced	O
glycation	O
end	I-protein
product	I-protein
(	O
AGE	O
)	O
activation	I-protein
of	I-protein
the	I-protein
signal-transducing	B-protein
receptor	I-protein
for	I-protein
AGE	O
(	O
RAGE	B-protein
)	O
has	O
been	O
linked	I-protein
to	I-protein
a	I-protein
proinflammatory	O
phenotypic	O
change	O
within	B-protein
cells	I-protein
.	O

However	O
,	O
the	I-protein
precise	O
intracellular	I-protein
signaling	O
pathways	O
involved	I-protein
have	O
not	I-protein
been	O
elucidated	O
.	O

We	O
demonstrate	O
here	O
that	O
human	O
serum	O
albumin	O
modified	O
with	I-protein
N	O
(	O
varepsilon	O
)	O
-	O
(	O
carboxymethyl	O
)	O
lysine	I-protein
(	O
CML	O
)	O
,	O
a	I-protein
major	O
AGE	O
adduct	O
that	O
progressively	O
accumulates	O
with	I-protein
aging	O
,	O
diabetes	O
,	O
and	I-protein
renal	O
failure	I-protein
,	O
induced	I-protein
nuclear	B-protein
factor	I-protein
(	O
NF	I-protein
)	O
-kappaB	I-protein
-driven	O
reporter	O
gene	O
expression	I-protein
in	I-protein
human	O
monocytic	I-protein
THP-1	O
cells	I-protein
.	O

The	O
NF-kappaB	B-protein
response	I-protein
was	O
blocked	B-protein
with	I-protein
a	I-protein
synthetic	I-protein
peptide	O
corresponding	O
to	I-protein
the	I-protein
putative	B-protein
ligand-binding	I-protein
domain	I-protein
of	I-protein
RAGE	B-protein
,	O
with	I-protein
anti-	O
RAGE	B-protein
antiserum	O
,	O
and	I-protein
by	I-protein
coexpression	O
of	I-protein
truncated	I-protein
receptors	I-protein
lacking	I-protein
the	I-protein
intracellular	I-protein
domain	I-protein
.	O

Signal	I-protein
transduction	I-protein
from	I-protein
RAGE	B-protein
to	I-protein
NF-kappaB	B-protein
involved	I-protein
the	I-protein
generation	O
of	I-protein
reactive	I-protein
oxygen	O
species	O
,	O
since	O
reporter	O
gene	O
expression	I-protein
was	O
blocked	B-protein
with	I-protein
the	I-protein
antioxidant	I-protein
N-acetyl-L-cysteine	O
.	O

CML-modified	B-protein
albumin	I-protein
produced	O
rapid	O
transient	O
activation	I-protein
of	I-protein
tyrosine	O
phosphorylation	I-protein
,	O
extracellular	B-protein
signal-regulated	I-protein
kinase	I-protein
1	I-protein
and	I-protein
2	I-protein
,	O
and	I-protein
p38	B-protein
mitogen-activated	I-protein
protein	I-protein
kinase	I-protein
(	O
MAPK	I-protein
)	O
,	O
but	O
not	I-protein
c-Jun	B-protein
NH	I-protein
(	O
2	I-protein
)	O
-terminal	I-protein
kinase	I-protein
.	O

RAGE	B-protein
-mediated	O
NF-kappaB	B-protein
activation	I-protein
was	O
suppressed	I-protein
by	I-protein
the	I-protein
selective	O
p38	B-protein
MAPK	I-protein
inhibitor	O
SB203580	O
and	I-protein
by	I-protein
coexpression	O
of	I-protein
a	I-protein
kinase-dead	O
p38	B-protein
dominant-negative	I-protein
mutant	O
.	O

Activation	O
of	I-protein
NF-kappaB	B-protein
by	I-protein
CML-modified	B-protein
albumin	I-protein
increased	I-protein
secretion	O
of	I-protein
proinflammatory	B-protein
cytokines	I-protein
(	O
tumor	B-protein
necrosis	I-protein
factor-alpha	I-protein
,	O
interleukin-1beta	O
,	O
and	I-protein
monocyte	B-protein
chemoattractant	I-protein
protein-1	I-protein
)	O
severalfold	O
,	O
and	I-protein
inhibition	O
of	I-protein
p38	B-protein
MAPK	I-protein
blocked	B-protein
these	O
increases	O
.	O

These	O
results	O
indicate	O
that	O
p38	B-protein
MAPK	I-protein
activation	I-protein
mediates	O
RAGE	B-protein
-induced	O
NF-kappaB	B-protein
-dependent	I-protein
secretion	O
of	I-protein
proinflammatory	B-protein
cytokines	I-protein
and	I-protein
suggest	O
that	O
accelerated	I-protein
inflammation	O
may	O
be	O
a	I-protein
consequence	O
of	I-protein
cellular	O
activation	I-protein
induced	I-protein
by	I-protein
this	O
receptor	O
.	O

###MEDLINE:21261983

Antigen-receptor	O
cross-linking	O
and	I-protein
lipopolysaccharide	B-protein
trigger	O
distinct	O
phosphoinositide	I-protein
3-kinase	I-protein
-dependent	I-protein
pathways	O
to	I-protein
NF-kappa	B-protein
B	I-protein
activation	I-protein
in	I-protein
primary	O
B	O
cells	I-protein
.	O

The	O
NF-kappaB/Rel	B-protein
transcription	I-protein
factors	I-protein
play	O
an	I-protein
important	O
role	O
in	I-protein
the	I-protein
expression	I-protein
of	I-protein
genes	I-protein
involved	I-protein
in	I-protein
B	O
cell	O
development	O
,	O
differentiation	I-protein
and	I-protein
function	I-protein
.	O

Nuclear	I-protein
NF-kappaB	B-protein
is	O
induced	I-protein
in	I-protein
B	O
cells	I-protein
by	I-protein
engagement	O
of	I-protein
either	O
the	I-protein
BCR	B-protein
or	I-protein
CD40	B-protein
or	I-protein
by	I-protein
stimulation	I-protein
with	I-protein
lipopolysaccharide	B-protein
(	O
LPS	B-protein
)	O
.	O

Despite	O
the	I-protein
importance	O
of	I-protein
NF-kappaB	B-protein
to	I-protein
B	O
cell	O
function	I-protein
,	O
little	O
is	O
known	O
about	O
the	I-protein
signaling	O
pathways	O
leading	O
to	I-protein
NF-kappaB	B-protein
activation	I-protein
.	O

In	O
this	O
report	O
we	O
address	O
the	I-protein
role	O
of	I-protein
phosphoinositide	I-protein
3'-kinase	I-protein
(	O
PI	I-protein
3-kinase	I-protein
)	O
in	I-protein
BCR	B-protein
-	O
and	I-protein
LPS-induced	O
NF-kappaB	B-protein
activation	I-protein
using	O
populations	O
of	I-protein
primary	O
murine	O
resting	O
B	O
cells	I-protein
.	O

Using	O
the	I-protein
specific	I-protein
pharmacological	O
inhibitors	I-protein
of	I-protein
PI	I-protein
3-kinase	I-protein
,	O
Wortmannin	O
and	I-protein
LY294002	O
,	O
we	O
demonstrate	O
that	O
PI	I-protein
3-kinase	I-protein
activity	I-protein
is	O
vital	O
for	I-protein
BCR	B-protein
-induced	O
NF-kappaB	B-protein
DNA-binding	O
activity	I-protein
.	O

Furthermore	O
,	O
we	O
show	O
that	O
this	O
is	O
achieved	O
via	I-protein
protein	B-protein
kinase	I-protein
C	I-protein
-dependent	I-protein
degradation	I-protein
of	I-protein
IkappaBalpha	B-protein
.	O

Similar	B-protein
analyses	O
reveal	O
that	O
PI	I-protein
3-kinase	I-protein
is	O
also	O
critical	I-protein
in	I-protein
triggering	O
NF-kappaB	B-protein
DNA-binding	O
activity	I-protein
and	I-protein
IkappaBalpha	B-protein
degradation	I-protein
following	O
LPS	B-protein
stimulation	I-protein
.	O

Interestingly	O
,	O
a	I-protein
PKC	B-protein
inhibitor	O
which	O
blocked	B-protein
the	I-protein
BCR	B-protein
-induced	O
IkappaBalpha	B-protein
degradation	I-protein
had	O
no	I-protein
effect	O
on	I-protein
the	I-protein
degradation	I-protein
of	I-protein
IkappaBalpha	B-protein
after	O
LPS	B-protein
stimulation	I-protein
.	O

Taken	O
together	O
,	O
our	O
results	O
indicate	O
the	I-protein
involvement	I-protein
of	I-protein
PI	I-protein
3-kinase	I-protein
in	I-protein
at	I-protein
least	O
two	O
distinct	O
signaling	O
pathways	O
leading	O
to	I-protein
activation	I-protein
of	I-protein
NF-kappaB	B-protein
in	I-protein
B	O
cells	I-protein
.	O

###MEDLINE:21259893

Tetramer-guided	O
epitope	I-protein
mapping	O
:	O
rapid	O
identification	O
and	I-protein
characterization	O
of	I-protein
immunodominant	O
CD4+	O
T	O
cell	O
epitopes	O
from	I-protein
complex	I-protein
antigens	I-protein
.	O

T	O
cell	O
responses	O
to	I-protein
Ags	B-protein
involve	O
recognition	I-protein
of	I-protein
selected	O
peptide	B-protein
epitopes	I-protein
contained	O
within	B-protein
the	I-protein
antigenic	I-protein
protein	I-protein
.	O

In	O
this	O
report	O
,	O
we	O
describe	O
a	I-protein
new	I-protein
approach	O
for	I-protein
direct	O
identification	O
of	I-protein
CD4+	O
T	O
cell	O
epitopes	O
of	I-protein
complex	I-protein
Ags	B-protein
that	O
uses	O
human	B-protein
class	I-protein
II	I-protein
tetramers	I-protein
to	I-protein
identify	O
reactive	I-protein
cells	I-protein
.	O

With	O
a	I-protein
panel	O
of	I-protein
60	I-protein
overlapping	I-protein
peptides	O
covering	O
the	I-protein
entire	O
sequence	I-protein
of	I-protein
the	I-protein
VP16	B-protein
protein	I-protein
,	O
a	I-protein
major	O
Ag	I-protein
for	I-protein
HSV-2	O
,	O
we	O
generated	O
a	I-protein
panel	O
of	I-protein
class	B-protein
II	I-protein
MHC	I-protein
tetramers	I-protein
loaded	O
with	I-protein
peptide	O
pools	O
that	O
were	O
used	O
to	I-protein
stain	O
peripheral	O
lymphocytes	O
of	I-protein
an	I-protein
HSV-2	O
infected	O
individual	O
.	O

With	O
this	O
approach	O
,	O
we	O
identified	I-protein
four	O
new	I-protein
DRA1*0101/DRB1*0401-	O
and	I-protein
two	O
DRA1*0101/DRB1*0404-restricted	O
,	O
VP16-specific	B-protein
epitopes	I-protein
.	O

By	O
using	O
tetramers	O
to	I-protein
sort	O
individual	O
cells	I-protein
,	O
we	O
easily	O
obtained	O
a	I-protein
large	O
number	I-protein
of	I-protein
clones	O
specific	I-protein
to	I-protein
these	O
epitopes	B-protein
.	O

Although	O
DRA1*0101/DRB1*0401	O
and	I-protein
DRA1*0101/DRB1*0404	O
are	O
structurally	O
very	O
similar	O
,	O
nonoverlapping	O
VP16	B-protein
epitopes	I-protein
were	O
identified	I-protein
,	O
illustrating	O
high	O
selectivity	O
of	I-protein
individual	O
allele	I-protein
polymorphisms	O
within	B-protein
common	I-protein
MHC	O
variants	O
.	O

This	O
rapid	O
approach	O
to	I-protein
detecting	O
CD4+	O
T	O
cell	O
epitopes	O
from	I-protein
complex	I-protein
Ags	B-protein
can	O
be	O
applied	O
to	I-protein
any	O
known	O
Ag	I-protein
that	O
gives	O
a	I-protein
T	O
cell	O
response	I-protein
.	O

###MEDLINE:21250583

Localized	O
pancreatic	O
NF-kappaB	B-protein
activation	I-protein
and	I-protein
inflammatory	O
response	I-protein
in	I-protein
taurocholate-induced	O
pancreatitis	O
.	O

Transcription	I-protein
factor	I-protein
nuclear	I-protein
factor-kappaB	I-protein
(	O
NF-kappaB	B-protein
)	O
is	O
activated	O
in	I-protein
cerulein	O
pancreatitis	O
and	I-protein
mediates	O
cytokine	O
expression	I-protein
.	O

The	O
role	O
of	I-protein
transcription	B-protein
factor	I-protein
activation	I-protein
in	I-protein
other	O
models	O
of	I-protein
pancreatitis	O
has	O
not	I-protein
been	O
established	O
.	O

Here	O
we	O
report	O
upregulation	O
of	I-protein
NF-kappaB	B-protein
and	I-protein
inflammatory	B-protein
molecules	I-protein
,	O
and	I-protein
their	O
correlation	O
with	I-protein
local	O
pancreatic	O
injury	O
,	O
in	I-protein
a	I-protein
model	I-protein
of	I-protein
severe	I-protein
pancreatitis	O
.	O

Rats	O
received	O
intraductal	O
infusion	O
of	I-protein
taurocholate	O
or	I-protein
saline	O
,	O
and	I-protein
the	I-protein
pancreatic	O
head	I-protein
and	I-protein
tail	I-protein
were	O
analyzed	O
separately	O
.	O

NF-kappaB	B-protein
and	I-protein
activator	B-protein
protein-1	I-protein
(	O
AP-1	I-protein
)	O
activation	I-protein
were	O
assessed	O
by	I-protein
gel	O
shift	O
assay	O
,	O
and	I-protein
mRNA	O
expression	I-protein
of	I-protein
interleukin-6	B-protein
,	O
tumor	B-protein
necrosis	I-protein
factor-alpha	I-protein
,	O
KC	O
,	O
monocyte	B-protein
chemoattractant	I-protein
protein-1	I-protein
,	O
and	I-protein
inducible	B-protein
nitric	B-protein
oxide	I-protein
synthase	I-protein
was	O
assessed	O
by	I-protein
semiquantitative	O
RT-PCR	O
.	O

Morphological	O
damage	I-protein
and	I-protein
trypsin	O
activation	I-protein
were	O
much	O
greater	O
in	I-protein
the	I-protein
pancreatic	O
head	I-protein
than	I-protein
tail	I-protein
,	O
in	I-protein
parallel	O
with	I-protein
a	I-protein
stronger	O
activation	I-protein
of	I-protein
NF-kappaB	B-protein
and	I-protein
cytokine	O
mRNA	O
.	O

Saline	O
infusion	O
mildly	O
affected	O
these	O
parameters	O
.	O

AP-1	I-protein
was	O
strongly	O
activated	O
in	I-protein
both	O
pancreatic	O
segments	O
after	O
either	O
taurocholate	O
or	I-protein
saline	O
infusion	O
.	O

NF-kappaB	B-protein
inhibition	O
with	I-protein
N-acetylcysteine	O
ameliorated	O
the	I-protein
local	O
inflammatory	O
response	I-protein
.	O

Correlation	O
between	O
localized	I-protein
NF-kappaB	B-protein
activation	I-protein
,	O
cytokine	O
upregulation	O
,	O
and	I-protein
tissue	O
damage	I-protein
suggests	O
a	I-protein
key	O
role	O
for	I-protein
NF-kappaB	B-protein
in	I-protein
the	I-protein
development	O
of	I-protein
the	I-protein
inflammatory	O
response	I-protein
of	I-protein
acute	O
pancreatitis	O
.	O

###MEDLINE:21240664

CD45	B-protein
tyrosine	I-protein
phosphatase	I-protein
controls	O
common	I-protein
gamma-chain	B-protein
cytokine	I-protein
-mediated	O
STAT	O
and	I-protein
extracellular	O
signal-related	O
kinase	O
phosphorylation	I-protein
in	I-protein
activated	O
human	O
lymphoblasts	O
:	O
inhibition	O
of	I-protein
proliferation	I-protein
without	I-protein
induction	I-protein
of	I-protein
apoptosis	O
.	O

The	O
objective	O
of	I-protein
this	O
study	O
was	O
to	I-protein
test	O
whether	O
CD45	B-protein
signals	I-protein
can	O
influence	O
signaling	O
processes	O
in	I-protein
activated	O
human	O
lymphoblasts	O
.	O

To	O
this	O
end	I-protein
,	O
we	O
generated	O
lymphoblasts	O
which	O
proliferate	O
in	I-protein
response	I-protein
to	I-protein
common	I-protein
gamma-chain	B-protein
cytokines	I-protein
,	O
but	O
readily	O
undergo	O
apoptosis	O
after	O
cytokine	O
withdrawal	O
.	O

In	O
experiments	O
with	I-protein
the	I-protein
CD45R0	B-protein
mAb	I-protein
UCHL-1	I-protein
,	O
but	O
not	I-protein
control	I-protein
CD45	B-protein
mAbs	I-protein
,	O
we	O
found	O
significant	O
inhibition	O
of	I-protein
proliferation	I-protein
.	O

Interestingly	O
,	O
the	I-protein
pan-CD45	B-protein
mAb	I-protein
GAP8.3	I-protein
,	O
which	O
is	O
most	O
effective	O
in	I-protein
inhibition	O
of	I-protein
OKT-3-mediated	O
proliferation	I-protein
in	I-protein
quiescent	O
lymphocytes	O
,	O
was	O
ineffective	O
in	I-protein
lymphoblasts	O
.	O

Addition	O
of	I-protein
CD3	B-protein
mAb	I-protein
OKT-3	I-protein
had	O
no	I-protein
influence	O
on	I-protein
IL-2-mediated	O
proliferation	I-protein
(	O
with	I-protein
or	I-protein
without	I-protein
UCHL-1	B-protein
)	O
.	O

In	O
contrast	O
,	O
after	O
addition	O
of	I-protein
OKT-3	B-protein
to	I-protein
IL-4	B-protein
-	O
and	I-protein
IL-7	B-protein
-stimulated	O
proliferation	I-protein
assays	O
,	O
UCHL-1	O
signals	I-protein
could	O
not	I-protein
significantly	O
alter	O
cellular	O
proliferation	I-protein
.	O

We	O
did	O
not	I-protein
find	O
induction	I-protein
of	I-protein
apoptosis	O
following	O
CD45R0	O
signaling	O
.	O

In	O
Western	O
blots	O
using	O
mAbs	B-protein
detecting	O
phosphorylated	B-protein
STAT-3	I-protein
,	O
STAT-5	I-protein
,	O
STAT-6	I-protein
,	O
or	I-protein
extracellular	B-protein
signal-related	I-protein
kinase	I-protein
1/2	I-protein
,	O
we	O
found	O
that	O
CD45R0	O
signaling	O
could	O
effectively	O
diminish	O
phosphorylation	I-protein
of	I-protein
these	O
intracellular	I-protein
signaling	O
components	O
.	O

Using	O
RT-PCR	O
,	O
we	O
found	O
that	O
CD45R0	O
signaling	O
inhibited	O
IL-2	B-protein
mRNA	O
production	I-protein
without	I-protein
major	O
influence	O
on	I-protein
IL-13	B-protein
,	O
IL-5	B-protein
,	O
or	I-protein
IFN-gamma	O
mRNA	O
levels	I-protein
.	O

Costimulation	O
with	I-protein
OKT-3	B-protein
and	I-protein
IL-2	B-protein
optimally	O
induced	I-protein
secretion	O
of	I-protein
IFN-gamma	B-protein
,	O
TNF-alpha	B-protein
,	O
and	I-protein
IL-5	B-protein
,	O
which	O
was	O
not	I-protein
decreased	O
by	I-protein
CD45	B-protein
signals	I-protein
.	O

In	O
conclusion	O
,	O
we	O
illustrate	O
that	O
CD45R0	O
signals	I-protein
control	I-protein
early	O
cytokine	O
receptor-associated	O
signaling	O
processes	O
and	I-protein
mRNA	O
and	I-protein
DNA	O
synthesis	I-protein
in	I-protein
activated	O
human	O
lymphoblasts	O
.	O

Furthermore	O
,	O
we	O
show	O
the	I-protein
existence	O
of	I-protein
CD45	B-protein
epitopes	I-protein
(	O
GAP8.3	B-protein
)	O
,	O
which	O
are	O
active	O
and	I-protein
critical	I-protein
for	I-protein
signaling	O
in	I-protein
quiescent	O
lymphocytes	O
,	O
but	O
are	O
nonfunctional	O
in	I-protein
activated	O
human	O
lymphoblasts	O
.	O

###MEDLINE:21240752

Pax5	O
determines	O
the	I-protein
identity	O
of	I-protein
B	O
cells	I-protein
from	I-protein
the	I-protein
beginning	O
to	I-protein
the	I-protein
end	I-protein
of	I-protein
B-lymphopoiesis	O
.	O

Despite	O
being	O
one	B-protein
of	I-protein
the	I-protein
most	O
intensively	O
studied	O
cell	O
types	I-protein
,	O
the	I-protein
molecular	I-protein
basis	O
of	I-protein
B	O
cell	O
specification	O
is	O
largely	O
unknown	O
.	O

The	O
Pax5	O
gene	O
encoding	I-protein
the	I-protein
transcription	B-protein
factor	I-protein
BSAP	B-protein
is	O
required	O
for	I-protein
progression	I-protein
of	I-protein
B-lymphopoiesis	O
beyond	O
the	I-protein
pro-B	O
cell	O
stage	I-protein
.	O

Pax5-deficient	O
pro-B	O
cells	I-protein
are	O
,	O
however	O
,	O
not	I-protein
yet	O
committed	O
to	I-protein
the	I-protein
B-lymphoid	O
lineage	I-protein
,	O
but	O
instead	I-protein
have	O
a	I-protein
broad	O
lymphomyeloid	O
developmental	O
potential	I-protein
.	O

Pax5	O
appears	O
to	I-protein
mediate	O
B-lineage	O
commitment	O
by	I-protein
repressing	I-protein
the	I-protein
transcription	O
of	I-protein
non-B-lymphoid	O
genes	I-protein
and	I-protein
by	I-protein
simultaneously	O
activating	O
the	I-protein
expression	I-protein
of	I-protein
B-lineage-specific	O
genes	I-protein
.	O

Pax5	O
thus	O
functions	O
both	O
as	O
a	I-protein
transcriptional	O
repressor	O
and	I-protein
activator	O
,	O
depending	O
on	I-protein
its	O
interactions	O
with	I-protein
corepressors	O
of	I-protein
the	I-protein
Groucho	B-protein
protein	I-protein
family	I-protein
or	I-protein
with	I-protein
positive	I-protein
regulators	O
such	O
as	O
the	I-protein
TATA-binding	B-protein
protein	I-protein
.	O

Once	O
committed	O
to	I-protein
the	I-protein
B-lineage	O
,	O
B	O
cells	I-protein
require	O
Pax5	O
function	I-protein
to	I-protein
maintain	O
their	O
B-lymphoid	O
identity	O
throughout	O
B	O
cell	O
development	O

###MEDLINE:21295479

Partners	O
in	I-protein
transcription	O
:	O
NFAT	B-protein
and	I-protein
AP-1	I-protein
.	O

Combinatorial	O
regulation	I-protein
is	O
a	I-protein
powerful	O
mechanism	O
that	O
enables	O
tight	O
control	I-protein
of	I-protein
gene	O
expression	I-protein
,	O
via	I-protein
integration	I-protein
of	I-protein
multiple	O
signaling	O
pathways	O
that	O
induce	O
different	O
transcription	B-protein
factors	I-protein
required	O
for	I-protein
enhanceosome	O
assembly	I-protein
.	O

The	O
four	O
calcium-regulated	O
transcription	B-protein
factors	I-protein
of	I-protein
the	I-protein
NFAT	B-protein
family	I-protein
act	O
synergistically	O
with	I-protein
AP-1	I-protein
(	O
Fos/Jun	I-protein
)	O
proteins	I-protein
on	I-protein
composite	O
DNA	O
elements	O
which	O
contain	O
adjacent	I-protein
NFAT	O
and	I-protein
AP-1	I-protein
binding	I-protein
sites	I-protein
,	O
where	O
they	O
form	I-protein
highly	O
stable	I-protein
ternary	O
complexes	O
to	I-protein
regulate	O
the	I-protein
expression	I-protein
of	I-protein
diverse	O
inducible	O
genes	I-protein
.	O

Concomitant	O
induction	I-protein
of	I-protein
NFAT	B-protein
and	I-protein
AP-1	I-protein
requires	O
concerted	O
activation	I-protein
of	I-protein
two	O
different	O
signaling	O
pathways	O
:	O
calcium/calcineurin	O
,	O
which	O
promotes	O
NFAT	O
dephosphorylation	O
,	O
nuclear	O
translocation	O
and	I-protein
activation	I-protein
;	O
and	I-protein
protein	B-protein
kinase	I-protein
C	I-protein
(	O
PKC	B-protein
)	O
/Ras	I-protein
,	O
which	O
promotes	O
the	I-protein
synthesis	I-protein
,	O
phosphorylation	I-protein
and	I-protein
activation	I-protein
of	I-protein
members	O
of	I-protein
the	I-protein
Fos	B-protein
and	I-protein
Jun	B-protein
families	I-protein
of	I-protein
transcription	B-protein
factors	I-protein
.	O

A	O
fifth	O
member	I-protein
of	I-protein
the	I-protein
NFAT	B-protein
family	I-protein
,	O
NFAT5	B-protein
,	O
controls	O
the	I-protein
cellular	O
response	I-protein
to	I-protein
osmotic	O
stress	O
,	O
by	I-protein
a	I-protein
mechanism	O
that	O
requires	O
dimer	O
formation	O
and	I-protein
is	O
independent	I-protein
of	I-protein
calcineurin	B-protein
or	I-protein
of	I-protein
interaction	I-protein
with	I-protein
AP-1	I-protein
.	O

Pharmacological	O
interference	O
with	I-protein
theNFAT	O
:	O
AP-1	I-protein
interaction	I-protein
may	O
be	O
useful	O
in	I-protein
selective	O
manipulation	O
of	I-protein
the	I-protein
immune	O
response	I-protein
.	O

Balanced	O
activation	I-protein
of	I-protein
NFAT	B-protein
and	I-protein
AP-1	I-protein
is	O
known	O
to	I-protein
be	O
required	O
for	I-protein
productive	O
immune	O
responses	O
,	O
but	O
the	I-protein
role	O
of	I-protein
NFAT	O
:	O
AP-1	I-protein
interactions	O
in	I-protein
other	O
cell	O
types	I-protein
and	I-protein
biological	O
processes	O
remains	O
to	I-protein
be	O
understood	O
.	O

###MEDLINE:21286716

Cytokine	O
production	I-protein
by	I-protein
Vgamma	O
(	O
+	O
)	O
-T-cell	O
subsets	O
is	O
an	I-protein
important	O
factor	I-protein
determining	I-protein
CD4	B-protein
(	O
+	O
)	O
-Th-cell	O
phenotype	O
and	I-protein
susceptibility	I-protein
of	I-protein
BALB/c	O
mice	O
to	I-protein
coxsackievirus	O
B3-induced	O
myocarditis	O
.	O

Two	O
coxsackievirus	O
B3	I-protein
(	O
CVB3	O
)	O
variants	O
(	O
H3	O
and	I-protein
H310A1	O
)	O
differ	O
by	I-protein
a	I-protein
single	O
amino	O
acid	O
mutation	I-protein
in	I-protein
the	I-protein
VP2	B-protein
capsid	I-protein
protein	I-protein
.	O

H3	O
induces	O
severe	I-protein
myocarditis	O
in	I-protein
BALB/c	O
mice	O
,	O
but	O
H310A1	O
is	O
amyocarditic	O
.	O

Infection	O
with	I-protein
H3	O
,	O
but	O
not	I-protein
H310A1	O
,	O
preferentially	O
activates	O
Vgamma4	O
Vdelta4	O
cells	I-protein
,	O
which	O
are	O
strongly	O
positive	I-protein
for	I-protein
gamma	B-protein
interferon	I-protein
(	O
IFN-gamma	B-protein
)	O
,	O
whereas	O
Vgamma1	O
Vdelta4	O
cells	I-protein
are	O
increased	I-protein
in	I-protein
both	O
H3	O
and	I-protein
H310A1	O
virus-infected	O
animals	O
.	O

Depletion	O
of	I-protein
Vgamma1	O
(	O
+	O
)	O
cells	I-protein
using	O
monoclonal	I-protein
anti-Vgamma1	I-protein
antibody	I-protein
enhanced	I-protein
myocarditis	O
and	I-protein
CD4	B-protein
(	O
+	O
)	O
-	O
,	O
IFN-gamma	B-protein
(	O
+	O
)	O
-cell	O
responses	O
in	I-protein
both	O
H3-	O
and	I-protein
H310A1-infected	O
mice	O
yet	O
decreased	O
the	I-protein
CD4	B-protein
(	O
+	O
)	O
-	O
,	O
IL-4	B-protein
(	O
+	O
)	O
-cell	O
response	I-protein
.	O

Depleting	O
Vgamma4	O
(	O
+	O
)	O
cells	I-protein
suppressed	I-protein
myocarditis	O
and	I-protein
reduced	O
CD4	B-protein
(	O
+	O
)	O
IFN-gamma	O
(	O
+	O
)	O
cells	I-protein
but	O
increased	I-protein
CD4	B-protein
(	O
+	O
)	O
IL-4	B-protein
(	O
+	O
)	O
T	O
cells	I-protein
.	O

The	O
role	O
of	I-protein
cytokine	O
production	I-protein
by	I-protein
Vgamma1	O
(	O
+	O
)	O
and	I-protein
Vgamma4	O
(	O
+	O
)	O
T	O
cells	I-protein
was	O
investigated	O
by	I-protein
adoptively	O
transferring	O
these	O
cells	I-protein
isolated	I-protein
from	I-protein
H3-infected	O
BALB/c	O
Stat4	O
knockout	O
(	O
Stat4ko	O
)	O
(	O
defective	O
in	I-protein
IFN-gamma	O
expression	I-protein
)	O
or	I-protein
BALB/c	O
Stat6ko	O
(	O
defective	O
in	I-protein
IL-4	B-protein
expression	I-protein
)	O
mice	O
into	O
H3	O
virus-infected	O
wild-type	I-protein
BALB/c	O
recipients	O
.	O

Vgamma4	O
and	I-protein
Vgamma1	O
(	O
+	O
)	O
T	O
cells	I-protein
from	I-protein
Stat4ko	O
mice	O
expressed	O
IL-4	B-protein
but	O
no	I-protein
or	I-protein
minimal	O
IFN-gamma	B-protein
,	O
whereas	O
these	O
cell	O
populations	O
derived	I-protein
from	I-protein
Stat6ko	O
mice	O
expressed	O
IFN-gamma	B-protein
but	O
no	I-protein
IL-4	B-protein
.	O

Stat4ko	O
Vgamma1	O
(	O
+	O
)	O
cells	I-protein
(	O
IL-4	B-protein
(	O
+	O
)	O
)	O
suppress	O
myocarditis	O
.	O

Stat6ko	O
Vgamma1	O
(	O
+	O
)	O
cells	I-protein
(	O
IFN-gamma	B-protein
(	O
+	O
)	O
)	O
were	O
not	I-protein
inhibitory	O
.	O

Stat6ko	O
Vgamma4	O
(	O
+	O
)	O
cells	I-protein
(	O
IFN-gamma	B-protein
(	O
+	O
)	O
)	O
significantly	O
enhanced	I-protein
myocarditis	O
.	O

Stat4ko	O
Vgamma4	O
(	O
+	O
)	O
cells	I-protein
(	O
IL-4	B-protein
(	O
+	O
)	O
)	O
neither	O
inhibited	O
nor	O
enhanced	I-protein
disease	I-protein
.	O

These	O
results	O
show	O
that	O
distinct	O
gammadelta-T-cell	O
subsets	O
control	I-protein
myocarditis	O
susceptibility	I-protein
and	I-protein
bias	O
the	I-protein
CD4	B-protein
(	O
+	O
)	O
-Th-cell	O
response	I-protein
.	O

The	O
cytokines	B-protein
produced	O
by	I-protein
the	I-protein
Vgamma	O
subpopulation	O
have	O
a	I-protein
significant	O
influence	O
on	I-protein
the	I-protein
CD4	B-protein
(	O
+	O
)	O
-Th-cell	O
phenotype	O
.	O

###MEDLINE:21282637

Plasmin	B-protein
-induced	O
expression	I-protein
of	I-protein
cytokines	B-protein
and	I-protein
tissue	B-protein
factor	I-protein
in	I-protein
human	O
monocytes	O
involves	O
AP-1	I-protein
and	I-protein
IKKbeta	B-protein
-mediated	O
NF-kappaB	B-protein
activation	I-protein
.	O

It	O
was	O
previously	O
shown	O
that	O
plasmin	B-protein
activates	O
human	O
peripheral	O
monocytes	O
in	I-protein
terms	O
of	I-protein
lipid	O
mediator	O
release	I-protein
and	I-protein
chemotactic	I-protein
migration	I-protein
.	O

Here	O
it	O
is	O
demonstrated	O
that	O
plasmin	B-protein
induces	O
proinflammatory	B-protein
cytokine	I-protein
release	I-protein
and	I-protein
tissue	B-protein
factor	I-protein
(	O
TF	B-protein
)	O
expression	I-protein
by	I-protein
monocytes	O
.	O

Plasmin	B-protein
0.043	O
to	I-protein
1.43	O
CTA	O
U/mL	O
,	O
but	O
not	I-protein
active	B-protein
site-blocked	I-protein
plasmin	I-protein
,	O
triggered	O
concentration-dependent	O
expression	I-protein
of	I-protein
mRNA	O
for	I-protein
interleukin-1alpha	O
(	O
IL-1alpha	B-protein
)	O
,	O
IL-1beta	B-protein
,	O
tumor	B-protein
necrosis	I-protein
factor-alpha	I-protein
(	O
TNF-alpha	B-protein
)	O
,	O
and	I-protein
TF	B-protein
with	I-protein
maximum	O
responses	O
after	O
4	I-protein
hours	O
.	O

Plasmin	B-protein
-mediated	O
mRNA	O
expression	I-protein
was	O
inhibited	O
in	I-protein
a	I-protein
concentration-dependent	O
manner	O
by	I-protein
the	I-protein
lysine	I-protein
analogue	O
trans-4-	O
(	O
aminomethyl	I-protein
)	O
cyclohexane-1-carboxylic	O
acid	O
(	O
t-AMCA	O
)	O
.	O

Increases	O
in	I-protein
mRNA	O
levels	I-protein
were	O
followed	O
by	I-protein
concentration-	O
and	I-protein
time-dependent	O
release	I-protein
of	I-protein
IL-1alpha	B-protein
,	O
IL-1beta	B-protein
and	I-protein
TNF-alpha	B-protein
and	I-protein
by	I-protein
TF	B-protein
expression	I-protein
on	I-protein
monocyte	B-protein
surfaces	O
.	O

Neither	O
cytokines	B-protein
nor	O
TF	B-protein
could	O
be	O
detected	O
when	O
monocytes	O
were	O
preincubated	O
with	I-protein
actinomycin	O
D	O
or	I-protein
cycloheximide	O
.	O

Electrophoretic	O
mobility	I-protein
shift	O
assays	O
indicated	O
plasmin	B-protein
-induced	O
activation	I-protein
of	I-protein
NF-kappaB	B-protein
;	O
DNA-binding	B-protein
complexes	I-protein
were	O
composed	O
of	I-protein
p50	B-protein
,	O
p65	B-protein
,	O
and	I-protein
c-Rel	B-protein
,	O
as	O
shown	O
by	I-protein
supershift	O
experiments	O
.	O

Nuclear	I-protein
translocation	O
of	I-protein
NF-kappaB/Rel	B-protein
proteins	I-protein
coincided	O
with	I-protein
IkappaBalpha	B-protein
degradation	I-protein
.	O

At	O
variance	O
with	I-protein
endotoxic	O
lipopolysaccharide	B-protein
,	O
plasmin	B-protein
elicited	O
the	I-protein
rapid	O
degradation	I-protein
of	I-protein
another	O
cytoplasmic	B-protein
NF-kappaB	B-protein
inhibitor	I-protein
,	O
p105	I-protein
.	O

Proteolysis	O
of	I-protein
NF-kappaB	B-protein
inhibitors	I-protein
was	O
apparently	O
due	I-protein
to	I-protein
transient	O
activation	I-protein
of	I-protein
IkappaB	B-protein
kinase	I-protein
(	O
IKK	I-protein
)	O
beta	I-protein
that	O
reached	O
maximum	O
activity	I-protein
at	I-protein
1	I-protein
hour	O
after	O
plasmin	O
stimulation	I-protein
.	O

In	O
addition	O
,	O
AP-1	I-protein
binding	I-protein
was	O
increased	I-protein
in	I-protein
plasmin	B-protein
-treated	O
monocytes	O
,	O
with	I-protein
most	O
complexes	O
composed	O
of	I-protein
JunD	B-protein
,	O
c-Fos	B-protein
,	O
and	I-protein
FosB	B-protein
.	O

These	O
findings	O
further	O
substantiate	O
the	I-protein
role	O
of	I-protein
plasmin	B-protein
as	O
a	I-protein
proinflammatory	B-protein
activator	I-protein
of	I-protein
human	O
monocytes	O
and	I-protein
reveal	O
an	I-protein
important	O
new	I-protein
link	I-protein
between	O
the	I-protein
plasminogen-plasmin	O
system	I-protein
and	I-protein
inflammation	O
.	O

(	O
Blood.	O
2001	O
;	O
97	I-protein
:	O
3941-3950	O
)	O

###MEDLINE:21272376

STAT3	B-protein
is	O
constitutively	O
active	O
in	I-protein
some	O
patients	O
with	I-protein
Polycythemia	O
rubra	O
vera	O
.	O

OBJECTIVE	O
:	O
Polycythemia	O
vera	O
is	O
a	I-protein
clonal	O
stem	I-protein
cell	O
disorder	I-protein
characterized	O
by	I-protein
hyperproliferation	O
of	I-protein
the	I-protein
erythroid	O
,	O
myeloid	O
,	O
and	I-protein
megakaryocytic	O
lineages	O
.	O

While	O
it	O
has	O
been	O
shown	O
that	O
progenitor	O
cells	I-protein
of	I-protein
P.	O
vera	O
patients	O
are	O
hypersensitive	O
to	I-protein
several	I-protein
growth	O
factors	I-protein
including	I-protein
erythropoietin	B-protein
,	O
insulin-like	B-protein
growth	I-protein
factor-1	I-protein
,	O
thrombopoietin	B-protein
,	O
interleukin-3	B-protein
,	O
and	I-protein
granulocyte/monocyte	B-protein
colony-stimulating	I-protein
factor	I-protein
,	O
the	I-protein
molecular	I-protein
pathogenesis	O
of	I-protein
this	O
disease	I-protein
remains	O
unknown	O
.	O

Growth	B-protein
factor	I-protein
hypersensitivity	O
could	O
be	O
mediated	I-protein
by	I-protein
changes	O
in	I-protein
signal	O
transduction	I-protein
pathways	O
.	O

We	O
therefore	O
investigated	O
a	I-protein
common	I-protein
downstream	O
effector	O
of	I-protein
cytokines	B-protein
,	O
the	I-protein
signal	B-protein
transducers	I-protein
and	I-protein
activators	I-protein
of	I-protein
transcription	I-protein
(	O
STATs	B-protein
)	O
.	O

A	O
constitutive	I-protein
activation	I-protein
of	I-protein
STAT	B-protein
factors	I-protein
could	O
explain	O
the	I-protein
increased	I-protein
proliferation	I-protein
of	I-protein
P.	O
vera	O
cells	I-protein
even	O
in	I-protein
the	I-protein
absence	I-protein
of	I-protein
growth	O
factor	I-protein
stimulation	I-protein
.	O

METHODS	O
:	O
Peripheral	O
granulocytes	O
from	I-protein
patients	O
with	I-protein
P.	O
vera	O
and	I-protein
from	I-protein
healthy	O
volunteers	O
were	O
assayed	O
for	I-protein
STAT1	B-protein
,	O
3	O
,	O
and	I-protein
5	O
DNA	O
binding	I-protein
by	I-protein
electrophoretic	O
mobility	I-protein
shift	O
assay	O
.	O

RESULTS	O
:	O
Four	O
of	I-protein
14	I-protein
P.	O
vera	O
patients	O
analyzed	O
showed	O
constitutive	I-protein
STAT3	B-protein
DNA	O
binding	I-protein
in	I-protein
unstimulated	O
peripheral	O
granulocytes	O
,	O
while	O
none	O
of	I-protein
the	I-protein
17	I-protein
healthy	O
volunteers	O
tested	O
did	O
.	O

None	O
of	I-protein
the	I-protein
subjects	O
showed	O
constitutive	I-protein
STAT1	B-protein
or	I-protein
STAT5	B-protein
activity	I-protein
.	O

Western	O
blotting	O
demonstrated	O
that	O
,	O
in	I-protein
the	I-protein
three	O
patients	O
,	O
STAT3	B-protein
is	O
constitutively	O
phosphorylated	O
on	I-protein
Tyr	O
705	O
,	O
whereas	O
it	O
is	O
unphosphorylated	O
in	I-protein
the	I-protein
other	O
patients	O
and	I-protein
in	I-protein
controls	O
.	O

Interestingly	O
,	O
constitutive	I-protein
STAT3	B-protein
activity	I-protein
did	O
not	I-protein
correlate	O
with	I-protein
the	I-protein
duration	O
of	I-protein
disease	I-protein
or	I-protein
the	I-protein
treatment	O
regimen	O
.	O

It	O
was	O
observed	O
in	I-protein
a	I-protein
recently	O
diagnosed	O
patient	O
and	I-protein
in	I-protein
two	O
patients	O
treated	O
only	I-protein
with	I-protein
phlebotomy	O
.	O

CONCLUSION	O
:	O
Our	O
data	O
suggest	O
that	O
constitutive	I-protein
phosphorylation	I-protein
and	I-protein
activation	I-protein
of	I-protein
STAT3	B-protein
is	O
not	I-protein
a	I-protein
secondary	O
event	O
induced	I-protein
by	I-protein
mutagenizing	O
agents	O
or	I-protein
by	I-protein
prolonged	O
hyperproliferation	O
of	I-protein
hematopoietic	O
cells	I-protein
,	O
but	O
rather	O
represents	O
a	I-protein
primary	O
molecular	I-protein
aberration	O
.	O

Constitutively	O
active	O
STAT3	B-protein
may	O
contribute	O
to	I-protein
the	I-protein
growth	O
factor	I-protein
hypersensitivity	O
of	I-protein
P.	O
vera	O
cells	I-protein
.	O

###MEDLINE:21359415

Identification	O
of	I-protein
phosphorylation	I-protein
sites	I-protein
for	I-protein
Bruton	B-protein
's	I-protein
tyrosine	I-protein
kinase	I-protein
within	B-protein
the	I-protein
transcriptional	B-protein
regulator	I-protein
BAP/TFII-I	I-protein
.	O

Bruton	B-protein
's	I-protein
tyrosine	I-protein
kinase	I-protein
(	O
Btk	B-protein
)	O
,	O
a	I-protein
member	I-protein
of	I-protein
the	I-protein
Tec	O
family	O
of	I-protein
cytosolic	B-protein
kinases	I-protein
,	O
is	O
essential	O
for	I-protein
B	O
cell	O
development	O
and	I-protein
function	I-protein
.	O

BAP/TFII-I	B-protein
,	O
a	I-protein
protein	O
implicated	O
in	I-protein
transcriptional	O
regulation	I-protein
,	O
is	O
associated	I-protein
with	I-protein
Btk	B-protein
in	I-protein
B	O
cells	I-protein
and	I-protein
is	O
transiently	O
phosphorylated	O
on	I-protein
tyrosine	O
following	O
B	O
cell	O
receptor	O
engagement	O
.	O

BAP/TFII-I	B-protein
is	O
a	I-protein
substrate	I-protein
for	I-protein
Btk	B-protein
in	I-protein
vitro	O
and	I-protein
is	O
hyperphosphorylated	O
on	I-protein
tyrosine	O
upon	O
coexpression	O
with	I-protein
Btk	B-protein
in	I-protein
mammalian	O
cells	I-protein
.	O

In	O
an	I-protein
effort	O
to	I-protein
understand	O
the	I-protein
physiologic	O
consequences	O
of	I-protein
BAP/TFII-I	B-protein
tyrosine	O
phosphorylation	I-protein
following	O
B	O
cell	O
receptor	O
stimulation	I-protein
,	O
site-directed	O
mutagenesis	O
and	I-protein
phosphopeptide	I-protein
mapping	O
were	O
used	O
to	I-protein
locate	O
the	I-protein
predominant	O
sites	I-protein
of	I-protein
BAP/TFII-I	B-protein
phosphorylation	I-protein
by	I-protein
Btk	B-protein
in	I-protein
vitro	O
.	O

These	O
residues	O
,	O
Tyr248	O
,	O
Tyr357	O
,	O
and	I-protein
Tyr462	O
,	O
were	O
also	O
found	O
to	I-protein
be	O
the	I-protein
major	O
sites	I-protein
for	I-protein
Btk	B-protein
-dependent	I-protein
phosphorylation	I-protein
of	I-protein
BAP/TFII-I	B-protein
in	I-protein
vivo	O
.	O

Residues	O
Tyr357	O
and	I-protein
Tyr462	O
are	O
contained	O
within	B-protein
the	I-protein
loop	I-protein
regions	I-protein
of	I-protein
adjacent	I-protein
helix-loop-helix-like	B-protein
repeats	I-protein
within	B-protein
BAP/TFII-I	B-protein
.	O

Mutation	O
of	I-protein
either	O
Tyr248	O
,	O
Tyr357	O
,	O
or	I-protein
Tyr462	O
to	I-protein
phenylalanine	O
reduced	O
transcription	O
from	I-protein
a	I-protein
c-fos	O
promoter	I-protein
relative	I-protein
to	I-protein
wild-type	I-protein
BAP/TFII-I	I-protein
in	I-protein
transfected	O
COS-7	O
cells	I-protein
,	O
consistent	O
with	I-protein
the	I-protein
interpretation	O
that	O
phosphorylation	I-protein
at	I-protein
these	O
sites	I-protein
contributes	O
to	I-protein
transcriptional	O
activation	I-protein
.	O

Phosphorylation	O
of	I-protein
BAP/TFII-I	B-protein
by	I-protein
Btk	B-protein
may	O
link	I-protein
engagement	O
of	I-protein
receptors	I-protein
such	O
as	O
surface	O
immunoglobulin	O
to	I-protein
modulation	O
of	I-protein
gene	O
expression	I-protein
.	O

###MEDLINE:21261560

Expression	O
of	I-protein
interferon	B-protein
consensus	I-protein
sequence	I-protein
binding	I-protein
protein	I-protein
induces	O
potent	O
immunity	O
against	I-protein
BCR/ABL-induced	O
leukemia	O
.	O

Mice	O
deficient	I-protein
in	I-protein
the	I-protein
interferon	B-protein
consensus	I-protein
sequence	I-protein
binding	I-protein
protein	I-protein
(	O
ICSBP	B-protein
)	O
develop	O
a	I-protein
disease	I-protein
resembling	O
chronic	O
myeloid	O
leukemia	O
(	O
CML	O
)	O
,	O
which	O
in	I-protein
humans	O
is	O
caused	O
by	I-protein
the	I-protein
BCR/ABL	B-protein
oncoprotein	B-protein
.	O

Interferon-alpha	B-protein
(	O
IFN-alpha	B-protein
)	O
induces	O
ICSBP	B-protein
expression	I-protein
and	I-protein
is	O
an	I-protein
effective	O
therapy	O
for	I-protein
CML	O
.	O

This	O
study	O
examined	O
whether	O
enforced	O
expression	I-protein
of	I-protein
ICSBP	B-protein
might	O
antagonize	O
BCR/ABL-induced	O
leukemia	O
;	O
results	O
demonstrated	O
that	O
ICSBP-modified	O
cells	I-protein
generated	O
a	I-protein
protective	O
CD8	O
(	O
+	O
)	O
cytotoxic	O
T-cell	O
response	I-protein
against	I-protein
BCR/ABL-transformed	O
BaF3	O
cells	I-protein
in	I-protein
a	I-protein
murine	O
leukemia	O
model	I-protein
.	O

ICSBP	B-protein
expression	I-protein
represents	O
a	I-protein
novel	O
means	O
of	I-protein
stimulating	I-protein
a	I-protein
host	O
immune	O
response	I-protein
to	I-protein
BCR/ABL	O
(	O
+	O
)	O
leukemia	O
cells	I-protein
and	I-protein
a	I-protein
potential	I-protein
strategy	O
for	I-protein
immunotherapy	O
of	I-protein
CML	O
.	O

(	O
Blood.	O
2001	O
;	O
97	I-protein
:	O
3491-3497	O
)	O

###MEDLINE:21259876

A	O
transcriptional	O
block	O
in	I-protein
the	I-protein
IL-2	B-protein
promoter	I-protein
at	I-protein
the	I-protein
-150	O
AP-1	I-protein
site	I-protein
in	I-protein
effector	O
CD8+	O
T	O
cells	I-protein
.	O

Both	O
CD4+	O
and	I-protein
CD8+	O
T	O
cells	I-protein
that	O
produce	O
IL-2	B-protein
in	I-protein
response	I-protein
to	I-protein
Ag	I-protein
recognition	I-protein
have	O
been	O
isolated	I-protein
.	O

However	O
,	O
most	O
effector	O
CD8+	O
T	O
cells	I-protein
recovered	O
after	O
exposure	O
to	I-protein
Ag	I-protein
do	O
not	I-protein
produce	O
sufficient	O
IL-2	B-protein
to	I-protein
sustain	O
growth	O
,	O
and	I-protein
depend	O
on	I-protein
CD4+	O
T	O
helper	I-protein
cells	I-protein
for	I-protein
this	O
obligate	O
growth	O
factor	I-protein
.	O

IL-2	B-protein
expression	I-protein
in	I-protein
CD4+	O
T	O
cells	I-protein
is	O
primarily	O
controlled	O
at	I-protein
the	I-protein
level	I-protein
of	I-protein
transcription	O
,	O
but	O
mechanisms	O
restricting	O
IL-2	B-protein
production	I-protein
in	I-protein
CD8+	O
T	O
cells	I-protein
have	O
not	I-protein
been	O
elucidated	O
.	O

To	O
evaluate	O
transcriptional	O
regulation	I-protein
of	I-protein
the	I-protein
IL-2	B-protein
gene	O
in	I-protein
CD8+	O
T	O
cells	I-protein
,	O
we	O
stably	O
transfected	O
reporter	O
genes	I-protein
into	O
Ag	I-protein
-specific	I-protein
CD8+	O
T	O
cell	O
clones	O
.	O

CD28+	O
CD8	O
(	O
+	O
)	O
T	O
cells	I-protein
unable	O
to	I-protein
transcribe	O
the	I-protein
IL-2	B-protein
gene	O
in	I-protein
response	I-protein
to	I-protein
antigenic	I-protein
stimulation	I-protein
had	O
a	I-protein
block	O
in	I-protein
transactivation	O
of	I-protein
the	I-protein
-150	O
CD28	B-protein
response	I-protein
element	I-protein
(	O
CD28RE	O
)	O
/AP-1	O
site	I-protein
of	I-protein
the	I-protein
IL-2	B-protein
promoter	I-protein
,	O
but	O
did	O
transactivate	O
the	I-protein
composite	O
NFAT/AP-1	O
and	I-protein
OCT/AP-1	O
sites	I-protein
,	O
and	I-protein
a	I-protein
consensus	O
AP-1	I-protein
motif	I-protein
.	O

Mutation	O
of	I-protein
the	I-protein
nonconsensus	O
-150	O
AP-1	I-protein
site	I-protein
to	I-protein
a	I-protein
consensus	O
AP-1	I-protein
site	I-protein
,	O
or	I-protein
insertion	I-protein
of	I-protein
a	I-protein
CD28RE/AP-1	O
consensus	O
site	I-protein
upstream	O
of	I-protein
the	I-protein
native	O
-150	O
CD28RE/AP-1	O
site	I-protein
restored	O
transactivation	O
of	I-protein
the	I-protein
altered	I-protein
promoter	I-protein
.	O

These	O
results	O
suggest	O
that	O
the	I-protein
defect	I-protein
at	I-protein
the	I-protein
-150	O
site	I-protein
may	O
reflect	O
the	I-protein
absence	I-protein
or	I-protein
inactivity	O
of	I-protein
a	I-protein
required	O
factor	I-protein
rather	O
than	I-protein
repression	I-protein
of	I-protein
the	I-protein
IL-2	B-protein
promoter	I-protein
.	O

###MEDLINE:21250679

Stem	B-protein
cell	I-protein
factor	I-protein
and	I-protein
interleukin-3	B-protein
induce	O
stepwise	O
generation	O
of	I-protein
erythroid	O
precursor	I-protein
cells	I-protein
from	I-protein
a	I-protein
basic	B-protein
fibroblast	I-protein
growth	I-protein
factor	I-protein
-dependent	I-protein
hematopoietic	O
stem	I-protein
cell	O
line	I-protein
,	O
A-6	O
.	O

A	O
m	I-protein
ultipotent	O
immature	B-protein
myeloid	O
cell	O
population	O
was	O
produced	O
from	I-protein
a	I-protein
basic	B-protein
fibroblast	I-protein
growth	I-protein
factor	I-protein
(	O
bFGF	B-protein
)	O
-dependent	I-protein
hematopoietic	O
stem	I-protein
cell	O
line	I-protein
,	O
A-6	O
,	O
when	O
cultured	O
with	I-protein
stem	I-protein
cell	I-protein
factor	I-protein
(	O
SCF	B-protein
)	O
replacing	O
bFGF	B-protein
.	O

Those	O
cells	I-protein
were	O
positive	I-protein
for	I-protein
stem	I-protein
cell	I-protein
markers	I-protein
,	O
c-kit	I-protein
and	I-protein
CD34	B-protein
,	O
and	I-protein
a	I-protein
myeloid	B-protein
cell	I-protein
marker	I-protein
,	O
F4/80	I-protein
.	O

Some	O
cell	O
fractions	O
were	O
also	O
positive	I-protein
for	I-protein
Mac-1	B-protein
,	O
a	I-protein
macrophage	I-protein
marker	I-protein
or	I-protein
Gr-1	B-protein
,	O
a	I-protein
granulocytic	I-protein
maker	I-protein
,	O
but	O
negative	O
for	I-protein
an	I-protein
erythroid	B-protein
marker	I-protein
TER119	I-protein
.	O

They	O
also	O
showed	O
the	I-protein
expression	I-protein
of	I-protein
mRNA	O
for	I-protein
the	I-protein
myeloid-specific	I-protein
PU.1	B-protein
but	O
did	O
not	I-protein
that	O
for	I-protein
the	I-protein
erythroid-specific	B-protein
GATA-1	I-protein
.	O

Among	O
various	O
cytokines	B-protein
,	O
interleukin-3	O
(	O
IL-3	B-protein
)	O
induced	I-protein
erythroid	O
precursor	I-protein
cells	I-protein
that	O
expressed	O
the	I-protein
erythroid-specific	B-protein
GATA-1	I-protein
and	I-protein
beta-major	B-protein
globin	I-protein
.	O

The	O
quantitative	I-protein
analysis	O
showed	O
that	O
erythroid	O
precursor	I-protein
cells	I-protein
were	O
newly	O
produced	O
from	I-protein
the	I-protein
immature	B-protein
myeloid	O
cells	I-protein
by	I-protein
cultivation	O
with	I-protein
IL-3	B-protein
.	O

SCF	B-protein
and	I-protein
IL-3	B-protein
induced	I-protein
stepwise	O
generation	O
of	I-protein
erythroid	O
precursor	I-protein
cells	I-protein
from	I-protein
an	I-protein
A-6	O
hematopoietic	O
stem	I-protein
cell	O
line	I-protein
.	O

Copyright	O
2001	O
Academic	O
Press	O
.	O

###MEDLINE:21240651

Distinct	O
BMI-1	B-protein
and	I-protein
EZH2	B-protein
expression	I-protein
patterns	O
in	I-protein
thymocytes	O
and	I-protein
mature	B-protein
T	O
cells	I-protein
suggest	O
a	I-protein
role	O
for	I-protein
Polycomb	O
genes	I-protein
in	I-protein
human	O
T	O
cell	O
differentiation	I-protein
.	O

BMI-1	B-protein
and	I-protein
EZH2	B-protein
Polycomb-group	I-protein
(	O
PcG	I-protein
)	O
proteins	I-protein
belong	O
to	I-protein
two	O
distinct	O
protein	O
complexes	O
involved	I-protein
in	I-protein
the	I-protein
regulation	I-protein
of	I-protein
hematopoiesis	I-protein
.	O

Using	O
unique	I-protein
PcG-specific	O
antisera	O
and	I-protein
triple	O
immunofluorescence	O
,	O
we	O
found	O
that	O
mature	B-protein
resting	O
peripheral	O
T	O
cells	I-protein
expressed	O
BMI-1	B-protein
,	O
whereas	O
dividing	O
blasts	O
were	O
EZH2	B-protein
(	O
+	O
)	O
.	O

By	O
contrast	O
,	O
subcapsular	O
immature	B-protein
double-negative	O
(	O
DN	O
)	O
(	O
CD4	B-protein
(	O
-	O
)	O
/CD8	O
(	O
-	O
)	O
)	O
T	O
cells	I-protein
in	I-protein
the	I-protein
thymus	I-protein
coexpressed	O
BMI-1	B-protein
and	I-protein
EZH2	B-protein
or	I-protein
were	O
BMI-1	O
single	O
positive	I-protein
.	O

Their	O
descendants	O
,	O
double-positive	O
(	O
DP	I-protein
;	O
CD4	B-protein
(	O
+	O
)	O
/CD8	O
(	O
+	O
)	O
)	O
cortical	I-protein
thymocytes	O
,	O
expressed	O
EZH2	B-protein
without	I-protein
BMI-1	B-protein
.	O

Most	O
EZH2	B-protein
(	O
+	O
)	O
DN	O
and	I-protein
DP	I-protein
thymocytes	O
were	O
dividing	O
,	O
while	O
DN	O
BMI-1	O
(	O
+	O
)	O
/EZH2	O
(	O
-	O
)	O
thymocytes	O
were	O
resting	O
and	I-protein
proliferation	I-protein
was	O
occasionally	O
noted	O
in	I-protein
DN	O
BMI-1	O
(	O
+	O
)	O
/EZH2	O
(	O
+	O
)	O
cells	I-protein
.	O

Maturation	O
of	I-protein
DP	I-protein
cortical	I-protein
thymocytes	O
to	I-protein
single-positive	O
(	O
CD4	B-protein
(	O
+	O
)	O
/CD8	O
(	O
-	O
)	O
or	I-protein
CD8	O
(	O
+	O
)	O
/CD4	O
(	O
-	O
)	O
)	O
medullar	O
thymocytes	O
correlated	O
with	I-protein
decreased	O
detectability	O
of	I-protein
EZH2	B-protein
and	I-protein
continued	O
relative	I-protein
absence	I-protein
of	I-protein
BMI-1	B-protein
.	O

Our	O
data	O
show	O
that	O
BMI-1	B-protein
and	I-protein
EZH2	B-protein
expression	I-protein
in	I-protein
mature	B-protein
peripheral	O
T	O
cells	I-protein
is	O
mutually	O
exclusive	O
and	I-protein
linked	I-protein
to	I-protein
proliferation	I-protein
status	I-protein
,	O
and	I-protein
that	O
this	O
pattern	I-protein
is	O
not	I-protein
yet	O
established	O
in	I-protein
thymocytes	O
of	I-protein
the	I-protein
cortex	I-protein
and	I-protein
medulla	O
.	O

T	O
cell	O
stage-specific	O
PcG	O
expression	I-protein
profiles	O
suggest	O
that	O
PcG	O
genes	I-protein
contribute	O
to	I-protein
regulation	I-protein
of	I-protein
T	O
cell	O
differentiation	I-protein
.	O

They	O
probably	O
reflect	O
stabilization	O
of	I-protein
cell	O
type-specific	O
gene	O
expression	I-protein
and	I-protein
irreversibility	O
of	I-protein
lineage	I-protein
choice	O
.	O

The	O
difference	O
in	I-protein
PcG	O
expression	I-protein
between	O
medullar	O
thymocytes	O
and	I-protein
mature	B-protein
interfollicular	O
T	O
cells	I-protein
indicates	O
that	O
additional	B-protein
maturation	I-protein
processes	O
occur	O
after	O
thymocyte	B-protein
transportation	O
from	I-protein
the	I-protein
thymus	I-protein
.	O

###MEDLINE:21240749

Stepwise	O
lineage	I-protein
restriction	O
of	I-protein
progenitors	O
in	I-protein
lympho-myelopoiesis	O
.	O

It	O
has	O
long	I-protein
been	O
controversial	O
whether	O
hematopoiesis	I-protein
progresses	O
through	I-protein
ordered	O
stages	O
of	I-protein
determination	I-protein
as	O
in	I-protein
embryonic	O
development	O
.	O

This	O
is	O
due	I-protein
to	I-protein
the	I-protein
absence	I-protein
of	I-protein
a	I-protein
methodology	O
capable	O
of	I-protein
exactly	O
determining	I-protein
the	I-protein
developmental	O
potential	I-protein
of	I-protein
hematopoietic	O
stem/progenitor	I-protein
cells	I-protein
.	O

The	O
multilineage	O
progenitor	O
(	O
MLP	B-protein
)	O
assay	O
enabled	B-protein
us	O
to	I-protein
discriminate	O
among	O
seven	O
types	I-protein
of	I-protein
hematopoietic	O
progenitors	O
,	O
which	O
are	O
multipotent	O
progenitor	O
p-MTB	O
(	O
capable	O
of	I-protein
generating	O
myeloid	O
,	O
T	O
and	I-protein
B	O
cells	I-protein
)	O
,	O
bipotent	O
progenitors	O
p-MT	O
,	O
p-MB	O
and	I-protein
p-TB	O
,	O
and	I-protein
unipotent	O
progenitors	O
p-M	O
,	O
p-T	O
and	I-protein
p-B	O
.	O

Among	O
these	O
seven	O
types	I-protein
,	O
the	I-protein
p-TB	O
type	O
progenitor	O
was	O
found	O
to	I-protein
be	O
absent	O
.	O

These	O
findings	O
indicate	O
that	O
the	I-protein
process	O
of	I-protein
lineage	I-protein
commitment	O
proceeds	O
through	I-protein
an	I-protein
ordered	O
but	O
not	I-protein
random	O
process	O
.	O

By	O
extending	O
the	I-protein
area	O
of	I-protein
investigation	O
to	I-protein
include	O
the	I-protein
erythroid	O
lineage	I-protein
,	O
more	O
convincing	O
evidence	O
for	I-protein
the	I-protein
ordered	O
process	O
was	O
obtained	O
.	O

Detailed	O
and	I-protein
exact	O
illustration	O
of	I-protein
the	I-protein
process	O
of	I-protein
hematopoiesis	I-protein
will	O
provide	O
an	I-protein
opportunity	O
to	I-protein
revive	O
hematopoiesis	I-protein
as	O
one	B-protein
of	I-protein
the	I-protein
most	O
fascinating	O
targets	O
of	I-protein
research	O
in	I-protein
developmental	O
biology	O

###MEDLINE:21226883

Epstein-Barr	B-protein
Virus	I-protein
and	I-protein
its	O
glycoprotein-350	O
upregulate	O
IL-6	B-protein
in	I-protein
human	O
B-lymphocytes	O
via	I-protein
CD21	B-protein
,	O
involving	O
activation	I-protein
of	I-protein
NF-kappaB	B-protein
and	I-protein
different	O
signaling	O
pathways	O
.	O

Epstein-Barr	B-protein
virus	I-protein
(	O
EBV	O
)	O
is	O
a	I-protein
ubiquitous	I-protein
and	I-protein
highly	O
immunotropic	O
gamma	O
herpesvirus	I-protein
that	O
infects	O
more	O
than	I-protein
90	I-protein
%	O
of	I-protein
humans	O
worldwide	O
.	O

Its	O
pathogenicity	O
leads	O
to	I-protein
a	I-protein
number	I-protein
of	I-protein
diseases	O
including	I-protein
tumors	I-protein
that	O
result	O
from	I-protein
EBV	O
's	I-protein
ability	O
to	I-protein
readily	O
transform	O
B-lymphocytes	O
and	I-protein
,	O
to	I-protein
a	I-protein
lesser	O
extent	O
,	O
epithelial	O
cells	I-protein
.	O

EBV	O
utilizes	O
CD21/CR2	B-protein
as	O
its	O
receptor	O
on	I-protein
B	O
cells	I-protein
to	I-protein
initiate	O
the	I-protein
infection	I-protein
process	O
.	O

EBV	O
binds	O
to	I-protein
CR2	B-protein
through	I-protein
its	O
major	B-protein
envelope	I-protein
glycoprotein-350	I-protein
(	O
gp350	O
)	O
and	I-protein
is	O
also	O
a	I-protein
remarkable	O
immunomodulating	O
agent	O
.	O

We	O
had	O
previously	O
shown	O
that	O
EBV	O
is	O
capable	O
of	I-protein
modulating	I-protein
the	I-protein
synthesis	I-protein
of	I-protein
a	I-protein
number	I-protein
of	I-protein
cytokines	B-protein
.	O

We	O
now	O
show	O
that	O
while	O
both	O
purified	O
recombinant	B-protein
gp350	I-protein
(	O
rgp350	B-protein
)	O
and	I-protein
EBV	O
upregulate	O
IL-6	B-protein
mRNA	O
synthesis	I-protein
in	I-protein
B	O
cells	I-protein
,	O
EBV-induced	O
IL-6	B-protein
gene	O
activation	I-protein
occurs	O
for	I-protein
a	I-protein
significantly	O
longer	O
period	B-protein
of	I-protein
time	O
(	O
i.e.	O
12	O
hours	O
for	I-protein
EBV	O
as	O
compared	O
to	I-protein
6	I-protein
hours	O
for	I-protein
rgp350	B-protein
)	O
.	O

Moreover	O
,	O
the	I-protein
half-life	O
of	I-protein
EBV-induced	O
IL-6	B-protein
mRNA	O
was	O
also	O
significantly	O
longer	O
(	O
10	I-protein
hours	O
)	O
than	I-protein
that	O
of	I-protein
mRNA	O
induced	I-protein
by	I-protein
rgp350	B-protein
(	O
about	O
6	I-protein
hours	O
)	O
.	O

Both	O
EBV	O
and	I-protein
gp350	B-protein
enhance	O
the	I-protein
binding	I-protein
of	I-protein
the	I-protein
NF-kappaB	B-protein
transcription	I-protein
factor	I-protein
,	O
as	O
determined	O
by	I-protein
band-shift	O
and	I-protein
augment	O
NF-kappaB	B-protein
-mediated	O
activation	I-protein
of	I-protein
a	I-protein
CAT	B-protein
reporter	O
plasmid	O
.	O

Furthermore	O
,	O
we	O
demonstrate	O
that	O
while	O
the	I-protein
activation	I-protein
of	I-protein
IL-6	B-protein
gene	O
expression	I-protein
by	I-protein
gp350	B-protein
is	O
mediated	I-protein
primarily	O
by	I-protein
the	I-protein
protein	B-protein
kinase	I-protein
C	I-protein
pathway	I-protein
,	O
EBV	O
can	O
mediate	O
its	O
effects	O
through	I-protein
multiple	O
signaling	O
pathways	O
.	O

To	O
our	O
knowledge	O
this	O
is	O
the	I-protein
first	O
report	O
showing	O
that	O
the	I-protein
binding	I-protein
of	I-protein
a	I-protein
herpesvirus	I-protein
envelope	I-protein
glycoprotein	I-protein
to	I-protein
CR2	B-protein
on	I-protein
human	O
B	O
cells	I-protein
results	O
in	I-protein
the	I-protein
activation	I-protein
of	I-protein
the	I-protein
NF-kappaB	B-protein
transcription	I-protein
factor	I-protein
leading	O
to	I-protein
the	I-protein
upregulation	O
of	I-protein
IL-6	B-protein
gene	O
expression	I-protein
in	I-protein
these	O
lymphocytes	O
.	O

Copyright	O
2001	O
Academic	O
Press	O
.	O

###MEDLINE:21216559

Gene-	O
and	I-protein
tissue-specificity	O
of	I-protein
mutation	I-protein
in	I-protein
Big	O
Blue	O
rats	O
treated	O
with	I-protein
the	I-protein
hepatocarcinogen	O
N-hydroxy-2-acetylaminofluorene	O
.	O

In	O
a	I-protein
previous	O
study	O
,	O
we	O
found	O
that	O
treating	O
transgenic	O
Big	O
Blue	O
rats	O
with	I-protein
the	I-protein
hepatocarcinogen	O
N-hydroxy-2-acetylaminofluorene	O
(	O
N-OH-AAF	O
)	O
produced	O
the	I-protein
same	O
major	O
DNA	O
adduct	O
in	I-protein
the	I-protein
target	O
liver	O
and	I-protein
the	I-protein
nontarget	O
spleen	B-protein
lymphocytes	O
and	I-protein
bone	O
marrow	I-protein
cells	I-protein
,	O
induced	I-protein
lacI	O
mutants	O
in	I-protein
the	I-protein
liver	O
,	O
and	I-protein
induced	I-protein
much	O
lower	I-protein
frequencies	O
of	I-protein
l	B-protein
acI	O
and	I-protein
hprt	O
mutants	O
in	I-protein
spleen	B-protein
lymphocytes	O
.	O

In	O
the	I-protein
present	O
study	O
,	O
sequence	I-protein
analysis	O
was	O
conducted	O
on	I-protein
lacI	O
DNA	O
and	I-protein
hprt	O
cDNA	I-protein
from	I-protein
the	I-protein
mutants	O
,	O
to	I-protein
determine	O
the	I-protein
mutational	O
specificity	I-protein
of	I-protein
N-OH-AAF	O
in	I-protein
the	I-protein
rat	I-protein
.	O

All	O
the	I-protein
mutation	I-protein
spectra	O
from	I-protein
N-OH-AAF-treated	O
rats	O
differed	O
significantly	O
from	I-protein
corresponding	O
mutation	I-protein
profiles	O
from	I-protein
untreated	O
animals	O
(	O
P	O
=	O
0.02	O
to	I-protein
P	O
<	O
0.0001	O
)	O
.	O

Although	O
there	O
were	O
similarities	O
among	O
the	I-protein
mutational	O
patterns	O
derived	I-protein
from	I-protein
N-OH-AAF-treated	O
rats	O
(	O
e.g.	O
,	O
G	O
:	O
C	O
--	I-protein
>	O
T	O
:	O
A	O
transversion	O
was	O
the	I-protein
most	O
common	I-protein
mutation	I-protein
in	I-protein
all	O
mutation	I-protein
sets	O
)	O
,	O
there	O
were	O
significant	O
differences	O
in	I-protein
the	I-protein
patterns	O
of	I-protein
basepair	O
substitution	O
and	I-protein
frameshift	O
mutation	I-protein
between	O
the	I-protein
liver	O
and	I-protein
spleen	B-protein
lymphocyte	O
lacI	O
mutants	O
(	O
P	O
=	O
0.02	O
)	O
and	I-protein
between	O
the	I-protein
spleen	B-protein
lymphocyte	O
lacI	O
and	I-protein
hprt	O
mutants	O
(	O
P	O
=	O
0.04	O
)	O
.	O

Also	O
,	O
multiplex	I-protein
PCR	O
analysis	O
of	I-protein
genomic	O
DNA	O
from	I-protein
the	I-protein
hprt	O
mutants	O
indicated	O
that	O
12	O
%	O
of	I-protein
mutants	O
from	I-protein
treated	O
rats	O
had	O
major	O
deletions	O
in	I-protein
the	I-protein
hprt	O
gene	O
;	O
no	I-protein
corresponding	O
incidence	O
of	I-protein
large	O
deletions	O
was	O
evident	O
among	O
lacI	O
mutations	I-protein
.	O

All	O
the	I-protein
mutation	I-protein
profiles	O
reflect	O
the	I-protein
general	O
mutational	O
specificity	I-protein
of	I-protein
the	I-protein
major	O
DNA	O
adduct	O
formed	O
by	I-protein
N-OH-AAF	O
.	O

The	O
differences	O
between	O
N-OH-AAF	O
mutation	I-protein
in	I-protein
the	I-protein
endogenous	O
gene	O
and	I-protein
transgene	O
can	O
be	O
partially	O
explained	O
by	I-protein
the	I-protein
structures	O
of	I-protein
the	I-protein
two	O
genes	I-protein
.	O

The	O
tissue-specificity	O
of	I-protein
the	I-protein
mutation	I-protein
spectra	O
may	O
contribute	O
to	I-protein
targeting	I-protein
tumor	O
formation	O
to	I-protein
the	I-protein
liver	O
.	O

Environ.	O
Mol.	O
Mutagen.	O
37	I-protein
:	O
203-214	O
,	O
2001	O
.	O

Published	O
2001	O
Wiley-Liss	O
,	O
Inc	O
.	O

###MEDLINE:21214521

Caspase	I-protein
-dependent	I-protein
cleavage	O
of	I-protein
the	I-protein
hematopoietic	B-protein
specific	I-protein
adaptor	I-protein
protein	I-protein
Gads	I-protein
alters	O
signalling	I-protein
from	I-protein
the	I-protein
T	B-protein
cell	I-protein
receptor	I-protein
.	O

Gads	B-protein
is	O
a	I-protein
SH2	B-protein
and	I-protein
SH3	I-protein
domain	I-protein
-containing	I-protein
,	O
hematopoietic-specific	B-protein
adaptor	I-protein
protein	I-protein
that	O
functions	O
in	I-protein
signalling	I-protein
from	I-protein
the	I-protein
T	B-protein
cell	I-protein
receptor	I-protein
.	O

Gads	B-protein
acts	O
by	I-protein
linking	I-protein
SLP-76	B-protein
,	O
bound	I-protein
by	I-protein
the	I-protein
carboxy-terminal	I-protein
Gads	I-protein
SH3	I-protein
domain	I-protein
,	O
to	I-protein
tyrosine	B-protein
phosphorylated	I-protein
LAT	B-protein
which	O
contains	I-protein
binding	I-protein
sites	I-protein
for	I-protein
the	I-protein
Gads	B-protein
SH2	I-protein
domain	I-protein
.	O

Gads	B-protein
is	O
distinguished	O
from	I-protein
Grb2	O
and	I-protein
the	I-protein
closely	O
related	O
Grap	B-protein
protein	I-protein
by	I-protein
the	I-protein
presence	O
of	I-protein
a	I-protein
120	I-protein
amino	I-protein
acid	I-protein
unique	I-protein
region	I-protein
between	O
the	I-protein
SH2	B-protein
domain	I-protein
and	I-protein
the	I-protein
carboxy	B-protein
terminal	I-protein
SH3	I-protein
domain	I-protein
.	O

Here	O
we	O
demonstrate	O
that	O
the	I-protein
unique	I-protein
region	O
of	I-protein
Gads	B-protein
contains	I-protein
a	I-protein
capase	B-protein
cleavage	I-protein
site	I-protein
.	O

Induction	O
of	I-protein
apoptosis	O
in	I-protein
lymphocytes	O
results	O
in	I-protein
detectable	O
Gads	B-protein
cleavage	O
by	I-protein
60	I-protein
min	O
.	O

Gads	B-protein
cleavage	O
is	O
blocked	B-protein
in	I-protein
vivo	O
by	I-protein
treating	O
cells	I-protein
with	I-protein
a	I-protein
caspase	O
3	O
inhibitor	O
.	O

A	O
putative	B-protein
caspase	I-protein
3	I-protein
cleavage	I-protein
site	I-protein
was	O
identified	I-protein
within	B-protein
the	I-protein
unique	I-protein
region	O
and	I-protein
mutation	I-protein
of	I-protein
this	O
site	I-protein
prevented	O
Gads	B-protein
cleavage	O
in	I-protein
vitro	O
,	O
and	I-protein
in	I-protein
vivo	O
.	O

The	O
Gads	B-protein
cleavage	O
products	O
retained	O
the	I-protein
predicted	I-protein
binding	I-protein
specificity	I-protein
for	I-protein
SLP-76	B-protein
and	I-protein
LAT	B-protein
.	O

Expression	O
of	I-protein
the	I-protein
Gads	B-protein
cleavage	O
products	O
in	I-protein
Jurkat	O
T	O
cells	I-protein
inhibited	O
NFAT	O
activation	I-protein
following	O
TCR	O
cross	I-protein
linking	I-protein
.	O

These	O
findings	O
indicate	O
that	O
cleavage	O
of	I-protein
Gads	B-protein
in	I-protein
vivo	O
could	O
function	I-protein
to	I-protein
alter	O
signalling	I-protein
downstream	O
of	I-protein
the	I-protein
T	B-protein
cell	I-protein
receptor	I-protein
by	I-protein
disrupting	O
cross	I-protein
talk	O
between	O
SLP-76	B-protein
and	I-protein
LAT	B-protein
.	O

###MEDLINE:21347868

Targeting	O
of	I-protein
p300	B-protein
to	I-protein
the	I-protein
interleukin-2	B-protein
promoter	I-protein
via	I-protein
CREB-Rel	O
cross-talk	O
during	I-protein
mitogen	O
and	I-protein
oncogenic	O
molecular	I-protein
signaling	O
in	I-protein
activated	O
T-cells	I-protein
.	O

In	O
this	O
report	O
,	O
we	O
explore	O
the	I-protein
mechanisms	O
of	I-protein
targeting	I-protein
of	I-protein
p300	B-protein
to	I-protein
the	I-protein
interleukin-2	B-protein
(	O
IL-2	B-protein
)	O
promoter	I-protein
in	I-protein
response	I-protein
to	I-protein
mitogenic	O
and	I-protein
oncogenic	O
molecular	I-protein
signals	I-protein
.	O

Recruitment	O
of	I-protein
p300	B-protein
by	I-protein
cAMP-responsive	B-protein
element-binding	I-protein
protein-Rel	I-protein
cross-talk	O
at	I-protein
the	I-protein
composite	O
CD28	B-protein
response	I-protein
element	I-protein
(	O
CD28RE	O
)	O
-	O
TRE	B-protein
element	I-protein
of	I-protein
the	I-protein
IL-2	B-protein
promoter	I-protein
is	O
essential	O
for	I-protein
promoter	I-protein
inducibility	O
during	I-protein
T-cell	O
activation	I-protein
,	O
and	I-protein
CD28RE-TRE	O
is	O
the	I-protein
exclusive	O
target	O
of	I-protein
the	I-protein
human	O
T-cell	O
lymphotropic	O
virus	I-protein
type	O
I	I-protein
oncoprotein	B-protein
Tax	I-protein
.	O

The	O
intrinsic	I-protein
histone	O
acetyltransferase	I-protein
activity	I-protein
of	I-protein
p300	B-protein
is	O
dispensable	O
for	I-protein
activation	I-protein
of	I-protein
the	I-protein
IL-2	B-protein
promoter	I-protein
,	O
and	I-protein
the	I-protein
N-terminal	B-protein
743	I-protein
residues	I-protein
contain	O
the	I-protein
minimal	O
structural	O
requirements	O
for	I-protein
synergistic	O
transactivation	O
of	I-protein
the	I-protein
CD28RE-TRE	O
,	O
the	I-protein
IL-2	B-protein
promoter	I-protein
,	O
and	I-protein
endogenous	O
IL-2	B-protein
gene	O
expression	I-protein
.	O

Mutational	O
analysis	O
of	I-protein
p300	B-protein
reveals	O
differential	O
structural	O
requirements	O
for	I-protein
the	I-protein
N-terminal	O
p300	O
module	I-protein
by	I-protein
individual	O
cis-elements	O
within	B-protein
the	I-protein
IL-2	B-protein
promoter	I-protein
.	O

These	O
findings	O
provide	O
evidence	O
that	O
p300	B-protein
assembles	O
at	I-protein
the	I-protein
IL-2	B-protein
promoter	I-protein
to	I-protein
form	I-protein
an	I-protein
enhanceosome-like	O
signal	O
transduction	I-protein
target	O
that	O
is	O
centrally	O
integrated	O
at	I-protein
the	I-protein
CD28RE-TRE	O
element	I-protein
of	I-protein
the	I-protein
IL-2	B-protein
promoter	I-protein
through	I-protein
specific	I-protein
protein	O
module-targeted	O
associations	O
in	I-protein
activated	O
T-cells	I-protein
.	O

###MEDLINE:21203274

Regulation	O
of	I-protein
cytokine	O
production	I-protein
in	I-protein
T-cell	O
responses	O
to	I-protein
inhalant	O
allergen	O
:	O
GATA-3	O
expression	I-protein
distinguishes	O
between	O
Th1-	O
and	I-protein
Th2-polarized	O
immunity	O
.	O

BACKGROUND	O
:	O
The	O
precise	O
nature	O
of	I-protein
allergen-specific	O
cytokine	O
responses	O
in	I-protein
atopics	O
versus	O
non-atopics	O
,	O
in	I-protein
particular	O
the	I-protein
'Th1	O
polarity	I-protein
'	O
of	I-protein
responses	O
in	I-protein
non-atopics	O
,	O
remains	O
controversial	O
.	O

This	O
is	O
due	I-protein
in	I-protein
part	I-protein
to	I-protein
the	I-protein
relative	I-protein
insensitivity	O
of	I-protein
cytokine	O
detection	O
systems	O
,	O
and	I-protein
associated	I-protein
variations	O
in	I-protein
kinetics	O
of	I-protein
cytokine	O
production	I-protein
and	I-protein
catabolism	O
in	I-protein
in	I-protein
vitro	O
culture	O
systems	O
.	O

As	O
an	I-protein
alternative	O
to	I-protein
cytokine	O
measurement	O
,	O
this	O
study	O
focuses	O
on	I-protein
expression	I-protein
of	I-protein
the	I-protein
transcription	B-protein
factor	I-protein
GATA-3	I-protein
for	I-protein
analysis	O
of	I-protein
allergen-specific	O
Th	O
cell	O
responses	O
.	O

METHODS	O
:	O
Cord	O
blood	O
mononuclear	O
cells	I-protein
were	O
Th1-	O
or	I-protein
Th2-polarized	O
by	I-protein
culture	O
in	I-protein
IL-12-	O
or	I-protein
IL-4-employing	O
established	O
methods	O
;	O
PBMC	O
from	I-protein
house	O
dust	O
mite	O
(	O
HDM	O
)	O
-sensitive	O
atopics	O
and	I-protein
controls	O
were	O
stimulated	O
overnight	O
with	I-protein
HDM	O
;	O
cytokine	O
production	I-protein
was	O
measured	O
by	I-protein
ELISA	O
and	I-protein
GATA-3	O
mRNA	O
expression	I-protein
by	I-protein
PCR	O
.	O

RESULTS	O
:	O
Cytokine	B-protein
-driven	O
Th2	O
polarization	O
of	I-protein
naive	O
T	O
cells	I-protein
is	O
associated	I-protein
with	I-protein
marked	O
upregulation	O
of	I-protein
GATA-3	B-protein
expression	I-protein
,	O
whereas	O
a	I-protein
reciprocal	O
expression	I-protein
pattern	I-protein
accompanies	O
differentiation	I-protein
towards	O
the	I-protein
Th1	O
cytokine	O
phenotype	O
.	O

In	O
T	O
cells	I-protein
from	I-protein
HDM	O
skin	O
prick	O
test-positive	O
(	O
HDM-SPT+/HDM-IgE+	O
)	O
volunteers	O
,	O
overnight	O
stimulation	I-protein
results	O
in	I-protein
marked	O
upregulation	O
of	I-protein
GATA-3	B-protein
expression	I-protein
,	O
compared	O
to	I-protein
an	I-protein
equally	O
marked	O
downregulation	O
of	I-protein
expression	I-protein
in	I-protein
T	O
cells	I-protein
from	I-protein
SPT-/IgE-	O
subjects	O
.	O

In	O
subjects	O
who	O
are	O
HDM-SPT+	O
but	O
IgE-	O
,	O
GATA-3	O
expression	I-protein
levels	I-protein
remained	O
relatively	O
stable	I-protein
during	I-protein
culture	O
with	I-protein
HDM	O
.	O

CONCLUSIONS	O
:	O
Upregulation	O
of	I-protein
GATA-3	B-protein
expression	I-protein
in	I-protein
PBMC	O
is	O
a	I-protein
hallmark	O
of	I-protein
the	I-protein
early	O
phase	I-protein
of	I-protein
Th2	O
recall	O
responses	O
to	I-protein
specific	I-protein
allergen	O
in	I-protein
atopics	O
.	O

The	O
reciprocal	O
expression	I-protein
pattern	I-protein
observed	O
in	I-protein
HDM-specific	O
recall	O
responses	O
of	I-protein
non-atopics	O
provides	O
independent	I-protein
confirmation	O
of	I-protein
the	I-protein
presence	O
of	I-protein
underlying	O
Th1-like	O
immunity	O
in	I-protein
these	O
subjects	O
.	O

The	O
parallel	O
findings	O
in	I-protein
neonatal	I-protein
T	O
cells	I-protein
suggest	O
that	O
the	I-protein
same	O
approach	O
may	O
be	O
utilized	O
for	I-protein
monitoring	O
the	I-protein
progress	O
of	I-protein
allergen-specific	O
Th1/Th2	O
memory	O
development	O
during	I-protein
early	O
childhood	I-protein
,	O
and	I-protein
hence	O
in	I-protein
assessment	O
of	I-protein
risk	O
for	I-protein
future	O
allergic	O
disease	I-protein
.	O

Copyright	O
2001	O
S.	I-protein
Karger	O
AG	I-protein
,	O
Basel	O

###MEDLINE:21210813

The	O
heat	O
shock	I-protein
response	I-protein
reduces	O
myelin	B-protein
oligodendrocyte	I-protein
glycoprotein	I-protein
-induced	O
experimental	O
autoimmune	B-protein
encephalomyelitis	O
in	I-protein
mice	O
.	O

The	O
stress	O
response	I-protein
(	O
SR	I-protein
)	O
can	O
block	O
inflammatory	O
gene	O
expression	I-protein
by	I-protein
preventing	O
activation	I-protein
of	I-protein
transcription	B-protein
factor	I-protein
nuclear	B-protein
factor-kappa	I-protein
B	I-protein
(	O
NF-kappaB	B-protein
)	O
.	O

As	O
inflammatory	O
gene	O
expression	I-protein
contributes	O
to	I-protein
the	I-protein
pathogenesis	O
of	I-protein
demyelinating	O
diseases	O
,	O
we	O
tested	O
the	I-protein
effects	O
of	I-protein
the	I-protein
SR	I-protein
on	I-protein
the	I-protein
progression	I-protein
of	I-protein
the	I-protein
demyelinating	O
disease	I-protein
experimental	O
autoimmune	B-protein
encephalomyelitis	O
(	O
EAE	O
)	O
.	O

EAE	O
was	O
actively	O
induced	I-protein
in	I-protein
C57BL/6	O
mice	O
using	O
an	I-protein
encephalitogenic	O
myelin	B-protein
oligodendrocyte	I-protein
glycoprotein	I-protein
(	O
MOG	B-protein
(	O
35-55	I-protein
)	O
)	O
peptide	O
.	O

Whole	O
body	O
hyperthermia	I-protein
was	O
used	O
to	I-protein
induce	O
a	I-protein
heat	O
shock	I-protein
response	I-protein
(	O
HSR	B-protein
)	O
in	I-protein
immunized	O
mice	O
2	I-protein
days	O
after	O
the	I-protein
booster	O
MOG	B-protein
(	O
35-55	O
)	O
peptide	O
injection	O
.	O

The	O
HSR	B-protein
reduced	O
the	I-protein
incidence	O
of	I-protein
EAE	O
by	I-protein
70	I-protein
%	O
,	O
delayed	O
disease	I-protein
onset	I-protein
by	I-protein
6	I-protein
days	O
,	O
and	I-protein
attenuated	O
disease	I-protein
severity	O
.	O

The	O
HSR	B-protein
attenuated	O
leukocyte	O
infiltration	O
into	O
CNS	O
assessed	O
by	I-protein
quantitation	O
of	I-protein
perivascular	O
infiltrates	O
,	O
and	I-protein
by	I-protein
reduced	O
staining	O
for	I-protein
CD4	B-protein
and	I-protein
CD25	B-protein
immunopositive	O
T-cells	I-protein
.	O

T-cell	O
activation	I-protein
,	O
assessed	O
by	I-protein
the	I-protein
production	I-protein
of	I-protein
interferon	B-protein
gamma	I-protein
(	O
IFNgamma	B-protein
)	O
in	I-protein
response	I-protein
to	I-protein
MOG	B-protein
(	O
35-55	I-protein
)	O
,	O
was	O
also	O
decreased	O
by	I-protein
the	I-protein
HSR	B-protein
.	O

The	O
HSR	B-protein
reduced	O
inflammatory	O
gene	O
expression	I-protein
in	I-protein
the	I-protein
brain	O
that	O
normally	O
occurs	O
during	I-protein
EAE	O
,	O
including	I-protein
the	I-protein
early	O
increase	O
in	I-protein
RANTES	B-protein
(	O
regulated	O
on	I-protein
activation	I-protein
of	I-protein
normal	O
T-cell	O
expressed	O
and	I-protein
secreted	O
)	O
expression	I-protein
,	O
and	I-protein
the	I-protein
later	O
expression	I-protein
of	I-protein
the	I-protein
inducible	O
form	I-protein
of	I-protein
nitric	B-protein
oxide	I-protein
synthase	I-protein
.	O

The	O
early	O
activation	I-protein
of	I-protein
transcription	B-protein
factor	I-protein
NF-kappaB	B-protein
was	O
also	O
blocked	B-protein
by	I-protein
the	I-protein
HSR	B-protein
.	O

The	O
finding	O
that	O
the	I-protein
SR	I-protein
reduces	O
inflammation	O
in	I-protein
the	I-protein
brain	O
and	I-protein
the	I-protein
clinical	I-protein
severity	O
of	I-protein
EAE	O
opens	O
a	I-protein
novel	O
therapeutic	O
approach	O
for	I-protein
prevention	O
of	I-protein
autoimmune	B-protein
diseases	O
.	O

###MEDLINE:21188582

In	O
vivo	O
detection	O
of	I-protein
intracellular	I-protein
signaling	O
pathways	O
in	I-protein
developing	B-protein
thymocytes	O
.	O

Information	O
regarding	O
the	I-protein
intracellular	I-protein
signaling	O
processes	O
that	O
occur	O
during	I-protein
the	I-protein
development	O
of	I-protein
T	O
cells	I-protein
has	O
largely	O
been	O
obtained	O
with	I-protein
the	I-protein
use	O
of	I-protein
transgenic	O
mouse	I-protein
models	O
,	O
which	O
although	O
providing	O
invaluable	O
information	I-protein
are	O
time	O
consuming	O
and	I-protein
costly	O
.	O

To	O
this	O
end	I-protein
,	O
we	O
have	O
developed	O
a	I-protein
novel	O
system	I-protein
that	O
facilitates	O
the	I-protein
in	I-protein
vivo	O
analysis	O
of	I-protein
signal	O
transduction	I-protein
pathways	O
during	I-protein
T-lymphocyte	I-protein
development	O
.	O

This	O
approach	O
uses	O
reporter-plasmids	O
for	I-protein
the	I-protein
detection	O
of	I-protein
intracellular	I-protein
signals	I-protein
mediated	I-protein
by	I-protein
the	I-protein
mitogen-activated	B-protein
protein	I-protein
kinase	I-protein
or	I-protein
cyclic	B-protein
AMP-dependent	I-protein
protein	I-protein
kinase	I-protein
.	O

Reporter-plasmids	O
are	O
transfected	O
into	O
thymocytes	O
in	I-protein
fetal	O
thymic	B-protein
organ	O
culture	O
by	I-protein
accelerated	I-protein
DNA/particle	O
bombardment	O
(	O
gene	O
gun	O
)	O
,	O
and	I-protein
the	I-protein
activation	I-protein
of	I-protein
a	I-protein
signaling	O
pathway	I-protein
is	O
determined	O
in	I-protein
the	I-protein
form	I-protein
of	I-protein
a	I-protein
standard	O
luciferase	O
assay	O
.	O

Importantly	O
,	O
this	O
powerful	O
technique	O
preserves	O
the	I-protein
structural	O
integrity	O
of	I-protein
the	I-protein
thymus	I-protein
,	O
and	I-protein
will	O
provide	O
an	I-protein
invaluable	O
tool	O
to	I-protein
study	O
how	O
thymocytes	O
respond	O
to	I-protein
normal	O
environmental	O
stimuli	O
encountered	O
during	I-protein
differentiation	I-protein
within	B-protein
the	I-protein
thymic	B-protein
milieu	O
.	O

Thus	O
,	O
this	O
method	O
allows	O
for	I-protein
the	I-protein
monitoring	O
of	I-protein
signals	I-protein
that	O
occur	O
in	I-protein
a	I-protein
biological	O
time	O
frame	I-protein
,	O
such	O
as	O
during	I-protein
differentiation	I-protein
,	O
and	I-protein
within	B-protein
the	I-protein
natural	O
environment	O
of	I-protein
differentiating	O
cells	I-protein
.	O

###MEDLINE:21185796

Core-binding	B-protein
factor	I-protein
beta	I-protein
(	O
CBFbeta	B-protein
)	O
,	O
but	O
not	I-protein
CBFbeta-smooth	B-protein
muscle	I-protein
myosin	I-protein
heavy	I-protein
chain	I-protein
,	O
rescues	O
definitive	O
hematopoiesis	I-protein
in	I-protein
CBFbeta	B-protein
-deficient	O
embryonic	O
stem	I-protein
cells	I-protein
.	O

Core-binding	B-protein
factor	I-protein
beta	I-protein
(	O
CBFbeta	B-protein
)	O
is	O
the	I-protein
non-DNA-binding	B-protein
subunit	I-protein
of	I-protein
the	I-protein
heterodimeric	B-protein
CBFs	I-protein
.	O

Genes	O
encoding	I-protein
CBFbeta	B-protein
(	O
CBFB	B-protein
)	O
,	O
and	I-protein
one	B-protein
of	I-protein
the	I-protein
DNA-binding	B-protein
CBFalpha	I-protein
subunits	I-protein
,	O
Runx1	I-protein
(	O
also	O
known	O
as	O
CBFalpha2	B-protein
,	O
AML1	B-protein
,	O
and	I-protein
PEBP2alphaB	B-protein
)	O
,	O
are	O
required	O
for	I-protein
normal	O
hematopoiesis	I-protein
and	I-protein
are	O
also	O
frequent	O
targets	O
of	I-protein
chromosomal	I-protein
translocations	O
in	I-protein
acute	O
leukemias	O
in	I-protein
humans	O
.	O

Homozygous	O
disruption	O
of	I-protein
either	O
the	I-protein
Runx1	B-protein
or	I-protein
Cbfb	O
gene	O
in	I-protein
mice	O
results	O
in	I-protein
embryonic	O
lethality	O
at	I-protein
midgestation	O
due	I-protein
to	I-protein
hemorrhaging	O
in	I-protein
the	I-protein
central	O
nervous	O
system	I-protein
,	O
and	I-protein
severely	O
impairs	O
fetal	O
liver	O
hematopoiesis	I-protein
.	O

Results	O
of	I-protein
this	O
study	O
show	O
that	O
Cbfb-deficient	O
mouse	I-protein
embryonic	O
stem	I-protein
(	O
ES	B-protein
)	O
cells	I-protein
can	O
differentiate	O
into	O
primitive	O
erythroid	O
colonies	O
in	I-protein
vitro	O
,	O
but	O
are	O
impaired	O
in	I-protein
their	O
ability	O
to	I-protein
produce	O
definitive	O
erythroid	O
and	I-protein
myeloid	O
colonies	O
,	O
mimicking	O
the	I-protein
in	I-protein
vivo	O
defect	I-protein
.	O

Definitive	O
hematopoiesis	I-protein
is	O
restored	O
by	I-protein
ectopic	I-protein
expression	I-protein
of	I-protein
full-length	O
Cbfb	O
transgenes	O
,	O
as	O
well	O
as	O
by	I-protein
a	I-protein
transgene	O
encoding	I-protein
only	I-protein
the	I-protein
heterodimerization	B-protein
domain	I-protein
of	I-protein
CBFbeta	B-protein
.	O

In	O
contrast	O
,	O
the	I-protein
CBFbeta	B-protein
-	O
smooth	I-protein
muscle	I-protein
myosin	I-protein
heavy	I-protein
chain	I-protein
(	O
SMMHC	B-protein
)	O
fusion	I-protein
protein	I-protein
generated	O
by	I-protein
the	I-protein
inv	O
(	O
16	I-protein
)	O
associated	I-protein
with	I-protein
acute	O
myeloid	O
leukemias	O
(	O
M4Eo	O
)	O
can	O
not	I-protein
rescue	O
definitive	O
hematopoiesis	I-protein
by	I-protein
Cbfb-deficient	O
ES	B-protein
cells	I-protein
.	O

Sequences	O
responsible	O
for	I-protein
the	I-protein
inability	O
of	I-protein
CBFbeta	B-protein
-SMMHC	O
to	I-protein
rescue	O
definitive	O
hematopoiesis	I-protein
reside	O
in	I-protein
the	I-protein
SMMHC	B-protein
portion	I-protein
of	I-protein
the	I-protein
fusion	B-protein
protein	I-protein
.	O

Results	O
also	O
show	O
that	O
the	I-protein
CBFbeta-SMMHC	B-protein
fusion	I-protein
protein	I-protein
transdominantly	O
inhibits	I-protein
definitive	O
hematopoiesis	I-protein
,	O
but	O
not	I-protein
to	I-protein
the	I-protein
same	O
extent	O
as	O
homozygous	O
loss	O
of	I-protein
Runx1	B-protein
or	I-protein
Cbfb	O
.	O

CBFbeta-SMMHC	B-protein
preferentially	O
inhibits	I-protein
the	I-protein
differentiation	I-protein
of	I-protein
myeloid	O
lineage	I-protein
cells	I-protein
,	O
while	O
increasing	O
the	I-protein
number	I-protein
of	I-protein
blastlike	O
cells	I-protein
in	I-protein
culture	O
.	O

###MEDLINE:21184079

The	O
latency	O
pattern	I-protein
of	I-protein
Epstein-Barr	B-protein
virus	I-protein
infection	I-protein
and	I-protein
viral	O
IL-10	B-protein
expression	I-protein
in	I-protein
cutaneous	O
natural	O
killer/T-cell	O
lymphomas	I-protein
.	O

The	O
nasal	O
type	O
,	O
extranodal	O
natural	O
killer	O
or	I-protein
T	O
(	O
NK/T	O
)	O
-cell	O
lymphoma	I-protein
is	O
usually	O
associated	I-protein
with	I-protein
latent	B-protein
Epstein-Barr	B-protein
virus	I-protein
(	O
EBV	O
)	O
infection	I-protein
.	O

In	O
order	O
to	I-protein
elucidate	O
the	I-protein
EBV	O
gene	O
expression	I-protein
patterns	O
in	I-protein
vivo	O
,	O
we	O
examined	O
eight	O
patients	O
with	I-protein
cutaneous	O
EBV-related	O
NK/T-cell	O
lymphomas	I-protein
,	O
including	I-protein
six	O
patients	O
with	I-protein
a	I-protein
NK-cell	O
phenotype	O
and	I-protein
two	O
patients	O
with	I-protein
a	I-protein
T-cell	O
phenotype	O
.	O

The	O
implication	O
of	I-protein
EBV	O
in	I-protein
the	I-protein
skin	O
lesions	O
was	O
determined	O
by	I-protein
the	I-protein
presence	O
of	I-protein
EBV-DNA	O
,	O
EBV-encoded	O
nuclear	O
RNA	O
(	O
EBER	O
)	O
and	I-protein
a	I-protein
clonality	O
of	I-protein
EBV-DNA	O
fragments	I-protein
containing	I-protein
the	I-protein
terminal	O
repeats	I-protein
.	O

Transcripts	O
of	I-protein
EBV-encoded	O
genes	I-protein
were	O
screened	O
by	I-protein
reverse	I-protein
transcription-	O
polymerase	O
chain	I-protein
reaction	I-protein
(	O
RT-PCR	O
)	O
,	O
and	I-protein
confirmed	O
by	I-protein
Southern	O
blot	O
hybridization	O
.	O

The	O
expression	I-protein
of	I-protein
EBV-related	B-protein
antigens	I-protein
was	O
examined	O
by	I-protein
immunostaining	O
using	O
paraffin-embedded	O
tissue	O
sections	O
and	I-protein
cell	O
pellets	O
of	I-protein
EBV-positive	O
cell	O
lines	B-protein
.	O

Our	O
study	O
demonstrated	O
that	O
all	O
samples	O
from	I-protein
the	I-protein
patients	O
contained	O
EBV	O
nuclear	O
antigen	O
(	O
EBNA	O
)	O
-1	I-protein
mRNA	O
which	O
was	O
transcribed	I-protein
using	O
the	I-protein
Q	I-protein
promoter	I-protein
,	O
whereas	O
both	O
the	I-protein
Q	I-protein
promoter	I-protein
and	I-protein
another	O
upstream	O
promoter	I-protein
(	O
Cp/Wp	O
)	O
were	O
used	O
in	I-protein
EBV-positive	O
cell	O
lines	B-protein
,	O
B95.8	O
,	O
Raji	O
and	I-protein
Jiyoye	O
.	O

Latent	O
membrane	O
protein-1	I-protein
(	O
LMP-1	O
)	O
mRNA	O
was	O
detected	O
in	I-protein
seven	O
of	I-protein
eight	O
patients	O
and	I-protein
all	O
cell	O
lines	B-protein
,	O
whereas	O
EBNA-2	O
transcripts	I-protein
were	O
found	O
only	I-protein
in	I-protein
the	I-protein
cell	O
lines	B-protein
.	O

Immunostaining	O
showed	O
no	I-protein
LMP-1	B-protein
,	O
EBNA-2	I-protein
or	I-protein
ZEBRA	I-protein
antigens	I-protein
in	I-protein
the	I-protein
paraffin-embedded	O
tissue	O
sections	O
,	O
although	O
they	O
were	O
positive	I-protein
in	I-protein
the	I-protein
cell	O
line	I-protein
cells	I-protein
.	O

Latent	O
BHRF1	O
transcripts	I-protein
encoding	I-protein
bcl-2	O
homologue	O
and	I-protein
BCRF1	O
transcripts	I-protein
encoding	I-protein
viral	B-protein
interleukin	I-protein
(	O
vIL	I-protein
)	O
-10	I-protein
were	O
detected	O
in	I-protein
one	B-protein
and	I-protein
two	O
of	I-protein
eight	O
patients	O
,	O
respectively	O
.	O

A	O
patient	O
with	I-protein
NK-cell	O
lymphoma	I-protein
expressing	O
both	O
transcripts	I-protein
died	O
of	I-protein
rapid	O
progression	I-protein
of	I-protein
the	I-protein
illness	O
.	O

Our	O
results	O
indicate	O
that	O
the	I-protein
restricted	I-protein
expression	I-protein
of	I-protein
the	I-protein
latency-associated	O
EBV	O
genes	I-protein
and	I-protein
the	I-protein
production	I-protein
of	I-protein
vIL-10	O
and	I-protein
bcl-2	O
homologue	O
may	O
favour	O
tumour	I-protein
growth	O
,	O
evading	O
the	I-protein
host	O
immune	O
surveillance	O
.	O

Copyright	O
2001	O
Cancer	O
Research	O
Campaign	O
.	O

###MEDLINE:21238271

Oxidized	O
alkyl	O
phospholipids	O
are	O
specific	I-protein
,	O
high	B-protein
affinity	I-protein
peroxisome	B-protein
proliferator-activated	I-protein
receptor	I-protein
gamma	I-protein
ligands	I-protein
and	I-protein
agonists	O
.	O

Synthetic	O
high	O
affinity	I-protein
peroxisome	B-protein
proliferator-activated	I-protein
receptor	O
(	O
PPAR	B-protein
)	O
agonists	O
are	O
known	O
,	O
but	O
biologic	O
ligands	O
are	O
of	I-protein
low	O
affinity	I-protein
.	O

Oxidized	B-protein
low	I-protein
density	I-protein
lipoprotein	I-protein
(	O
oxLDL	O
)	O
is	O
inflammatory	O
and	I-protein
signals	I-protein
through	I-protein
PPARs	B-protein
.	O

We	O
showed	O
,	O
by	I-protein
phospholipase	O
A	O
(	O
1	I-protein
)	O
digestion	O
,	O
that	O
PPARgamma	O
agonists	O
in	I-protein
oxLDL	O
arise	O
from	I-protein
the	I-protein
small	O
pool	O
of	I-protein
alkyl	O
phosphatidylcholines	O
in	I-protein
LDL	O
.	O

We	O
identified	I-protein
an	I-protein
abundant	I-protein
oxidatively	O
fragmented	O
alkyl	O
phospholipid	O
in	I-protein
oxLDL	O
,	O
hexadecyl	O
azelaoyl	O
phosphatidylcholine	O
(	O
azPC	O
)	O
,	O
as	O
a	I-protein
high	O
affinity	I-protein
ligand	O
and	I-protein
agonist	I-protein
for	I-protein
PPARgamma	B-protein
.	O

[	O
(	O
3	O
)	O
H	I-protein
]	O
azPC	O
bound	I-protein
recombinant	B-protein
PPARgamma	I-protein
with	I-protein
an	I-protein
affinity	I-protein
(	O
K	O
(	O
d	I-protein
)	O
(	O
(	O
app	O
)	O
)	O
approximately	O
40	I-protein
nm	O
)	O
that	O
was	O
equivalent	O
to	I-protein
rosiglitazone	O
(	O
BRL49653	O
)	O
,	O
and	I-protein
competition	O
with	I-protein
rosiglitazone	O
showed	O
that	O
binding	I-protein
occurred	O
in	I-protein
the	I-protein
ligand-binding	B-protein
pocket	I-protein
.	O

azPC	O
induced	I-protein
PPRE	O
reporter	O
gene	O
expression	I-protein
,	O
as	O
did	O
rosiglitazone	O
,	O
with	I-protein
a	I-protein
half-maximal	O
effect	O
at	I-protein
100	I-protein
nm	O
.	O

Overexpression	O
of	I-protein
PPARalpha	B-protein
or	I-protein
PPARgamma	B-protein
revealed	O
that	O
azPC	O
was	O
a	I-protein
specific	I-protein
PPARgamma	O
agonist	I-protein
.	O

The	O
scavenger	B-protein
receptor	I-protein
CD36	B-protein
is	O
encoded	O
by	I-protein
a	I-protein
PPRE-responsive	O
gene	O
,	O
and	I-protein
azPC	O
enhanced	I-protein
expression	I-protein
of	I-protein
CD36	B-protein
in	I-protein
primary	O
human	O
monocytes	O
.	O

We	O
found	O
that	O
anti-CD36	O
inhibited	O
azPC	O
uptake	I-protein
,	O
and	I-protein
it	O
inhibited	O
PPRE	O
reporter	O
induction	I-protein
.	O

Results	O
with	I-protein
a	I-protein
small	O
molecule	I-protein
phospholipid	B-protein
flippase	I-protein
mimetic	I-protein
suggest	O
azPC	O
acts	O
intracellularly	O
and	I-protein
that	O
cellular	O
azPC	O
accumulation	I-protein
was	O
efficient	O
.	O

Thus	O
,	O
certain	O
alkyl	O
phospholipid	O
oxidation	O
products	O
in	I-protein
oxLDL	O
are	O
specific	I-protein
,	O
high	O
affinity	I-protein
extracellular	O
ligands	O
and	I-protein
agonists	O
for	I-protein
PPARgamma	B-protein
that	O
induce	O
PPAR-responsive	O
genes	I-protein

###MEDLINE:21326158

Regulation	O
of	I-protein
the	I-protein
human	O
MAT2B	B-protein
gene	O
encoding	I-protein
the	I-protein
regulatory	B-protein
beta	I-protein
subunit	I-protein
of	I-protein
methionine	B-protein
adenosyltransferase	I-protein
,	O
MAT	B-protein
II	I-protein
.	O

Methionine	B-protein
adenosyltransferase	I-protein
(	O
MAT	B-protein
)	O
catalyzes	O
the	I-protein
biosynthesis	I-protein
of	I-protein
S-adenosylmethionine	B-protein
(	O
AdoMet	B-protein
)	O
,	O
a	I-protein
key	O
molecule	I-protein
in	I-protein
transmethylation	O
reactions	O
and	I-protein
polyamine	B-protein
biosynthesis	I-protein
.	O

The	O
MAT	B-protein
II	I-protein
isozyme	I-protein
consists	O
of	I-protein
a	I-protein
catalytic	I-protein
alpha2	I-protein
and	I-protein
a	I-protein
regulatory	I-protein
beta	I-protein
subunit	I-protein
.	O

Down-regulation	O
of	I-protein
the	I-protein
MAT	B-protein
II	I-protein
beta	I-protein
subunit	I-protein
expression	I-protein
causes	O
a	I-protein
6-10-fold	O
increase	O
in	I-protein
intracellular	I-protein
AdoMet	B-protein
levels	I-protein
.	O

To	O
understand	O
the	I-protein
mechanism	O
by	I-protein
which	O
the	I-protein
beta	B-protein
subunit	I-protein
expression	I-protein
is	O
regulated	O
,	O
we	O
cloned	O
the	I-protein
MAT2B	B-protein
gene	O
,	O
determined	O
its	O
organization	O
,	O
characterized	O
its	O
5'-flanking	O
sequences	I-protein
,	O
and	I-protein
elucidated	O
the	I-protein
in	I-protein
vitro	O
and	I-protein
in	I-protein
vivo	O
regulation	I-protein
of	I-protein
its	O
promoter	I-protein
.	O

Transcription	I-protein
of	I-protein
the	I-protein
MAT2B	B-protein
gene	O
initiates	O
at	I-protein
position	O
-203	O
relative	I-protein
to	I-protein
the	I-protein
translation	I-protein
start	O
site	I-protein
.	O

Promoter	O
deletion	I-protein
analysis	O
defined	I-protein
a	I-protein
minimal	O
promoter	I-protein
between	O
positions	O
+52	O
and	I-protein
+93	O
base	I-protein
pairs	O
,	O
a	I-protein
GC-rich	O
region	O
.	O

Inclusion	O
of	I-protein
the	I-protein
sequences	I-protein
between	O
-4	I-protein
and	I-protein
+52	O
enhanced	I-protein
promoter	I-protein
activity	I-protein
;	O
this	O
was	O
primarily	O
because	O
of	I-protein
an	I-protein
Sp1	O
recognition	I-protein
site	I-protein
at	I-protein
+9/+15	O
.	O

The	O
inclusion	B-protein
of	I-protein
sequences	I-protein
up	O
to	I-protein
position	O
-115	O
provided	O
full	O
activity	I-protein
;	O
this	O
was	O
attributed	O
to	I-protein
a	I-protein
TATA	O
at	I-protein
-32	O
.	O

The	O
Sp1	O
site	I-protein
at	I-protein
position	O
+9	O
was	O
key	O
for	I-protein
the	I-protein
formation	O
of	I-protein
protein.DNA	O
complexes	O
.	O

Mutation	O
of	I-protein
both	O
the	I-protein
Sp1	O
site	I-protein
at	I-protein
+9	O
and	I-protein
the	I-protein
TATA	O
at	I-protein
-32	O
reduced	O
promoter	I-protein
activity	I-protein
to	I-protein
its	O
minimal	O
level	I-protein
.	O

Supershift	O
assays	O
showed	O
no	I-protein
effect	O
of	I-protein
the	I-protein
anti-Sp1	B-protein
antibody	I-protein
on	I-protein
complex	I-protein
formation	O
,	O
whereas	O
the	I-protein
anti-Sp3	B-protein
antibody	I-protein
had	O
a	I-protein
strong	O
effect	O
on	I-protein
protein.DNA	O
complex	I-protein
formation	O
,	O
suggesting	O
that	O
Sp3	B-protein
is	O
one	B-protein
of	I-protein
the	I-protein
main	O
factors	I-protein
binding	I-protein
to	I-protein
this	O
Sp1	O
site	I-protein
.	O

Chromatin	I-protein
immunoprecipitation	O
assays	O
supported	I-protein
the	I-protein
involvement	I-protein
of	I-protein
both	O
Sp1	B-protein
and	I-protein
Sp3	B-protein
in	I-protein
complexes	O
formed	O
on	I-protein
the	I-protein
MAT2B	B-protein
promoter	I-protein
.	O

The	O
data	O
show	O
that	O
the	I-protein
5'-untranslated	O
sequences	I-protein
play	O
an	I-protein
important	O
role	O
in	I-protein
regulating	O
the	I-protein
MAT2B	B-protein
gene	O
and	I-protein
identifies	O
the	I-protein
Sp1	O
site	I-protein
at	I-protein
+9	O
as	O
a	I-protein
potential	I-protein
target	O
for	I-protein
modulating	I-protein
MAT2B	B-protein
expression	I-protein
,	O
a	I-protein
process	O
that	O
can	O
have	O
a	I-protein
major	O
effect	O
on	I-protein
intracellular	I-protein
AdoMet	B-protein
levels	I-protein
.	O

###MEDLINE:21225972

Molecular	O
pathogenesis	O
of	I-protein
influenza	O
A	O
virus	I-protein
infection	I-protein
and	I-protein
virus-induced	B-protein
regulation	I-protein
of	I-protein
cytokine	O
gene	O
expression	I-protein
.	O

Despite	O
vaccines	O
and	I-protein
antiviral	I-protein
substances	O
influenza	O
still	O
causes	O
significant	O
morbidity	O
and	I-protein
mortality	B-protein
world	O
wide	O
.	O

Better	O
understanding	O
of	I-protein
the	I-protein
molecular	I-protein
mechanisms	O
of	I-protein
influenza	O
virus	I-protein
replication	O
,	O
pathogenesis	O
and	I-protein
host	O
immune	O
responses	O
is	O
required	O
for	I-protein
the	I-protein
development	O
of	I-protein
more	O
efficient	O
means	O
of	I-protein
prevention	O
and	I-protein
treatment	O
of	I-protein
influenza	O
.	O

Influenza	O
A	O
virus	I-protein
,	O
which	O
replicates	O
in	I-protein
epithelial	O
cells	I-protein
and	I-protein
leukocytes	O
,	O
regulates	O
host	O
cell	O
transcriptional	O
and	I-protein
translational	I-protein
systems	O
and	I-protein
activates	O
,	O
as	O
well	O
as	O
downregulates	O
apoptotic	O
pathways	O
.	O

Influenza	O
A	O
virus	I-protein
infection	I-protein
results	O
in	I-protein
the	I-protein
production	I-protein
of	I-protein
chemotactic	I-protein
(	O
RANTES	B-protein
,	O
MIP-1	B-protein
alpha	I-protein
,	O
MCP-1	B-protein
,	O
MCP-3	B-protein
,	O
and	I-protein
IP-10	B-protein
)	O
,	O
pro-inflammatory	O
(	O
IL-1	B-protein
beta	I-protein
,	O
IL-6	B-protein
,	O
IL-18	B-protein
,	O
and	I-protein
TNF-alpha	B-protein
)	O
,	O
and	I-protein
antiviral	I-protein
(	O
IFN-alpha/beta	B-protein
)	O
cytokines	I-protein
.	O

Cytokine	O
gene	O
expression	I-protein
is	O
associated	I-protein
with	I-protein
the	I-protein
activation	I-protein
of	I-protein
NF-kappa	B-protein
B	I-protein
,	O
AP-1	I-protein
,	O
STAT	B-protein
and	I-protein
IRF	B-protein
signal	I-protein
transducing	I-protein
molecules	I-protein
in	I-protein
influenza	O
A	O
virus-infected	O
cells	I-protein
.	O

In	O
addition	O
of	I-protein
upregulating	O
cytokine	O
gene	O
expression	I-protein
,	O
influenza	O
A	O
virus	I-protein
infection	I-protein
activates	O
caspase-1	B-protein
enzyme	I-protein
,	O
which	O
is	O
involved	I-protein
in	I-protein
the	I-protein
proteolytic	I-protein
processing	O
of	I-protein
proIL-1	B-protein
beta	I-protein
and	I-protein
proIL-18	O
into	O
their	O
biologically	O
active	O
forms	I-protein
.	O

Influenza	O
A	O
virus-induced	B-protein
IFN-alpha/beta	B-protein
is	O
essential	O
in	I-protein
host	O
's	I-protein
antiviral	I-protein
defence	O
by	I-protein
activating	O
the	I-protein
expression	I-protein
of	I-protein
antiviral	I-protein
Mx	O
,	O
PKR	B-protein
and	I-protein
oligoadenylate	O
synthetase	I-protein
genes	I-protein
.	O

IFN-alpha/beta	B-protein
also	O
prolongs	O
T	O
cell	O
survival	B-protein
,	O
upregulates	O
IL-12	B-protein
and	I-protein
IL-18	B-protein
receptor	O
gene	O
expression	I-protein
and	I-protein
together	O
with	I-protein
IL-18	B-protein
stimulates	O
NK	I-protein
and	I-protein
T	O
cell	O
IFN-gamma	O
production	I-protein
and	I-protein
the	I-protein
development	O
of	I-protein
Th1-type	O
immune	O
response	I-protein
.	O

###MEDLINE:21216558

Comparison	O
of	I-protein
hprt	O
and	I-protein
lacI	O
mutant	O
frequency	O
with	I-protein
DNA	O
adduct	O
formation	O
in	I-protein
N-hydroxy-2-acetylaminofluorene-treated	O
Big	O
Blue	O
rats	O
.	O

N-Hydroxy-2-acetylaminofluorene	O
(	O
N-OH-AAF	O
)	O
is	O
the	I-protein
proximate	O
carcinogenic	O
metabolite	O
of	I-protein
the	I-protein
powerful	O
rat	I-protein
liver	O
carcinogen	O
2-acetylaminofluorene	O
.	O

In	O
this	O
study	O
,	O
transgenic	O
Big	O
Blue	O
(	O
R	I-protein
)	O
rats	O
were	O
used	O
to	I-protein
examine	O
the	I-protein
relationship	O
between	O
in	I-protein
vivo	O
mutagenicity	O
and	I-protein
DNA	O
adduct	O
formation	O
by	I-protein
N-OH-AAF	O
in	I-protein
the	I-protein
target	O
liver	O
compared	O
with	I-protein
that	O
in	I-protein
nontarget	O
tissues	O
.	O

Male	O
rats	O
were	O
given	O
one	B-protein
,	O
two	O
,	O
or	I-protein
four	O
doses	O
of	I-protein
25	I-protein
mg	O
N-OH-AAF/kg	O
body	O
weight	I-protein
by	I-protein
i.p.	O
injection	O
at	I-protein
4-day	O
intervals	O
,	O
and	I-protein
groups	O
of	I-protein
treated	O
and	I-protein
control	I-protein
rats	O
were	O
euthanized	O
up	O
to	I-protein
10	I-protein
weeks	O
after	O
beginning	O
the	I-protein
dosing	O
.	O

Mutant	O
frequencies	O
were	O
measured	O
in	I-protein
the	I-protein
spleen	B-protein
lymphocyte	O
hprt	O
gene	O
,	O
and	I-protein
lacI	O
mutant	O
frequencies	O
were	O
determined	O
in	I-protein
the	I-protein
liver	O
and	I-protein
spleen	B-protein
lymphocytes	O
.	O

At	O
6	I-protein
weeks	O
after	O
beginning	O
the	I-protein
dosing	O
,	O
the	I-protein
hprt	O
mutant	O
frequency	O
in	I-protein
spleen	B-protein
lymphocytes	O
from	I-protein
the	I-protein
four-dose	O
group	I-protein
was	O
16.5	O
x	I-protein
10	I-protein
(	O
-6	I-protein
)	O
compared	O
with	I-protein
3.2	O
x	I-protein
10	I-protein
(	O
-6	I-protein
)	O
in	I-protein
control	I-protein
animals	O
.	O

Also	O
at	I-protein
6	I-protein
weeks	O
,	O
rats	O
given	O
one	B-protein
,	O
two	O
,	O
or	I-protein
four	O
doses	O
of	I-protein
N-OH-AAF	O
had	O
lacI	O
mutant	O
frequencies	O
in	I-protein
the	I-protein
liver	O
of	I-protein
97.6	O
,	O
155.6	O
,	O
and	I-protein
406.8	O
x	I-protein
10	I-protein
(	O
-6	I-protein
)	O
,	O
respectively	O
,	O
compared	O
with	I-protein
a	I-protein
control	I-protein
frequency	O
of	I-protein
25.7	O
x	I-protein
10	I-protein
(	O
-6	I-protein
)	O
;	O
rats	O
given	O
four	O
doses	O
had	O
lacI	O
mutant	O
frequencies	O
in	I-protein
spleen	B-protein
lymphocytes	O
of	I-protein
55.8	O
x	I-protein
10	I-protein
(	O
-6	I-protein
)	O
compared	O
with	I-protein
a	I-protein
control	I-protein
frequency	O
of	I-protein
20.4	O
x	I-protein
10	I-protein
(	O
-6	I-protein
)	O
.	O

Additional	O
rats	O
were	O
evaluated	O
for	I-protein
DNA	O
adduct	O
formation	O
in	I-protein
the	I-protein
liver	O
,	O
spleen	B-protein
lymphocytes	O
,	O
and	I-protein
bone	O
marrow	I-protein
by	I-protein
(	O
32	I-protein
)	O
P-postlabeling	O
.	O

Adduct	O
analysis	O
was	O
conducted	O
1	I-protein
day	O
after	O
one	B-protein
,	O
two	O
,	O
and	I-protein
four	O
treatments	O
with	I-protein
N-OH-AAF	O
,	O
5	O
days	O
after	O
one	B-protein
treatment	O
,	O
and	I-protein
9	I-protein
days	O
after	O
two	O
treatments	O
.	O

N-	O
(	O
Deoxyguanosin-8-yl	O
)	O
-2-aminofluorene	O
was	O
the	I-protein
major	O
DNA	O
adduct	O
identified	I-protein
in	I-protein
all	O
the	I-protein
tissues	O
examined	O
.	O

Adduct	O
concentrations	O
increased	I-protein
with	I-protein
total	O
dose	O
to	I-protein
maximum	O
values	O
in	I-protein
samples	O
taken	O
1	I-protein
day	O
after	O
two	O
doses	O
,	O
and	I-protein
remained	O
essentially	O
the	I-protein
same	O
after	O
four	O
doses	O
.	O

In	O
samples	O
taken	O
after	O
four	O
doses	O
,	O
adduct	O
levels	I-protein
were	O
103	I-protein
,	O
28	I-protein
,	O
and	I-protein
7	I-protein
fmol/microg	O
of	I-protein
DNA	O
in	I-protein
liver	O
,	O
spleen	B-protein
lymphocytes	O
,	O
and	I-protein
bone	O
marrow	I-protein
,	O
respectively	O
.	O

The	O
results	O
indicate	O
that	O
the	I-protein
extent	O
of	I-protein
both	O
DNA	O
adduct	O
formation	O
and	I-protein
mutant	O
induction	I-protein
correlates	O
with	I-protein
the	I-protein
organ	O
specificity	I-protein
for	I-protein
N-OH-AAF	O
carcinogenesis	O
in	I-protein
the	I-protein
rat	I-protein
.	O

Environ.	O
Mol.	O
Mutagen.	O
37	I-protein
:	O
195-202	O
,	O
2001	O
.	O

Published	O
2001	O
Wiley-Liss	O
,	O
Inc	O
.	O

###MEDLINE:21214517

Expression	O
of	I-protein
Mad1	B-protein
in	I-protein
T	O
cells	I-protein
leads	O
to	I-protein
reduced	O
thymic	B-protein
cellularity	O
and	I-protein
impaired	O
mitogen-induced	O
proliferation	I-protein
.	O

To	O
investigate	O
Mad1	B-protein
function	I-protein
in	I-protein
vivo	O
,	O
transgenic	O
mice	O
were	O
generated	O
that	O
express	O
a	I-protein
Mad1	O
transgene	O
in	I-protein
T	O
lineage	I-protein
cells	I-protein
under	O
the	I-protein
control	I-protein
of	I-protein
the	I-protein
proximal	I-protein
lck	O
promoter	I-protein
.	O

Thymus	O
size	O
in	I-protein
lck-Mad1	O
transgenic	O
mice	O
is	O
drastically	O
reduced	O
although	O
representation	O
of	I-protein
the	I-protein
various	O
thymocyte	B-protein
sub	O
populations	O
appears	O
normal	O
.	O

To	O
investigate	O
more	O
closely	O
any	O
effects	O
of	I-protein
Mad1	O
expression	I-protein
on	I-protein
thymocytes	O
,	O
we	O
examined	O
thymic	B-protein
selection	O
using	O
MHC	O
class	O
I-restricted	O
H-Y-TCR	O
transgenic	O
mice	O
.	O

Mad1	O
expression	I-protein
in	I-protein
vivo	O
reduces	O
the	I-protein
efficiency	O
of	I-protein
positive	I-protein
selection	O
.	O

Furthermore	O
,	O
thymocytes	O
and	I-protein
splenic	O
T	O
cells	I-protein
from	I-protein
lck-Mad1	O
transgenic	O
mice	O
display	O
a	I-protein
profound	O
proliferative	O
defect	I-protein
in	I-protein
response	I-protein
to	I-protein
activation	I-protein
with	I-protein
either	O
PMA/Ionomycin	O
or	I-protein
immobilized	B-protein
anti-CD3/CD28	I-protein
antibody	I-protein
.	O

This	O
proliferative	O
defect	I-protein
is	O
not	I-protein
reversed	O
by	I-protein
addition	O
of	I-protein
exogenous	B-protein
IL-2	B-protein
and	I-protein
is	O
p53-independent	O
.	O

The	O
growth	O
inhibition	O
caused	O
by	I-protein
Mad1	B-protein
is	O
overcome	O
by	I-protein
expression	I-protein
of	I-protein
active	B-protein
c-Myc	B-protein
.	O

###MEDLINE:21213531

Differential	O
requirement	O
for	I-protein
the	I-protein
transcription	B-protein
factor	I-protein
PU.1	B-protein
in	I-protein
the	I-protein
generation	O
of	I-protein
natural	O
killer	O
cells	I-protein
versus	O
B	O
and	I-protein
T	O
cells	I-protein
.	O

PU.1	B-protein
is	O
a	I-protein
member	I-protein
of	I-protein
the	I-protein
Ets	B-protein
family	I-protein
of	I-protein
transcription	B-protein
factors	I-protein
required	O
for	I-protein
the	I-protein
development	O
of	I-protein
various	O
lymphoid	O
and	I-protein
myeloid	O
cell	O
lineages	O
,	O
but	O
its	O
role	O
in	I-protein
natural	O
killer	O
(	O
NK	I-protein
)	O
cell	O
development	O
is	O
not	I-protein
known	O
.	O

The	O
study	O
shows	O
that	O
PU.1	B-protein
is	O
expressed	O
in	I-protein
NK	I-protein
cells	I-protein
and	I-protein
that	O
,	O
on	I-protein
cell	O
transfer	O
into	O
alymphoid	O
Rag2/gammac	O
(	O
-/-	O
)	O
mice	O
,	O
hematopoietic	O
progenitors	O
of	I-protein
PU.1	B-protein
(	O
-/-	O
)	O
fetal	O
liver	O
cells	I-protein
could	O
generate	O
functional	O
NK	I-protein
cells	I-protein
but	O
not	I-protein
B	O
or	I-protein
T	O
cells	I-protein
.	O

Nevertheless	O
,	O
the	I-protein
numbers	O
of	I-protein
bone	O
marrow	I-protein
NK	I-protein
cell	O
precursors	O
and	I-protein
splenic	O
mature	B-protein
NK	I-protein
cells	I-protein
were	O
reduced	O
compared	O
to	I-protein
controls	O
.	O

Moreover	O
,	O
PU.1	B-protein
(	O
-/-	O
)	O
NK	I-protein
cells	I-protein
displayed	O
reduced	O
expression	I-protein
of	I-protein
the	I-protein
receptors	I-protein
for	I-protein
stem	I-protein
cell	I-protein
factor	I-protein
and	I-protein
interleukin	B-protein
(	O
IL	I-protein
)	O
-7	I-protein
,	O
suggesting	O
a	I-protein
nonredundant	O
role	O
for	I-protein
PU.1	B-protein
in	I-protein
regulating	O
the	I-protein
expression	I-protein
of	I-protein
these	O
cytokine	O
receptor	O
genes	I-protein
during	I-protein
NK	I-protein
cell	O
development	O
.	O

PU.1	B-protein
(	O
-/-	O
)	O
NK	I-protein
cells	I-protein
also	O
showed	O
defective	O
expression	I-protein
of	I-protein
inhibitory	O
and	I-protein
activating	O
members	O
of	I-protein
the	I-protein
Ly49	B-protein
family	I-protein
and	I-protein
failed	O
to	I-protein
proliferate	O
in	I-protein
response	I-protein
to	I-protein
IL-2	B-protein
and	I-protein
IL-12	B-protein
.	O

Thus	O
,	O
despite	O
the	I-protein
less	O
stringent	O
requirement	O
for	I-protein
PU.1	B-protein
in	I-protein
NK	I-protein
cell	O
development	O
compared	O
to	I-protein
B	O
and	I-protein
T	O
cells	I-protein
,	O
PU.1	B-protein
regulates	O
NK	I-protein
cell	O
differentiation	I-protein
and	I-protein
homeostasis	I-protein
.	O

###MEDLINE:21203088

Benzene-extracted	O
components	O
are	O
important	O
for	I-protein
the	I-protein
major	O
activity	I-protein
of	I-protein
diesel	O
exhaust	O
particles	O
:	O
effect	O
on	I-protein
interleukin-8	O
gene	O
expression	I-protein
in	I-protein
human	O
bronchial	O
epithelial	O
cells	I-protein
.	O

Epidemiologic	O
and	I-protein
experimental	O
studies	O
suggest	O
that	O
diesel	O
exhaust	O
particles	O
(	O
DEPs	O
)	O
may	O
be	O
related	O
to	I-protein
increasing	O
respiratory	I-protein
mortality	B-protein
and	I-protein
morbidity	O
.	O

We	O
have	O
shown	O
that	O
DEPs	O
augmented	O
the	I-protein
production	I-protein
of	I-protein
inflammatory	B-protein
cytokines	I-protein
by	I-protein
human	O
airway	I-protein
epithelial	O
cells	I-protein
in	I-protein
vitro	O
.	O

To	O
better	O
understand	O
the	I-protein
mechanisms	O
of	I-protein
their	O
proinflammatory	O
activities	O
,	O
we	O
studied	O
the	I-protein
effects	O
of	I-protein
several	I-protein
components	O
extracted	O
from	I-protein
DEPs	O
on	I-protein
interleukin	O
(	O
IL	O
)	O
-8	O
expression	I-protein
in	I-protein
human	O
bronchial	O
epithelial	O
cell	O
line	I-protein
BEAS-2B	O
and	I-protein
normal	O
human	O
airway	I-protein
epithelial	O
cells	I-protein
obtained	O
from	I-protein
very	O
peripheral	O
airways	O
by	I-protein
an	I-protein
ultrathin	O
bronchoscope	O
.	O

We	O
used	O
several	I-protein
agents	O
active	O
on	I-protein
signal	O
transduction	I-protein
pathways	O
in	I-protein
cytokine	O
expression	I-protein
,	O
such	O
as	O
the	I-protein
protein	O
kinase	O
C	O
inhibitor	O
staurosporin	O
,	O
antioxidant	I-protein
agents	O
including	I-protein
N-acetyl	I-protein
cysteine	O
(	O
NAC	B-protein
)	O
and	I-protein
pyrrolidine	O
dithiocarbamate	O
(	O
PDTC	O
)	O
,	O
and	I-protein
p38	B-protein
mitogen-activated	I-protein
protein	I-protein
kinase	I-protein
(	O
MAPK	I-protein
)	O
inhibitor	O
SB203580	O
.	O

Benzene-extracted	O
components	O
showed	O
effects	O
mimicking	O
DEPs	O
on	I-protein
IL-8	O
gene	O
expression	I-protein
,	O
release	I-protein
of	I-protein
several	I-protein
cytokines	B-protein
(	O
IL-8	B-protein
;	O
granulocyte	I-protein
macrophage	I-protein
colony-stimulating	I-protein
factor	I-protein
;	O
and	I-protein
regulated	O
on	I-protein
activation	I-protein
,	O
normal	O
T	O
cells	I-protein
expressed	O
and	I-protein
secreted	O
)	O
and	I-protein
nuclear	B-protein
factor	I-protein
(	O
NF	I-protein
)	O
-kappa	I-protein
B	I-protein
activation	I-protein
.	O

We	O
also	O
found	O
that	O
NAC	B-protein
,	O
PDTC	O
,	O
and	I-protein
SB203580	O
suppressed	I-protein
the	I-protein
activities	O
of	I-protein
DEPs	O
and	I-protein
their	O
benzene	O
extracts	O
,	O
suggesting	O
the	I-protein
roles	O
of	I-protein
oxidants-mediated	O
NF-kappa	O
B	O
activation	I-protein
and	I-protein
p38MAPK	O
pathways	O
.	O

Finally	O
,	O
benzo	O
[	O
a	I-protein
]	O
pyrene	O
,	O
one	B-protein
of	I-protein
the	I-protein
important	O
compounds	O
included	I-protein
in	I-protein
the	I-protein
benzene	O
component	O
,	O
replicated	O
the	I-protein
activities	O
shown	O
by	I-protein
DEPs	O
.	O

###MEDLINE:21195296

The	O
nuclear	B-protein
receptor	I-protein
PPAR	B-protein
gamma	I-protein
is	O
expressed	O
by	I-protein
mouse	I-protein
T	O
lymphocytes	O
and	I-protein
PPAR	B-protein
gamma	O
agonists	O
induce	O
apoptosis	O
.	O

Peroxisome	I-protein
proliferator-activated	I-protein
receptor	I-protein
(	O
PPAR	B-protein
)	O
-gamma	I-protein
is	O
a	I-protein
nuclear	B-protein
hormone	I-protein
receptor	I-protein
that	O
serves	O
as	O
a	I-protein
trans	I-protein
factor	I-protein
to	I-protein
regulate	O
lipid	O
metabolism	I-protein
.	O

Intense	O
interest	I-protein
is	O
focused	O
on	I-protein
PPAR-gamma	B-protein
and	I-protein
its	O
ligands	O
owing	O
to	I-protein
its	O
putative	O
role	O
in	I-protein
adipocyte	I-protein
differentiation	I-protein
.	O

Little	O
is	O
known	O
,	O
however	O
,	O
about	O
the	I-protein
functions	O
of	I-protein
PPAR-gamma	B-protein
in	I-protein
the	I-protein
immune	O
system	I-protein
,	O
especially	O
in	I-protein
T	O
lymphocytes	O
.	O

We	O
demonstrate	O
that	O
both	O
naive	O
and	I-protein
activated	O
ovalbumin-specific	O
T	O
cells	I-protein
from	I-protein
DO11.10-transgenic	O
mice	O
express	O
PPAR-gamma	O
mRNA	O
and	I-protein
protein	O
.	O

In	O
order	O
to	I-protein
determine	O
the	I-protein
function	I-protein
of	I-protein
PPAR-gamma	B-protein
,	O
T	O
cells	I-protein
were	O
stimulated	O
with	I-protein
phorbol	O
12-myristate	O
13-acetate	O
and	I-protein
ionomycin	O
or	I-protein
antigen	O
and	I-protein
antigen-presenting	O
cells	I-protein
.	O

Simultaneous	O
exposure	O
to	I-protein
PPAR-gamma	O
ligands	O
(	O
e.g.	O
15-deoxy-Delta	O
(	O
12	O
,	O
14	I-protein
)	O
-prostaglandin	O
J	I-protein
(	O
2	I-protein
)	O
,	O
troglitazone	O
)	O
showed	O
drastic	O
inhibition	O
of	I-protein
proliferation	I-protein
and	I-protein
significant	O
decreases	O
in	I-protein
cell	O
viability	O
.	O

The	O
decrease	O
in	I-protein
cell	O
viability	O
was	O
due	I-protein
to	I-protein
apoptosis	O
of	I-protein
the	I-protein
T	O
lymphocytes	O
,	O
and	I-protein
occurred	O
only	I-protein
when	O
cells	I-protein
were	O
treated	O
with	I-protein
PPAR-gamma	B-protein
,	O
and	I-protein
not	I-protein
PPAR-alpha	O
agonists	O
,	O
revealing	O
specificity	I-protein
of	I-protein
this	O
response	I-protein
for	I-protein
PPAR-gamma	B-protein
.	O

These	O
observations	O
suggest	O
that	O
PPAR-gamma	O
agonists	O
play	O
an	I-protein
important	O
role	O
in	I-protein
regulating	O
T	O
cell-mediated	O
immune	O
responses	O
by	I-protein
inducing	I-protein
apoptosis	O
.	O

T	O
cell	O
death	O
via	I-protein
PPAR-gamma	O
ligation	O
may	O
act	O
as	O
a	I-protein
potent	O
anti-inflammatory	O
signal	O
in	I-protein
the	I-protein
immune	O
system	I-protein
,	O
and	I-protein
ligands	O
could	O
possibly	O
be	O
used	O
to	I-protein
control	I-protein
disorders	O
in	I-protein
which	O
excessive	I-protein
inflammation	O
occurs	O
.	O

###MEDLINE:21188436

Suppression	O
of	I-protein
lung	O
inflammation	O
in	I-protein
rats	O
by	I-protein
prevention	O
of	I-protein
NF-kappaB	B-protein
activation	I-protein
in	I-protein
the	I-protein
liver	O
.	O

Activation	O
of	I-protein
NF-kappaB	B-protein
and	I-protein
production	I-protein
of	I-protein
NF-kappaB	B-protein
-dependent	I-protein
chemokines	O
are	O
thought	O
to	I-protein
be	O
involved	I-protein
in	I-protein
the	I-protein
pathogenesis	O
of	I-protein
neutrophilic	O
lung	O
inflammation	O
.	O

Calpain-1	O
inhibitor	O
(	O
CI-1	O
)	O
blocks	O
activation	I-protein
of	I-protein
NF-kappaB	B-protein
by	I-protein
preventing	O
proteolysis	O
of	I-protein
the	I-protein
inhibitory	B-protein
protein	I-protein
IkappaB-alpha	B-protein
by	I-protein
the	I-protein
ubiquitin/proteasome	O
pathway	I-protein
.	O

We	O
hypothesized	O
that	O
inhibition	O
of	I-protein
proteasome	O
function	I-protein
with	I-protein
CI-1	O
would	O
block	O
NF-kappaB	B-protein
activation	I-protein
in	I-protein
vivo	O
after	O
intraperitoneal	O
(	O
i.p.	O
)	O
treatment	O
with	I-protein
bacterial	I-protein
lipopolysaccharide	B-protein
(	O
LPS	B-protein
)	O
,	O
and	I-protein
that	O
NF-kappaB	B-protein
inhibition	O
would	O
be	O
associated	I-protein
with	I-protein
suppression	O
of	I-protein
chemokine	O
gene	O
expression	I-protein
and	I-protein
attenuation	O
of	I-protein
neutrophilic	O
alveolitis	O
.	O

We	O
treated	O
rats	O
with	I-protein
a	I-protein
single	O
i.p.	O
injection	O
of	I-protein
CI-1	O
(	O
10	I-protein
mg/kg	O
)	O
two	O
hours	O
prior	O
to	I-protein
i.p.	O
LPS	B-protein
(	O
7	I-protein
mg/kg	O
)	O
.	O

Treatment	O
with	I-protein
Cl-1	O
prevented	O
degradation	I-protein
of	I-protein
IkappaB-alpha	B-protein
and	I-protein
activation	I-protein
of	I-protein
NF-kappaB	B-protein
in	I-protein
the	I-protein
liver	O
in	I-protein
response	I-protein
to	I-protein
LPS	B-protein
;	O
however	O
,	O
Cl-1	O
treatment	O
had	O
no	I-protein
detected	O
effect	O
on	I-protein
NF-kappaB	B-protein
activation	I-protein
in	I-protein
lung	O
tissue	O
.	O

CI-1	O
treatment	O
prior	O
to	I-protein
LPS	B-protein
resulted	O
in	I-protein
40	I-protein
%	O
lower	I-protein
MIP-2	O
concentration	I-protein
in	I-protein
lung	O
lavage	O
fluid	I-protein
compared	O
to	I-protein
rats	O
treated	O
with	I-protein
vehicle	O
prior	O
to	I-protein
LPS	B-protein
(	O
502	I-protein
+/-	O
112	I-protein
pg/ml	O
vs.	O
859	O
+/-144	O
pg/ml	O
,	O
P	O
<	O
0.05	O
)	O
.	O

In	O
addition	O
,	O
CI-1	O
treatment	O
substantially	O
inhibited	O
LPS-induced	O
neutrophilic	O
alveolitis	O
(	O
2.7+	O
/-	O
1.2	I-protein
x	I-protein
10	I-protein
(	O
5	O
)	O
vs.	O
43.7	O
+/-	O
12.2	O
x	I-protein
10	I-protein
(	O
5	O
)	O
lung	O
lavage	O
neutrophils	O
,	O
P	O
<	O
0.01	O
)	O
.	O

These	O
data	O
indicate	O
that	O
NF-kappaB	B-protein
inhibition	O
in	I-protein
the	I-protein
liver	O
can	O
alter	O
lung	O
inflammation	O
induced	I-protein
by	I-protein
systemic	B-protein
LPS	B-protein
treatment	O
and	I-protein
suggest	O
that	O
a	I-protein
liver-lung	O
interaction	I-protein
contributes	O
to	I-protein
the	I-protein
inflammatory	O
response	I-protein
of	I-protein
the	I-protein
lung	O
.	O

###MEDLINE:21186394

Notch1	B-protein
regulates	O
maturation	I-protein
of	I-protein
CD4+	O
and	I-protein
CD8+	O
thymocytes	O
by	I-protein
modulating	I-protein
TCR	O
signal	O
strength	O
.	O

Notch	B-protein
signaling	O
regulates	O
cell	O
fate	O
decisions	O
in	I-protein
multiple	O
lineages	O
.	O

We	O
demonstrate	O
in	I-protein
this	O
report	O
that	O
retroviral	O
expression	I-protein
of	I-protein
activated	O
Notch1	B-protein
in	I-protein
mouse	I-protein
thymocytes	O
abrogates	O
differentiation	I-protein
of	I-protein
immature	B-protein
CD4+CD8+	O
thymocytes	O
into	O
both	O
CD4	B-protein
and	I-protein
CD8	O
mature	B-protein
single-positive	O
T	O
cells	I-protein
.	O

The	O
ability	O
of	I-protein
Notch1	B-protein
to	I-protein
inhibit	O
T	O
cell	O
development	O
was	O
observed	O
in	I-protein
vitro	O
and	I-protein
in	I-protein
vivo	O
with	I-protein
both	O
normal	O
and	I-protein
TCR	O
transgenic	O
thymocytes	O
.	O

Notch1	B-protein
-mediated	O
developmental	O
arrest	I-protein
was	O
dose	O
dependent	I-protein
and	I-protein
was	O
associated	I-protein
with	I-protein
impaired	O
thymocyte	B-protein
responses	O
to	I-protein
TCR	O
stimulation	I-protein
.	O

Notch1	B-protein
also	O
inhibited	O
TCR-mediated	O
signaling	O
in	I-protein
Jurkat	O
T	O
cells	I-protein
.	O

These	O
data	O
indicate	O
that	O
constitutively	O
active	O
Notch1	B-protein
abrogates	O
CD4+	O
and	I-protein
CD8+	O
maturation	I-protein
by	I-protein
interfering	I-protein
with	I-protein
TCR	O
signal	O
strength	O
and	I-protein
provide	O
an	I-protein
explanation	O
for	I-protein
the	I-protein
physiological	O
regulation	I-protein
of	I-protein
Notch	B-protein
expression	I-protein
during	I-protein
thymocyte	B-protein
development	O
.	O

###MEDLINE:21184078

Expression	O
of	I-protein
SART3	B-protein
antigen	I-protein
and	I-protein
induction	I-protein
of	I-protein
CTLs	O
by	I-protein
SART3-derived	O
peptides	O
in	I-protein
breast	O
cancer	O
patients	O
.	O

We	O
recently	O
reported	O
the	I-protein
SART3	B-protein
tumour-rejection	I-protein
antigen	I-protein
as	O
possessing	O
tumour	I-protein
epitopes	O
capable	O
of	I-protein
inducing	I-protein
HLA-class	O
I-restricted	O
cytotoxic	O
T	O
lymphocytes	O
(	O
CTLs	O
)	O
.	O

This	O
study	O
investigated	O
expression	I-protein
of	I-protein
the	I-protein
SART3	B-protein
antigen	I-protein
in	I-protein
breast	O
cancer	O
to	I-protein
explore	O
an	I-protein
appropriate	O
molecule	I-protein
for	I-protein
use	O
in	I-protein
specific	I-protein
immunotherapy	O
of	I-protein
breast	O
cancer	O
patients	O
.	O

The	O
SART3	B-protein
antigen	I-protein
was	O
detected	O
in	I-protein
all	O
of	I-protein
the	I-protein
breast	O
cancer	O
cell	O
lines	B-protein
tested	O
,	O
30	I-protein
of	I-protein
40	I-protein
(	O
75	I-protein
%	O
)	O
breast	O
cancer	O
tissue	O
samples	O
,	O
and	I-protein
0	I-protein
of	I-protein
3	O
non-tumourous	O
breast	O
tissue	O
samples	O
.	O

SART3	B-protein
derived	I-protein
peptides	O
at	I-protein
positions	O
109-118	O
and	I-protein
315-323	O
induced	I-protein
HLA-A24	O
restricted	I-protein
CTLs	O
that	O
reacted	O
to	I-protein
breast	O
cancer	O
cells	I-protein
from	I-protein
the	I-protein
peripheral	O
blood	O
mononuclear	O
cells	I-protein
(	O
PBMCs	O
)	O
of	I-protein
breast	O
cancer	O
patients	O
.	O

Therefore	O
,	O
the	I-protein
SART3	B-protein
antigen	I-protein
and	I-protein
its	O
peptides	O
could	O
be	O
an	I-protein
appropriate	O
molecule	I-protein
for	I-protein
use	O
in	I-protein
specific	I-protein
immunotherapy	O
of	I-protein
the	I-protein
majority	O
of	I-protein
HLA-A24-positive	O
breast	O
cancer	O
patients	O

###MEDLINE:21232503

Autostimulation	O
of	I-protein
the	I-protein
Epstein-Barr	B-protein
virus	I-protein
BRLF1	O
promoter	I-protein
is	O
mediated	I-protein
through	I-protein
consensus	O
Sp1	O
and	I-protein
Sp3	B-protein
binding	I-protein
sites	I-protein
.	O

As	O
an	I-protein
essential	O
step	O
in	I-protein
the	I-protein
lytic	O
cascade	O
,	O
the	I-protein
Rta	O
homologues	O
of	I-protein
gammaherpesviruses	O
all	O
activate	O
their	O
own	O
expression	I-protein
.	O

Consistent	O
with	I-protein
this	O
biologic	O
function	I-protein
,	O
the	I-protein
Epstein-Barr	B-protein
virus	I-protein
(	O
EBV	O
)	O
Rta	B-protein
protein	I-protein
powerfully	O
stimulates	O
the	I-protein
promoter	I-protein
of	I-protein
its	O
own	O
gene	O
,	O
Rp	O
,	O
in	I-protein
EBV-positive	O
B	O
cells	I-protein
in	I-protein
transient-transfection	O
reporter-based	O
assays	O
.	O

We	O
analyzed	O
the	I-protein
activity	I-protein
of	I-protein
RpCAT	O
in	I-protein
response	I-protein
to	I-protein
Rta	B-protein
by	I-protein
deletional	O
and	I-protein
site-directed	O
mutagenesis	O
.	O

Two	O
cognate	I-protein
Sp1	O
binding	I-protein
sites	I-protein
located	O
at	I-protein
-279	O
and	I-protein
-45	O
relative	I-protein
to	I-protein
the	I-protein
transcriptional	O
start	O
site	I-protein
proved	O
crucial	O
for	I-protein
Rta-mediated	O
activation	I-protein
.	O

Previously	O
described	O
binding	I-protein
sites	I-protein
for	I-protein
the	I-protein
cellular	B-protein
transcription	I-protein
factor	I-protein
Zif268	I-protein
and	I-protein
the	I-protein
viral	B-protein
transactivator	I-protein
ZEBRA	I-protein
were	O
found	O
to	I-protein
be	O
dispensable	O
for	I-protein
activation	I-protein
of	I-protein
RpCAT	O
by	I-protein
Rta	B-protein
.	O

Gel	O
shift	O
analysis	O
,	O
using	O
extracts	O
of	I-protein
B	O
cells	I-protein
in	I-protein
latency	O
or	I-protein
induced	I-protein
into	O
the	I-protein
lytic	O
cycle	I-protein
,	O
identified	I-protein
Sp1	B-protein
and	I-protein
Sp3	B-protein
as	O
the	I-protein
predominant	O
cellular	B-protein
proteins	I-protein
bound	I-protein
to	I-protein
Rp	O
near	O
-45	O
.	O

During	O
the	I-protein
lytic	O
cycle	I-protein
,	O
ZEBRA	B-protein
bound	I-protein
Rp	O
near	O
the	I-protein
Sp1/Sp3	O
site	I-protein
.	O

The	O
binding	I-protein
of	I-protein
Sp1	B-protein
and	I-protein
Sp3	B-protein
to	I-protein
Rp	O
correlated	O
with	I-protein
the	I-protein
reporter	O
activities	O
in	I-protein
the	I-protein
mutagenesis	O
study	O
,	O
establishing	O
a	I-protein
direct	O
link	I-protein
between	O
transcriptional	O
activation	I-protein
of	I-protein
Rp	O
by	I-protein
Rta	B-protein
and	I-protein
DNA	O
binding	I-protein
by	I-protein
Sp1	B-protein
and/or	O
Sp3	B-protein
.	O

The	O
relative	I-protein
abundance	O
or	I-protein
functional	O
state	I-protein
of	I-protein
the	I-protein
cellular	O
Sp1	B-protein
and	I-protein
Sp3	B-protein
transcription	I-protein
factors	I-protein
may	O
be	O
altered	I-protein
in	I-protein
response	I-protein
to	I-protein
stimuli	O
that	O
induce	O
the	I-protein
BRLF1	O
promoter	I-protein
and	I-protein
thereby	O
contribute	O
to	I-protein
the	I-protein
activation	I-protein
of	I-protein
the	I-protein
viral	O
lytic	O
cycle	I-protein
.	O

###MEDLINE:21221189

Gene	I-protein
transfer	O
of	I-protein
antisense	O
hypoxia	B-protein
inducible	I-protein
factor-1	I-protein
alpha	I-protein
enhances	O
the	I-protein
therapeutic	O
efficacy	O
of	I-protein
cancer	O
immunotherapy	O
.	O

Solid	O
tumors	I-protein
meet	O
their	O
demands	O
for	I-protein
nascent	O
blood	O
vessels	O
and	I-protein
increased	I-protein
glycolysis	O
,	O
to	I-protein
combat	O
hypoxia	B-protein
,	O
by	I-protein
activating	O
multiple	O
genes	I-protein
involved	I-protein
in	I-protein
angiogenesis	I-protein
and	I-protein
glucose	O
metabolism	I-protein
.	O

Hypoxia	B-protein
inducible	I-protein
factor-1	I-protein
(	O
HIF-1	B-protein
)	O
is	O
a	I-protein
constitutively	O
expressed	O
basic	B-protein
helix-loop-helix	I-protein
transcription	I-protein
factor	I-protein
,	O
formed	O
by	I-protein
the	I-protein
assembly	I-protein
of	I-protein
HIF-1alpha	B-protein
and	I-protein
HIF-1beta	B-protein
(	O
Arnt	O
)	O
,	O
that	O
is	O
stablized	O
in	I-protein
response	I-protein
to	I-protein
hypoxia	B-protein
,	O
and	I-protein
rapidly	I-protein
degraded	O
under	O
normoxic	O
conditions	O
.	O

It	O
activates	O
the	I-protein
transcription	O
of	I-protein
genes	I-protein
important	O
for	I-protein
maintaining	O
oxygen	O
homeostasis	I-protein
.	O

Here	O
,	O
we	O
demonstrate	O
that	O
engineered	O
down-regulation	O
of	I-protein
HIF-1alpha	B-protein
by	I-protein
intratumoral	O
gene	O
transfer	O
of	I-protein
an	I-protein
antisense	O
HIF-1alpha	B-protein
plasmid	O
leads	O
to	I-protein
the	I-protein
down-regulation	O
of	I-protein
VEGF	B-protein
,	O
and	I-protein
decreased	O
tumor	O
microvessel	O
density	I-protein
.	O

Antisense	O
HIF-1alpha	B-protein
monotherapy	O
resulted	O
in	I-protein
the	I-protein
complete	O
and	I-protein
permanent	O
rejection	O
of	I-protein
small	O
(	O
0.1	O
cm	O
in	I-protein
diameter	O
)	O
EL-4	O
tumors	I-protein
,	O
which	O
is	O
unusual	I-protein
for	I-protein
an	I-protein
anti-angiogenic	O
agent	O
where	O
transient	O
suppression	O
of	I-protein
tumor	O
growth	O
is	O
the	I-protein
norm	O
.	O

It	O
induced	I-protein
NK	I-protein
cell	O
-dependent	I-protein
rejection	O
of	I-protein
tumors	I-protein
,	O
but	O
failed	O
to	I-protein
stimulate	O
systemic	B-protein
T	O
cell	O
-mediated	O
anti-tumor	O
immunity	O
,	O
and	I-protein
synergized	O
with	I-protein
B7-1-mediated	O
immunotherapy	O
to	I-protein
cause	O
the	I-protein
NK	I-protein
cell	O
and	I-protein
CD8	O
T	O
cell	O
-dependent	I-protein
rejection	O
of	I-protein
larger	O
EL-4	O
tumors	I-protein
(	O
0.4	O
cm	O
in	I-protein
diameter	O
)	O
that	O
were	O
refractory	O
to	I-protein
monotherapies	O
.	O

Mice	O
cured	O
of	I-protein
their	O
tumors	I-protein
by	I-protein
combination	O
therapy	O
resisted	O
a	I-protein
rechallenge	O
with	I-protein
parental	O
tumor	O
cells	I-protein
,	O
indicating	O
systemic	B-protein
antitumor	O
immunity	O
had	O
been	O
achieved	O
.	O

In	O
summary	O
,	O
whilst	O
intensive	O
investigations	O
are	O
in	I-protein
progress	O
to	I-protein
target	O
the	I-protein
many	O
HIF-1	B-protein
effectors	O
,	O
the	I-protein
results	O
herein	O
indicate	O
that	O
blocking	O
hypoxia-inducible	B-protein
pathways	O
and	I-protein
enhancing	I-protein
NK-mediated	O
antitumor	O
immunity	O
by	I-protein
targeting	I-protein
HIF-1	B-protein
itself	O
may	O
be	O
advantageous	O
,	O
especially	O
when	O
combined	O
with	I-protein
cancer	O
immunotherapy	O
.	O

###MEDLINE:21214420

Runx2	O
:	O
a	I-protein
novel	O
oncogenic	O
effector	O
revealed	O
by	I-protein
in	I-protein
vivo	O
complementation	I-protein
and	I-protein
retroviral	O
tagging	O
.	O

The	O
Runx2	O
(	O
Cbfa1	O
,	O
Pebp2alphaA	O
,	O
Aml3	O
)	O
gene	O
was	O
previously	O
identified	I-protein
as	O
a	I-protein
frequent	O
target	O
for	I-protein
transcriptional	O
activation	I-protein
by	I-protein
proviral	I-protein
insertion	I-protein
in	I-protein
T-cell	O
lymphomas	I-protein
of	I-protein
CD2-MYC	O
transgenic	O
mice	O
.	O

We	O
have	O
recently	O
shown	O
that	O
over-expression	O
of	I-protein
the	I-protein
full-length	O
,	O
most	O
highly	O
expressed	O
Runx2	O
isoform	I-protein
in	I-protein
the	I-protein
thymus	I-protein
perturbs	O
T-cell	O
development	O
,	O
leads	O
to	I-protein
development	O
of	I-protein
spontaneous	O
lymphomas	I-protein
at	I-protein
low	O
frequency	O
and	I-protein
is	O
strongly	O
synergistic	O
with	I-protein
Myc	I-protein
.	O

To	O
gain	O
further	O
insight	O
into	O
the	I-protein
relationship	O
of	I-protein
Runx2	O
to	I-protein
other	O
lymphomagenic	O
pathways	O
,	O
we	O
tested	O
the	I-protein
effect	O
of	I-protein
combining	O
the	I-protein
CD2-Runx2	O
transgene	O
either	O
with	I-protein
a	I-protein
Pim1	O
transgene	O
(	O
E	O
(	O
mu	I-protein
)	O
-Pim1	O
)	O
or	I-protein
with	I-protein
the	I-protein
p53	B-protein
null	O
genotype	O
,	O
as	O
each	O
of	I-protein
these	O
displays	O
independent	I-protein
synergy	O
with	I-protein
Myc	I-protein
.	O

In	O
both	O
cases	O
we	O
observed	O
synergistic	O
tumour	I-protein
development	O
.	O

However	O
,	O
Runx2	O
appeared	O
to	I-protein
have	O
a	I-protein
dominant	I-protein
effect	O
on	I-protein
the	I-protein
tumour	I-protein
phenotype	O
in	I-protein
each	O
case	O
,	O
with	I-protein
most	O
tumours	O
conforming	O
to	I-protein
the	I-protein
CD3	B-protein
(	O
+	O
)	O
,	O
CD8	O
(	O
+	O
)	O
,	O
CD4	B-protein
(	O
+/-	O
)	O
phenotype	O
seen	O
in	I-protein
CD2-Runx2	O
mice	O
.	O

Neonatal	O
infection	I-protein
of	I-protein
CD2-Runx2	O
mice	O
with	I-protein
Moloney	O
murine	O
leukaemia	O
virus	I-protein
(	O
Moloney	O
MLV	O
)	O
also	O
led	O
to	I-protein
a	I-protein
dramatic	O
acceleration	O
of	I-protein
tumour	I-protein
onset	I-protein
.	O

Analysis	O
of	I-protein
known	O
Moloney	O
MLV	O
target	O
genes	I-protein
in	I-protein
these	O
lymphomas	I-protein
showed	O
a	I-protein
high	O
frequency	O
of	I-protein
rearrangement	O
at	I-protein
c-Myc	B-protein
or	I-protein
N-Myc	O
(	O
82	I-protein
%	O
)	O
,	O
and	I-protein
a	I-protein
significant	O
number	I-protein
at	I-protein
Pim1	O
or	I-protein
Pim2	O
(	O
23	I-protein
%	O
)	O
,	O
and	I-protein
at	I-protein
Pal1/Gfi1	O
(	O
18	I-protein
%	O
)	O
.	O

These	O
results	O
indicate	O
that	O
Runx2	B-protein
makes	O
a	I-protein
distinct	O
contribution	O
to	I-protein
T-cell	O
lymphoma	I-protein
development	O
which	O
does	O
not	I-protein
coincide	O
with	I-protein
any	O
of	I-protein
the	I-protein
oncogene	I-protein
complementation	I-protein
groups	O
previously	O
identified	I-protein
by	I-protein
retroviral	O
tagging	O
.	O

###MEDLINE:21214119

The	O
involvement	I-protein
of	I-protein
TNF-alpha	B-protein
-related	I-protein
apoptosis-inducing	O
ligand	O
in	I-protein
the	I-protein
enhanced	I-protein
cytotoxicity	I-protein
of	I-protein
IFN-beta	B-protein
-stimulated	O
human	O
dendritic	B-protein
cells	I-protein
to	I-protein
tumor	O
cells	I-protein
.	O

TNF-alpha	B-protein
-related	I-protein
apoptosis-inducing	O
ligand	O
(	O
TRAIL	B-protein
)	O
is	O
characterized	O
by	I-protein
its	O
preferential	O
induction	I-protein
of	I-protein
apoptosis	O
of	I-protein
tumor	O
cells	I-protein
but	O
not	I-protein
normal	O
cells	I-protein
.	O

Dendritic	O
cells	I-protein
(	O
DCs	O
)	O
,	O
besides	O
their	O
role	O
as	O
APCs	O
,	O
now	O
have	O
been	O
demonstrated	O
to	I-protein
exert	O
cytotoxicity	I-protein
or	I-protein
cytostasis	O
on	I-protein
some	O
tumor	O
cells	I-protein
.	O

Here	O
,	O
we	O
report	O
that	O
both	O
human	O
CD34	B-protein
(	O
+	O
)	O
stem	I-protein
cell	O
-derived	O
DCs	O
(	O
CD34DCs	O
)	O
and	I-protein
human	O
CD14	B-protein
(	O
+	O
)	O
monocyte	B-protein
-derived	O
DCs	O
(	O
MoDCs	O
)	O
express	O
TRAIL	B-protein
and	I-protein
exhibit	O
cytotoxicity	I-protein
to	I-protein
some	O
types	I-protein
of	I-protein
tumor	O
cells	I-protein
partially	O
through	I-protein
TRAIL	B-protein
.	O

Moderate	O
expression	I-protein
of	I-protein
TRAIL	B-protein
appeared	O
on	I-protein
CD34DCs	O
from	I-protein
the	I-protein
8th	O
day	O
of	I-protein
culture	O
and	I-protein
was	O
also	O
seen	O
on	I-protein
freshly	O
isolated	I-protein
monocytes	O
.	O

The	O
level	I-protein
of	I-protein
TRAIL	B-protein
expression	I-protein
remained	O
constant	I-protein
until	O
DC	O
maturation	I-protein
.	O

TRAIL	B-protein
expression	I-protein
on	I-protein
immature	B-protein
CD34DCs	O
or	I-protein
MoDCs	O
was	O
greatly	O
up-regulated	O
after	O
IFN-beta	O
stimulation	I-protein
.	O

Moreover	O
,	O
IFN-beta	B-protein
could	O
strikingly	O
enhance	O
the	I-protein
ability	O
of	I-protein
CD34DCs	O
or	I-protein
MoDCs	O
to	I-protein
kill	O
TRAIL-sensitive	O
tumor	O
cells	I-protein
,	O
but	O
LPS	B-protein
did	O
not	I-protein
have	O
such	O
an	I-protein
effect	O
.	O

The	O
up-regulation	O
of	I-protein
TRAIL	B-protein
on	I-protein
IFN-beta	B-protein
-stimulated	O
DCs	O
partially	O
contributed	O
to	I-protein
the	I-protein
increased	I-protein
cytotoxicity	I-protein
of	I-protein
DCS	O
:	O
Pretreatment	O
of	I-protein
TRAIL-sensitive	O
tumor	O
cells	I-protein
with	I-protein
caspase-3	O
inhibitor	O
could	O
significantly	O
increase	O
their	O
resistance	O
to	I-protein
the	I-protein
cytotoxicity	I-protein
of	I-protein
IFN-beta	B-protein
-stimulated	O
DCS	O
:	O
In	O
contrast	O
,	O
NF-kappaB	B-protein
inhibitor	O
could	O
significantly	O
increase	O
the	I-protein
sensitivity	I-protein
of	I-protein
tumor	O
cells	I-protein
to	I-protein
the	I-protein
killing	O
by	I-protein
nonstimulated	O
or	I-protein
LPS-stimulated	O
DCS	O
:	O
Our	O
studies	O
demonstrate	O
that	O
IFN-beta	B-protein
-stimulated	O
DCs	O
are	O
functionally	O
cytotoxic	O
.	O

Thus	O
,	O
an	I-protein
innate	O
mechanism	O
of	I-protein
DC-mediated	O
antitumor	O
immunity	O
might	O
exist	O
in	I-protein
vivo	O
in	I-protein
which	O
DCs	O
act	O
as	O
effectors	O
to	I-protein
directly	O
kill	O
tumor	O
cells	I-protein
partially	O
via	I-protein
TRAIL	B-protein
.	O

Subsequently	O
,	O
DCs	O
act	O
as	O
APCs	O
involved	I-protein
in	I-protein
the	I-protein
uptake	I-protein
,	O
processing	O
,	O
and	I-protein
presentation	O
of	I-protein
apoptotic	B-protein
tumor	I-protein
Ags	I-protein
to	I-protein
cross-prime	O
CD8	O
(	O
+	O
)	O
CTL	O
cells	I-protein
.	O

###MEDLINE:21205813

Tumor	O
cells	I-protein
regulate	O
the	I-protein
lytic	O
activity	I-protein
of	I-protein
tumor-specific	O
cytotoxic	O
t	I-protein
lymphocytes	O
by	I-protein
modulating	I-protein
the	I-protein
inhibitory	O
natural	O
killer	O
receptor	O
function	I-protein
.	O

Tumor-infiltrating	O
p58+	O
T	O
cells	I-protein
from	I-protein
a	I-protein
renal	O
tumor	O
were	O
specifically	O
expanded	B-protein
in	I-protein
response	I-protein
to	I-protein
tumor	O
cell	O
stimulation	I-protein
and	I-protein
cloned	O
.	O

These	O
p58+	O
T	O
cells	I-protein
were	O
found	O
to	I-protein
express	O
a	I-protein
memory	O
phenotype	O
and	I-protein
corresponded	O
to	I-protein
clonal	O
TCRBV3	O
T-cell	O
expansion	O
.	O

Functionally	O
,	O
p58	O
(	O
+	O
)	O
CTLs	O
displayed	O
a	I-protein
low	O
lytic	O
activity	I-protein
for	I-protein
HLA-A2	O
tumor	O
and	I-protein
normal	O
cells	I-protein
.	O

However	O
,	O
this	O
lytic	O
activity	I-protein
was	O
significantly	O
increased	I-protein
after	O
blockade	O
of	I-protein
p58	B-protein
with	I-protein
specific	I-protein
monoclonal	I-protein
antibodies	I-protein
.	O

Interestingly	O
,	O
we	O
demonstrated	O
that	O
stimulation	I-protein
by	I-protein
tumor	O
cells	I-protein
was	O
required	O
to	I-protein
trigger	O
the	I-protein
inhibitory	O
effect	O
of	I-protein
p58	B-protein
on	I-protein
the	I-protein
lytic	O
activity	I-protein
of	I-protein
antigen-specific	O
CTLs	O
and	I-protein
that	O
stimulation	I-protein
of	I-protein
the	I-protein
inhibitory	O
function	I-protein
of	I-protein
p58	B-protein
by	I-protein
tumor	O
cells	I-protein
correlated	O
with	I-protein
an	I-protein
inhibition	O
of	I-protein
nuclear	B-protein
factor-kappaB	I-protein
activation	I-protein
in	I-protein
p58+	O
tumor-specific	O
CTLS	O
.	O

###MEDLINE:21198003

T-cell	B-protein
factor-1	I-protein
expression	I-protein
during	I-protein
human	O
natural	O
killer	O
cell	O
development	O
and	I-protein
in	I-protein
circulating	O
CD56	B-protein
(	O
+	O
)	O
bright	O
natural	O
killer	O
cells	I-protein
.	O

Transcription	I-protein
factors	I-protein
are	O
essential	O
to	I-protein
govern	O
differentiation	I-protein
along	O
the	I-protein
lymphoid	O
lineage	I-protein
from	I-protein
uncommitted	O
hematopoietic	O
stem	I-protein
cells	I-protein
.	O

Although	O
many	O
of	I-protein
these	O
transcription	B-protein
factors	I-protein
have	O
putative	O
roles	O
based	O
on	I-protein
murine	O
knockout	O
experiments	O
,	O
their	O
function	I-protein
in	I-protein
human	O
lymphoid	O
development	O
is	O
less	O
known	O
and	I-protein
was	O
studied	O
further	O
.	O

Transcription	I-protein
factor	I-protein
expression	I-protein
in	I-protein
fresh	O
and	I-protein
cultured	O
adult	O
human	O
bone	O
marrow	I-protein
and	I-protein
umbilical	O
cord	O
blood	O
progenitors	O
was	O
evaluated	O
.	O

We	O
found	O
that	O
fresh	O
CD34	B-protein
(	O
+	O
)	O
Lin	O
(	O
-	O
)	O
cells	I-protein
that	O
are	O
human	O
leukocyte	O
antigen	O
(	O
HLA	O
)	O
-DR	O
(	O
-	O
)	O
or	I-protein
CD38	B-protein
(	O
-	O
)	O
constitutively	O
express	O
GATA-3	B-protein
but	O
not	I-protein
T-cell	B-protein
factor-1	I-protein
(	O
TCF-1	B-protein
)	O
or	I-protein
Id-3	B-protein
.	O

Culture	O
with	I-protein
the	I-protein
murine	O
fetal	O
liver	O
cell	O
line	I-protein
AFT024	O
and	I-protein
defined	I-protein
cytokines	B-protein
was	O
capable	O
of	I-protein
inducing	I-protein
TCF-1	B-protein
mRNA	O
.	O

However	O
,	O
no	I-protein
T-cell	O
receptor	O
gene	O
rearrangement	O
was	O
identified	I-protein
in	I-protein
cultured	O
progeny	O
.	O

Id-3	B-protein
,	O
a	I-protein
basic	B-protein
helix	I-protein
loop	I-protein
helix	I-protein
factor	I-protein
with	I-protein
dominant	I-protein
negative	O
function	I-protein
for	I-protein
T-cell	O
differentiation	I-protein
transcription	B-protein
factors	I-protein
,	O
also	O
was	O
upregulated	O
and	I-protein
may	O
explain	O
unsuccessful	O
T-cell	O
maturation	I-protein
.	O

To	O
better	O
understand	O
the	I-protein
developmental	O
link	I-protein
between	O
natural	O
killer	O
(	O
NK	I-protein
)	O
cells	I-protein
derived	I-protein
from	I-protein
progenitors	O
,	O
we	O
studied	O
NK	I-protein
cell	O
subsets	O
circulating	O
in	I-protein
blood	O
.	O

CD56	B-protein
(	O
+bright	O
)	O
,	O
but	O
not	I-protein
CD56	B-protein
(	O
+dim	O
)	O
,	O
NK	I-protein
cells	I-protein
constitutively	O
express	O
TCF-1	B-protein
by	I-protein
reverse	I-protein
transcriptase	I-protein
polymerase	O
chain	I-protein
reaction	I-protein
and	I-protein
Western	O
blot	O
analysis	O
.	O

The	O
TCF-1	B-protein
isoform	I-protein
found	O
in	I-protein
CD56	B-protein
(	O
+bright	O
)	O
cells	I-protein
,	O
which	O
express	O
lectin	B-protein
but	O
not	I-protein
immunoglobulin	B-protein
class	I-protein
I	I-protein
recognizing	I-protein
inhibitory	I-protein
receptors	I-protein
,	O
was	O
identical	O
to	I-protein
that	O
induced	I-protein
in	I-protein
NK	I-protein
cell	O
differentiation	I-protein
culture	O
and	I-protein
was	O
distinctly	O
different	O
from	I-protein
isoforms	I-protein
in	I-protein
T	O
cells	I-protein
.	O

These	O
results	O
suggest	O
that	O
TCF-1	B-protein
does	O
not	I-protein
target	O
human	O
killer	O
immunoglobulin	O
receptor	O
genes	I-protein
,	O
TCF-1	B-protein
is	O
uniquely	O
expressed	O
in	I-protein
circulating	O
CD56	B-protein
(	O
+bright	O
)	O
NK	I-protein
cells	I-protein
,	O
and	I-protein
specific	I-protein
TCF-1	B-protein
isoforms	I-protein
may	O
play	O
an	I-protein
important	O
role	O
in	I-protein
regulating	O
NK	I-protein
differentiation	I-protein
from	I-protein
a	I-protein
common	I-protein
NK/T-cell	O
progenitor	O
.	O

###MEDLINE:21293104

Transcriptional	I-protein
activation	I-protein
by	I-protein
a	I-protein
matrix	B-protein
associating	I-protein
region-binding	I-protein
protein	I-protein
.	O

contextual	O
requirements	O
for	I-protein
the	I-protein
function	I-protein
of	I-protein
bright	B-protein
.	O

Bright	B-protein
(	O
B	B-protein
cell	I-protein
regulator	I-protein
of	I-protein
IgH	I-protein
transcription	I-protein
)	O
is	O
a	I-protein
B	O
cell	O
-specific	I-protein
,	O
matrix	B-protein
associating	I-protein
region-binding	I-protein
protein	I-protein
that	O
transactivates	O
gene	O
expression	I-protein
from	I-protein
the	I-protein
IgH	O
intronic	I-protein
enhancer	O
(	O
E	O
mu	I-protein
)	O
.	O

We	O
show	O
here	O
that	O
Bright	B-protein
has	O
multiple	O
contextual	O
requirements	O
to	I-protein
function	I-protein
as	O
a	I-protein
transcriptional	B-protein
activator	I-protein
.	O

Bright	B-protein
can	O
not	I-protein
transactivate	O
via	I-protein
out	O
of	I-protein
context	O
,	O
concatenated	O
binding	I-protein
sites	I-protein
.	O

Transactivation	O
is	O
maximal	O
on	I-protein
integrated	O
substrates	O
.	O

Two	O
of	I-protein
the	I-protein
three	O
previously	O
identified	I-protein
binding	I-protein
sites	I-protein
in	I-protein
E	O
mu	I-protein
are	O
required	O
for	I-protein
full	O
Bright	B-protein
transactivation	O
.	O

The	O
Bright	B-protein
DNA	I-protein
binding	I-protein
domain	I-protein
defined	I-protein
a	I-protein
new	I-protein
family	O
,	O
which	O
includes	I-protein
SWI1	B-protein
,	O
a	I-protein
component	O
of	I-protein
the	I-protein
SWI.SNF	B-protein
complex	I-protein
shown	O
to	I-protein
have	O
high	O
mobility	I-protein
group-like	I-protein
DNA	O
binding	I-protein
characteristics	O
.	O

Similar	B-protein
to	I-protein
one	B-protein
group	I-protein
of	I-protein
high	B-protein
mobility	I-protein
group	I-protein
box	I-protein
proteins	I-protein
,	O
Bright	B-protein
distorts	O
E	O
mu	I-protein
binding	I-protein
site	I-protein
-containing	I-protein
DNA	O
on	I-protein
binding	I-protein
,	O
supporting	O
the	I-protein
concept	O
that	O
it	O
mediates	O
E	O
mu	I-protein
remodeling	B-protein
.	O

Transfection	O
studies	O
further	O
implicate	O
Bright	B-protein
in	I-protein
facilitating	O
spatially	O
separated	O
promoter-enhancer	O
interactions	O
in	I-protein
both	O
transient	O
and	I-protein
stable	I-protein
assays	O
.	O

Finally	O
,	O
we	O
show	O
that	O
overexpression	O
of	I-protein
Bright	B-protein
leads	O
to	I-protein
enhanced	I-protein
DNase	I-protein
I	I-protein
sensitivity	I-protein
of	I-protein
the	I-protein
endogenous	O
E	O
mu	I-protein
matrix	O
associating	I-protein
regions	O
.	O

These	O
data	O
further	O
suggest	O
that	O
Bright	B-protein
may	O
contribute	O
to	I-protein
increased	I-protein
gene	O
expression	I-protein
by	I-protein
remodeling	B-protein
the	I-protein
immunoglobulin	O
locus	O
during	I-protein
B	O
cell	O
development	O
.	O

###MEDLINE:21185814

Analysis	O
of	I-protein
BCL-6	O
mutations	I-protein
in	I-protein
classic	O
Hodgkin	B-protein
disease	I-protein
of	I-protein
the	I-protein
B-	O
and	I-protein
T-cell	O
type	O
.	O

BCL-6	B-protein
is	O
essential	O
for	I-protein
germinal	B-protein
center	I-protein
formation	O
and	I-protein
thus	O
for	I-protein
affinity	I-protein
maturation	I-protein
of	I-protein
immunoglobulin	O
(	O
Ig	I-protein
)	O
genes	I-protein
by	I-protein
somatic	I-protein
mutations	I-protein
.	O

The	O
5'-noncoding	O
region	O
of	I-protein
the	I-protein
BCL-6	O
gene	O
is	O
even	O
a	I-protein
target	O
for	I-protein
the	I-protein
mutation	I-protein
machinery	I-protein
.	O

Translocations	O
of	I-protein
the	I-protein
BCL-6	O
gene	O
to	I-protein
heterologous	O
promoters	O
and	I-protein
mutations	I-protein
of	I-protein
its	O
5'-noncoding	O
regulatory	O
region	O
were	O
reported	O
to	I-protein
be	O
potential	I-protein
mechanisms	O
for	I-protein
deregulating	O
BCL-6	O
expression	I-protein
and	I-protein
for	I-protein
playing	O
a	I-protein
role	O
in	I-protein
the	I-protein
genesis	O
of	I-protein
non-Hodgkin	O
lymphoma	I-protein
.	O

In	O
line	I-protein
with	I-protein
this	O
hypothesis	O
is	O
the	I-protein
observation	O
that	O
B-cell	O
lymphoma	I-protein
with	I-protein
somatic	I-protein
mutations	I-protein
,	O
such	O
as	O
diffuse	B-protein
large	O
B-cell	O
lymphoma	I-protein
and	I-protein
follicular	B-protein
lymphoma	I-protein
,	O
also	O
carry	O
BCL-6	O
mutations	I-protein
,	O
some	O
of	I-protein
which	O
are	O
recurrently	O
detectable	O
.	O

Classic	O
Hodgkin	B-protein
disease	I-protein
(	O
cHD	O
)	O
is	O
also	O
derived	I-protein
from	I-protein
B	O
cells	I-protein
with	I-protein
high	O
loads	O
of	I-protein
somatic	I-protein
mutations	I-protein
and	I-protein
thus	O
a	I-protein
further	O
candidate	O
for	I-protein
BCL-6	O
mutations	I-protein
.	O

To	O
determine	O
the	I-protein
presence	O
and	I-protein
potential	I-protein
role	O
of	I-protein
BCL-6	O
mutations	I-protein
in	I-protein
cHD	O
,	O
the	I-protein
5'-noncoding	O
BCL-6	O
proportion	O
of	I-protein
single	O
Hodgkin	B-protein
and	I-protein
Reed-Sternberg	O
(	O
HRS	B-protein
)	O
cells	I-protein
from	I-protein
6	I-protein
cases	O
of	I-protein
cHD	O
and	I-protein
6	I-protein
cases	O
of	I-protein
HD-derived	O
cell	O
lines	B-protein
was	O
analyzed	O
.	O

All	O
B-cell-derived	O
HD	O
cases	O
and	I-protein
cell	O
lines	B-protein
harbored	O
BCL-6	O
mutations	I-protein
.	O

In	O
contrast	O
,	O
both	O
T-cell-derived	O
HD	O
cases	O
and	I-protein
cell	O
lines	B-protein
were	O
devoid	O
of	I-protein
BCL-6	O
mutations	I-protein
.	O

With	O
only	I-protein
one	B-protein
exception	O
,	O
there	O
were	O
no	I-protein
lymphoma-specific	O
recurrent	O
BCL-6	O
mutations	I-protein
detected	O
,	O
and	I-protein
BCL-6	B-protein
protein	I-protein
was	O
absent	O
from	I-protein
the	I-protein
HRS	B-protein
cells	I-protein
of	I-protein
most	O
cases	O
.	O

In	O
conclusion	O
,	O
(	O
1	I-protein
)	O
somatic	I-protein
BCL-6	O
mutations	I-protein
are	O
restricted	I-protein
to	I-protein
cHD	O
cases	O
of	I-protein
B-cell	O
origin	O
,	O
and	I-protein
(	O
2	I-protein
)	O
the	I-protein
BCL-6	O
mutations	I-protein
represent	O
mostly	O
irrelevant	O
somatic	I-protein
base	I-protein
substitutions	O
without	I-protein
consequences	O
for	I-protein
BCL-6	B-protein
protein	I-protein
expression	I-protein
and	I-protein
the	I-protein
pathogenesis	O
of	I-protein
cHD	O
.	O

###MEDLINE:21184779

Gadd45gamma	O
is	O
dispensable	O
for	I-protein
normal	O
mouse	I-protein
development	O
and	I-protein
T-cell	O
proliferation	I-protein
.	O

Gadd45gamma	O
,	O
a	I-protein
family	O
member	I-protein
of	I-protein
the	I-protein
growth	O
arrest	I-protein
and	I-protein
DNA	O
damage-inducible	O
gene	O
family	O
45	I-protein
(	O
Gadd45	O
)	O
,	O
is	O
strongly	O
induced	I-protein
by	I-protein
interleukin-2	B-protein
(	O
IL-2	B-protein
)	O
in	I-protein
peripheral	O
T	O
cells	I-protein
.	O

While	O
in	I-protein
most	O
tissues	O
all	O
Gadd45	O
family	O
members	O
are	O
expressed	O
,	O
Gadd45gamma	O
is	O
the	I-protein
only	I-protein
member	I-protein
that	O
is	O
induced	I-protein
by	I-protein
IL-2	B-protein
.	O

Here	O
we	O
show	O
that	O
the	I-protein
IL-2	B-protein
-induced	O
expression	I-protein
of	I-protein
Gadd45gamma	O
is	O
dependent	I-protein
on	I-protein
a	I-protein
signaling	O
pathway	I-protein
mediated	I-protein
by	I-protein
the	I-protein
tyrosine	B-protein
kinase	I-protein
Jak3	I-protein
and	I-protein
the	I-protein
transcription	B-protein
factors	I-protein
Stat5a	B-protein
and	I-protein
Stat5b	B-protein
(	O
signal	B-protein
transducer	I-protein
and	I-protein
activator	I-protein
of	I-protein
transcription	I-protein
)	O
.	O

Previous	O
studies	O
with	I-protein
ectopically	O
overexpressed	O
Gadd45gamma	O
in	I-protein
various	O
cell	O
lines	B-protein
implicated	O
its	O
function	I-protein
in	I-protein
negative	O
growth	O
control	I-protein
.	O

To	O
analyze	O
the	I-protein
physiological	O
role	O
of	I-protein
Gadd45gamma	O
we	O
used	O
homologous	I-protein
recombination	O
to	I-protein
generate	O
mice	O
lacking	I-protein
Gadd45gamma	O
.	O

Gadd45gamma	O
-deficient	O
mice	O
develop	O
normally	O
,	O
are	O
indistinguishable	O
from	I-protein
their	O
littermates	O
,	O
and	I-protein
are	O
fertile	O
.	O

Furthermore	O
,	O
hematopoiesis	I-protein
in	I-protein
mice	O
lacking	I-protein
Gadd45gamma	O
is	O
not	I-protein
impaired	O
and	I-protein
Gadd45gamma	O
-deficient	O
T	O
lymphocytes	O
show	O
normal	O
responses	O
to	I-protein
IL-2	B-protein
.	O

These	O
data	O
demonstrate	O
that	O
Gadd45gamma	O
is	O
not	I-protein
essential	O
for	I-protein
normal	O
mouse	I-protein
development	O
and	I-protein
hematopoiesis	I-protein
,	O
possibly	O
due	I-protein
to	I-protein
functional	O
redundancy	O
among	O
the	I-protein
Gadd45	O
family	O
members	O
.	O

Gadd45gamma	O
is	O
also	O
dispensable	O
for	I-protein
IL-2	B-protein
-induced	O
T-cell	O
proliferation	I-protein
.	O

###MEDLINE:21179339

Decreased	O
expression	I-protein
of	I-protein
c-myc	B-protein
family	O
genes	I-protein
in	I-protein
thymuses	O
from	I-protein
myasthenia	B-protein
gravis	I-protein
patients	O
.	O

The	O
thymus	I-protein
is	O
a	I-protein
critical	I-protein
organ	O
for	I-protein
the	I-protein
elimination	O
of	I-protein
autoreactive	O
T	O
cells	I-protein
by	I-protein
apoptosis	O
.	O

We	O
studied	O
the	I-protein
expression	I-protein
of	I-protein
apoptosis-associated	O
genes	I-protein
,	O
bcl-xL	B-protein
,	O
bad	O
,	O
caspase-3	B-protein
,	O
and	I-protein
c-myc	B-protein
family	O
genes	I-protein
in	I-protein
myasthenia	B-protein
gravis	I-protein
(	O
MG	O
)	O
thymuses	O
.	O

We	O
observed	O
that	O
the	I-protein
mRNA	O
levels	I-protein
of	I-protein
myc	B-protein
family	O
genes	I-protein
,	O
c-myc	B-protein
and	I-protein
max	O
,	O
were	O
markedly	O
reduced	O
in	I-protein
MG	O
thymuses	O
.	O

These	O
results	O
indicate	O
that	O
c-myc	B-protein
-mediated	O
signaling	O
is	O
abnormal	I-protein
in	I-protein
MG	O
thymuses	O
.	O

The	O
levels	I-protein
of	I-protein
molecules	O
whose	O
expressions	O
are	O
associated	I-protein
with	I-protein
myc	B-protein
,	O
such	O
as	O
STAM	B-protein
,	O
prothymosin-alpha	O
,	O
and	I-protein
NFkappaB	B-protein

###MEDLINE:21174076

Immunohistochemical	O
detection	O
of	I-protein
interferon-gamma-producing	O
cells	I-protein
in	I-protein
dermatophytosis	O
.	O

Skin	O
lesions	O
of	I-protein
dermatophytosis	O
are	O
thought	O
to	I-protein
be	O
a	I-protein
result	O
of	I-protein
a	I-protein
T	O
cell	O
-dependent	I-protein
inflammatory	O
response	I-protein
that	O
is	O
mediated	I-protein
by	I-protein
various	O
cytokines	B-protein
.	O

We	O
examined	O
whether	O
IFN-gamma-positive	O
cells	I-protein
(	O
as	O
expression	I-protein
of	I-protein
Th1	O
response	I-protein
)	O
were	O
present	O
in	I-protein
the	I-protein
skin	O
lesions	O
of	I-protein
dermatophytosis	O
in	I-protein
situ	O
by	I-protein
immunohistochemical	O
techniques	O
.	O

Mixtures	O
of	I-protein
CD4-positive	O
T	O
cells	I-protein
and	I-protein
CD8-positive	O
T	O
cells	I-protein
were	O
found	O
to	I-protein
be	O
present	O
in	I-protein
the	I-protein
dermal	B-protein
infiltrates	O
of	I-protein
the	I-protein
lesions	O
.	O

Considerable	O
numbers	O
of	I-protein
CD1a-positive	O
cells	I-protein
were	O
detected	O
in	I-protein
the	I-protein
upper	O
dermis	O
and	I-protein
epidermis	O
.	O

A	O
marked	O
accumulation	I-protein
of	I-protein
CD68-positive	O
cells	I-protein
was	O
found	O
in	I-protein
the	I-protein
upper	O
dermis	O
.	O

IFN-gamma-positive	O
cells	I-protein
were	O
present	O
in	I-protein
the	I-protein
upper	O
dermis	O
of	I-protein
the	I-protein
lesions	O
.	O

The	O
pattern	I-protein
of	I-protein
IFN-gamma	B-protein
staining	O
appeared	O
to	I-protein
be	O
intracellular	I-protein
in	I-protein
mononuclear	O
lymphoid	O
cells	I-protein
.	O

The	O
staining	O
was	O
considered	O
to	I-protein
be	O
highly	O
specific	I-protein
because	O
it	O
could	O
be	O
completely	O
blocked	B-protein
by	I-protein
preabsorption	O
with	I-protein
recombinant	B-protein
IFN-gamma	I-protein
.	O

Our	O
data	O
support	I-protein
the	I-protein
hypothesis	O
that	O
the	I-protein
skin	O
lesions	O
of	I-protein
dermatophytosis	O
may	O
be	O
associated	I-protein
with	I-protein
a	I-protein
Th1	O
response	I-protein
.	O

Th1	O
response	I-protein
,	O
which	O
is	O
characterized	O
by	I-protein
IFN-gamma	B-protein
release	I-protein
,	O
is	O
thought	O
to	I-protein
be	O
involved	I-protein
in	I-protein
the	I-protein
host	O
defense	O
against	I-protein
dermatophytes	O
and	I-protein
to	I-protein
reflect	O
cutaneous	O
reaction	I-protein
in	I-protein
dermatophytosis	O
.	O

###MEDLINE:21170151

Regulation	O
of	I-protein
the	I-protein
helix-loop-helix	I-protein
proteins	I-protein
,	O
E2A	B-protein
and	I-protein
Id3	B-protein
,	O
by	I-protein
the	I-protein
Ras	B-protein
-	O
ERK	B-protein
MAPK	I-protein
cascade	O
.	O

Activation	O
of	I-protein
mitogen-activated	B-protein
protein	I-protein
kinase	I-protein
(	O
MAPK	I-protein
)	O
pathways	O
leads	O
to	I-protein
cellular	O
differentiation	I-protein
and/or	O
proliferation	I-protein
in	I-protein
a	I-protein
wide	O
variety	O
of	I-protein
cell	O
types	I-protein
,	O
including	I-protein
developing	B-protein
thymocytes	O
.	O

The	O
basic	B-protein
helix-loop-helix	I-protein
(	O
bHLH	I-protein
)	O
proteins	I-protein
E12	B-protein
and	I-protein
E47	B-protein
and	I-protein
an	I-protein
inhibitor	B-protein
HLH	I-protein
protein	I-protein
,	O
Id3	B-protein
,	O
play	O
key	O
roles	O
in	I-protein
thymocyte	B-protein
differentiation	I-protein
.	O

We	O
show	O
here	O
that	O
E2A	O
DNA	O
binding	I-protein
is	O
lowered	O
in	I-protein
primary	O
immature	B-protein
thymocytes	O
consequent	O
to	I-protein
T	B-protein
cell	I-protein
receptor	I-protein
(	O
TCR	B-protein
)	O
-mediated	O
ligation	O
.	O

Whereas	O
expression	I-protein
of	I-protein
E2A	O
mRNA	O
and	I-protein
protein	O
are	O
unaltered	O
,	O
Id3	O
transcripts	I-protein
are	O
rapidly	I-protein
induced	I-protein
upon	O
signaling	O
from	I-protein
the	I-protein
TCR	B-protein
.	O

Activation	O
of	I-protein
Id3	O
transcription	O
is	O
regulated	O
in	I-protein
a	I-protein
dose-dependent	O
manner	O
by	I-protein
the	I-protein
extracellular	B-protein
signal-regulated	I-protein
kinase	I-protein
(	O
ERK	B-protein
)	O
MAPK	I-protein
module	I-protein
.	O

These	O
observations	O
directly	O
connect	O
the	I-protein
ERK	B-protein
MAPK	I-protein
cascade	O
and	I-protein
HLH	B-protein
proteins	I-protein
in	I-protein
a	I-protein
linear	O
pathway	I-protein
.	O

###MEDLINE:21158232

Retinoic	I-protein
acid	O
up-regulates	O
myeloid	O
ICAM-3	O
expression	I-protein
and	I-protein
function	I-protein
in	I-protein
a	I-protein
cell-specific	I-protein
fashion	O
--	I-protein
evidence	O
for	I-protein
retinoid	B-protein
signaling	O
pathways	O
in	I-protein
the	I-protein
mast	O
cell	O
lineage	I-protein
.	O

Investigation	O
of	I-protein
mast	O
cell	O
responsiveness	O
toward	O
retinoic	O
acid	O
(	O
RA	B-protein
)	O
revealed	O
selective	O
promotion	O
of	I-protein
ICAM-3	B-protein
expression	I-protein
in	I-protein
the	I-protein
human	O
mast	O
cell	O
line	I-protein
HMC-1	O
.	O

This	O
process	O
was	O
dose-	O
and	I-protein
time-dependent	O
and	I-protein
detectable	O
by	I-protein
flow	O
cytometry	O
,	O
Western	O
blot	O
analysis	O
,	O
ELISA	O
,	O
and	I-protein
Northern	O
blot	O
analysis	O
.	O

ICAM-3	B-protein
modulation	O
was	O
found	O
to	I-protein
be	O
cell-type	O
dependent	I-protein
,	O
detectable	O
also	O
for	I-protein
HL-60	O
cells	I-protein
and	I-protein
monocytes	O
but	O
not	I-protein
U-937	O
and	I-protein
only	I-protein
weakly	B-protein
for	I-protein
KU812	O
cells	I-protein
.	O

Terminally	O
differentiated	O
skin	O
mast	O
cells	I-protein
also	O
failed	O
to	I-protein
up-modulate	O
their	O
ICAM-3	B-protein
,	O
suggesting	O
the	I-protein
requirement	O
for	I-protein
some	O
degree	O
of	I-protein
immaturity	O
for	I-protein
the	I-protein
process	O
.	O

RA-mediated	O
effects	O
on	I-protein
ICAM-1	B-protein
expression	I-protein
,	O
studied	O
in	I-protein
parallel	O
,	O
were	O
clearly	O
distinct	O
from	I-protein
those	O
on	I-protein
ICAM-3	B-protein
.	O

Investigation	O
of	I-protein
retinoid	B-protein
receptor	I-protein
expression	I-protein
,	O
known	O
to	I-protein
mediate	O
intracellular	I-protein
RA	B-protein
signaling	O
,	O
revealed	O
presence	O
of	I-protein
RAR	B-protein
alpha	I-protein
,	O
RAR	B-protein
gamma	O
,	O
RXR	B-protein
beta	I-protein
,	O
and	I-protein
RXR	O
gamma	O
transcripts	I-protein
in	I-protein
all	O
cell	O
lines	B-protein
studied	O
,	O
and	I-protein
HMC-1	O
cells	I-protein
were	O
the	I-protein
only	I-protein
line	I-protein
lacking	I-protein
RXR	B-protein
alpha	I-protein
.	O

RAR	B-protein
beta	O
,	O
not	I-protein
expressed	O
at	I-protein
baseline	O
,	O
was	O
induced	I-protein
by	I-protein
RA	B-protein
in	I-protein
a	I-protein
fashion	O
obviously	O
correlating	O
with	I-protein
ICAM-3	B-protein
up-regulation	O
.	O

Increased	O
ICAM-3	B-protein
expression	I-protein
was	O
of	I-protein
functional	O
significance	O
,	O
such	O
that	O
processes	O
stimulated	O
or	I-protein
co-stimulated	O
via	I-protein
ICAM-3	B-protein
(	O
homotypic	O
aggregation	I-protein
,	O
IL-8	O
secretion	O
)	O
were	O
clearly	O
enhanced	I-protein
upon	O
RA	B-protein
pretreatment	O
,	O
suggesting	O
that	O
RA	B-protein
may	O
contribute	O
via	I-protein
hitherto	O
unrecognized	O
pathways	O
to	I-protein
immune	O
function	I-protein
and	I-protein
host	O
defense	O
.	O

###MEDLINE:21155831

CD28	B-protein
and	I-protein
T	O
cell	O
co-stimulation	O
.	O

Over	O
the	I-protein
last	O
decade	O
the	I-protein
concept	O
of	I-protein
T	O
cell	O
co-stimulation	O
has	O
emerged	O
to	I-protein
take	O
a	I-protein
central	O
role	O
in	I-protein
the	I-protein
process	O
of	I-protein
T	O
cell	O
activation	I-protein
.	O

However	O
,	O
the	I-protein
exact	O
definition	O
of	I-protein
co-stimulation	O
is	O
still	O
unclear	O
.	O

In	O
this	O
review	O
,	O
we	O
re-examine	O
the	I-protein
concept	O
of	I-protein
co-stimulation	O
.	O

We	O
suggest	O
that	O
while	O
co-stimulation	O
is	O
important	O
,	O
there	O
is	O
little	O
evidence	O
to	I-protein
link	I-protein
co-stimulation	O
with	I-protein
T	O
cell	O
anergy	O
.	O

We	O
then	O
suggest	O
a	I-protein
framework	O
for	I-protein
studying	O
co-stimulation	O
.	O

Focusing	O
on	I-protein
recent	O
advances	O
in	I-protein
our	O
understanding	O
of	I-protein
CD28	B-protein
,	O
we	O
discuss	O
four	O
areas	O
of	I-protein
T	O
cell	O
activation	I-protein
where	O
co-stimulation	O
may	O
play	O
a	I-protein
role	O
.	O

###MEDLINE:21154038

Regulation	O
of	I-protein
activator	B-protein
protein-1	I-protein
and	I-protein
NF-kappa	B-protein
B	I-protein
in	I-protein
CD8+	O
T	O
cells	I-protein
exposed	O
to	I-protein
peripheral	B-protein
self-antigens	I-protein
.	O

The	O
transcriptional	O
events	O
that	O
control	I-protein
T	O
cell	O
tolerance	I-protein
to	I-protein
peripheral	B-protein
self	I-protein
Ags	I-protein
are	O
still	O
unknown	O
.	O

In	O
this	O
study	O
,	O
we	O
analyzed	O
the	I-protein
regulation	I-protein
of	I-protein
AP-1	I-protein
-	O
and	I-protein
NF-kappa	B-protein
B	I-protein
-mediated	O
transcription	O
during	I-protein
in	I-protein
vivo	O
induction	I-protein
of	I-protein
tolerance	I-protein
to	I-protein
a	I-protein
self	B-protein
Ag	I-protein
expressed	O
exclusively	O
on	I-protein
hepatocytes	I-protein
.	O

Naive	O
CD8	O
(	O
+	O
)	O
Desire	O
(	O
Des	O
)	O
(	O
+	O
)	O
T	O
cells	I-protein
isolated	I-protein
from	I-protein
the	I-protein
Des	O
TCR-transgenic	O
mice	O
that	O
are	O
specific	I-protein
for	I-protein
the	I-protein
H-2K	B-protein
(	O
b	I-protein
)	O
class	I-protein
I	I-protein
Ag	I-protein
were	O
transferred	O
into	O
Alb-K	O
(	O
b	O
)	O
-transgenic	O
mice	O
that	O
express	O
the	I-protein
H-2K	B-protein
(	O
b	I-protein
)	O
Ag	I-protein
on	I-protein
hepatocytes	I-protein
only	I-protein
.	O

Tolerance	O
develops	O
in	I-protein
these	O
mice	O
.	O

We	O
found	O
that	O
the	I-protein
self-reactive	O
CD8	O
(	O
+	O
)	O
Des	O
(	O
+	O
)	O
T	O
cells	I-protein
were	O
transiently	O
activated	O
,	O
then	O
became	O
unresponsive	O
and	I-protein
were	O
further	O
deleted	O
.	O

In	O
contrast	O
to	I-protein
CD8	O
(	O
+	O
)	O
Des	O
(	O
+	O
)	O
T	O
cells	I-protein
activated	O
in	I-protein
vivo	O
with	I-protein
APCs	O
,	O
which	O
express	O
high	O
AP-1	I-protein
and	I-protein
high	O
NF-kappa	B-protein
B	I-protein
transcriptional	O
activity	I-protein
,	O
the	I-protein
unresponsive	O
CD8	O
(	O
+	O
)	O
Des	O
(	O
+	O
)	O
T	O
cells	I-protein
expressed	O
no	I-protein
AP-1	I-protein
and	I-protein
only	I-protein
weak	I-protein
NF-kappa	B-protein
B	I-protein
transcriptional	O
activity	I-protein
.	O

The	O
differences	O
in	I-protein
NF-kappa	B-protein
B	I-protein
transcriptional	O
activity	I-protein
correlated	O
with	I-protein
the	I-protein
generation	O
of	I-protein
distinct	O
NF-kappa	B-protein
B	I-protein
complexes	I-protein
.	O

Indeed	O
,	O
in	I-protein
vivo	O
primed	O
T	O
cells	I-protein
predominantly	O
express	O
p50/p50	B-protein
and	I-protein
p65/p50	I-protein
dimers	I-protein
,	O
whereas	O
these	O
p50-containing	B-protein
complexes	I-protein
are	O
barely	O
detectable	O
in	I-protein
tolerant	O
T	O
cells	I-protein
that	O
express	O
p65-	B-protein
and	I-protein
c-Rel-containing	I-protein
complexes	I-protein
.	O

These	O
observations	O
suggest	O
that	O
fine	O
regulation	I-protein
of	I-protein
NF-kappa	B-protein
B	I-protein
complex	I-protein
formation	O
may	O
determine	O
T	O
cell	O
fate	O
.	O

###MEDLINE:21145240

Transcriptional	I-protein
regulation	I-protein
in	I-protein
lymphocytes	O
.	O

Lymphocytes	O
have	O
been	O
used	O
to	I-protein
investigate	O
many	O
cellular	O
processes	O
,	O
including	I-protein
lineage	I-protein
commitment	O
,	O
differentiation	I-protein
,	O
proliferation	I-protein
and	I-protein
apoptosis	O
.	O

The	O
transcription	B-protein
factors	I-protein
that	O
mediate	O
these	O
processes	O
are	O
often	O
expressed	O
broadly	O
in	I-protein
many	O
cell	O
types	I-protein
.	O

The	O
emerging	O
theme	O
is	O
one	B-protein
of	I-protein
cell-type-specific	O
regulation	I-protein
,	O
affecting	O
not	I-protein
only	I-protein
the	I-protein
functional	O
activation	I-protein
of	I-protein
transcription	B-protein
factors	I-protein
but	O
also	O
their	O
access	O
to	I-protein
appropriate	O
regions	O
of	I-protein
DNA	O
.	O

###MEDLINE:21133063

Existence	O
of	I-protein
retinoic	B-protein
acid-receptor	I-protein
-independent	O
retinoid	B-protein
X-receptor	I-protein
-dependent	I-protein
pathway	I-protein
in	I-protein
myeloid	O
cell	O
function	I-protein
.	O

We	O
previously	O
reported	O
that	O
ER-27191	O
(	O
4-	O
[	O
4	I-protein
,	O
5	O
,	O
7	I-protein
,	O
8	I-protein
,	O
9	I-protein
,	O
10-hexahydro-7	O
,	O
7	I-protein
,	O
10	I-protein
,	O
10-tetramethyl-1-	O
(	O
3-pyridylmethyl	O
)	O
anthra	O
[	O
1	I-protein
,	O
2-b	O
]	O
pyrrol-3-yl	O
]	O
benzoic	O
acid	O
)	O
is	O
a	I-protein
potent	O
antagonist	O
of	I-protein
retinoic	B-protein
acid	I-protein
receptor	I-protein
(	O
RAR	B-protein
)	O
,	O
and	I-protein
ER-35795	O
(	O
(	O
2E	I-protein
,	O
4E	I-protein
,	O
6E	I-protein
)	O
-7-	O
[	O
1-	O
(	O
1-methylethyl	O
)	O
-8-chloro-1	O
,	O
2	I-protein
,	O
3	O
,	O
4-tetrahydroquinolin-6-yl	O
]	O
-6-fluoro-3-methyl-2	O
,	O
4	I-protein
,	O
6-nonatrienoic	O
acid	O
)	O
is	O
a	I-protein
novel	O
retinoid	B-protein
X	I-protein
receptor	I-protein
(	O
RXR	B-protein
)	O
-specific	I-protein
agonist	I-protein
.	O

By	O
using	O
these	O
compounds	O
,	O
we	O
investigated	O
whether	O
distinct	O
RAR	B-protein
-dependent	I-protein
and	I-protein
RXR	B-protein
-dependent	I-protein
pathways	O
operate	O
to	I-protein
mediate	O
the	I-protein
diverse	O
activities	O
of	I-protein
retinoids	O
,	O
particularly	O
,	O
the	I-protein
effects	O
of	I-protein
the	I-protein
RXR	B-protein
pathway	I-protein
on	I-protein
cellular	O
function	I-protein
.	O

ER-27191	O
completely	O
antagonized	O
HL60	O
cell	O
differentiation	I-protein
induced	I-protein
by	I-protein
all-trans-retinoic	O
acid	O
(	O
atRA	O
)	O
.	O

However	O
,	O
the	I-protein
differentiation	I-protein
induced	I-protein
by	I-protein
the	I-protein
ER-35795	O
was	O
not	I-protein
antagonized	O
at	I-protein
all	O
by	I-protein
the	I-protein
RAR	B-protein
antagonist	O
,	O
but	O
was	O
inhibited	O
by	I-protein
an	I-protein
RXR	O
homodimer	B-protein
antagonist	O
(	O
LGD100754	O
,	O
(	O
2E	I-protein
,	O
4E	I-protein
,	O
6Z	O
)	O
-7-	O
(	O
3-n-propoxy-5	O
,	O
6	I-protein
,	O
7	I-protein
,	O
8-tetrahydro-5	O
,	O
5	O
,	O
8	I-protein
,	O
8-tetramethylnaphthalen-2-yl	O
)	O
-3-methylocta-2	O
,	O
4	I-protein
,	O
6-trienoic	O
acid	O
)	O
.	O

Its	O
agonistic	O
action	O
on	I-protein
RXR/RAR	B-protein
heterodimer	I-protein
,	O
on	I-protein
the	I-protein
other	O
hand	O
,	O
was	O
neutralized	O
by	I-protein
the	I-protein
RAR	B-protein
antagonist	O
.	O

During	O
HL60	O
cell	O
differentiation	I-protein
,	O
atRA	O
induced	I-protein
RARbeta	O
mRNA	O
,	O
while	O
the	I-protein
RXR	B-protein
had	O
no	I-protein
effect	O
.	O

Interestingly	O
,	O
a	I-protein
functional	O
RXR	B-protein
-pathway	O
was	O
also	O
seen	O
in	I-protein
lipopolysaccharide-induced	B-protein
inhibition	O
of	I-protein
mouse	I-protein
splenocyte	O
proliferation	I-protein
.	O

These	O
results	O
strongly	O
suggest	O
the	I-protein
existence	O
of	I-protein
a	I-protein
pharmacological	O
RXR	B-protein
-dependent	I-protein
pathway	I-protein
that	O
is	O
activated	O
by	I-protein
a	I-protein
ligand	O
that	O
can	O
bind	O
to	I-protein
RXR	B-protein
.	O

###MEDLINE:21136373

Targeting	O
Src	B-protein
homology	I-protein
2	I-protein
domain-containing	I-protein
tyrosine	I-protein
phosphatase	I-protein
(	O
SHP-1	B-protein
)	O
into	O
lipid	O
rafts	O
inhibits	I-protein
CD3	B-protein
-induced	O
T	O
cell	O
activation	I-protein
.	O

To	O
study	O
the	I-protein
mechanism	O
by	I-protein
which	O
protein	B-protein
tyrosine	I-protein
phosphatases	I-protein
(	O
PTPs	B-protein
)	O
regulate	O
CD3	B-protein
-induced	O
tyrosine	O
phosphorylation	I-protein
,	O
we	O
investigated	O
the	I-protein
distribution	I-protein
of	I-protein
PTPs	B-protein
in	I-protein
subdomains	O
of	I-protein
plasma	O
membrane	O
.	O

We	O
report	O
here	O
that	O
the	I-protein
bulk	O
PTP	B-protein
activity	I-protein
associated	I-protein
with	I-protein
T	O
cell	O
membrane	O
is	O
present	O
outside	O
the	I-protein
lipid	O
rafts	O
,	O
as	O
determined	O
by	I-protein
sucrose	O
density	I-protein
gradient	I-protein
sedimentation	O
.	O

In	O
Jurkat	O
T	O
cells	I-protein
,	O
approximately	O
5	O
--	I-protein
10	I-protein
%	O
of	I-protein
Src	B-protein
homology	I-protein
2	I-protein
domain-containing	I-protein
tyrosine	I-protein
phosphatase	I-protein
(	O
SHP-1	B-protein
)	O
is	O
constitutively	O
associated	I-protein
with	I-protein
plasma	O
membrane	O
,	O
and	I-protein
nearly	O
50	I-protein
%	O
of	I-protein
SHP-2	I-protein
is	O
translocated	O
to	I-protein
plasma	O
membrane	O
after	O
vanadate	O
treatment	O
.	O

Similar	B-protein
to	I-protein
transmembrane	B-protein
PTP	I-protein
,	O
CD45	B-protein
,	O
the	I-protein
membrane-associated	O
populations	O
of	I-protein
SHP-1	B-protein
and	I-protein
SHP-2	I-protein
are	O
essentially	O
excluded	O
from	I-protein
lipid	O
rafts	O
,	O
where	O
other	O
signaling	O
molecules	O
such	O
as	O
Lck	B-protein
,	O
linker	O
for	I-protein
activation	I-protein
of	I-protein
T	O
cells	I-protein
,	O
and	I-protein
CD3	B-protein
zeta	I-protein
are	O
enriched	I-protein
.	O

We	O
further	O
demonstrated	O
that	O
CD3	B-protein
-induced	O
tyrosine	O
phosphorylation	I-protein
of	I-protein
these	O
substrates	O
is	O
largely	O
restricted	I-protein
to	I-protein
lipid	O
rafts	O
,	O
unless	O
PTPs	B-protein
are	O
inhibited	O
.	O

It	O
suggests	O
that	O
a	I-protein
restricted	I-protein
partition	O
of	I-protein
PTPs	B-protein
among	O
membrane	O
subdomains	O
may	O
regulate	O
protein	O
tyrosine	O
phosphorylation	I-protein
in	I-protein
T	O
cell	O
membrane	O
.	O

To	O
test	O
this	O
hypothesis	O
,	O
we	O
targeted	O
SHP-1	B-protein
into	O
lipid	O
rafts	O
by	I-protein
using	O
the	I-protein
N-terminal	B-protein
region	I-protein
of	I-protein
Lck	B-protein
(	O
residues	I-protein
1	I-protein
--	I-protein
14	I-protein
)	O
.	O

The	O
results	O
indicate	O
that	O
the	I-protein
expression	I-protein
of	I-protein
Lck/SHP-1	B-protein
chimera	I-protein
inside	O
lipid	O
rafts	O
profoundly	O
inhibits	I-protein
CD3	B-protein
-induced	O
tyrosine	O
phosphorylation	I-protein
of	I-protein
CD3	B-protein
zeta/epsilon	I-protein
,	O
IL-2	B-protein
generation	O
,	O
and	I-protein
nuclear	O
mobilization	O
of	I-protein
NF-AT	B-protein
.	O

Collectively	O
,	O
these	O
results	O
suggest	O
that	O
the	I-protein
exclusion	O
of	I-protein
PTPs	B-protein
from	I-protein
lipid	O
rafts	O
may	O
be	O
a	I-protein
mechanism	O
that	O
potentiates	O
TCR	B-protein
/	O
CD3	B-protein
activation	I-protein

###MEDLINE:21136244

An	O
instructive	O
component	O
in	I-protein
T	O
helper	I-protein
cell	O
type	O
2	I-protein
(	O
Th2	O
)	O
development	O
mediated	I-protein
by	I-protein
GATA-3	B-protein
.	O

Although	O
interleukin	B-protein
(	O
IL	I-protein
)	O
-12	I-protein
and	I-protein
IL-4	B-protein
polarize	O
naive	O
CD4	B-protein
(	O
+	O
)	O
T	O
cells	I-protein
toward	O
T	O
helper	I-protein
cell	O
type	O
1	I-protein
(	O
Th1	O
)	O
or	I-protein
Th2	O
phenotypes	O
,	O
it	O
is	O
not	I-protein
known	O
whether	O
cytokines	B-protein
instruct	O
the	I-protein
developmental	O
fate	O
in	I-protein
uncommitted	O
progenitors	O
or	I-protein
select	O
for	I-protein
outgrowth	I-protein
of	I-protein
cells	I-protein
that	O
have	O
stochastically	O
committed	O
to	I-protein
a	I-protein
particular	O
fate	O
.	O

To	O
distinguish	O
these	O
instructive	O
and	I-protein
selective	O
models	O
,	O
we	O
used	O
surface	O
affinity	I-protein
matrix	O
technology	O
to	I-protein
isolate	O
committed	O
progenitors	O
based	O
on	I-protein
cytokine	O
secretion	O
phenotype	O
and	I-protein
developed	O
retroviral-based	O
tagging	O
approaches	O
to	I-protein
directly	O
monitor	O
individual	O
progenitor	O
fate	O
decisions	O
at	I-protein
the	I-protein
clonal	O
and	I-protein
population	O
levels	I-protein
.	O

We	O
observe	O
IL-4	B-protein
-dependent	I-protein
redirection	O
of	I-protein
phenotype	O
in	I-protein
cells	I-protein
that	O
have	O
already	O
committed	O
to	I-protein
a	I-protein
non-IL-4-producing	O
fate	O
,	O
inconsistent	O
with	I-protein
predictions	O
of	I-protein
the	I-protein
selective	O
model	I-protein
.	O

Further	O
,	O
retroviral	O
tagging	O
of	I-protein
naive	O
progenitors	O
with	I-protein
the	I-protein
Th2-specific	B-protein
transcription	I-protein
factor	I-protein
GATA-3	I-protein
provided	O
direct	O
evidence	O
for	I-protein
instructive	O
differentiation	I-protein
,	O
and	I-protein
no	I-protein
evidence	O
for	I-protein
the	I-protein
selective	O
outgrowth	I-protein
of	I-protein
cells	I-protein
committed	O
to	I-protein
either	O
the	I-protein
Th1	O
or	I-protein
Th2	O
fate	O
.	O

These	O
data	O
would	O
seem	O
to	I-protein
exclude	O
selection	O
as	O
an	I-protein
exclusive	O
mechanism	O
in	I-protein
Th1	O
/	O
Th2	O
differentiation	I-protein
,	O
and	I-protein
support	I-protein
an	I-protein
instructive	O
model	I-protein
of	I-protein
cytokine-driven	O
transcriptional	O
programming	O
of	I-protein
cell	O
fate	O
decisions	O
.	O

###MEDLINE:21131863

In	O
vitro-activated	O
human	O
lupus	O
T	O
cells	I-protein
express	O
normal	O
estrogen	B-protein
receptor	I-protein
proteins	I-protein
which	O
bind	O
to	I-protein
the	I-protein
estrogen	O
response	I-protein
element	I-protein
.	O

We	O
have	O
shown	O
that	O
estrogen	B-protein
receptor	I-protein
(	O
ERalpha	B-protein
,	O
ERbeta	B-protein
)	O
transcripts	I-protein
are	O
expressed	O
in	I-protein
SLE	O
and	I-protein
normal	O
T	O
cells	I-protein
.	O

In	O
this	O
study	O
,	O
T	O
cell	O
nuclear	O
extracts	O
from	I-protein
female	I-protein
lupus	O
patients	O
and	I-protein
normal	O
donors	O
were	O
tested	O
for	I-protein
biologically	O
active	O
ER	B-protein
proteins	I-protein
capable	O
of	I-protein
binding	I-protein
to	I-protein
the	I-protein
human	O
estrogen	O
response	I-protein
element	I-protein
(	O
hERE	O
)	O
by	I-protein
electrophoretic	O
mobility	I-protein
shift	O
assays	O
.	O

When	O
peripheral	O
blood	O
T	O
cells	I-protein
were	O
stimulated	O
with	I-protein
17beta-estradiol	O
(	O
E2	O
)	O
,	O
PMA	O
and	I-protein
ionomycin	O
,	O
two	O
major	O
retarded	O
bands	O
in	I-protein
T	O
cell	O
nuclear	O
extracts	O
exhibited	O
a	I-protein
migration	I-protein
pattern	I-protein
similar	O
to	I-protein
slow	I-protein
migrating	O
protein-ERE	B-protein
complexes	I-protein
in	I-protein
human	O
breast	O
cancer	O
cell	O
extracts	O
.	O

T	O
cells	I-protein
cultured	O
only	I-protein
with	I-protein
E2	O
did	O
not	I-protein
have	O
these	O
complexes	O
.	O

The	O
formation	O
of	I-protein
the	I-protein
complexes	O
was	O
inhibited	O
by	I-protein
competition	O
with	I-protein
the	I-protein
hERE	O
cold	O
oligonucleotide	O
and	I-protein
partially	O
with	I-protein
anti-ERalpha	B-protein
antibodies	I-protein
.	O

There	O
was	O
no	I-protein
notable	O
difference	O
in	I-protein
the	I-protein
migration	I-protein
pattern	I-protein
of	I-protein
ERE-binding	B-protein
proteins	I-protein
between	O
the	I-protein
SLE	O
and	I-protein
normal	O
T	O
cell	O
extracts	O
.	O

Together	O
,	O
these	O
results	O
suggest	O
that	O
activated	O
human	O
T	O
cells	I-protein
,	O
whether	O
lupus-derived	O
or	I-protein
normal-derived	O
,	O
contain	O
biologically	O
active	O
ERalpha	B-protein
proteins	I-protein
.	O

Other	O
factors	I-protein
may	O
be	O
responsible	O
for	I-protein
differential	O
sensitivity	I-protein
of	I-protein
lupus	O
T	O
cells	I-protein
to	I-protein
estrogen	O
.	O

###MEDLINE:21115153

Mechanism	O
of	I-protein
the	I-protein
inhibitory	O
effect	O
of	I-protein
protease	O
inhibitor	O
on	I-protein
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
production	I-protein
of	I-protein
monocytes	O
.	O

If	O
the	I-protein
inflammatory	O
response	I-protein
becomes	O
excessive	I-protein
or	I-protein
uncontrolled	O
by	I-protein
some	O
stimuli	O
,	O
inappropriate	O
inflammatory	O
responses	O
occur	O
.	O

Monocytes	O
are	O
extremely	O
important	O
cells	I-protein
for	I-protein
regulating	O
the	I-protein
cytokine	O
network	I-protein
and	I-protein
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
(	O
TNFalpha	B-protein
)	O
and	I-protein
interleukin-	B-protein
(	O
IL	I-protein
)	O
10	I-protein
,	O
which	O
are	O
mainly	O
synthesized	O
by	I-protein
monocytes	O
,	O
are	O
representative	O
cytokines	B-protein
that	O
play	O
a	I-protein
central	O
role	O
in	I-protein
the	I-protein
cytokine	O
network	I-protein
.	O

Protease	O
inhibitors	I-protein
such	O
as	O
gabexate	O
mesilate	O
(	O
GM	O
)	O
and	I-protein
ulinastatin	O
(	O
UTI	B-protein
)	O
have	O
been	O
shown	O
to	I-protein
have	O
various	O
beneficial	O
effects	O
by	I-protein
inhibiting	I-protein
the	I-protein
activation	I-protein
of	I-protein
leukocytes	O
,	O
but	O
the	I-protein
mechanism	O
for	I-protein
this	O
has	O
yet	O
to	I-protein
be	O
fully	O
elucidated	O
.	O

In	O
this	O
study	O
we	O
investigated	O
the	I-protein
mechanism	O
of	I-protein
the	I-protein
inhibitory	O
effect	O
of	I-protein
protease	O
inhibitors	I-protein
on	I-protein
the	I-protein
proinflammatory	O
cytokine	O
production	I-protein
of	I-protein
lipopolysaccharide-	O
(	O
LPS	B-protein
)	O
stimulated	O
monocytes	O
.	O

LPS-stimulated	O
monocytes	O
were	O
treated	O
with	I-protein
GM	O
or	I-protein
UTI	B-protein
.	O

The	O
value	O
of	I-protein
TNFalpha	B-protein
and	I-protein
IL-10	B-protein
in	I-protein
the	I-protein
culture	O
medium	I-protein
of	I-protein
monocytes	O
was	O
measured	O
and	I-protein
each	O
mRNA	O
expression	I-protein
was	O
assayed	O
.	O

The	O
inhibitory	O
effect	O
of	I-protein
protease	O
inhibitors	I-protein
on	I-protein
the	I-protein
activity	I-protein
of	I-protein
intracellular	I-protein
signal	O
transduction	I-protein
pathways	O
such	O
as	O
protein	B-protein
kinase	I-protein
C	I-protein
(	O
PKC	B-protein
)	O
and	I-protein
nuclear	B-protein
factor	I-protein
kappa	I-protein
B	I-protein
(	O
NFkappaB	B-protein
)	O
were	O
also	O
evaluated	O
.	O

GM	O
decreased	O
the	I-protein
TNFalpha	B-protein
production	I-protein
of	I-protein
LPS-stimulated	O
monocytes	O
as	O
shown	O
by	I-protein
the	I-protein
inhibition	O
of	I-protein
mRNA	O
expression	I-protein
and	I-protein
increased	I-protein
the	I-protein
IL-10	B-protein
production	I-protein
of	I-protein
LPS-stimulated	O
monocytes	O
.	O

GM	O
also	O
suppressed	I-protein
the	I-protein
NFkappaB	B-protein
activity	I-protein
of	I-protein
LPS-stimulated	O
monocytes	O
.	O

UTI	B-protein
decreased	O
the	I-protein
TNFalpha	B-protein
production	I-protein
of	I-protein
LPS-stimulated	O
monocytes	O
,	O
but	O
did	O
not	I-protein
inhibit	O
the	I-protein
TNFalpha	O
mRNA	O
expression	I-protein
.	O

The	O
present	O
study	O
shows	O
that	O
the	I-protein
inhibitory	O
effect	O
of	I-protein
GM	O
on	I-protein
the	I-protein
TNFalpha	B-protein
production	I-protein
of	I-protein
activated	O
human	O
monocytes	O
is	O
mediated	I-protein
by	I-protein
the	I-protein
suppression	O
of	I-protein
NFkappaB	O
activation	I-protein
,	O
while	O
the	I-protein
mechanism	O
of	I-protein
UTI	B-protein
inhibiting	I-protein
TNFalpha	B-protein
production	I-protein
of	I-protein
human	O
monocytes	O
may	O
be	O
due	I-protein
to	I-protein
the	I-protein
inhibition	O
of	I-protein
either	O
the	I-protein
translation	I-protein
or	I-protein
secretion	O
of	I-protein
TNFalpha	B-protein
.	O

###MEDLINE:21084706

Homocysteine	O
stimulates	O
the	I-protein
expression	I-protein
of	I-protein
monocyte	B-protein
chemoattractant	I-protein
protein-1	I-protein
in	I-protein
endothelial	O
cells	I-protein
leading	O
to	I-protein
enhanced	I-protein
monocyte	B-protein
chemotaxis	O
.	O

Hyperhomocysteinemia	O
has	O
been	O
identified	I-protein
as	O
an	I-protein
independent	I-protein
risk	O
factor	I-protein
for	I-protein
atherosclerosis	B-protein
.	O

The	O
infiltration	O
of	I-protein
monocytes	O
into	O
the	I-protein
arterial	I-protein
wall	O
is	O
one	B-protein
of	I-protein
the	I-protein
key	O
events	O
during	I-protein
atherogenesis	O
.	O

Monocyte	I-protein
chemoattractant	I-protein
protein-1	I-protein
(	O
MCP-1	B-protein
)	O
is	O
a	I-protein
potent	O
chemokine	O
that	O
stimulates	O
the	I-protein
migration	I-protein
of	I-protein
monocytes	O
into	O
the	I-protein
intima	O
of	I-protein
the	I-protein
arterial	I-protein
wall	O
.	O

The	O
mechanism	O
by	I-protein
which	O
increased	I-protein
monocyte	B-protein
infiltration	O
occurs	O
in	I-protein
atherosclerotic	O
lesions	O
in	I-protein
patients	O
with	I-protein
hyperhomocysteinemia	O
has	O
not	I-protein
been	O
delineated	O
.	O

The	O
objective	O
of	I-protein
the	I-protein
present	O
study	O
was	O
to	I-protein
investigate	O
the	I-protein
effect	O
of	I-protein
homocysteine	O
on	I-protein
MCP-1	B-protein
production	I-protein
in	I-protein
endothelial	O
cells	I-protein
.	O

Cells	O
were	O
incubated	O
with	I-protein
homocysteine	O
.	O

The	O
secretion	O
of	I-protein
MCP-1	B-protein
protein	I-protein
was	O
significantly	O
increased	I-protein
(	O
195	I-protein
%	O
as	O
compared	O
to	I-protein
the	I-protein
control	I-protein
)	O
in	I-protein
cells	I-protein
treated	O
with	I-protein
pathological	O
concentrations	O
of	I-protein
homocysteine	O
.	O

Such	O
effect	O
was	O
accompanied	O
by	I-protein
an	I-protein
increased	I-protein
expression	I-protein
of	I-protein
MCP-1	B-protein
mRNA	O
(	O
176	I-protein
%	O
as	O
compared	O
to	I-protein
the	I-protein
control	I-protein
)	O
in	I-protein
endothelial	O
cells	I-protein
which	O
resulted	O
in	I-protein
enhanced	I-protein
monocyte	B-protein
chemotaxis	O
.	O

The	O
p38	B-protein
MAP	I-protein
kinase	I-protein
as	O
well	O
as	O
other	O
members	O
of	I-protein
the	I-protein
p38	B-protein
MAP	I-protein
kinase	I-protein
pathway	I-protein
,	O
including	I-protein
MKK3	B-protein
,	O
MKK6	B-protein
,	O
ATF-2	B-protein
and	I-protein
Elk-1	I-protein
,	O
were	O
activated	O
in	I-protein
homocysteine-treated	O
cells	I-protein
.	O

Homocysteine-induced	O
MCP-1	B-protein
expression	I-protein
and	I-protein
subsequent	O
monocyte	B-protein
chemotaxis	O
were	O
blocked	B-protein
by	I-protein
a	I-protein
p38	B-protein
MAP	O
kinase	O
inhibitor	O
(	O
SB203580	O
)	O
suggesting	O
that	O
the	I-protein
p38	B-protein
MAP	I-protein
kinase	I-protein
pathway	I-protein
might	O
be	O
involved	I-protein
in	I-protein
homocysteine-induced	O
MCP-1	B-protein
expression	I-protein
in	I-protein
endothelial	O
cells	I-protein
.	O

In	O
contrast	O
,	O
staurosporine	O
,	O
a	I-protein
protein	B-protein
kinase	I-protein
C	I-protein
inhibitor	O
,	O
had	O
no	I-protein
effect	O
on	I-protein
homocysteine-induced	O
MCP-1	B-protein
expression	I-protein
.	O

In	O
conclusion	O
,	O
our	O
results	O
indicate	O
that	O
homocysteine	O
stimulates	O
MCP-1	B-protein
expression	I-protein
in	I-protein
endothelial	O
cells	I-protein
leading	O
to	I-protein
enhanced	I-protein
monocyte	B-protein
chemotaxis	O
.	O

###MEDLINE:21031071

Inducible	I-protein
resistance	O
to	I-protein
Fas-mediated	O
apoptosis	O
in	I-protein
B	O
cells	I-protein
.	O

Apoptosis	I-protein
produced	O
in	I-protein
B	O
cells	I-protein
through	I-protein
Fas	B-protein
(	O
APO-1	B-protein
,	O
CD95	B-protein
)	O
triggering	O
is	O
regulated	O
by	I-protein
signals	I-protein
derived	I-protein
from	I-protein
other	O
surface	B-protein
receptors	I-protein
:	O
CD40	B-protein
engagement	O
produces	O
upregulation	O
of	I-protein
Fas	B-protein
expression	I-protein
and	I-protein
marked	O
susceptibility	I-protein
to	I-protein
Fas	B-protein
-induced	O
cell	O
death	O
,	O
whereas	O
antigen	O
receptor	O
engagement	O
,	O
or	I-protein
IL-4R	O
engagement	O
,	O
inhibits	I-protein
Fas	B-protein
killing	O
and	I-protein
in	I-protein
so	O
doing	O
induces	O
a	I-protein
state	I-protein
of	I-protein
Fas	B-protein
-resistance	O
,	O
even	O
in	I-protein
otherwise	O
sensitive	I-protein
,	O
CD40	B-protein
-stimulated	O
targets	O
.	O

Surface	B-protein
immunoglobulin	I-protein
and	I-protein
IL-4R	B-protein
utilize	O
at	I-protein
least	O
partially	O
distinct	O
pathways	O
to	I-protein
produce	O
Fas	B-protein
-resistance	O
that	O
differentially	O
depend	O
on	I-protein
PKC	B-protein
and	I-protein
STAT6	B-protein
,	O
respectively	O
.	O

Further	O
,	O
surface	O
immunoglobulin	O
signaling	O
for	I-protein
inducible	O
Fas	B-protein
-resistance	O
bypasses	O
Btk	B-protein
,	O
requires	O
NF-kappaB	B-protein
,	O
and	I-protein
entails	O
new	I-protein
macromolecular	O
synthesis	I-protein
.	O

Terminal	O
effectors	O
of	I-protein
B	O
cell	O
Fas	B-protein
-resistance	O
include	O
the	I-protein
known	O
anti-apoptotic	I-protein
gene	I-protein
products	I-protein
,	O
Bcl-xL	O
and	I-protein
FLIP	B-protein
,	O
and	I-protein
a	I-protein
novel	O
anti-apoptotic	I-protein
gene	O
that	O
encodes	O
FAIM	B-protein
(	O
Fas	B-protein
Apoptosis	I-protein
Inhibitory	I-protein
Molecule	I-protein
)	O
.	O

faim	O
was	O
identified	I-protein
by	I-protein
differential	O
display	O
and	I-protein
exists	O
in	I-protein
two	O
alternatively	I-protein
spliced	I-protein
forms	I-protein
;	O
faim-S	O
is	O
broadly	O
expressed	O
,	O
but	O
faim-L	O
expression	I-protein
is	O
tissue-specific	O
.	O

The	O
FAIM	B-protein
sequence	I-protein
is	O
highly	O
evolu-	O
tionarily	O
conserved	O
,	O
suggesting	O
an	I-protein
important	O
role	O
for	I-protein
this	O
molecule	I-protein
throughout	O
phylogeny	O
.	O

Inducible	I-protein
resistance	O
to	I-protein
Fas	B-protein
killing	O
is	O
hypothesized	O
to	I-protein
protect	O
foreign	O
antigen-specific	O
B	O
cells	I-protein
during	I-protein
potentially	O
hazardous	O
interactions	O
with	I-protein
FasL-bearing	O
T	O
cells	I-protein
,	O
whereas	O
autoreactive	O
B	O
cells	I-protein
fail	O
to	I-protein
become	O
Fas	B-protein
-resistant	O
and	I-protein
are	O
deleted	O
via	I-protein
Fas	B-protein
-dependent	I-protein
cytotoxicity	I-protein
.	O

Inadvertent	O
or	I-protein
aberrant	O
acquisition	O
of	I-protein
Fas	B-protein
-resistance	O
may	O
permit	O
autoreactive	O
B	O
cells	I-protein
to	I-protein
escape	I-protein
Fas	B-protein
deletion	I-protein
,	O
and	I-protein
malignant	O
lymphocytes	O
to	I-protein
impede	O
anti-tumor	O
immunity	O
.	O

###MEDLINE:21142766

Stromal	I-protein
cell-derived	I-protein
factor	I-protein
1	I-protein
alpha	I-protein
-induced	O
chemotaxis	O
in	I-protein
T	O
cells	I-protein
is	O
mediated	I-protein
by	I-protein
nitric	B-protein
oxide	I-protein
signaling	O
pathways	O
.	O

Stromal	I-protein
cell-derived	I-protein
factor	I-protein
1	I-protein
alpha	I-protein
(	O
SDF1	B-protein
alpha	I-protein
)	O
and	I-protein
its	O
cognate	I-protein
chemokine	B-protein
receptor	I-protein
CXCR4	B-protein
act	O
as	O
potent	O
chemoattractants	O
and	I-protein
regulate	O
trafficking	O
and	I-protein
homing	O
of	I-protein
hematopoietic	O
progenitor	O
cells	I-protein
and	I-protein
lymphocytes	O
.	O

However	O
,	O
the	I-protein
molecular	I-protein
mechanisms	O
regulating	O
SDF1	B-protein
alpha	I-protein
-driven	O
cell	O
migration	I-protein
are	O
not	I-protein
well	O
defined	I-protein
.	O

In	O
this	O
study	O
,	O
we	O
have	O
explored	O
the	I-protein
roles	O
of	I-protein
the	I-protein
second	O
messenger	O
NO	I-protein
and	I-protein
the	I-protein
transcription	B-protein
factor	I-protein
NF-kappa	I-protein
B	I-protein
in	I-protein
SDF1	B-protein
alpha	I-protein
-induced	O
T	O
cell	O
migration	I-protein
.	O

SDF1	B-protein
alpha	I-protein
treatment	O
of	I-protein
Jurkat	O
T	O
cells	I-protein
increased	I-protein
the	I-protein
activity	I-protein
of	I-protein
NO	I-protein
synthase	I-protein
,	O
which	O
catalyzes	O
the	I-protein
generation	O
of	I-protein
NO	I-protein
.	O

We	O
observed	O
that	O
pretreatment	O
of	I-protein
Jurkat	O
cells	I-protein
or	I-protein
activated	O
PBLs	O
with	I-protein
several	I-protein
NO	I-protein
donors	O
significantly	O
enhanced	I-protein
the	I-protein
SDF1	B-protein
alpha	I-protein
-induced	O
migration	I-protein
,	O
whereas	O
various	O
inhibitors	I-protein
of	I-protein
NO	I-protein
synthase	I-protein
markedly	O
abrogated	O
the	I-protein
chemotactic	I-protein
response	I-protein
in	I-protein
a	I-protein
concentration-dependent	O
manner	O
.	O

Furthermore	O
,	O
we	O
observed	O
that	O
inhibitors	I-protein
of	I-protein
the	I-protein
transcription	B-protein
factor	I-protein
NF-kappa	I-protein
B	I-protein
,	O
which	O
is	O
linked	I-protein
to	I-protein
NO	I-protein
signaling	O
pathways	O
,	O
also	O
significantly	O
blocked	B-protein
the	I-protein
SDF1	B-protein
alpha	I-protein
-induced	O
chemotactic	I-protein
response	I-protein
.	O

However	O
,	O
these	O
compounds	O
did	O
not	I-protein
have	O
a	I-protein
significant	O
effect	O
on	I-protein
SDF1	B-protein
alpha	I-protein
-induced	O
mitogen-activated	B-protein
protein	I-protein
kinase	I-protein
activity	I-protein
.	O

In	O
addition	O
,	O
the	I-protein
MAP/Erk	O
kinase	O
kinase	O
inhibitor	O
PD98059	O
did	O
not	I-protein
abrogate	O
SDF1	B-protein
alpha	I-protein
-induced	O
chemotaxis	O
.	O

AKT	B-protein
,	O
which	O
has	O
been	O
shown	O
to	I-protein
mediate	O
NO	I-protein
production	I-protein
,	O
was	O
also	O
phosphorylated	O
upon	O
SDF1	B-protein
alpha	I-protein
stimulation	I-protein
.	O

These	O
studies	O
suggest	O
that	O
NO-related	O
signaling	O
pathways	O
may	O
mediate	O
SDF1	B-protein
alpha	I-protein
-induced	O
chemotaxis	O
,	O
but	O
not	I-protein
mitogen-activated	B-protein
protein	I-protein
kinase	I-protein
activation	I-protein
.	O

###MEDLINE:21110357

The	O
lack	O
of	I-protein
NF-kappa	O
B	O
transactivation	O
and	I-protein
PKC	B-protein
epsilon	I-protein
expression	I-protein
in	I-protein
CD4	B-protein
(	O
+	O
)	O
CD8	O
(	O
+	O
)	O
thymocytes	O
correlates	O
with	I-protein
negative	O
selection	O
.	O

Deletion	O
of	I-protein
autoreactive	O
thymocytes	O
at	I-protein
the	I-protein
DP	I-protein
stage	I-protein
is	O
the	I-protein
basis	O
for	I-protein
tolerance	I-protein
to	I-protein
thymus-expressed	B-protein
self	I-protein
antigens	I-protein
.	O

In	O
this	O
study	O
we	O
investigated	O
whether	O
distinct	O
signalling	I-protein
pathways	O
are	O
induced	I-protein
in	I-protein
DP	I-protein
thymocytes	O
as	O
compared	O
to	I-protein
mature	B-protein
T	O
cells	I-protein
upon	O
stimulation	I-protein
with	I-protein
antigen	O
.	O

Using	O
triple	O
transgenic	O
mice	O
expressing	O
a	I-protein
TCR	O
transgene	O
,	O
dominant	I-protein
negative	I-protein
ras/Mek	I-protein
proteins	I-protein
and	I-protein
a	I-protein
reporter	O
gene	O
construct	O
with	I-protein
AP-1	I-protein
or	I-protein
NF-kappa	B-protein
B	I-protein
binding	I-protein
sites	I-protein
,	O
we	O
showed	O
a	I-protein
complete	O
lack	O
of	I-protein
transcriptional	O
activity	I-protein
of	I-protein
NF-kappa	B-protein
B	I-protein
but	O
not	I-protein
AP-1	I-protein
in	I-protein
DP	I-protein
thymocytes	O
,	O
whereas	O
both	O
were	O
transcriptionally	O
active	O
in	I-protein
mature	B-protein
T	O
cells	I-protein
after	O
antigenic	I-protein
stimulation	I-protein
.	O

Lack	O
of	I-protein
NF-kappa	B-protein
B	I-protein
induction	I-protein
correlated	O
with	I-protein
increased	I-protein
death	O
in	I-protein
response	I-protein
to	I-protein
antigen	O
.	O

AP-1	I-protein
induction	I-protein
was	O
dependent	I-protein
on	I-protein
the	I-protein
integrity	O
of	I-protein
the	I-protein
ras/Mek	O
pathway	I-protein
indicating	O
that	O
this	O
pathway	I-protein
was	O
activated	O
in	I-protein
the	I-protein
DP	I-protein
thymocytes	O
.	O

In	O
contrast	O
,	O
we	O
found	O
a	I-protein
complete	O
lack	O
of	I-protein
constitutive	I-protein
expression	I-protein
of	I-protein
the	I-protein
epsilon	I-protein
isoform	I-protein
of	I-protein
Protein	I-protein
Kinase	I-protein
C	I-protein
(	O
PKC	B-protein
)	O
in	I-protein
DP	I-protein
thymocytes	O
,	O
although	O
it	O
was	O
present	O
in	I-protein
mature	B-protein
thymocytes	O
and	I-protein
peripheral	O
T	O
cells	I-protein
.	O

Taken	O
together	O
the	I-protein
results	O
suggest	O
that	O
the	I-protein
lack	O
of	I-protein
PKC	B-protein
epsilon	I-protein
in	I-protein
DP	I-protein
thymocytes	O
could	O
lead	O
to	I-protein
the	I-protein
absence	I-protein
of	I-protein
NF-kappa	B-protein
B	I-protein
activity	I-protein
after	O
antigenic	I-protein
stimulation	I-protein
contributing	O
to	I-protein
negative	O
selection	O
.	O

Cell	I-protein
Death	I-protein
and	I-protein
Differentiation	O
(	O
2000	O
)	O
7	I-protein
,	O
1253	O
-	O
1262	O
.	O

###MEDLINE:21099673

CD2	B-protein
stimulation	I-protein
leads	O
to	I-protein
the	I-protein
delayed	O
and	I-protein
prolonged	O
activation	I-protein
of	I-protein
STAT1	B-protein
in	I-protein
T	O
cells	I-protein
but	O
not	I-protein
NK	I-protein
cells	I-protein
.	O

OBJECTIVE	O
:	O
T	O
lymphocytes	O
can	O
be	O
activated	O
by	I-protein
soluble	I-protein
factors	I-protein
such	O
as	O
cytokines	B-protein
or	I-protein
through	I-protein
direct	O
cell-cell	O
interactions	O
.	O

Although	O
cytokine	B-protein
receptors	I-protein
are	O
known	O
to	I-protein
signal	O
through	I-protein
STAT	B-protein
family	I-protein
transcription	I-protein
factors	I-protein
,	O
the	I-protein
mechanisms	O
by	I-protein
which	O
other	O
cell-surface	B-protein
molecules	I-protein
,	O
such	O
as	O
CD2	B-protein
,	O
transduce	O
signals	I-protein
is	O
unclear	O
.	O

The	O
goal	O
of	I-protein
this	O
study	O
was	O
to	I-protein
determine	O
whether	O
stimulation	I-protein
of	I-protein
T	O
cells	I-protein
through	I-protein
CD2	B-protein
recapitulates	O
aspects	O
of	I-protein
cytokine	B-protein
-induced	O
T-cell	O
activation	I-protein
by	I-protein
use	O
of	I-protein
STAT	B-protein
transcription	I-protein
factors	I-protein
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
T	O
cells	I-protein
were	O
treated	O
with	I-protein
anti-CD2	B-protein
antibodies	I-protein
or	I-protein
cells	I-protein
bearing	O
the	I-protein
natural	O
CD2	B-protein
ligand	I-protein
CD58	B-protein
,	O
after	O
which	O
signaling	O
through	I-protein
STAT	B-protein
transcription	I-protein
factors	I-protein
was	O
assessed	O
.	O

RESULTS	O
:	O
Stimulation	O
of	I-protein
CD2	B-protein
on	I-protein
primary	O
T	O
lymphocytes	O
leads	O
to	I-protein
the	I-protein
tyrosine	O
phosphorylation	I-protein
,	O
nuclear	O
translocation	O
,	O
and	I-protein
DNA	O
binding	I-protein
of	I-protein
STAT1	B-protein
.	O

In	O
contrast	O
to	I-protein
stimulation	I-protein
by	I-protein
cytokines	B-protein
,	O
the	I-protein
activation	I-protein
of	I-protein
STAT1	B-protein
in	I-protein
response	I-protein
to	I-protein
CD2	B-protein
ligation	O
is	O
delayed	O
and	I-protein
does	O
not	I-protein
involve	O
Jak	B-protein
kinases	I-protein
.	O

Furthermore	O
,	O
while	O
STAT	O
phosphorylation	I-protein
induced	I-protein
by	I-protein
cytokines	B-protein
is	O
generally	O
transient	O
,	O
STAT1	B-protein
phosphorylation	I-protein
following	O
CD2	B-protein
stimulation	I-protein
persists	O
for	I-protein
a	I-protein
period	B-protein
of	I-protein
days	O
.	O

Transcription	I-protein
of	I-protein
key	O
target	O
genes	I-protein
such	O
as	O
IRF1	B-protein
and	I-protein
c-fos	O
proceeds	O
with	I-protein
delayed	O
kinetics	O
following	O
CD2	B-protein
stimulation	I-protein
,	O
suggesting	O
that	O
this	O
unique	I-protein
pattern	I-protein
of	I-protein
STAT	O
activation	I-protein
may	O
lead	O
to	I-protein
a	I-protein
distinct	O
cellular	O
response	I-protein
following	O
CD2	B-protein
ligation	O
.	O

This	O
pathway	I-protein
appears	O
to	I-protein
be	O
restricted	I-protein
to	I-protein
T	O
cells	I-protein
,	O
as	O
stimulation	I-protein
of	I-protein
CD2	B-protein
on	I-protein
NK	I-protein
cells	I-protein
does	O
not	I-protein
lead	O
to	I-protein
STAT1	B-protein
activation	I-protein
.	O

CONCLUSION	O
:	O
Stimulation	O
of	I-protein
T	O
cells	I-protein
through	I-protein
cell-surface	B-protein
molecules	I-protein
such	O
as	O
CD2	B-protein
involves	O
activation	I-protein
of	I-protein
STAT	B-protein
transcription	I-protein
factors	I-protein
,	O
thus	O
recapitulating	O
elements	O
of	I-protein
cytokine	O
signaling	O
.	O

###MEDLINE:21109735

NFATc1	B-protein
and	I-protein
NFATc2	B-protein
together	O
control	I-protein
both	O
T	O
and	I-protein
B	O
cell	O
activation	I-protein
and	I-protein
differentiation	I-protein
.	O

NFAT	B-protein
transcription	I-protein
factors	I-protein
play	O
critical	I-protein
roles	O
in	I-protein
gene	O
transcription	O
during	I-protein
immune	O
responses	O
.	O

To	O
investigate	O
further	O
the	I-protein
two	O
most	O
prominent	O
NFAT	B-protein
family	I-protein
members	I-protein
,	O
NFATc1	B-protein
and	I-protein
NFATc2	B-protein
,	O
we	O
generated	O
mice	O
bearing	O
lymphoid	O
systems	O
devoid	O
of	I-protein
both	O
.	O

Doubly	O
deficient	I-protein
T	O
cells	I-protein
displayed	O
cell	O
surface	O
markers	O
of	I-protein
activation	I-protein
yet	O
were	O
significantly	O
deficient	I-protein
in	I-protein
the	I-protein
development	O
of	I-protein
multiple	O
effector	O
functions	O
,	O
including	I-protein
Th	B-protein
cytokine	I-protein
production	I-protein
,	O
surface	B-protein
effector	I-protein
molecule	I-protein
expression	I-protein
,	O
and	I-protein
cytolytic	O
activity	I-protein
.	O

Nevertheless	O
,	O
doubly	O
deficient	I-protein
B	O
cells	I-protein
were	O
hyperactivated	O
,	O
as	O
evidenced	O
by	I-protein
extremely	O
elevated	I-protein
serum	O
IgG1	O
and	I-protein
IgE	B-protein
,	O
as	O
well	O
as	O
plasma	O
cell	O
expansion	O
and	I-protein
infiltration	O
of	I-protein
end	I-protein
organs	O
.	O

Thus	O
,	O
in	I-protein
T	O
cells	I-protein
,	O
NFATc1	B-protein
and	I-protein
NFATc2	B-protein
are	O
dispensable	O
for	I-protein
inflammatory	O
reactivity	O
but	O
are	O
required	O
for	I-protein
effector	O
differentiation	I-protein
,	O
while	O
in	I-protein
B	O
cells	I-protein
,	O
NFATs	B-protein
regulate	O
both	O
normal	O
homeostasis	I-protein
and	I-protein
differentiation	I-protein
.	O

###MEDLINE:21105279

Epstein-barr	O
virus	I-protein
immediate-early	B-protein
protein	I-protein
BZLF1	I-protein
is	O
SUMO-1	B-protein
modified	O
and	I-protein
disrupts	O
promyelocytic	O
leukemia	O
bodies	I-protein
.	O

Although	O
the	I-protein
immediate-early	B-protein
proteins	I-protein
of	I-protein
both	O
herpes	O
simplex	I-protein
virus	I-protein
(	O
HSV	O
)	O
and	I-protein
cytomegalovirus	O
(	O
CMV	O
)	O
are	O
known	O
to	I-protein
modify	O
promyelocytic	O
leukemia	O
(	O
PML	B-protein
)	O
(	O
ND10	O
)	O
bodies	I-protein
in	I-protein
the	I-protein
nucleus	I-protein
of	I-protein
the	I-protein
host	O
cell	O
,	O
it	O
has	O
been	O
unclear	O
whether	O
lytic	O
infection	I-protein
with	I-protein
gamma	O
herpesviruses	O
induces	O
a	I-protein
similar	O
effect	O
.	O

The	O
PML	B-protein
protein	I-protein
is	O
induced	I-protein
by	I-protein
interferon	B-protein
,	O
involved	I-protein
in	I-protein
major	B-protein
histocompatibility	I-protein
complex	I-protein
class	I-protein
I	I-protein
presentation	O
,	O
and	I-protein
necessary	O
for	I-protein
certain	O
types	I-protein
of	I-protein
apoptosis	O
.	O

Therefore	O
,	O
it	O
is	O
likely	B-protein
that	O
PML	O
bodies	I-protein
function	I-protein
in	I-protein
an	I-protein
antiviral	I-protein
capacity	O
.	O

SUMO-1	B-protein
modification	I-protein
of	I-protein
PML	B-protein
is	O
known	O
to	I-protein
be	O
required	O
for	I-protein
the	I-protein
formation	O
of	I-protein
PML	O
bodies	I-protein
.	O

To	O
examine	O
whether	O
Epstein-Barr	B-protein
virus	I-protein
(	O
EBV	O
)	O
lytic	O
replication	O
interferes	O
with	I-protein
PML	O
bodies	I-protein
,	O
we	O
expressed	O
the	I-protein
EBV	O
immediate-early	O
genes	I-protein
BZLF1	O
(	O
Z	I-protein
)	O
and	I-protein
BRLF1	O
(	O
R	I-protein
)	O
in	I-protein
EBV-positive	O
cell	O
lines	B-protein
and	I-protein
examined	O
PML	B-protein
localization	I-protein
.	O

Both	O
Z	I-protein
and	I-protein
R	I-protein
expression	I-protein
resulted	O
in	I-protein
PML	B-protein
dispersion	I-protein
in	I-protein
EBV-positive	O
cells	I-protein
.	O

Z	I-protein
but	O
not	I-protein
R	I-protein
expression	I-protein
is	O
sufficient	O
to	I-protein
disrupt	O
PML	O
bodies	I-protein
in	I-protein
EBV-negative	O
cell	O
lines	B-protein
.	O

We	O
show	O
that	O
dispersion	I-protein
of	I-protein
PML	O
bodies	I-protein
by	I-protein
Z	I-protein
requires	O
a	I-protein
portion	O
of	I-protein
the	I-protein
transcriptional	B-protein
activation	I-protein
domain	I-protein
of	I-protein
Z	I-protein
but	O
not	I-protein
the	I-protein
DNA-binding	O
function	I-protein
.	O

As	O
was	O
previously	O
reported	O
for	I-protein
the	I-protein
HSV-1	B-protein
ICP0	I-protein
and	I-protein
CMV	I-protein
IE1	I-protein
proteins	I-protein
,	O
Z	I-protein
reduces	O
the	I-protein
amount	O
of	I-protein
SUMO-1-modified	B-protein
PML	I-protein
.	O

We	O
also	O
found	O
that	O
Z	I-protein
itself	O
is	O
SUMO-1	B-protein
modified	O
(	O
through	I-protein
amino	O
acid	O
12	O
)	O
and	I-protein
that	O
Z	I-protein
competes	O
with	I-protein
PML	B-protein
for	I-protein
limiting	O
amounts	O
of	I-protein
SUMO-1	B-protein
.	O

These	O
results	O
suggest	O
that	O
disruption	O
of	I-protein
PML	O
bodies	I-protein
is	O
important	O
for	I-protein
efficient	O
lytic	O
replication	O
of	I-protein
EBV	O
.	O

Furthermore	O
,	O
Z	I-protein
may	O
potentially	O
alter	O
the	I-protein
function	I-protein
of	I-protein
a	I-protein
variety	O
of	I-protein
cellular	B-protein
proteins	I-protein
by	I-protein
inhibiting	I-protein
SUMO-1	B-protein
modification	I-protein

###MEDLINE:21136001

Suppression	O
of	I-protein
nuclear	B-protein
factor-kappaB	I-protein
and	I-protein
stimulation	I-protein
of	I-protein
inhibitor	B-protein
kappaB	I-protein
by	I-protein
troglitazone	O
:	O
evidence	O
for	I-protein
an	I-protein
anti-inflammatory	O
effect	O
and	I-protein
a	I-protein
potential	I-protein
antiatherosclerotic	O
effect	O
in	I-protein
the	I-protein
obese	O
.	O

To	O
elucidate	O
whether	O
troglitazone	O
exerts	O
an	I-protein
antiinflammatory	O
effect	O
in	I-protein
humans	O
,	O
in	I-protein
vivo	O
,	O
we	O
investigated	O
the	I-protein
suppression	O
of	I-protein
nuclear	B-protein
factor	I-protein
kappaB	I-protein
(	O
NFkappaB	B-protein
)	O
in	I-protein
mononuclear	O
cells	I-protein
(	O
MNC	O
)	O
by	I-protein
this	O
drug	O
.	O

We	O
measured	O
intranuclear	B-protein
NFkappaB	I-protein
,	O
total	O
cellular	B-protein
NFkappaB	I-protein
,	O
inhibitor	B-protein
kappaB	I-protein
(	O
IkappaB	I-protein
)	O
alpha	I-protein
,	O
reactive	I-protein
oxygen	O
species	O
(	O
ROS	B-protein
)	O
generation	O
,	O
and	I-protein
p47	B-protein
(	O
phox	I-protein
)	O
subunit	I-protein
(	O
a	I-protein
key	O
component	O
protein	O
of	I-protein
nicotinamide	B-protein
adenine	I-protein
dinucleotide	I-protein
phosphate	I-protein
oxidase	I-protein
)	O
in	I-protein
MNC	O
.	O

Plasma	I-protein
tumor	I-protein
necrosis	I-protein
factor	I-protein
(	O
TNF	I-protein
)	O
-alpha	I-protein
,	O
soluble	I-protein
intercellular	B-protein
adhesion	I-protein
molecule-1	I-protein
(	O
sICAM-1	O
)	O
,	O
monocyte	B-protein
chemoattractant	I-protein
protein-1	I-protein
(	O
MCP-1	B-protein
)	O
,	O
plasminogen	B-protein
activator	I-protein
inhibitor	I-protein
type	I-protein
1	I-protein
(	O
PAI-1	B-protein
)	O
,	O
C-reactive	B-protein
protein	I-protein
(	O
CRP	B-protein
)	O
,	O
and	I-protein
interleukin	B-protein
(	O
IL	I-protein
)	O
-10	I-protein
(	O
antiinflammatory	B-protein
cytokine	I-protein
)	O
concentrations	O
were	O
also	O
measured	O
as	O
mediators	O
of	I-protein
inflammatory	O
activity	I-protein
that	O
are	O
regulated	O
by	I-protein
the	I-protein
proinflammatory	B-protein
transcription	I-protein
factor	I-protein
NFkappaB	I-protein
.	O

Seven	O
nondiabetic	O
obese	O
patients	O
were	O
given	O
400	O
mg	O
troglitazone	O
daily	O
for	I-protein
4	I-protein
weeks	O
.	O

Blood	B-protein
samples	O
were	O
collected	O
before	O
and	I-protein
at	I-protein
weekly	O
intervals	O
thereafter	O
.	O

MNC	O
were	O
separated	O
;	O
and	I-protein
the	I-protein
levels	I-protein
of	I-protein
intranuclear	B-protein
NFkappaB	I-protein
,	O
total	O
cellular	B-protein
NFkappaB	I-protein
,	O
IkappaBalpha	B-protein
,	O
and	I-protein
p47	B-protein
(	O
phox	I-protein
)	O
subunit	I-protein
and	I-protein
ROS	B-protein
generation	O
were	O
determined	O
.	O

Plasma	I-protein
was	O
used	O
to	I-protein
measure	O
insulin	O
glucose	O
,	O
TNFalpha	B-protein
,	O
sICAM	O
,	O
MCP-1	B-protein
,	O
PAI-1	B-protein
,	O
CRP	B-protein
,	O
and	I-protein
IL-10	B-protein
.	O

Plasma	I-protein
insulin	O
concentrations	O
fell	O
significantly	O
at	I-protein
week	O
1	I-protein
,	O
from	I-protein
31.2	O
+/-	O
29.1	O
to	I-protein
14.2	O
+/-	O
11.4	O
mU/L	O
(	O
P	O
<	O
0.01	O
)	O
and	I-protein
remained	O
low	O
throughout	O
4	I-protein
weeks	O
.	O

Plasma	I-protein
glucose	O
concentrations	O
did	O
not	I-protein
alter	O
significantly	O
.	O

There	O
was	O
a	I-protein
fall	O
in	I-protein
intranuclear	B-protein
NFkappaB	I-protein
,	O
total	O
cellular	B-protein
NFkappaB	I-protein
,	O
and	I-protein
p47	B-protein
(	O
phox	I-protein
)	O
subunit	I-protein
,	O
with	I-protein
an	I-protein
increase	O
in	I-protein
cellular	O
IkappaBalpha	B-protein
at	I-protein
week	O
2	I-protein
,	O
which	O
persisted	O
until	O
week	O
4	I-protein
.	O

There	O
was	O
a	I-protein
parallel	O
fall	O
in	I-protein
ROS	B-protein
generation	O
by	I-protein
MNC	O
at	I-protein
week	O
1	I-protein
;	O
this	O
progressed	O
and	I-protein
persisted	O
until	O
week	O
4	I-protein
(	O
P	O
<	O
0.001	O
)	O
.	O

Plasma	I-protein
TNF-alpha	B-protein
,	O
sICAM-1	B-protein
,	O
MCP-1	B-protein
,	O
and	I-protein
PAI-1	B-protein
concentrations	O
fell	O
significantly	O
at	I-protein
week	O
4	I-protein
.	O

Plasma	I-protein
IL-10	B-protein
concentration	I-protein
increased	I-protein
significantly	O
,	O
whereas	O
plasma	B-protein
CRP	B-protein
concentrations	O
decreased	O
.	O

We	O
conclude	O
that	O
troglitazone	O
has	O
an	I-protein
antiinflammatory	O
action	O
that	O
may	O
contribute	O
to	I-protein
its	O
putative	O
antiatherosclerotic	O
effects	O
.	O

###MEDLINE:21153258

Tyrosine	O
phosphorylation-dependent	O
activation	I-protein
of	I-protein
NF-kappa	B-protein
B	I-protein
.	O

Requirement	O
for	I-protein
p56	B-protein
LCK	B-protein
and	I-protein
ZAP-70	B-protein
protein	I-protein
tyrosine	I-protein
kinases	I-protein
.	O

Phosphorylation	O
of	I-protein
the	I-protein
N-terminal	B-protein
domain	I-protein
of	I-protein
I	I-protein
kappa	I-protein
B	I-protein
inhibitory	I-protein
subunits	I-protein
induces	O
activation	I-protein
of	I-protein
the	I-protein
transcription	B-protein
factor	I-protein
NF-kappa	I-protein
B	I-protein
.	O

Although	O
serine	O
phosphorylation	I-protein
has	O
been	O
shown	O
to	I-protein
induce	O
ubiquitination	B-protein
and	I-protein
subsequent	O
proteasome-mediated	O
degradation	I-protein
of	I-protein
I	I-protein
kappa	I-protein
B-alpha	I-protein
,	O
little	O
is	O
known	O
about	O
the	I-protein
mechanisms	O
that	O
lead	O
to	I-protein
release	I-protein
of	I-protein
active	B-protein
NF-kappa	I-protein
B	I-protein
in	I-protein
T	O
cells	I-protein
as	O
a	I-protein
consequence	O
of	I-protein
tyrosine	O
phosphorylation	I-protein
of	I-protein
I	I-protein
kappa	I-protein
B-alpha	I-protein
[	O
Imbert	O
,	O
V.	O
,	O
Rupec	O
,	O
R.A.	O
,	O
Livolsi	O
,	O
A.	I-protein
,	O
Pahl	O
,	O
H.L.	O
,	O
Traenckner	O
,	O
B.M.	O
,	O
Mueller-Dieckmann	O
,	O
C.	I-protein
,	O
Farahifar	O
,	O
D.	O
,	O
Rossi	O
,	O
B.	O
,	O
Auberger	O
,	O
P.	O
,	O
Baeuerle	O
,	O
P.	O
&	O
Peyron	O
,	O
J.F.	O
(	O
1996	O
)	O
Cell	I-protein
86	I-protein
,	O
787	I-protein
--	I-protein
798	O
]	O
.	O

The	O
involvement	I-protein
of	I-protein
the	I-protein
tyrosine	B-protein
kinases	I-protein
p56	B-protein
(	O
lck	I-protein
)	O
and	I-protein
ZAP-70	B-protein
in	I-protein
this	O
reaction	I-protein
is	O
demonstrated	O
here	O
using	O
specific	I-protein
pharmacological	O
inhibitors	I-protein
and	I-protein
Jurkat	O
mutants	O
unable	O
to	I-protein
express	O
these	O
kinases	I-protein
.	O

Although	O
the	I-protein
inhibitors	I-protein
prevented	O
both	O
pervanadate-induced	O
phosphorylation	I-protein
of	I-protein
I	I-protein
kappa	I-protein
B-alpha	I-protein
on	I-protein
Tyr42	O
and	I-protein
NF-kappa	B-protein
B	I-protein
activation	I-protein
,	O
we	O
observed	O
that	O
,	O
in	I-protein
p56	B-protein
(	O
lck	O
)	O
-deficient	O
Jurkat	O
mutants	O
,	O
NF-kappa	B-protein
B	I-protein
could	O
still	O
associate	O
with	I-protein
I	I-protein
kappa	I-protein
B-alpha	I-protein
despite	O
phosphorylation	I-protein
on	I-protein
Tyr42	O
.	O

Furthermore	O
,	O
the	I-protein
SH2	B-protein
domain	I-protein
of	I-protein
p56	B-protein
(	O
lck	I-protein
)	O
appeared	O
to	I-protein
be	O
required	O
for	I-protein
pervanadate-induced	O
NF-kappa	B-protein
B	I-protein
activation	I-protein
but	O
not	I-protein
for	I-protein
Tyr42	O
phosphorylation	I-protein
.	O

These	O
results	O
show	O
that	O
p56	B-protein
(	O
lck	I-protein
)	O
and	I-protein
ZAP-70	B-protein
are	O
key	O
components	O
of	I-protein
the	I-protein
signaling	O
pathway	I-protein
that	O
leads	O
to	I-protein
phosphotyrosine-dependent	O
NF-kappa	B-protein
B	I-protein
activation	I-protein
in	I-protein
T	O
cells	I-protein
and	I-protein
confirm	O
that	O
tyrosine	B-protein
kinases	I-protein
must	O
control	I-protein
at	I-protein
least	O
two	O
different	O
steps	O
to	I-protein
induce	O
activation	I-protein
of	I-protein
NF-kappa	B-protein
B	I-protein
.	O

Finally	O
,	O
we	O
show	O
that	O
H	I-protein
(	O
2	I-protein
)	O
O	I-protein
(	O
2	I-protein
)	O
,	O
which	O
stimulates	O
p56	B-protein
(	O
lck	I-protein
)	O
and	I-protein
ZAP-70	B-protein
in	I-protein
T	O
cells	I-protein
,	O
is	O
an	I-protein
activator	O
of	I-protein
NF-kappa	B-protein
B	I-protein
through	I-protein
tyrosine	O
phosphorylation	I-protein
of	I-protein
I	I-protein
kappa	I-protein
B-alpha	I-protein
.	O

###MEDLINE:21163376

Specific	B-protein
missense	O
mutations	I-protein
in	I-protein
NEMO	B-protein
result	O
in	I-protein
hyper-IgM	I-protein
syndrome	I-protein
with	I-protein
hypohydrotic	O
ectodermal	I-protein
dysplasia	I-protein
.	O

The	O
gene	O
that	O
encodes	O
nuclear	B-protein
factor	I-protein
kappaB	I-protein
(	O
NF-kappaB	B-protein
)	O
essential	O
modulator	O
(	O
or	I-protein
NEMO	B-protein
,	O
also	O
known	O
as	O
IKKgamma	O
)	O
is	O
required	O
for	I-protein
activation	I-protein
of	I-protein
the	I-protein
transcription	B-protein
factor	I-protein
NF-kappaB	B-protein
.	O

We	O
describe	O
mutations	I-protein
in	I-protein
the	I-protein
putative	B-protein
zinc-finger	I-protein
domain	I-protein
of	I-protein
NEMO	B-protein
that	O
result	O
in	I-protein
an	I-protein
X-linked	O
primary	O
immunodeficiency	I-protein
characterized	O
by	I-protein
hyper-IgM	I-protein
syndrome	I-protein
and	I-protein
hypohydrotic	O
ectodermal	I-protein
dysplasia	I-protein
(	O
XHM-ED	O
)	O
.	O

These	O
mutations	I-protein
prevent	O
CD40	B-protein
ligand	I-protein
(	O
CD40L	B-protein
)	O
-mediated	O
degradation	I-protein
of	I-protein
inhibitor	O
of	I-protein
NF-kappaB	B-protein
alpha	I-protein
(	O
IkappaB-alpha	B-protein
)	O
and	I-protein
account	O
for	I-protein
the	I-protein
following	O
observations	O
:	O
B	O
cells	I-protein
from	I-protein
XHM-ED	O
patients	O
are	O
unable	O
to	I-protein
undergo	O
immunoglobulin	O
class-switch	O
recombination	O
and	I-protein
antigen-presenting	O
cells	I-protein
(	O
APCs	O
)	O
are	O
unable	O
to	I-protein
synthesize	O
the	I-protein
NF-kappaB-regulated	B-protein
cytokines	I-protein
interleukin	B-protein
12	I-protein
(	O
IL-12	B-protein
)	O
or	I-protein
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
(	O
TNF-alpha	B-protein
)	O
when	O
stimulated	O
with	I-protein
CD40L	B-protein
.	O

Nevertheless	O
,	O
innate	O
immunity	O
is	O
preserved	O
in	I-protein
XHM-ED	O
patients	O
because	O
APCs	O
retain	O
the	I-protein
capacity	O
to	I-protein
respond	O
to	I-protein
stimulation	I-protein
by	I-protein
lipopolysaccharide	B-protein
or	I-protein
Staphylococcus	B-protein
aureus	I-protein
Cowan	I-protein
's	I-protein
antigen	I-protein
(	O
SAC	B-protein
)	O
.	O

Overall	O
,	O
the	I-protein
phenotype	O
observed	O
in	I-protein
XHM-ED	O
patients	O
shows	O
that	O
the	I-protein
putative	B-protein
zinc-finger	I-protein
domain	I-protein
of	I-protein
NEMO	B-protein
has	O
a	I-protein
regulatory	O
function	I-protein
and	I-protein
demonstrates	O
the	I-protein
definite	O
requirement	O
of	I-protein
CD40	B-protein
-mediated	O
NF-kappaB	B-protein
activation	I-protein
for	I-protein
B	O
cell	O
immunoglobulin	O
class-switching	O
.	O

###MEDLINE:21079795

Granulocytic	O
differentiation	I-protein
of	I-protein
human	O
NB4	O
promyelocytic	O
leukemia	O
cells	I-protein
induced	I-protein
by	I-protein
all-trans	I-protein
retinoic	O
acid	O
metabolites	O
.	O

The	O
metabolism	I-protein
of	I-protein
all-trans	I-protein
retinoic	O
acid	O
(	O
ATRA	O
)	O
has	O
been	O
reported	O
to	I-protein
be	O
partly	O
responsible	O
for	I-protein
the	I-protein
in	I-protein
vivo	O
resistance	O
to	I-protein
ATRA	O
seen	O
in	I-protein
the	I-protein
treatment	O
of	I-protein
human	O
acute	O
promyelocytic	O
leukemia	O
(	O
APL	O
)	O
.	O

However	O
,	O
ATRA	O
metabolism	I-protein
appears	O
to	I-protein
be	O
involved	I-protein
in	I-protein
the	I-protein
growth	O
inhibition	O
of	I-protein
several	I-protein
cancer	O
cell	O
lines	B-protein
in	I-protein
vitro	O
.	O

The	O
purpose	O
of	I-protein
this	O
study	O
was	O
to	I-protein
evaluate	O
the	I-protein
in	I-protein
vitro	O
activity	I-protein
of	I-protein
the	I-protein
principal	O
metabolites	O
of	I-protein
ATRA	O
[	O
4-hydroxy-retinoic	O
acid	O
(	O
4-OH-RA	O
)	O
,	O
18-hydroxy-retinoic	O
acid	O
(	O
18-OH-RA	O
)	O
,	O
4-oxo-retinoic	O
acid	O
(	O
4-oxo-RA	O
)	O
,	O
and	I-protein
5	O
,	O
6-epoxy-retinoic	O
acid	O
(	O
5	O
,	O
6-epoxy-RA	O
)	O
]	O
in	I-protein
NB4	O
,	O
a	I-protein
human	O
promyelocytic	O
leukemia	O
cell	O
line	I-protein
that	O
exhibits	O
the	I-protein
APL	O
diagnostic	O
t	I-protein
(	O
15	O
;	O
17	I-protein
)	O
chromosomal	I-protein
translocation	O
and	I-protein
expresses	O
the	I-protein
PML-RAR	B-protein
alpha	I-protein
fusion	I-protein
protein	I-protein
.	O

We	O
established	O
that	O
the	I-protein
four	O
ATRA	O
metabolites	O
were	O
indeed	O
formed	O
by	I-protein
the	I-protein
NB4	O
cells	I-protein
in	I-protein
vitro	O
.	O

NB4	O
cell	O
growth	O
was	O
inhibited	O
(	O
69-78	O
%	O
at	I-protein
120	I-protein
h	I-protein
)	O
and	I-protein
cell	O
cycle	I-protein
progression	I-protein
in	I-protein
the	I-protein
G1	O
phase	I-protein
(	O
82-85	O
%	O
at	I-protein
120	I-protein
h	I-protein
)	O
was	O
blocked	B-protein
by	I-protein
ATRA	O
and	I-protein
all	O
of	I-protein
the	I-protein
metabolites	O
at	I-protein
1	I-protein
microM	O
concentration	I-protein
.	O

ATRA	O
and	I-protein
its	O
metabolites	O
could	O
induce	O
NB4	O
cells	I-protein
differentiation	I-protein
with	I-protein
similar	O
activity	I-protein
,	O
as	O
evaluated	O
by	I-protein
cell	O
morphology	O
,	O
by	I-protein
the	I-protein
nitroblue	O
tetrazolium	O
reduction	I-protein
test	O
(	O
82-88	O
%	O
at	I-protein
120	I-protein
h	I-protein
)	O
or	I-protein
by	I-protein
the	I-protein
expression	I-protein
of	I-protein
the	I-protein
maturation	I-protein
specific	I-protein
cell	I-protein
surface	I-protein
marker	I-protein
CD11c	I-protein
.	O

In	O
addition	O
,	O
nuclear	O
body	O
reorganization	O
to	I-protein
macropunctated	O
structures	O
,	O
as	O
well	O
as	O
the	I-protein
degradation	I-protein
of	I-protein
PML-RAR	B-protein
alpha	I-protein
,	O
was	O
found	O
to	I-protein
be	O
similar	O
for	I-protein
ATRA	O
and	I-protein
all	O
of	I-protein
its	O
metabolites	O
.	O

Comparison	O
of	I-protein
the	I-protein
relative	I-protein
potency	O
of	I-protein
the	I-protein
retinoids	O
using	O
the	I-protein
nitroblue	O
tetrazolium	O
reduction	I-protein
test	O
showed	O
effective	O
concentrations	O
required	O
to	I-protein
differentiate	O
50	I-protein
%	O
of	I-protein
cells	I-protein
in	I-protein
72	I-protein
h	I-protein
as	O
follows	O
:	O
ATRA	O
,	O
15.8	O
+/-	O
1.7	O
nM	O
;	O
4-oxo-RA	O
,	O
38.3	O
+/-	O
1.3	O
nM	O
;	O
18-OH-RA	O
,	O
55.5	O
+/-	O
1.8	O
nM	O
;	O
4-OH-RA	O
,	O
79.8	O
+/-	O
1.8	O
nM	O
;	O
and	I-protein
5	O
,	O
6-epoxy-RA	O
,	O
99.5	O
+/-	O
1.5	I-protein
nM	O
.	O

The	O
ATRA	O
metabolites	O
were	O
found	O
to	I-protein
exert	O
their	O
differentiation	I-protein
effects	O
via	I-protein
the	I-protein
RAR	B-protein
alpha	I-protein
nuclear	I-protein
receptors	I-protein
,	O
because	O
the	I-protein
RAR	B-protein
alpha-specific	O
antagonist	O
BMS614	O
blocked	B-protein
metabolite-induced	O
CD11c	O
expression	I-protein
in	I-protein
NB4	O
cells	I-protein
.	O

These	O
data	O
demonstrate	O
that	O
the	I-protein
principal	O
ATRA	O
Phase	O
1	I-protein
metabolites	O
can	O
elicit	O
leukemia	O
cell	O
growth	O
inhibition	O
and	I-protein
differentiation	I-protein
in	I-protein
vitro	O
through	I-protein
the	I-protein
RAR	B-protein
alpha	O
signaling	O
pathway	I-protein
,	O
and	I-protein
they	O
suggest	O
that	O
these	O
metabolites	O
may	O
play	O
a	I-protein
role	O
in	I-protein
ATRA	O
antileukemic	O
activity	I-protein
in	I-protein
vivo	O
.	O

###MEDLINE:21108585

Expression	O
of	I-protein
oestrogen	B-protein
and	I-protein
progesterone	B-protein
receptors	I-protein
by	I-protein
mast	O
cells	I-protein
alone	O
,	O
but	O
not	I-protein
lymphocytes	O
,	O
macrophages	O
or	I-protein
other	O
immune	O
cells	I-protein
in	I-protein
human	O
upper	O
airways	O
.	O

BACKGROUND	O
:	O
Nasal	O
polyposis	I-protein
often	O
coexists	O
with	I-protein
asthma	I-protein
in	I-protein
airway	I-protein
inflammatory	O
conditions	O
characterised	O
by	I-protein
the	I-protein
infiltration	O
of	I-protein
a	I-protein
range	O
of	I-protein
immune	O
cells	I-protein
.	O

A	O
potentially	O
important	O
role	O
for	I-protein
ovarian	I-protein
hormones	I-protein
has	O
been	O
implicated	O
in	I-protein
airway	I-protein
inflammation	O
but	O
the	I-protein
cellular	O
target	O
for	I-protein
such	O
action	O
is	O
not	I-protein
known	O
.	O

METHODS	O
:	O
Expression	O
of	I-protein
oestrogen	B-protein
receptors	I-protein
(	O
ER	B-protein
)	O
and	I-protein
progesterone	B-protein
receptors	I-protein
(	O
PR	B-protein
)	O
was	O
examined	O
using	O
immunohistochemistry	O
in	I-protein
formalin	O
fixed	O
nasal	O
polyp	O
tissues	O
from	I-protein
47	I-protein
subjects	O
.	O

The	O
cells	I-protein
positive	I-protein
for	I-protein
ER	B-protein
or	I-protein
PR	B-protein
were	O
confirmed	O
by	I-protein
spatial	B-protein
location	O
,	O
dual	O
immunolabelling	O
,	O
and	I-protein
histochemical	O
staining	O
.	O

RESULTS	O
:	O
Consistent	O
with	I-protein
the	I-protein
known	O
features	I-protein
of	I-protein
nasal	O
polyps	O
,	O
CD4+	O
(	O
T	O
helper/inducer	O
)	O
,	O
CD8+	O
(	O
cytotoxic/suppressor	O
)	O
,	O
CD68+	O
(	O
macrophages	O
)	O
,	O
mast	O
cells	I-protein
,	O
eosinophils	O
and	I-protein
neutrophils	O
were	O
all	O
clearly	O
detected	O
by	I-protein
their	O
relevant	I-protein
monoclonal	I-protein
antibodies	I-protein
or	I-protein
appropriate	O
histochemical	O
staining	O
,	O
but	O
only	I-protein
mast	O
cells	I-protein
tested	O
positive	I-protein
for	I-protein
ER	B-protein
/PR	O
labelling	O
with	I-protein
their	O
polyclonal	I-protein
and	I-protein
monoclonal	I-protein
antibodies	I-protein
.	O

The	O
frequencies	O
for	I-protein
expression	I-protein
were	O
61.7	O
%	O
for	I-protein
ER	O
positive	I-protein
and	I-protein
59.6	O
%	O
for	I-protein
PR	O
positive	I-protein
cells	I-protein
.	O

The	O
expression	I-protein
of	I-protein
ER	B-protein
/	O
PR	B-protein
was	O
independent	I-protein
of	I-protein
patient	O
sex	O
and	I-protein
age	I-protein
but	O
was	O
highly	O
correlated	O
with	I-protein
the	I-protein
numbers	O
of	I-protein
mast	O
cells	I-protein
(	O
r	I-protein
=	O
0.973	O
,	O
p	O
<	O
0.001	O
for	I-protein
ER	B-protein
;	O
r	I-protein
=	O
0.955	O
,	O
p	O
<	O
0.001	O
for	I-protein
PR	B-protein
)	O
.	O

Fewer	O
than	I-protein
5	O
%	O
of	I-protein
mast	O
cells	I-protein
were	O
found	O
to	I-protein
be	O
negative	O
for	I-protein
ER	B-protein
/	O
PR	B-protein
expression	I-protein
.	O

CONCLUSIONS	O
:	O
Mast	I-protein
cells	I-protein
alone	O
,	O
but	O
not	I-protein
lymphocytes	O
,	O
macrophages	O
,	O
or	I-protein
other	O
immune	O
cells	I-protein
,	O
express	O
ER	B-protein
/	O
PR	B-protein
in	I-protein
human	O
upper	O
airways	O
.	O

Numerous	O
ER/PR	O
positive	I-protein
mast	O
cells	I-protein
exist	O
in	I-protein
nasal	O
polyps	O
,	O
indicating	O
that	O
this	O
may	O
be	O
a	I-protein
major	O
route	O
for	I-protein
the	I-protein
involvement	I-protein
of	I-protein
sex	O
hormones	I-protein
in	I-protein
airway	I-protein
inflammation	O
when	O
exposed	O
to	I-protein
the	I-protein
higher	O
and	I-protein
varying	O
concentration	I-protein
of	I-protein
oestrogen	O
and	I-protein
progesterone	B-protein
characteristic	O
of	I-protein
females	O
.	O

###MEDLINE:21093289

NF	O
kappa	I-protein
b	O
signaling	O
in	I-protein
posthypoxic	O
endothelial	O
cells	I-protein
:	O
relevance	O
to	I-protein
E-selectin	O
expression	I-protein
and	I-protein
neutrophil	O
adhesion	O
.	O

Our	O
previous	O
studies	O
have	O
implicated	O
the	I-protein
nuclear	B-protein
transcription	I-protein
factor	I-protein
kappa	I-protein
B	I-protein
(	O
NF	B-protein
kappa	I-protein
B	I-protein
)	O
in	I-protein
the	I-protein
regulation	I-protein
of	I-protein
adhesion	O
molecule	I-protein
expression	I-protein
in	I-protein
endothelial	O
cells	I-protein
exposed	O
to	I-protein
anoxia-reoxygenation	O
(	O
A/R	O
)	O
or	I-protein
a	I-protein
redox	O
imbalance	O
.	O

The	O
objectives	O
of	I-protein
this	O
study	O
were	O
(	O
1	I-protein
)	O
to	I-protein
define	O
the	I-protein
kinetics	O
of	I-protein
NF	B-protein
kappa	I-protein
B	I-protein
activation	I-protein
by	I-protein
examining	O
I	I-protein
kappa	I-protein
B	O
alpha	O
degradation	I-protein
and	I-protein
the	I-protein
nuclear	O
translocation	O
of	I-protein
p65	B-protein
in	I-protein
response	I-protein
to	I-protein
A/R	O
or	I-protein
redox	O
imbalance	O
(	O
induced	I-protein
by	I-protein
treatment	O
of	I-protein
cells	I-protein
with	I-protein
diamide	O
and	I-protein
buthionine	O
sulfoximine	O
)	O
and	I-protein
(	O
2	I-protein
)	O
to	I-protein
determine	O
whether	O
the	I-protein
signal	O
for	I-protein
I	I-protein
kappa	I-protein
B	O
alpha	O
degradation	I-protein
,	O
nuclear	O
translocation	O
of	I-protein
p65	B-protein
,	O
and	I-protein
E-selectin	B-protein
-mediated	O
neutrophil	O
adhesion	O
is	O
related	O
to	I-protein
the	I-protein
activity	I-protein
of	I-protein
protein	B-protein
tyrosine	I-protein
kinase	I-protein
(	O
PTK	B-protein
)	O
,	O
protein	B-protein
tyrosine	I-protein
phosphatase	I-protein
(	O
PTPase	O
)	O
and/or	O
protein	B-protein
kinase	I-protein
C	I-protein
(	O
PKC	B-protein
)	O
.	O

The	O
results	O
demonstrate	O
that	O
both	O
A/R	O
and	I-protein
redox	O
imbalance	O
led	O
to	I-protein
I	I-protein
kappa	I-protein
B	O
alpha	O
degradation	I-protein
within	B-protein
30	I-protein
min	O
and	I-protein
the	I-protein
concomitant	O
appearance	O
of	I-protein
p65	B-protein
in	I-protein
the	I-protein
nucleus	I-protein
,	O
consistent	O
with	I-protein
rapid	O
cytosolic	O
activation	I-protein
of	I-protein
NF	B-protein
kappa	I-protein
B	I-protein
and	I-protein
subsequent	O
nuclear	O
translocation	O
of	I-protein
the	I-protein
activated	B-protein
p65	I-protein
subunit	I-protein
.	O

Inhibition	O
of	I-protein
PKC	B-protein
blocked	B-protein
I	I-protein
kappa	I-protein
B	O
alpha	O
degradation	I-protein
and	I-protein
p65	B-protein
translocation	O
in	I-protein
A/R-challenged	O
,	O
but	O
not	I-protein
redox-altered	O
,	O
endothelial	O
cells	I-protein
.	O

However	O
,	O
both	O
A/R-	O
and	I-protein
redox-induced	O
NF	O
kappa	I-protein
B	O
activation	I-protein
was	O
blocked	B-protein
by	I-protein
inhibition	O
of	I-protein
PTK	B-protein
.	O

Similarly	O
,	O
A/R-induced	O
E-selectin	O
expression	I-protein
and	I-protein
neutrophil-endothelial	O
cell	O
adhesion	O
were	O
blocked	B-protein
by	I-protein
inhibition	O
of	I-protein
PKC	B-protein
or	I-protein
PTK	B-protein
,	O
while	O
only	I-protein
PTK	B-protein
inhibited	O
the	I-protein
redox-induced	O
adhesion	O
response	I-protein
.	O

Pretreatment	O
of	I-protein
cells	I-protein
with	I-protein
N-acetyl	I-protein
cysteine	O
effectively	O
blocked	B-protein
A/R-	O
or	I-protein
redox-induced	O
I	I-protein
kappa	I-protein
B	O
degradation	I-protein
and	I-protein
significantly	O
attenuated	O
the	I-protein
respective	O
neutrophil	O
adhesion	O
responses	O
.	O

Collectively	O
,	O
these	O
findings	O
indicate	O
that	O
A/R-induced	O
E-selectin	O
expression	I-protein
and	I-protein
neutrophil-endothelial	O
cell	O
adhesion	O
are	O
mediated	I-protein
by	I-protein
both	O
PKC	B-protein
and	I-protein
PTK	B-protein
,	O
which	O
signal	O
rapid	O
activation	I-protein
of	I-protein
NF	B-protein
kappa	I-protein
B	I-protein
.	O

This	O
A/R-induced	O
NF	B-protein
kappa	I-protein
B	I-protein
signaling	O
response	I-protein
appears	O
to	I-protein
be	O
mediated	I-protein
,	O
at	I-protein
least	O
in	I-protein
part	I-protein
,	O
by	I-protein
intracellular	I-protein
redox	O
imbalance	O
.	O

Copyright	O
2001	O
S.	I-protein
Karger	O
AG	I-protein
,	O
Basel	O

###MEDLINE:21100758

Induction	O
of	I-protein
apoptosis	O
in	I-protein
human	O
lymphocytes	O
by	I-protein
the	I-protein
herbicide	O
2	I-protein
,	O
4-dichlorophenoxyacetic	O
acid	O
.	O

Dimethylammonium	O
salt	O
of	I-protein
2	I-protein
,	O
4-dichlorophenoxyacetic	O
acid	O
(	O
DMA-2	O
,	O
4-D	O
)	O
is	O
a	I-protein
widely	B-protein
used	O
herbicide	O
that	O
is	O
considered	O
moderately	O
toxic	O
.	O

In	O
the	I-protein
present	O
study	O
we	O
found	O
that	O
DMA-2	O
,	O
4-D	O
is	O
able	O
to	I-protein
cause	O
apoptosis	O
in	I-protein
peripheral	O
blood	O
lymphocytes	O
of	I-protein
healthy	O
individuals	O
and	I-protein
Jurkat	O
T	O
cells	I-protein
.	O

Apoptosis	I-protein
induced	I-protein
by	I-protein
DMA-2	O
,	O
4-D	O
was	O
dose	O
and	I-protein
time	O
dependent	I-protein
,	O
independent	I-protein
of	I-protein
Fas	B-protein
,	O
TNF	B-protein
receptor	I-protein
1	I-protein
or	I-protein
the	I-protein
aromatic	I-protein
hydrocarbon	I-protein
receptor	I-protein
,	O
and	I-protein
involved	I-protein
disruption	O
of	I-protein
the	I-protein
mitochondrial	O
transmembrane	O
potential	I-protein
and	I-protein
activation	I-protein
of	I-protein
caspase-9	B-protein
.	O

ZVAD-FMK	O
,	O
a	I-protein
broad-spectrum	O
inhibitor	O
of	I-protein
caspases	B-protein
,	O
blocked	B-protein
DMA-2	O
,	O
4-D-induced	O
apoptosis	O
completely	O
.	O

While	O
an	I-protein
inhibitor	O
of	I-protein
caspase-9	B-protein
,	O
as	O
well	O
as	O
caspase-9	B-protein
and	I-protein
caspase-3	O
inhibitors	I-protein
in	I-protein
combination	O
,	O
strongly	O
blocked	B-protein
DMA-2	O
,	O
4-D-induced	O
apoptosis	O
,	O
an	I-protein
inhibitor	O
of	I-protein
caspase-3	B-protein
had	O
a	I-protein
moderate	O
inhibitory	O
effect	O
.	O

Unlike	O
Fas	B-protein
-mediated	O
apoptosis	O
,	O
the	I-protein
initiator	I-protein
caspase	I-protein
,	O
caspase-8	O
,	O
was	O
not	I-protein
involved	I-protein
in	I-protein
DMA-2	O
,	O
4-D-induced	O
apoptosis	O
.	O

Transfection	O
of	I-protein
Jurkat	O
cells	I-protein
with	I-protein
Bcl-2	B-protein
prevented	O
DMA-2	O
,	O
4-D-induced	O
disruption	O
of	I-protein
the	I-protein
mitochondrial	O
transmembrane	O
potential	I-protein
and	I-protein
led	O
to	I-protein
a	I-protein
complete	O
blockage	O
of	I-protein
apoptosis	O
.	O

Our	O
data	O
indicate	O
that	O
DMA-2	O
,	O
4-D	O
kills	O
human	O
lymphocytes	O
by	I-protein
initiating	O
apoptosis	O
via	I-protein
a	I-protein
direct	O
effect	O
on	I-protein
mitochondria	O
.	O

The	O
activation	I-protein
of	I-protein
caspases	B-protein
occurs	O
downstream	O
of	I-protein
mitochondrial	O
damage	I-protein
,	O
and	I-protein
the	I-protein
dysfunction	O
of	I-protein
mitochondria	O
appears	O
to	I-protein
be	O
sufficient	O
for	I-protein
triggering	O
all	O
downstream	O
events	O
leading	O
to	I-protein
apoptosis	O
.	O

###MEDLINE:21036309

Inhibition	O
of	I-protein
Th1	O
differentiation	I-protein
by	I-protein
IL-6	B-protein
is	O
mediated	I-protein
by	I-protein
SOCS1	B-protein
.	O

Interleukin	B-protein
6	I-protein
(	O
IL-6	B-protein
)	O
is	O
a	I-protein
cytokine	B-protein
produced	O
by	I-protein
immune	O
and	I-protein
nonimmune	O
cells	I-protein
and	I-protein
exhibits	O
functional	O
pleiotropy	O
and	I-protein
redundancy	O
.	O

IL-6	B-protein
plays	O
an	I-protein
important	O
role	O
in	I-protein
the	I-protein
differentiation	I-protein
of	I-protein
several	I-protein
cell	O
types	I-protein
.	O

Here	O
,	O
we	O
describe	O
a	I-protein
novel	O
function	I-protein
of	I-protein
IL-6	B-protein
:	O
the	I-protein
negative	O
regulation	I-protein
of	I-protein
CD4	B-protein
+	O
Th1	O
cell	O
differentiation	I-protein
.	O

While	O
IL-6	B-protein
-directed	O
CD4	B-protein
+	O
Th2	O
differentiation	I-protein
is	O
mediated	I-protein
by	I-protein
IL-4	B-protein
,	O
inhibition	O
of	I-protein
Th1	O
differentiation	I-protein
by	I-protein
IL-6	B-protein
is	O
independent	I-protein
of	I-protein
IL-4	B-protein
.	O

IL-6	B-protein
upregulates	O
suppressor	B-protein
of	I-protein
cytokine	I-protein
signaling	I-protein
1	I-protein
(	O
SOCS1	B-protein
)	O
expression	I-protein
in	I-protein
activated	O
CD4+	O
T	O
cells	I-protein
,	O
thereby	O
interfering	I-protein
with	I-protein
signal	B-protein
transducer	I-protein
and	I-protein
activator	I-protein
of	I-protein
transcription	I-protein
1	I-protein
(	O
STAT1	B-protein
)	O
phosphorylation	I-protein
induced	I-protein
by	I-protein
interferon	B-protein
gamma	I-protein
(	O
IFNgamma	B-protein
)	O
.	O

Inhibition	O
of	I-protein
IFNgamma	B-protein
receptor-mediated	O
signals	I-protein
by	I-protein
IL-6	B-protein
prevents	O
autoregulation	O
of	I-protein
IFNgamma	O
gene	O
expression	I-protein
by	I-protein
IFNgamma	B-protein
during	I-protein
CD4+	O
T	O
cell	O
activation	I-protein
,	O
thereby	O
preventing	O
Th1	O
differentiation	I-protein
.	O

Thus	O
,	O
IL-6	B-protein
promotes	O
CD4	B-protein
+	O
Th2	O
differentiation	I-protein
and	I-protein
inhibits	I-protein
Th1	O
differentiation	I-protein
by	I-protein
two	O
independent	I-protein
molecular	I-protein
mechanisms	O
.	O

###MEDLINE:21105220

Interaction	O
between	O
CCAAT/enhancer	B-protein
binding	I-protein
protein	I-protein
and	I-protein
cyclic	B-protein
AMP	I-protein
response	I-protein
element	I-protein
binding	I-protein
protein	I-protein
1	I-protein
regulates	O
human	O
immunodeficiency	I-protein
virus	I-protein
type	O
1	I-protein
transcription	O
in	I-protein
cells	I-protein
of	I-protein
the	I-protein
monocyte/macrophage	I-protein
lineage	I-protein
.	O

Recent	O
observations	O
have	O
shown	O
two	O
CCAAT/enhancer	B-protein
binding	I-protein
protein	O
(	O
C/EBP	I-protein
)	O
binding	I-protein
sites	I-protein
to	I-protein
be	O
critically	O
important	O
for	I-protein
efficient	O
human	O
immunodeficiency	I-protein
virus	I-protein
type	O
1	I-protein
(	O
HIV-1	O
)	O
replication	O
within	B-protein
cells	I-protein
of	I-protein
the	I-protein
monocyte/macrophage	I-protein
lineage	I-protein
,	O
a	I-protein
cell	O
type	O
likely	B-protein
involved	I-protein
in	I-protein
transport	I-protein
of	I-protein
the	I-protein
virus	I-protein
to	I-protein
the	I-protein
brain	O
.	O

Additionally	O
,	O
sequence	I-protein
variation	I-protein
at	I-protein
C/EBP	I-protein
site	I-protein
I	I-protein
,	O
which	O
lies	O
immediately	O
upstream	O
of	I-protein
the	I-protein
distal	I-protein
nuclear	O
factor	I-protein
kappa	I-protein
B	O
site	I-protein
and	I-protein
immediately	O
downstream	O
of	I-protein
a	I-protein
binding	I-protein
site	I-protein
for	I-protein
activating	B-protein
transcription	I-protein
factor	I-protein
(	O
ATF	B-protein
)	O
/	O
cyclic	B-protein
AMP	I-protein
response	I-protein
element	I-protein
binding	I-protein
protein	I-protein
(	O
CREB	B-protein
)	O
,	O
has	O
been	O
shown	O
to	I-protein
affect	O
HIV-1	O
long	I-protein
terminal	O
repeat	I-protein
(	O
LTR	O
)	O
activity	I-protein
.	O

Given	O
that	O
C/EBP	I-protein
proteins	I-protein
have	O
been	O
shown	O
to	I-protein
interact	O
with	I-protein
many	O
other	O
transcription	B-protein
factors	I-protein
including	I-protein
members	O
of	I-protein
the	I-protein
ATF/CREB	B-protein
family	I-protein
,	O
we	O
proceeded	O
to	I-protein
determine	O
whether	O
an	I-protein
adjacent	I-protein
ATF/CREB	O
binding	I-protein
site	I-protein
could	O
affect	O
C/EBP	I-protein
protein	I-protein
binding	I-protein
to	I-protein
C/EBP	I-protein
site	I-protein
I	I-protein
.	O

Electrophoretic	O
mobility	I-protein
shift	O
analyses	O
indicated	O
that	O
selected	O
ATF/CREB	O
site	I-protein
variants	O
assisted	O
in	I-protein
the	I-protein
recruitment	I-protein
of	I-protein
C/EBP	I-protein
proteins	I-protein
to	I-protein
an	I-protein
adjacent	I-protein
,	O
naturally	O
occurring	O
,	O
low-affinity	I-protein
C/EBP	I-protein
site	I-protein
.	O

This	O
biophysical	O
interaction	I-protein
appears	O
to	I-protein
occur	O
via	I-protein
at	I-protein
least	O
two	O
mechanisms	O
.	O

First	O
,	O
low	O
amounts	O
of	I-protein
CREB-1	B-protein
and	I-protein
C/EBP	I-protein
appear	O
to	I-protein
heterodimerize	O
and	I-protein
bind	O
to	I-protein
a	I-protein
site	I-protein
consisting	O
of	I-protein
a	I-protein
half	I-protein
site	I-protein
from	I-protein
both	O
the	I-protein
ATF/CREB	O
and	I-protein
C/EBP	I-protein
binding	I-protein
sites	I-protein
.	O

In	O
addition	O
,	O
CREB-1	B-protein
homodimers	I-protein
bind	O
to	I-protein
the	I-protein
ATF/CREB	O
site	I-protein
and	I-protein
recruit	O
C/EBP	I-protein
dimers	I-protein
to	I-protein
their	O
cognate	I-protein
weak	I-protein
binding	I-protein
sites	I-protein
.	O

This	O
interaction	I-protein
is	O
reciprocal	O
,	O
since	O
C/EBP	I-protein
dimer	I-protein
binding	I-protein
to	I-protein
a	I-protein
strong	O
C/EBP	I-protein
site	I-protein
leads	O
to	I-protein
enhanced	I-protein
CREB-1	O
recruitment	I-protein
to	I-protein
ATF/CREB	O
sites	I-protein
that	O
are	O
weakly	B-protein
bound	I-protein
by	I-protein
CREB	B-protein
.	O

Sequence	O
variation	I-protein
at	I-protein
both	O
C/EBP	I-protein
and	I-protein
ATF/CREB	O
sites	I-protein
affects	O
the	I-protein
molecular	I-protein
interactions	O
involved	I-protein
in	I-protein
mediating	I-protein
both	O
of	I-protein
these	O
mechanisms	O
.	O

Most	O
importantly	O
,	O
sequence	I-protein
variation	I-protein
at	I-protein
the	I-protein
ATF/CREB	O
binding	I-protein
site	I-protein
affected	O
basal	O
LTR	O
activity	I-protein
as	O
well	O
as	O
LTR	O
function	I-protein
following	O
interleukin-6	O
stimulation	I-protein
,	O
a	I-protein
treatment	O
that	O
leads	O
to	I-protein
increases	O
in	I-protein
C/EBP	I-protein
activation	I-protein
.	O

Thus	O
,	O
HIV-1	O
LTR	O
ATF/CREB	O
binding	I-protein
site	I-protein
sequence	I-protein
variation	I-protein
may	O
modulate	O
cellular	O
signaling	O
at	I-protein
the	I-protein
viral	O
promoter	I-protein
through	I-protein
the	I-protein
C/EBP	I-protein
pathway	I-protein

###MEDLINE:21134520

Selective	O
inhibition	O
of	I-protein
interleukin-4	I-protein
gene	O
expression	I-protein
in	I-protein
human	O
T	O
cells	I-protein
by	I-protein
aspirin	O
.	O

Previous	O
studies	O
indicated	O
that	O
aspirin	O
(	O
acetylsalicylic	O
acid	O
[	O
ASA	O
]	O
)	O
can	O
have	O
profound	O
immunomodulatory	O
effects	O
by	I-protein
regulating	O
cytokine	O
gene	O
expression	I-protein
in	I-protein
several	I-protein
types	I-protein
of	I-protein
cells	I-protein
.	O

This	O
study	O
is	O
the	I-protein
first	O
in	I-protein
which	O
concentrations	O
of	I-protein
ASA	O
in	I-protein
the	I-protein
therapeutic	O
range	O
were	O
found	O
to	I-protein
significantly	O
reduce	O
interleukin	B-protein
(	O
IL	I-protein
)	O
-4	I-protein
secretion	O
and	I-protein
RNA	O
expression	I-protein
in	I-protein
freshly	O
isolated	I-protein
and	I-protein
mitogen-primed	O
human	O
CD4+	O
T	O
cells	I-protein
.	O

In	O
contrast	O
,	O
ASA	O
did	O
not	I-protein
affect	O
IL-13	B-protein
,	O
interferon-gamma	B-protein
,	O
and	I-protein
IL-2	B-protein
expression	I-protein
.	O

ASA	O
inhibited	O
IL-4	B-protein
,	O
but	O
not	I-protein
IL-2	B-protein
,	O
promoter-driven	O
chloramphenicol	O
acetyltransferase	I-protein
expression	I-protein
in	I-protein
transiently	O
transfected	O
Jurkat	O
T	O
cells	I-protein
.	O

The	O
structurally	O
unrelated	O
nonsteroidal	O
anti-inflammatory	O
drugs	O
indomethacin	O
and	I-protein
flurbiprofen	O
did	O
not	I-protein
affect	O
cytokine	O
gene	O
expression	I-protein
in	I-protein
T	O
cells	I-protein
,	O
whereas	O
the	I-protein
weak	I-protein
cyclo-oxygenase	O
inhibitor	O
salicylic	O
acid	O
was	O
at	I-protein
least	O
as	O
effective	O
as	O
ASA	O
in	I-protein
inhibiting	I-protein
IL-4	B-protein
expression	I-protein
and	I-protein
promoter	I-protein
activity	I-protein
.	O

The	O
inhibitory	O
effect	O
of	I-protein
ASA	O
on	I-protein
IL-4	B-protein
transcription	O
was	O
not	I-protein
mediated	I-protein
by	I-protein
decreased	O
nuclear	O
expression	I-protein
of	I-protein
the	I-protein
known	O
salicylate	B-protein
target	I-protein
nuclear	I-protein
factor	I-protein
(	O
NF	I-protein
)	O
-kappaB	I-protein
and	I-protein
was	O
accompanied	O
by	I-protein
reduced	O
binding	I-protein
of	I-protein
an	I-protein
inducible	O
factor	I-protein
to	I-protein
an	I-protein
IL-4	B-protein
promoter	I-protein
region	O
upstream	O
of	I-protein
,	O
but	O
not	I-protein
overlapping	I-protein
,	O
the	I-protein
NF	O
of	I-protein
activated	O
T	O
cells-	O
and	I-protein
NF-kappaB-binding	O
P1	I-protein
element	I-protein
.	O

It	O
is	O
concluded	O
that	O
anti-inflammatory	O
salicylates	O
,	O
by	I-protein
means	O
of	I-protein
a	I-protein
previously	O
unrecognized	O
mechanism	O
of	I-protein
action	O
,	O
can	O
influence	O
the	I-protein
nature	O
of	I-protein
adaptive	O
immune	O
responses	O
by	I-protein
selectively	O
inhibiting	I-protein
the	I-protein
expression	I-protein
of	I-protein
IL-4	B-protein
,	O
a	I-protein
critical	I-protein
effector	O
of	I-protein
these	O
responses	O
,	O
in	I-protein
CD4+	O
T	O
cells	I-protein
.	O

###MEDLINE:21121146

Molecular	O
and	I-protein
cellular	O
mediators	O
of	I-protein
interleukin-1	B-protein
-dependent	I-protein
acute	O
inflammatory	O
arthritis	I-protein
.	O

OBJECTIVE	O
:	O
To	O
examine	O
the	I-protein
molecular	I-protein
and	I-protein
cellular	O
mechanisms	O
in	I-protein
a	I-protein
model	I-protein
of	I-protein
acute	O
inflammatory	O
monarticular	O
arthritis	I-protein
induced	I-protein
by	I-protein
methylated	B-protein
bovine	I-protein
serum	I-protein
albumin	I-protein
(	O
mBSA	B-protein
)	O
and	I-protein
interleukin-1	B-protein
(	O
IL-1	B-protein
)	O
.	O

METHODS	O
:	O
Mice	O
were	O
injected	O
intraarticularly	O
with	I-protein
mBSA	B-protein
on	I-protein
day	O
0	I-protein
and	I-protein
subcutaneously	O
with	I-protein
recombinant	B-protein
human	I-protein
IL-1beta	I-protein
on	I-protein
days	O
0-2	O
.	O

At	O
day	O
7	I-protein
,	O
knee	O
joints	I-protein
were	O
removed	O
and	I-protein
assessed	O
histologically	O
.	O

Flow	O
cytometry	O
and	I-protein
RNase	I-protein
protection	I-protein
were	O
used	O
to	I-protein
analyze	O
IL-1	B-protein
-dependent	I-protein
events	O
.	O

RESULTS	O
:	O
C57BL/6	O
(	O
B6	I-protein
)	O
,	O
129/Sv	O
,	O
and	I-protein
(	O
B6	I-protein
x	I-protein
129/	O
Sv	O
)	O
F1	I-protein
hybrid	O
mice	O
,	O
all	O
H-2b	O
strains	O
,	O
were	O
susceptible	O
to	I-protein
mBSA	B-protein
/IL-1-induced	O
arthritis	I-protein
,	O
whereas	O
C3H/HeJ	O
(	O
H-2k	O
)	O
mice	O
were	O
not	I-protein
.	O

B6	I-protein
mice	O
lacking	I-protein
T	O
and	I-protein
B	O
cells	I-protein
(	O
RAG1-/-	O
)	O
or	I-protein
major	B-protein
histocompatibility	I-protein
complex	I-protein
(	O
MHC	I-protein
)	O
class	I-protein
II	I-protein
antigens	I-protein
(	O
MHCII-/-	O
)	O
,	O
and	I-protein
B6	I-protein
mice	O
treated	O
with	I-protein
a	I-protein
CD4+	B-protein
T	I-protein
cell-depleting	I-protein
monoclonal	I-protein
antibody	I-protein
,	O
were	O
resistant	I-protein
to	I-protein
disease	I-protein
.	O

In	O
contrast	O
,	O
B	O
cell-deficient	O
(	O
muMT/	O
muMT	O
)	O
mice	O
developed	O
arthritis	I-protein
at	I-protein
an	I-protein
incidence	O
and	I-protein
severity	O
similar	O
to	I-protein
that	O
of	I-protein
controls	O
.	O

RelB-deficient	O
(	O
RelB-/-	O
)	O
bone	O
marrow	I-protein
chimeric	O
mice	O
had	O
arthritis	I-protein
that	O
was	O
significantly	O
reduced	O
in	I-protein
incidence	O
and	I-protein
severity	O
.	O

In	O
B6	I-protein
mice	O
,	O
flow	O
cytometry	O
demonstrated	O
an	I-protein
IL-1-dependent	O
leukocyte	O
infiltration	O
into	O
the	I-protein
synovial	O
compartment	I-protein
and	I-protein
RNase	I-protein
protection	I-protein
assays	O
revealed	O
induction	I-protein
of	I-protein
messenger	O
RNA	O
(	O
mRNA	O
)	O
for	I-protein
the	I-protein
chemokines	B-protein
monocyte	B-protein
chemoattractant	I-protein
protein	I-protein
1	I-protein
,	O
macrophage	B-protein
inhibitory	I-protein
protein	I-protein
2	I-protein
(	O
MIP-2	B-protein
)	O
,	O
RANTES	B-protein
,	O
MIP-1alpha	B-protein
,	O
and	I-protein
MIP-1beta	B-protein
,	O
in	I-protein
vivo	O
and	I-protein
in	I-protein
vitro	O
.	O

CONCLUSION	O
:	O
Arthritis	O
induced	I-protein
by	I-protein
mBSA	B-protein
/	O
IL-1	B-protein
is	O
strain	O
specific	I-protein
and	I-protein
dependent	I-protein
on	I-protein
CD4+	O
T	O
lymphocytes	O
and	I-protein
at	I-protein
least	O
partially	O
on	I-protein
RelB	B-protein
,	O
but	O
not	I-protein
on	I-protein
B	O
lymphocytes	O
or	I-protein
antibody	I-protein
.	O

IL-1	B-protein
contributes	O
to	I-protein
leukocyte	O
recruitment	I-protein
to	I-protein
the	I-protein
synovium	O
and	I-protein
directly	O
induces	O
chemokine	O
mRNA	O
production	I-protein
by	I-protein
synovial	O
cells	I-protein
.	O

This	O
model	I-protein
of	I-protein
acute	O
monarticular	O
arthritis	I-protein
is	O
particularly	O
suitable	O
for	I-protein
further	O
investigations	O
into	O
cell-mediated	O
immunity	O
in	I-protein
arthritis	I-protein
and	I-protein
the	I-protein
role	O
of	I-protein
IL-1	B-protein
.	O

###MEDLINE:21124335

Positive	O
and	I-protein
negative	O
regulation	I-protein
of	I-protein
granulopoiesis	O
by	I-protein
endogenous	B-protein
RARalpha	I-protein
.	O

Acute	B-protein
promyelocytic	O
leukemia	O
(	O
APL	O
)	O
is	O
always	O
associated	I-protein
with	I-protein
chromosomal	I-protein
translocations	O
that	O
disrupt	O
the	I-protein
retinoic	B-protein
acid	I-protein
receptor	I-protein
alpha	I-protein
(	O
RARalpha	I-protein
)	O
gene	O
.	O

Whether	O
these	O
translocations	O
relate	O
to	I-protein
a	I-protein
role	O
for	I-protein
endogenous	B-protein
RARalpha	I-protein
in	I-protein
normal	O
granulopoiesis	O
remains	O
uncertain	O
because	O
most	O
studies	O
addressing	O
this	O
question	O
have	O
used	O
non-physiological	O
overexpression	O
systems	O
.	O

Granulocyte	O
differentiation	I-protein
in	I-protein
cells	I-protein
derived	I-protein
from	I-protein
RARalpha-deficient	O
(	O
RARalpha	O
(	O
-/-	O
)	O
)	O
mice	O
was	O
studied	O
and	I-protein
evaluated	O
in	I-protein
the	I-protein
context	O
of	I-protein
agonist-bound	B-protein
and	I-protein
ligand-free	I-protein
RARalpha	I-protein
.	O

Our	O
results	O
demonstrate	O
that	O
RARalpha	B-protein
is	O
dispensable	O
for	I-protein
granulopoiesis	O
,	O
as	O
RARalpha	O
(	O
-/-	O
)	O
mice	O
have	O
a	I-protein
normal	O
granulocyte	I-protein
population	O
despite	O
an	I-protein
impaired	O
ability	O
to	I-protein
respond	O
to	I-protein
retinoids	O
.	O

However	O
,	O
although	O
it	O
is	O
not	I-protein
absolutely	O
required	O
,	O
RARalpha	B-protein
can	O
bidirectionally	O
modulate	O
granulopoiesis	O
.	O

RARalpha	B-protein
stimulates	O
differentiation	I-protein
in	I-protein
response	I-protein
to	I-protein
exogenous	O
retinoic	O
acid	O
.	O

Furthermore	O
,	O
endogenous	O
retinoids	O
control	I-protein
granulopoiesis	O
in	I-protein
vivo	O
,	O
as	O
either	O
vitamin	O
A-deficient	I-protein
mice	O
or	I-protein
animals	O
treated	O
with	I-protein
an	I-protein
RAR	B-protein
antagonist	O
accumulate	O
more	O
immature	B-protein
granulocytes	O
in	I-protein
their	O
bone	O
marrow	I-protein
.	O

Conversely	O
,	O
RARalpha	B-protein
acts	O
to	I-protein
limit	O
differentiation	I-protein
in	I-protein
the	I-protein
absence	I-protein
of	I-protein
ligand	B-protein
because	O
granulocyte	I-protein
precursors	O
from	I-protein
RARalpha	O
(	O
-/-	O
)	O
mice	O
differentiate	O
earlier	O
in	I-protein
culture	O
.	O

Thus	O
,	O
the	I-protein
block	O
in	I-protein
granulopoiesis	O
exerted	O
by	I-protein
RARalpha	B-protein
fusion	I-protein
proteins	I-protein
expressed	O
in	I-protein
APL	O
cells	I-protein
may	O
correspond	O
to	I-protein
an	I-protein
amplification	O
of	I-protein
a	I-protein
normal	O
function	I-protein
of	I-protein
unliganded	B-protein
RARalpha	I-protein
.	O

###MEDLINE:21077029

Expression	O
and	I-protein
function	I-protein
of	I-protein
a	I-protein
stem	I-protein
cell	O
promoter	I-protein
for	I-protein
the	I-protein
murine	O
CBFalpha2	O
gene	O
:	O
distinct	O
roles	O
and	I-protein
regulation	I-protein
in	I-protein
natural	O
killer	O
and	I-protein
T	O
cell	O
development	O
.	O

The	O
Runt	B-protein
family	I-protein
transcription	I-protein
factor	I-protein
CBFalpha2	B-protein
(	O
AML1	B-protein
,	O
PEBP2alphaB	B-protein
,	O
or	I-protein
Runx1	B-protein
)	O
is	O
required	O
by	I-protein
hematopoietic	O
stem	I-protein
cells	I-protein
and	I-protein
expressed	O
at	I-protein
high	O
levels	I-protein
in	I-protein
T-lineage	O
cells	I-protein
.	O

In	O
human	O
T	O
cells	I-protein
CBFalpha2	B-protein
is	O
usually	O
transcribed	I-protein
from	I-protein
a	I-protein
different	O
promoter	I-protein
(	O
distal	I-protein
promoter	I-protein
)	O
than	I-protein
in	I-protein
myeloid	O
cells	I-protein
(	O
proximal	I-protein
promoter	I-protein
)	O
,	O
but	O
the	I-protein
developmental	O
and	I-protein
functional	O
significance	O
of	I-protein
this	O
promoter	I-protein
switch	I-protein
has	O
not	I-protein
been	O
known	O
.	O

Here	O
,	O
we	O
report	O
that	O
both	O
coding	I-protein
and	I-protein
noncoding	I-protein
sequences	I-protein
of	I-protein
the	I-protein
distal	I-protein
5	O
'	O
end	I-protein
are	O
highly	O
conserved	O
between	O
the	I-protein
human	O
and	I-protein
the	I-protein
murine	O
genes	I-protein
,	O
and	I-protein
the	I-protein
distal	I-protein
promoter	I-protein
is	O
responsible	O
for	I-protein
the	I-protein
overwhelming	O
majority	O
of	I-protein
CBFalpha2	B-protein
expression	I-protein
in	I-protein
murine	O
hematopoietic	O
stem	I-protein
cells	I-protein
as	O
well	O
as	O
in	I-protein
T	O
cells	I-protein
.	O

Distal	B-protein
promoter	I-protein
activity	I-protein
is	O
maintained	O
throughout	O
T	O
cell	O
development	O
and	I-protein
at	I-protein
lower	I-protein
levels	I-protein
in	I-protein
B	O
cell	O
development	O
,	O
but	O
downregulated	O
in	I-protein
natural	O
killer	O
cell	O
development	O
.	O

The	O
distal	I-protein
N-terminal	O
isoform	I-protein
binds	O
to	I-protein
functionally	O
important	O
regulatory	O
sites	I-protein
from	I-protein
known	O
target	O
genes	I-protein
with	I-protein
two-	O
to	I-protein
threefold	O
higher	O
affinity	I-protein
than	I-protein
the	I-protein
proximal	I-protein
N-terminal	O
isoform	I-protein
.	O

Neither	O
full-length	O
isoform	I-protein
alters	O
growth	O
of	I-protein
a	I-protein
myeloid	O
cell	O
line	I-protein
under	O
nondifferentiating	O
conditions	O
,	O
but	O
the	I-protein
proximal	I-protein
isoform	I-protein
selectively	O
delays	O
mitotic	I-protein
arrest	I-protein
of	I-protein
the	I-protein
cell	O
line	I-protein
under	O
differentiating	O
conditions	O
,	O
resulting	O
in	I-protein
the	I-protein
generation	O
of	I-protein
greater	O
numbers	O
of	I-protein
neutrophils	O
.	O

###MEDLINE:21115099

Constitutive	O
PI3-K	O
activity	I-protein
is	O
essential	O
for	I-protein
proliferation	I-protein
,	O
but	O
not	I-protein
survival	B-protein
,	O
of	I-protein
Theileria	O
parva-transformed	O
B	O
cells	I-protein
.	O

Theileria	O
is	O
an	I-protein
intracellular	I-protein
parasite	O
that	O
causes	O
lymphoproliferative	I-protein
disorders	O
in	I-protein
cattle	O
,	O
and	I-protein
infection	I-protein
of	I-protein
leucocytes	O
induces	O
a	I-protein
transformed	I-protein
phenotype	O
similar	O
to	I-protein
tumour	I-protein
cells	I-protein
,	O
but	O
the	I-protein
mechanisms	O
by	I-protein
which	O
the	I-protein
parasite	O
induces	O
this	O
phenotype	O
are	O
not	I-protein
understood	O
.	O

Here	O
,	O
we	O
show	O
that	O
infected	O
B	O
lymphocytes	O
display	O
constitutive	I-protein
phosphoinositide	I-protein
3-kinase	I-protein
(	O
PI3-K	B-protein
)	O
activity	I-protein
,	O
which	O
appears	O
to	I-protein
be	O
necessary	O
for	I-protein
proliferation	I-protein
,	O
but	O
not	I-protein
survival	B-protein
.	O

Importantly	O
,	O
we	O
demonstrate	O
that	O
one	B-protein
mechanism	O
by	I-protein
which	O
PI3-K	B-protein
mediates	O
the	I-protein
proliferation	I-protein
of	I-protein
infected	O
B	O
lymphocytes	O
is	O
through	I-protein
the	I-protein
induction	I-protein
of	I-protein
a	I-protein
granulocyte-monocyte	B-protein
colony-stimulating	I-protein
factor	I-protein
(	O
GM-CSF	B-protein
)	O
-dependent	I-protein
autocrine	B-protein
loop	I-protein
.	O

PI3-K	O
induction	I-protein
of	I-protein
GM-CSF	B-protein
appears	O
to	I-protein
be	O
at	I-protein
the	I-protein
transcriptional	O
level	I-protein
and	I-protein
,	O
consistently	O
,	O
we	O
demonstrate	O
that	O
PI3-K	B-protein
is	O
also	O
involved	I-protein
in	I-protein
the	I-protein
constitutive	I-protein
induction	I-protein
of	I-protein
AP-1	I-protein
and	I-protein
NF-kappaB	B-protein
,	O
which	O
characterizes	O
Theileria-infected	O
leucocytes	O
.	O

Taken	O
together	O
,	O
our	O
results	O
highlight	O
a	I-protein
novel	O
strategy	O
exploited	O
by	I-protein
the	I-protein
intracellular	I-protein
parasite	O
Theileria	O
to	I-protein
induce	O
continued	O
proliferation	I-protein
of	I-protein
its	O
host	O
leucocyte	O
.	O

###MEDLINE:21099489

Lymphokine	B-protein
dependence	O
of	I-protein
STAT3	B-protein
activation	I-protein
produced	O
by	I-protein
surface	O
immunoglobulin	O
cross-linking	O
and	I-protein
by	I-protein
phorbol	O
ester	I-protein
plus	O
calcium	O
ionophore	O
treatment	O
in	I-protein
B	O
cells	I-protein
.	O

Stimulation	O
of	I-protein
B	O
cells	I-protein
by	I-protein
surface	O
immunoglobulin	O
(	O
sIg	O
)	O
triggering	O
,	O
or	I-protein
through	I-protein
the	I-protein
mitogenic	O
combination	O
of	I-protein
phorbol	O
ester	I-protein
and	I-protein
calcium	O
ionophore	O
,	O
is	O
accompanied	O
by	I-protein
activation	I-protein
of	I-protein
STAT	B-protein
transcription	I-protein
factors	I-protein
.	O

The	O
mechanism	O
responsible	O
for	I-protein
the	I-protein
delayed	O
nuclear	O
accumulation	I-protein
of	I-protein
phosphorylated	B-protein
STAT3	B-protein
was	O
examined	O
in	I-protein
detail	O
,	O
focusing	O
on	I-protein
the	I-protein
role	O
of	I-protein
B	B-protein
cell-derived	I-protein
lymphokines	I-protein
.	O

sIg	B-protein
-induced	O
activation	I-protein
of	I-protein
STAT3	B-protein
was	O
partially	O
inhibited	O
in	I-protein
B	O
cells	I-protein
obtained	O
from	I-protein
IL-6-	O
or	I-protein
IL-10-deficient	O
mice	O
,	O
and	I-protein
was	O
partially	O
blocked	B-protein
by	I-protein
neutralizing	B-protein
antibodies	I-protein
directed	I-protein
against	I-protein
either	O
of	I-protein
these	O
lymphokines	O
.	O

sIg	B-protein
-induced	O
STAT3	B-protein
activation	I-protein
was	O
completely	O
inhibited	O
by	I-protein
combining	O
IL-6-	B-protein
and	I-protein
IL-10-specific	I-protein
neutralizing	I-protein
antibodies	I-protein
,	O
or	I-protein
by	I-protein
adding	O
individual	O
neutralizing	B-protein
antibodies	I-protein
to	I-protein
B	O
cells	I-protein
obtained	O
from	I-protein
lymphokine-deficient	O
animals	O
.	O

In	O
contrast	O
,	O
IL-10	B-protein
alone	O
appeared	O
to	I-protein
account	O
for	I-protein
STAT3	B-protein
activation	I-protein
resulting	O
from	I-protein
B	O
cell	O
stimulation	I-protein
with	I-protein
phorbol	O
ester	I-protein
and	I-protein
calcium	O
ionophore	O
.	O

In	O
keeping	O
with	I-protein
these	O
results	O
,	O
soluble	I-protein
IL-6	B-protein
and	I-protein
IL-10	B-protein
were	O
found	O
in	I-protein
supernatant	O
fluid	I-protein
obtained	O
from	I-protein
stimulated	O
B	O
cells	I-protein
.	O

This	O
work	O
indicates	O
that	O
a	I-protein
lymphokine	B-protein
pathway	I-protein
is	O
responsible	O
for	I-protein
STAT3	B-protein
activation	I-protein
that	O
occurs	O
late	O
after	O
B	O
cell	O
stimulation	I-protein
,	O
and	I-protein
points	O
out	O
differences	O
in	I-protein
B	O
cell	O
activation	I-protein
that	O
result	O
from	I-protein
stimulation	I-protein
through	I-protein
the	I-protein
antigen	O
receptor	O
and	I-protein
through	I-protein
pharmacological	O
mimicry	O
of	I-protein
signaling	O
mediators	O
.	O

###MEDLINE:21092954

Transcription	I-protein
factor	I-protein
AP-4	I-protein
is	O
a	I-protein
ligand	O
for	I-protein
immunoglobulin-kappa	O
promoter	I-protein
E-box	I-protein
elements	O
.	O

Immunoglobulin	O
(	O
Ig	I-protein
)	O
-kappa	O
promoters	O
from	I-protein
humans	O
and	I-protein
mice	O
share	O
conserved	O
sequences	I-protein
.	O

The	O
octamer	O
element	I-protein
is	O
common	I-protein
to	I-protein
all	O
Ig	I-protein
promoters	O
and	I-protein
pivotal	O
for	I-protein
their	O
function	I-protein
.	O

However	O
,	O
other	O
conserved	O
sequence	I-protein
motifs	I-protein
,	O
that	O
differ	O
between	O
Ig	I-protein
variable	O
gene	O
families	O
,	O
are	O
required	O
for	I-protein
normal	O
promoter	I-protein
function	I-protein
.	O

These	O
conserved	O
motifs	I-protein
do	O
not	I-protein
stimulate	O
transcription	O
in	I-protein
the	I-protein
absence	I-protein
of	I-protein
an	I-protein
octamer	O
.	O

One	I-protein
example	O
is	O
an	I-protein
E-box	I-protein
of	I-protein
the	I-protein
E47/E12	O
type	O
(	O
5'-CAGCTG-3	O
'	O
)	O
,	O
which	O
is	O
found	O
in	I-protein
all	O
promoters	O
of	I-protein
the	I-protein
human	O
and	I-protein
murine	O
Ig-kappa	O
gene	O
subgroups/families	O
,	O
with	I-protein
the	I-protein
exception	O
of	I-protein
subgroups	O
II	I-protein
and	I-protein
VI	I-protein
and	I-protein
their	O
related	O
murine	O
families	O
.	O

In	O
the	I-protein
present	O
study	O
we	O
show	O
that	O
the	I-protein
ubiquitously	O
expressed	O
transcription	B-protein
factor	I-protein
AP-4	I-protein
,	O
and	I-protein
not	I-protein
E47	B-protein
,	O
interacts	I-protein
specifically	O
with	I-protein
the	I-protein
kappa	I-protein
promoter	I-protein
E-boxes	O
when	O
tested	O
in	I-protein
electrophoretic	O
mobility-shift	O
assays	O
using	O
nuclear	O
extracts	O
derived	I-protein
from	I-protein
human	O
and	I-protein
murine	O
B-cell	O
lines	B-protein
.	O

Furthermore	O
,	O
AP-4	B-protein
,	O
unlike	O
E47	B-protein
,	O
did	O
not	I-protein
act	O
as	O
a	I-protein
transactivator	I-protein
,	O
which	O
is	O
in	I-protein
agreement	O
with	I-protein
previous	O
studies	O
on	I-protein
intact	O
kappa	I-protein
promoters	O
,	O
showing	O
that	O
transcription	O
is	O
absent	O
when	O
the	I-protein
octamer	O
element	I-protein
has	O
been	O
mutated	O
.	O

Based	O
on	I-protein
these	O
data	O
,	O
and	I-protein
the	I-protein
conservation	O
of	I-protein
the	I-protein
5'-CAGCTG-3	O
'	O
motif	I-protein
among	O
human	O
and	I-protein
murine	O
kappa	I-protein
promoters	O
,	O
we	O
propose	O
that	O
AP-4	B-protein
is	O
the	I-protein
major	O
ligand	O
for	I-protein
Ig-kappa	O
promoter	I-protein
E-boxes	O
.	O

###MEDLINE:21108989

A	O
16-mer	O
peptide	O
(	O
RQIKIWFQNRRMKWKK	O
)	O
from	I-protein
antennapedia	O
preferentially	O
targets	O
the	I-protein
Class	I-protein
I	I-protein
pathway	I-protein
.	O

Translocation	O
of	I-protein
antigenic	I-protein
peptides	O
into	O
the	I-protein
cytosol	I-protein
of	I-protein
antigen	O
presenting	O
cells	I-protein
facilitates	O
proteosomal	O
processing	O
and	I-protein
loading	O
into	O
Class	I-protein
I	I-protein
molecules	I-protein
for	I-protein
MHC	O
presentation	O
on	I-protein
the	I-protein
cell	O
surface	O
.	O

The	O
DNA	B-protein
binding	I-protein
domain	I-protein
of	I-protein
the	I-protein
Drosophila	I-protein
transcription	I-protein
factor	I-protein
(	O
Antennapedia	B-protein
)	O
,	O
a	I-protein
60	I-protein
amino	I-protein
acid	I-protein
protein	I-protein
,	O
is	O
rapidly	I-protein
taken	O
up	O
by	I-protein
cells	I-protein
and	I-protein
has	O
been	O
fused	O
to	I-protein
selected	O
antigens	I-protein
to	I-protein
enhance	O
their	O
immunogenicity	O
.	O

We	O
now	O
demonstrate	O
that	O
a	I-protein
16	I-protein
amino	O
acid	O
peptide	O
from	I-protein
antennapedia	O
can	O
facilitate	O
the	I-protein
cytoplasmic	O
uptake	I-protein
of	I-protein
CTL	O
epitope	I-protein
9-mer	O
peptides	O
.	O

Synthetic	O
peptides	O
were	O
made	O
containing	I-protein
the	I-protein
16-mer	O
antennapedia	O
peptide	O
linked	I-protein
in	I-protein
tandem	I-protein
to	I-protein
the	I-protein
ovalbumin	I-protein
SIINFEKL	O
CTL	O
peptide	O
.	O

The	O
peptide	O
complex	I-protein
was	O
shown	O
to	I-protein
rapidly	I-protein
internalise	O
into	O
APCs	O
by	I-protein
confocal	O
microscopy	O
.	O

This	O
peptide	O
induced	I-protein
CTL	O
in	I-protein
C57BL/6	O
mice	O
and	I-protein
protected	O
them	O
against	I-protein
growth	O
of	I-protein
an	I-protein
ovalbumin	I-protein
expressing	O
tumour	I-protein
cell	O
line	I-protein
(	O
E.G7-OVA	O
)	O
.	O

The	O
ability	O
of	I-protein
the	I-protein
hybrid	O
peptide	O
to	I-protein
be	O
processed	O
and	I-protein
presented	O
by	I-protein
APCs	O
was	O
similar	O
,	O
whether	O
the	I-protein
SIINFEKL	O
sequence	I-protein
was	O
appended	O
at	I-protein
the	I-protein
C-terminus	B-protein
or	I-protein
N-terminus	B-protein
of	I-protein
the	I-protein
Antennapedia	O
peptide	O
.	O

The	O
production	I-protein
of	I-protein
synthetic	I-protein
peptides	O
containing	I-protein
other	O
CTL	O
peptide	O
epitopes	O
may	O
be	O
useful	O
for	I-protein
priming	O
CTLs	O
in	I-protein
vitro	O
and	I-protein
in	I-protein
vivo	O

###MEDLINE:21100729

Bone	B-protein
marrow	I-protein
cells	I-protein
promote	O
TH2	O
polarization	O
and	I-protein
inhibit	O
virus-specific	O
CTL	O
generation	O
.	O

This	O
laboratory	O
recently	O
reported	O
that	O
human	O
bone	O
marrow	I-protein
cells	I-protein
(	O
BMC	O
)	O
inhibit	O
the	I-protein
generation	O
of	I-protein
virus-specific	O
CTL	O
in	I-protein
culture	O
.	O

The	O
culture	O
supernatants	O
contained	O
increased	I-protein
levels	I-protein
of	I-protein
prostaglandin	B-protein
E	I-protein
(	O
2	I-protein
)	O
(	O
PGE	I-protein
(	O
2	I-protein
)	O
)	O
(	O
shown	O
to	I-protein
favor	O
TH2	O
cell	O
development	O
)	O
and	I-protein
also	O
inhibited	O
EBV-CTL	O
effector	O
cell	O
development	O
.	O

In	O
this	O
study	O
,	O
we	O
obtained	O
PBL	O
from	I-protein
Epstein-Barr	B-protein
virus	I-protein
(	O
EBV	O
)	O
IgG	I-protein
antibody	I-protein
positive	I-protein
kidney	O
transplant	O
recipients	O
(	O
R	I-protein
)	O
and	I-protein
their	O
living-related	O
donors	O
(	O
LRD	O
)	O
one	B-protein
year	O
after	O
renal	O
transplantation	I-protein
.	O

EBV-specific	O
CTL	O
were	O
then	O
generated	O
in	I-protein
vitro	O
by	I-protein
stimulating	I-protein
PBL	O
with	I-protein
autologous	O
EBV-transformed	O
B	O
cells	I-protein
(	O
EBV-B	O
)	O
in	I-protein
the	I-protein
presence	O
or	I-protein
absence	I-protein
of	I-protein
autologous	O
BMC	O
.	O

The	O
addition	O
of	I-protein
BMC	O
to	I-protein
the	I-protein
EBV-CTL	O
generation	O
cultures	O
increased	I-protein
the	I-protein
intracellular	I-protein
expression	I-protein
in	I-protein
CD3+	O
cells	I-protein
of	I-protein
IL-4	B-protein
,	O
-5	I-protein
,	O
-6	I-protein
,	O
-10	I-protein
,	O
and	I-protein
-13	I-protein
.	O

These	O
CD3+	O
cells	I-protein
also	O
expressed	O
increased	I-protein
levels	I-protein
of	I-protein
the	I-protein
TH2	B-protein
associated	I-protein
receptor	I-protein
CCR3	B-protein
.	O

Inhibition	O
was	O
even	O
observed	O
by	I-protein
preparing	O
EBV-CTL	O
generating	O
cultures	O
in	I-protein
trans-wells	O
that	O
separated	O
the	I-protein
autologous	O
BMC	O
from	I-protein
the	I-protein
PBL	O
+	O
EBV-B	O
.	O

It	O
was	O
then	O
observed	O
that	O
CD3+	O
cells	I-protein
obtained	O
after	O
7	I-protein
days	O
of	I-protein
culture	O
in	I-protein
the	I-protein
presence	O
of	I-protein
autologous	O
BMC	O
could	O
be	O
used	O
as	O
inhibitors	I-protein
of	I-protein
EBV-CTL	O
generation	O
.	O

Protein	I-protein
Kinase	I-protein
A	I-protein
(	O
PKA	B-protein
)	O
,	O
a	I-protein
cAMP	B-protein
kinase	I-protein
that	O
is	O
involved	I-protein
in	I-protein
the	I-protein
upregulation	O
of	I-protein
TH2	B-protein
cytokine	I-protein
activity	I-protein
,	O
was	O
increased	I-protein
in	I-protein
EBV-CTL	O
cultures	O
by	I-protein
the	I-protein
presence	O
of	I-protein
BMC	O
.	O

Additionally	O
,	O
IL-4-mediated	O
signal	O
transduction	I-protein
and	I-protein
activation	I-protein
of	I-protein
transcription	O
(	O
STAT-6	B-protein
)	O
phosphorylation	I-protein
was	O
slightly	O
increased	I-protein
.	O

These	O
results	O
show	O
that	O
the	I-protein
BMC	O
inhibition	O
is	O
mediated	I-protein
by	I-protein
soluble	I-protein
factors	I-protein
(	O
cytokines	B-protein
)	O
and	I-protein
that	O
cell-cell	O
contact	O
in	I-protein
this	O
autologous	O
system	I-protein
is	O
not	I-protein
required	O
,	O
so	O
that	O
BMC	O
(	O
at	I-protein
least	O
partially	O
,	O
via	I-protein
cytokine	O
production	I-protein
)	O
promote	O
TH2	O
polarization	O
in	I-protein
culture	O
.	O

Moreover	O
,	O
TH2	O
cells	I-protein
induced	I-protein
by	I-protein
culturing	O
with	I-protein
autologous	O
BMC	O
directly	O
inhibit	O
EBV-CTL	O
generation	O
,	O
and	I-protein
TH2	O
associated	I-protein
PKA	B-protein
,	O
CCR3	B-protein
,	O
and	I-protein
STAT-6	O
phosphorylation	I-protein
are	O
enhanced	I-protein
by	I-protein
BMC	O
.	O

###MEDLINE:21103296

Reduction	O
in	I-protein
DNA	O
binding	I-protein
activity	I-protein
of	I-protein
the	I-protein
transcription	B-protein
factor	I-protein
Pax-5a	B-protein
in	I-protein
B	O
lymphocytes	O
of	I-protein
aged	O
mice	O
.	O

Aging	O
has	O
been	O
associated	I-protein
with	I-protein
intrinsic	I-protein
changes	O
of	I-protein
the	I-protein
humoral	O
immune	O
response	I-protein
,	O
which	O
may	O
lead	O
to	I-protein
an	I-protein
increased	I-protein
occurrence	O
of	I-protein
autoimmune	B-protein
disorders	O
and	I-protein
pathogenic	O
susceptibility	I-protein
.	O

The	O
transcription	B-protein
factor	I-protein
Pax-5	I-protein
is	O
a	I-protein
key	O
regulator	O
of	I-protein
B	O
cell	O
development	O
.	O

Pax-5a/B	B-protein
cell-specific	I-protein
activator	I-protein
protein	I-protein
and	I-protein
an	I-protein
alternatively	I-protein
spliced	I-protein
isoform	I-protein
,	O
Pax-5d	I-protein
,	O
may	O
have	O
opposing	O
functions	O
in	I-protein
transcriptional	O
regulation	I-protein
due	I-protein
to	I-protein
the	I-protein
lack	O
of	I-protein
a	I-protein
transactivation	B-protein
domain	I-protein
in	I-protein
Pax-5d	O
.	O

To	O
study	O
B	O
cell	O
-specific	I-protein
changes	O
that	O
occur	O
during	I-protein
the	I-protein
aging	O
process	O
,	O
we	O
investigated	O
expression	I-protein
patterns	O
of	I-protein
Pax-5a	B-protein
and	I-protein
5d	I-protein
in	I-protein
mature	B-protein
B	O
cells	I-protein
of	I-protein
young	I-protein
and	I-protein
aged	O
mice	O
.	O

RNase	I-protein
protection	I-protein
assays	O
showed	O
a	I-protein
similar	O
transcriptional	O
pattern	I-protein
for	I-protein
both	O
age	I-protein
groups	O
that	O
indicates	O
that	O
aging	O
has	O
no	I-protein
affect	O
on	I-protein
transcription	O
initiation	I-protein
or	I-protein
alternative	O
splicing	O
for	I-protein
either	O
isoform	I-protein
.	O

In	O
contrast	O
,	O
a	I-protein
significant	O
reduction	I-protein
in	I-protein
the	I-protein
DNA	O
binding	I-protein
activity	I-protein
of	I-protein
Pax-5a	B-protein
but	O
not	I-protein
Pax-5d	B-protein
protein	I-protein
was	O
observed	O
in	I-protein
aged	O
B	O
cells	I-protein
in	I-protein
vitro	O
,	O
while	O
Western	O
blot	O
analyses	O
showed	O
that	O
similar	O
levels	I-protein
of	I-protein
Pax-5a	B-protein
and	I-protein
5d	I-protein
proteins	I-protein
were	O
present	O
in	I-protein
both	O
age	I-protein
groups	O
.	O

The	O
observed	O
decrease	O
in	I-protein
Pax-5a	O
binding	I-protein
activity	I-protein
correlated	O
with	I-protein
changes	O
in	I-protein
expression	I-protein
of	I-protein
two	O
Pax-5	O
target	O
genes	I-protein
in	I-protein
aged	O
B	O
cells	I-protein
.	O

Expression	O
of	I-protein
the	I-protein
Ig	I-protein
J	I-protein
chain	I-protein
and	I-protein
the	I-protein
secreted	O
form	I-protein
of	I-protein
Ig	I-protein
mu	I-protein
,	O
which	O
are	O
both	O
known	O
to	I-protein
be	O
suppressed	I-protein
by	I-protein
Pax-5a	B-protein
in	I-protein
mature	B-protein
B	O
cells	I-protein
,	O
were	O
increased	I-protein
in	I-protein
B	O
cells	I-protein
of	I-protein
aged	O
mice	O
.	O

Together	O
,	O
our	O
studies	O
suggest	O
that	O
changes	O
associated	I-protein
with	I-protein
the	I-protein
aging	O
phenotype	O
cause	O
posttranslational	O
modification	I-protein
(	O
s	I-protein
)	O
of	I-protein
Pax-5a	B-protein
but	O
not	I-protein
Pax-5d	B-protein
,	O
which	O
may	O
lead	O
to	I-protein
an	I-protein
abnormal	I-protein
B	O
cell	O
phenotype	O
in	I-protein
aged	O
mice	O
,	O
associated	I-protein
with	I-protein
elevated	I-protein
levels	I-protein
of	I-protein
J	I-protein
chain	I-protein
,	O
and	I-protein
secretion	O
of	I-protein
IgM	I-protein

###MEDLINE:21103247

NF-kappa	O
B/Rel	O
participation	O
in	I-protein
the	I-protein
lymphokine-dependent	O
proliferation	I-protein
of	I-protein
T	O
lymphoid	O
cells	I-protein
.	O

Proliferative	O
responses	O
of	I-protein
lymphoid	O
cells	I-protein
to	I-protein
IL-2	B-protein
and	I-protein
IL-4	B-protein
depend	O
on	I-protein
activation	I-protein
of	I-protein
the	I-protein
cells	I-protein
,	O
but	O
the	I-protein
mechanism	O
(	O
s	I-protein
)	O
by	I-protein
which	O
activation	I-protein
enhances	O
cellular	O
competence	O
to	I-protein
respond	O
to	I-protein
cytokines	B-protein
is	O
not	I-protein
fully	O
understood	O
.	O

The	O
NF-kappaB/Rel	B-protein
family	I-protein
represents	O
one	B-protein
signal	O
transduction	I-protein
pathway	I-protein
induced	I-protein
during	I-protein
such	O
activation	I-protein
.	O

We	O
show	O
in	I-protein
this	O
study	O
that	O
inhibition	O
of	I-protein
NF-kappaB	B-protein
through	I-protein
the	I-protein
expression	I-protein
of	I-protein
an	I-protein
IkappaBalpha	B-protein
(	O
inhibitory	B-protein
protein	I-protein
that	O
dissociates	O
from	I-protein
NF-kappaB	B-protein
)	O
mutant	O
refractory	O
to	I-protein
signal-induced	B-protein
degradation	I-protein
(	O
IkappaBalpha	B-protein
(	O
DeltaN	I-protein
)	O
)	O
interfered	O
with	I-protein
the	I-protein
acquisition	O
of	I-protein
competence	O
to	I-protein
proliferate	O
in	I-protein
response	I-protein
to	I-protein
IL-4	B-protein
as	O
well	O
as	O
IL-2	B-protein
.	O

Thymocytes	O
and	I-protein
T	O
cells	I-protein
from	I-protein
IkappaBalpha	B-protein
(	O
DeltaN	I-protein
)	O
transgenic	O
mice	O
expressed	O
normal	O
levels	I-protein
of	I-protein
IL-2R	B-protein
subunits	I-protein
.	O

However	O
,	O
transgenic	O
cells	I-protein
exhibited	O
a	I-protein
dramatic	O
defect	I-protein
in	I-protein
Stat5A	O
activation	I-protein
treatment	O
with	I-protein
IL-2	B-protein
,	O
and	I-protein
a	I-protein
similar	O
defect	I-protein
was	O
observed	O
for	I-protein
IL-4	B-protein
-induced	O
Stat5	O
.	O

In	O
contrast	O
,	O
T	O
lymphoid	O
cells	I-protein
with	I-protein
inhibition	O
of	I-protein
NF-kappaB	B-protein
showed	O
normal	O
insulin	O
receptor	O
substrate-2	O
phosphorylation	I-protein
and	I-protein
only	I-protein
a	I-protein
modest	O
decrease	O
in	I-protein
Stat6	O
activation	I-protein
and	I-protein
insulin	O
receptor	O
substrate-1	O
phosphorylation	I-protein
after	O
IL-4	B-protein
stimulation	I-protein
.	O

These	O
results	O
indicate	O
that	O
the	I-protein
NF-kappaB/Rel/IkappaBalpha	O
system	I-protein
can	O
regulate	O
cytokine	B-protein
receptor	I-protein
capacitation	O
through	I-protein
effects	O
on	I-protein
the	I-protein
induction	I-protein
of	I-protein
downstream	O
signaling	O
by	I-protein
the	I-protein
Stat	B-protein
transcription	I-protein
factor	I-protein
family	I-protein
.	O

###MEDLINE:21111553

BMS-189453	O
,	O
a	I-protein
novel	O
retinoid	B-protein
receptor	I-protein
antagonist	O
,	O
is	O
a	I-protein
potent	O
testicular	O
toxin	I-protein
.	O

BMS-189453	O
is	O
a	I-protein
synthetic	I-protein
retinoid	B-protein
that	O
acts	O
as	O
an	I-protein
antagonist	O
at	I-protein
retinoic	B-protein
acid	I-protein
receptors	I-protein
alpha	I-protein
,	O
beta	I-protein
,	O
and	I-protein
gamma	I-protein
.	O

In	O
Sprague	O
Dawley	O
rats	O
at	I-protein
daily	O
oral	B-protein
doses	O
of	I-protein
15	O
,	O
60	I-protein
,	O
or	I-protein
240	I-protein
mg/kg	O
for	I-protein
1	I-protein
month	O
,	O
BMS-189453	O
produced	O
increases	O
in	I-protein
leukocyte	O
counts	O
,	O
alkaline	B-protein
phosphatase	I-protein
and	I-protein
alanine	I-protein
aminotransferase	I-protein
levels	I-protein
,	O
and	I-protein
marked	O
testicular	O
degeneration	I-protein
and	I-protein
atrophy	I-protein
at	I-protein
all	O
doses	O
.	O

Significant	O
overt	O
signs	O
of	I-protein
toxicity	O
and	I-protein
deaths	O
occurred	O
at	I-protein
240	I-protein
mg/kg	O
,	O
whereas	O
body-weight	O
and	I-protein
food-consumption	O
decreases	O
occurred	O
at	I-protein
60	I-protein
and	I-protein
240	I-protein
mg/kg	O
.	O

When	O
BMS-189453	O
was	O
administered	O
to	I-protein
male	O
rats	O
at	I-protein
daily	O
doses	O
ranging	O
from	I-protein
12.5	O
to	I-protein
100	I-protein
mg/kg	O
for	I-protein
1	I-protein
week	O
,	O
only	I-protein
minimal	O
testicular	O
changes	O
occurred	O
at	I-protein
all	O
doses	O
,	O
shortly	O
after	O
the	I-protein
dosing	O
period	B-protein
.	O

However	O
,	O
after	O
a	I-protein
1-month	O
drug-free	O
observation	O
period	B-protein
,	O
marked	O
testicular	O
atrophy	I-protein
was	O
evident	O
at	I-protein
all	O
doses	O
.	O

BMS-189453	O
was	O
then	O
administered	O
at	I-protein
doses	O
of	I-protein
2	I-protein
,	O
10	I-protein
,	O
or	I-protein
50	I-protein
mg/kg	O
to	I-protein
male	O
rats	O
for	I-protein
1	I-protein
,	O
3	O
,	O
or	I-protein
7	I-protein
consecutive	O
days	O
.	O

Dose-	O
and	I-protein
duration-dependent	O
testicular	O
toxicity	O
that	O
occurred	O
after	O
a	I-protein
1-month	O
observation	O
period	B-protein
did	O
not	I-protein
recover	O
,	O
and	I-protein
,	O
in	I-protein
some	O
cases	O
,	O
was	O
more	O
severe	I-protein
4	I-protein
months	O
after	O
the	I-protein
last	O
dose	O
.	O

In	O
rabbits	O
administered	O
BMS-189453	O
at	I-protein
oral	B-protein
doses	O
of	I-protein
2	I-protein
,	O
10	I-protein
,	O
or	I-protein
50	I-protein
mg/kg	O
for	I-protein
1	I-protein
week	O
,	O
testicular	O
degeneration	I-protein
and	I-protein
atrophy	I-protein
were	O
evident	O
in	I-protein
the	I-protein
high-dose	O
group	I-protein
at	I-protein
1	I-protein
month	O
following	O
treatment	O
.	O

These	O
studies	O
indicate	O
that	O
retinoid	B-protein
antagonists	O
can	O
selectively	O
produce	O
progressive	O
and	I-protein
prolonged	O
testicular	O
toxicity	O
after	O
single	O
or	I-protein
repeated	O
oral	B-protein
doses	O
that	O
are	O
otherwise	O
well	O
tolerated	O
.	O

###MEDLINE:20216392

Sequential	O
involvement	I-protein
of	I-protein
NFAT	B-protein
and	I-protein
Egr	B-protein
transcription	I-protein
factors	I-protein
in	I-protein
FasL	O
regulation	I-protein
.	O

The	O
critical	I-protein
function	I-protein
of	I-protein
NFAT	B-protein
proteins	I-protein
in	I-protein
maintaining	O
lymphoid	O
homeostasis	I-protein
was	O
revealed	O
in	I-protein
mice	O
lacking	I-protein
both	O
NFATp	B-protein
and	I-protein
NFAT4	B-protein
(	O
DKO	O
)	O
.	O

DKO	O
mice	O
exhibit	O
increased	I-protein
lymphoproliferation	O
,	O
decreased	O
activation-induced	B-protein
cell	O
death	O
,	O
and	I-protein
impaired	O
induction	I-protein
of	I-protein
FasL	B-protein
.	O

The	O
transcription	B-protein
factors	I-protein
Egr2	B-protein
and	I-protein
Egr3	O
are	O
potent	O
activators	I-protein
of	I-protein
FasL	B-protein
expression	I-protein
.	O

Here	O
we	O
find	O
that	O
Egr2	O
and	I-protein
Egr3	O
are	O
NFAT	O
target	O
genes	I-protein
.	O

Activation	O
of	I-protein
FasL	B-protein
occurs	O
via	I-protein
the	I-protein
NFAT	B-protein
-dependent	I-protein
induction	I-protein
of	I-protein
Egr3	O
,	O
as	O
demonstrated	O
by	I-protein
the	I-protein
ability	O
of	I-protein
exogenously	O
provided	O
NFATp	B-protein
to	I-protein
restore	O
Egr	B-protein
-dependent	I-protein
FasL	O
promoter	I-protein
activity	I-protein
in	I-protein
DKO	O
lymph	O
node	I-protein
cells	I-protein
.	O

Further	O
,	O
Egr3	O
expression	I-protein
is	O
enriched	I-protein
in	I-protein
Th1	O
cells	I-protein
,	O
suggesting	O
a	I-protein
molecular	I-protein
basis	O
for	I-protein
the	I-protein
known	O
preferential	O
expression	I-protein
of	I-protein
FasL	B-protein
in	I-protein
the	I-protein
Th1	O
versus	O
Th2	O
subset	I-protein
.	O

###MEDLINE:21028948

Mechanisms	O
and	I-protein
clinical	I-protein
relevance	O
of	I-protein
nongenomic	O
glucocorticoid	O
actions	O
.	O

Glucocorticoids	O
have	O
profound	O
anti-inflammatory	O
and	I-protein
immunosuppressive	O
actions	O
when	O
used	O
therapeutically	O
.	O

The	O
therapeutic	O
dose	O
is	O
quite	O
variable	O
and	I-protein
depends	O
on	I-protein
the	I-protein
disease	I-protein
,	O
but	O
ranges	O
from	I-protein
very	O
low	O
to	I-protein
extremely	O
high	O
.	O

The	O
rationale	O
for	I-protein
the	I-protein
use	O
of	I-protein
various	O
dosage	I-protein
regimens	O
for	I-protein
specific	I-protein
clinical	I-protein
indications	O
is	O
the	I-protein
existence	O
of	I-protein
three	O
distinct	O
,	O
therapeutically	O
relevant	I-protein
effects	O
:	O
genomic	O
,	O
specific	I-protein
nongenomic	O
and	I-protein
unspecific	O
nongenomic	O
.	O

Genomic	O
effects	O
are	O
mediated	I-protein
by	I-protein
cytosolic	B-protein
receptors	I-protein
that	O
alter	O
expression	I-protein
of	I-protein
specific	I-protein
genes	I-protein
.	O

Specific	B-protein
nongenomic	O
effects	O
occur	O
within	B-protein
a	I-protein
few	O
minutes	O
and	I-protein
are	O
mediated	I-protein
by	I-protein
steroid-selective	B-protein
membrane	I-protein
receptors	I-protein
.	O

Unspecific	O
nongenomic	O
effects	O
occur	O
within	B-protein
seconds	O
,	O
but	O
only	I-protein
at	I-protein
high	O
glucocorticoid	O
dosages	O
,	O
and	I-protein
seem	O
to	I-protein
result	O
from	I-protein
direct	O
interactions	O
with	I-protein
biological	O
membranes	O
.	O

For	O
unspecific	O
nongenomic	O
effects	O
,	O
methylprednisolone	O
and	I-protein
other	O
glucocorticoids	O
have	O
been	O
shown	O
to	I-protein
inhibit	O
cation	O
cycling	O
across	O
the	I-protein
plasma	O
membrane	O
,	O
but	O
to	I-protein
have	O
little	O
effect	O
on	I-protein
protein	O
synthesis	I-protein
.	O

Thus	O
,	O
glucocorticoids	O
could	O
diminish	O
or	I-protein
prevent	O
the	I-protein
acute	O
immune	O
response	I-protein
by	I-protein
interfering	I-protein
with	I-protein
processes	O
such	O
as	O
the	I-protein
rise	O
in	I-protein
intracellular	I-protein
Ca2+	I-protein
concentration	I-protein
.	O

It	O
is	O
proposed	O
that	O
the	I-protein
additional	B-protein
therapeutic	O
benefit	O
of	I-protein
higher	O
doses	O
is	O
obtained	O
via	I-protein
these	O
nongenomic	O
effects	O
.	O

###MEDLINE:21026273

High	O
glucose-induced	O
intercellular	B-protein
adhesion	I-protein
molecule-1	I-protein
(	O
ICAM-1	B-protein
)	O
expression	I-protein
through	I-protein
an	I-protein
osmotic	O
effect	O
in	I-protein
rat	I-protein
mesangial	O
cells	I-protein
is	O
PKC-NF-kappa	O
B-dependent	O
.	O

AIMS/HYPOTHESIS	O
:	O
Infiltration	O
of	I-protein
mononuclear	O
cells	I-protein
and	I-protein
glomerular	O
enlargement	O
accompanied	O
by	I-protein
glomerular	O
cell	O
proliferation	I-protein
are	O
very	O
early	O
characteristics	O
of	I-protein
the	I-protein
pathophysiology	O
of	I-protein
diabetes	O
.	O

To	O
clarify	O
the	I-protein
mechanism	O
of	I-protein
early	O
diabetic	B-protein
nephropathy	O
,	O
we	O
measured	O
[	O
3H	I-protein
]	O
-thymidine	O
incorporation	O
and	I-protein
cell	O
numbers	O
to	I-protein
show	O
the	I-protein
influence	O
of	I-protein
a	I-protein
high	O
ambient	O
glucose	O
concentration	I-protein
and	I-protein
the	I-protein
osmotic	O
effect	O
on	I-protein
rat	I-protein
mesangial	O
cell	O
proliferation	I-protein
.	O

We	O
also	O
measured	O
the	I-protein
effect	O
of	I-protein
high	O
glucose	O
on	I-protein
the	I-protein
expression	I-protein
of	I-protein
intercellular	B-protein
adhesion	I-protein
molecule-1	I-protein
and	I-protein
vascular	B-protein
adhesion	I-protein
molecule-1	I-protein
by	I-protein
flow	O
cytometry	O
and	I-protein
semiquantitative	O
RT-PCR	O
in	I-protein
mesangial	O
cells	I-protein
and	I-protein
the	I-protein
adhesion	O
of	I-protein
leukocytes	O
to	I-protein
mesangial	O
cells	I-protein
.	O

METHODS/RESULTS	O
:	O
Cells	O
exposed	O
to	I-protein
high	O
D-glucose	O
(	O
30	I-protein
mmol/l	O
)	O
caused	O
an	I-protein
increase	O
in	I-protein
[	O
3H	I-protein
]	O
-thymidine	O
incorporation	O
and	I-protein
cell	O
numbers	O
at	I-protein
24	I-protein
and	I-protein
48	I-protein
h	I-protein
and	I-protein
normalized	O
at	I-protein
72	I-protein
h	I-protein
(	O
p	O
<	O
0.05	O
)	O
,	O
whereas	O
these	O
changes	O
were	O
not	I-protein
found	O
in	I-protein
high	O
mannitol	O
(	O
30	I-protein
mmol/l	O
)	O
,	O
IL-1	B-protein
beta	I-protein
,	O
or	I-protein
TNF	B-protein
alpha	I-protein
-stimulated	O
mesangial	O
cells	I-protein
.	O

Cells	O
exposed	O
to	I-protein
high-glucose	O
(	O
15	O
,	O
30	I-protein
,	O
or	I-protein
60	I-protein
mmol/l	O
)	O
or	I-protein
osmotic	O
agents	O
(	O
L-glucose	O
,	O
raffinose	O
and	I-protein
mannitol	O
)	O
showed	O
that	O
intercellular	B-protein
adhesion	I-protein
molecule-1	I-protein
expression	I-protein
began	O
to	I-protein
increase	O
after	O
24	I-protein
h	I-protein
,	O
reached	O
its	O
maximum	O
at	I-protein
24	I-protein
and	I-protein
48	I-protein
h	I-protein
and	I-protein
gradually	O
decreased	O
afterwards	O
.	O

The	O
stimulatory	I-protein
effects	O
of	I-protein
high	O
glucose	O
and	I-protein
high	O
mannitol	O
on	I-protein
mRNA	O
expression	I-protein
were	O
observed	O
as	O
early	O
as	O
6	I-protein
h	I-protein
and	I-protein
reached	O
its	O
maximum	O
at	I-protein
12	O
h	I-protein
.	O

Up-regulation	O
of	I-protein
ICAM-1	B-protein
protein	I-protein
and	I-protein
mRNA	O
was	O
also	O
found	O
in	I-protein
IL-1-beta	O
and	I-protein
TNF-alpha	B-protein
-stimulated	O
mesangial	O
cells	I-protein
.	O

Neither	O
vascular	B-protein
adhesion	I-protein
molecule-1	I-protein
protein	O
nor	O
mRNA	O
expression	I-protein
was	O
,	O
however	O
,	O
affected	O
by	I-protein
high	O
glucose	O
and	I-protein
high	O
mannitol	O
.	O

Notably	O
,	O
the	I-protein
protein	O
kinase	O
C	O
inhibitors	I-protein
calphostin	O
C	O
and	I-protein
staurosporine	O
reduced	O
high	O
glucose-	O
or	I-protein
high	O
mannitol-induced	O
intercellular	B-protein
adhesion	O
molecule-1	O
mRNA	O
expression	I-protein
and	I-protein
high	O
glucose-induced	O
proliferation	I-protein
.	O

Furthermore	O
,	O
the	I-protein
NF-kappa	O
B	O
inhibitor	O
N-tosyl-L-phenylalanine	O
chloromethyl	O
ketone	O
reduced	O
high	O
glucose-	O
or	I-protein
high	O
mannitol-induced	O
intercellular	B-protein
adhesion	O
molecule-1	O
mRNA	O
expression	I-protein
and	I-protein
high	O
glucose-induced	O
proliferation	I-protein
.	O

Results	O
showed	O
that	O
high	O
glucose	O
(	O
15	O
,	O
30	I-protein
mmol/l	O
)	O
or	I-protein
high	O
concentrations	O
of	I-protein
osmotic	O
agents	O
remarkably	O
increased	I-protein
the	I-protein
number	I-protein
of	I-protein
adherent	O
leukocytes	O
to	I-protein
mesangial	O
cells	I-protein
(	O
p	O
<	O
0.01	O
)	O
compared	O
with	I-protein
control	I-protein
cells	I-protein
(	O
5	O
mmol/l	O
D-glucose	O
)	O
.	O

Functional	O
blocking	O
of	I-protein
intercellular	B-protein
adhesion	I-protein
molecule-1	I-protein
on	I-protein
mesangial	O
cells	I-protein
with	I-protein
rat	I-protein
intercellular	B-protein
adhesion	I-protein
molecule-1	I-protein
monoclonal	I-protein
antibody	I-protein
,	O
calphostin	O
C	O
,	O
staurosporine	O
,	O
or	I-protein
N-tosyl-L-phenylalanine	O
chloromethyl	O
ketone	O
significantly	O
inhibited	O
high	O
glucose-	O
or	I-protein
high	O
mannitol-induced	O
increase	O
in	I-protein
leukocyte	O
adhesion	O
(	O
p	O
<	O
<	O
0.05	O
)	O
.	O

CONCLUSION/INTERPRETATION	O
:	O
These	O
results	O
suggest	O
that	O
high	O
glucose	O
can	O
upregulate	O
intercellular	B-protein
adhesion	I-protein
molecule-1	I-protein
protein	O
and	I-protein
mRNA	O
expression	I-protein
but	O
not	I-protein
vascular	O
adhesion	O
molecule-1	O
expression	I-protein
in	I-protein
mesangial	O
cells	I-protein
and	I-protein
promote	O
leukocyte	O
adhesion	O
through	I-protein
up-regulation	O
of	I-protein
intercellular	B-protein
adhesion	I-protein
molecule-1	I-protein
through	I-protein
osmotic	O
effect	O
,	O
possibly	O
depending	O
on	I-protein
the	I-protein
protein	B-protein
kinase	I-protein
C	I-protein
nuclear	B-protein
factor-kappa	I-protein
B	I-protein
(	O
PKC	B-protein
-	O
NF-kappa	B-protein
B	I-protein
)	O
pathway	I-protein
.	O

High	O
glucose	O
itself	O
can	O
also	O
promote	O
mesangial	O
cell	O
proliferation	I-protein
through	I-protein
the	I-protein
PKC-NF-kappa	O
B	O
pathways	O
.	O

We	O
conclude	O
that	O
hyperglycaemia	O
in	I-protein
itself	O
seems	O
to	I-protein
be	O
an	I-protein
important	O
factor	I-protein
in	I-protein
the	I-protein
development	O
of	I-protein
early	O
diabetic	B-protein
nephropathy	O
.	O

###MEDLINE:20582375

Combined	O
corticosteroid/	O
granulocyte	I-protein
colony-stimulating	I-protein
factor	I-protein
(	O
G-CSF	B-protein
)	O
therapy	O
in	I-protein
the	I-protein
treatment	O
of	I-protein
severe	I-protein
congenital	O
neutropenia	O
unresponsive	O
to	I-protein
G-CSF	B-protein
:	O
Activated	I-protein
glucocorticoid	I-protein
receptors	I-protein
synergize	O
with	I-protein
G-CSF	B-protein
signals	I-protein
.	O

More	O
than	I-protein
90	I-protein
%	O
of	I-protein
patients	O
with	I-protein
severe	I-protein
congenital	O
neutropenia	O
(	O
SCN	B-protein
)	O
respond	O
to	I-protein
granulocyte	I-protein
colony-stimulating	I-protein
factor	I-protein
(	O
G-CSF	B-protein
)	O
therapy	O
.	O

The	O
basis	O
for	I-protein
the	I-protein
refractory	O
state	I-protein
in	I-protein
the	I-protein
remaining	O
patients	O
is	O
unknown	O
.	O

To	O
address	O
this	O
issue	O
,	O
we	O
studied	O
a	I-protein
child	O
with	I-protein
SCN	B-protein
who	O
was	O
totally	O
unresponsive	O
to	I-protein
G-CSF	B-protein
and	I-protein
had	O
a	I-protein
novel	O
point	O
mutation	I-protein
in	I-protein
the	I-protein
extracellular	B-protein
domain	I-protein
of	I-protein
the	I-protein
G-CSF	B-protein
receptor	I-protein
(	O
GCSF-R	B-protein
)	O
.	O

Marrow	O
stromal	O
support	I-protein
of	I-protein
granulopoiesis	O
was	O
evaluated	O
by	I-protein
plating	O
CD34	B-protein
(	O
+	O
)	O
cells	I-protein
on	I-protein
preformed	O
stromal	O
layers	O
.	O

Nonadherent	O
cells	I-protein
were	O
harvested	O
and	I-protein
assayed	O
in	I-protein
clonogenic	O
assays	O
for	I-protein
granulocytic	O
colony	O
production	I-protein
.	O

The	O
in	I-protein
vitro	O
effect	O
of	I-protein
G-CSF	B-protein
and	I-protein
corticosteroids	O
on	I-protein
granulopoiesis	O
was	O
evaluated	O
in	I-protein
clonogenic	O
assays	O
of	I-protein
marrow	I-protein
mononuclear	O
cells	I-protein
,	O
by	I-protein
proliferation	I-protein
studies	O
of	I-protein
the	I-protein
murine	O
myeloid	O
cell	O
line	I-protein
32D	O
expressing	O
the	I-protein
patient	O
's	I-protein
mutated	B-protein
G-CSFR	I-protein
,	O
and	I-protein
by	I-protein
measuring	O
STAT5	B-protein
activation	I-protein
in	I-protein
nuclear	O
extracts	O
from	I-protein
stimulated	O
cells	I-protein
.	O

Patient	O
's	I-protein
stroma	O
supported	I-protein
granulopoiesis	O
derived	I-protein
from	I-protein
control	I-protein
marrow	I-protein
CD34	B-protein
(	O
+	O
)	O
cells	I-protein
in	I-protein
a	I-protein
normal	O
manner	O
.	O

Normal	O
stroma	O
,	O
however	O
,	O
failed	O
to	I-protein
induce	O
granulopoiesis	O
from	I-protein
patient	O
's	I-protein
CD34	B-protein
(	O
+	O
)	O
cells	I-protein
.	O

Clonogenic	O
assays	O
of	I-protein
the	I-protein
patient	O
's	I-protein
marrow	I-protein
mononuclear	O
cells	I-protein
incorporating	O
either	O
G-CSF	B-protein
or	I-protein
hydrocortisone	O
produced	O
little	O
neutrophil	O
growth	O
.	O

In	O
contrast	O
,	O
inclusion	B-protein
of	I-protein
both	O
G-CSF	B-protein
and	I-protein
hydrocortisone	O
in	I-protein
the	I-protein
cytokine	B-protein
``	I-protein
cocktail	I-protein
''	I-protein
markedly	O
increased	I-protein
the	I-protein
neutrophil	O
numbers	O
.	O

Proliferation	O
of	I-protein
32D	O
cells	I-protein
expressing	O
the	I-protein
mutated	B-protein
receptor	I-protein
and	I-protein
STAT5	B-protein
activation	I-protein
were	O
improved	O
by	I-protein
a	I-protein
combination	O
of	I-protein
G-CSF	B-protein
and	I-protein
dexamethasone	O
.	O

When	O
small	O
daily	O
doses	O
of	I-protein
oral	B-protein
prednisone	O
were	O
then	O
administered	O
to	I-protein
the	I-protein
patient	O
with	I-protein
conventional	O
doses	O
of	I-protein
subcutaneous	B-protein
G-CSF	B-protein
,	O
the	I-protein
patient	O
responded	O
with	I-protein
increased	I-protein
neutrophil	O
numbers	O
and	I-protein
with	I-protein
a	I-protein
complete	O
reversal	O
of	I-protein
the	I-protein
infectious	O
problems	O
.	O

These	O
data	O
provide	O
insight	O
into	O
SCN	B-protein
unresponsive	O
to	I-protein
standard	O
G-CSF	B-protein
treatment	O
and	I-protein
to	I-protein
the	I-protein
potential	I-protein
corrective	O
action	O
of	I-protein
combined	O
treatment	O
with	I-protein
G-CSF	B-protein
and	I-protein
corticosteroids	O
through	I-protein
synergistic	O
activation	I-protein
of	I-protein
STAT5	B-protein
.	O

###MEDLINE:20580277

Human	O
renal	O
mesangial	O
cells	I-protein
are	O
a	I-protein
target	O
for	I-protein
the	I-protein
anti-inflammatory	O
action	O
of	I-protein
9-cis	O
retinoic	O
acid	O
.	O

Mesangial	O
cells	I-protein
play	O
an	I-protein
active	O
role	O
in	I-protein
the	I-protein
inflammatory	O
response	I-protein
to	I-protein
glomerular	O
injury	O
.	O

We	O
have	O
studied	O
in	I-protein
cultured	O
human	O
mesangial	O
cells	I-protein
(	O
CHMC	O
)	O
several	I-protein
effects	O
of	I-protein
9-cis	O
retinoic	O
acid	O
(	O
9-cRA	O
)	O
,	O
an	I-protein
activator	O
of	I-protein
both	O
retinoic	B-protein
acid	I-protein
receptors	I-protein
(	O
RARs	B-protein
)	O
and	I-protein
retinoid	B-protein
X	I-protein
receptors	I-protein
(	O
RXRs	B-protein
)	O
.	O

9-cRA	O
inhibited	O
foetal	O
calf	O
serum-induced	O
CHMC	O
proliferation	I-protein
.	O

It	O
also	O
prevented	O
CHMC	O
death	O
induced	I-protein
by	I-protein
the	I-protein
inflammatory	O
mediator	O
H	I-protein
(	O
2	I-protein
)	O
O	I-protein
(	O
2	I-protein
)	O
.	O

This	O
preventive	O
effect	O
was	O
not	I-protein
due	I-protein
to	I-protein
any	O
increase	O
in	I-protein
H	I-protein
(	O
2	I-protein
)	O
O	I-protein
(	O
2	I-protein
)	O
catabolism	O
and	I-protein
it	O
persisted	O
even	O
when	O
both	O
catalase	B-protein
and	I-protein
glutathione	O
synthesis	I-protein
were	O
inhibited	O
.	O

Finally	O
,	O
9-cRA	O
diminished	O
monocyte	B-protein
adhesion	O
to	I-protein
FCS-stimulated	O
CHMC	O
.	O

Interestingly	O
,	O
the	I-protein
retinoid	B-protein
also	O
inhibited	O
in	I-protein
FCS-stimulated	O
cells	I-protein
the	I-protein
protein	O
expression	I-protein
of	I-protein
two	O
mesangial	B-protein
adhesion	I-protein
molecules	I-protein
,	O
fibronectin	B-protein
and	I-protein
osteopontin	O
,	O
but	O
it	O
did	O
not	I-protein
modify	O
the	I-protein
protein	O
expression	I-protein
of	I-protein
intercellular	B-protein
adhesion	I-protein
molecule-1	I-protein
and	I-protein
vascular	B-protein
adhesion	I-protein
molecule-1	I-protein
.	O

All	O
major	O
RARs	B-protein
and	I-protein
RXRs	I-protein
isotypes	I-protein
were	O
expressed	O
in	I-protein
CHMC	O
regardless	O
of	I-protein
the	I-protein
presence	O
or	I-protein
absence	I-protein
of	I-protein
9-cRA	O
.	O

Transcripts	O
to	I-protein
RAR-alpha	O
,	O
RAR-beta	I-protein
and	I-protein
RXR-alpha	O
increased	I-protein
after	O
incubation	O
with	I-protein
9-cRA	O
whereas	O
RXR-gamma	O
was	O
inhibited	O
,	O
suggesting	O
a	I-protein
major	O
role	O
for	I-protein
RARs	B-protein
and	I-protein
RXRs	B-protein
in	I-protein
9-cRA-anti-inflammatory	O
effects	O
.	O

9-cRA	O
was	O
toxic	O
only	I-protein
at	I-protein
50	I-protein
microM	O
(	O
a	I-protein
concentration	I-protein
50	I-protein
-	O
5000	O
times	O
higher	O
than	I-protein
required	O
for	I-protein
the	I-protein
effects	O
above	O
)	O
.	O

Cell	I-protein
death	O
occurred	O
by	I-protein
apoptosis	O
,	O
whose	O
onset	I-protein
was	O
associated	I-protein
with	I-protein
a	I-protein
pronounced	O
increase	O
in	I-protein
catalase	B-protein
activity	I-protein
and	I-protein
reduced	O
glutathione	O
content	O
,	O
being	O
more	O
effectively	O
induced	I-protein
by	I-protein
all-trans	I-protein
retinoic	O
acid	O
.	O

Modulation	O
of	I-protein
the	I-protein
oxidant/antioxidant	O
balance	O
failed	O
to	I-protein
inhibit	O
apoptosis	O
.	O

We	O
conclude	O
that	O
mesangial	O
cells	I-protein
might	O
be	O
a	I-protein
target	O
for	I-protein
the	I-protein
treatment	O
of	I-protein
inflammatory	O
glomerulopathies	O
with	I-protein
9-cRA	O
.	O

###MEDLINE:21011862

Expression	O
of	I-protein
mammalian	O
defensin	O
genes	I-protein
.	O

Antimicrobial	O
peptides	O
are	O
a	I-protein
prevalent	O
mechanism	O
of	I-protein
host	O
defense	O
found	O
throughout	O
nature	O
.	O

In	O
mammals	O
,	O
defensins	O
are	O
among	O
the	I-protein
most	O
abundant	I-protein
of	I-protein
these	O
broad-spectrum	O
antibiotics	O
,	O
and	I-protein
are	O
expressed	O
in	I-protein
epithelial	O
and	I-protein
hematopoietic	O
cells	I-protein
.	O

The	O
defensin	O
peptides	O
are	O
especially	O
abundant	I-protein
in	I-protein
neutrophils	O
;	O
however	O
,	O
gene	O
expression	I-protein
is	O
limited	O
to	I-protein
the	I-protein
promyelocyte	O
stage	I-protein
.	O

In	O
epithelial	O
cells	I-protein
,	O
defensin	O
genes	I-protein
are	O
found	O
as	O
both	O
constitutively	O
expressed	O
and	I-protein
inducible	O
.	O

Induction	O
has	O
been	O
observed	O
in	I-protein
vitro	O
by	I-protein
stimulation	I-protein
with	I-protein
bacterial	I-protein
lipopolysaccharide	B-protein
as	O
well	O
as	O
inflammatory	O
mediators	O
.	O

In	O
vivo	O
,	O
up-regulation	O
of	I-protein
several	I-protein
defensin	O
genes	I-protein
occurs	O
in	I-protein
both	O
infectious	O
and	I-protein
inflammatory	O
states	O
.	O

Gene	I-protein
regulation	I-protein
occurs	O
via	I-protein
signal	O
transduction	I-protein
pathways	O
common	I-protein
to	I-protein
other	O
innate	O
immune	O
responses	O
,	O
utilizing	O
transcription	B-protein
factors	I-protein
such	O
as	O
nuclear	B-protein
factor	I-protein
(	O
NF	I-protein
)	O
-kappaB	I-protein
and	I-protein
NF	B-protein
interleukin-6	I-protein
.	O

Together	O
,	O
the	I-protein
data	O
suggest	O
a	I-protein
broad-based	O
innate	O
host	O
defense	O
whereby	O
potent	O
antimicrobial	I-protein
peptides	O
are	O
present	O
to	I-protein
prevent	O
initial	O
colonization	O
by	I-protein
pathogenic	O
microorganisms	O
.	O

In	O
addition	O
,	O
the	I-protein
recognition	I-protein
of	I-protein
bacteria	O
coupled	I-protein
with	I-protein
a	I-protein
nascent	O
inflammatory	O
response	I-protein
can	O
bolster	O
this	O
defense	O
by	I-protein
a	I-protein
coordinated	O
up-regulation	O
of	I-protein
the	I-protein
peptides	O
.	O

###MEDLINE:20571908

Multiple	B-protein
signals	I-protein
required	O
for	I-protein
cyclic	B-protein
AMP-responsive	I-protein
element	I-protein
binding	I-protein
protein	I-protein
(	O
CREB	B-protein
)	O
binding	I-protein
protein	O
interaction	I-protein
induced	I-protein
by	I-protein
CD3/CD28	O
costimulation	O
.	O

The	O
optimal	O
activation	I-protein
of	I-protein
cAMP-responsive	B-protein
element	I-protein
binding	I-protein
protein	I-protein
(	O
CREB	B-protein
)	O
,	O
similar	O
to	I-protein
the	I-protein
full	O
activation	I-protein
of	I-protein
T	O
lymphocytes	O
,	O
requires	O
the	I-protein
stimulation	I-protein
of	I-protein
both	O
CD3	B-protein
and	I-protein
CD28	B-protein
.	O

Using	O
a	I-protein
reporter	O
system	I-protein
to	I-protein
detect	O
interaction	I-protein
of	I-protein
CREB	B-protein
and	I-protein
CREB-binding	B-protein
protein	I-protein
(	O
CBP	B-protein
)	O
,	O
in	I-protein
this	O
study	O
we	O
found	O
that	O
CREB	B-protein
binds	O
to	I-protein
CBP	B-protein
only	I-protein
by	I-protein
engagement	O
of	I-protein
both	O
CD3	B-protein
and	I-protein
CD28	B-protein
.	O

CD3/CD28	B-protein
-promoted	O
CREB	B-protein
-	O
CBP	B-protein
interaction	I-protein
was	O
dependent	I-protein
on	I-protein
p38	B-protein
mitogen-activated	I-protein
protein	I-protein
kinase	I-protein
(	O
MAPK	I-protein
)	O
and	I-protein
calcium/calmodulin-dependent	B-protein
protein	I-protein
kinase	I-protein
(	O
CaMK	I-protein
)	O
IV	I-protein
in	I-protein
addition	O
to	I-protein
the	I-protein
previously	O
identified	I-protein
extracellular	O
signal-regulated	O
kinase	O
pathway	I-protein
.	O

Extracellular	B-protein
signal-regulated	I-protein
kinase	I-protein
,	O
CaMKIV	B-protein
,	O
and	I-protein
p38	B-protein
MAPK	I-protein
were	O
also	O
the	I-protein
kinases	I-protein
involved	I-protein
in	I-protein
CREB	B-protein
Ser	O
(	O
133	I-protein
)	O
phosphorylation	I-protein
induced	I-protein
by	I-protein
CD3/CD28	B-protein
.	O

A	O
reconstitution	O
experiment	O
illustrated	O
that	O
optimum	O
CREB	B-protein
-	O
CBP	B-protein
interaction	I-protein
and	I-protein
CREB	B-protein
trans-activation	O
were	O
attained	O
when	O
these	O
three	O
kinase	O
pathways	O
were	O
simultaneously	O
activated	O
in	I-protein
T	O
cells	I-protein
.	O

Our	O
results	O
demonstrate	O
that	O
coordinated	O
activation	I-protein
of	I-protein
different	O
kinases	I-protein
leads	O
to	I-protein
full	O
activation	I-protein
of	I-protein
CREB	B-protein
.	O

Notably	O
,	O
CD28	B-protein
ligation	O
activated	O
p38	B-protein
MAPK	I-protein
and	I-protein
CaMKIV	B-protein
,	O
the	I-protein
kinases	I-protein
stimulated	O
by	I-protein
CD3	O
engagement	O
,	O
suggesting	O
that	O
CD28	B-protein
acts	O
by	I-protein
increasing	O
the	I-protein
activation	I-protein
extent	O
of	I-protein
p38	B-protein
MAPK	I-protein
and	I-protein
CaMKIV	B-protein
.	O

These	O
results	O
support	I-protein
the	I-protein
model	I-protein
of	I-protein
a	I-protein
minimum	O
activation	I-protein
threshold	I-protein
for	I-protein
CREB	B-protein
-	O
CBP	B-protein
interaction	I-protein
that	O
can	O
be	O
reached	O
only	I-protein
when	O
both	O
CD3	B-protein
and	I-protein
CD28	B-protein
are	O
stimulated	O
.	O

###MEDLINE:20570937

The	O
murine	O
IL-2	B-protein
promoter	I-protein
contains	I-protein
distal	I-protein
regulatory	O
elements	O
responsive	I-protein
to	I-protein
the	I-protein
Ah	B-protein
receptor	I-protein
,	O
a	I-protein
member	I-protein
of	I-protein
the	I-protein
evolutionarily	O
conserved	O
bHLH-PAS	B-protein
transcription	I-protein
factor	I-protein
family	I-protein
.	O

Signaling	O
through	I-protein
the	I-protein
TCR	B-protein
and	I-protein
costimulatory	O
signals	I-protein
primarily	O
control	I-protein
transcription	O
of	I-protein
the	I-protein
IL-2	B-protein
gene	O
in	I-protein
naive	O
T	O
cells	I-protein
.	O

The	O
minimal	O
promoter	I-protein
necessary	O
for	I-protein
this	O
expression	I-protein
lies	O
proximal	I-protein
,	O
between	O
-300	O
and	I-protein
the	I-protein
transcription	O
start	O
site	I-protein
.	O

We	O
had	O
previously	O
shown	O
that	O
activation	I-protein
of	I-protein
the	I-protein
arylhydrocarbon	B-protein
receptor	I-protein
(	O
AHR	B-protein
)	O
,	O
a	I-protein
member	I-protein
of	I-protein
the	I-protein
bHLH-PAS	B-protein
family	I-protein
of	I-protein
transcription	B-protein
factors	I-protein
,	O
leads	O
to	I-protein
increased	I-protein
mRNA	O
expression	I-protein
of	I-protein
IL-2	B-protein
in	I-protein
murine	O
fetal	O
thymocytes	O
.	O

The	O
AHR	B-protein
is	O
abundant	I-protein
in	I-protein
the	I-protein
thymus	I-protein
and	I-protein
may	O
play	O
a	I-protein
role	O
for	I-protein
the	I-protein
development	O
of	I-protein
the	I-protein
immune	O
system	I-protein
.	O

Moreover	O
,	O
its	O
overactivation	O
by	I-protein
chemicals	O
such	O
as	O
dioxins	O
leads	O
to	I-protein
immunosuppression	O
and	I-protein
thymic	B-protein
involution	O
.	O

Binding	O
motifs	I-protein
for	I-protein
the	I-protein
liganded	B-protein
AHR	B-protein
can	O
be	O
identified	I-protein
in	I-protein
the	I-protein
distal	I-protein
region	O
-1300	O
to	I-protein
-800	O
of	I-protein
the	I-protein
mouse	I-protein
IL-2	B-protein
promoter	I-protein
.	O

We	O
show	O
here	O
that	O
these	O
DNA	O
motifs	I-protein
,	O
the	I-protein
so-called	O
dioxin	O
response	I-protein
elements	O
,	O
after	O
binding	I-protein
to	I-protein
the	I-protein
liganded	B-protein
AHR	B-protein
are	O
sufficient	O
to	I-protein
transactivate	O
luciferase	O
expression	I-protein
in	I-protein
a	I-protein
reporter	O
gene	O
system	I-protein
.	O

The	O
IL-2	B-protein
gene	O
can	O
be	O
induced	I-protein
by	I-protein
the	I-protein
AHR	B-protein
also	O
in	I-protein
thymocytes	O
in	I-protein
vivo	O
after	O
injection	O
of	I-protein
2	I-protein
,	O
3	O
,	O
7	I-protein
,	O
8-tetrachlorodibenzo-p-dioxin	O
,	O
a	I-protein
potent	O
ligand	O
of	I-protein
the	I-protein
AHR	B-protein
.	O

The	O
AHR	B-protein
mediates	O
the	I-protein
IL-2	B-protein
induction	I-protein
as	O
shown	O
with	I-protein
AHR	B-protein
-deficient	O
mice	O
.	O

However	O
,	O
in	I-protein
spleen	B-protein
cells	I-protein
in	I-protein
vitro	O
costimulation	O
via	I-protein
the	I-protein
TCR	B-protein
is	O
necessary	O
for	I-protein
optimal	O
IL-2	B-protein
gene	O
induction	I-protein
.	O

Thus	O
,	O
the	I-protein
IL-2	B-protein
promoter	I-protein
region	O
contains	I-protein
novel	O
distal	I-protein
regulatory	O
elements	O
that	O
can	O
be	O
addressed	O
by	I-protein
the	I-protein
AHR	B-protein
to	I-protein
induce	O
IL-2	B-protein
and	I-protein
can	O
cooperate	O
with	I-protein
the	I-protein
proximal	I-protein
promoter	I-protein

###MEDLINE:21103162

Visualization	O
of	I-protein
Syk-antigen	B-protein
receptor	I-protein
interactions	O
using	O
green	B-protein
fluorescent	I-protein
protein	I-protein
:	O
differential	O
roles	O
for	I-protein
Syk	B-protein
and	I-protein
Lyn	I-protein
in	I-protein
the	I-protein
regulation	I-protein
of	I-protein
receptor	O
capping	O
and	I-protein
internalization	O
.	O

The	O
cross-linking	O
of	I-protein
the	I-protein
B	B-protein
cell	I-protein
Ag	I-protein
receptor	I-protein
(	O
BCR	B-protein
)	O
is	O
coupled	I-protein
to	I-protein
the	I-protein
stimulation	I-protein
of	I-protein
multiple	O
intracellular	I-protein
signal	O
transduction	I-protein
cascades	O
via	I-protein
receptor-associated	O
,	O
protein	B-protein
tyrosine	I-protein
kinases	I-protein
of	I-protein
both	O
the	I-protein
Src	B-protein
and	I-protein
Syk	I-protein
families	I-protein
.	O

To	O
monitor	O
changes	O
in	I-protein
the	I-protein
subcellular	O
distribution	I-protein
of	I-protein
Syk	B-protein
in	I-protein
B	O
cells	I-protein
responding	O
to	I-protein
BCR	B-protein
cross-linking	O
,	O
we	O
expressed	O
in	I-protein
Syk	B-protein
-deficient	O
DT40	O
B	O
cells	I-protein
a	I-protein
fusion	B-protein
protein	I-protein
consisting	O
of	I-protein
Syk	B-protein
coupled	I-protein
to	I-protein
green	B-protein
fluorescent	I-protein
protein	I-protein
.	O

Treatment	O
of	I-protein
these	O
cells	I-protein
with	I-protein
anti-IgM	B-protein
Abs	I-protein
leads	O
to	I-protein
the	I-protein
recruitment	I-protein
of	I-protein
the	I-protein
kinase	O
from	I-protein
cytoplasmic	O
and	I-protein
nuclear	O
compartments	O
to	I-protein
the	I-protein
site	I-protein
of	I-protein
the	I-protein
cross-linked	B-protein
receptor	I-protein
at	I-protein
the	I-protein
plasma	O
membrane	O
.	O

The	O
Syk-receptor	B-protein
complexes	I-protein
aggregate	O
into	O
membrane	O
patches	O
that	O
redistribute	O
to	I-protein
form	I-protein
a	I-protein
cap	I-protein
at	I-protein
one	B-protein
pole	I-protein
of	I-protein
the	I-protein
cell	O
.	O

Syk	B-protein
is	O
not	I-protein
demonstrably	O
associated	I-protein
with	I-protein
the	I-protein
internalized	B-protein
receptor	I-protein
.	O

Catalytically	O
active	O
Syk	B-protein
promotes	O
and	I-protein
stabilizes	O
the	I-protein
formation	O
of	I-protein
tightly	B-protein
capped	I-protein
BCR	B-protein
complexes	I-protein
at	I-protein
the	I-protein
plasma	O
membrane	O
.	O

Lyn	I-protein
is	O
not	I-protein
required	O
for	I-protein
the	I-protein
recruitment	I-protein
of	I-protein
Syk	B-protein
to	I-protein
the	I-protein
cross-linked	B-protein
receptor	I-protein
,	O
but	O
is	O
required	O
for	I-protein
the	I-protein
internalization	O
of	I-protein
the	I-protein
clustered	O
BCR	B-protein
complexes	I-protein
.	O

In	O
the	I-protein
absence	I-protein
of	I-protein
Lyn	I-protein
,	O
receptor-Syk	B-protein
complexes	I-protein
at	I-protein
the	I-protein
plasma	O
membrane	O
are	O
long	I-protein
lived	O
,	O
and	I-protein
the	I-protein
receptor-mediated	O
activation	I-protein
of	I-protein
the	I-protein
NF-AT	B-protein
transcription	I-protein
factor	I-protein
is	O
enhanced	I-protein
.	O

Thus	O
,	O
Lyn	I-protein
appears	O
to	I-protein
function	I-protein
to	I-protein
negatively	O
regulate	O
aspects	O
of	I-protein
BCR	B-protein
-dependent	I-protein
signaling	O
by	I-protein
stimulating	I-protein
receptor	O
internalization	O
and	I-protein
down-regulation	O
.	O

###MEDLINE:21093708

Renal	O
interstitial	I-protein
fibrosis	O
is	O
reduced	O
in	I-protein
angiotensin	B-protein
II	I-protein
type	I-protein
1a	I-protein
receptor	I-protein
-deficient	O
mice	O
.	O

Unilateral	O
ureteral	O
obstruction	I-protein
(	O
UUO	O
)	O
results	O
in	I-protein
tubulointerstitial	B-protein
fibrosis	O
of	I-protein
the	I-protein
affected	O
kidney	O
by	I-protein
stimulating	I-protein
the	I-protein
renin-angiotensin	O
system	I-protein
.	O

This	O
study	O
established	O
a	I-protein
UUO	O
model	I-protein
in	I-protein
angiotensin	B-protein
type	I-protein
1a	I-protein
receptor	I-protein
(	O
AT1a	B-protein
)	O
deficient	I-protein
(	O
mutant	O
)	O
mice	O
to	I-protein
elucidate	O
the	I-protein
role	O
of	I-protein
angiotensin	B-protein
II	I-protein
through	I-protein
AT1a	B-protein
on	I-protein
the	I-protein
fibrosis	O
of	I-protein
the	I-protein
obstructed	O
kidney	O
(	O
OBK	O
)	O
.	O

The	O
relative	I-protein
volume	O
of	I-protein
the	I-protein
tubulointerstitium	O
was	O
measured	O
by	I-protein
an	I-protein
image	O
analyzer	O
;	O
deposition	O
of	I-protein
collagen	B-protein
types	I-protein
III	I-protein
and	I-protein
IV	I-protein
and	I-protein
monocyte	B-protein
/	O
macrophage	O
infiltration	O
were	O
histologically	O
examined	O
using	O
specific	I-protein
antibodies	I-protein
.	O

Also	O
determined	O
were	O
the	I-protein
mRNA	O
levels	I-protein
of	I-protein
transforming	B-protein
growth	I-protein
factor-beta	I-protein
by	I-protein
Northern	O
blot	O
analysis	O
.	O

Nuclear	I-protein
factor-kappaB	I-protein
activity	I-protein
was	O
assessed	O
by	I-protein
gel	O
shift	O
assay	O
.	O

UUO	O
in	I-protein
wild	O
mice	O
resulted	O
in	I-protein
a	I-protein
marked	O
expansion	O
of	I-protein
relative	I-protein
volume	O
of	I-protein
the	I-protein
tubulointerstitium	O
,	O
together	O
with	I-protein
increased	I-protein
deposition	O
of	I-protein
collagen	B-protein
types	I-protein
III	I-protein
and	I-protein
IV	I-protein
and	I-protein
number	I-protein
of	I-protein
infiltrated	O
monocytes	O
/	O
macrophages	O
in	I-protein
the	I-protein
interstitium	O
,	O
relative	I-protein
to	I-protein
sham-operated	O
mice	O
.	O

In	O
comparison	O
,	O
these	O
changes	O
were	O
significantly	O
lower	I-protein
in	I-protein
mutant	O
mice	O
with	I-protein
UUO	O
.	O

The	O
mRNA	O
level	I-protein
of	I-protein
transforming	B-protein
growth	I-protein
factor-beta	I-protein
was	O
significantly	O
higher	O
in	I-protein
the	I-protein
OBK	O
of	I-protein
wild	O
mice	O
with	I-protein
UUO	O
compared	O
with	I-protein
sham-operated	O
mice	O
.	O

In	O
contrast	O
,	O
the	I-protein
increase	O
in	I-protein
mRNA	O
level	I-protein
in	I-protein
the	I-protein
OBK	O
of	I-protein
mutant	O
mice	O
was	O
significantly	O
less	O
than	I-protein
in	I-protein
wild	O
mice	O
.	O

Finally	O
,	O
UUO	O
resulted	O
in	I-protein
activation	I-protein
of	I-protein
nuclear	B-protein
factor-kappaB	I-protein
in	I-protein
wild	O
mice	O
but	O
was	O
inhibited	O
in	I-protein
the	I-protein
OBK	O
of	I-protein
mutant	O
mice	O
.	O

The	O
results	O
provide	O
direct	O
evidence	O
that	O
angiotensin	B-protein
II	I-protein
acting	O
via	I-protein
the	I-protein
AT1a	B-protein
plays	O
a	I-protein
pivotal	O
role	O
in	I-protein
the	I-protein
development	O
of	I-protein
tubulointerstitial	B-protein
fibrosis	O
in	I-protein
UUO	O
.	O

###MEDLINE:20219263

HLA-DQ	B-protein
tetramers	I-protein
identify	O
epitope-specific	O
T	O
cells	I-protein
in	I-protein
peripheral	O
blood	O
of	I-protein
herpes	O
simplex	I-protein
virus	I-protein
type	O
2-infected	O
individuals	O
:	O
direct	O
detection	O
of	I-protein
immunodominant	O
antigen-responsive	O
cells	I-protein
.	O

Ag-specific	O
CD4+	O
T	O
cells	I-protein
are	O
present	O
in	I-protein
peripheral	O
blood	O
in	I-protein
low	O
frequency	O
,	O
where	O
they	O
undergo	O
recruitment	I-protein
and	I-protein
expansion	O
during	I-protein
immune	O
responses	O
and	I-protein
in	I-protein
the	I-protein
pathogenesis	O
of	I-protein
numerous	O
autoimmune	B-protein
diseases	O
.	O

MHC	B-protein
tetramers	I-protein
,	O
which	O
constitute	O
a	I-protein
labeled	B-protein
MHC-peptide	I-protein
ligand	I-protein
suitable	O
for	I-protein
binding	I-protein
to	I-protein
the	I-protein
Ag-specific	B-protein
receptor	I-protein
on	I-protein
T	O
cells	I-protein
,	O
provide	O
a	I-protein
novel	O
approach	O
for	I-protein
the	I-protein
detection	O
and	I-protein
characterization	O
of	I-protein
such	O
rare	I-protein
cells	I-protein
.	O

In	O
this	O
study	O
,	O
we	O
utilized	O
this	O
technology	O
to	I-protein
identify	O
HLA	B-protein
DQ	I-protein
-restricted	O
Ag-specific	O
T	O
cells	I-protein
in	I-protein
the	I-protein
peripheral	O
blood	O
of	I-protein
human	O
subjects	O
and	I-protein
to	I-protein
identify	O
immunodominant	O
epitopes	O
associated	I-protein
with	I-protein
viral	O
infection	I-protein
.	O

Peptides	O
representing	O
potential	I-protein
epitope	I-protein
regions	O
of	I-protein
the	I-protein
VP16	B-protein
protein	I-protein
from	I-protein
HSV-2	O
were	O
loaded	O
onto	O
recombinant	B-protein
DQ0602	I-protein
molecules	I-protein
to	I-protein
generate	O
a	I-protein
panel	O
of	I-protein
Ag-specific	B-protein
DQ0602	I-protein
tetramers	I-protein
.	O

VP16	B-protein
Ag	I-protein
-specific	I-protein
DQ-restricted	O
T	O
cells	I-protein
were	O
identified	I-protein
and	I-protein
expanded	B-protein
from	I-protein
the	I-protein
peripheral	O
blood	O
of	I-protein
HSV-2-infected	O
individuals	O
,	O
representing	O
two	O
predominant	O
epitope	I-protein
specificities	O
.	O

Although	O
the	I-protein
VP16	O
369-380	O
peptide	O
has	O
a	I-protein
lower	I-protein
binding	I-protein
affinity	I-protein
for	I-protein
DQ0602	B-protein
molecules	I-protein
than	I-protein
the	I-protein
VP16	O
33-52	O
peptide	O
,	O
T	O
cells	I-protein
that	O
recognized	I-protein
the	I-protein
VP16	O
369-380	O
peptide	O
occurred	O
at	I-protein
a	I-protein
much	O
higher	O
frequency	O
than	I-protein
those	O
that	O
were	O
specific	I-protein
for	I-protein
the	I-protein
VP16	O
33-52	O
peptide	O
.	O

###MEDLINE:20584588

Down-regulation	O
of	I-protein
BOB.1/OBF.1	B-protein
and	I-protein
Oct2	B-protein
in	I-protein
classical	O
Hodgkin	B-protein
disease	I-protein
but	O
not	I-protein
in	I-protein
lymphocyte	O
predominant	O
Hodgkin	B-protein
disease	I-protein
correlates	O
with	I-protein
immunoglobulin	O
transcription	O
.	O

In	O
contrast	O
to	I-protein
the	I-protein
tumor	O
cells	I-protein
(	O
L	O
&	O
H	I-protein
cells	I-protein
)	O
of	I-protein
lymphocyte	O
predominant	O
Hodgkin	B-protein
disease	I-protein
(	O
LPHD	O
)	O
,	O
Hodgkin	B-protein
and	I-protein
Reed-Sternberg	O
(	O
HRS	B-protein
)	O
cells	I-protein
of	I-protein
classical	O
Hodgkin	B-protein
disease	I-protein
(	O
cHD	O
)	O
are	O
unable	O
to	I-protein
transcribe	O
immunoglobulin	O
,	O
despite	O
the	I-protein
presence	O
of	I-protein
rearranged	O
immunoglobulin	O
genes	I-protein
.	O

Although	O
initial	O
studies	O
have	O
suggested	O
crippling	O
immunoglobulin	O
gene	O
mutations	I-protein
to	I-protein
be	O
the	I-protein
cause	O
of	I-protein
absent	O
immunoglobulin	O
expression	I-protein
in	I-protein
cHD	O
,	O
recent	O
work	O
of	I-protein
our	O
group	I-protein
has	O
demonstrated	O
an	I-protein
impaired	O
activation	I-protein
of	I-protein
the	I-protein
immunoglobulin	O
promoter	I-protein
as	O
a	I-protein
superior	I-protein
mechanism	O
.	O

As	O
immunoglobulin	O
transcription	O
is	O
mainly	O
regulated	O
by	I-protein
the	I-protein
B-cell	B-protein
transcription	I-protein
factors	I-protein
Oct2	B-protein
and	I-protein
BOB.1/OBF.1	B-protein
,	O
we	O
analyzed	O
35	I-protein
cases	O
of	I-protein
LPHD	O
,	O
32	I-protein
cases	O
of	I-protein
cHD	O
,	O
and	I-protein
2	I-protein
Hodgkin	B-protein
disease	I-protein
cell	O
lines	B-protein
for	I-protein
the	I-protein
expression	I-protein
of	I-protein
these	O
transcription	B-protein
factors	I-protein
and	I-protein
also	O
in	I-protein
parallel	O
for	I-protein
immunoglobulin	O
expression	I-protein
.	O

Our	O
results	O
demonstrate	O
an	I-protein
absence	I-protein
of	I-protein
Oct2	B-protein
and/or	O
BOB.1/OBF.1	B-protein
in	I-protein
cHD	O
and	I-protein
a	I-protein
striking	O
overexpression	O
of	I-protein
Oct2	B-protein
in	I-protein
LPHD	O
.	O

Immunoglobulin	O
expression	I-protein
was	O
lacking	I-protein
in	I-protein
cHD	O
but	O
present	O
in	I-protein
LPHD	O
.	O

Furthermore	O
,	O
the	I-protein
reintroduction	O
of	I-protein
BOB.1/OBF.1	B-protein
and	I-protein
Oct2	B-protein
into	O
cultured	O
HRS	B-protein
cells	I-protein
restored	O
the	I-protein
activity	I-protein
of	I-protein
cotransduced	O
immunoglobulin	O
promoter	I-protein
constructs	O
.	O

Our	O
findings	O
dismiss	O
the	I-protein
concept	O
that	O
the	I-protein
different	O
immunoglobulin	O
expression	I-protein
in	I-protein
cHD	O
and	I-protein
LPHD	O
is	O
due	I-protein
to	I-protein
disrupting	O
mutations	I-protein
of	I-protein
immunoglobulin	O
V	O
genes	I-protein
in	I-protein
cHD	O
but	O
is	O
most	O
likely	B-protein
due	I-protein
to	I-protein
a	I-protein
down-regulation	O
of	I-protein
Oct2	B-protein
and/or	O
BOB.1/OBF.1	B-protein
.	O

This	O
study	O
further	O
revealed	O
Oct2	B-protein
as	O
a	I-protein
new	I-protein
and	I-protein
valuable	O
marker	I-protein
for	I-protein
the	I-protein
identification	O
of	I-protein
L	O
&	O
H	I-protein
cells	I-protein
and	I-protein
their	O
distinction	O
from	I-protein
HRS	B-protein
cells	I-protein
.	O

The	O
impairment	I-protein
of	I-protein
immunoglobulin	O
transcription	O
with	I-protein
a	I-protein
down-regulated	I-protein
synthesis	I-protein
of	I-protein
Oct2	B-protein
and	I-protein
BOB.1/OBF.1	B-protein
is	O
the	I-protein
first	O
established	O
general	O
recurrent	O
defect	I-protein
found	O
in	I-protein
HRS	B-protein
cells	I-protein
.	O

###MEDLINE:20584330

Constitutive	O
expression	I-protein
of	I-protein
NF-kappa	B-protein
B	I-protein
is	O
a	I-protein
characteristic	O
feature	O
of	I-protein
mycosis	O
fungoides	O
:	O
implications	O
for	I-protein
apoptosis	O
resistance	O
and	I-protein
pathogenesis	O
.	O

The	O
NF-kappa	B-protein
B	I-protein
family	I-protein
of	I-protein
transcription	B-protein
factors	I-protein
is	O
an	I-protein
important	O
regulator	O
of	I-protein
genes	I-protein
expressed	O
during	I-protein
inflammatory	O
responses	O
,	O
immunoglobulin	O
(	O
Ig	I-protein
)	O
class	O
switching	O
,	O
cellular	O
differentiation	I-protein
,	O
and	I-protein
apoptosis	O
.	O

Recently	O
,	O
members	O
of	I-protein
the	I-protein
NF-kappaB	B-protein
family	I-protein
,	O
including	I-protein
p65	B-protein
(	O
Rel	I-protein
A	I-protein
)	O
,	O
have	O
been	O
implicated	O
in	I-protein
promoting	I-protein
survival	B-protein
of	I-protein
various	O
hematopoeitic	O
neoplasms	O
,	O
including	I-protein
T	O
cell	O
malignancies	O
such	O
as	O
adult	O
T	O
cell	O
leukemia-lymphoma	O
.	O

We	O
investigated	O
the	I-protein
expression	I-protein
of	I-protein
active	B-protein
NF-kappa	I-protein
B	I-protein
p65	I-protein
(	O
Rel	I-protein
A	I-protein
)	O
in	I-protein
cases	O
of	I-protein
mycosis	O
fungoides	O
(	O
MF	O
)	O
and	I-protein
the	I-protein
effect	O
of	I-protein
chemical	O
inhibitors	I-protein
of	I-protein
NF-kappa	B-protein
B	I-protein
on	I-protein
apoptosis	O
in	I-protein
cutaneous	O
T	O
cell	O
lymphoma	I-protein
(	O
CTCL	B-protein
)	O
cell	O
lines	B-protein
.	O

Paraffin-embedded	O
tissues	O
from	I-protein
23	I-protein
cutaneous	O
lesions	O
and	I-protein
a	I-protein
single	O
lymph	O
node	I-protein
biopsy	O
from	I-protein
patients	O
diagnosed	O
with	I-protein
MF	O
were	O
evaluated	O
for	I-protein
p65	B-protein
(	O
Rel	I-protein
A	I-protein
)	O
expression	I-protein
by	I-protein
using	O
a	I-protein
monoclonal	I-protein
mouse	I-protein
antibody	I-protein
that	O
detects	O
the	I-protein
activated	O
form	I-protein
of	I-protein
p65	B-protein
(	O
Rel	I-protein
A	I-protein
)	O
.	O

Apoptosis	I-protein
after	O
treatment	O
with	I-protein
the	I-protein
NF-kappa	O
B	O
inhibitors	I-protein
gliotoxin	O
,	O
MG132	O
,	O
BAY	O
11-7082	O
,	O
and	I-protein
BAY	O
11-7085	O
was	O
quantitatively	O
measured	O
in	I-protein
the	I-protein
CTCL	B-protein
cell	O
lines	B-protein
HuT-78	O
and	I-protein
HH	O
by	I-protein
propidium	O
iodide	I-protein
(	O
PI	I-protein
)	O
/cell	O
cycle	I-protein
analysis	O
for	I-protein
detection	O
of	I-protein
a	I-protein
hypodiploid	O
(	O
sub-G	O
(	O
0	I-protein
)	O
)	O
population	O
and	I-protein
by	I-protein
determination	I-protein
of	I-protein
increased	I-protein
Annexin	I-protein
V/7-amino-actinomycin	O
D	O
(	O
7-AAD	O
)	O
expression	I-protein
.	O

Nuclear	I-protein
extracts	O
from	I-protein
CTCL	B-protein
cells	I-protein
before	O
and	I-protein
after	O
chemical	O
inhibition	O
were	O
analyzed	O
for	I-protein
NF-kappa	B-protein
B	I-protein
nuclear	O
DNA-binding	O
activity	I-protein
by	I-protein
electrophoretic	O
mobility	I-protein
shift	O
assay	O
(	O
EMSA	O
)	O
with	I-protein
quantitative	I-protein
densitometry	O
.	O

Nuclear	I-protein
expression	I-protein
of	I-protein
p65	B-protein
(	O
Rel	I-protein
A	I-protein
)	O
before	O
and	I-protein
after	O
treatment	O
with	I-protein
the	I-protein
various	O
inhibitory	O
compounds	O
was	O
measured	O
by	I-protein
immunofluorescence	O
staining	O
in	I-protein
each	O
CTCL	B-protein
cell	O
line	I-protein
.	O

Neoplastic	O
T	O
lymphocytes	O
from	I-protein
22	I-protein
of	I-protein
24	I-protein
cases	O
of	I-protein
MF	O
showed	O
strong	O
nuclear	O
and	I-protein
cytoplasmic	O
expression	I-protein
of	I-protein
active	B-protein
p65	I-protein
(	O
Rel	I-protein
A	I-protein
)	O
.	O

Compared	O
with	I-protein
untreated	O
control	I-protein
cells	I-protein
,	O
a	I-protein
marked	O
increase	O
in	I-protein
apoptosis	O
,	O
a	I-protein
significant	O
decrease	O
in	I-protein
NF-kappa	O
B	O
DNA-binding	O
activity	I-protein
,	O
and	I-protein
a	I-protein
marked	O
decrease	O
in	I-protein
nuclear	B-protein
p65	I-protein
(	O
Rel	I-protein
A	I-protein
)	O
expression	I-protein
were	O
seen	O
in	I-protein
cells	I-protein
from	I-protein
both	O
CTCL	B-protein
cell	O
lines	B-protein
after	O
chemical	O
NF-kappa	O
B	O
inhibition	O
.	O

These	O
data	O
show	O
that	O
the	I-protein
active	O
form	I-protein
of	I-protein
NF-kappa	B-protein
B	I-protein
p65	I-protein
(	O
Rel	I-protein
A	I-protein
)	O
is	O
commonly	O
expressed	O
in	I-protein
neoplastic	I-protein
T	O
lymphocytes	O
in	I-protein
patients	O
with	I-protein
MF	O
.	O

In	O
CTCL	B-protein
cell	O
lines	B-protein
,	O
the	I-protein
significant	O
decrease	O
in	I-protein
nuclear	O
NF-kappa	O
B	O
expression	I-protein
and	I-protein
the	I-protein
marked	O
increase	O
in	I-protein
spontaneous	O
apoptosis	O
caused	O
by	I-protein
chemical	O
NF-kappa	O
B	O
inhibition	O
suggest	O
a	I-protein
critical	I-protein
role	O
for	I-protein
NF-kappa	B-protein
B	I-protein
in	I-protein
the	I-protein
pathogenesis	O
and	I-protein
tumor	O
cell	O
maintenance	I-protein
of	I-protein
CTCLs	O
.	O

HUM	O
PATHOL	O
31	I-protein
:	O
1482-1490	O
.	O

###MEDLINE:21066742

Human	O
T-cell	O
leukemia	O
virus	I-protein
type	O
1	I-protein
tax	B-protein
protein	I-protein
activates	O
transcription	O
through	I-protein
AP-1	I-protein
site	I-protein
by	I-protein
inducing	I-protein
DNA	O
binding	I-protein
activity	I-protein
in	I-protein
T	O
cells	I-protein
.	O

Human	O
T-cell	O
leukemia	O
virus	I-protein
type	O
1	I-protein
(	O
HTLV-1	B-protein
)	O
Tax	B-protein
protein	I-protein
induces	O
the	I-protein
expression	I-protein
of	I-protein
various	O
family	O
members	O
of	I-protein
the	I-protein
transcription	B-protein
factor	I-protein
AP-1	I-protein
,	O
such	O
as	O
c-Jun	B-protein
,	O
JunD	B-protein
,	O
c-Fos	B-protein
,	O
and	I-protein
Fra-1	B-protein
,	O
at	I-protein
the	I-protein
level	I-protein
of	I-protein
RNA	O
expression	I-protein
in	I-protein
T	O
cells	I-protein
.	O

We	O
examined	O
the	I-protein
activity	I-protein
of	I-protein
Tax	B-protein
in	I-protein
transcription	O
through	I-protein
AP-1-binding	O
sites	I-protein
(	O
AP-1	I-protein
site	I-protein
)	O
in	I-protein
T	O
cells	I-protein
.	O

Transient	I-protein
transfection	O
studies	O
showed	O
that	O
Tax	B-protein
activated	O
the	I-protein
expression	I-protein
of	I-protein
a	I-protein
luciferase	O
gene	O
regulated	O
by	I-protein
two	O
copies	O
of	I-protein
an	I-protein
AP-1	I-protein
site	I-protein
in	I-protein
the	I-protein
human	O
Jurkat	O
T-cell	O
line	I-protein
.	O

Tax	B-protein
activates	O
the	I-protein
expression	I-protein
of	I-protein
viral	O
and	I-protein
cellular	O
genes	I-protein
through	I-protein
two	O
different	O
enhancers	O
:	O
a	I-protein
cAMP-responsive	O
(	O
CRE	O
)	O
-like	I-protein
element	I-protein
and	I-protein
a	I-protein
kappaB	I-protein
element	I-protein
.	O

Two	O
Tax	B-protein
mutants	I-protein
differentially	O
activated	O
expression	I-protein
of	I-protein
these	O
two	O
elements	O
.	O

Tax703	B-protein
preferentially	O
activated	O
the	I-protein
kappaB	I-protein
element	I-protein
but	O
not	I-protein
the	I-protein
CRE-like	O
one	B-protein
,	O
whereas	O
TaxM22	B-protein
showed	O
the	I-protein
reverse	I-protein
.	O

In	O
addition	O
,	O
Tax703	B-protein
and	I-protein
Tax	B-protein
,	O
but	O
not	I-protein
TaxM22	B-protein
,	O
converted	O
cell	O
growth	O
of	I-protein
a	I-protein
mouse	I-protein
T-cell	O
line	I-protein
from	I-protein
being	O
interleukin	O
(	O
IL	O
)	O
-2-dependent	O
to	I-protein
being	O
IL-2-independent	O
.	O

Unlike	O
the	I-protein
wild-type	I-protein
Tax	I-protein
,	O
Tax703	B-protein
and	I-protein
TaxM22	B-protein
only	I-protein
weakly	B-protein
activated	O
the	I-protein
AP-1	I-protein
site	I-protein
in	I-protein
the	I-protein
T-cell	O
line	I-protein
.	O

Thus	O
,	O
Tax	B-protein
seems	O
to	I-protein
activate	O
the	I-protein
AP-1	I-protein
site	I-protein
via	I-protein
mechanisms	O
distinct	O
from	I-protein
those	O
of	I-protein
kappaB	I-protein
or	I-protein
CRE-like	O
elements	O
,	O
and	I-protein
the	I-protein
activation	I-protein
of	I-protein
the	I-protein
AP-1	I-protein
site	I-protein
is	O
dispensable	O
for	I-protein
IL-2-independent	O
growth	O
of	I-protein
CTLL-2	O
.	O

Electrophoretic	O
mobility	I-protein
shift	O
assays	O
showed	O
that	O
Tax	B-protein
induced	I-protein
strong	O
binding	I-protein
activity	I-protein
to	I-protein
an	I-protein
AP-1	I-protein
site	I-protein
in	I-protein
CTLL-2	O
,	O
whereas	O
Tax703	B-protein
did	O
not	I-protein
,	O
indicating	O
that	O
the	I-protein
induction	I-protein
of	I-protein
binding	I-protein
activity	I-protein
to	I-protein
the	I-protein
AP-1	I-protein
site	I-protein
is	O
essential	O
for	I-protein
the	I-protein
transcriptional	O
activation	I-protein
by	I-protein
Tax	B-protein
.	O

The	O
binding	I-protein
complex	I-protein
induced	I-protein
by	I-protein
Tax	B-protein
in	I-protein
CTLL-2	O
contained	O
JunD	B-protein
and	I-protein
Fra-2	B-protein
.	O

Other	O
AP-1	I-protein
proteins	I-protein
were	O
undetectable	O
.	O

Activation	O
of	I-protein
transcription	O
through	I-protein
the	I-protein
AP-1	I-protein
site	I-protein
in	I-protein
Jurkat	O
cells	I-protein
by	I-protein
JunD	B-protein
and/or	O
Fra-2	B-protein
was	O
weak	I-protein
.	O

c-Jun	B-protein
,	O
JunB	B-protein
,	O
and	I-protein
c-Fos	O
activation	I-protein
was	O
greater	O
,	O
although	O
the	I-protein
level	I-protein
was	O
still	O
less	O
than	I-protein
that	O
with	I-protein
Tax	B-protein
.	O

Thus	O
,	O
the	I-protein
induction	I-protein
of	I-protein
AP-1	I-protein
mRNA	O
by	I-protein
Tax	B-protein
may	O
not	I-protein
be	O
sufficient	O
for	I-protein
a	I-protein
complete	O
activation	I-protein
of	I-protein
AP-1	I-protein
site	I-protein
by	I-protein
Tax	B-protein
.	O

Our	O
results	O
suggest	O
that	O
Tax	B-protein
activates	O
the	I-protein
transcription	O
of	I-protein
cellular	O
genes	I-protein
with	I-protein
AP-1	I-protein
sites	I-protein
by	I-protein
inducing	I-protein
the	I-protein
DNA-binding	O
activity	I-protein
of	I-protein
AP-1	I-protein
proteins	I-protein
in	I-protein
T	O
cells	I-protein
,	O
a	I-protein
mechanism	O
distinct	O
from	I-protein
those	O
of	I-protein
CRE-like	O
and	I-protein
kappaB	I-protein
elements	O
.	O

Copyright	O
2001	O
Academic	O
Press	O
.	O

###MEDLINE:20578233

Strict	O
control	I-protein
of	I-protein
human	O
immunodeficiency	I-protein
virus	I-protein
type	O
1	I-protein
replication	O
by	I-protein
a	I-protein
genetic	O
switch	I-protein
:	O
Tet	O
for	I-protein
Tat	I-protein
.	O

Live-attenuated	O
human	O
immunodeficiency	I-protein
virus	I-protein
type	O
1	I-protein
(	O
HIV-1	O
)	O
variants	O
have	O
shown	O
great	O
promise	O
as	O
AIDS	O
vaccines	O
,	O
but	O
continued	O
replication	O
can	O
lead	O
to	I-protein
the	I-protein
selection	O
of	I-protein
faster-replicating	O
variants	O
that	O
are	O
pathogenic	O
.	O

We	O
therefore	O
designed	O
HIV-1	O
genomes	O
that	O
replicate	O
exclusively	O
upon	O
addition	O
of	I-protein
the	I-protein
nontoxic	O
effector	O
doxycycline	O
(	O
dox	O
)	O
.	O

This	O
was	O
achieved	O
by	I-protein
replacement	I-protein
of	I-protein
the	I-protein
viral	O
TAR-Tat	O
system	I-protein
for	I-protein
transcriptional	O
activation	I-protein
by	I-protein
the	I-protein
Escherichia	O
coli-derived	O
Tet	O
system	I-protein
for	I-protein
inducible	O
gene	O
expression	I-protein
.	O

These	O
designer	O
``	O
HIV-rtTA	O
''	I-protein
viruses	O
replicate	O
in	I-protein
a	I-protein
strictly	O
dox-dependent	O
manner	O
both	O
in	I-protein
a	I-protein
T-cell	O
line	I-protein
and	I-protein
in	I-protein
primary	O
blood	O
cells	I-protein
,	O
and	I-protein
the	I-protein
rate	I-protein
of	I-protein
replication	O
can	O
be	O
fine-tuned	O
by	I-protein
simple	O
variation	I-protein
of	I-protein
the	I-protein
dox	O
concentration	I-protein
.	O

These	O
HIV-rtTA	O
viruses	O
provide	O
a	I-protein
tool	O
to	I-protein
perform	O
genetics	O
,	O
e.g.	O
,	O
selection	O
and	I-protein
optimization	I-protein
experiments	O
,	O
with	I-protein
the	I-protein
E.	I-protein
coli-derived	O
Tet	O
reagents	O
in	I-protein
a	I-protein
eukaryotic	O
background	O
.	O

Furthermore	O
,	O
such	O
viruses	O
may	O
represent	O
improved	O
vaccine	O
candidates	O
because	O
their	O
replication	O
can	O
be	O
turned	O
on	I-protein
and	I-protein
off	O
at	I-protein
will	O
.	O

###MEDLINE:21011278

Synovial	O
fluid	I-protein
induced	I-protein
nuclear	B-protein
factor-kappaB	I-protein
DNA	O
binding	I-protein
in	I-protein
a	I-protein
monocytic	I-protein
cell	O
line	I-protein
.	O

OBJECTIVE	O
:	O
To	O
determine	O
the	I-protein
effects	O
of	I-protein
synovial	O
fluids	O
(	O
SF	O
)	O
on	I-protein
DNA	O
binding	I-protein
activity	I-protein
of	I-protein
transcription	B-protein
factor	I-protein
nuclear	I-protein
factor-kappaB	I-protein
(	O
NF-kappaB	B-protein
)	O
in	I-protein
the	I-protein
Mono	O
Mac	O
6	I-protein
monocytic/macrophage	O
cell	O
line	I-protein
as	O
a	I-protein
model	I-protein
for	I-protein
the	I-protein
interaction	I-protein
between	O
SF	O
and	I-protein
synovial	O
tissue	O
macrophages	O
in	I-protein
arthritis	I-protein
.	O

METHODS	O
:	O
Mono	O
Mac	O
6	I-protein
cells	I-protein
were	O
incubated	O
with	I-protein
SF	O
from	I-protein
the	I-protein
knee	O
joints	I-protein
of	I-protein
human	O
subjects	O
with	I-protein
rheumatoid	O
arthritis	I-protein
(	O
RA	B-protein
)	O
,	O
undifferentiated	B-protein
seronegative	O
oligoarthritis	O
,	O
and	I-protein
osteoarthritis	I-protein
(	O
OA	O
)	O
.	O

Nuclear	I-protein
extracts	O
prepared	O
from	I-protein
the	I-protein
Mono	O
Mac	O
6	I-protein
cells	I-protein
and	I-protein
RA	B-protein
synovial	O
tissue	O
were	O
analyzed	O
by	I-protein
electrophoretic	O
mobility	I-protein
shift	O
analysis	O
(	O
EMSA	O
)	O
for	I-protein
NF-kappaB	B-protein
DNA	I-protein
binding	I-protein
proteins	I-protein
.	O

RESULTS	O
:	O
Induction	O
of	I-protein
NF-kappaB	B-protein
DNA	O
binding	I-protein
by	I-protein
the	I-protein
p65	B-protein
(	O
RelA	I-protein
)	O
/p50	I-protein
heterodimer	I-protein
was	O
observed	O
in	I-protein
response	I-protein
to	I-protein
incubation	O
of	I-protein
Mono	O
Mac	O
6	I-protein
cells	I-protein
with	I-protein
SF	O
(	O
20	I-protein
%	O
in	I-protein
culture	O
medium	I-protein
)	O
from	I-protein
5	O
of	I-protein
8	I-protein
subjects	O
with	I-protein
RA	B-protein
,	O
4	I-protein
of	I-protein
5	O
with	I-protein
OA	O
,	O
and	I-protein
none	O
of	I-protein
3	O
with	I-protein
undifferentiated	B-protein
seronegative	O
oligoarthritis	O
.	O

Incubation	O
of	I-protein
SF	O
with	I-protein
neutralizing	B-protein
antibodies	I-protein
against	I-protein
tumor	B-protein
necrosis	I-protein
factor-alpha	I-protein
(	O
TNF-alpha	B-protein
)	O
,	O
but	O
not	I-protein
antibodies	I-protein
against	I-protein
interleukin	B-protein
6	I-protein
(	O
IL-6	B-protein
)	O
,	O
significantly	O
reduced	O
the	I-protein
induction	I-protein
of	I-protein
p65/p50	O
binding	I-protein
activity	I-protein
in	I-protein
SF	O
from	I-protein
subjects	O
with	I-protein
RA	B-protein
and	I-protein
OA	O
.	O

Unexpectedly	O
,	O
a	I-protein
slowly	O
migrating	O
SF	O
inducible	O
NF-kappaB	B-protein
-binding	I-protein
complex	I-protein
was	O
observed	O
in	I-protein
EMSA	O
of	I-protein
Mono	O
Mac	O
6	I-protein
cells	I-protein
after	O
incubation	O
with	I-protein
SF	O
from	I-protein
5	O
of	I-protein
8	I-protein
RA	B-protein
and	I-protein
2	I-protein
of	I-protein
5	O
OA	O
subjects	O
.	O

The	O
induction	I-protein
of	I-protein
this	O
complex	I-protein
by	I-protein
SF	O
was	O
not	I-protein
affected	O
by	I-protein
neutralization	O
of	I-protein
TNF-alpha	B-protein
or	I-protein
IL-6	B-protein
in	I-protein
SF	O
,	O
and	I-protein
the	I-protein
complex	I-protein
was	O
not	I-protein
inducible	O
by	I-protein
TNF-alpha	B-protein
,	O
IL-1beta	B-protein
,	O
TNF-alpha	B-protein
/	O
IL-1beta	B-protein
,	O
IL-6	B-protein
,	O
platelet	B-protein
derived	I-protein
growth	I-protein
factor	I-protein
,	O
lipopolysaccharide	B-protein
,	O
or	I-protein
tetradecanoyl	O
phorbol	O
acetate	O
.	O

The	O
slowly	O
migrating	B-protein
complex	I-protein
could	O
not	I-protein
be	O
supershifted	O
with	I-protein
antibodies	I-protein
against	I-protein
NF-kappaB	B-protein
,	O
Jun	B-protein
,	O
or	I-protein
the	I-protein
transcriptional	O
coactivators	O
p300	B-protein
or	I-protein
CBP	B-protein
.	O

A	O
NF-kappaB-binding	B-protein
complex	I-protein
with	I-protein
similar	O
slow	I-protein
mobility	I-protein
was	O
observed	O
in	I-protein
nuclear	O
extracts	O
prepared	O
from	I-protein
fresh	O
human	O
RA	B-protein
synovial	O
tissue	O
.	O

CONCLUSION	O
:	O
Biological	O
activity	I-protein
of	I-protein
TNF-alpha	B-protein
in	I-protein
SF	O
from	I-protein
RA	B-protein
and	I-protein
OA	O
subjects	O
is	O
capable	O
of	I-protein
inducing	I-protein
p65/p50	B-protein
NF-kappaB	B-protein
DNA	O
binding	I-protein
activity	I-protein
in	I-protein
macrophages	O
.	O

A	O
property	O
of	I-protein
SF	O
that	O
is	O
independent	I-protein
of	I-protein
TNF-alpha	B-protein
and	I-protein
other	O
cytokines	B-protein
is	O
responsible	O
for	I-protein
the	I-protein
induction	I-protein
of	I-protein
a	I-protein
novel	O
slowly	O
migrating	O
NF-kappaB-binding	B-protein
complex	I-protein
.	O

Soluble	O
mediators	O
in	I-protein
SF	O
of	I-protein
subjects	O
with	I-protein
RA	B-protein
and	I-protein
OA	O
can	O
therefore	O
modulate	O
binding	I-protein
of	I-protein
nuclear	B-protein
proteins	I-protein
to	I-protein
the	I-protein
NF-kappaB	B-protein
binding	I-protein
site	I-protein
in	I-protein
macrophages	O
and	I-protein
may	O
play	O
a	I-protein
role	O
in	I-protein
inflammatory	O
gene	O
expression	I-protein
in	I-protein
arthritis	I-protein
.	O

###MEDLINE:20570933

Peroxisome	I-protein
proliferator	I-protein
activator	I-protein
receptor-gamma	I-protein
agonists	O
and	I-protein
15-deoxy-Delta	O
(	O
12	O
,	O
14	I-protein
)	O
(	O
12	O
,	O
14	I-protein
)	O
-PGJ	O
(	O
2	I-protein
)	O
induce	O
apoptosis	O
in	I-protein
normal	O
and	I-protein
malignant	O
B-lineage	O
cells	I-protein
.	O

The	O
research	O
described	O
herein	O
evaluates	O
the	I-protein
expression	I-protein
and	I-protein
functional	O
significance	O
of	I-protein
peroxisome	B-protein
proliferator	I-protein
activator	I-protein
receptor-gamma	I-protein
(	O
PPAR-gamma	I-protein
)	O
on	I-protein
B-lineage	O
cells	I-protein
.	O

Normal	O
mouse	I-protein
B	O
cells	I-protein
and	I-protein
a	I-protein
variety	O
of	I-protein
B	O
lymphoma	I-protein
cells	I-protein
reflective	O
of	I-protein
stages	O
of	I-protein
B	O
cell	O
differentiation	I-protein
(	O
e.g.	O
,	O
70Z/3	O
,	O
CH31	O
,	O
WEHI-231	O
,	O
CH12	O
,	O
and	I-protein
J558	O
)	O
express	O
PPAR-gamma	O
mRNA	O
and	I-protein
,	O
by	I-protein
Western	O
blot	O
analysis	O
,	O
the	I-protein
67-kDa	B-protein
PPAR-gamma	I-protein
protein	I-protein
.	O

15-Deoxy-Delta	O
(	O
12	O
,	O
14	I-protein
)	O
-PGJ	O
(	O
2	I-protein
)	O
(	O
15d-PGJ	O
(	O
2	I-protein
)	O
)	O
,	O
a	I-protein
PPAR-gamma	O
agonist	I-protein
,	O
has	O
a	I-protein
dose-dependent	O
antiproliferative	O
and	I-protein
cytotoxic	O
effect	O
on	I-protein
normal	O
and	I-protein
malignant	O
B	O
cells	I-protein
as	O
shown	O
by	I-protein
[	O
(	O
3	O
)	O
H	I-protein
]	O
thymidine	B-protein
and	I-protein
3-	O
[	O
4	I-protein
,	O
5-dimethylthiazol-2-yl	O
]	O
-2	O
,	O
5-diphenyltetrazolium	O
bromide	O
assays	O
.	O

Only	O
PPAR-gamma	O
agonists	O
(	O
thiazolidinediones	O
)	O
,	O
and	I-protein
not	I-protein
PPAR-alpha	O
agonists	O
,	O
mimicked	O
the	I-protein
effect	O
of	I-protein
15d-PGJ	O
(	O
2	I-protein
)	O
on	I-protein
B-lineage	O
cells	I-protein
,	O
indicating	O
that	O
the	I-protein
mechanism	O
by	I-protein
which	O
15d-PGJ	O
(	O
2	I-protein
)	O
negatively	O
affects	O
B-lineage	O
cells	I-protein
involves	O
in	I-protein
part	I-protein
PPAR-gamma	B-protein
.	O

The	O
mechanism	O
by	I-protein
which	O
PPAR-gamma	O
agonists	O
induce	O
cytotoxicity	I-protein
is	O
via	I-protein
apoptosis	O
,	O
as	O
shown	O
by	I-protein
annexin	B-protein
V	O
staining	O
and	I-protein
as	O
confirmed	O
by	I-protein
DNA	O
fragmentation	I-protein
detected	O
using	O
the	I-protein
TUNEL	O
assay	O
.	O

Interestingly	O
,	O
addition	O
of	I-protein
PGF	B-protein
(	O
2alpha	O
)	O
,	O
which	O
was	O
not	I-protein
known	O
to	I-protein
affect	O
lymphocytes	O
,	O
dramatically	O
attenuated	O
the	I-protein
deleterious	O
effects	O
of	I-protein
PPAR-gamma	O
agonists	O
on	I-protein
B	O
lymphomas	I-protein
.	O

Surprisingly	O
,	O
15d-PGJ	O
(	O
2	I-protein
)	O
induced	I-protein
a	I-protein
massive	O
increase	O
in	I-protein
nuclear	O
mitogen-activated	O
protein	O
kinase	O
activation	I-protein
,	O
and	I-protein
pretreatment	O
with	I-protein
PGF	B-protein
(	O
2alpha	O
)	O
blunted	O
the	I-protein
mitogen-activated	B-protein
protein	I-protein
kinase	I-protein
activation	I-protein
.	O

This	O
is	O
the	I-protein
first	O
study	O
evaluating	O
PPAR-gamma	O
expression	I-protein
and	I-protein
its	O
significance	O
on	I-protein
B	O
lymphocytes	O
.	O

PPAR-gamma	O
agonists	O
may	O
serve	O
as	O
a	I-protein
counterbalance	O
to	I-protein
the	I-protein
stimulating	I-protein
effects	O
of	I-protein
other	O
PGs	O
,	O
namely	O
PGE	I-protein
(	O
2	I-protein
)	O
,	O
which	O
promotes	O
B	O
cell	O
differentiation	I-protein
.	O

Finally	O
,	O
the	I-protein
use	O
of	I-protein
PGs	O
,	O
such	O
as	O
15d-PGJ	O
(	O
2	I-protein
)	O
,	O
and	I-protein
synthetic	I-protein
PPAR-gamma	O
agonists	O
to	I-protein
induce	O
apoptosis	O
in	I-protein
B-lineage	O
cells	I-protein
may	O
lead	O
to	I-protein
the	I-protein
development	O
of	I-protein
novel	O
therapies	O
for	I-protein
fatal	I-protein
B	O
lymphomas	I-protein

###MEDLINE:21102393

Inhibition	O
of	I-protein
STAT3	B-protein
signaling	O
leads	O
to	I-protein
apoptosis	O
of	I-protein
leukemic	O
large	O
granular	O
lymphocytes	O
and	I-protein
decreased	O
Mcl-1	O
expression	I-protein
.	O

Large	O
granular	O
lymphocyte	O
(	O
LGL	O
)	O
leukemia	O
is	O
characterized	O
by	I-protein
the	I-protein
expansion	O
of	I-protein
antigen-activated	O
cytotoxic	O
T	O
lymphocytes	O
.	O

These	O
leukemic	O
cells	I-protein
are	O
resistant	I-protein
to	I-protein
Fas-mediated	O
apoptosis	O
despite	O
expressing	O
high	O
levels	I-protein
of	I-protein
Fas	B-protein
.	O

We	O
found	O
that	O
leukemic	O
LGL	O
from	I-protein
19	I-protein
patients	O
displayed	O
high	O
levels	I-protein
of	I-protein
activated	B-protein
STAT3	B-protein
.	O

Treatment	O
of	I-protein
leukemic	O
LGL	O
with	I-protein
the	I-protein
JAK-selective	O
tyrosine	O
kinase	O
inhibitor	O
AG-490	O
induced	I-protein
apoptosis	O
with	I-protein
a	I-protein
corresponding	O
decrease	O
in	I-protein
STAT	O
-DNA	O
binding	I-protein
activity	I-protein
.	O

Moreover	O
,	O
using	O
an	I-protein
antisense	O
oligonucleotide	O
approach	O
to	I-protein
diminish	O
STAT3	B-protein
expression	I-protein
,	O
we	O
found	O
that	O
Fas	O
sensitivity	I-protein
was	O
restored	O
in	I-protein
leukemic	O
LGL	O
.	O

AG-490-induced	O
apoptosis	O
in	I-protein
leukemic	O
LGL	O
was	O
independent	I-protein
of	I-protein
Bcl-xL	O
or	I-protein
Bcl-2	B-protein
expression	I-protein
.	O

However	O
,	O
we	O
found	O
that	O
the	I-protein
Bcl-2-family	B-protein
protein	I-protein
Mcl-1	I-protein
was	O
significantly	O
reduced	O
by	I-protein
AG-490	O
treatment	O
.	O

Activated	I-protein
STAT3	B-protein
was	O
shown	O
to	I-protein
bind	O
an	I-protein
SIE-related	O
element	I-protein
in	I-protein
the	I-protein
murine	O
mcl-1	O
promoter	I-protein
.	O

Using	O
a	I-protein
luciferase	O
reporter	O
assay	O
,	O
we	O
demonstrated	O
that	O
v-src	B-protein
overexpression	O
in	I-protein
NIH3T3	O
induced	I-protein
STAT3	B-protein
-dependent	I-protein
transcriptional	O
activity	I-protein
from	I-protein
the	I-protein
mcl-1	O
promoter	I-protein
and	I-protein
increased	I-protein
endogenous	O
Mcl-1	O
protein	O
levels	I-protein
.	O

We	O
conclude	O
that	O
STAT3	B-protein
activation	I-protein
contributed	O
to	I-protein
accumulation	I-protein
of	I-protein
the	I-protein
leukemic	O
LGL	O
clones	O
.	O

These	O
findings	O
suggest	O
that	O
investigation	O
should	O
focus	I-protein
on	I-protein
novel	O
strategies	O
targeting	I-protein
STAT3	B-protein
in	I-protein
the	I-protein
treatment	O
of	I-protein
LGL	O
leukemia	O
.	O

###MEDLINE:21095203

Decreased	O
immediate	B-protein
inflammatory	O
gene	O
induction	I-protein
in	I-protein
activating	B-protein
transcription	I-protein
factor-2	I-protein
mutant	O
mice	O
.	O

Transcription	I-protein
factor	I-protein
activating	I-protein
transcription	I-protein
factor	I-protein
(	O
ATF	B-protein
)	O
-2	I-protein
is	O
activated	O
by	I-protein
inflammatory	O
signals	I-protein
transduced	O
by	I-protein
the	I-protein
JNK	B-protein
and	I-protein
p38	B-protein
MAP	I-protein
kinase	I-protein
pathways	O
.	O

To	O
better	O
define	O
the	I-protein
role	O
of	I-protein
ATF-2	B-protein
in	I-protein
inflammation	O
,	O
adult	O
mice	O
expressing	O
small	O
amounts	O
of	I-protein
a	I-protein
mutant	B-protein
ATF-2	I-protein
protein	I-protein
were	O
challenged	O
with	I-protein
lipopolysaccharide	B-protein
(	O
LPS	B-protein
)	O
,	O
anti-CD3	B-protein
antibody	I-protein
or	I-protein
virus	I-protein
.	O

Within	O
3	O
h	I-protein
of	I-protein
challenge	O
by	I-protein
LPS	B-protein
,	O
ATF-2	O
mutant	O
mice	O
had	O
decreased	O
induction	I-protein
of	I-protein
the	I-protein
adhesion	B-protein
molecules	I-protein
E-selectin	B-protein
,	O
P-selectin	B-protein
and	I-protein
VCAM-1	B-protein
as	O
well	O
as	O
the	I-protein
cytokines	B-protein
tumor	B-protein
necrosis	I-protein
factor-alpha	I-protein
,	O
IL-1beta	B-protein
and	I-protein
IL-6	B-protein
compared	O
with	I-protein
control	I-protein
mice	O
.	O

Stimulation	O
of	I-protein
T	O
lymphocytes	O
by	I-protein
anti-CD3	B-protein
antibody	I-protein
also	O
showed	O
less	O
induction	I-protein
of	I-protein
IL-1	B-protein
and	I-protein
IL-6	B-protein
in	I-protein
ATF-2	O
mutant	O
tissues	O
.	O

ATF-2	O
mutant	O
thymocytes	O
treated	O
with	I-protein
anti-CD3	B-protein
antibody	I-protein
in	I-protein
vitro	O
demonstrated	O
reduced	O
induction	I-protein
of	I-protein
c-Jun	B-protein
,	O
JunB	B-protein
,	O
JunD	B-protein
and	I-protein
Fra-2	B-protein
.	O

However	O
,	O
similar	O
to	I-protein
what	O
was	O
observed	O
after	O
p38	B-protein
kinase	O
inhibition	O
in	I-protein
normal	O
mice	O
,	O
relative	I-protein
ATF-2	O
deficiency	I-protein
did	O
not	I-protein
prevent	O
the	I-protein
development	O
of	I-protein
a	I-protein
mononuclear	O
cell	O
infiltrate	O
in	I-protein
the	I-protein
week	O
following	O
an	I-protein
inflammatory	O
stimulus	O
.	O

ATF-2	O
mutant	O
mice	O
proved	O
more	O
susceptible	O
to	I-protein
death	O
than	I-protein
control	I-protein
mice	O
from	I-protein
LPS	B-protein
plus	O
D-galactosamine	O
injection	O
or	I-protein
Coxsackievirus	O
B3	I-protein
infection	I-protein
and	I-protein
had	O
a	I-protein
higher	O
incidence	O
of	I-protein
mononuclear	O
pulmonary	I-protein
infiltrates	O
after	O
exposure	O
to	I-protein
Herpes	O
simplex	I-protein
virus-1	O
.	O

ATF-2	B-protein
is	O
essential	O
for	I-protein
maximal	O
immediate	B-protein
induction	I-protein
of	I-protein
adhesion	B-protein
molecules	I-protein
and	I-protein
cytokine	O
genes	I-protein
,	O
but	O
at	I-protein
later	O
time	O
points	O
may	O
even	O
protect	O
against	I-protein
overactive	O
immune	O
responses	O
.	O

###MEDLINE:20219245

LIGHT	B-protein
,	O
a	I-protein
TNF-like	B-protein
molecule	I-protein
,	O
costimulates	O
T	O
cell	O
proliferation	I-protein
and	I-protein
is	O
required	O
for	I-protein
dendritic	B-protein
cell	O
-mediated	O
allogeneic	O
T	O
cell	O
response	I-protein
.	O

LIGHT	B-protein
is	O
a	I-protein
recently	O
identified	I-protein
member	I-protein
of	I-protein
the	I-protein
TNF	B-protein
superfamily	I-protein
and	I-protein
its	O
receptors	I-protein
,	O
herpesvirus	I-protein
entry	I-protein
mediator	I-protein
and	I-protein
lymphotoxin	B-protein
beta	I-protein
receptor	I-protein
,	O
are	O
found	O
in	I-protein
T	O
cells	I-protein
and	I-protein
stromal	O
cells	I-protein
.	O

In	O
this	O
study	O
,	O
we	O
demonstrate	O
that	O
LIGHT	B-protein
is	O
selectively	O
expressed	O
on	I-protein
immature	B-protein
dendritic	B-protein
cells	I-protein
(	O
DCs	O
)	O
generated	O
from	I-protein
human	O
PBMCs	O
.	O

In	O
contrast	O
,	O
LIGHT	B-protein
is	O
not	I-protein
detectable	O
in	I-protein
DCs	O
either	O
freshly	O
isolated	I-protein
from	I-protein
PBMCs	O
or	I-protein
rendered	O
mature	B-protein
in	I-protein
vitro	O
by	I-protein
LPS	B-protein
treatment	O
.	O

Blockade	O
of	I-protein
LIGHT	B-protein
by	I-protein
its	O
soluble	I-protein
receptors	I-protein
,	O
lymphotoxin	B-protein
beta	I-protein
receptor-Ig	I-protein
or	I-protein
HVEM-Ig	B-protein
,	O
inhibits	I-protein
the	I-protein
induction	I-protein
of	I-protein
DC	O
-mediated	O
primary	O
allogeneic	O
T	O
cell	O
response	I-protein
.	O

Furthermore	O
,	O
engagement	O
of	I-protein
LIGHT	B-protein
costimulates	O
human	O
T	O
cell	O
proliferation	I-protein
,	O
amplifies	O
the	I-protein
NF-kappaB	B-protein
signaling	O
pathway	I-protein
,	O
and	I-protein
preferentially	O
induces	O
the	I-protein
production	I-protein
of	I-protein
IFN-gamma	B-protein
,	O
but	O
not	I-protein
IL-4	B-protein
,	O
in	I-protein
the	I-protein
presence	O
of	I-protein
an	I-protein
antigenic	I-protein
signal	O
.	O

Our	O
results	O
suggest	O
that	O
LIGHT	B-protein
is	O
a	I-protein
costimulatory	O
molecule	I-protein
involved	I-protein
in	I-protein
DC	O
-mediated	O
cellular	O
immune	O
responses	O
.	O

###MEDLINE:20584648

Suppression	O
of	I-protein
HIV	I-protein
type	O
1	I-protein
replication	O
by	I-protein
a	I-protein
dominant-negative	I-protein
Ets-1	I-protein
mutant	I-protein
.	O

Activity	O
of	I-protein
the	I-protein
distal	I-protein
region	O
of	I-protein
the	I-protein
human	O
immunodeficiency	I-protein
virus	I-protein
(	O
HIV-1	O
)	O
long	I-protein
terminal	O
repeat	I-protein
(	O
LTR	O
)	O
,	O
which	O
contains	I-protein
binding	I-protein
sites	I-protein
for	I-protein
the	I-protein
Ets-1	B-protein
and	I-protein
USF-1	I-protein
proteins	I-protein
,	O
is	O
integral	O
for	I-protein
HIV-1	O
replication	O
.	O

The	O
Ets-1	B-protein
and	I-protein
USF-1	I-protein
proteins	I-protein
play	O
a	I-protein
critical	I-protein
role	O
in	I-protein
the	I-protein
activity	I-protein
of	I-protein
the	I-protein
HIV-1	O
LTR	O
distal	I-protein
enhancer	O
region	O
,	O
as	O
indicated	O
by	I-protein
the	I-protein
potent	O
dominant	I-protein
negative	O
effect	O
of	I-protein
a	I-protein
mutant	O
Ets-1	O
lacking	I-protein
trans-activation	O
domains	I-protein
on	I-protein
the	I-protein
transcriptional	O
activity	I-protein
of	I-protein
the	I-protein
LTR	O
.	O

To	O
determine	O
the	I-protein
biological	O
relevance	O
of	I-protein
the	I-protein
Ets-1	B-protein
and	I-protein
USF-1	I-protein
proteins	I-protein
in	I-protein
HIV-1	O
replication	O
,	O
we	O
examined	O
the	I-protein
effect	O
of	I-protein
expression	I-protein
of	I-protein
the	I-protein
dominant-negative	I-protein
mutant	O
of	I-protein
Ets-1	O
(	O
dnEts-1	O
)	O
on	I-protein
HIV-1	O
infection	I-protein
of	I-protein
T	O
cells	I-protein
.	O

We	O
demonstrated	O
that	O
expression	I-protein
of	I-protein
dnEts	O
markedly	O
suppressed	I-protein
HIV-1	O
infection	I-protein
of	I-protein
a	I-protein
T	O
cell	O
line	I-protein
.	O

This	O
finding	O
indicates	O
that	O
formation	O
of	I-protein
a	I-protein
transcriptionaly	B-protein
active	I-protein
USF-1/Ets-1	I-protein
complex	I-protein
is	O
important	O
in	I-protein
the	I-protein
productive	O
infection	I-protein
of	I-protein
cells	I-protein
by	I-protein
HIV-1	O
,	O
and	I-protein
suggests	O
that	O
inhibition	O
of	I-protein
the	I-protein
interaction	I-protein
between	O
USF-1	B-protein
and	I-protein
Ets-1	O
with	I-protein
the	I-protein
HIV-1	O
LTR	O
may	O
provide	O
a	I-protein
new	I-protein
target	O
for	I-protein
anti-HIV-1	O
gene	O
therapy	O
.	O

###MEDLINE:20582895

Human	O
eosinophils	O
constitutively	O
express	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	O
T	O
cells	I-protein
p	O
and	I-protein
c	I-protein
.	O

BACKGROUND	O
:	O
Eosinophils	O
are	O
now	O
known	O
to	I-protein
produce	O
a	I-protein
variety	O
of	I-protein
proinflammatory	B-protein
cytokines	I-protein
,	O
although	O
the	I-protein
molecular	I-protein
factors	I-protein
that	O
regulate	O
their	O
production	I-protein
are	O
poorly	O
understood	O
.	O

The	O
expression	I-protein
of	I-protein
almost	O
all	O
of	I-protein
the	I-protein
cytokines	B-protein
produced	O
by	I-protein
eosinophils	O
,	O
including	I-protein
the	I-protein
proallergic	B-protein
cytokine	I-protein
IL-4	B-protein
,	O
is	O
now	O
known	O
to	I-protein
be	O
regulated	O
at	I-protein
the	I-protein
level	I-protein
of	I-protein
transcription	O
by	I-protein
members	O
of	I-protein
the	I-protein
nuclear	B-protein
factor	I-protein
of	I-protein
activated	O
T	O
cells	I-protein
(	O
NFAT	B-protein
)	O
family	O
of	I-protein
transcription	B-protein
factors	I-protein
.	O

OBJECTIVE	O
:	O
We	O
sought	O
to	I-protein
characterize	O
the	I-protein
expression	I-protein
of	I-protein
different	O
NFAT	B-protein
proteins	I-protein
in	I-protein
resting	O
and	I-protein
activated	O
eosinophils	O
.	O

METHODS	O
:	O
Nuclear	I-protein
and	I-protein
whole	O
cell	O
extracts	O
were	O
obtained	O
from	I-protein
both	O
peripheral	O
blood	O
eosinophils	O
and	I-protein
those	O
obtained	O
from	I-protein
bronchoalveolar	O
lavage	O
fluid	I-protein
of	I-protein
asthmatic	O
subjects	O
after	O
endobronchial	O
allergen	O
challenge	O
.	O

NFAT	O
expression	I-protein
was	O
determined	O
by	I-protein
using	O
immunoprecipitation	O
and	I-protein
Western	O
blot	O
analysis	O
,	O
DNA-binding	O
assays	O
,	O
and	I-protein
RT-PCR	O
analysis	O
of	I-protein
eosinophil	O
mRNA	O
.	O

RESULTS	O
:	O
Both	O
peripheral	O
blood	O
and	I-protein
bronchoalveolar	O
lavage	O
fluid	I-protein
eosinophils	O
expressed	O
NFATp	B-protein
and	I-protein
NFATc	B-protein
protein	I-protein
.	O

Unlike	O
activated	O
T	O
cells	I-protein
,	O
which	O
express	O
multiple	O
NFATc	B-protein
isoforms	I-protein
,	O
eosinophils	O
preferentially	O
express	O
the	I-protein
approximately	O
85-kd	O
isoform	I-protein
.	O

In	O
addition	O
,	O
eosinophils	O
were	O
found	O
to	I-protein
constitutively	O
express	O
NFATc	B-protein
mRNA	O
.	O

A	O
brief	O
incubation	O
with	I-protein
the	I-protein
T	B-protein
(	O
H	I-protein
)	O
2	I-protein
cytokines	I-protein
IL-4	B-protein
and	I-protein
IL-5	B-protein
was	O
sufficient	O
to	I-protein
induce	O
the	I-protein
nuclear	O
translocation	O
of	I-protein
NFATc	B-protein
.	O

Eosinophil	O
nuclear	O
extracts	O
contain	O
multiple	O
factors	I-protein
that	O
can	O
specifically	O
recognize	O
the	I-protein
IL-4	B-protein
promoter	I-protein
P1	I-protein
NFAT	O
site	I-protein
in	I-protein
DNA-binding	O
assays	O
,	O
including	I-protein
NFATp	B-protein
.	O

CONCLUSION	O
:	O
NFATp	O
and	I-protein
NFATc	B-protein
can	O
regulate	O
the	I-protein
expression	I-protein
of	I-protein
cytokines	B-protein
and	I-protein
other	O
genes	I-protein
in	I-protein
eosinophils	O
but	O
appear	O
to	I-protein
be	O
regulated	O
by	I-protein
a	I-protein
novel	O
signal	O
transduction	I-protein
mechanism	O
in	I-protein
these	O
cells	I-protein
.	O

###MEDLINE:21066549

BLyS	B-protein
BINDS	O
TO	O
B	O
CELLS	O
WITH	O
HIGH	O
AFFINITY	O
AND	O
INDUCES	O
ACTIVATION	O
OF	O
THE	O
TRANSCRIPTION	B-protein
FACTORS	I-protein
NF-kappaB	B-protein
AND	I-protein
ELF-1	B-protein
.	O

B	B-protein
lymphocyte	I-protein
stimulator	I-protein
(	O
BLyS	B-protein
)	O
is	O
a	I-protein
novel	O
member	I-protein
of	I-protein
the	I-protein
TNF	B-protein
family	I-protein
of	I-protein
proteins	I-protein
expressed	O
by	I-protein
myeloid	O
cells	I-protein
as	O
membrane-bound	O
and	I-protein
soluble	I-protein
forms	I-protein
.	O

BLyS	B-protein
was	O
shown	O
to	I-protein
act	O
specifically	O
on	I-protein
B	O
cells	I-protein
,	O
inducing	I-protein
proliferation	I-protein
and	I-protein
immunoglobulin	O
production	I-protein
both	O
in	I-protein
vitro	O
and	I-protein
in	I-protein
vivo	O
.	O

The	O
present	O
study	O
was	O
undertaken	O
to	I-protein
characterize	O
binding	I-protein
of	I-protein
radiolabeled	B-protein
BLyS	I-protein
to	I-protein
its	O
cognate	I-protein
receptor	I-protein
on	I-protein
human	O
B	O
lymphocytes	O
and	I-protein
examine	O
intracellular	I-protein
events	O
initiated	O
by	I-protein
BLyS	B-protein
binding	I-protein
.	O

Similar	B-protein
to	I-protein
other	O
TNF	B-protein
family	I-protein
members	I-protein
,	O
BLyS	B-protein
is	O
present	O
in	I-protein
solution	O
as	O
a	I-protein
homotrimer	I-protein
as	O
determined	O
by	I-protein
gel	O
filtration	O
chromatography	O
and	I-protein
light	I-protein
scattering	O
analysis	O
.	O

BLyS	B-protein
binding	I-protein
to	I-protein
B	O
cells	I-protein
is	O
specific	I-protein
as	O
other	O
TNF	B-protein
family	I-protein
members	I-protein
tested	O
did	O
not	I-protein
compete	O
for	I-protein
(	O
125	I-protein
)	O
I-	O
BLyS	O
binding	I-protein
.	O

Analysis	O
of	I-protein
equilibrium	O
binding	I-protein
of	I-protein
(	O
125	I-protein
)	O
I-labeled	I-protein
BLyS	I-protein
to	I-protein
purified	O
human	O
tonsillar	O
B	O
cells	I-protein
demonstrated	O
saturable	O
binding	I-protein
.	O

Scatchard	O
analysis	O
of	I-protein
the	I-protein
binding	I-protein
data	O
revealed	O
a	I-protein
single	O
class	O
of	I-protein
high-affinity	O
binding	I-protein
on	I-protein
human	O
B	O
cells	I-protein
with	I-protein
approximately	O
2600	O
binding	I-protein
sites	I-protein
per	O
cell	O
and	I-protein
an	I-protein
apparent	O
dissociation	I-protein
constant	I-protein
(	O
K	O
(	O
D	O
)	O
)	O
of	I-protein
about	O
0.1	O
nM	O
.	O

In	O
addition	O
we	O
report	O
that	O
BLyS	B-protein
binding	I-protein
to	I-protein
B	O
cells	I-protein
results	O
in	I-protein
the	I-protein
activation	I-protein
of	I-protein
NF-kappaB	B-protein
and	I-protein
the	I-protein
Ets	B-protein
family	I-protein
transcription	I-protein
factor	I-protein
,	O
ELF-1	B-protein
,	O
and	I-protein
in	I-protein
the	I-protein
induction	I-protein
of	I-protein
mRNA	O
for	I-protein
Polo-like	I-protein
kinase	I-protein
(	O
PLK	B-protein
)	O
.	O

Copyright	O
2001	O
Academic	O
Press	O
.	O

###MEDLINE:20578218

Design	O
and	I-protein
use	O
of	I-protein
an	I-protein
inducibly	O
activated	O
human	O
immunodeficiency	I-protein
virus	I-protein
type	O
1	I-protein
Nef	B-protein
to	I-protein
study	O
immune	O
modulation	O
.	O

The	O
Nef	B-protein
protein	I-protein
of	I-protein
the	I-protein
human	O
immunodeficiency	I-protein
virus	I-protein
type	O
1	I-protein
(	O
HIV-1	O
)	O
has	O
been	O
shown	O
to	I-protein
enhance	O
the	I-protein
infectivity	O
of	I-protein
virus	I-protein
particles	O
,	O
downmodulate	O
cell	B-protein
surface	I-protein
proteins	I-protein
,	O
and	I-protein
associate	O
with	I-protein
many	O
intracellular	I-protein
proteins	I-protein
that	O
are	O
thought	O
to	I-protein
facilitate	O
HIV	I-protein
infection	I-protein
.	O

One	I-protein
of	I-protein
the	I-protein
challenges	O
in	I-protein
defining	O
the	I-protein
molecular	I-protein
events	O
regulated	O
by	I-protein
Nef	B-protein
has	O
been	O
obtaining	O
good	O
expression	I-protein
of	I-protein
Nef	B-protein
protein	I-protein
in	I-protein
T	O
cells	I-protein
.	O

This	O
has	O
been	O
attributed	O
to	I-protein
effects	O
of	I-protein
Nef	B-protein
on	I-protein
cell	O
proliferation	I-protein
and	I-protein
apoptosis	O
.	O

We	O
have	O
designed	O
a	I-protein
Nef	B-protein
protein	I-protein
that	O
is	O
readily	O
expressed	O
in	I-protein
T-cell	O
lines	B-protein
and	I-protein
whose	O
function	I-protein
is	O
inducibly	O
activated	O
.	O

It	O
is	O
composed	O
of	I-protein
a	I-protein
fusion	O
between	O
full-length	B-protein
Nef	I-protein
and	I-protein
the	I-protein
estrogen	B-protein
receptor	I-protein
hormone-binding	I-protein
domain	I-protein
(	O
Nef-ER	B-protein
)	O
.	O

The	O
Nef-ER	B-protein
is	O
kept	O
in	I-protein
an	I-protein
inactive	O
state	I-protein
due	I-protein
to	I-protein
steric	O
hindrance	O
,	O
and	I-protein
addition	O
of	I-protein
the	I-protein
membrane-permeable	O
drug	O
4-hydroxytamoxifen	O
(	O
4-HT	O
)	O
,	O
which	O
binds	O
to	I-protein
the	I-protein
ER	B-protein
domain	I-protein
,	O
leads	O
to	I-protein
inducible	O
activation	I-protein
of	I-protein
Nef-ER	B-protein
within	B-protein
cells	I-protein
.	O

We	O
demonstrate	O
that	O
Nef-ER	B-protein
inducibly	O
associates	O
with	I-protein
the	I-protein
62-kDa	B-protein
Ser/Thr	I-protein
kinase	I-protein
and	I-protein
is	O
localized	I-protein
to	I-protein
specific	I-protein
membrane	O
microdomains	I-protein
(	O
lipid	O
rafts	O
)	O
only	I-protein
after	O
activation	I-protein
.	O

Using	O
this	O
inducible	O
Nef	B-protein
,	O
we	O
also	O
compared	O
the	I-protein
specific	I-protein
requirements	O
for	I-protein
CD4	B-protein
and	I-protein
HLA-A2	B-protein
downmodulation	O
in	I-protein
a	I-protein
SupT1	O
T-cell	O
line	I-protein
.	O

Half-maximal	O
downmodulation	O
of	I-protein
cell	B-protein
surface	I-protein
CD4	B-protein
required	O
very	O
little	O
active	O
Nef-ER	B-protein
and	I-protein
occurred	O
as	O
early	O
as	O
4	I-protein
h	I-protein
after	O
addition	O
of	I-protein
4-HT	O
.	O

In	O
contrast	O
,	O
50	I-protein
%	O
downmodulation	O
of	I-protein
HLA-A2	B-protein
by	I-protein
Nef	B-protein
required	O
16	I-protein
to	I-protein
24	I-protein
h	I-protein
and	I-protein
about	O
50-	O
to	I-protein
100-fold-greater	O
concentrations	O
of	I-protein
4-HT	O
.	O

These	O
data	O
suggest	O
that	O
HLA-A2	B-protein
downmodulation	O
may	O
require	O
certain	O
threshold	I-protein
levels	I-protein
of	I-protein
active	O
Nef	B-protein
.	O

The	O
differential	O
timing	O
of	I-protein
CD4	B-protein
and	I-protein
HLA-A2	B-protein
downmodulation	O
may	O
have	O
implications	O
for	I-protein
HIV	I-protein
pathogenesis	O
and	I-protein
immune	O
evasion	O
.	O

###MEDLINE:21012803

Regulation	O
of	I-protein
chemokine	O
mRNA	O
expression	I-protein
in	I-protein
a	I-protein
rat	I-protein
model	I-protein
of	I-protein
vanadium-induced	O
pulmonary	I-protein
inflammation	O
.	O

Environmental	O
and	I-protein
occupational	O
exposure	O
to	I-protein
vanadium	O
dusts	O
results	O
in	I-protein
toxic	O
effects	O
mainly	O
confined	O
to	I-protein
the	I-protein
respiratory	I-protein
system	I-protein
.	O

Using	O
a	I-protein
rat	I-protein
model	I-protein
of	I-protein
acute	O
lung	O
inflammation	O
induced	I-protein
by	I-protein
intratracheal	O
instillation	O
of	I-protein
sodium	O
metavanadate	O
(	O
NaVO3	O
)	O
at	I-protein
the	I-protein
dose	O
of	I-protein
200	I-protein
microg	O
V/kg	O
,	O
we	O
investigated	O
the	I-protein
relationship	O
between	O
the	I-protein
cytologic	O
characterization	O
of	I-protein
pulmonary	I-protein
inflammation	O
and	I-protein
the	I-protein
expression	I-protein
of	I-protein
chemokine	O
mRNA	O
.	O

Significant	O
polymorphonuclear	O
leukocyte	O
(	O
PMN	O
)	O
influx	O
(	O
P	O
<	O
0.01	O
)	O
into	O
the	I-protein
lung	O
was	O
noted	O
4	I-protein
h	I-protein
after	O
NaVO3	O
instillation	O
,	O
whereas	O
alveolar	O
macrophages	O
(	O
AMs	O
)	O
in	I-protein
bronchoalveolar	O
lavage	O
(	O
BAL	B-protein
)	O
cells	I-protein
appeared	O
to	I-protein
decrease	O
significantly	O
.	O

In	O
contrast	O
,	O
neither	O
PMNs	O
nor	O
AMs	O
changed	O
substantially	O
1	I-protein
h	I-protein
after	O
NaVO3	O
instillation	O
.	O

By	O
Northern	O
analysis	O
,	O
macrophage	O
inflammatory	O
protein	O
(	O
MIP	B-protein
)	O
-2	O
mRNA	O
in	I-protein
BAL	B-protein
cells	I-protein
increased	I-protein
markedly	O
1	I-protein
h	I-protein
after	O
NaVO3	O
instillation	O
and	I-protein
reduced	O
a	I-protein
little	O
bit	O
at	I-protein
4	I-protein
h	I-protein
,	O
whereas	O
MIP-1alpha	O
mRNA	O
in	I-protein
BAL	B-protein
cells	I-protein
was	O
expressed	O
relatively	O
high	O
1	I-protein
h	I-protein
after	O
NaVO3	O
instillation	O
,	O
although	O
a	I-protein
basal	O
expression	I-protein
was	O
detected	O
in	I-protein
control	I-protein
group	I-protein
,	O
and	I-protein
returned	O
rapidly	I-protein
nearly	O
to	I-protein
control	I-protein
level	I-protein
at	I-protein
4	I-protein
h	I-protein
.	O

Since	O
MIP-2	B-protein
is	O
a	I-protein
potent	O
PMN	O
chemoattractant	I-protein
and	I-protein
MIP-1alpha	B-protein
is	O
a	I-protein
potent	O
macrophage/monocyte	O
chemoattractant	I-protein
has	O
been	O
well	O
known	O
.	O

The	O
facts	O
that	O
PMN	O
influx	O
was	O
preceded	O
by	I-protein
increased	I-protein
MIP-2	O
mRNA	O
expression	I-protein
,	O
suggesting	O
that	O
MIP-2	B-protein
is	O
involved	I-protein
in	I-protein
the	I-protein
development	O
of	I-protein
NaVO3-induced	O
pulmonary	I-protein
inflammation	O
,	O
whereas	O
increased	I-protein
MIP-1alpha	O
mRNA	O
expression	I-protein
was	O
followed	O
by	I-protein
decreased	O
AMs	O
in	I-protein
BAL	B-protein
cells	I-protein
,	O
suggesting	O
AMs	O
might	O
be	O
activated	O
by	I-protein
MIP-1alpha	B-protein
,	O
adherent	O
to	I-protein
the	I-protein
lining	O
surface	O
of	I-protein
the	I-protein
airways	O
and	I-protein
then	O
resistant	I-protein
to	I-protein
be	O
washed	O
out	O
.	O

To	O
delineate	O
the	I-protein
mechanisms	O
of	I-protein
transcriptional	O
activation	I-protein
,	O
we	O
recently	O
cloned	O
the	I-protein
5'-flanking	O
region	O
of	I-protein
the	I-protein
MIP-2	O
gene	O
.	O

The	O
promotor	O
region	O
contains	I-protein
consensus	O
binding	I-protein
sites	I-protein
for	I-protein
transcription	B-protein
factor	I-protein
nuclear	I-protein
factor	I-protein
kappaB	I-protein
(	O
NF-kappaB	B-protein
)	O
and	I-protein
activator	B-protein
protein-1	I-protein
(	O
AP-1	I-protein
)	O
.	O

Using	O
electrophoretic	O
mobility	I-protein
shift	O
assay	O
,	O
increased	I-protein
nuclear	B-protein
NF-kappaB	B-protein
,	O
not	I-protein
AP-1	I-protein
,	O
binding	I-protein
activity	I-protein
was	O
detected	O
1	I-protein
h	I-protein
after	O
NaVO3	O
instillation	O
,	O
which	O
correlated	O
with	I-protein
the	I-protein
induction	I-protein
of	I-protein
MIP-2	O
mRNA	O
.	O

p65	B-protein
(	O
Rel	I-protein
A	I-protein
)	O
and	I-protein
p50	B-protein
protein	I-protein
appears	O
to	I-protein
be	O
involved	I-protein
in	I-protein
MIP-2	O
NF-kappaB	B-protein
binding	I-protein
.	O

Taken	O
together	O
,	O
our	O
studies	O
suggest	O
that	O
MIP-2	B-protein
is	O
an	I-protein
important	O
mediator	O
of	I-protein
NaVO3-induced	O
pulmonary	I-protein
inflammation	O
in	I-protein
the	I-protein
rat	I-protein
model	I-protein
.	O

In	O
addition	O
,	O
elevated	I-protein
MIP-2	O
mRNA	O
levels	I-protein
are	O
accompanied	O
by	I-protein
increased	I-protein
NF-kappaB	B-protein
binding	I-protein
activity	I-protein
in	I-protein
BAL	B-protein
cells	I-protein
,	O
suggesting	O
possible	O
MIP-2	O
transcriptional	O
regulation	I-protein
through	I-protein
NF-kappaB	B-protein
.	O

###MEDLINE:20573243

Activation	O
of	I-protein
signal	O
transduction	I-protein
and	I-protein
apoptosis	O
in	I-protein
healthy	O
lymphomonocytes	O
exposed	O
to	I-protein
bystander	O
HIV-1-infected	O
cells	I-protein
.	O

Persistent	O
activation	I-protein
of	I-protein
the	I-protein
immune	O
system	I-protein
is	O
one	B-protein
of	I-protein
the	I-protein
hallmarks	O
of	I-protein
HIV-1	O
infection	I-protein
.	O

In	O
this	O
study	O
we	O
analysed	O
the	I-protein
induction	I-protein
of	I-protein
factors	I-protein
involved	I-protein
in	I-protein
cytokine	O
signal	O
transduction	I-protein
,	O
such	O
as	O
STAT	B-protein
1	I-protein
proteins	I-protein
and	I-protein
IRF-1	B-protein
mRNA	O
,	O
in	I-protein
normal	O
peripheral	O
blood	O
mononuclear	O
cells	I-protein
(	O
PBMC	O
)	O
exposed	O
to	I-protein
HIV-infected	O
cells	I-protein
,	O
and	I-protein
the	I-protein
induction	I-protein
of	I-protein
apoptosis	O
.	O

Western	O
blot	O
analyses	O
and	I-protein
reverse	I-protein
transcriptase-polymerase	O
chain	I-protein
reaction	I-protein
results	O
indicate	O
that	O
both	O
cells	I-protein
infected	O
with	I-protein
a	I-protein
X4	I-protein
strain	O
and	I-protein
cells	I-protein
infected	O
with	I-protein
a	I-protein
R5	O
strain	O
are	O
able	O
to	I-protein
increase	O
intracellular	I-protein
levels	I-protein
of	I-protein
STAT	B-protein
1alpha	I-protein
and	I-protein
beta	I-protein
proteins	I-protein
as	O
well	O
as	O
IRF-1	B-protein
mRNA	O
.	O

This	O
effect	O
was	O
prevented	O
by	I-protein
neutralizing	B-protein
antibodies	I-protein
against	I-protein
interferon-alpha	B-protein
(	O
IFN-alpha	B-protein
)	O
.	O

HIV-1-infected	O
cells	I-protein
dose-dependently	O
induced	I-protein
apoptotic	O
commitment	O
in	I-protein
normal	O
PBMC	O
,	O
as	O
revealed	O
by	I-protein
DNA	O
fragmentation	I-protein
analysis	O
,	O
but	O
this	O
was	O
not	I-protein
accompanied	O
by	I-protein
an	I-protein
increase	O
of	I-protein
caspase-3	B-protein
activity	I-protein
,	O
even	O
if	O
a	I-protein
slight	O
up-regulation	O
of	I-protein
IL-1beta-converting	O
enzyme	I-protein
mRNA	O
was	O
detected	O
.	O

Apoptosis	I-protein
induction	I-protein
could	O
be	O
abrogated	O
mainly	O
by	I-protein
antibodies	I-protein
against	I-protein
tumour	I-protein
necrosis	I-protein
factor-alpha	I-protein
(	O
TNF-alpha	B-protein
)	O
and	I-protein
,	O
to	I-protein
a	I-protein
lesser	O
extent	O
,	O
by	I-protein
antibodies	I-protein
against	I-protein
IFN-gamma	B-protein
.	O

All	O
these	O
findings	O
suggest	O
that	O
uninfected	O
PBMC	O
can	O
undergo	O
activation	I-protein
of	I-protein
signal	O
transduction	I-protein
and	I-protein
apoptosis	O
after	O
exposure	O
to	I-protein
bystander	O
HIV-infected	O
cells	I-protein
,	O
subsequent	O
to	I-protein
the	I-protein
induction	I-protein
of	I-protein
cytokines	B-protein
such	O
as	O
IFNs	B-protein
and	I-protein
TNF-alpha	B-protein
.	O

###MEDLINE:20570932

The	O
physical	O
association	I-protein
of	I-protein
protein	B-protein
kinase	I-protein
C	I-protein
theta	I-protein
with	I-protein
a	I-protein
lipid	O
raft-associated	O
inhibitor	O
of	I-protein
kappa	I-protein
B	I-protein
factor	I-protein
kinase	I-protein
(	O
IKK	I-protein
)	O
complex	I-protein
plays	O
a	I-protein
role	O
in	I-protein
the	I-protein
activation	I-protein
of	I-protein
the	I-protein
NF-kappa	O
B	O
cascade	O
by	I-protein
TCR	B-protein
and	I-protein
CD28	B-protein
.	O

We	O
investigated	O
the	I-protein
role	O
of	I-protein
protein	B-protein
kinase	I-protein
C	I-protein
theta	I-protein
(	O
PKCtheta	B-protein
)	O
in	I-protein
the	I-protein
activation	I-protein
of	I-protein
the	I-protein
NF-kappaB	B-protein
cascade	O
in	I-protein
primary	O
human	O
CD4	B-protein
(	O
+	O
)	O
lymphocytes	O
.	O

Among	O
six	O
or	I-protein
so	O
PKC	B-protein
isoforms	I-protein
expressed	O
in	I-protein
T	O
cells	I-protein
,	O
only	I-protein
PKCtheta	B-protein
participates	O
in	I-protein
the	I-protein
assembly	I-protein
of	I-protein
the	I-protein
supramolecular	O
activation	I-protein
clusters	O
at	I-protein
the	I-protein
contact	O
site	I-protein
of	I-protein
the	I-protein
TCR	B-protein
with	I-protein
Ag	I-protein
.	O

Signaling	O
via	I-protein
both	O
the	I-protein
TCR	B-protein
and	I-protein
CD28	B-protein
is	O
required	O
for	I-protein
optimal	O
activation	I-protein
of	I-protein
the	I-protein
multisubunit	B-protein
IkappaB	I-protein
kinase	I-protein
(	O
IKK	I-protein
)	O
complex	I-protein
in	I-protein
primary	O
human	O
T	O
lymphocytes	O
;	O
this	O
activation	I-protein
could	O
be	O
inhibited	O
by	I-protein
a	I-protein
Ca	O
(	O
2+	I-protein
)	O
-independent	O
PKC	B-protein
isoform	I-protein
inhibitor	O
,	O
rottlerin	O
.	O

Moreover	O
,	O
endogenous	O
PKCtheta	B-protein
physically	O
associates	O
with	I-protein
activated	O
IKK	B-protein
complexes	I-protein
in	I-protein
CD3/CD28-costimulated	O
primary	O
CD4	B-protein
(	O
+	O
)	O
T	O
cells	I-protein
.	O

The	O
same	O
set	O
of	I-protein
stimuli	O
also	O
induced	I-protein
relocation	O
of	I-protein
endogenous	O
PKCtheta	B-protein
and	I-protein
IKKs	B-protein
to	I-protein
a	I-protein
GM1	O
ganglioside-enriched	O
,	O
detergent-insoluble	O
membrane	O
compartment	I-protein
in	I-protein
primary	O
T	O
cells	I-protein
.	O

IKKs	B-protein
recruited	O
to	I-protein
these	O
lipid	O
rafts	O
were	O
capable	O
of	I-protein
phosphorylating	O
a	I-protein
recombinant	O
IkappaBalpha	B-protein
sustrate	O
.	O

Confocal	O
microscopy	O
further	O
demonstrated	O
that	O
exogenously	O
expressed	O
PKCtheta	B-protein
and	I-protein
IKKss	B-protein
colocalize	O
in	I-protein
the	I-protein
membrane	O
of	I-protein
CD3/CD28-costimulated	O
Jurkat	O
T	O
cells	I-protein
.	O

Constitutively	O
active	O
but	O
not	I-protein
kinase-inactive	B-protein
PKCtheta	I-protein
activated	O
IKKbeta	B-protein
in	I-protein
Jurkat	O
T	O
cells	I-protein
.	O

Expression	O
of	I-protein
dominant-active	B-protein
PKCtheta	I-protein
also	O
had	O
stimulatory	I-protein
effects	O
on	I-protein
the	I-protein
CD28	B-protein
response	I-protein
element	I-protein
of	I-protein
the	I-protein
IL-2	B-protein
promoter	I-protein
.	O

Taken	O
together	O
,	O
these	O
data	O
show	O
that	O
the	I-protein
activation	I-protein
of	I-protein
PKCtheta	B-protein
by	I-protein
the	I-protein
TCR	B-protein
and	I-protein
CD28	B-protein
plays	O
an	I-protein
important	O
role	O
in	I-protein
the	I-protein
assembly	I-protein
and	I-protein
activation	I-protein
of	I-protein
IKK	B-protein
complexes	I-protein
in	I-protein
the	I-protein
T	O
cell	O
membrane	O

###MEDLINE:21003826

T-cell	O
-mediated	O
regulation	I-protein
of	I-protein
osteoclastogenesis	O
by	I-protein
signalling	I-protein
cross-talk	O
between	O
RANKL	B-protein
and	I-protein
IFN-gamma	B-protein
.	O

Bone	B-protein
resorption	O
is	O
regulated	O
by	I-protein
the	I-protein
immune	O
system	I-protein
,	O
where	O
T-cell	O
expression	I-protein
of	I-protein
RANKL	B-protein
(	O
receptor	I-protein
activator	I-protein
of	I-protein
nuclear	I-protein
factor	I-protein
(	O
NF	I-protein
)	O
-kappaB	I-protein
ligand	I-protein
)	O
,	O
a	I-protein
member	I-protein
of	I-protein
the	I-protein
tumour-necrosis	B-protein
factor	I-protein
family	I-protein
that	O
is	O
essential	O
for	I-protein
osteoclastogenesis	O
,	O
may	O
contribute	O
to	I-protein
pathological	O
conditions	O
,	O
such	O
as	O
autoimmune	B-protein
arthritis	I-protein
.	O

However	O
,	O
whether	O
activated	O
T	O
cells	I-protein
maintain	O
bone	O
homeostasis	I-protein
by	I-protein
counterbalancing	O
the	I-protein
action	O
of	I-protein
RANKL	B-protein
remains	O
unknown	O
.	O

Here	O
we	O
show	O
that	O
T-cell	O
production	I-protein
of	I-protein
interferon	B-protein
(	O
IFN	B-protein
)	O
-gamma	I-protein
strongly	O
suppresses	O
osteoclastogenesis	O
by	I-protein
interfering	I-protein
with	I-protein
the	I-protein
RANKL	B-protein
-RANK	O
signalling	I-protein
pathway	I-protein
.	O

IFN-gamma	O
induces	O
rapid	O
degradation	I-protein
of	I-protein
the	I-protein
RANK	B-protein
adapter	I-protein
protein	I-protein
,	O
TRAF6	B-protein
(	O
tumour	I-protein
necrosis	I-protein
factor	I-protein
receptor-associated	I-protein
factor	I-protein
6	I-protein
)	O
,	O
which	O
results	O
in	I-protein
strong	O
inhibition	O
of	I-protein
the	I-protein
RANKL	B-protein
-induced	O
activation	I-protein
of	I-protein
the	I-protein
transcription	B-protein
factor	I-protein
NF-kappaB	B-protein
and	I-protein
JNK	B-protein
.	O

This	O
inhibition	O
of	I-protein
osteoclastogenesis	O
is	O
rescued	O
by	I-protein
overexpressing	O
TRAF6	B-protein
in	I-protein
precursor	I-protein
cells	I-protein
,	O
which	O
indicates	O
that	O
TRAF6	B-protein
is	O
the	I-protein
target	O
critical	I-protein
for	I-protein
the	I-protein
IFN-gamma	O
action	O
.	O

Furthermore	O
,	O
we	O
provide	O
evidence	O
that	O
the	I-protein
accelerated	I-protein
degradation	I-protein
of	I-protein
TRAF6	B-protein
requires	O
both	O
its	O
ubiquitination	B-protein
,	O
which	O
is	O
initiated	O
by	I-protein
RANKL	B-protein
,	O
and	I-protein
IFN-gamma	B-protein
-induced	O
activation	I-protein
of	I-protein
the	I-protein
ubiquitin-proteasome	O
system	I-protein
.	O

Our	O
study	O
shows	O
that	O
there	O
is	O
cross-talk	O
between	O
the	I-protein
tumour	I-protein
necrosis	I-protein
factor	I-protein
and	I-protein
IFN	B-protein
families	I-protein
of	I-protein
cytokines	B-protein
,	O
through	I-protein
which	O
IFN-gamma	B-protein
provides	O
a	I-protein
negative	O
link	I-protein
between	O
T-cell	O
activation	I-protein
and	I-protein
bone	O
resorption	O
.	O

Our	O
results	O
may	O
offer	O
a	I-protein
therapeutic	O
approach	O
to	I-protein
treat	O
the	I-protein
inflammation-induced	O
tissue	O
breakdown	O
.	O

###MEDLINE:20563930

Stromal-derived	B-protein
factor	I-protein
1	I-protein
and	I-protein
thrombopoietin	B-protein
regulate	O
distinct	O
aspects	O
of	I-protein
human	O
megakaryopoiesis	O
.	O

The	O
role	O
of	I-protein
the	I-protein
chemokine	B-protein
binding	I-protein
stromal-derived	I-protein
factor	I-protein
1	I-protein
(	O
SDF-1	B-protein
)	O
in	I-protein
normal	O
human	O
megakaryopoiesis	O
at	I-protein
the	I-protein
cellular	O
and	I-protein
molecular	I-protein
levels	I-protein
and	I-protein
its	O
comparison	O
with	I-protein
that	O
of	I-protein
thrombopoietin	B-protein
(	O
TPO	B-protein
)	O
have	O
not	I-protein
been	O
determined	O
.	O

In	O
this	O
study	O
it	O
was	O
found	O
that	O
SDF-1	B-protein
,	O
unlike	O
TPO	B-protein
,	O
does	O
not	I-protein
stimulate	O
alpha	O
(	O
IIb	I-protein
)	O
beta	O
(	O
3	O
)	O
(	O
+	O
)	O
cell	O
proliferation	I-protein
or	I-protein
differentiation	I-protein
or	I-protein
have	O
an	I-protein
antiapoptotic	O
effect	O
.	O

However	O
,	O
it	O
does	O
induce	O
chemotaxis	O
,	O
trans-Matrigel	O
migration	I-protein
,	O
and	I-protein
secretion	O
of	I-protein
matrix	B-protein
metalloproteinase	I-protein
9	I-protein
(	O
MMP-9	B-protein
)	O
and	I-protein
vascular	B-protein
endothelial	I-protein
growth	I-protein
factor	I-protein
(	O
VEGF	B-protein
)	O
by	I-protein
these	O
cells	I-protein
,	O
and	I-protein
both	O
SDF-1	B-protein
and	I-protein
TPO	B-protein
increase	O
the	I-protein
adhesion	O
of	I-protein
alpha	O
(	O
IIb	I-protein
)	O
beta	O
(	O
3	O
)	O
(	O
+	O
)	O
cells	I-protein
to	I-protein
fibrinogen	B-protein
and	I-protein
vitronectin	B-protein
.	O

Investigating	O
the	I-protein
intracellular	I-protein
signaling	O
pathways	O
induced	I-protein
by	I-protein
SDF-1	B-protein
and	I-protein
TPO	B-protein
revealed	O
some	O
overlapping	I-protein
patterns	O
of	I-protein
protein	O
phosphorylation/activation	O
(	O
mitogen-activated	B-protein
protein	I-protein
kinase	I-protein
[	O
MAPK	I-protein
]	O
p42/44	I-protein
,	O
MAPK	I-protein
p38	B-protein
,	O
and	I-protein
AKT	B-protein
[	O
protein	I-protein
kinase	I-protein
B	I-protein
]	O
)	O
and	I-protein
some	O
that	O
were	O
distinct	O
for	I-protein
TPO	B-protein
(	O
eg	O
,	O
JAK-STAT	B-protein
)	O
and	I-protein
for	I-protein
SDF-1	B-protein
(	O
eg	O
,	O
NF-kappa	B-protein
B	I-protein
)	O
.	O

It	O
was	O
also	O
found	O
that	O
though	O
inhibition	O
of	I-protein
phosphatidyl-inositol	B-protein
3-kinase	I-protein
(	O
PI-3K	B-protein
)	O
by	I-protein
LY294002	O
in	I-protein
alpha	O
(	O
IIb	I-protein
)	O
beta	O
(	O
3	O
)	O
(	O
+	O
)	O
cells	I-protein
induced	I-protein
apoptosis	O
and	I-protein
inhibited	O
chemotaxis	O
adhesion	O
and	I-protein
the	I-protein
secretion	O
of	I-protein
MMP-9	B-protein
and	I-protein
VEGF	B-protein
,	O
the	I-protein
inhibition	O
of	I-protein
MAPK	I-protein
p42/44	I-protein
(	O
by	I-protein
the	I-protein
MEK	O
inhibitor	O
U0126	O
)	O
had	O
no	I-protein
effect	O
on	I-protein
the	I-protein
survival	B-protein
,	O
proliferation	I-protein
,	O
and	I-protein
migration	I-protein
of	I-protein
these	O
cells	I-protein
.	O

Hence	O
,	O
it	O
is	O
suggested	O
that	O
the	I-protein
proliferative	O
effect	O
of	I-protein
TPO	B-protein
is	O
more	O
related	O
to	I-protein
activation	I-protein
of	I-protein
the	I-protein
JAK-STAT	O
pathway	I-protein
(	O
unique	I-protein
to	I-protein
TPO	B-protein
)	O
,	O
and	I-protein
the	I-protein
PI-3K-AKT	O
axis	O
is	O
differentially	O
involved	I-protein
in	I-protein
TPO-	O
and	I-protein
SDF-1-dependent	O
signaling	O
.	O

Accordingly	O
,	O
PI-3K	B-protein
is	O
involved	I-protein
in	I-protein
TPO	B-protein
-mediated	O
inhibition	O
of	I-protein
apoptosis	O
,	O
TPO-	O
and	I-protein
SDF-1-regulated	O
adhesion	O
to	I-protein
fibrinogen	B-protein
and	I-protein
vitronectin	B-protein
,	O
and	I-protein
SDF-1	B-protein
-mediated	O
migration	I-protein
.	O

This	O
study	O
expands	O
the	I-protein
understanding	O
of	I-protein
the	I-protein
role	O
of	I-protein
SDF-1	B-protein
and	I-protein
TPO	B-protein
in	I-protein
normal	O
human	O
megakaryopoiesis	O
and	I-protein
indicates	O
the	I-protein
molecular	I-protein
basis	O
of	I-protein
the	I-protein
observed	O
differences	O
in	I-protein
cellular	O
responses	O
.	O

(	O
Blood.	O
2000	O
;	O
96	I-protein
:	O
4142-4151	O
)	O

###MEDLINE:20546999

Adhesion	O
of	I-protein
immature	B-protein
and	I-protein
mature	B-protein
T	O
cells	I-protein
induces	O
in	I-protein
human	O
thymic	B-protein
epithelial	O
cells	I-protein
(	O
TEC	B-protein
)	O
activation	I-protein
of	I-protein
IL-6	B-protein
gene	I-protein
trascription	I-protein
factors	I-protein
(	O
NF-kappaB	B-protein
and	I-protein
NF-IL6	B-protein
)	O
and	I-protein
IL-6	B-protein
gene	O
expression	I-protein
:	O
role	O
of	I-protein
alpha3beta1	B-protein
and	I-protein
alpha6beta4	I-protein
integrins	I-protein
.	O

T	O
cell	O
precursors	O
homed	O
to	I-protein
thymus	I-protein
develop	O
in	I-protein
close	I-protein
contact	O
with	I-protein
stromal	O
cells	I-protein
.	O

Among	O
them	O
,	O
thymic	B-protein
epithelial	O
cells	I-protein
(	O
TEC	B-protein
)	O
are	O
known	O
to	I-protein
exert	O
dominant	I-protein
roles	O
in	I-protein
their	O
survival	B-protein
and	I-protein
functional	O
shaping	O
.	O

Key	O
molecules	O
mediating	I-protein
TEC	B-protein
/	O
thymocytes	O
interactions	O
include	O
cytokines	B-protein
and	I-protein
growth	B-protein
factors	I-protein
secreted	O
by	I-protein
the	I-protein
two	O
cell	O
types	I-protein
and	I-protein
adhesion	B-protein
receptors	I-protein
mediating	I-protein
cell	O
contact	O
.	O

Signaling	O
events	O
triggered	O
in	I-protein
thymocytes	O
by	I-protein
adhesion	O
to	I-protein
epithelial	O
cells	I-protein
have	O
been	O
extensively	O
investigated	O
,	O
whereas	O
little	O
is	O
known	O
on	I-protein
the	I-protein
opposite	O
phenomenon	O
.	O

We	O
have	O
previously	O
investigated	O
this	O
issue	O
in	I-protein
a	I-protein
co-culture	O
system	I-protein
composed	O
of	I-protein
TEC	B-protein
cultures	O
derived	I-protein
from	I-protein
human	O
normal	O
thymus	I-protein
and	I-protein
heterologous	O
thymocytes	O
.	O

We	O
demonstrated	O
that	O
thymocytes	O
adhere	O
to	I-protein
TEC	B-protein
involving	O
beta1	B-protein
and	I-protein
beta4	I-protein
integrins	I-protein
and	I-protein
induce	O
the	I-protein
clustering	O
of	I-protein
alpha3beta1	B-protein
and	I-protein
alpha6beta4	I-protein
heterodimers	I-protein
at	I-protein
the	I-protein
TEC	B-protein
surface	O
.	O

In	O
addition	O
thymocyte	B-protein
adhesion	O
was	O
followed	O
by	I-protein
activation	I-protein
of	I-protein
NF-kappaB	B-protein
and	I-protein
NF-IL6	B-protein
gene	I-protein
transcription	I-protein
factors	I-protein
and	I-protein
enhanced	I-protein
IL-6	B-protein
production	I-protein
.	O

The	O
two	O
latter	O
phenomena	O
were	O
reproduced	O
by	I-protein
the	I-protein
cross-linking	O
of	I-protein
the	I-protein
alpha3	O
,	O
alpha6	O
,	O
beta1	B-protein
and	I-protein
beta4	I-protein
integrins	I-protein
,	O
thus	O
implying	O
that	O
the	I-protein
alpha3beta1	B-protein
and	I-protein
alpha6beta4	I-protein
heterodimers	I-protein
can	O
signal	O
during	I-protein
thymocyte	B-protein
adhesion	O
.	O

We	O
have	O
extended	O
our	O
previous	O
work	O
investigating	O
in	I-protein
the	I-protein
same	O
experimental	O
setting	O
the	I-protein
inducing	I-protein
activity	I-protein
of	I-protein
non	O
stimulated	O
or	I-protein
activated	O
policlonal	O
or	I-protein
clonal	O
mature	B-protein
T	O
cells	I-protein
as	O
representative	O
of	I-protein
the	I-protein
more	O
mature	B-protein
thymocyte	B-protein
subset	I-protein
.	O

We	O
found	O
that	O
adhesion	O
of	I-protein
unstimulated	O
T	O
cell	O
i	I-protein
)	O
involved	I-protein
beta1	O
,	O
but	O
not	I-protein
beta4	O
integrin	O
functions	O
at	I-protein
the	I-protein
surface	O
ii	O
)	O
induced	I-protein
the	I-protein
clustering	O
of	I-protein
alpha3beta1	O
,	O
but	O
not	I-protein
alpha2beta1	B-protein
heterodimers	I-protein
at	I-protein
the	I-protein
TEC	B-protein
surface	O
and	I-protein
iii	O
)	O
up-regulated	O
the	I-protein
nuclear	O
binding	I-protein
activity	I-protein
of	I-protein
NF-kappaB	B-protein
transcription	I-protein
factor	I-protein
and	I-protein
the	I-protein
IL-6	B-protein
secretion	O
.	O

We	O
propose	O
that	O
alpha3beta1	B-protein
and	I-protein
alpha6beta4	I-protein
heterodimers	I-protein
are	O
induced	I-protein
to	I-protein
cluster	I-protein
at	I-protein
the	I-protein
TEC	B-protein
surface	O
recognizing	O
yet	O
unknown	O
cellular	B-protein
ligands	I-protein
differentially	O
expressed	O
during	I-protein
T	O
cell	O
development	O
.	O

###MEDLINE:20545190

Identification	O
and	I-protein
characterization	O
of	I-protein
SKAT-2	O
,	O
a	I-protein
novel	O
Th2-specific	O
zinc	O
finger	I-protein
gene	O
.	O

We	O
have	O
identified	I-protein
a	I-protein
novel	O
Kruppel-type	O
zinc	O
finger	I-protein
(	O
ZF	O
)	O
gene	O
,	O
SKAT-2	O
,	O
which	O
is	O
selectively	O
expressed	O
by	I-protein
murine	O
Th2	O
cells	I-protein
.	O

The	O
protein	O
encoded	O
by	I-protein
this	O
gene	O
has	O
14	I-protein
C2H2-type	O
ZF	O
tandemly	O
arrayed	O
at	I-protein
its	O
C	O
terminus	I-protein
and	I-protein
N-terminal	O
SCAN	O
box	I-protein
and	I-protein
KRAB	O
domains	I-protein
.	O

SKAT-2	O
is	O
tissue	O
restricted	I-protein
in	I-protein
expression	I-protein
at	I-protein
the	I-protein
RNA	O
level	I-protein
,	O
detectable	O
only	I-protein
in	I-protein
brain	O
and	I-protein
at	I-protein
low	O
levels	I-protein
in	I-protein
kidney	O
and	I-protein
spleen	B-protein
and	I-protein
few	O
hematopoietic	O
cell	O
lines	B-protein
.	O

By	O
in	I-protein
situ	O
hybridization	O
,	O
SKAT-2	O
expression	I-protein
was	O
found	O
to	I-protein
peak	O
in	I-protein
antigen-stimulated	O
CD4	B-protein
(	O
+	O
)	O
T	O
cells	I-protein
after	O
2-3	I-protein
days	O
of	I-protein
culture	O
under	O
Th2	O
but	O
not	I-protein
Th1	O
biasing	O
conditions	O
.	O

This	O
pattern	I-protein
of	I-protein
expression	I-protein
closely	O
mirrored	O
that	O
of	I-protein
GATA-3	B-protein
in	I-protein
the	I-protein
same	O
cells	I-protein
.	O

In	O
transient	O
transfection	O
experiments	O
in	I-protein
phorbol	O
12-myristate	O
13-acetate/ionomycin-stimulated	O
EL4	O
cells	I-protein
,	O
SKAT-2	O
was	O
found	O
to	I-protein
up-regulate	O
the	I-protein
activity	I-protein
of	I-protein
the	I-protein
IL-4	B-protein
but	O
not	I-protein
the	I-protein
IL-5	B-protein
promoter	I-protein
,	O
contrasting	O
with	I-protein
the	I-protein
ability	O
of	I-protein
GATA-3	B-protein
to	I-protein
activate	O
both	O
promoters	O
.	O

This	O
result	O
was	O
confirmed	O
using	O
clones	O
of	I-protein
EL4	O
cells	I-protein
stably	O
expressing	O
an	I-protein
inducible	O
form	I-protein
of	I-protein
SKAT-2	O
,	O
thus	O
SKAT-2	O
is	O
a	I-protein
novel	O
Th2-specific	O
gene	O
that	O
may	O
play	O
a	I-protein
role	O
in	I-protein
selective	O
regulation	I-protein
of	I-protein
cytokine	O
genes	I-protein
in	I-protein
T	O
cells	I-protein
.	O

###MEDLINE:20541385

hsp70	B-protein
interacting	I-protein
protein	I-protein
Hip	I-protein
does	O
not	I-protein
affect	O
glucocorticoid	B-protein
receptor	I-protein
folding	I-protein
by	I-protein
the	I-protein
hsp90-based	O
chaperone	O
machinery	I-protein
except	O
to	I-protein
oppose	O
the	I-protein
effect	O
of	I-protein
BAG-1	I-protein
.	O

Reticulocyte	I-protein
lysate	O
contains	I-protein
a	I-protein
chaperone	O
system	I-protein
that	O
assembles	O
glucocorticoid	B-protein
receptor	I-protein
(	O
GR	B-protein
)	O
.hsp90	I-protein
heterocomplexes	I-protein
.	O

Using	O
purified	B-protein
proteins	I-protein
,	O
we	O
have	O
prepared	O
a	I-protein
five-protein	O
heterocomplex	O
assembly	I-protein
system	I-protein
consisting	O
of	I-protein
two	O
proteins	I-protein
essential	O
for	I-protein
heterocomplex	O
assembly-	O
hsp90	B-protein
and	I-protein
hsp70	B-protein
-and	O
three	O
proteins	I-protein
that	O
act	O
as	O
co-chaperones	O
to	I-protein
enhance	O
assembly-	O
Hop	B-protein
,	O
hsp40	O
,	O
p23	O
[	O
Morishima	O
,	O
Y.	O
,	O
Kanelakis	O
,	O
K.	O
C.	I-protein
,	O
Silverstein	O
,	O
A.	I-protein
M.	O
,	O
Dittmar	O
,	O
K.	O
D.	O
,	O
Estrada	O
,	O
L.	O
,	O
and	I-protein
Pratt	O
,	O
W.	O
B.	O
(	O
2000	O
)	O
J.	O
Biol.	O
Chem.	O
275	I-protein
,	O
6894-6900	O
]	O
.	O

The	O
hsp70	B-protein
co-chaperone	I-protein
Hip	I-protein
has	O
been	O
recovered	O
in	I-protein
receptor.hsp90	B-protein
heterocomplexes	I-protein
at	I-protein
an	I-protein
intermediate	O
stage	I-protein
of	I-protein
assembly	I-protein
in	I-protein
reticulocyte	O
lysate	O
,	O
and	I-protein
Hip	B-protein
is	O
also	O
thought	O
to	I-protein
be	O
an	I-protein
intrinsic	I-protein
component	O
of	I-protein
the	I-protein
assembly	I-protein
machinery	I-protein
.	O

Here	O
we	O
show	O
that	O
immunodepletion	O
of	I-protein
Hip	B-protein
from	I-protein
reticulocyte	O
lysate	O
or	I-protein
addition	O
of	I-protein
high	O
levels	I-protein
of	I-protein
Hip	B-protein
to	I-protein
the	I-protein
purified	O
five-protein	O
system	I-protein
does	O
not	I-protein
affect	O
GR.hsp90	O
heterocomplex	O
assembly	I-protein
or	I-protein
the	I-protein
activation	I-protein
of	I-protein
steroid	O
binding	I-protein
activity	I-protein
that	O
occurs	O
with	I-protein
assembly	I-protein
.	O

Despite	O
the	I-protein
fact	O
that	O
Hip	B-protein
does	O
not	I-protein
affect	O
assembly	I-protein
,	O
it	O
is	O
recovered	O
in	I-protein
GR.hsp90	B-protein
heterocomplexes	I-protein
assembled	O
by	I-protein
both	O
systems	O
.	O

In	O
the	I-protein
five-protein	O
system	I-protein
,	O
Hip	B-protein
prevents	O
inhibition	O
of	I-protein
assembly	I-protein
by	I-protein
the	I-protein
hsp70	B-protein
co-chaperone	I-protein
BAG-1	I-protein
,	O
and	I-protein
cotransfection	O
of	I-protein
Hip	B-protein
with	I-protein
BAG-1	I-protein
opposes	O
BAG-1	I-protein
reduction	I-protein
of	I-protein
steroid	O
binding	I-protein
activity	I-protein
in	I-protein
COS	O
cells	I-protein
.	O

We	O
conclude	O
that	O
Hip	B-protein
is	O
not	I-protein
a	I-protein
component	O
of	I-protein
the	I-protein
assembly	I-protein
machinery	I-protein
but	O
that	O
it	O
could	O
play	O
a	I-protein
regulatory	O
role	O
in	I-protein
opposition	O
to	I-protein
BAG-1	I-protein
.	O

###MEDLINE:20540051

Cutting	O
edge	O
:	O
STAT6-deficient	O
mice	O
have	O
enhanced	I-protein
tumor	O
immunity	O
to	I-protein
primary	O
and	I-protein
metastatic	O
mammary	I-protein
carcinoma	I-protein
.	O

STAT4	B-protein
and	I-protein
STAT6	B-protein
are	O
essential	O
for	I-protein
the	I-protein
development	O
of	I-protein
CD4	B-protein
(	O
+	O
)	O
Th1	O
and	I-protein
Th2	O
development	O
,	O
respectively	O
.	O

Tumor	O
immunologists	O
have	O
hypothesized	O
that	O
Th1	O
cells	I-protein
are	O
critical	I-protein
in	I-protein
tumor	O
immunity	O
because	O
they	O
facilitate	O
differentiation	I-protein
of	I-protein
CD8	O
(	O
+	O
)	O
T	O
cells	I-protein
,	O
which	O
are	O
potent	O
anti-tumor	O
effectors	O
.	O

We	O
have	O
used	O
STAT4	B-protein
(	O
-/-	O
)	O
and	I-protein
STAT6	B-protein
(	O
-/-	O
)	O
mice	O
to	I-protein
test	O
this	O
hypothesis	O
.	O

BALB/c	O
and	I-protein
knockout	O
mice	O
were	O
challenged	O
in	I-protein
the	I-protein
mammary	I-protein
gland	I-protein
with	I-protein
the	I-protein
highly	O
malignant	O
and	I-protein
spontaneously	O
metastatic	O
BALB/c-derived	O
4T1	O
mammary	I-protein
carcinoma	I-protein
.	O

Primary	O
tumor	O
growth	O
and	I-protein
metastatic	O
disease	I-protein
are	O
reduced	O
in	I-protein
STAT6	B-protein
(	O
-/-	O
)	O
mice	O
relative	I-protein
to	I-protein
BALB/c	O
and	I-protein
STAT4	B-protein
(	O
-/-	O
)	O
mice	O
.	O

Ab	O
depletions	O
demonstrate	O
that	O
the	I-protein
effect	O
is	O
mediated	I-protein
by	I-protein
CD8	O
(	O
+	O
)	O
T	O
cells	I-protein
,	O
and	I-protein
immunized	O
STAT6	B-protein
(	O
-/-	O
)	O
mice	O
have	O
higher	O
levels	I-protein
of	I-protein
4T1-specific	O
CTL	O
than	I-protein
BALB/c	O
or	I-protein
STAT4	B-protein
(	O
-/-	O
)	O
mice	O
.	O

Surprisingly	O
,	O
Th1	O
or	I-protein
Th2	O
cells	I-protein
are	O
not	I-protein
involved	I-protein
,	O
because	O
CD4	B-protein
depletion	O
does	O
not	I-protein
diminish	O
the	I-protein
anti-tumor	O
effect	O
.	O

Therefore	O
,	O
deletion	I-protein
of	I-protein
the	I-protein
STAT6	B-protein
gene	O
facilitates	O
development	O
of	I-protein
potent	O
anti-tumor	O
immunity	O
via	I-protein
a	I-protein
CD4	B-protein
(	O
+	O
)	O
-independent	O
pathway	I-protein
.	O

###MEDLINE:20535109

Activation	O
of	I-protein
oncogenic	B-protein
transcription	I-protein
factor	I-protein
AP-1	I-protein
in	I-protein
T	O
cells	I-protein
infected	O
with	I-protein
human	O
T	O
cell	O
leukemia	O
virus	I-protein
type	O
1	I-protein
.	O

Human	O
T	O
cell	O
leukemia	O
virus	I-protein
type	O
1	I-protein
(	O
HTLV-1	B-protein
)	O
Tax	B-protein
protein	I-protein
transforms	O
primary	O
human	O
T	O
cells	I-protein
in	I-protein
vitro	O
.	O

We	O
previously	O
showed	O
that	O
Tax	B-protein
induces	O
the	I-protein
expression	I-protein
of	I-protein
various	O
family	O
members	O
of	I-protein
the	I-protein
transcription	B-protein
factor	I-protein
AP-1	I-protein
such	O
as	O
c-Jun	B-protein
,	O
JunD	B-protein
,	O
c-Fos	B-protein
,	O
and	I-protein
Fra-1	B-protein
at	I-protein
the	I-protein
mRNA	O
level	I-protein
in	I-protein
T	O
cells	I-protein
.	O

In	O
this	O
study	O
,	O
we	O
have	O
examined	O
the	I-protein
ability	O
of	I-protein
Tax	B-protein
to	I-protein
activate	O
transcription	O
through	I-protein
the	I-protein
AP-1-binding	O
site	I-protein
(	O
AP-1	I-protein
site	I-protein
)	O
.	O

A	O
transient	O
transfection	O
study	O
showed	O
that	O
Tax	B-protein
can	O
activate	O
transcription	O
through	I-protein
the	I-protein
AP-1-binding	O
site	I-protein
in	I-protein
a	I-protein
human	O
T	O
cell	O
line	I-protein
,	O
whereas	O
any	O
combination	O
of	I-protein
AP-1	I-protein
proteins	I-protein
did	O
so	O
much	O
less	O
than	I-protein
Tax	B-protein
,	O
indicating	O
that	O
the	I-protein
activation	I-protein
of	I-protein
the	I-protein
AP-1	I-protein
site	I-protein
by	I-protein
Tax	B-protein
may	O
require	O
a	I-protein
mechanism	O
other	O
than	I-protein
the	I-protein
induction	I-protein
of	I-protein
AP-1	I-protein
mRNA	O
.	O

Fresh	O
peripheral	O
blood	O
leukemia	O
cells	I-protein
of	I-protein
all	O
surveyed	O
ATL	O
patients	O
displayed	O
constitutive	I-protein
AP-1	I-protein
DNA-binding	O
activity	I-protein
,	O
whereas	O
no	I-protein
normal	O
individuals	O
did	O
.	O

However	O
,	O
the	I-protein
HTLV-1	B-protein
genes	I-protein
,	O
including	I-protein
tax	B-protein
,	O
are	O
not	I-protein
significantly	O
expressed	O
in	I-protein
fresh	O
leukemia	O
cells	I-protein
from	I-protein
ATL	O
patients	O
.	O

Our	O
present	O
results	O
suggest	O
that	O
activation	I-protein
of	I-protein
AP-1	I-protein
occurs	O
through	I-protein
Tax-dependent	O
and	I-protein
-independent	O
mechanisms	O
in	I-protein
HTLV-1-infected	O
T	O
cells	I-protein
,	O
which	O
may	O
play	O
some	O
roles	O
in	I-protein
dysregulated	O
phenotypes	O
of	I-protein
HTLV-1-infected	O
cells	I-protein
.	O

###MEDLINE:20530853

2	I-protein
,	O
2	I-protein
'	O
,	O
4	I-protein
,	O
6	I-protein
,	O
6'-pentachlorobiphenyl	O
induces	O
apoptosis	O
in	I-protein
human	O
monocytic	I-protein
cells	I-protein
.	O

Polychlorinatedbiphenyls	O
(	O
PCBs	O
)	O
are	O
a	I-protein
group	I-protein
of	I-protein
persistent	I-protein
and	I-protein
widely	B-protein
dispersed	O
environmental	O
pollutants	O
,	O
some	O
of	I-protein
which	O
may	O
be	O
immunotoxic	O
.	O

In	O
the	I-protein
present	O
study	O
,	O
we	O
investigated	O
the	I-protein
effect	O
of	I-protein
PCBs	O
on	I-protein
immune	O
system	I-protein
by	I-protein
assessing	O
apoptotic	O
cell	O
death	O
in	I-protein
human	O
monocytic	I-protein
U937	O
cells	I-protein
.	O

Among	O
the	I-protein
various	O
congeners	O
tested	O
,	O
2	I-protein
,	O
2	I-protein
'	O
,	O
4	I-protein
,	O
6	I-protein
,	O
6'-pentachlorobiphenyl	O
(	O
PeCB	O
)	O
,	O
a	I-protein
highly	O
ortho-substituted	O
congener	O
,	O
specifically	O
induced	I-protein
DNA	O
fragmentation	I-protein
,	O
a	I-protein
hallmark	O
of	I-protein
apoptosis	O
,	O
while	O
the	I-protein
other	O
examined	O
di-	O
,	O
tri-	O
,	O
tetra-	O
,	O
and	I-protein
pentachlorobiphenyls	O
did	O
not	I-protein
.	O

To	O
further	O
study	O
the	I-protein
2	I-protein
,	O
2	I-protein
'	O
,	O
4	I-protein
,	O
6	I-protein
,	O
6'-PeCB-induced	O
cell	O
death	O
,	O
various	O
features	I-protein
of	I-protein
apoptosis	O
were	O
examined	O
.	O

2	I-protein
,	O
2	I-protein
'	O
,	O
4	I-protein
,	O
6	I-protein
,	O
6'-PeCB	O
caused	O
a	I-protein
decrease	O
in	I-protein
cell	O
viability	O
and	I-protein
induced	I-protein
cellular	O
morphologic	O
features	I-protein
characteristic	O
of	I-protein
apoptosis	O
such	O
as	O
chromatin	O
aggregation	I-protein
and	I-protein
apoptotic	O
bodies	I-protein
.	O

In	O
addition	O
,	O
caspase-3	O
,	O
an	I-protein
executioner	O
of	I-protein
apoptosis	O
,	O
was	O
activated	O
and	I-protein
its	O
substrate	I-protein
,	O
poly	B-protein
(	O
ADP-ribose	I-protein
)	O
polymerase	I-protein
(	O
PARP	B-protein
)	O
,	O
was	O
cleaved	O
during	I-protein
2	I-protein
,	O
2	I-protein
'	O
,	O
4	I-protein
,	O
6	I-protein
,	O
6'-PeCB-induced	O
apoptosis	O
.	O

In	O
contrast	O
,	O
3	O
,	O
3	O
'	O
,	O
4	I-protein
,	O
4	I-protein
'	O
,	O
5-PeCB	O
,	O
a	I-protein
congener	O
of	I-protein
coplanar	O
structure	O
,	O
as	O
well	O
as	O
2	I-protein
,	O
3	O
,	O
7	I-protein
,	O
8-TCDD	O
did	O
not	I-protein
induce	O
apoptosis	O
in	I-protein
these	O
human	O
monocytic	I-protein
cells	I-protein
,	O
although	O
they	O
potently	O
induced	I-protein
CYP	B-protein
1A1	B-protein
in	I-protein
human	O
hepatoma	B-protein
Hep	O
G2	I-protein
cells	I-protein
.	O

Taken	O
together	O
,	O
the	I-protein
data	O
indicate	O
that	O
2	I-protein
,	O
2	I-protein
'	O
,	O
4	I-protein
,	O
6	I-protein
,	O
6'-PeCB	O
induces	O
apoptosis	O
in	I-protein
human	O
monocytic	I-protein
cells	I-protein
through	I-protein
a	I-protein
mechanism	O
that	O
is	O
independent	I-protein
of	I-protein
the	I-protein
arylhydrocarbon	B-protein
receptor	I-protein
.	O

This	O
suggests	O
a	I-protein
possibly	O
separate	O
mechanism	O
by	I-protein
which	O
PCBs	O
cause	O
immunosuppression	O
.	O

###MEDLINE:20518810

Effects	O
of	I-protein
deregulated	O
Raf	I-protein
activation	I-protein
on	I-protein
integrin	O
,	O
cytokine-receptor	O
expression	I-protein
and	I-protein
the	I-protein
induction	I-protein
of	I-protein
apoptosis	O
in	I-protein
hematopoietic	O
cells	I-protein
.	O

The	O
effects	O
of	I-protein
deregulated	O
Raf	I-protein
activation	I-protein
on	I-protein
the	I-protein
growth	O
and	I-protein
differentiation	I-protein
of	I-protein
hematopoietic	O
cells	I-protein
were	O
investigated	O
.	O

The	O
cytokine-dependent	O
murine	O
myeloid	O
FDC-P1	O
and	I-protein
human	O
erythroleukemic	O
TF-1	O
cell	O
lines	B-protein
were	O
transformed	I-protein
to	I-protein
grow	O
in	I-protein
response	I-protein
to	I-protein
deregulated	O
Raf	I-protein
expression	I-protein
in	I-protein
the	I-protein
absence	I-protein
of	I-protein
exogenous	B-protein
cytokines	I-protein
.	O

The	O
conditionally	O
active	O
Raf	I-protein
proteins	I-protein
were	O
regulated	O
by	I-protein
beta-estradiol	O
as	O
cDNAs	O
containing	I-protein
the	I-protein
Raf	I-protein
catalytic	I-protein
,	O
but	O
lacking	I-protein
negative-regulatory	B-protein
domains	I-protein
,	O
were	O
ligated	O
to	I-protein
the	I-protein
hormone	I-protein
binding	I-protein
domain	I-protein
of	I-protein
the	I-protein
estrogen	B-protein
receptor	I-protein
(	O
deltaRaf	B-protein
:	O
ER	I-protein
)	O
.	O

Continuous	O
deltaRaf	B-protein
expression	I-protein
prevented	O
apoptosis	O
in	I-protein
the	I-protein
absence	I-protein
of	I-protein
exogenous	B-protein
cytokines	I-protein
and	I-protein
altered	I-protein
the	I-protein
morphology	O
of	I-protein
the	I-protein
FD/deltaRaf	O
:	O
ER	O
cells	I-protein
as	O
they	O
grew	O
in	I-protein
large	O
aggregated	O
masses	O
(	O
>	O
100	I-protein
cells	I-protein
)	O
whereas	O
the	I-protein
parental	O
cytokine-dependent	O
FDC-P1	O
cells	I-protein
grew	O
in	I-protein
smaller	O
grape-like	O
clusters	O
(	O
<	O
10	I-protein
cells	I-protein
)	O
.	O

FD/deltaRaf-1	O
:	O
ER	O
cells	I-protein
growing	O
in	I-protein
response	I-protein
to	I-protein
Raf	I-protein
activation	I-protein
displayed	O
decreased	O
levels	I-protein
of	I-protein
the	I-protein
Mac-2	B-protein
and	I-protein
Mac-3	I-protein
molecules	I-protein
on	I-protein
their	O
cell	O
surface	O
.	O

In	O
contrast	O
,	O
when	O
these	O
cells	I-protein
were	O
cultured	O
in	I-protein
IL-3	B-protein
,	O
higher	O
levels	I-protein
of	I-protein
these	O
adhesion	B-protein
molecules	I-protein
were	O
detected	O
.	O

Expression	O
of	I-protein
activated	O
Raf	I-protein
oncoproteins	I-protein
also	O
abrogated	O
cytokine	O
dependency	O
and	I-protein
prevented	O
apoptosis	O
of	I-protein
TF-1	O
cells	I-protein
.	O

Moreover	O
,	O
the	I-protein
differentiation	I-protein
status	I-protein
of	I-protein
these	O
Raf-responsive	O
cells	I-protein
was	O
more	O
immature	B-protein
upon	O
Raf	I-protein
activation	I-protein
as	O
culture	O
with	I-protein
the	I-protein
differentiation-inducing	O
agent	O
phorbol	O
12	O
myristate	O
13-acetate	O
(	O
PMA	O
)	O
and	I-protein
beta-estradiol	O
resulted	O
in	I-protein
decreased	O
levels	I-protein
of	I-protein
the	I-protein
CD11b	B-protein
and	I-protein
CD18	B-protein
integrin	I-protein
molecules	I-protein
on	I-protein
the	I-protein
cell	O
surface	O
.	O

In	O
contrast	O
when	O
the	I-protein
Raf-responsive	O
cells	I-protein
were	O
induced	I-protein
to	I-protein
differentiate	O
with	I-protein
PMA	O
and	I-protein
GM-CSF	B-protein
,	O
in	I-protein
the	I-protein
absence	I-protein
of	I-protein
deltaRaf	B-protein
:	O
ER	I-protein
activation	I-protein
,	O
increased	I-protein
levels	I-protein
of	I-protein
the	I-protein
CD11b	B-protein
and	I-protein
CD18	B-protein
molecules	I-protein
were	O
detected	O
.	O

Retinoic	I-protein
acid	O
(	O
RA	B-protein
)	O
inhibited	O
3H-thymidine	O
incorporation	O
in	I-protein
response	I-protein
to	I-protein
GM-CSF	B-protein
.	O

Interestingly	O
,	O
Raf	I-protein
activation	I-protein
counterbalanced	O
the	I-protein
inhibition	O
of	I-protein
DNA	O
synthesis	I-protein
caused	O
by	I-protein
RA	B-protein
but	O
not	I-protein
PMA	O
.	O

Thus	O
deregulated	O
Raf	I-protein
expression	I-protein
can	O
alter	O
cytokine	O
dependency	O
,	O
integrin	O
expression	I-protein
and	I-protein
the	I-protein
stage	I-protein
of	I-protein
differentiation	I-protein
.	O

These	O
Raf-responsive	O
cell	O
lines	B-protein
will	O
be	O
useful	O
in	I-protein
elucidating	O
the	I-protein
roles	O
of	I-protein
the	I-protein
MAP	O
kinase	O
cascade	O
on	I-protein
hematopoietic	O
cell	O
differentiation	I-protein
and	I-protein
malignant	O
transformation	I-protein

###MEDLINE:20521735

Cyclic	I-protein
AMP	O
activates	O
p38	B-protein
mitogen-activated	I-protein
protein	I-protein
kinase	I-protein
in	I-protein
Th2	O
cells	I-protein
:	O
phosphorylation	I-protein
of	I-protein
GATA-3	B-protein
and	I-protein
stimulation	I-protein
of	I-protein
Th2	O
cytokine	O
gene	O
expression	I-protein
.	O

cAMP	O
is	O
an	I-protein
important	O
second	O
messenger	O
with	I-protein
immunomodulatory	O
properties	O
.	O

Elevation	O
of	I-protein
intracellular	I-protein
cAMP	O
in	I-protein
T	O
cells	I-protein
,	O
induced	I-protein
by	I-protein
agents	O
such	O
as	O
IL-1alpha	B-protein
or	I-protein
PGs	O
,	O
inhibits	I-protein
T	O
cell	O
activation	I-protein
.	O

In	O
effector	O
T	O
cells	I-protein
,	O
an	I-protein
increase	O
in	I-protein
the	I-protein
level	I-protein
of	I-protein
intracellular	I-protein
cAMP	O
inhibits	I-protein
cytokine	O
production	I-protein
in	I-protein
Th1	O
cells	I-protein
but	O
stimulates	O
cytokine	O
production	I-protein
in	I-protein
Th2	O
cells	I-protein
.	O

Here	O
we	O
report	O
that	O
cAMP-induced	O
effects	O
in	I-protein
Th2	O
cells	I-protein
occur	O
independently	O
of	I-protein
the	I-protein
protein	O
kinase	O
A	O
pathway	I-protein
,	O
which	O
is	O
the	I-protein
major	O
mediator	O
of	I-protein
cAMP-induced	O
signaling	O
events	O
in	I-protein
most	O
cell	O
types	I-protein
.	O

Instead	O
,	O
cAMP	O
stimulates	O
activation	I-protein
of	I-protein
p38	B-protein
mitogen-activated	I-protein
protein	I-protein
kinase	I-protein
in	I-protein
Th2	O
cells	I-protein
.	O

This	O
appears	O
to	I-protein
be	O
a	I-protein
Th2	O
-selective	O
event	O
because	O
cAMP	O
barely	O
increased	I-protein
p38	B-protein
phosphorylation	I-protein
in	I-protein
Th1	O
cells	I-protein
.	O

We	O
show	O
that	O
in	I-protein
Th2	O
cells	I-protein
,	O
cAMP	O
promotes	O
the	I-protein
production	I-protein
of	I-protein
both	O
IL-5	B-protein
and	I-protein
IL-13	B-protein
,	O
which	O
play	O
distinct	O
but	O
critical	I-protein
roles	O
in	I-protein
asthma	I-protein
pathogenesis	O
.	O

Our	O
data	O
also	O
show	O
that	O
cAMP	O
causes	O
increased	I-protein
phosphorylation	I-protein
of	I-protein
the	I-protein
transcription	B-protein
factor	I-protein
GATA-3	I-protein
,	O
which	O
we	O
have	O
shown	O
is	O
a	I-protein
critical	I-protein
regulator	O
of	I-protein
Th2	O
cytokine	O
gene	O
expression	I-protein
and	I-protein
,	O
in	I-protein
turn	O
,	O
of	I-protein
airway	I-protein
inflammation	O
in	I-protein
mice	O
.	O

Thus	O
,	O
Th2	O
-specific	I-protein
GATA-3	B-protein
expression	I-protein
and	I-protein
p38	B-protein
mitogen-activated	I-protein
protein	I-protein
kinase	I-protein
activation	I-protein
together	O
provide	O
a	I-protein
molecular	I-protein
basis	O
for	I-protein
the	I-protein
differential	O
effects	O
of	I-protein
cAMP	O
in	I-protein
the	I-protein
two	O
T	O
helper	I-protein
cell	O
subsets	O
.	O

###MEDLINE:20514082

Characterization	O
of	I-protein
IL-4	B-protein
and	I-protein
IL-13	B-protein
signals	I-protein
dependent	I-protein
on	I-protein
the	I-protein
human	B-protein
IL-13	B-protein
receptor	I-protein
alpha	I-protein
chain	I-protein
1	I-protein
:	O
redundancy	O
of	I-protein
requirement	O
of	I-protein
tyrosine	O
residue	I-protein
for	I-protein
STAT3	B-protein
activation	I-protein
.	O

IL-4	B-protein
and	I-protein
IL-13	B-protein
are	O
pleiotropic	B-protein
cytokines	I-protein
whose	O
biological	O
activities	O
overlap	O
with	I-protein
each	O
other	O
.	O

IL-13	B-protein
receptor	I-protein
alpha	I-protein
chain	I-protein
1	I-protein
(	O
IL-13R	B-protein
alpha	I-protein
1	I-protein
)	O
is	O
necessary	O
for	I-protein
binding	I-protein
to	I-protein
IL-13	B-protein
,	O
and	I-protein
the	I-protein
heterodimer	O
composed	O
of	I-protein
IL-13R	B-protein
alpha	I-protein
1	I-protein
and	I-protein
IL-4R	B-protein
alpha	I-protein
chain	I-protein
transduces	O
IL-13	B-protein
and	I-protein
IL-4	B-protein
signals	I-protein
;	O
however	O
,	O
the	I-protein
functional	O
mapping	O
of	I-protein
the	I-protein
intracellular	I-protein
domain	I-protein
of	I-protein
IL-13R	B-protein
alpha	I-protein
1	I-protein
is	O
not	I-protein
fully	O
understood	O
.	O

In	O
this	O
study	O
,	O
we	O
constructed	O
wild	O
and	I-protein
mutated	O
types	I-protein
of	I-protein
human	B-protein
IL-13R	B-protein
alpha	I-protein
1	I-protein
,	O
and	I-protein
analyzed	O
IL-4	B-protein
and	I-protein
IL-13	B-protein
signals	I-protein
using	O
an	I-protein
IL-13R	B-protein
alpha	I-protein
1	I-protein
-transfected	O
human	O
B	O
cell	O
line	I-protein
.	O

Expression	O
of	I-protein
IL-13R	B-protein
alpha	I-protein
1	I-protein
evoked	O
STAT3	B-protein
activation	I-protein
by	I-protein
IL-4	B-protein
and	I-protein
IL-13	B-protein
,	O
and	I-protein
in	I-protein
stimulated	O
human	O
B	O
cells	I-protein
,	O
on	I-protein
which	O
IL-13R	B-protein
alpha	I-protein
1	I-protein
was	O
highly	O
expressed	O
,	O
IL-4	B-protein
and	I-protein
IL-13	B-protein
induced	I-protein
STAT3	B-protein
activation	I-protein
.	O

Replacement	O
of	I-protein
the	I-protein
two	O
tyrosine	O
residues	O
completely	O
abolished	O
STAT3	B-protein
activation	I-protein
,	O
although	O
replacing	O
either	O
tyrosine	O
residue	I-protein
alone	O
retained	O
it	O
.	O

Furthermore	O
,	O
we	O
found	O
that	O
the	I-protein
Box1	B-protein
region	I-protein
and	I-protein
the	I-protein
C-terminal	B-protein
tail	I-protein
of	I-protein
IL-13R	B-protein
alpha	I-protein
1	I-protein
were	O
critical	I-protein
for	I-protein
binding	I-protein
to	I-protein
Tyk2	B-protein
,	O
and	I-protein
activation	I-protein
of	I-protein
Jak1	B-protein
,	O
Tyk2	B-protein
,	O
the	I-protein
insulin	B-protein
receptor	I-protein
substrate-1	I-protein
and	I-protein
STAT6	B-protein
respectively	O
.	O

These	O
results	O
suggest	O
that	O
STAT3	B-protein
activation	I-protein
is	O
involved	I-protein
with	I-protein
IL-4	B-protein
and	I-protein
IL-13	B-protein
signals	I-protein
in	I-protein
human	O
B	O
cells	I-protein
along	O
with	I-protein
the	I-protein
activation	I-protein
of	I-protein
STAT6	B-protein
,	O
and	I-protein
that	O
there	O
is	O
a	I-protein
unique	I-protein
sequence	I-protein
in	I-protein
IL-13R	B-protein
alpha	I-protein
1	I-protein
to	I-protein
activate	O
STAT3	B-protein
.	O

###MEDLINE:20501115

Functional	O
uncoupling	B-protein
of	I-protein
the	I-protein
Janus	O
kinase	O
3-Stat5	O
pathway	I-protein
in	I-protein
malignant	O
growth	O
of	I-protein
human	O
T	O
cell	O
leukemia	O
virus	I-protein
type	O
1-transformed	O
human	O
T	O
cells	I-protein
.	O

Human	O
T	O
cell	O
leukemia	O
virus	I-protein
type	O
1	I-protein
(	O
HTLV-1	B-protein
)	O
transforms	O
cytokine	B-protein
-dependent	I-protein
T	O
lymphocytes	O
and	I-protein
causes	O
adult	O
T	O
cell	O
leukemia	O
.	O

Janus	B-protein
tyrosine	I-protein
kinase	I-protein
(	O
Jak	I-protein
)	O
3	I-protein
and	I-protein
transcription	I-protein
factors	I-protein
Stat5a	B-protein
and	I-protein
Stat5b	B-protein
are	O
essential	O
for	I-protein
the	I-protein
proliferation	I-protein
of	I-protein
normal	O
T	O
cells	I-protein
and	I-protein
are	O
constitutively	O
hyperactivated	O
in	I-protein
both	O
HTLV-1-transformed	O
human	O
T	O
cell	O
lines	B-protein
and	I-protein
lymphocytes	O
isolated	I-protein
from	I-protein
HTLV-1-infected	O
patients	O
;	O
therefore	O
,	O
a	I-protein
critical	I-protein
role	O
for	I-protein
the	I-protein
Jak3-Stat5	O
pathway	I-protein
in	I-protein
the	I-protein
progression	I-protein
of	I-protein
this	O
disease	I-protein
has	O
been	O
postulated	O
.	O

We	O
recently	O
reported	O
that	O
tyrphostin	O
AG-490	O
selectively	O
blocked	B-protein
IL-2	B-protein
activation	I-protein
of	I-protein
Jak3/Stat5	B-protein
and	I-protein
growth	O
of	I-protein
murine	O
T	O
cell	O
lines	B-protein
.	O

Here	O
we	O
demonstrate	O
that	O
disruption	O
of	I-protein
Jak3/Stat5a/b	O
signaling	O
with	I-protein
AG-490	O
(	O
50	I-protein
&	O
mgr	O
;	O
M	I-protein
)	O
blocked	B-protein
the	I-protein
proliferation	I-protein
of	I-protein
primary	O
human	O
T	O
lymphocytes	O
,	O
but	O
paradoxically	O
failed	O
to	I-protein
inhibit	O
the	I-protein
proliferation	I-protein
of	I-protein
HTLV-1-transformed	O
human	O
T	O
cell	O
lines	B-protein
,	O
HuT-102	O
and	I-protein
MT-2	O
.	O

Structural	O
homologues	O
of	I-protein
AG-490	O
also	O
inhibited	O
the	I-protein
proliferation	I-protein
of	I-protein
primary	O
human	O
T	O
cells	I-protein
,	O
but	O
not	I-protein
HTLV-1-infected	O
cells	I-protein
.	O

Disruption	O
of	I-protein
constitutive	I-protein
Jak3/Stat5	O
activation	I-protein
by	I-protein
AG-490	O
was	O
demonstrated	O
by	I-protein
inhibition	O
of	I-protein
1	I-protein
)	O
tyrosine	O
phosphorylation	I-protein
of	I-protein
Jak3	B-protein
,	O
Stat5a	B-protein
(	O
Tyr	O
(	O
694	O
)	O
)	O
,	O
and	I-protein
Stat5b	B-protein
(	O
Tyr	O
(	O
699	I-protein
)	O
)	O
;	O
2	I-protein
)	O
serine	O
phosphorylation	I-protein
of	I-protein
Stat5a	B-protein
(	O
Ser	O
(	O
726	I-protein
)	O
)	O
as	O
determined	O
by	I-protein
a	I-protein
novel	O
phosphospecific	B-protein
Ab	I-protein
;	O
and	I-protein
3	O
)	O
Stat5a/b	O
DNA	O
binding	I-protein
to	I-protein
the	I-protein
Stat5-responsive	O
beta-casein	O
promoter	I-protein
.	O

In	O
contrast	O
,	O
AG-490	O
had	O
no	I-protein
effect	O
on	I-protein
DNA	O
binding	I-protein
by	I-protein
p50/p65	B-protein
components	I-protein
of	I-protein
NF-kappaB	B-protein
,	O
a	I-protein
transcription	B-protein
factor	I-protein
activated	O
by	I-protein
the	I-protein
HTLV-1-encoded	B-protein
phosphoprotein	I-protein
,	O
Tax	I-protein
.	O

Collectively	O
,	O
these	O
data	O
suggest	O
that	O
the	I-protein
Jak3-Stat5	O
pathway	I-protein
in	I-protein
HTLV-1-transformed	O
T	O
cells	I-protein
has	O
become	O
functionally	O
redundant	O
for	I-protein
proliferation	I-protein
.	O

Reversal	O
of	I-protein
this	O
functional	O
uncoupling	B-protein
may	O
be	O
required	O
before	O
Jak3/Stat5	O
inhibitors	I-protein
will	O
be	O
useful	O
in	I-protein
the	I-protein
treatment	O
of	I-protein
this	O
malignancy	O
.	O

###MEDLINE:20499068

The	O
Epstein-Barr	B-protein
virus	I-protein
promoter	I-protein
initiating	O
B-cell	O
transformation	I-protein
is	O
activated	O
by	I-protein
RFX	B-protein
proteins	I-protein
and	I-protein
the	I-protein
B-cell-specific	B-protein
activator	I-protein
protein	I-protein
BSAP/Pax5	I-protein
.	O

Epstein-Barr	B-protein
virus	I-protein
(	O
EBV	O
)	O
-induced	O
B-cell	O
growth	O
transformation	I-protein
,	O
a	I-protein
central	O
feature	O
of	I-protein
the	I-protein
virus	I-protein
'	O
strategy	O
for	I-protein
colonizing	O
the	I-protein
human	O
B-cell	O
system	I-protein
,	O
requires	O
full	O
virus	I-protein
latent	B-protein
gene	O
expression	I-protein
and	I-protein
is	O
initiated	O
by	I-protein
transcription	O
from	I-protein
the	I-protein
viral	O
promoter	I-protein
Wp	O
.	O

Interestingly	O
,	O
when	O
EBV	O
accesses	O
other	O
cell	O
types	I-protein
,	O
this	O
growth-transforming	O
program	O
is	O
not	I-protein
activated	O
.	O

The	O
present	O
work	O
focuses	O
on	I-protein
a	I-protein
region	O
of	I-protein
Wp	O
which	O
in	I-protein
reporter	O
assays	O
confers	O
B-cell	O
-specific	I-protein
activity	I-protein
.	O

Bandshift	O
studies	O
indicate	O
that	O
this	O
region	O
contains	I-protein
three	O
factor	I-protein
binding	I-protein
sites	I-protein
,	O
termed	O
sites	I-protein
B	O
,	O
C	O
,	O
and	I-protein
D	O
,	O
in	I-protein
addition	O
to	I-protein
a	I-protein
previously	O
characterized	O
CREB	B-protein
site	I-protein
.	O

Here	O
we	O
show	O
that	O
site	I-protein
C	O
binds	O
members	O
of	I-protein
the	I-protein
ubiquitously	O
expressed	O
RFX	B-protein
family	I-protein
of	I-protein
proteins	I-protein
,	O
notably	O
RFX1	B-protein
,	O
RFX3	B-protein
,	O
and	I-protein
the	I-protein
associated	I-protein
factor	I-protein
MIBP1	B-protein
,	O
whereas	O
sites	I-protein
B	O
and	I-protein
D	O
both	O
bind	O
the	I-protein
B-cell-specific	B-protein
activator	I-protein
protein	I-protein
BSAP/Pax5	I-protein
.	O

In	O
reporter	O
assays	O
with	I-protein
mutant	O
Wp	O
constructs	O
,	O
the	I-protein
loss	O
of	I-protein
factor	I-protein
binding	I-protein
to	I-protein
any	O
one	B-protein
of	I-protein
these	O
sites	I-protein
severely	O
impaired	O
promoter	I-protein
activity	I-protein
in	I-protein
B	O
cells	I-protein
,	O
while	O
the	I-protein
wild-type	I-protein
promoter	I-protein
could	O
be	O
activated	O
in	I-protein
non-B	O
cells	I-protein
by	I-protein
ectopic	I-protein
BSAP	B-protein
expression	I-protein
.	O

We	O
suggest	O
that	O
Wp	O
regulation	I-protein
by	I-protein
BSAP	B-protein
helps	O
to	I-protein
ensure	O
the	I-protein
B-cell	O
specificity	I-protein
of	I-protein
EBV	O
's	I-protein
growth-transforming	O
function	I-protein
.	O

###MEDLINE:20497005

Activation	O
of	I-protein
the	I-protein
Lck	B-protein
tyrosine	I-protein
protein	I-protein
kinase	I-protein
by	I-protein
the	I-protein
Herpesvirus	O
saimiri	O
tip	B-protein
protein	I-protein
involves	O
two	O
binding	I-protein
interactions	O
.	O

The	O
Tip	B-protein
protein	I-protein
of	I-protein
Herpesvirus	O
saimiri	O
strain	O
484C	O
binds	O
to	I-protein
and	I-protein
activates	O
the	I-protein
Lck	B-protein
tyrosine	I-protein
protein	I-protein
kinase	I-protein
.	O

Two	O
sequences	I-protein
in	I-protein
the	I-protein
Tip	B-protein
protein	I-protein
were	O
previously	O
shown	O
to	I-protein
be	O
involved	I-protein
in	I-protein
binding	I-protein
to	I-protein
Lck	B-protein
.	O

A	O
proline-rich	O
region	O
,	O
residues	O
132-141	O
,	O
binds	O
to	I-protein
the	I-protein
SH3	B-protein
domain	I-protein
of	I-protein
the	I-protein
Lck	B-protein
protein	I-protein
.	O

We	O
show	O
here	O
that	O
the	I-protein
other	O
Lck-binding	B-protein
domain	I-protein
,	O
residues	O
104-113	O
,	O
binds	O
to	I-protein
the	I-protein
carboxyl-terminal	I-protein
half	I-protein
of	I-protein
Lck	B-protein
and	I-protein
that	O
this	O
binding	I-protein
does	O
not	I-protein
require	O
the	I-protein
Lck	B-protein
SH3	I-protein
domain	I-protein
.	O

Mutated	I-protein
Tip	B-protein
containing	I-protein
only	I-protein
one	B-protein
functional	O
Lck-binding	B-protein
domain	I-protein
can	O
bind	O
stably	O
to	I-protein
Lck	B-protein
,	O
although	O
not	I-protein
as	O
strongly	O
as	O
wild-type	I-protein
Tip	I-protein
.	O

Interaction	O
of	I-protein
Tip	B-protein
with	I-protein
Lck	B-protein
through	I-protein
either	O
Lck-binding	B-protein
domain	I-protein
increases	O
the	I-protein
activity	I-protein
of	I-protein
Lck	B-protein
in	I-protein
vivo	O
.	O

Simultaneous	O
binding	I-protein
of	I-protein
both	O
domains	I-protein
is	O
required	O
for	I-protein
maximal	O
activation	I-protein
of	I-protein
Lck	B-protein
.	O

The	O
transient	O
expression	I-protein
of	I-protein
Tip	B-protein
in	I-protein
T	O
cells	I-protein
was	O
found	O
to	I-protein
stimulate	O
both	O
Stat3	B-protein
-dependent	I-protein
and	I-protein
NF-AT	B-protein
-dependent	I-protein
transcription	O
.	O

Mutant	O
forms	I-protein
of	I-protein
Tip	B-protein
lacking	I-protein
one	B-protein
or	I-protein
the	I-protein
other	O
of	I-protein
the	I-protein
two	O
Lck-binding	B-protein
domains	I-protein
retained	O
the	I-protein
ability	O
to	I-protein
stimulate	O
Stat3	B-protein
-dependent	I-protein
transcription	O
.	O

Tip	B-protein
lacking	I-protein
the	I-protein
proline-rich	O
Lck-binding	B-protein
domain	I-protein
exhibited	O
almost	O
wild-type	I-protein
activity	I-protein
in	I-protein
this	O
assay	O
.	O

In	O
contrast	O
,	O
ablation	O
of	I-protein
either	O
Lck-binding	B-protein
domain	I-protein
abolished	O
the	I-protein
ability	O
of	I-protein
Tip	B-protein
to	I-protein
stimulate	O
NF-AT	B-protein
-dependent	I-protein
transcription	O
.	O

Full	O
biological	O
activity	I-protein
of	I-protein
Tip	B-protein
,	O
therefore	O
,	O
appears	O
to	I-protein
require	O
both	O
Lck-binding	B-protein
domains	I-protein
.	O

###MEDLINE:20491906

Accumulation	O
of	I-protein
RXR	B-protein
alpha	I-protein
during	I-protein
activation	I-protein
of	I-protein
cycling	O
human	O
T	O
lymphocytes	O
:	O
modulation	O
of	I-protein
RXRE	O
transactivation	O
function	I-protein
by	I-protein
mitogen-activated	O
protein	O
kinase	O
pathways	O
.	O

We	O
have	O
previously	O
reported	O
that	O
the	I-protein
activation	I-protein
of	I-protein
resting	O
human	O
immature	B-protein
peripheral	O
blood	O
T	O
(	O
PBT	B-protein
)	O
lymphocytes	O
is	O
associated	I-protein
with	I-protein
the	I-protein
loss	O
of	I-protein
retinoid	B-protein
X	I-protein
receptor	I-protein
alpha	I-protein
(	O
RXRalpha	B-protein
)	O
expression	I-protein
.	O

In	O
the	I-protein
present	O
study	O
,	O
we	O
have	O
demonstrated	O
that	O
,	O
unlike	O
resting	O
cells	I-protein
,	O
activation	I-protein
of	I-protein
cycling	O
human	O
mature	B-protein
PBT	B-protein
lymphocytes	O
,	O
and	I-protein
T	O
lymphocyte	O
leukemia	O
cell	O
lines	B-protein
is	O
accompanied	O
by	I-protein
the	I-protein
accumulation	I-protein
of	I-protein
RXRalpha	O
mRNA	O
and	I-protein
protein	O
.	O

Interestingly	O
,	O
cyclosporin	O
A	O
further	O
augmented	O
RXRalpha	B-protein
expression	I-protein
,	O
indicating	O
the	I-protein
involvement	I-protein
of	I-protein
calcineurin	O
pathways	O
in	I-protein
the	I-protein
process	O
.	O

9-cis	O
retinoic	O
acid	O
inhibited	O
the	I-protein
accumulation	I-protein
,	O
suggesting	O
that	O
retinoids	O
can	O
regulate	O
the	I-protein
synthesis	I-protein
of	I-protein
their	O
own	O
receptors	I-protein
during	I-protein
T	O
cell	O
activation	I-protein
.	O

Transfection	O
analysis	O
in	I-protein
Jurkat	O
cells	I-protein
,	O
using	O
RXRE-dependent	O
reporter	O
assays	O
,	O
showed	O
that	O
RXRalpha	B-protein
accumulated	O
during	I-protein
T	O
cell	O
activation	I-protein
was	O
transcriptionally	O
inactive	O
.	O

To	O
investigate	O
the	I-protein
mechanism	O
of	I-protein
such	O
inhibition	O
,	O
the	I-protein
role	O
of	I-protein
two	O
mitogen-activated	O
protein	O
kinase	O
pathways	O
,	O
c-Jun	B-protein
N-terminal	I-protein
kinase	I-protein
(	O
JNK	B-protein
)	O
and	I-protein
extracellular	B-protein
signal-regulated	I-protein
kinase	I-protein
(	O
ERK	B-protein
)	O
,	O
in	I-protein
modulating	I-protein
RXRE-dependent	O
transcription	O
,	O
was	O
explored	O
.	O

The	O
expression	I-protein
of	I-protein
constitutively	O
active	O
MAP/ERK	B-protein
kinase	I-protein
kinase	I-protein
1	I-protein
(	O
MEKK1	B-protein
)	O
inhibited	O
RXRE-dependent	O
transcription	O
,	O
whereas	O
dominant	I-protein
negative	I-protein
MEKK1	B-protein
increased	I-protein
the	I-protein
transcription	O
,	O
indicating	O
the	I-protein
involvement	I-protein
of	I-protein
JNK	B-protein
signaling	O
pathways	O
in	I-protein
the	I-protein
process	O
.	O

In	O
contrast	O
,	O
expression	I-protein
of	I-protein
constitutively	B-protein
active	I-protein
MEK1	B-protein
,	O
which	O
activates	O
ERK	B-protein
pathway	I-protein
,	O
enhanced	I-protein
RXRE-dependent	O
activation	I-protein
.	O

When	O
both	O
were	O
activated	O
simultaneously	O
,	O
JNK	O
pathway	I-protein
was	O
dominant	I-protein
over	O
ERK	B-protein
pathway	I-protein
and	I-protein
resulted	O
in	I-protein
inhibition	O
of	I-protein
RXRE-mediated	O
transcription	O
.	O

These	O
data	O
demonstrate	O
a	I-protein
dual	O
regulatory	O
control	I-protein
of	I-protein
RXRalpha	B-protein
expression	I-protein
during	I-protein
the	I-protein
activation	I-protein
of	I-protein
resting	O
and	I-protein
cycling	O
T	O
lymphocytes	O
and	I-protein
indicate	O
a	I-protein
dynamic	O
balance	O
between	O
JNK	B-protein
and	I-protein
ERK	B-protein
pathways	O
in	I-protein
modulating	I-protein
RXRE-mediated	O
transactivation	O
.	O

###MEDLINE:20576378

The	O
proteasome	B-protein
regulates	O
receptor-mediated	O
endocytosis	I-protein
of	I-protein
interleukin-2	B-protein
.	O

Recent	O
studies	O
have	O
increasingly	O
implicated	O
the	I-protein
proteasome	B-protein
in	I-protein
the	I-protein
regulation	I-protein
of	I-protein
cell	B-protein
surface	I-protein
receptors	I-protein
.	O

In	O
the	I-protein
present	O
study	O
,	O
we	O
investigated	O
the	I-protein
role	O
of	I-protein
the	I-protein
proteasome	B-protein
for	I-protein
ligand-dependent	O
endocytosis	I-protein
and	I-protein
degradation	I-protein
of	I-protein
the	I-protein
interleukin-2	B-protein
(	O
IL-2	B-protein
)	O
-interleukin-2	I-protein
receptor	I-protein
(	O
IL-2R	I-protein
)	O
complex	I-protein
.	O

Proteasome	I-protein
inhibitors	I-protein
impaired	O
internalization	O
of	I-protein
IL-2.IL-2R	B-protein
and	I-protein
prevented	O
the	I-protein
lysosomal	O
degradation	I-protein
of	I-protein
this	O
cytokine	O
.	O

Based	O
on	I-protein
time-course	O
studies	O
,	O
proteasome	B-protein
activity	I-protein
is	O
primarily	O
required	O
after	O
initial	O
endocytosis	I-protein
of	I-protein
the	I-protein
IL-2.IL-2R	B-protein
.	O

Proteasome	I-protein
function	I-protein
was	O
also	O
necessary	O
for	I-protein
the	I-protein
lysosomal	O
degradation	I-protein
of	I-protein
IL-2	B-protein
internalized	O
by	I-protein
IL-2R	B-protein
that	O
were	O
comprised	O
of	I-protein
cytoplasmic	B-protein
tailless	I-protein
beta-	I-protein
or	I-protein
gamma	I-protein
c-subunits	I-protein
,	O
suggesting	O
that	O
the	I-protein
target	O
protein	O
for	I-protein
the	I-protein
proteasome	B-protein
is	O
independent	I-protein
of	I-protein
either	O
the	I-protein
cytoplasmic	B-protein
tail	I-protein
of	I-protein
the	I-protein
IL-2R	O
beta-	I-protein
or	I-protein
gamma	I-protein
c-subunits	I-protein
and	I-protein
their	O
associated	I-protein
signaling	O
components	O
.	O

Therefore	O
,	O
a	I-protein
functional	O
proteasome	B-protein
is	O
required	O
for	I-protein
optimal	O
endocytosis	I-protein
of	I-protein
the	I-protein
IL-2R/ligand	B-protein
complex	I-protein
and	I-protein
is	O
essential	O
for	I-protein
the	I-protein
subsequent	O
lysosomal	O
degradation	I-protein
of	I-protein
IL-2	B-protein
,	O
possibly	O
by	I-protein
regulating	O
trafficking	O
to	I-protein
the	I-protein
lysosome	O
.	O

###MEDLINE:20483847

Functional	O
characterization	O
of	I-protein
the	I-protein
two	O
alternative	O
promoters	O
of	I-protein
human	O
p45	O
NF-E2	B-protein
gene	O
.	O

OBJECTIVE	O
:	O
The	O
transcription	B-protein
factor	I-protein
NF-E2	B-protein
,	O
a	I-protein
heterodimeric	B-protein
protein	I-protein
complex	I-protein
composed	O
of	I-protein
p45	B-protein
and	I-protein
small	O
Maf	B-protein
family	I-protein
proteins	I-protein
,	O
is	O
considered	O
crucial	O
for	I-protein
the	I-protein
proper	O
differentiation	I-protein
of	I-protein
erythrocytes	O
and	I-protein
megakaryocytes	O
in	I-protein
vivo	O
.	O

We	O
report	O
the	I-protein
results	O
of	I-protein
studies	O
aimed	O
at	I-protein
understanding	O
the	I-protein
regulatory	O
mechanisms	O
controlling	I-protein
p45	O
gene	O
expression	I-protein
in	I-protein
erythroid	O
cells	I-protein
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
Human	O
p45	O
mRNAs	O
have	O
two	O
alternative	O
isoforms	I-protein
,	O
aNF-E2	O
and	I-protein
fNF-E2	O
,	O
and	I-protein
these	O
isoforms	I-protein
are	O
transcribed	I-protein
from	I-protein
the	I-protein
alternative	O
promoters	O
.	O

We	O
investigated	O
lineage-specific	O
expression	I-protein
of	I-protein
both	O
isomers	O
in	I-protein
human	O
erythroid	O
and	I-protein
megakaryocytic	O
cells	I-protein
by	I-protein
reverse	I-protein
transcriptase	I-protein
polymerase	O
chain	I-protein
reaction	I-protein
or	I-protein
Northern	O
blot	O
analysis	O
.	O

For	O
functional	O
characterization	O
of	I-protein
both	O
promoters	O
,	O
plasmids	O
in	I-protein
which	O
reporter	O
genes	I-protein
were	O
placed	O
under	O
the	I-protein
control	I-protein
of	I-protein
a	I-protein
series	O
of	I-protein
truncated	I-protein
or	I-protein
mutated	O
promoter	I-protein
fragments	I-protein
were	O
transfected	O
to	I-protein
human	O
hematopoietic	O
cell	O
lines	B-protein
.	O

RESULTS	O
:	O
When	O
CD34	B-protein
(	O
+	O
)	O
cells	I-protein
isolated	I-protein
from	I-protein
human	O
cord	O
blood	O
were	O
induced	I-protein
to	I-protein
unilineage	O
erythroid	O
or	I-protein
megakaryocytic	O
differentiation	I-protein
in	I-protein
liquid	O
suspension	O
culture	O
,	O
both	O
transcripts	I-protein
,	O
although	O
barely	O
detected	O
at	I-protein
day	O
0	I-protein
,	O
were	O
induced	I-protein
in	I-protein
both	O
erythroid	O
and	I-protein
megakaryocytic	O
cultures	O
.	O

fNF-E2	O
mRNA	O
was	O
found	O
to	I-protein
be	O
more	O
abundant	I-protein
in	I-protein
erythroid	O
cells	I-protein
than	I-protein
megakaryocytic	O
cells	I-protein
at	I-protein
day	O
7	I-protein
of	I-protein
culture	O
.	O

Although	O
both	O
isomers	O
were	O
expressed	O
in	I-protein
human	O
erythroid-megakaryocytic	O
cell	O
lines	B-protein
,	O
megakaryocytic	O
maturation	I-protein
with	I-protein
loss	O
of	I-protein
erythroid	O
phenotype	O
induced	I-protein
by	I-protein
phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
)	O
resulted	O
in	I-protein
exclusive	O
downregulation	O
of	I-protein
fNF-E2	O
,	O
suggesting	O
that	O
fNF-E2	O
promoter	I-protein
is	O
more	O
erythroid	O
specific	I-protein
.	O

Functional	O
analysis	O
of	I-protein
fNF-E2	O
promoter	I-protein
showed	O
that	O
the	I-protein
promoter	I-protein
is	O
active	O
only	I-protein
in	I-protein
erythroid-megakaryocytic	O
cells	I-protein
and	I-protein
that	O
the	I-protein
double	O
GATA	B-protein
sit	B-protein
e	O
in	I-protein
the	I-protein
proximal	I-protein
region	O
is	O
necessary	O
for	I-protein
its	O
efficient	O
activity	I-protein
.	O

CONCLUSION	O
:	O
These	O
results	O
suggest	O
that	O
GATA	B-protein
proteins	I-protein
,	O
which	O
govern	O
the	I-protein
differentiation	I-protein
of	I-protein
erythroid	O
lineage	I-protein
cells	I-protein
,	O
are	O
required	O
for	I-protein
full	O
promoter	I-protein
activity	I-protein
of	I-protein
the	I-protein
p45	O
gene	O
.	O

###MEDLINE:20470674

Transcriptional	I-protein
activation	I-protein
of	I-protein
heme	O
oxygenase-1	O
and	I-protein
its	O
functional	O
significance	O
in	I-protein
acetaminophen-induced	O
hepatitis	B-protein
and	I-protein
hepatocellular	O
injury	O
in	I-protein
the	I-protein
rat	I-protein
.	O

BACKGROUND/AIM	O
:	O
Glutathione	I-protein
depletion	O
contributes	O
to	I-protein
acetaminophen	O
hepatotoxicity	O
and	I-protein
is	O
known	O
to	I-protein
induce	O
the	I-protein
oxidative	B-protein
stress	O
reactant	O
heme	O
oxygenase-1	O
.	O

The	O
metabolites	O
of	I-protein
the	I-protein
heme	O
oxygenase	I-protein
pathway	I-protein
,	O
biliverdin	B-protein
,	O
carbon	I-protein
monoxide	O
,	O
and	I-protein
iron	I-protein
may	O
modulate	O
acetaminophen	O
toxicity	O
.	O

The	O
aim	O
of	I-protein
this	O
study	O
was	O
to	I-protein
assess	O
cell-type	O
specific	I-protein
expression	I-protein
of	I-protein
heme	O
oxygenase-1	O
and	I-protein
its	O
impact	O
on	I-protein
liver	O
injury	O
and	I-protein
microcirculatory	O
disturbances	O
in	I-protein
a	I-protein
model	I-protein
of	I-protein
acetaminophen-induced	O
hepatitis	B-protein
.	O

METHODS	O
:	O
Gene	I-protein
expression	I-protein
of	I-protein
heme	O
oxygenase-1	O
was	O
studied	O
by	I-protein
Northern-	O
and	I-protein
Western	O
analysis	O
as	O
well	O
as	O
immunohistochemistry	O
.	O

The	O
time	O
course	O
of	I-protein
heme	B-protein
oxygenase-1	I-protein
and	I-protein
-2	I-protein
,	O
cytokine-induced	B-protein
neutrophil	I-protein
chemoattractant-1	I-protein
,	O
and	I-protein
intercellular	B-protein
adhesion	I-protein
molecule-1	I-protein
was	O
studied	O
by	I-protein
Northern	O
analysis	O
.	O

DNA-binding	O
activity	I-protein
of	I-protein
nuclear	B-protein
factor-kappaB	I-protein
was	O
determined	O
by	I-protein
electrophoretic	O
mobility	I-protein
shift	O
assay	O
.	O

Sinusoidal	O
perfusion	O
and	I-protein
leukocyte-endothelial	O
interactions	O
were	O
assessed	O
by	I-protein
intravital	O
microscopy	O
.	O

RESULTS	O
:	O
Acetaminophen	O
caused	O
a	I-protein
moderate	O
sinusoidal	O
perfusion	O
failure	I-protein
(	O
-15	O
%	O
)	O
and	I-protein
infiltration	O
of	I-protein
neutrophils	O
along	O
with	I-protein
activation	I-protein
of	I-protein
nuclear	B-protein
factor-kappaB	I-protein
and	I-protein
intercellular	B-protein
adhesion	I-protein
molecule-1	I-protein
and	I-protein
cytokine-induced	B-protein
neutrophil	I-protein
chemoattractant-1	I-protein
mRNAs	O
.	O

Induction	O
of	I-protein
heme	O
oxygenase-1	O
mRNA	O
and	I-protein
protein	O
(	O
approximately	O
30-fold	O
)	O
in	I-protein
hepatocytes	I-protein
and	I-protein
non-parenchymal	O
cells	I-protein
paralleled	O
the	I-protein
inflammatory	O
response	I-protein
.	O

Blockade	O
of	I-protein
heme	O
oxygenase	I-protein
activity	I-protein
with	I-protein
tin-protoporphyrin-IX	O
abrogated	O
acetaminophen-induced	O
hepatic	O
neutrophil	O
accumulation	I-protein
and	I-protein
nuclear	B-protein
factor-kappaB	I-protein
activation	I-protein
,	O
but	O
failed	O
to	I-protein
affect	O
sinusoidal	O
perfusion	O
and	I-protein
liver	O
injury	O
.	O

CONCLUSIONS	O
:	O
The	O
inflammatory	O
response	I-protein
associated	I-protein
with	I-protein
acetaminophen	O
hepatotoxicity	O
is	O
modulated	I-protein
by	I-protein
the	I-protein
parallel	O
induction	I-protein
of	I-protein
the	I-protein
heme	O
oxygenase-1	O
gene	O
.	O

However	O
,	O
heme	O
oxygenase-1	O
has	O
no	I-protein
permissive	O
effect	O
on	I-protein
sinusoidal	O
perfusion	O
and	I-protein
does	O
not	I-protein
affect	O
liver	O
injury	O
in	I-protein
this	O
model	I-protein
.	O

These	O
data	O
argue	O
against	I-protein
a	I-protein
central	O
role	O
of	I-protein
nuclear	B-protein
factor-kappaB	I-protein
activation	I-protein
and	I-protein
neutrophil	O
infiltration	O
as	O
perpetuating	O
factors	I-protein
of	I-protein
liver	O
injury	O
in	I-protein
acetaminophen	O
toxicity	O
.	O

###MEDLINE:20465088

Tumor	B-protein
necrosis	I-protein
factor-alpha	I-protein
-induced	O
proliferation	I-protein
requires	O
synthesis	I-protein
of	I-protein
granulocyte-macrophage	I-protein
colony-stimulating	I-protein
factor	I-protein
.	O

OBJECTIVE	O
:	O
Tumor	B-protein
necrosis	I-protein
factor-	I-protein
alpha	I-protein
(	O
TNF-alpha	B-protein
)	O
induces	O
a	I-protein
variety	O
of	I-protein
cellular	O
responses	O
,	O
some	O
of	I-protein
them	O
being	O
at	I-protein
least	O
seemingly	O
contradictory	O
.	O

Thus	O
,	O
we	O
set	O
out	O
to	I-protein
find	O
differences	O
in	I-protein
the	I-protein
modes	O
of	I-protein
proliferative	O
and	I-protein
apoptotic	O
responses	O
to	I-protein
TNF-	B-protein
alpha	I-protein
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
We	O
screened	O
a	I-protein
panel	O
of	I-protein
acute	O
myeloid	O
leukemia-derived	O
cell	O
lines	B-protein
for	I-protein
TNF-	B-protein
alpha	I-protein
-responsiveness	O
.	O

In	O
two	O
lines	B-protein
(	O
OCI-AML-1	O
,	O
OCI-AML-11	O
)	O
,	O
TNF-	B-protein
alpha	I-protein
acted	O
as	O
an	I-protein
apoptotic	O
agent	O
;	O
in	I-protein
others	O
(	O
HU-3	B-protein
,	O
M-07e	O
,	O
TF-1	O
)	O
,	O
it	O
had	O
the	I-protein
opposite	O
effect	O
,	O
preventing	O
apoptosis	O
and	I-protein
inducing	I-protein
proliferation	I-protein
.	O

Direct	O
and	I-protein
indirect	O
signaling	O
mechanisms	O
,	O
including	I-protein
NF-kappaB	B-protein
activation	I-protein
and	I-protein
cytokine	O
synthesis	I-protein
,	O
were	O
analyzed	O
.	O

RESULTS	O
:	O
All	O
cell	O
lines	B-protein
tested	O
expressed	O
TNF-	B-protein
alpha	I-protein
receptors	I-protein
I	I-protein
and	I-protein
II	I-protein
and	I-protein
responded	O
to	I-protein
TNF-	B-protein
alpha	I-protein
by	I-protein
upregulation	O
of	I-protein
intercellular	B-protein
adhesion	I-protein
molecule-1	I-protein
.	O

In	O
contrast	O
to	I-protein
granulocyte-macrophage	I-protein
colony-stimulating	I-protein
factor	I-protein
(	O
GM-CSF	B-protein
)	O
,	O
TNF-	B-protein
alpha	I-protein
did	O
not	I-protein
activate	O
the	I-protein
MAP	B-protein
kinase	I-protein
and	I-protein
p70S6	O
kinase	O
pathways	O
.	O

Nevertheless	O
,	O
inhibitors	I-protein
of	I-protein
these	O
pathways	O
clearly	O
reduced	O
the	I-protein
TNF-alpha	B-protein
-induced	O
cell	O
growth	O
,	O
indicating	O
that	O
TNF-	O
alpha-proliferative	O
cells	I-protein
produced	O
a	I-protein
growth	O
factor	I-protein
that	O
induced	I-protein
proliferation	I-protein
upon	O
stimulation	I-protein
of	I-protein
the	I-protein
above	O
pathways	O
.	O

Anti-GM-CSF	B-protein
antibodies	I-protein
inhibited	O
the	I-protein
TNF-alpha	B-protein
-induced	O
growth	O
,	O
suggesting	O
the	I-protein
presence	O
of	I-protein
an	I-protein
autocrine	B-protein
loop	I-protein
for	I-protein
cell	O
proliferation	I-protein
mediated	I-protein
by	I-protein
GM-CSF	B-protein
.	O

Supporting	O
this	O
notion	O
,	O
TNF-alpha	B-protein
-induced	O
upregulation	O
of	I-protein
GM-CSF	O
mRNA	O
levels	I-protein
and	I-protein
protein	O
secretion	O
in	I-protein
the	I-protein
TNF-alpha	B-protein
-proliferative	O
,	O
but	O
not	I-protein
in	I-protein
the	I-protein
TNF-alpha-apoptotic	O
cell	O
lines	B-protein
.	O

CONCLUSION	O
:	O
These	O
data	O
identify	O
GM-CSF	B-protein
synthesis	I-protein
as	O
an	I-protein
early	O
and	I-protein
essential	O
step	O
in	I-protein
TNF-	O
alpha-induced	I-protein
proliferation	I-protein
.	O

We	O
show	O
for	I-protein
the	I-protein
first	O
time	O
that	O
TNF-alpha-treated	O
cell	O
lines	B-protein
producing	O
no	I-protein
or	I-protein
only	I-protein
minimal	O
amounts	O
of	I-protein
GM-CSF	B-protein
demonstrate	O
an	I-protein
apoptotic	O
phenotype	O
,	O
while	O
cell	O
lines	B-protein
with	I-protein
high	O
GM-CSF	O
expression	I-protein
rates	O
can	O
escape	I-protein
from	I-protein
growth	O
arrest	I-protein
or	I-protein
even	O
apoptosis	O
.	O

In	O
this	O
context	O
,	O
we	O
discuss	O
arguments	O
pointing	O
at	I-protein
NF-kappaB	B-protein
as	O
regulator	O
of	I-protein
GM-CSF	B-protein
synthesis	I-protein
and	I-protein
thus	O
indirectly	O
as	O
regulator	O
for	I-protein
the	I-protein
escape	I-protein
of	I-protein
TNF-alpha	B-protein
-induced	O
apoptosis	O

###MEDLINE:81143525

Glucocorticoid	B-protein
receptor	I-protein
content	O
of	I-protein
T	O
lymphocytes	O
:	O
evidence	O
for	I-protein
heterogeneity	O
.	O

Glucocorticoid	B-protein
receptors	I-protein
were	O
measured	O
in	I-protein
T	O
lymphocytes	O
that	O
were	O
isolated	I-protein
from	I-protein
peripheral	O
blood	O
by	I-protein
either	O
nylon	O
wool	O
filtration	O
or	I-protein
E-rosette	O
sedimentation	O
.	O

T	O
cells	I-protein
isolated	I-protein
by	I-protein
nylon	O
wool	O
filtration	O
specifically	O
bind	O
6.7	O
+/-	O
0.2	O
fmol	O
of	I-protein
dexamethasone	O
per	O
million	O
cells	I-protein
(	O
equivalent	O
to	I-protein
4000	O
+/-	O
200	I-protein
receptors	I-protein
per	O
cell	O
)	O
,	O
whereas	O
T	O
cells	I-protein
isolated	I-protein
by	I-protein
E-rosette	O
sedimentation	O
bind	O
12.0	O
+/-	O
0.7	O
fmol	O
of	I-protein
dexamethasone	O
per	O
million	O
cells	I-protein
(	O
equivalent	O
to	I-protein
7200	O
+/-	O
400	O
receptors	I-protein
per	O
cell	O
)	O
.	O

This	O
difference	O
in	I-protein
the	I-protein
amount	O
of	I-protein
dexamethasone	O
bound	I-protein
by	I-protein
the	I-protein
two	O
T	O
cell	O
preparations	O
was	O
significant	O
(	O
p	O
less	O
than	I-protein
.001	O
)	O
and	I-protein
was	O
present	O
immediately	O
after	O
cell	O
isolation	O
.	O

The	O
binding	I-protein
affinities	O
of	I-protein
the	I-protein
different	O
T	O
cell	O
preparations	O
for	I-protein
dexamethasone	O
were	O
similar	O
.	O

T	O
cells	I-protein
that	O
are	O
isolated	I-protein
by	I-protein
a	I-protein
combination	O
of	I-protein
nylon	O
wool	O
filtration	O
followed	O
by	I-protein
E-rosette	O
sedimentation	O
bind	O
the	I-protein
same	O
amount	O
of	I-protein
dexamethasone	O
as	O
T	O
cells	I-protein
isolated	I-protein
by	I-protein
nylon	O
wool	O
filtration	O
alone	O
.	O

T	O
cells	I-protein
isolated	I-protein
by	I-protein
a	I-protein
combination	O
of	I-protein
E-rosette	O
sedimentation	O
following	O
by	I-protein
nylon	O
wool	O
filtration	O
bind	O
less	O
dexamethasone	O
than	I-protein
do	O
T	O
cells	I-protein
isolated	I-protein
by	I-protein
E-rosette	O
sedimentation	O
alone	O
.	O

These	O
findings	O
suggest	O
that	O
T	O
cells	I-protein
are	O
heterogeneous	O
with	I-protein
respect	O
to	I-protein
their	O
quantity	O
of	I-protein
glucocorticoid	B-protein
receptors	I-protein
.	O

Isolation	O
of	I-protein
T	O
cells	I-protein
by	I-protein
E-rosette	O
sedimentation	O
enriches	O
for	I-protein
T	O
cells	I-protein
that	O
have	O
a	I-protein
greater	O
number	I-protein
of	I-protein
glucocorticoid	B-protein
receptors	I-protein
,	O
and	I-protein
isolation	O
of	I-protein
T	O
cells	I-protein
by	I-protein
nylon	O
wool	O
filtration	O
enriches	O
for	I-protein
T	O
cells	I-protein
that	O
have	O
a	I-protein
lesser	O
number	I-protein
of	I-protein
glucocorticoid	B-protein
receptors	I-protein
.	O

###MEDLINE:81141012

Glucocorticoid	B-protein
receptors	I-protein
and	I-protein
glucocorticoid	O
sensitivity	I-protein
of	I-protein
human	O
leukemic	O
cells	I-protein
.	O

We	O
have	O
established	O
optimal	O
conditions	O
for	I-protein
the	I-protein
measurement	O
of	I-protein
glucocorticoid	B-protein
receptors	I-protein
(	O
GR	B-protein
)	O
in	I-protein
human	O
white	I-protein
cells	I-protein
using	O
a	I-protein
whole-cell	O
binding	I-protein
assay	O
with	I-protein
[	O
3H	I-protein
]	O
dexamethasone	O
as	O
the	I-protein
ligand	O
,	O
and	I-protein
the	I-protein
subsequent	O
determination	I-protein
of	I-protein
the	I-protein
GR	B-protein
content	O
in	I-protein
normal	O
human	O
lymphocytes	O
and	I-protein
in	I-protein
leukemic	O
cells	I-protein
of	I-protein
patients	O
with	I-protein
various	O
forms	I-protein
of	I-protein
acute	O
and	I-protein
chronic	O
leukemia	O
.	O

A	O
number	I-protein
of	I-protein
leukemia	O
cell	O
lines	B-protein
in	I-protein
continuous	O
culture	O
were	O
also	O
subjected	O
to	I-protein
the	I-protein
GR	B-protein
assay	O
,	O
and	I-protein
the	I-protein
results	O
were	O
correlated	O
with	I-protein
the	I-protein
sensitivity	I-protein
of	I-protein
these	O
cell	O
lines	B-protein
to	I-protein
glucocorticoid	O
steroids	O
in	I-protein
vitro	O
.	O

The	O
GR	B-protein
content	O
of	I-protein
normal	O
human	O
lymphocytes	O
amounted	O
to	I-protein
4	I-protein
,	O
850	O
+/-	O
1	I-protein
,	O
340	I-protein
(	O
mean	I-protein
+/-	O
SD	O
)	O
receptors/cell	O
.	O

The	O
mean	I-protein
equilibrium	O
dissociation	I-protein
constant	I-protein
(	O
KD	O
)	O
of	I-protein
the	I-protein
interaction	I-protein
of	I-protein
[	O
3H	I-protein
]	O
dexamethasone	O
with	I-protein
the	I-protein
GR	B-protein
was	O
1.2	I-protein
x	I-protein
10	I-protein
(	O
-8	O
)	O
M	I-protein
.	O

Steroidal	O
compounds	O
with	I-protein
a	I-protein
known	O
glucocorticoid	O
potency	O
effectively	O
competed	O
for	I-protein
the	I-protein
binding	I-protein
,	O
whereas	O
steroids	O
devoid	O
of	I-protein
glucocorticoid	O
activity	I-protein
(	O
e.g.	O
estradiol-17	O
beta	O
and	I-protein
testosterone	O
)	O
were	O
ineffective	O
.	O

The	O
GR	B-protein
content	O
of	I-protein
the	I-protein
blast	O
cells	I-protein
obtained	O
from	I-protein
eight	O
patients	O
suffering	O
from	I-protein
acute	O
leukemia	O
and	I-protein
four	O
patients	O
with	I-protein
a	I-protein
blast	O
crisis	O
of	I-protein
chronic	O
myelocytic	O
leukemia	O
was	O
found	O
to	I-protein
be	O
highly	O
variable	O
(	O
3	O
,	O
230-29	O
,	O
900	O
receptors/cell	O
)	O
,	O
while	O
the	I-protein
lymphocytes	O
of	I-protein
six	O
patients	O
with	I-protein
chronic	O
lymphatic	B-protein
leukemia	O
contained	O
a	I-protein
rather	O
stable	I-protein
GR	B-protein
content	O
(	O
2	I-protein
,	O
930-5	O
,	O
120	I-protein
receptors/cell	O
)	O
,	O
which	O
was	O
comparable	O
with	I-protein
that	O
of	I-protein
normal	O
lymphocytes	O
.	O

GR	B-protein
was	O
identified	I-protein
in	I-protein
all	O
the	I-protein
12	O
malignant	O
continuous	O
white	I-protein
cell	O
lines	B-protein
studied	O
.	O

Large	O
cells	I-protein
contained	O
more	O
GR	B-protein
than	I-protein
the	I-protein
smaller	O
ones	O
.	O

There	O
was	O
no	I-protein
apparent	O
correlation	O
between	O
the	I-protein
GR	B-protein
concentration	I-protein
and	I-protein
the	I-protein
sensitivity	I-protein
of	I-protein
the	I-protein
cells	I-protein
in	I-protein
vitro	O
to	I-protein
glucocorticoids	O
as	O
judged	O
by	I-protein
[	O
3H	I-protein
]	O
thymidine	B-protein
incorporation	O
studies	O
.	O

Distribution	O
of	I-protein
the	I-protein
surface	O
markers	O
in	I-protein
the	I-protein
leukemic	O
cell	O
lines	B-protein
did	O
not	I-protein
relate	O
to	I-protein
the	I-protein
GR	B-protein
concentration	I-protein
.	O

We	O
conclude	O
that	O
the	I-protein
presence	O
of	I-protein
GR	B-protein
is	O
probably	O
a	I-protein
universal	O
feature	O
of	I-protein
the	I-protein
leukemic	O
cells	I-protein
,	O
and	I-protein
,	O
from	I-protein
a	I-protein
clinical	I-protein
standpoint	O
,	O
probably	O
does	O
not	I-protein
alone	O
imply	O
steroid	O
responsiveness	O
.	O

###MEDLINE:81229128

Evidence	O
for	I-protein
a	I-protein
steroid	B-protein
receptor	I-protein
in	I-protein
rheumatoid	O
synovial	O
tissue	O
cells	I-protein
.	O

One	I-protein
mechanism	O
by	I-protein
which	O
glucocorticoids	O
could	O
exert	O
their	O
anti-inflammatory	O
action	O
is	O
via	I-protein
rapidly	I-protein
saturable	O
,	O
stereo-specific	B-protein
cytoplasmic	I-protein
protein	I-protein
receptors	I-protein
.	O

This	O
report	O
is	O
of	I-protein
an	I-protein
investigation	O
into	O
such	O
a	I-protein
possibility	O
in	I-protein
synovial	O
cells	I-protein
.	O

Synovium	O
,	O
obtained	O
from	I-protein
knee	O
joints	I-protein
of	I-protein
rheumatoid	O
patients	O
undergoing	O
surgery	O
,	O
was	O
incubated	O
with	I-protein
clostridiopeptidase	B-protein
A	I-protein
and	I-protein
trypsin-EDTA	O
to	I-protein
obtain	O
cell	O
suspensions	O
.	O

These	O
,	O
together	O
with	I-protein
cells	I-protein
obtained	O
from	I-protein
synovial	O
fluid	I-protein
aspirated	O
from	I-protein
patients	O
with	I-protein
rheumatoid	O
arthritis	I-protein
,	O
were	O
identified	I-protein
by	I-protein
electron	O
microscopy	O
.	O

Duplicate	O
samples	O
of	I-protein
these	O
cell	O
suspensions	O
were	O
incubated	O
with	I-protein
increasing	O
concentrations	O
of	I-protein
H3Dexamethasone	O
(	O
1	I-protein
x	I-protein
10	I-protein
(	O
-10	O
)	O
M-1	O
x	I-protein
10	I-protein
(	O
-9	O
)	O
M	I-protein
)	O
for	I-protein
30	I-protein
minutes	O
at	I-protein
37	I-protein
degrees	O
C	O
.	O

Analysis	O
of	I-protein
the	I-protein
proportion	O
of	I-protein
steroid	O
bound	I-protein
to	I-protein
whole	O
cells	I-protein
showed	O
evidence	O
for	I-protein
specific	I-protein
,	O
rapidly	I-protein
saturable	O
,	O
receptors	I-protein
in	I-protein
the	I-protein
cells	I-protein
obtained	O
from	I-protein
synovial	O
tissue	O
,	O
but	O
this	O
was	O
not	I-protein
found	O
in	I-protein
synovial	O
fluid	I-protein
cells	I-protein
.	O

Electron	O
micrographs	O
showed	O
that	O
cells	I-protein
obtained	O
from	I-protein
synovial	O
tissue	O
consisted	O
of	I-protein
synovial	O
fibroblast	O
-	O
and	I-protein
macrophage-types	O
,	O
lymphocytes	O
,	O
monocytes	O
and	I-protein
macrophages	O
.	O

Polymorphonuclear	O
leucocytes	O
appeared	O
to	I-protein
be	O
absent	O
.	O

However	O
,	O
in	I-protein
synovial	O
fluid	I-protein
cell	O
type	O
polymorphonuclear	O
leucocytes	O
were	O
the	I-protein
predominant	O
cell	O
type	O
.	O

We	O
concluded	O
from	I-protein
this	O
,	O
that	O
one	B-protein
or	I-protein
more	O
of	I-protein
the	I-protein
cell	O
types	I-protein
present	O
in	I-protein
synovial	O
tissue	O
contain	O
a	I-protein
specific	I-protein
steroid	B-protein
receptor	I-protein
,	O
but	O
that	O
this	O
is	O
lacking	I-protein
in	I-protein
synovial	O
fluid	I-protein
polymorphonuclear	O
leucocytes	O
.	O

###MEDLINE:79022914

Clinical	O
implications	O
of	I-protein
glucocorticoid	B-protein
receptors	I-protein
in	I-protein
human	O
leukemia	O
.	O

Glucorticoid	B-protein
receptors	I-protein
were	O
studied	O
in	I-protein
various	O
populations	O
of	I-protein
normal	O
human	O
peripheral	O
blood	O
lymphocytes	O
and	I-protein
leukemic	O
lymphoblasts	O
.	O

Normal	O
lymphocytes	O
contain	O
low	O
levels	I-protein
of	I-protein
glucocorticoid	B-protein
receptor	I-protein
(	O
approximately	O
2	I-protein
,	O
500	I-protein
sites/cell	O
)	O
which	O
are	O
identical	O
in	I-protein
T-	O
and	I-protein
non-T-fractions	O
.	O

Phytohemagglutinin	B-protein
treatment	O
increases	O
levels	I-protein
about	O
3-fold	O
.	O

Leukemic	O
lymphoblasts	O
contain	O
larger	O
numbers	O
of	I-protein
receptor	O
sites	I-protein
.	O

Presence	O
of	I-protein
receptor	O
is	O
correlated	O
with	I-protein
in	I-protein
vitro	O
sensitivitiy	O
to	I-protein
glucocorticoids	O
and	I-protein
in	I-protein
vivo	O
response	I-protein
to	I-protein
therapy	O
.	O

Quantity	O
of	I-protein
receptor	O
is	O
also	O
correlated	O
with	I-protein
complete	O
remission	O
duration	O
independently	O
of	I-protein
leukemic	O
cell	O
type	O
(	O
T	O
or	I-protein
null	O
)	O
,	O
initial	O
WBC	O
,	O
or	I-protein
age	I-protein
of	I-protein
patient	O
.	O

Quantitative	O
determination	I-protein
of	I-protein
glucocorticoid	B-protein
receptor	I-protein
levels	I-protein
in	I-protein
acute	O
lymphoblastic	O
leukemia	O
may	O
be	O
of	I-protein
value	O
both	O
as	O
an	I-protein
independent	I-protein
prognostic	O
variable	O
and	I-protein
in	I-protein
suggesting	O
which	O
patients	O
should	O
receive	O
glucocorticoid	O
therapy	O
.	O

###MEDLINE:94086562

Functional	O
and	I-protein
physical	O
interaction	I-protein
of	I-protein
protein-tyrosine	I-protein
kinases	I-protein
Fyn	I-protein
and	I-protein
Csk	I-protein
in	I-protein
the	I-protein
T-cell	O
signaling	O
system	I-protein
.	O

The	O
Src-like	B-protein
protein-tyrosine	I-protein
kinase	I-protein
Fyn	I-protein
is	O
associated	I-protein
with	I-protein
T-cell	B-protein
antigen	I-protein
receptor	I-protein
.	O

Transient	I-protein
expression	I-protein
of	I-protein
actively	O
mutated	O
Fyn	B-protein
,	O
having	O
Phe-528	O
instead	I-protein
of	I-protein
Tyr-528	O
or	I-protein
Thr-338	O
instead	I-protein
of	I-protein
Ile-338	O
,	O
in	I-protein
Jurkat	O
T-cells	I-protein
stimulated	O
the	I-protein
serum	O
response	I-protein
element	I-protein
(	O
SRE	O
)	O
,	O
12-O-tetradecanoyl-phorbol-13-acetate	O
response	I-protein
element	I-protein
,	O
cyclic	O
AMP	O
response	I-protein
element	I-protein
,	O
and	I-protein
c-fos	O
promoter	I-protein
.	O

The	O
stimulation	I-protein
of	I-protein
SRE	O
was	O
particularly	O
prominent	O
not	I-protein
only	I-protein
with	I-protein
active	O
Fyn	B-protein
but	O
also	O
with	I-protein
normal	B-protein
(	O
wild-type	I-protein
)	O
Fyn	I-protein
.	O

SRE	O
was	O
also	O
stimulated	O
by	I-protein
both	O
normal	B-protein
and	I-protein
active	I-protein
Lck	B-protein
.	O

Furthermore	O
,	O
normal	B-protein
and	I-protein
active	I-protein
Fyn	I-protein
stimulated	O
transcription	O
from	I-protein
the	I-protein
IL-2	B-protein
gene	O
promoter	I-protein
when	O
transfected	O
cells	I-protein
were	O
stimulated	O
by	I-protein
concanavalin	B-protein
A	I-protein
plus	O
12-O-tetradecanoylphorbol-13-acetate	O
.	O

Under	O
the	I-protein
same	O
conditions	O
,	O
Lck	B-protein
did	O
not	I-protein
stimulate	O
IL-2	B-protein
promoter	I-protein
unless	O
it	O
was	O
activated	O
by	I-protein
mutation	I-protein
.	O

Interestingly	O
,	O
a	I-protein
mutant	B-protein
Fyn	I-protein
,	O
which	O
has	O
deletions	O
within	B-protein
the	I-protein
SH2	B-protein
region	I-protein
and	I-protein
so	O
is	O
able	O
to	I-protein
transform	O
chicken	I-protein
embryo	O
fibroblasts	O
,	O
did	O
not	I-protein
stimulate	O
either	O
the	I-protein
c-fos	B-protein
or	I-protein
IL-2	B-protein
promoter	I-protein
,	O
suggesting	O
the	I-protein
importance	O
of	I-protein
this	O
region	O
in	I-protein
T-cell	O
signaling	O
.	O

Csk	B-protein
,	O
which	O
phosphorylates	O
tyrosine	O
residues	O
in	I-protein
the	I-protein
negative	O
regulatory	O
sites	I-protein
of	I-protein
Src	B-protein
family	I-protein
kinases	I-protein
,	O
down-regulated	I-protein
Fyn-	O
and	I-protein
Lck-mediated	O
stimulation	I-protein
of	I-protein
the	I-protein
serum	O
response	I-protein
element	I-protein
and	I-protein
Fyn-mediated	O
enhancement	O
of	I-protein
IL-2	B-protein
promoter	I-protein
activity	I-protein
.	O

These	O
data	O
suggest	O
that	O
Fyn	B-protein
and	I-protein
Lck	B-protein
,	O
whose	O
activities	O
are	O
regulated	O
by	I-protein
Csk	B-protein
,	O
are	O
involved	I-protein
in	I-protein
different	O
phases	O
of	I-protein
T-cell	O
activation	I-protein
.	O

###MEDLINE:94067143

A	O
novel	O
NF-kappa	B-protein
B	I-protein
complex	I-protein
containing	I-protein
p65	B-protein
homodimers	I-protein
:	O
implications	O
for	I-protein
transcriptional	O
control	I-protein
at	I-protein
the	I-protein
level	I-protein
of	I-protein
subunit	I-protein
dimerization	I-protein
.	O

The	O
predominant	O
inducible	O
form	I-protein
of	I-protein
the	I-protein
NF-kappa	B-protein
B	I-protein
transcription	I-protein
factor	I-protein
is	O
a	I-protein
heteromeric	B-protein
complex	I-protein
containing	I-protein
two	O
Rel-related	B-protein
DNA-binding	I-protein
subunits	I-protein
,	O
termed	O
p65	B-protein
and	I-protein
p50	B-protein
.	O

Prior	O
transfection	O
studies	O
have	O
shown	O
that	O
when	O
these	O
p65	B-protein
and	I-protein
p50	I-protein
subunits	I-protein
are	O
expressed	O
independently	O
as	O
stable	I-protein
homodimers	I-protein
,	O
p65	B-protein
stimulates	O
kappa	I-protein
B-directed	O
transcription	O
,	O
whereas	O
p50	B-protein
functions	O
as	O
a	I-protein
kappa	I-protein
B-specific	O
repressor	O
.	O

While	O
authentic	O
p50	B-protein
homodimers	I-protein
(	O
previously	O
termed	O
KBF1	B-protein
)	O
have	O
been	O
detected	O
in	I-protein
nuclear	O
extracts	O
from	I-protein
nontransfected	O
cells	I-protein
,	O
experimental	O
evidence	O
supporting	O
the	I-protein
existence	O
of	I-protein
p65	B-protein
homodimers	I-protein
in	I-protein
vivo	O
was	O
lacking	I-protein
.	O

We	O
now	O
provide	O
direct	O
biochemical	O
evidence	O
for	I-protein
the	I-protein
presence	O
of	I-protein
an	I-protein
endogenous	O
pool	O
of	I-protein
inducible	O
p65	B-protein
homodimers	I-protein
in	I-protein
intact	O
human	O
T	O
cells	I-protein
.	O

As	O
with	I-protein
the	I-protein
prototypical	O
NF-kappa	B-protein
B	I-protein
p50-p65	I-protein
heterodimer	I-protein
,	O
this	O
novel	O
p65	B-protein
homodimeric	I-protein
form	I-protein
of	I-protein
NF-kappa	B-protein
B	I-protein
is	O
functionally	O
sequestered	O
in	I-protein
the	I-protein
cytoplasm	O
but	O
rapidly	I-protein
appears	O
in	I-protein
the	I-protein
nuclear	O
compartment	I-protein
following	O
cellular	O
stimulation	I-protein
.	O

Site-directed	O
mutagenesis	O
studies	O
indicate	O
that	O
the	I-protein
homodimerization	O
function	I-protein
of	I-protein
p65	B-protein
is	O
dependent	I-protein
upon	O
the	I-protein
presence	O
of	I-protein
cysteine	O
216	I-protein
and	I-protein
a	I-protein
conserved	O
recognition	I-protein
motif	I-protein
for	I-protein
protein	B-protein
kinase	I-protein
A	I-protein
(	O
RRPS	O
;	O
amino	O
acids	I-protein
273	I-protein
to	I-protein
276	I-protein
)	O
,	O
both	O
of	I-protein
which	O
reside	O
within	B-protein
a	I-protein
91-amino-acid	O
segment	I-protein
of	I-protein
the	I-protein
Rel	B-protein
homology	I-protein
domain	I-protein
that	O
mediates	O
self-association	O
.	O

In	O
contrast	O
,	O
mutations	I-protein
at	I-protein
these	O
two	O
sites	I-protein
do	O
not	I-protein
affect	O
heterodimerization	O
of	I-protein
p65	B-protein
with	I-protein
p50	B-protein
or	I-protein
its	O
functional	O
interaction	I-protein
with	I-protein
I	I-protein
kappa	I-protein
B	I-protein
alpha	I-protein
.	O

These	O
later	O
findings	O
indicate	O
that	O
neither	O
homo-	O
nor	O
heterodimer	O
formation	O
is	O
an	I-protein
absolute	O
prerequisite	O
for	I-protein
I	I-protein
kappa	I-protein
B	I-protein
alpha	I-protein
recognition	I-protein
of	I-protein
p65	B-protein
.	O

Taken	O
together	O
with	I-protein
prior	O
in	I-protein
vivo	O
transcription	O
studies	O
,	O
these	O
results	O
suggest	O
that	O
the	I-protein
biological	O
activities	O
of	I-protein
p65	B-protein
and	I-protein
p50	B-protein
homodimers	I-protein
are	O
independently	O
regulated	O
,	O
thereby	O
providing	O
an	I-protein
integrated	O
and	I-protein
flexible	I-protein
control	I-protein
mechanism	O
for	I-protein
the	I-protein
rapid	O
activation	I-protein
and	I-protein
repression	I-protein
of	I-protein
NF-kappa	B-protein
B	I-protein
/	O
Rel	B-protein
-directed	O
gene	O
expression	I-protein
.	O

###MEDLINE:94044828

Carrier	O
determination	I-protein
for	I-protein
X-linked	O
agammaglobulinemia	O
using	O
X	O
inactivation	O
analysis	O
of	I-protein
purified	O
B	O
cells	I-protein
.	O

We	O
report	O
the	I-protein
development	O
of	I-protein
a	I-protein
relatively	O
quick	O
and	I-protein
simple	O
method	O
for	I-protein
the	I-protein
assessment	O
of	I-protein
X	O
inactivation	O
status	I-protein
for	I-protein
carrier	I-protein
determination	I-protein
in	I-protein
families	O
affected	O
by	I-protein
X-linked	O
agammaglobulinemia	O
(	O
XLA	B-protein
)	O
.	O

This	O
method	O
utilises	O
an	I-protein
immunomagnetic	O
separation	O
technique	O
for	I-protein
B	O
cell	O
purification	O
and	I-protein
a	I-protein
polymerase	O
chain	I-protein
reaction	I-protein
(	O
PCR	O
)	O
based	O
assay	O
for	I-protein
the	I-protein
determination	I-protein
of	I-protein
methylation	O
status	I-protein
at	I-protein
the	I-protein
androgen	B-protein
receptor	I-protein
(	O
AR	I-protein
)	O
gene	O
locus	O
to	I-protein
assess	O
whether	O
X	O
inactivation	O
is	O
random	O
or	I-protein
non-random	O
at	I-protein
this	O
locus	O
.	O

We	O
report	O
the	I-protein
results	O
we	O
have	O
obtained	O
using	O
this	O
assay	O
to	I-protein
investigate	O
females	O
known	O
to	I-protein
be	O
carriers	O
of	I-protein
various	O
X-linked	O
immunodeficiency	I-protein
disorders	O
.	O

In	O
addition	O
,	O
we	O
investigated	O
four	O
females	O
from	I-protein
different	O
families	O
affected	O
by	I-protein
XLA	B-protein
,	O
two	O
of	I-protein
whom	O
were	O
of	I-protein
unknown	O
carrier	I-protein
status	I-protein
,	O
and	I-protein
we	O
discuss	O
the	I-protein
results	O
obtained	O
with	I-protein
this	O
and	I-protein
other	O
X-inactivation	O
assays	O
.	O

A	O
similar	O
assay	O
has	O
recently	O
been	O
described	O
by	I-protein
Allen	O
et	I-protein
al.	O
(	O
1992	O
)	O
and	I-protein
applied	O
to	I-protein
members	O
of	I-protein
one	B-protein
family	O
affected	O
by	I-protein
XLA	B-protein
.	O

###MEDLINE:94049846

Effects	O
of	I-protein
IL-4	B-protein
and	I-protein
Fc	B-protein
gamma	I-protein
receptor	I-protein
II	I-protein
engagement	O
on	I-protein
Egr-1	O
expression	I-protein
during	I-protein
stimulation	I-protein
of	I-protein
B	O
lymphocytes	O
by	I-protein
membrane	O
immunoglobulin	O
crosslinking	I-protein
.	O

Egr-1	B-protein
is	O
an	I-protein
immediate	B-protein
early	O
gene	O
that	O
is	O
rapidly	I-protein
upregulated	O
in	I-protein
response	I-protein
to	I-protein
mitogenic	O
signals	I-protein
induced	I-protein
by	I-protein
antigen	O
receptor	O
crosslinking	I-protein
on	I-protein
murine	O
B	O
lymphocytes	O
.	O

It	O
has	O
been	O
shown	O
that	O
levels	I-protein
of	I-protein
Egr-1	O
expression	I-protein
are	O
closely	O
correlated	O
with	I-protein
B	O
cell	O
proliferation	I-protein
in	I-protein
several	I-protein
models	O
of	I-protein
B	O
cell	O
activation	I-protein
and	I-protein
tolerance	I-protein
.	O

We	O
compared	O
the	I-protein
expression	I-protein
of	I-protein
Egr-1	B-protein
during	I-protein
B	O
cell	O
stimulation	I-protein
with	I-protein
Fab'2	B-protein
and	I-protein
IgG	I-protein
anti-immunoglobulin	I-protein
(	O
anti-Ig	O
)	O
,	O
since	O
it	O
is	O
known	O
that	O
Fab'2	B-protein
anti-Ig	I-protein
is	O
mitogenic	O
while	O
IgG	I-protein
anti-Ig	I-protein
is	O
not	I-protein
,	O
owing	O
to	I-protein
a	I-protein
dominant	I-protein
inhibitory	O
effect	O
of	I-protein
crosslinking	I-protein
the	I-protein
B	B-protein
cell	I-protein
Fc	I-protein
gamma	I-protein
RII	I-protein
to	I-protein
membrane	B-protein
Ig	I-protein
.	O

While	O
mitogenic	O
doses	O
of	I-protein
Fab'2	B-protein
anti-Ig	I-protein
induce	O
large	O
and	I-protein
rapid	O
increases	O
in	I-protein
Egr-1	O
expression	I-protein
,	O
IgG	I-protein
anti-Ig	I-protein
results	O
in	I-protein
smaller	O
increases	O
in	I-protein
Egr-1	O
mRNA	O
,	O
comparable	O
to	I-protein
that	O
seen	O
with	I-protein
submitogenic	O
concentrations	O
of	I-protein
Fab'2	B-protein
anti-Ig	I-protein
.	O

However	O
,	O
the	I-protein
correlation	O
between	O
Egr-1	O
expression	I-protein
and	I-protein
B	O
cell	O
proliferation	I-protein
breaks	O
down	O
when	O
IL-4	B-protein
is	O
added	O
as	O
a	I-protein
co-mitogen	O
to	I-protein
induce	O
B	O
cell	O
proliferation	I-protein
with	I-protein
IgG	I-protein
anti-Ig	I-protein
or	I-protein
submitogenic	O
concentrations	O
of	I-protein
Fab'2	B-protein
anti-Ig	I-protein
.	O

No	I-protein
corresponding	O
increases	O
in	I-protein
Egr-1	O
mRNA	O
levels	I-protein
are	O
observed	O
when	O
IL-4	B-protein
is	O
added	O
.	O

Therefore	O
,	O
IL-4	B-protein
overcomes	O
Fc	O
receptor-mediated	O
inhibition	O
of	I-protein
B	O
cell	O
proliferation	I-protein
without	I-protein
affecting	O
inhibition	O
of	I-protein
Egr-1	O
mRNA	O
induction	I-protein
,	O
as	O
demonstrated	O
earlier	O
for	I-protein
c-myc	B-protein
mRNA	O
in	I-protein
this	O
system	I-protein
.	O

###MEDLINE:93389400

Identification	O
of	I-protein
a	I-protein
novel	O
cyclosporin-sensitive	O
element	I-protein
in	I-protein
the	I-protein
human	O
tumor	O
necrosis	I-protein
factor	I-protein
alpha	O
gene	O
promoter	I-protein
.	O

Tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
(	O
TNF-alpha	B-protein
)	O
,	O
a	I-protein
cytokine	O
with	I-protein
pleiotropic	B-protein
biological	O
effects	O
,	O
is	O
produced	O
by	I-protein
a	I-protein
variety	O
of	I-protein
cell	O
types	I-protein
in	I-protein
response	I-protein
to	I-protein
induction	I-protein
by	I-protein
diverse	O
stimuli	O
.	O

In	O
this	O
paper	O
,	O
TNF-alpha	B-protein
mRNA	O
is	O
shown	O
to	I-protein
be	O
highly	O
induced	I-protein
in	I-protein
a	I-protein
murine	O
T	O
cell	O
clone	I-protein
by	I-protein
stimulation	I-protein
with	I-protein
T	B-protein
cell	I-protein
receptor	I-protein
(	O
TCR	B-protein
)	O
ligands	O
or	I-protein
by	I-protein
calcium	O
ionophores	O
alone	O
.	O

Induction	O
is	O
rapid	O
,	O
does	O
not	I-protein
require	O
de	I-protein
novo	O
protein	O
synthesis	I-protein
,	O
and	I-protein
is	O
completely	O
blocked	B-protein
by	I-protein
the	I-protein
immunosuppressant	O
cyclosporin	O
A	O
(	O
CsA	O
)	O
.	O

We	O
have	O
identified	I-protein
a	I-protein
human	O
TNF-alpha	B-protein
promoter	I-protein
element	I-protein
,	O
kappa	I-protein
3	O
,	O
which	O
plays	O
a	I-protein
key	O
role	O
in	I-protein
the	I-protein
calcium-mediated	O
inducibility	O
and	I-protein
CsA	O
sensitivity	I-protein
of	I-protein
the	I-protein
gene	O
.	O

In	O
electrophoretic	O
mobility	I-protein
shift	O
assays	O
,	O
an	I-protein
oligonucleotide	O
containing	I-protein
kappa	I-protein
3	O
forms	I-protein
two	O
DNA	B-protein
protein	I-protein
complexes	I-protein
with	I-protein
proteins	I-protein
that	O
are	O
present	O
in	I-protein
extracts	O
from	I-protein
unstimulated	O
T	O
cells	I-protein
.	O

These	O
complexes	O
appear	O
in	I-protein
nuclear	O
extracts	O
only	I-protein
after	O
T	O
cell	O
stimulation	I-protein
.	O

Induction	O
of	I-protein
the	I-protein
inducible	O
nuclear	B-protein
complexes	I-protein
is	O
rapid	O
,	O
independent	I-protein
of	I-protein
protein	O
synthesis	I-protein
,	O
and	I-protein
blocked	B-protein
by	I-protein
CsA	O
,	O
and	I-protein
thus	O
,	O
exactly	O
parallels	O
the	I-protein
induction	I-protein
of	I-protein
TNF-alpha	B-protein
mRNA	O
by	I-protein
TCR	O
ligands	O
or	I-protein
by	I-protein
calcium	O
ionophore	O
.	O

Our	O
studies	O
indicate	O
that	O
the	I-protein
kappa	I-protein
3	I-protein
binding	I-protein
factor	I-protein
resembles	O
the	I-protein
preexisting	O
component	O
of	I-protein
nuclear	B-protein
factor	I-protein
of	I-protein
activated	O
T	O
cells	I-protein
.	O

Thus	O
,	O
the	I-protein
TNF-alpha	B-protein
gene	O
is	O
an	I-protein
immediate	B-protein
early	O
gene	O
in	I-protein
activated	O
T	O
cells	I-protein
and	I-protein
provides	O
a	I-protein
new	I-protein
model	I-protein
system	I-protein
in	I-protein
which	O
to	I-protein
study	O
CsA-sensitive	O
gene	O
induction	I-protein
in	I-protein
activated	O
T	O
cells	I-protein
.	O

###MEDLINE:93371352

Differences	O
in	I-protein
expression	I-protein
of	I-protein
transcription	B-protein
factor	I-protein
AP-1	I-protein
in	I-protein
human	O
promyelocytic	O
HL-60	O
cells	I-protein
during	I-protein
differentiation	I-protein
towards	O
macrophages	O
versus	O
granulocytes	O
.	O

Commitment	O
of	I-protein
HL-60	O
cells	I-protein
to	I-protein
macrophage	O
or	I-protein
granulocytic	O
differentiation	I-protein
was	O
achieved	O
by	I-protein
incubation	O
with	I-protein
4	I-protein
beta-phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
)	O
for	I-protein
30-60	O
min	O
or	I-protein
with	I-protein
dimethyl	O
sulphoxide	O
(	O
DMSO	O
)	O
for	I-protein
24	I-protein
h	I-protein
respectively	O
.	O

The	O
commitment	O
stage	I-protein
towards	O
PMA-induced	O
macrophage	O
differentiation	I-protein
was	O
associated	I-protein
with	I-protein
increases	O
in	I-protein
jun	B-protein
B	O
and	I-protein
c-fos	O
mRNA	O
levels	I-protein
,	O
as	O
well	O
as	O
with	I-protein
an	I-protein
increase	O
in	I-protein
the	I-protein
binding	I-protein
activity	I-protein
of	I-protein
transcription	B-protein
factor	I-protein
AP-1	I-protein
.	O

Nevertheless	O
,	O
gel	O
retardation	I-protein
analysis	O
indicated	O
that	O
the	I-protein
AP-1	I-protein
activity	I-protein
detected	O
in	I-protein
untreated	O
cells	I-protein
was	O
drastically	O
reduced	O
during	I-protein
the	I-protein
commitment	O
stage	I-protein
of	I-protein
DMSO-induced	O
HL-60	O
differentiation	I-protein
towards	O
granulocytes	O
.	O

When	O
HL-60	O
cells	I-protein
were	O
treated	O
with	I-protein
sodium	O
butyrate	O
,	O
which	O
induced	I-protein
monocytic	I-protein
differentiation	I-protein
,	O
a	I-protein
remarkable	O
increase	O
in	I-protein
AP-1	I-protein
binding	I-protein
activity	I-protein
was	O
detected	O
.	O

Treatment	O
of	I-protein
HL-60	O
cells	I-protein
with	I-protein
1	I-protein
alpha	O
,	O
25-dihydroxyvitamin	O
D3	I-protein
,	O
another	O
monocytic	I-protein
differentiation	I-protein
agent	O
,	O
induced	I-protein
a	I-protein
weak	I-protein
,	O
but	O
appreciable	O
,	O
increase	O
in	I-protein
AP-1	I-protein
activity	I-protein
.	O

Furthermore	O
,	O
addition	O
of	I-protein
sodium	O
butyrate	O
or	I-protein
1	I-protein
alpha	O
,	O
25-dihydroxyvitamin	O
D3	I-protein
to	I-protein
HL-60	O
cells	I-protein
induced	I-protein
the	I-protein
expression	I-protein
of	I-protein
c-fos	B-protein
,	O
c-jun	B-protein
,	O
jun	B-protein
B	O
and	I-protein
jun	B-protein
D	O
proto-oncogenes	O
.	O

In	O
contrast	O
,	O
when	O
HL-60	O
cells	I-protein
were	O
treated	O
with	I-protein
retinoic	O
acid	O
,	O
a	I-protein
granulocytic	O
differentiation	I-protein
inducer	I-protein
,	O
no	I-protein
enhanced	I-protein
AP-1	I-protein
binding	I-protein
activity	I-protein
was	O
observed	O
,	O
and	I-protein
only	I-protein
a	I-protein
weak	I-protein
increase	O
in	I-protein
jun	B-protein
D	O
mRNA	O
level	I-protein
was	O
detected	O
.	O

These	O
data	O
indicate	O
that	O
formation	O
of	I-protein
AP-1	I-protein
is	O
not	I-protein
required	O
for	I-protein
the	I-protein
induction	I-protein
of	I-protein
HL-60	O
differentiation	I-protein
towards	O
granulocytes	O
,	O
whereas	O
induction	I-protein
of	I-protein
monocytic	I-protein
differentiation	I-protein
is	O
correlated	O
with	I-protein
an	I-protein
increase	O
in	I-protein
AP-1	I-protein
activity	I-protein
.	O

The	O
differential	O
expression	I-protein
of	I-protein
AP-1	I-protein
activity	I-protein
may	O
be	O
critical	I-protein
in	I-protein
the	I-protein
differentiation	I-protein
of	I-protein
HL-60	O
cells	I-protein
towards	O
monocytic	I-protein
or	I-protein
granulocytic	O
lineages	O

###MEDLINE:81161585

Glucocorticoid	B-protein
receptors	I-protein
and	I-protein
sensitivity	I-protein
in	I-protein
leukemias	O
.	O

In	O
an	I-protein
attempt	O
to	I-protein
investigate	O
the	I-protein
utility	O
of	I-protein
glucocorticoid	B-protein
receptor	I-protein
determination	I-protein
to	I-protein
predict	O
clinical	I-protein
responsiveness	O
in	I-protein
human	O
leukemias	O
we	O
have	O
studied	O
glucocorticoid	B-protein
receptors	I-protein
in	I-protein
the	I-protein
leukemic	O
cells	I-protein
from	I-protein
46	I-protein
patients	O
and	I-protein
in	I-protein
the	I-protein
lymphocytes	O
from	I-protein
18	I-protein
normal	O
donors	O
.	O

In	O
the	I-protein
normal	O
lymphocytes	O
there	O
were	O
3	O
,	O
875	O
(	O
Median	O
)	O
specific	I-protein
binding	I-protein
sites	I-protein
per	O
cell	O
.	O

The	O
blasts	O
from	I-protein
17	I-protein
patients	O
with	I-protein
ANLL	O
had	O
on	I-protein
average	O
higher	O
levels	I-protein
of	I-protein
binding	I-protein
sites	I-protein
per	O
cell	O
(	O
Median	O
=	O
7	I-protein
,	O
250	I-protein
,	O
range	O
:	O
0	I-protein
to	I-protein
15	O
,	O
295	I-protein
)	O
than	I-protein
the	I-protein
other	O
leukemias	O
.	O

Of	O
the	I-protein
15	O
patients	O
with	I-protein
CLL	O
,	O
six	O
had	O
received	O
glucocorticoid	O
treatment	O
for	I-protein
3	O
to	I-protein
5	O
years	O
.	O

Their	O
lymphocytes	O
had	O
lower	I-protein
number	I-protein
of	I-protein
receptors	I-protein
(	O
Median	O
=	O
2	I-protein
,	O
000	O
)	O
than	I-protein
the	I-protein
other	O
cases	O
which	O
were	O
newly	O
diagnosed	O
(	O
Median	O
=	O
4	I-protein
,	O
500	I-protein
)	O
.	O

Four	O
patients	O
had	O
ALL/AUL	O
,	O
three	O
patients	O
had	O
blast	O
crisis	O
as	O
terminal	O
phase	I-protein
of	I-protein
CML	O
,	O
and	I-protein
seven	O
had	O
leukemic	O
Non-Hodgkin	O
lymphomas	I-protein
(	O
Median	O
=	O
3	O
,	O
500	I-protein
sites/cell	O
)	O
.	O

In	O
24	I-protein
patients	O
we	O
have	O
also	O
studied	O
the	I-protein
in	I-protein
vitro	O
sensitivity	I-protein
of	I-protein
the	I-protein
leukemic	O
cells	I-protein
to	I-protein
dexamethasone	O
.	O

There	O
was	O
no	I-protein
marked	O
correlation	O
between	O
glucocorticoid	B-protein
receptor	I-protein
levels	I-protein
and	I-protein
in	I-protein
vitro	O
sensitivity	I-protein
.	O

An	O
attempt	O
to	I-protein
correlate	O
receptor	O
levels	I-protein
with	I-protein
clinical	I-protein
responsiveness	O
demonstrated	O
that	O
glucocorticoid	B-protein
receptor	I-protein
determination	I-protein
might	O
be	O
of	I-protein
value	O
in	I-protein
patients	O
with	I-protein
lymphoid	O
malignancies	O
but	O
probably	O
not	I-protein
in	I-protein
patients	O
with	I-protein
other	O
leukemias	O
.	O

###MEDLINE:80254646

'Activation-labile	B-protein
'	O
glucocorticoid-receptor	I-protein
complexes	I-protein
of	I-protein
a	I-protein
steroid-resistant	I-protein
variant	I-protein
of	I-protein
CEM-C7	O
human	O
lymphoid	O
cells	I-protein
.	O

For	O
cytoplasmic	B-protein
glucocorticoid-receptor	I-protein
complexes	I-protein
to	I-protein
enter	O
and	I-protein
accumulate	O
in	I-protein
the	I-protein
nucleus	I-protein
a	I-protein
temperature-dependent	O
event	O
,	O
'activation	O
'	O
is	O
required	O
.	O

Activation	O
can	O
be	O
achieved	O
in	I-protein
vitro	O
by	I-protein
increased	I-protein
ionic	O
strength	O
,	O
dilution	I-protein
or	I-protein
gel	O
filtration	O
and	I-protein
is	O
manifested	O
by	I-protein
an	I-protein
increased	I-protein
affinity	I-protein
of	I-protein
steroid-receptor	B-protein
complex	I-protein
for	I-protein
DNA	O
and	I-protein
an	I-protein
altered	I-protein
elution	O
profile	O
from	I-protein
ion-exchange	O
resins	O
.	O

Munck	O
and	I-protein
Foley	O
have	O
shown	O
that	O
activated	B-protein
complexes	I-protein
isolated	I-protein
from	I-protein
thymocytes	O
elute	O
from	I-protein
DEAE-cellulose	O
in	I-protein
a	I-protein
manner	O
identical	O
to	I-protein
complexes	O
activated	O
in	I-protein
vitro	O
.	O

We	O
report	O
here	O
that	O
DEAE-cellulose	O
chromatography	O
of	I-protein
steroid-receptor	B-protein
complexes	I-protein
from	I-protein
CEM-C7	O
,	O
a	I-protein
cloned	O
human	O
leukaemic	O
T-cell	O
line	I-protein
sensitive	I-protein
to	I-protein
the	I-protein
cytolytic	O
action	O
of	I-protein
glucocorticoids	O
,	O
and	I-protein
its	O
steroid-resistant	I-protein
subclone	O
4R4	O
demonstrated	O
that	O
steroid	B-protein
receptors	I-protein
of	I-protein
clone	I-protein
4R4	O
can	O
not	I-protein
form	I-protein
stable	I-protein
activated	O
complexes	O
.	O

This	O
defines	O
a	I-protein
new	I-protein
defect	I-protein
in	I-protein
receptor	O
action	O
,	O
activation	I-protein
lability	O
(	O
r+act1	O
)	O
,	O
which	O
is	O
unlike	O
either	O
the	I-protein
r-	O
,	O
r+nt-	O
,	O
or	I-protein
r+nti	O
phenotypes	O
previously	O
described	O
for	I-protein
mouse	I-protein
lymphoid	O
variants	O
.	O

###MEDLINE:80074787

Granulocytes	O
in	I-protein
the	I-protein
endometrium	O
of	I-protein
post-partum	O
women	O
.	O

Endometrial	O
samples	O
of	I-protein
women	O
at	I-protein
various	O
stages	O
of	I-protein
gonadal	B-protein
activity	I-protein
after	O
parturition	O
were	O
examined	O
for	I-protein
the	I-protein
presence	O
and	I-protein
numbers	O
of	I-protein
endometrial	I-protein
granulocytes	O
.	O

Although	O
samples	O
at	I-protein
all	O
the	I-protein
stages	O
contained	O
significant	O
numbers	O
of	I-protein
the	I-protein
granulocytes	O
(	O
i.e.	O
greater	O
than	I-protein
7/high-power	O
field	O
)	O
,	O
the	I-protein
100	I-protein
%	O
values	O
for	I-protein
late-proliferative	O
and	I-protein
adaptation	O
hyperplasia	I-protein
were	O
significantly	O
higher	O
than	I-protein
the	I-protein
values	O
for	I-protein
the	I-protein
resting	O
(	O
81.8	O
%	O
)	O
,	O
early	O
(	O
82.4	O
%	O
)	O
and	I-protein
mid-	O
(	O
87.9	O
%	O
)	O
proliferative	O
and	I-protein
secretory	O
(	O
83.3	O
%	O
)	O
phases	O
.	O

We	O
suggest	O
that	O
this	O
correlates	O
with	I-protein
the	I-protein
suggestion	O
that	O
the	I-protein
granulocytes	O
constitute	O
a	I-protein
receptor	O
system	I-protein
for	I-protein
oestrogens	O
.	O

###MEDLINE:78243961

Interaction	O
of	I-protein
glucocorticoids	O
with	I-protein
macrophages	O
.	O

Identification	O
of	I-protein
glucocorticoid	B-protein
receptors	I-protein
in	I-protein
monocytes	O
and	I-protein
macrophages	O
.	O

Glucocorticoid	O
binding	I-protein
was	O
measured	O
in	I-protein
resident	O
and	I-protein
thioglycollate-elicited	O
mouse	I-protein
peritoneal	O
macrophages	O
,	O
rabbit	O
alveolar	O
macrophages	O
,	O
and	I-protein
human	O
monocytes	O
.	O

Two	O
assays	O
of	I-protein
binding	I-protein
were	O
used	O
--	I-protein
an	I-protein
assay	O
with	I-protein
intact	O
cells	I-protein
in	I-protein
suspension	O
or	I-protein
monolayers	O
,	O
and	I-protein
an	I-protein
assay	O
of	I-protein
cytosol	I-protein
and	I-protein
nuclear	O
forms	I-protein
of	I-protein
glucocorticoid	B-protein
receptors	I-protein
.	O

The	O
mononuclear	O
phagocytes	O
contained	O
approximately	O
equal	O
to	I-protein
4	I-protein
--	I-protein
10	I-protein
X	O
10	I-protein
(	O
3	O
)	O
high	O
affinity	I-protein
receptor	O
sites	I-protein
per	O
cell	O
,	O
with	I-protein
dissociation	I-protein
constants	O
of	I-protein
approximately	O
equal	O
to	I-protein
2	I-protein
--	I-protein
8	I-protein
nM	O
dexamethasone	O
.	O

The	O
binding	I-protein
to	I-protein
the	I-protein
saturable	O
sites	I-protein
was	O
specific	I-protein
for	I-protein
steroids	O
with	I-protein
glucocorticoid	O
or	I-protein
antiglucocorticoid	O
activity	I-protein
.	O

Cortisol	O
,	O
corticosterone	O
,	O
and	I-protein
progesterone	B-protein
competed	O
with	I-protein
dexamethasone	O
for	I-protein
binding	I-protein
,	O
whereas	O
estradiol	O
,	O
dihydrotestosterone	I-protein
,	O
and	I-protein
11-epicortisol	O
competed	O
very	O
little	O
.	O

Binding	O
of	I-protein
dexamethasone	O
to	I-protein
cytosol	I-protein
and	I-protein
nuclear	O
forms	I-protein
of	I-protein
the	I-protein
receptor	O
complex	I-protein
and	I-protein
temperature-sensitive	O
translocation	O
of	I-protein
cytosol	I-protein
forms	I-protein
to	I-protein
nuclear	O
forms	I-protein
were	O
shown	O
.	O

At	O
37	I-protein
degrees	O
C	O
the	I-protein
predominant	O
form	I-protein
of	I-protein
the	I-protein
hormone-receptor	B-protein
complex	I-protein
was	O
nuclear	O
.	O

These	O
results	O
demonstrate	O
that	O
corticosteroids	O
interact	O
with	I-protein
macrophages	O
at	I-protein
physiological	O
concentrations	O
.	O

###MEDLINE:94081368

Nitric	I-protein
oxide	I-protein
signaling	O
:	O
a	I-protein
possible	O
role	O
for	I-protein
G	B-protein
proteins	I-protein
.	O

We	O
have	O
previously	O
reported	O
various	O
inductive	O
effects	O
of	I-protein
nitric	B-protein
oxide	I-protein
on	I-protein
human	O
PBMC	O
.	O

We	O
describe	O
a	I-protein
novel	O
and	I-protein
potentially	O
important	O
mechanism	O
of	I-protein
nitric	B-protein
oxide	I-protein
signaling-through	O
direct	O
activation	I-protein
of	I-protein
guanine	B-protein
nucleotide-binding	I-protein
proteins	I-protein
(	O
G	B-protein
proteins	I-protein
)	O
.	O

We	O
have	O
found	O
that	O
nitric	B-protein
oxide	I-protein
treatment	O
of	I-protein
membranes	O
isolated	I-protein
from	I-protein
fresh	O
human	O
PBMC	O
enhances	O
the	I-protein
ability	O
of	I-protein
these	O
membranes	O
to	I-protein
hydrolyze	O
[	O
gamma-32P	O
]	O
GTP	O
and	I-protein
bind	O
[	O
gamma-35S	O
]	O
GTP	O
.	O

In	O
addition	O
,	O
treatment	O
of	I-protein
whole	O
cells	I-protein
with	I-protein
nitric	B-protein
oxide	I-protein
yielded	O
membranes	O
with	I-protein
enhanced	I-protein
GTPase	O
activity	I-protein
.	O

Furthermore	O
,	O
the	I-protein
GTPase	O
activity	I-protein
of	I-protein
pure	I-protein
,	O
recombinant	B-protein
Gs	I-protein
alpha	I-protein
,	O
Gi	B-protein
alpha	I-protein
1	I-protein
,	O
and	I-protein
p21ras	B-protein
was	O
greatly	O
enhanced	I-protein
by	I-protein
nitric	B-protein
oxide	I-protein
.	O

In	O
support	I-protein
of	I-protein
the	I-protein
existence	O
of	I-protein
this	O
pathway	I-protein
in	I-protein
whole	O
cells	I-protein
,	O
we	O
found	O
that	O
the	I-protein
G	O
protein	O
inhibitor	O
,	O
GDP-beta-S	O
,	O
blocked	B-protein
NF-kappa	O
B	O
translocation	O
induced	I-protein
by	I-protein
nitric	B-protein
oxide	I-protein
or	I-protein
LPS	B-protein
in	I-protein
permeabilized	O
cells	I-protein
.	O

In	O
addition	O
,	O
nitric	B-protein
oxide	I-protein
greatly	O
reduced	O
the	I-protein
pertussis	O
toxin-mediated	O
ADP-ribosylation	O
of	I-protein
45-	B-protein
and	I-protein
41-kDa	I-protein
proteins	I-protein
in	I-protein
membranes	O
of	I-protein
these	O
cells	I-protein
.	O

Because	O
G	B-protein
proteins	I-protein
play	O
a	I-protein
central	O
role	O
in	I-protein
many	O
diverse	O
signaling	O
systems	O
,	O
activation	I-protein
by	I-protein
an	I-protein
endogenous	O
and	I-protein
inducible	O
oxidant	O
may	O
represent	O
a	I-protein
novel	O
signaling	O
pathway	I-protein
.	O

###MEDLINE:94067100

The	O
granulocyte-macrophage	I-protein
colony-stimulating	I-protein
factor	I-protein
promoter	I-protein
cis-acting	O
element	I-protein
CLE0	O
mediates	O
induction	I-protein
signals	I-protein
in	I-protein
T	O
cells	I-protein
and	I-protein
is	O
recognized	I-protein
by	I-protein
factors	I-protein
related	O
to	I-protein
AP1	B-protein
and	I-protein
NFAT	B-protein
.	O

Expression	O
of	I-protein
the	I-protein
granulocyte-macrophage	I-protein
colony-stimulating	I-protein
factor	I-protein
(	O
GM-CSF	B-protein
)	O
gene	O
in	I-protein
T	O
cells	I-protein
is	O
activated	O
by	I-protein
the	I-protein
combination	O
of	I-protein
phorbol	O
ester	I-protein
(	O
phorbol	O
myristate	O
acetate	O
)	O
and	I-protein
calcium	O
ionophore	O
(	O
A23187	O
)	O
,	O
which	O
mimic	O
antigen	O
stimulation	I-protein
through	I-protein
the	I-protein
T-cell	B-protein
receptor	I-protein
.	O

We	O
have	O
previously	O
shown	O
that	O
a	I-protein
fragment	I-protein
containing	I-protein
bp	O
-95	O
to	I-protein
+27	O
of	I-protein
the	I-protein
mouse	I-protein
GM-CSF	O
promoter	I-protein
can	O
confer	O
inducibility	O
to	I-protein
reporter	O
genes	I-protein
in	I-protein
the	I-protein
human	O
Jurkat	O
T-cell	O
line	I-protein
.	O

Here	O
we	O
use	O
an	I-protein
in	I-protein
vitro	O
transcription	O
system	I-protein
to	I-protein
demonstrate	O
that	O
a	I-protein
cis-acting	O
element	I-protein
(	O
positions	O
-54	O
to	I-protein
-40	O
)	O
,	O
referred	O
to	I-protein
as	O
CLE0	O
,	O
is	O
a	I-protein
target	O
for	I-protein
the	I-protein
induction	I-protein
signals	I-protein
.	O

We	O
observed	O
induction	I-protein
with	I-protein
templates	O
containing	I-protein
intact	O
CLE0	O
but	O
not	I-protein
with	I-protein
templates	O
with	I-protein
deleted	O
or	I-protein
mutated	O
CLE0	O
.	O

We	O
also	O
observed	O
that	O
two	O
distinct	O
signals	I-protein
were	O
required	O
for	I-protein
the	I-protein
stimulation	I-protein
through	I-protein
CLE0	O
,	O
since	O
only	I-protein
extracts	O
from	I-protein
cells	I-protein
treated	O
with	I-protein
both	O
phorbol	O
myristate	O
acetate	O
and	I-protein
A23187	O
supported	I-protein
optimal	O
induction	I-protein
.	O

Stimulation	O
probably	O
was	O
mediated	I-protein
by	I-protein
CLE0-binding	B-protein
proteins	I-protein
because	O
depletion	O
of	I-protein
these	O
proteins	I-protein
specifically	O
reduced	O
GM-CSF	B-protein
transcription	O
.	O

One	I-protein
of	I-protein
the	I-protein
binding	I-protein
factors	I-protein
possessed	O
biochemical	O
and	I-protein
immunological	O
features	I-protein
identical	O
to	I-protein
those	O
of	I-protein
the	I-protein
transcription	B-protein
factor	I-protein
AP1	B-protein
.	O

Another	I-protein
factor	I-protein
resembled	O
the	I-protein
T-cell-specific	B-protein
factor	I-protein
NFAT	I-protein
.	O

The	O
characteristics	O
of	I-protein
these	O
two	O
factors	I-protein
are	O
consistent	O
with	I-protein
their	O
involvement	I-protein
in	I-protein
GM-CSF	B-protein
induction	I-protein
.	O

The	O
presence	O
of	I-protein
CLE0-like	O
elements	O
in	I-protein
the	I-protein
promoters	O
of	I-protein
interleukin-3	B-protein
(	O
IL-3	B-protein
)	O
,	O
IL-4	B-protein
,	O
IL-5	B-protein
,	O
GM-CSF	B-protein
,	O
and	I-protein
NFAT	O
sites	I-protein
in	I-protein
the	I-protein
IL-2	B-protein
promoter	I-protein
suggests	O
that	O
the	I-protein
factors	I-protein
we	O
detected	O
,	O
or	I-protein
related	O
factors	I-protein
that	O
recognize	O
these	O
sites	I-protein
,	O
may	O
account	O
for	I-protein
the	I-protein
coordinate	O
induction	I-protein
of	I-protein
these	O
genes	I-protein
during	I-protein
T-cell	O
activation	I-protein
.	O

###MEDLINE:94019377

Identification	O
and	I-protein
characterization	O
of	I-protein
an	I-protein
Alu-containing	O
,	O
T-cell-specific	O
enhancer	O
located	O
in	I-protein
the	I-protein
last	O
intron	O
of	I-protein
the	I-protein
human	O
CD8	O
alpha	O
gene	O
.	O

Expression	O
of	I-protein
the	I-protein
human	O
CD8	O
alpha	O
gene	O
is	O
restricted	I-protein
to	I-protein
cells	I-protein
of	I-protein
the	I-protein
lymphoid	O
lineage	I-protein
and	I-protein
developmentally	O
regulated	O
during	I-protein
thymopoiesis	O
.	O

As	O
an	I-protein
initial	O
step	O
towards	O
understanding	O
the	I-protein
molecular	I-protein
basis	O
for	I-protein
tissue-specific	O
expression	I-protein
of	I-protein
this	O
gene	O
,	O
we	O
surveyed	O
the	I-protein
surrounding	O
chromatin	O
structure	O
for	I-protein
potential	I-protein
cis-acting	O
regulatory	O
regions	O
by	I-protein
DNase	I-protein
I	I-protein
hypersensitivity	O
mapping	O
and	I-protein
found	O
four	O
hypersensitive	O
sites	I-protein
,	O
three	O
of	I-protein
which	O
were	O
T	O
cell	O
restricted	I-protein
.	O

By	O
using	O
a	I-protein
reporter-based	O
expression	I-protein
approach	O
,	O
a	I-protein
T-cell-specific	O
enhancer	O
was	O
identified	I-protein
by	I-protein
its	O
close	I-protein
association	I-protein
with	I-protein
a	I-protein
prominent	O
T-cell-restricted	O
hypersensitive	O
sites	I-protein
in	I-protein
the	I-protein
last	O
intron	O
of	I-protein
the	I-protein
CD8	O
alpha	O
gene	O
.	O

Deletion	O
studies	O
demonstrated	O
that	O
the	I-protein
minimal	O
enhancer	O
is	O
adjacent	I-protein
to	I-protein
a	I-protein
negative	O
regulatory	O
element	I-protein
.	O

DNA	O
sequence	I-protein
analysis	O
of	I-protein
the	I-protein
minimal	O
enhancer	O
revealed	O
a	I-protein
striking	O
cluster	I-protein
of	I-protein
consensus	O
binding	I-protein
sites	I-protein
for	I-protein
Ets-1	B-protein
,	O
TCF-1	B-protein
,	O
CRE	I-protein
,	O
GATA-3	I-protein
,	O
LyF-1	I-protein
,	O
and	I-protein
bHLH	I-protein
proteins	I-protein
which	O
were	O
verified	O
by	I-protein
electrophoretic	O
mobility	I-protein
shift	O
assays	O
.	O

In	O
addition	O
,	O
the	I-protein
5	O
'	O
end	I-protein
of	I-protein
the	I-protein
enhancer	O
was	O
composed	O
of	I-protein
an	I-protein
Alu	I-protein
repeat	I-protein
which	O
contained	O
the	I-protein
GATA-3	B-protein
,	O
bHLH	O
,	O
and	I-protein
LyF-1	O
binding	I-protein
sites	I-protein
.	O

Site-directed	O
mutation	I-protein
of	I-protein
the	I-protein
Ets-1	B-protein
and	I-protein
GATA-3	O
sites	I-protein
dramatically	O
reduced	O
enhancer	O
activity	I-protein
.	O

The	O
functional	O
importance	O
of	I-protein
the	I-protein
other	O
binding	I-protein
sites	I-protein
only	I-protein
became	O
apparent	O
when	O
combinations	O
of	I-protein
mutations	I-protein
were	O
analyzed	O
.	O

Taken	O
together	O
,	O
these	O
results	O
suggest	O
that	O
the	I-protein
human	O
CD8	O
alpha	O
gene	O
is	O
regulated	O
by	I-protein
the	I-protein
interaction	I-protein
of	I-protein
multiple	O
T-cell	B-protein
nuclear	I-protein
proteins	I-protein
with	I-protein
a	I-protein
transcriptional	O
enhancer	O
located	O
in	I-protein
the	I-protein
last	O
intron	O
of	I-protein
the	I-protein
gene	O
.	O

Comparison	O
of	I-protein
the	I-protein
CD8	O
alpha	O
enhancer	O
with	I-protein
other	O
recently	O
identified	I-protein
T-cell-specific	O
regulatory	O
elements	O
suggests	O
that	O
a	I-protein
common	I-protein
set	O
of	I-protein
transcription	B-protein
factors	I-protein
regulates	O
several	I-protein
T-cell	O
genes	I-protein
.	O

###MEDLINE:94045455

Molecular	O
regulation	I-protein
of	I-protein
the	I-protein
human	O
IL-3	B-protein
gene	O
:	O
inducible	O
T	O
cell-restricted	O
expression	I-protein
requires	O
intact	O
AP-1	I-protein
and	I-protein
Elf-1	O
nuclear	O
protein	O
binding	I-protein
sites	I-protein
.	O

Interleukin	B-protein
3	I-protein
(	O
IL-3	B-protein
)	O
is	O
a	I-protein
hematopoietic	B-protein
stem-cell	I-protein
growth	I-protein
and	I-protein
differentiation	I-protein
factor	I-protein
that	O
is	O
expressed	O
solely	O
in	I-protein
activated	O
T	O
and	I-protein
NK	I-protein
cells	I-protein
.	O

Studies	O
to	I-protein
date	O
have	O
identified	I-protein
elements	O
5	O
'	O
to	I-protein
the	I-protein
IL-3	B-protein
coding	I-protein
sequences	I-protein
that	O
regulate	O
its	O
transcription	O
,	O
but	O
the	I-protein
sequences	I-protein
that	O
confer	O
T	O
cell-specific	I-protein
expression	I-protein
remain	O
to	I-protein
be	O
clearly	O
defined	I-protein
.	O

We	O
have	O
now	O
identified	I-protein
DNA	O
sequences	I-protein
that	O
are	O
required	O
for	I-protein
T	O
cell-restricted	O
IL-3	B-protein
gene	O
transcription	O
.	O

A	O
series	O
of	I-protein
transient	O
transfections	O
performed	O
with	I-protein
human	O
IL-3-chloramphenicol	O
acetyltransferase	I-protein
(	O
CAT	B-protein
)	O
reporter	O
plasmids	O
in	I-protein
T	O
and	I-protein
non-T	O
cells	I-protein
revealed	O
that	O
a	I-protein
plasmid	O
containing	I-protein
319	I-protein
bp	O
of	I-protein
5	O
'	O
flanking	O
sequences	I-protein
was	O
active	O
exclusively	O
in	I-protein
T	O
cells	I-protein
.	O

Deletion	O
analysis	O
revealed	O
that	O
T	O
cell	O
specificity	I-protein
was	O
conferred	O
by	I-protein
a	I-protein
49-bp	O
fragment	I-protein
(	O
bp	O
-319	O
to	I-protein
-270	O
)	O
that	O
included	I-protein
a	I-protein
potential	I-protein
binding	I-protein
site	I-protein
for	I-protein
AP-1	I-protein
transcription	I-protein
factors	I-protein
6	I-protein
bp	O
upstream	O
of	I-protein
a	I-protein
binding	I-protein
site	I-protein
for	I-protein
Elf-1	O
,	O
a	I-protein
member	I-protein
of	I-protein
the	I-protein
Ets	B-protein
family	I-protein
of	I-protein
transcription	B-protein
factors	I-protein
.	O

DNaseI	O
footprint	O
and	I-protein
electrophoretic	O
mobility	I-protein
shift	O
assay	O
analyses	O
performed	O
with	I-protein
MLA-144	O
T	O
cell	O
nuclear	O
extracts	O
demonstrated	O
that	O
this	O
49-bp	O
region	O
contains	I-protein
a	I-protein
nuclear	B-protein
protein	I-protein
binding	I-protein
region	I-protein
that	O
includes	I-protein
consensus	O
AP-1	I-protein
and	I-protein
Elf-1	O
binding	I-protein
sites	I-protein
.	O

In	O
addition	O
,	O
extracts	O
prepared	O
from	I-protein
purified	O
human	O
T	O
cells	I-protein
contained	O
proteins	I-protein
that	O
bound	I-protein
to	I-protein
synthetic	I-protein
oligonucleotides	O
corresponding	O
to	I-protein
the	I-protein
AP-1	I-protein
and	I-protein
Elf-1	O
binding	I-protein
sites	I-protein
.	O

In	O
vitro-transcribed	O
and	I-protein
-translated	O
Elf-1	B-protein
protein	I-protein
bound	I-protein
specifically	O
to	I-protein
the	I-protein
Elf-1	O
site	I-protein
,	O
and	I-protein
Elf-1	O
antisera	O
competed	O
and	I-protein
super	O
shifted	O
nuclear	O
protein	O
complexes	O
present	O
in	I-protein
MLA-144	O
nuclear	O
extracts	O
.	O

Moreover	O
,	O
addition	O
of	I-protein
anti-Jun	O
family	O
antiserum	O
in	I-protein
electrophoretic	O
mobility	I-protein
shift	O
assay	O
reactions	O
completely	O
blocked	B-protein
formation	O
of	I-protein
the	I-protein
AP-1-related	B-protein
complexes	I-protein
.	O

Transient	I-protein
transfection	O
studies	O
in	I-protein
MLA-144	O
T	O
cells	I-protein
revealed	O
that	O
constructs	O
containing	I-protein
mutations	I-protein
in	I-protein
the	I-protein
AP-1	I-protein
site	I-protein
almost	O
completely	O
abolished	O
CAT	B-protein
activity	I-protein
while	O
mutation	I-protein
of	I-protein
the	I-protein
Elf-1	O
site	I-protein
or	I-protein
the	I-protein
NF-IL-3	O
site	I-protein
,	O
a	I-protein
previously	O
described	O
nuclear	O
protein	O
binding	I-protein
site	I-protein
(	O
bp.	O
-155	O
to	I-protein
-148	O
)	O
in	I-protein
the	I-protein
IL-3	B-protein
promoter	I-protein
,	O
reduced	O
CAT	B-protein
activity	I-protein
to	I-protein
<	O
25	I-protein
%	O
of	I-protein
the	I-protein
activity	I-protein
given	O
by	I-protein
wild-type	I-protein
constructs	O
.	O

We	O
conclude	O
that	O
expression	I-protein
of	I-protein
the	I-protein
human	O
IL-3	B-protein
gene	O
requires	O
the	I-protein
AP-1	I-protein
and	I-protein
Elf-1	O
binding	I-protein
sites	I-protein
;	O
however	O
,	O
unlike	O
other	O
previously	O
characterized	O
cytokine	O
genes	I-protein
such	O
as	O
IL-2	B-protein
,	O
the	I-protein
AP-1	I-protein
and	I-protein
Elf-1	B-protein
factors	I-protein
can	O
bind	O
independently	O
in	I-protein
the	I-protein
IL-3	B-protein
gene	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
400	O
WORDS	O
)	O

###MEDLINE:93389174

Combination	O
IL-2	B-protein
and	I-protein
IL-4	B-protein
reduces	O
glucocorticoid	O
receptor-binding	O
affinity	I-protein
and	I-protein
T	O
cell	O
response	I-protein
to	I-protein
glucocorticoids	O
.	O

The	O
mechanisms	O
contributing	O
to	I-protein
persistent	I-protein
T	O
cell	O
activation	I-protein
and	I-protein
poor	O
response	I-protein
to	I-protein
glucocorticoids	O
in	I-protein
chronic	O
inflammatory	O
illnesses	O
such	O
as	O
steroid	O
resistant	I-protein
(	O
SR	I-protein
)	O
asthma	I-protein
are	O
poorly	O
defined	I-protein
.	O

We	O
examined	O
the	I-protein
possibility	O
that	O
certain	O
cytokines	B-protein
,	O
specifically	O
IL-2	B-protein
and	I-protein
IL-4	B-protein
,	O
could	O
affect	O
T	O
cell	O
response	I-protein
to	I-protein
glucocorticoids	O
.	O

A	O
[	O
3H	I-protein
]	O
dexamethasone	O
radioligand-binding	O
assay	O
was	O
used	O
to	I-protein
measure	O
the	I-protein
number	I-protein
of	I-protein
glucocorticoid	B-protein
receptors	I-protein
(	O
GR	B-protein
)	O
and	I-protein
dissociation	I-protein
constant	I-protein
(	O
Kd	O
)	O
in	I-protein
PBMC	O
from	I-protein
normal	O
donors	O
and	I-protein
patients	O
with	I-protein
SR	I-protein
asthma	I-protein
,	O
cultured	O
in	I-protein
the	I-protein
absence	I-protein
and	I-protein
presence	O
of	I-protein
these	O
cytokines	B-protein
.	O

PBMC	O
from	I-protein
normal	O
donors	O
incubated	O
for	I-protein
48	I-protein
h	I-protein
in	I-protein
the	I-protein
presence	O
of	I-protein
combination	O
IL-2	B-protein
+	O
IL-4	B-protein
had	O
nuclear	O
GR	O
with	I-protein
significantly	O
reduced	O
binding	I-protein
affinity	I-protein
(	O
GR	O
Kd	O
=	O
36.1	O
+/-	O
1.63	O
nM	O
,	O
mean	I-protein
+/-	O
SEM	O
;	O
p	O
=	O
0.0001	O
)	O
as	O
compared	O
with	I-protein
PBMC	O
incubated	O
with	I-protein
medium	I-protein
alone	O
(	O
GR	O
Kd	O
=	O
6.74	O
+/-	O
0.46	O
nM	O
)	O
.	O

The	O
cytosolic	O
GR	O
Kd	O
remained	O
unchanged	O
.	O

However	O
,	O
when	O
PBMC	O
were	O
incubated	O
with	I-protein
IL-2	B-protein
alone	O
or	I-protein
IL-4	B-protein
alone	O
,	O
no	I-protein
change	O
in	I-protein
GR-binding	O
affinity	I-protein
was	O
observed	O
.	O

Furthermore	O
,	O
when	O
T	O
cells	I-protein
and	I-protein
non-T	O
cells	I-protein
were	O
individually	O
stimulated	O
with	I-protein
combination	O
IL-2	B-protein
+	O
IL-4	B-protein
,	O
a	I-protein
significant	O
reduction	I-protein
in	I-protein
GR-binding	O
affinity	I-protein
was	O
observed	O
only	I-protein
in	I-protein
the	I-protein
T	O
cell	O
population	O
(	O
p	O
=	O
0.0001	O
)	O
.	O

The	O
IL-2	B-protein
+	O
IL-4-induced	O
alteration	O
in	I-protein
PBMC	O
GR	O
Kd	O
was	O
associated	I-protein
with	I-protein
an	I-protein
increase	O
in	I-protein
GR	B-protein
number	I-protein
(	O
8348	O
+/-	O
964	O
vs	O
1710	O
+/-	O
228	I-protein
sites/cell	O
;	O
p	O
=	O
0.0003	O
)	O
.	O

More	O
importantly	O
,	O
the	I-protein
alteration	O
in	I-protein
PBMC	O
GR-binding	O
affinity	I-protein
with	I-protein
IL-2	B-protein
+	O
IL-4	B-protein
was	O
associated	I-protein
with	I-protein
a	I-protein
functional	O
change	O
in	I-protein
T	O
cell	O
response	I-protein
to	I-protein
methylprednisolone	O
MPN	O
,	O
i.e.	O
,	O
a	I-protein
reduced	O
inhibitory	O
effect	O
of	I-protein
MPN	O
on	I-protein
PMA/ionomycin-induced	O
T	O
cell	O
proliferation	I-protein
.	O

These	O
effects	O
of	I-protein
IL-2	B-protein
+	O
IL-4	B-protein
on	I-protein
PBMC	O
GR	O
affinity	I-protein
and	I-protein
response	I-protein
to	I-protein
MPN	O
were	O
blocked	B-protein
by	I-protein
co-incubation	O
with	I-protein
IFN-gamma	B-protein
.	O

Freshly	O
isolated	I-protein
PBMC	O
from	I-protein
four	O
patients	O
with	I-protein
SR	I-protein
asthma	I-protein
had	O
a	I-protein
significantly	O
reduced	O
GR-binding	O
affinity	I-protein
(	O
Kd	O
=	O
40.0	O
+/-	O
2.68	O
nM	O
;	O
p	O
=	O
0.0001	O
)	O
when	O
compared	O
with	I-protein
seven	O
normal	O
subjects	O
(	O
7.15	O
+/-	O
0.41	O
nM	O
)	O
.	O

The	O
altered	I-protein
PBMC	O
GR	O
binding	I-protein
from	I-protein
patients	O
with	I-protein
SR	I-protein
asthma	I-protein
reversed	O
to	I-protein
normal	O
when	O
incubated	O
with	I-protein
medium	I-protein
alone	O
,	O
but	O
was	O
sustained	O
with	I-protein
IL-2	B-protein
+	O
IL-4	B-protein
.	O

These	O
observations	O
suggest	O
that	O
with	I-protein
persistent	I-protein
inflammation	O
certain	O
cytokines	B-protein
may	O
contribute	O
to	I-protein
an	I-protein
impaired	O
response	I-protein
to	I-protein
glucocorticoids	O
.	O

Furthermore	O
,	O
the	I-protein
effects	O
of	I-protein
IL-2	B-protein
and	I-protein
IL-4	B-protein
were	O
blocked	B-protein
by	I-protein
IFN-gamma	B-protein
.	O

###MEDLINE:93361522

Characterization	O
of	I-protein
the	I-protein
human	O
CD4	B-protein
gene	O
promoter	I-protein
:	O
transcription	O
from	I-protein
the	I-protein
CD4	B-protein
gene	O
core	O
promoter	I-protein
is	O
tissue-specific	O
and	I-protein
is	O
activated	O
by	I-protein
Ets	B-protein
proteins	I-protein
.	O

We	O
analyzed	O
the	I-protein
5	O
'	O
transcription	O
control	I-protein
sequences	I-protein
of	I-protein
the	I-protein
human	O
CD4	B-protein
gene	O
.	O

We	O
located	O
the	I-protein
transcription	O
initiation	I-protein
site	I-protein
and	I-protein
showed	O
that	O
the	I-protein
CD4	B-protein
core	O
promoter	I-protein
(	O
positions	O
-40	O
to	I-protein
+16	O
)	O
lacks	O
a	I-protein
classical	O
``	O
TATA	O
''	I-protein
or	I-protein
initiator	I-protein
positioning	O
consensus	O
sequence	I-protein
but	O
directs	I-protein
precise	O
and	I-protein
efficient	O
transcription	O
when	O
coupled	I-protein
to	I-protein
the	I-protein
ubiquitously	O
active	O
simian	O
virus	I-protein
40	I-protein
enhancer	O
.	O

The	O
transcriptional	O
activity	I-protein
of	I-protein
the	I-protein
CD4	B-protein
gene	O
promoter	I-protein
correlated	O
with	I-protein
CD4	B-protein
expression	I-protein
in	I-protein
various	O
cell	O
types	I-protein
.	O

Interestingly	O
,	O
the	I-protein
CD4	B-protein
core	O
promoter	I-protein
also	O
displayed	O
a	I-protein
tissue-specific	O
transcriptional	O
activity	I-protein
.	O

Within	O
this	O
fragment	I-protein
,	O
three	O
nucleic	I-protein
acid	O
sequences	I-protein
are	O
completely	O
conserved	O
in	I-protein
the	I-protein
murine	O
CD4	B-protein
gene	O
.	O

One	I-protein
of	I-protein
these	O
sequences	I-protein
contains	I-protein
a	I-protein
perfect	O
ETS	O
consensus	O
sequence	I-protein
.	O

Another	I-protein
ETS	O
consensus	O
sequence	I-protein
is	O
located	O
1060	O
nt	O
upstream	O
.	O

Electrophoretic-mobility-shift	O
assays	O
showed	O
that	O
the	I-protein
core	O
promoter	I-protein
ETS	O
motif	I-protein
binds	O
an	I-protein
Ets-related	B-protein
protein	I-protein
specifically	O
expressed	O
at	I-protein
high	O
levels	I-protein
in	I-protein
CD4+	O
cells	I-protein
.	O

Moreover	O
,	O
in	I-protein
CD4-	O
cells	I-protein
,	O
overexpression	O
of	I-protein
Ets-1	B-protein
or	I-protein
Ets-2	B-protein
efficiently	O
and	I-protein
specifically	O
activated	O
transcription	O
from	I-protein
the	I-protein
CD4	B-protein
promoter	I-protein
and	I-protein
core	O
promoter	I-protein
.	O

These	O
data	O
indicate	O
that	O
Ets	B-protein
transcription	I-protein
factors	I-protein
play	O
a	I-protein
central	O
role	O
in	I-protein
controlling	I-protein
CD4	B-protein
gene	O
expression	I-protein
,	O
by	I-protein
binding	I-protein
to	I-protein
both	O
a	I-protein
classical	O
remote	O
site	I-protein
and	I-protein
an	I-protein
unusual	I-protein
proximal	I-protein
activator	O
sequence	I-protein

###MEDLINE:81093967

Glucocorticoid	O
receptor	O
activation	I-protein
and	I-protein
inactivation	O
in	I-protein
c	I-protein
ultured	O
human	O
lymphocytes	O
.	O

Although	O
glucocorticoids	O
are	O
not	I-protein
cytolytic	O
for	I-protein
and	I-protein
do	O
not	I-protein
inhibit	O
the	I-protein
growth	O
of	I-protein
the	I-protein
IM-9	O
line	I-protein
of	I-protein
cultured	O
human	O
lymphoblasts	O
,	O
these	O
cells	I-protein
have	O
a	I-protein
high	O
steroid-binding	O
capacity	O
.	O

We	O
have	O
used	O
IM-9	O
cells	I-protein
in	I-protein
order	O
to	I-protein
examine	O
whether	O
unoccupied	B-protein
glucocorticoid	I-protein
receptors	I-protein
are	O
inactivated	I-protein
and	I-protein
activated	O
in	I-protein
intact	O
cells	I-protein
.	O

when	O
IM-9	O
cells	I-protein
are	O
incubated	O
in	I-protein
glucose-free	O
medium	I-protein
in	I-protein
a	I-protein
nitrogen	I-protein
atmosphere	O
,	O
both	O
their	O
ability	O
to	I-protein
bind	O
triamcinolone	O
acetonide	O
and	I-protein
their	O
ATP	O
levels	I-protein
decline	O
and	I-protein
,	O
when	O
glucose	O
and	I-protein
oxygen	O
are	O
reintroduced	O
,	O
ATP	O
levels	I-protein
and	I-protein
receptor	O
activity	I-protein
return	I-protein
.	O

The	O
specific	I-protein
glucocorticoid-binding	O
activity	I-protein
of	I-protein
cytosol	I-protein
prepared	O
from	I-protein
cells	I-protein
exposed	O
to	I-protein
various	O
degrees	O
of	I-protein
energy	O
limitation	O
is	O
directly	O
correlated	O
with	I-protein
the	I-protein
ATP	O
content	O
.	O

Receptor	I-protein
activation	I-protein
in	I-protein
intact	O
cells	I-protein
is	O
rapid	O
and	I-protein
independent	I-protein
of	I-protein
protein	O
synthesis	I-protein
.	O

Cytosol	O
prepared	O
from	I-protein
inactivated	I-protein
cells	I-protein
can	O
not	I-protein
be	O
activated	O
by	I-protein
addition	O
of	I-protein
ATP	O
.	O

The	O
inactivation	O
of	I-protein
glucocorticoid	B-protein
receptors	I-protein
that	O
occurs	O
when	O
cytosol	I-protein
from	I-protein
normal	O
IM-9	O
cells	I-protein
is	O
incubated	O
at	I-protein
25	I-protein
degrees	O
C	O
is	O
inhibited	O
by	I-protein
molybdate	O
,	O
vanadate	O
,	O
fluoride	O
,	O
ATP	O
,	O
and	I-protein
several	I-protein
other	O
nucleotides	O
.	O

The	O
experiments	O
with	I-protein
intact	O
human	O
lymphoblasts	O
suggest	O
that	O
assays	O
of	I-protein
specific	I-protein
glucocorticoid-binding	O
capacity	O
do	O
not	I-protein
necessarily	O
reflect	O
the	I-protein
cellular	O
content	O
of	I-protein
receptor	O
protein	O
.	O

###MEDLINE:80205384

Glucocorticoids	O
and	I-protein
lymphocytes	O
.	O

II	I-protein
.	O

Cell	I-protein
cycle-dependent	O
changes	O
in	I-protein
glucocorticoid	B-protein
receptor	I-protein
content	O
.	O

To	O
study	O
variations	O
in	I-protein
glucocorticoid	B-protein
receptor	I-protein
levels	I-protein
during	I-protein
the	I-protein
cell	O
cycle	I-protein
,	O
we	O
have	O
separated	O
mitogen-stimulated	O
human	O
peripheral	O
lymphocytes	O
and	I-protein
rat	I-protein
lymph	O
node	I-protein
cells	I-protein
by	I-protein
unit	I-protein
gravity	O
sedimentation	O
and	I-protein
measured	O
glucocorticoid	O
binding	I-protein
in	I-protein
the	I-protein
resultant	O
fractions	O
.	O

By	O
morphologic	O
criteria	O
and	I-protein
thymidine	B-protein
incorporation	O
,	O
the	I-protein
fractions	O
were	O
separated	O
into	O
populations	O
of	I-protein
G0	O
and	I-protein
G1	O
phase	I-protein
and	I-protein
S	I-protein
and	I-protein
post-S	O
phase	I-protein
cells	I-protein
.	O

A	O
2-	O
to	I-protein
3-fold	O
increase	O
in	I-protein
glucocorticoid	O
receptor	O
sites	I-protein
per	O
cell	O
,	O
for	I-protein
cells	I-protein
in	I-protein
the	I-protein
S	I-protein
and	I-protein
post-S	O
phase	I-protein
over	O
those	O
in	I-protein
G0	O
and	I-protein
G1	O
,	O
was	O
observed	O
with	I-protein
both	O
nonstimulated	O
rat	I-protein
lymph	O
node	I-protein
cell	O
suspensions	O
and	I-protein
concanavalin	O
A-stimulated	O
human	O
peripheral	O
lymphocytes	O
.	O

These	O
observations	O
together	O
with	I-protein
those	O
from	I-protein
other	O
studies	O
indicate	O
that	O
formation	O
of	I-protein
new	I-protein
glucocorticoid	B-protein
receptors	I-protein
near	O
the	I-protein
S	I-protein
phase	I-protein
may	O
be	O
a	I-protein
general	O
phenomenon	O
in	I-protein
proliferating	B-protein
cells	I-protein
.	O

We	O
propose	O
that	O
this	O
increase	O
in	I-protein
glucocorticoid	B-protein
receptors	I-protein
during	I-protein
the	I-protein
cell	O
cycle	I-protein
may	O
explain	O
the	I-protein
increase	O
in	I-protein
glucocorticoid	B-protein
receptors	I-protein
in	I-protein
mitogen-stimulated	O
lymphocytes	O
.	O

###MEDLINE:79225924

The	O
leukocyte	O
migration	I-protein
inhibition	O
response	I-protein
to	I-protein
certain	O
breast	B-protein
cancer-related	I-protein
antigens	I-protein
(	O
MCF-7	B-protein
and	I-protein
MuMTV	B-protein
)	O
:	O
their	O
potential	I-protein
as	O
discriminants	O
.	O

Certain	O
oncogenic	O
viruses	O
have	O
been	O
implicated	O
in	I-protein
human	O
breast	O
cancer	O
,	O
including	I-protein
the	I-protein
murine	O
mammary	I-protein
tumor	O
virus	I-protein
(	O
MuMTV	B-protein
)	O
and	I-protein
the	I-protein
Mason-Pfizer	O
monkey	O
virus	I-protein
(	O
MPMV	B-protein
)	O
.	O

We	O
have	O
used	O
the	I-protein
leukocyte	O
migration	I-protein
inhibition	O
(	O
LMI	O
)	O
response	I-protein
to	I-protein
assay	O
the	I-protein
response	I-protein
to	I-protein
several	I-protein
potential	I-protein
breast	O
cancer-related	I-protein
antigens	I-protein
,	O
including	I-protein
MuMTV	B-protein
,	O
MPMV	B-protein
,	O
and	I-protein
a	I-protein
breast	O
cancer	O
cultured	O
cell	O
line	I-protein
,	O
MCF-7	B-protein
,	O
in	I-protein
96	I-protein
breast	O
cancer	O
patients	O
,	O
in	I-protein
32	I-protein
women	O
with	I-protein
benign	O
breast	O
disease	I-protein
,	O
and	I-protein
in	I-protein
67	I-protein
normal	O
women	O
.	O

The	O
lowest	O
tenth	O
percentile	O
of	I-protein
control	I-protein
(	O
LMI	O
)	O
responses	O
was	O
used	O
as	O
the	I-protein
cutoff	O
point	O
to	I-protein
designate	O
responders	O
.	O

Breast	B-protein
cancer	O
patients	O
showed	O
significant	O
responses	O
to	I-protein
MuMTV	B-protein
(	O
49	I-protein
%	O
and	I-protein
to	I-protein
MCF-7	O
(	O
50	I-protein
%	O
)	O
,	O
but	O
not	I-protein
to	I-protein
MPMV	B-protein
(	O
29	I-protein
%	O
)	O
.	O

In	O
a	I-protein
paired-antigen	O
study	O
using	O
MuMTV	B-protein
and	I-protein
MCF-7	B-protein
,	O
75	I-protein
%	O
of	I-protein
the	I-protein
breast	O
cancer	O
patients	O
responded	O
,	O
versus	O
18	I-protein
%	O
of	I-protein
the	I-protein
normal	O
women	O
(	O
P	O
less	O
than	I-protein
0.0050	O
)	O
.	O

The	O
potential	I-protein
for	I-protein
this	O
assay	O
to	I-protein
distinguish	O
``	O
normal	O
''	I-protein
from	I-protein
``	O
breast	O
cancer	O
''	I-protein
was	O
analyzed	O
using	O
a	I-protein
migration	I-protein
index	I-protein
derived	I-protein
from	I-protein
discriminant	O
analysis	O
.	O

The	O
ability	O
of	I-protein
the	I-protein
assay	O
to	I-protein
discriminate	O
``	O
normal	O
''	I-protein
from	I-protein
``	O
cancer	O
''	I-protein
was	O
significant	O
(	O
P	O
less	O
than	I-protein
0.001	O
)	O
and	I-protein
showed	O
a	I-protein
sensitivity	I-protein
of	I-protein
detecting	O
``	O
cancer	O
''	I-protein
of	I-protein
75	I-protein
%	O
.	O

The	O
overall	O
responses	O
to	I-protein
MuMTV	B-protein
and	I-protein
MCF-7	B-protein
were	O
analyzed	O
with	I-protein
reference	O
to	I-protein
certain	O
prognostic	O
factors	I-protein
,	O
but	O
showed	O
no	I-protein
relation	O
to	I-protein
age	I-protein
,	O
menstrual	O
status	I-protein
,	O
estrogen	B-protein
receptor	I-protein
status	I-protein
,	O
or	I-protein
stage	I-protein
of	I-protein
disease	I-protein
.	O

The	O
above	O
reactions	O
suggest	O
that	O
a	I-protein
large	O
proportion	O
of	I-protein
breast	O
cancer	O
patients	O
exhibit	O
presensitization	O
to	I-protein
antigenfs	O
found	O
in	I-protein
MuMTV	B-protein
and	I-protein
MCF-7	B-protein
,	O
which	O
may	O
be	O
cross-reactive	I-protein
with	I-protein
antigens	I-protein
in	I-protein
the	I-protein
primary	O
cancer	O
.	O

These	O
responses	O
appear	O
to	I-protein
be	O
independent	I-protein
of	I-protein
major	O
prognostic	O
variables	O
.	O

Further	O
refinement	O
of	I-protein
this	O
assay	O
may	O
yield	O
one	B-protein
which	O
is	O
more	O
highly	O
discriminating	O
for	I-protein
breast	O
cancer	O
.	O

###MEDLINE:78165928

Chronic	O
lymphatic	B-protein
leukaemia	O
:	O
cellular	O
effects	O
of	I-protein
glucocorticoids	O
in	I-protein
vitro	O
.	O

Glucocorticoid	B-protein
receptor	I-protein
levels	I-protein
and	I-protein
steroid	O
induced	I-protein
inhibition	O
of	I-protein
nucleic	I-protein
acid	O
precursors	O
have	O
been	O
examined	O
in	I-protein
lymphocytes	O
from	I-protein
27	I-protein
patients	O
at	I-protein
different	O
stages	O
of	I-protein
chronic	O
lymphatic	B-protein
leukaemia	O
.	O

No	I-protein
correlation	O
can	O
be	O
found	O
between	O
the	I-protein
level	I-protein
of	I-protein
glucocorticoid	B-protein
receptors	I-protein
and	I-protein
the	I-protein
stage	I-protein
of	I-protein
the	I-protein
disease	I-protein
.	O

On	O
the	I-protein
other	O
hand	O
,	O
a	I-protein
significant	O
difference	O
(	O
P	O
less	O
than	I-protein
0.02	O
)	O
was	O
found	O
between	O
stage	I-protein
O	I-protein
and	I-protein
stage	I-protein
III/IV	O
patients	O
,	O
in	I-protein
terms	O
of	I-protein
the	I-protein
in	I-protein
vitro	O
effect	O
of	I-protein
dexamethasone	O
on	I-protein
[	O
3H	I-protein
]	O
uridine	B-protein
incorporation	O
.	O

###MEDLINE:94081349

Pyrrolidine	O
dithiocarbamate	O
inhibits	I-protein
NF-kappa	B-protein
B	I-protein
mobilization	O
and	I-protein
TNF	B-protein
production	I-protein
in	I-protein
human	O
monocytes	O
.	O

The	O
human	O
TNF	O
promoter	I-protein
contains	I-protein
four	O
potential	I-protein
nuclear	O
factor-kappa	O
B	O
(	O
NF-kappa	B-protein
B	I-protein
)	O
-binding	I-protein
sites	I-protein
,	O
with	I-protein
the	I-protein
strongest	O
binding	I-protein
seen	O
for	I-protein
the	I-protein
-605	O
motif	I-protein
.	O

Nuclear	I-protein
extracts	O
from	I-protein
unstimulated	O
cells	I-protein
of	I-protein
the	I-protein
human	O
monocytic	I-protein
cell	O
line	I-protein
,	O
Mono	O
Mac	O
6	I-protein
,	O
contain	O
one	B-protein
specific	I-protein
binding	I-protein
protein	I-protein
(	O
complex	I-protein
II	I-protein
)	O
,	O
consistent	O
with	I-protein
a	I-protein
constitutive	I-protein
p50	I-protein
homodimer	B-protein
.	O

Stimulation	O
of	I-protein
Mono	O
Mac	O
6	I-protein
cells	I-protein
with	I-protein
LPS	B-protein
will	O
increase	O
complex	I-protein
II	I-protein
and	I-protein
will	O
strongly	O
induce	O
a	I-protein
second	O
specific	I-protein
complex	I-protein
(	O
complex	I-protein
I	I-protein
)	O
,	O
which	O
represents	O
the	I-protein
p50/65	B-protein
heterodimer	I-protein
.	O

Treatment	O
of	I-protein
Mono	O
Mac	O
6	I-protein
cells	I-protein
with	I-protein
pyrrolidine-dithiocarbamate	O
(	O
PDTC	O
)	O
at	I-protein
300	I-protein
microM	O
will	O
block	O
the	I-protein
LPS-induced	B-protein
complex	I-protein
I	I-protein
almost	O
completely	O
and	I-protein
will	O
reduce	O
complex	I-protein
II	I-protein
to	I-protein
the	I-protein
constitutive	I-protein
level	I-protein
.	O

Binding	O
activity	I-protein
of	I-protein
other	O
nuclear	B-protein
factors	I-protein
that	O
recognize	O
the	I-protein
SP-1	O
and	I-protein
c/EBP	O
motifs	I-protein
of	I-protein
the	I-protein
human	O
TNF	O
promoter	I-protein
is	O
not	I-protein
affected	O
by	I-protein
such	O
treatment	O
.	O

Northern	O
blot	O
analysis	O
demonstrates	O
that	O
PDTC	O
treatment	O
will	O
strongly	O
reduce	O
LPS-induced	B-protein
TNF	I-protein
transcripts	I-protein
.	O

Secreted	O
TNF	B-protein
protein	I-protein
as	O
detected	O
in	I-protein
the	I-protein
Wehi	O
164S/ActD	O
bioassay	O
and	I-protein
in	I-protein
a	I-protein
sandwich	O
immunoassay	O
was	O
similarly	O
reduced	O
by	I-protein
PDTC	O
.	O

Kinetic	O
analyses	O
show	O
that	O
after	O
LPS	B-protein
stimulation	I-protein
,	O
NF-kappa	B-protein
B	I-protein
will	O
peak	O
at	I-protein
1	I-protein
h	I-protein
,	O
TNF	O
transcript	O
prevalence	O
at	I-protein
2	I-protein
h	I-protein
,	O
and	I-protein
TNF	B-protein
protein	I-protein
at	I-protein
4	I-protein
h	I-protein
.	O

PDTC	O
did	O
not	I-protein
shift	O
this	O
response	I-protein
to	I-protein
LPS	B-protein
to	I-protein
a	I-protein
later	O
time	O
,	O
but	O
suppressed	I-protein
NF-kappa	O
B	O
mobilization	O
,	O
TNF	B-protein
transcripts	I-protein
,	O
and	I-protein
TNF	B-protein
protein	I-protein
over	O
the	I-protein
entire	O
8-h	O
observation	O
period	B-protein
.	O

Analysis	O
of	I-protein
freshly	O
isolated	I-protein
,	O
LPS-stimulated	O
blood	O
monocytes	O
showed	O
a	I-protein
similar	O
blockade	O
of	I-protein
NF-kappa	B-protein
B	I-protein
.	O

Furthermore	O
,	O
in	I-protein
these	O
primary	O
cells	I-protein
,	O
induction	I-protein
of	I-protein
TNF	B-protein
transcripts	I-protein
,	O
as	O
determined	O
by	I-protein
Northern	O
blot	O
analysis	O
and	I-protein
by	I-protein
quantitative	I-protein
polymerase	O
chain	I-protein
reaction	I-protein
,	O
was	O
prevented	O
by	I-protein
PDTC	O
as	O
was	O
TNF	B-protein
protein	I-protein
production	I-protein
.	O

These	O
data	O
show	O
that	O
dithiocarbamates	O
can	O
profoundly	O
affect	O
cytokine	O
expression	I-protein
and	I-protein
suggest	O
that	O
NF-kappa	B-protein
B	I-protein
is	O
involved	I-protein
in	I-protein
LPS-induced	O
TNF	O
gene	O
expression	I-protein
in	I-protein
human	O
monocytes	O
.	O

###MEDLINE:94047364

Comparing	O
regions	O
of	I-protein
the	I-protein
Epstein-Barr	B-protein
virus	I-protein
ZEBRA	I-protein
protein	I-protein
which	O
function	I-protein
as	O
transcriptional	O
activating	O
sequences	I-protein
in	I-protein
Saccharomyces	O
cerevisiae	I-protein
and	I-protein
in	I-protein
B	O
cells	I-protein
.	O

The	O
ZEBRA	B-protein
protein	I-protein
activates	O
expression	I-protein
of	I-protein
Epstein-Barr	B-protein
virus	I-protein
early-lytic-cycle	O
genes	I-protein
in	I-protein
human	O
B	O
lymphocytes	O
.	O

Here	O
it	O
is	O
shown	O
that	O
ZEBRA	B-protein
also	O
behaves	O
as	O
a	I-protein
sequence-specific	B-protein
transcriptional	I-protein
activator	I-protein
in	I-protein
Saccharomyces	O
cerevisiae	I-protein
.	O

Deletional	O
mutagenesis	O
defined	I-protein
three	O
regions	O
of	I-protein
ZEBRA	B-protein
that	O
participate	O
in	I-protein
activation	I-protein
in	I-protein
S.	I-protein
cerevisiae	I-protein
.	O

These	O
regions	O
are	O
designated	O
YI	O
(	O
amino	O
acids	I-protein
[	O
aa	O
]	O
1	I-protein
to	I-protein
25	I-protein
)	O
,	O
YII	O
(	O
aa	B-protein
51	I-protein
to	I-protein
102	I-protein
)	O
,	O
and	I-protein
YIII	B-protein
(	O
aa	B-protein
228	I-protein
to	I-protein
245	I-protein
)	O
.	O

Two	O
of	I-protein
the	I-protein
three	O
regions	O
of	I-protein
the	I-protein
native	O
ZEBRA	B-protein
protein	I-protein
act	O
together	O
to	I-protein
mediate	O
activation	I-protein
when	O
assayed	O
on	I-protein
ZEBRA	B-protein
binding	I-protein
sites	I-protein
.	O

However	O
,	O
when	O
fused	O
to	I-protein
the	I-protein
DNA	B-protein
binding	I-protein
domain	I-protein
of	I-protein
GAL	B-protein
4	I-protein
and	I-protein
assayed	O
on	I-protein
GAL4	B-protein
binding	I-protein
sites	I-protein
,	O
regions	B-protein
YII	I-protein
and	I-protein
YIII	I-protein
were	O
each	O
sufficient	O
to	I-protein
confer	O
activation	I-protein
in	I-protein
S.	I-protein
cerevisiae	I-protein
.	O

Regions	O
of	I-protein
ZEBRA	B-protein
which	O
affected	O
activation	I-protein
in	I-protein
S.	I-protein
cerevisiae	I-protein
were	O
also	O
required	O
in	I-protein
human	O
B	O
lymphocytes	O
.	O

The	O
amino-terminal	B-protein
region	I-protein
of	I-protein
ZEBRA	B-protein
(	O
aa	B-protein
1	I-protein
to	I-protein
98	I-protein
)	O
was	O
required	O
for	I-protein
activation	I-protein
both	O
in	I-protein
S.	I-protein
cerevisiae	I-protein
and	I-protein
in	I-protein
human	O
B	O
cells	I-protein
;	O
deletion	I-protein
of	I-protein
the	I-protein
carboxy-terminal	I-protein
18	I-protein
aa	I-protein
also	O
significantly	O
reduced	O
activation	I-protein
in	I-protein
both	O
cell	O
types	I-protein
.	O

Thus	O
,	O
the	I-protein
behavior	B-protein
of	I-protein
ZEBRA	B-protein
in	I-protein
human	O
B	O
cells	I-protein
and	I-protein
S.	I-protein
cerevisiae	I-protein
suggests	O
that	O
the	I-protein
protein	O
contains	I-protein
universal	O
activation	I-protein
motifs	I-protein
that	O
interact	O
with	I-protein
conserved	O
components	O
of	I-protein
the	I-protein
transcription	O
machinery	I-protein
.	O

However	O
,	O
certain	O
deletion	I-protein
mutants	O
of	I-protein
ZEBRA	B-protein
containing	I-protein
mutations	I-protein
in	I-protein
the	I-protein
N-terminal	B-protein
region	I-protein
exhibited	O
discordant	O
behaviors	O
in	I-protein
S.	I-protein
cerevisiae	I-protein
and	I-protein
in	I-protein
B	O
cells	I-protein
.	O

For	O
example	O
,	O
deletion	I-protein
of	I-protein
ZEBRA	B-protein
aa	I-protein
26	I-protein
to	I-protein
51	I-protein
impaired	O
activation	I-protein
to	I-protein
a	I-protein
great	O
extent	O
in	I-protein
B	O
cells	I-protein
but	O
had	O
little	O
or	I-protein
no	I-protein
effect	O
in	I-protein
S.	I-protein
cerevisiae	I-protein
.	O

The	O
discordant	O
mutants	O
may	O
reflect	O
interactions	O
with	I-protein
a	I-protein
variable	B-protein
domain	I-protein
of	I-protein
a	I-protein
conserved	O
component	O
or	I-protein
unique	I-protein
interactions	O
with	I-protein
specialized	O
components	O
of	I-protein
the	I-protein
basal	O
transcription	O
apparatus	I-protein
in	I-protein
different	O
cells	I-protein
.	O

###MEDLINE:94019346

Functional	O
interaction	I-protein
of	I-protein
the	I-protein
v-Rel	B-protein
and	I-protein
c-Rel	I-protein
oncoproteins	I-protein
with	I-protein
the	I-protein
TATA-binding	B-protein
protein	I-protein
and	I-protein
association	I-protein
with	I-protein
transcription	B-protein
factor	I-protein
IIB	I-protein
.	O

Rel	B-protein
family	I-protein
proteins	I-protein
regulate	O
the	I-protein
expression	I-protein
of	I-protein
genes	I-protein
linked	I-protein
to	I-protein
kappa	I-protein
B-binding	O
motifs	I-protein
.	O

Little	O
is	O
known	O
,	O
however	O
,	O
of	I-protein
the	I-protein
mechanism	O
by	I-protein
which	O
they	O
enhance	O
transcription	O
.	O

We	O
have	O
investigated	O
the	I-protein
ability	O
of	I-protein
the	I-protein
v-Rel	B-protein
and	I-protein
c-Rel	I-protein
oncoproteins	I-protein
to	I-protein
interact	O
with	I-protein
components	O
of	I-protein
the	I-protein
basal	O
transcription	O
machinery	I-protein
.	O

Here	O
we	O
report	O
that	O
both	O
the	I-protein
acidic	O
transcription	O
activation	I-protein
domain	I-protein
mapping	O
to	I-protein
the	I-protein
unique	I-protein
C	O
terminus	I-protein
of	I-protein
chicken	I-protein
c-Rel	I-protein
and	I-protein
the	I-protein
F9	B-protein
cell-specific	I-protein
activation	I-protein
region	I-protein
common	I-protein
to	I-protein
both	O
v-Rel	O
and	I-protein
c-Rel	B-protein
interact	O
with	I-protein
the	I-protein
TATA-binding	B-protein
protein	I-protein
(	O
TBP	B-protein
)	O
and	I-protein
transcription	B-protein
factor	I-protein
IIB	I-protein
(	O
TFIIB	B-protein
)	O
in	I-protein
vitro	O
and	I-protein
in	I-protein
vivo	O
.	O

We	O
also	O
demonstrate	O
that	O
TPB	B-protein
interaction	I-protein
with	I-protein
Rel	O
activation	I-protein
regions	O
leads	O
to	I-protein
synergistic	O
activation	I-protein
of	I-protein
transcription	O
of	I-protein
a	I-protein
kappa	I-protein
B-linked	O
reporter	O
gene	O
.	O

Combined	O
with	I-protein
the	I-protein
observation	O
that	O
the	I-protein
mouse	I-protein
c-Rel	I-protein
and	I-protein
human	I-protein
RelA	I-protein
proteins	I-protein
also	O
interact	O
with	I-protein
TBP	B-protein
and	I-protein
TFIIB	B-protein
in	I-protein
vitro	O
,	O
these	O
results	O
suggest	O
that	O
association	I-protein
with	I-protein
basal	B-protein
transcription	I-protein
factors	I-protein
is	O
important	O
for	I-protein
the	I-protein
transcriptional	O
activities	O
of	I-protein
Rel	B-protein
family	I-protein
proteins	I-protein
.	O

###MEDLINE:94045438

p21ras	B-protein
and	I-protein
calcineurin	O
synergize	O
to	I-protein
regulate	O
the	I-protein
nuclear	B-protein
factor	I-protein
of	I-protein
activated	O
T	O
cells	I-protein
.	O

In	O
T	O
lymphocytes	O
,	O
triggering	O
of	I-protein
the	I-protein
T	B-protein
cell	I-protein
receptor	I-protein
(	O
TCR	B-protein
)	O
induces	O
several	I-protein
signaling	O
cascades	O
which	O
ultimately	O
synergize	O
to	I-protein
induce	O
the	I-protein
activity	I-protein
of	I-protein
the	I-protein
nuclear	B-protein
factor	I-protein
of	I-protein
activated	O
T	O
cells	I-protein
(	O
NFAT	B-protein
)	O
,	O
a	I-protein
DNA	B-protein
binding	I-protein
complex	I-protein
critical	I-protein
to	I-protein
the	I-protein
inducibility	O
and	I-protein
T	O
cell	O
specificity	I-protein
of	I-protein
the	I-protein
T	B-protein
cell	I-protein
growth	I-protein
factor	I-protein
interleukin	B-protein
2	I-protein
.	O

One	I-protein
immediate	B-protein
consequence	O
of	I-protein
T	O
cell	O
activation	I-protein
via	I-protein
the	I-protein
TCR	B-protein
is	O
an	I-protein
increase	O
in	I-protein
cytosolic	O
calcium	O
.	O

Calcium	I-protein
signals	I-protein
are	O
important	O
for	I-protein
NFAT	O
induction	I-protein
,	O
and	I-protein
recent	O
studies	O
have	O
identified	I-protein
calcineurin	B-protein
,	O
a	I-protein
calcium-calmodulin	B-protein
dependent	I-protein
serine-threonine	I-protein
phosphatase	I-protein
,	O
as	O
a	I-protein
prominent	O
component	O
of	I-protein
the	I-protein
calcium	O
signaling	O
pathway	I-protein
in	I-protein
T	O
cells	I-protein
.	O

A	O
second	O
important	O
molecule	I-protein
in	I-protein
TCR	O
signal	O
transduction	I-protein
is	O
the	I-protein
guanine	B-protein
nucleotide	I-protein
binding	I-protein
protein	I-protein
,	O
p21ras	B-protein
,	O
which	O
is	O
coupled	I-protein
to	I-protein
the	I-protein
TCR	B-protein
by	I-protein
a	I-protein
protein	B-protein
tyrosine	I-protein
kinase	I-protein
dependent	I-protein
mechanism	O
.	O

The	O
experiments	O
presented	O
here	O
show	O
that	O
expression	I-protein
by	I-protein
transfection	O
of	I-protein
mutationally	O
activated	O
calcineurin	B-protein
or	I-protein
activated	O
p21ras	B-protein
alone	O
is	O
insufficient	O
for	I-protein
NFAT	O
transactivation	O
.	O

However	O
,	O
coexpression	O
of	I-protein
the	I-protein
activated	O
calcineurin	B-protein
with	I-protein
activated	O
p21ras	B-protein
could	O
mimic	O
TCR	O
signals	I-protein
in	I-protein
NFAT	O
induction	I-protein
.	O

These	O
data	O
identify	O
calcineurin	B-protein
and	I-protein
p21ras	B-protein
as	O
cooperative	O
partners	O
in	I-protein
T	O
cell	O
activation	I-protein
.	O

###MEDLINE:94116450

Expression	O
of	I-protein
the	I-protein
chicken	I-protein
GATA	B-protein
factor	I-protein
family	I-protein
during	I-protein
early	O
erythroid	O
development	O
and	I-protein
differentiation	I-protein
.	O

The	O
DNA	O
motif	I-protein
WGATAR	O
has	O
been	O
identified	I-protein
within	B-protein
transcriptional	O
regulatory	O
domains	I-protein
of	I-protein
globin	I-protein
and	I-protein
other	O
erythroid-specific	O
genes	I-protein
and	I-protein
the	I-protein
activator	B-protein
proteins	I-protein
that	O
bind	O
to	I-protein
this	O
regulatory	O
element	I-protein
,	O
the	I-protein
GATA	B-protein
factors	I-protein
,	O
belong	O
to	I-protein
a	I-protein
multi-gene	B-protein
family	I-protein
that	O
is	O
expressed	O
in	I-protein
chicken	I-protein
erythroid	O
cells	I-protein
.	O

Here	O
we	O
show	O
that	O
,	O
as	O
in	I-protein
chickens	O
,	O
multiple	O
members	O
of	I-protein
the	I-protein
GATA	B-protein
factor	I-protein
family	I-protein
are	O
expressed	O
in	I-protein
human	O
and	I-protein
murine	O
erythroid	O
cells	I-protein
.	O

During	O
the	I-protein
early	O
stages	O
of	I-protein
chicken	I-protein
embryogenesis	O
(	O
well	O
before	O
blood	O
island	I-protein
formation	O
)	O
,	O
each	O
of	I-protein
the	I-protein
GATA	B-protein
family	I-protein
members	I-protein
is	O
transcribed	I-protein
with	I-protein
a	I-protein
unique	I-protein
temporal	I-protein
and	I-protein
spatial	B-protein
pattern	I-protein
.	O

In	O
the	I-protein
primitive	O
erythroid	O
lineage	I-protein
,	O
transcription	O
of	I-protein
the	I-protein
embryonic	O
epsilon-globin	O
gene	O
parallels	O
GATA-1	O
expression	I-protein
while	O
the	I-protein
switch	I-protein
to	I-protein
beta-globin	O
transcription	O
in	I-protein
definitive	O
erythroid	O
cells	I-protein
is	O
directly	O
preceded	O
by	I-protein
a	I-protein
pronounced	O
increase	O
in	I-protein
GATA-3	O
accumulation	I-protein
.	O

The	O
timing	O
and	I-protein
pattern	I-protein
of	I-protein
expression	I-protein
of	I-protein
these	O
different	O
mRNAs	O
during	I-protein
avian	I-protein
erythroid	O
development	O
and	I-protein
differentiation	I-protein
suggests	O
that	O
temporally	O
regulated	O
changes	O
in	I-protein
GATA	B-protein
factor	I-protein
expression	I-protein
are	O
required	O
for	I-protein
vertebrate	O
hematopoiesis	I-protein
.	O

###MEDLINE:93361521

Molecular	O
regulation	I-protein
of	I-protein
human	B-protein
interleukin	I-protein
2	I-protein
and	I-protein
T-cell	O
function	I-protein
by	I-protein
interleukin	B-protein
4	I-protein
.	O

Distinct	O
functional	O
T-cell	O
subsets	O
,	O
differing	O
in	I-protein
the	I-protein
patterns	O
of	I-protein
lymphokines	B-protein
produced	O
,	O
regulate	O
cell-mediated	O
and	I-protein
humoral	O
immune	O
responses	O
.	O

The	O
two	O
major	O
types	I-protein
and	I-protein
their	O
principal	O
products	O
,	O
interleukin	B-protein
4	I-protein
and	I-protein
interferon	B-protein
gamma	I-protein
(	O
IL-4	B-protein
and	I-protein
IFN-gamma	B-protein
)	O
,	O
are	O
reciprocally	O
negatively	O
interactive	I-protein
.	O

To	O
analyze	O
the	I-protein
molecular	I-protein
mechanism	O
of	I-protein
IL-4-mediated	O
suppression	O
of	I-protein
cell-mediated	O
immunity	O
we	O
studied	O
its	O
effects	O
on	I-protein
expression	I-protein
of	I-protein
interleukin	B-protein
2	I-protein
(	O
IL-2	B-protein
)	O
and	I-protein
IFN-gamma	B-protein
.	O

IL-4	B-protein
pretreatment	O
of	I-protein
Jurkat	O
cells	I-protein
prior	O
to	I-protein
stimulation	I-protein
resulted	O
in	I-protein
a	I-protein
decrease	O
in	I-protein
transcription	O
of	I-protein
the	I-protein
IL2	B-protein
gene	O
.	O

IL-4	B-protein
suppressed	I-protein
IL-2	B-protein
and	I-protein
IFN-gamma	O
mRNA	O
levels	I-protein
in	I-protein
primary	O
human	O
T	O
cells	I-protein
,	O
and	I-protein
addition	O
of	I-protein
anti-CD28	B-protein
antibodies	I-protein
relieved	O
this	O
suppression	O
.	O

Using	O
enhancer-reporter	O
constructs	O
,	O
IL-4	B-protein
specifically	O
down-regulated	I-protein
the	I-protein
NFIL-2B	O
element	I-protein
.	O

Electrophoretic	O
mobility	I-protein
shift	O
assays	O
using	O
a	I-protein
DNA	O
oligomer	O
containing	I-protein
the	I-protein
NFIL-2B	O
binding	I-protein
site	I-protein
indicated	O
that	O
IL-4	B-protein
inhibited	O
the	I-protein
NFIL-2B	B-protein
complex	I-protein
and	I-protein
that	O
the	I-protein
NFIL-2B	B-protein
DNA	I-protein
binding	I-protein
factor	I-protein
is	O
distinct	O
from	I-protein
AP-	O
1	I-protein
.	O

These	O
results	O
suggest	O
that	O
IL-4	B-protein
may	O
regulate	O
development	O
and	I-protein
function	I-protein
of	I-protein
T-cell	O
subsets	O
involved	I-protein
in	I-protein
cell-mediated	O
immunity	O
in	I-protein
part	I-protein
by	I-protein
inhibiting	I-protein
factors	I-protein
required	O
for	I-protein
transcription	O
of	I-protein
the	I-protein
IL2	B-protein
gene	O

###MEDLINE:81088140

Immunochemical	O
differences	O
between	O
glucocorticoid	B-protein
receptors	I-protein
from	I-protein
corticoid-sensitive	O
and	I-protein
-resistant	O
malignant	O
lymphocytes	O
.	O

We	O
have	O
explored	O
the	I-protein
possibility	O
of	I-protein
using	O
antibodies	I-protein
against	I-protein
purified	O
rat	I-protein
liver	O
glucocorticoid	B-protein
receptors	I-protein
to	I-protein
study	O
the	I-protein
immunochemical	O
properties	O
of	I-protein
glucocorticoid	B-protein
receptors	I-protein
from	I-protein
murine	O
and	I-protein
human	O
malignant	O
lymphocytes	O
.	O

For	O
this	O
purpose	O
,	O
purified	B-protein
immune	I-protein
immunoglobulin	I-protein
G	I-protein
was	O
covalently	I-protein
linked	I-protein
to	I-protein
Sepharose	B-protein
CL-4B	I-protein
.	O

We	O
then	O
examined	O
the	I-protein
ability	O
of	I-protein
the	I-protein
affinity	I-protein
gel	O
to	I-protein
recognize	O
cytosolic	B-protein
[	O
3H	I-protein
]	O
triamcinolone	I-protein
acetonide-receptor	I-protein
complexes	I-protein
from	I-protein
the	I-protein
corticoid-sensitive	O
(	O
CS	O
)	O
and	I-protein
-resistant	O
strains	O
of	I-protein
mouse	I-protein
lymphoma	I-protein
P1798	O
,	O
from	I-protein
CS	O
lymphocytes	O
of	I-protein
patients	O
with	I-protein
chronic	O
lymphatic	B-protein
leukemia	O
,	O
and	I-protein
from	I-protein
a	I-protein
CS	O
clone	I-protein
of	I-protein
human	O
leukemic	O
lymphoblasts	O
in	I-protein
tissue	O
culture	O
(	O
CH6	O
)	O
.	O

Mouse	B-protein
thymus	I-protein
was	O
used	O
as	O
a	I-protein
source	O
of	I-protein
glucocorticoid	B-protein
receptor	I-protein
from	I-protein
normal	O
CS	O
lymphocytes	O
.	O

Whereas	O
the	I-protein
immunoaffinity	O
column	O
retained	O
70	I-protein
to	I-protein
84	I-protein
%	O
of	I-protein
the	I-protein
58-	O
to	I-protein
62-A	O
(	O
Stokes	O
radius	I-protein
)	O
[	O
3H	I-protein
]	O
triamcinolone	O
acetonide-receptor	O
complexes	O
characteristic	O
of	I-protein
the	I-protein
CS	O
mouse	I-protein
and	I-protein
human	O
lymphocytes	O
,	O
it	O
failed	O
to	I-protein
recognize	O
the	I-protein
27-	O
to	I-protein
28-A	O
(	O
Stokes	O
radius	I-protein
)	O
glucocorticoid	B-protein
receptor	I-protein
present	O
in	I-protein
corticoid-resistant	O
mouse	I-protein
lymphoma	I-protein
P1798	O
cells	I-protein
.	O

Therefore	O
,	O
under	O
appropriate	O
experimental	O
conditions	O
,	O
it	O
was	O
possible	O
to	I-protein
demonstrate	O
cross-reactivity	O
between	O
the	I-protein
antiserum	O
against	I-protein
rat	I-protein
liver	I-protein
glucocorticoid	I-protein
receptor	I-protein
and	I-protein
the	I-protein
58-	O
to	I-protein
62-A	O
(	O
Stokes	O
radius	I-protein
)	O
glucocorticoid	B-protein
receptor	I-protein
from	I-protein
species	O
as	O
diverse	O
as	O
mouse	I-protein
and	I-protein
humans	O
.	O

###MEDLINE:80222614

Heterogeneity	O
of	I-protein
the	I-protein
in	I-protein
vitro	O
responses	O
to	I-protein
glucocorticoids	O
in	I-protein
acute	O
leukemia	O
.	O

In	O
leukocyte	O
population	O
freshly	O
isolated	I-protein
from	I-protein
the	I-protein
blood	O
of	I-protein
26	O
patients	O
with	I-protein
acute	O
leukemia	O
,	O
we	O
have	O
measured	O
several	I-protein
parameters	O
including	I-protein
glucocorticoid	B-protein
receptors	I-protein
,	O
nucleoside	O
incorporation	O
,	O
percentage	O
of	I-protein
cells	I-protein
in	I-protein
S	I-protein
phase	I-protein
,	O
and	I-protein
steroid-induced	O
cell	O
lysis	O
.	O

In	O
addition	O
,	O
in	I-protein
some	O
cases	O
,	O
the	I-protein
short-term	O
response	I-protein
to	I-protein
steroid	O
therapy	O
was	O
determined	O
.	O

Although	O
,	O
in	I-protein
all	O
the	I-protein
patients	O
studied	O
,	O
leukocytes	O
were	O
found	O
to	I-protein
contain	O
glucocorticoid	B-protein
receptors	I-protein
,	O
we	O
failed	O
to	I-protein
demonstrate	O
any	O
correlation	O
between	O
the	I-protein
level	I-protein
of	I-protein
binding	I-protein
sites	I-protein
and	I-protein
the	I-protein
in	I-protein
vitro	O
or	I-protein
in	I-protein
vivo	O
response	I-protein
to	I-protein
glucocorticoids	O
.	O

This	O
absence	I-protein
of	I-protein
correlation	O
could	O
be	O
in	I-protein
part	I-protein
explained	O
by	I-protein
the	I-protein
marked	O
heterogeneity	O
of	I-protein
the	I-protein
steroid	O
response	I-protein
demonstrated	O
in	I-protein
leukocyte	O
subpopulations	O
.	O

It	O
appears	O
,	O
however	O
,	O
that	O
the	I-protein
degree	O
of	I-protein
steroid	O
action	O
in	I-protein
vitro	O
as	O
well	O
as	O
the	I-protein
extent	O
of	I-protein
spontaneous	O
and	I-protein
dexamethasone-induced	O
cell	O
death	O
may	O
be	O
related	O
to	I-protein
the	I-protein
number	I-protein
of	I-protein
cells	I-protein
in	I-protein
the	I-protein
S	I-protein
phase	I-protein
of	I-protein
the	I-protein
cell	O
cycle	I-protein
.	O

###MEDLINE:80068767

Glucocorticoid	B-protein
receptors	I-protein
in	I-protein
cytosol	I-protein
and	I-protein
nuclear	O
extract	O
of	I-protein
human	O
leukocytes	O
.	O

Cortisol	O
binding	I-protein
by	I-protein
cytosol	I-protein
and	I-protein
0.4	O
M	I-protein
KCl	O
extract	O
of	I-protein
the	I-protein
nuclear	O
fraction	O
of	I-protein
human	O
leukocytes	O
were	O
studied	O
by	I-protein
gel	O
chromatography	O
and	I-protein
ion	I-protein
exchange	I-protein
filtration	O
on	I-protein
DEAE	O
cellulose	O
.	O

The	O
cytoplasmic	B-protein
cortisol	I-protein
binding	I-protein
protein	I-protein
has	O
a	I-protein
molecular	I-protein
weight	I-protein
95	I-protein
000	O
and	I-protein
the	I-protein
soluble	I-protein
nuclear	B-protein
binding	I-protein
protein	I-protein
50	I-protein
000	O
.	O

The	O
absence	I-protein
of	I-protein
the	I-protein
uptake	I-protein
of	I-protein
radioactive	O
cortisol	O
by	I-protein
isolated	I-protein
nuclei	O
and	I-protein
the	I-protein
apparent	O
requirement	O
of	I-protein
the	I-protein
cytosol	I-protein
for	I-protein
glucocorticoid	O
specific	I-protein
binding	I-protein
in	I-protein
nuclear	O
receptor	O
sites	I-protein
was	O
observed	O
.	O

The	O
association	I-protein
constant	I-protein
characterising	O
the	I-protein
binding	I-protein
of	I-protein
cortisol	O
to	I-protein
cytosol	I-protein
was	O
KA	O
=	O
3.5	O
.	O
10	I-protein
(	O
9	I-protein
)	O
l/mol	O
.	O

###MEDLINE:78142957

Corticosteroid-induced	O
lymphopenia	O
,	O
immunosuppression	O
,	O
and	I-protein
body	O
defense	O
.	O

The	O
apparent	O
paradox	O
of	I-protein
heightened	O
adrenal	I-protein
corticosteroid	O
levels	I-protein
associated	I-protein
with	I-protein
reduction	I-protein
in	I-protein
the	I-protein
competence	O
of	I-protein
the	I-protein
body	O
's	I-protein
defensive	O
apparatus	I-protein
to	I-protein
cope	O
with	I-protein
exposure	O
to	I-protein
new	I-protein
microbial	B-protein
antigens	I-protein
is	O
considered	O
.	O

The	O
question	O
is	O
asked	O
how	O
this	O
lowered	O
defensive	O
capability	O
,	O
which	O
occurs	O
in	I-protein
the	I-protein
face	O
of	I-protein
a	I-protein
threat	O
to	I-protein
body	O
integrity	O
,	O
is	O
consistent	O
with	I-protein
Cannon	O
's	I-protein
principals	O
of	I-protein
the	I-protein
``	O
wisdom	O
of	I-protein
the	I-protein
body.	O
''	I-protein

The	O
suggestion	O
is	O
offered	O
that	O
the	I-protein
immunologic	O
response	I-protein
to	I-protein
self-antigens	B-protein
exposed	O
by	I-protein
disease	I-protein
or	I-protein
trauma	O
may	O
be	O
suppressed	I-protein
by	I-protein
corticosteroid	O
to	I-protein
offset	O
the	I-protein
likelihood	O
of	I-protein
autoimmune	B-protein
attack	O
.	O

###MEDLINE:94081319

Protein	I-protein
tyrosine	I-protein
kinase	I-protein
activation	I-protein
is	O
required	O
for	I-protein
lipopolysaccharide	B-protein
induction	I-protein
of	I-protein
cytokines	B-protein
in	I-protein
human	O
blood	O
monocytes	O
.	O

Bacterial	O
LPS	B-protein
induce	O
production	I-protein
of	I-protein
cytokines	B-protein
such	O
as	O
IL-1	B-protein
,	O
IL-6	B-protein
,	O
and	I-protein
TNF	B-protein
in	I-protein
mononuclear	O
phagocytes	O
,	O
and	I-protein
this	O
represents	O
a	I-protein
central	O
component	O
in	I-protein
the	I-protein
pathogenesis	O
of	I-protein
septic	O
shock	I-protein
syndrome	I-protein
.	O

However	O
,	O
the	I-protein
mechanisms	O
by	I-protein
which	O
LPS	B-protein
activates	O
these	O
cells	I-protein
to	I-protein
express	O
cytokines	B-protein
are	O
not	I-protein
completely	O
characterized	O
.	O

The	O
present	O
study	O
addressed	O
the	I-protein
role	O
of	I-protein
different	O
protein	B-protein
kinases	I-protein
in	I-protein
the	I-protein
LPS	B-protein
induction	I-protein
of	I-protein
cytokines	B-protein
.	O

It	O
is	O
shown	O
that	O
LPS	B-protein
induced	I-protein
a	I-protein
12-	O
to	I-protein
16-fold	O
increase	O
in	I-protein
IL-1	O
beta	O
,	O
IL-6	B-protein
,	O
and	I-protein
TNF-alpha	B-protein
mRNA	O
levels	I-protein
,	O
and	I-protein
this	O
was	O
completely	O
or	I-protein
more	O
than	I-protein
80	I-protein
%	O
blocked	B-protein
by	I-protein
the	I-protein
protein	O
tyrosine	O
kinase	O
specific	I-protein
inhibitors	I-protein
herbimycin	O
A	O
and	I-protein
genistein	O
at	I-protein
the	I-protein
concentrations	O
of	I-protein
1.7	O
and	I-protein
37	I-protein
microM	O
,	O
respectively	O
.	O

Protein	I-protein
kinase	I-protein
C	I-protein
inhibition	O
by	I-protein
staurosporine	O
reduced	O
LPS	B-protein
induction	I-protein
of	I-protein
TNF-alpha	B-protein
,	O
whereas	O
it	O
had	O
no	I-protein
effects	O
on	I-protein
IL-6	B-protein
and	I-protein
IL-1	B-protein
beta	I-protein
.	O

Inhibition	O
of	I-protein
protein	B-protein
kinase	I-protein
A	I-protein
by	I-protein
H89	O
reduced	O
IL-6	B-protein
mRNA	O
levels	I-protein
but	O
did	O
not	I-protein
detectably	O
change	O
IL-1	O
beta	O
or	I-protein
TNF-alpha	B-protein
mRNA	O
levels	I-protein
.	O

In	O
contrast	O
,	O
LPS	B-protein
did	O
not	I-protein
increase	O
leukemia	O
inhibitory	O
factor	I-protein
mRNA	O
,	O
which	O
was	O
constitutively	O
expressed	O
and	I-protein
not	I-protein
significantly	O
reduced	O
by	I-protein
these	O
inhibitors	I-protein
.	O

In	O
addition	O
to	I-protein
cytokine	O
mRNA	O
levels	I-protein
,	O
LPS-induced	O
IL-6	B-protein
protein	O
synthesis	I-protein
and	I-protein
IL-6	B-protein
bioactivity	O
were	O
also	O
reduced	O
to	I-protein
baseline	O
levels	I-protein
by	I-protein
the	I-protein
PTK	B-protein
inhibitors	I-protein
herbimycin	O
A	O
and	I-protein
genistein	O
.	O

Both	O
PTK	B-protein
inhibitors	I-protein
also	O
reduced	O
the	I-protein
LPS	B-protein
activation	I-protein
of	I-protein
nuclear	B-protein
factor-kappa	I-protein
B	I-protein
(	O
NF-kappa	B-protein
B	I-protein
)	O
,	O
which	O
is	O
a	I-protein
transcription	B-protein
factor	I-protein
involved	I-protein
in	I-protein
the	I-protein
expression	I-protein
of	I-protein
cytokine	O
genes	I-protein
such	O
as	O
IL-6	B-protein
and	I-protein
TNF-alpha	B-protein
.	O

The	O
activation	I-protein
of	I-protein
NF-kappa	B-protein
B	I-protein
was	O
also	O
reduced	O
by	I-protein
H89	O
,	O
whereas	O
staurosporine	O
had	O
no	I-protein
effect	O
on	I-protein
this	O
response	I-protein
.	O

In	O
summary	O
,	O
these	O
findings	O
suggest	O
that	O
protein	B-protein
kinase	I-protein
C	I-protein
and	I-protein
protein	B-protein
kinase	I-protein
A	I-protein
appear	O
to	I-protein
have	O
selective	O
effects	O
in	I-protein
the	I-protein
LPS	B-protein
induction	I-protein
of	I-protein
cytokines	B-protein
,	O
whereas	O
PTK	B-protein
is	O
required	O
for	I-protein
LPS	B-protein
induction	I-protein
of	I-protein
a	I-protein
broad	O
spectrum	O
of	I-protein
cytokines	B-protein
and	I-protein
NF-kappa	B-protein
B	I-protein
activation	I-protein
in	I-protein
monocytes	O
.	O

###MEDLINE:94038952

In	O
vivo	O
control	I-protein
of	I-protein
NF-kappa	B-protein
B	I-protein
activation	I-protein
by	I-protein
I	I-protein
kappa	I-protein
B	I-protein
alpha	I-protein
.	O

The	O
transcription	B-protein
factor	I-protein
NF-kappa	I-protein
B	I-protein
is	O
stored	O
in	I-protein
the	I-protein
cytoplasm	O
in	I-protein
complexes	O
with	I-protein
the	I-protein
inhibitor	B-protein
protein	I-protein
I	I-protein
kappa	I-protein
B	I-protein
alpha	I-protein
.	O

It	O
has	O
been	O
shown	O
in	I-protein
vitro	O
that	O
dissociation	I-protein
of	I-protein
I	I-protein
kappa	I-protein
B	I-protein
alpha	I-protein
from	I-protein
these	O
complexes	O
results	O
in	I-protein
active	O
NF-kappa	B-protein
B	I-protein
.	O

In	O
this	O
report	O
we	O
show	O
that	O
lipopolysaccharide	B-protein
(	O
LPS	B-protein
)	O
-induced	O
activation	I-protein
of	I-protein
B	O
or	I-protein
pre-B	B-protein
cells	I-protein
results	O
in	I-protein
loss	O
of	I-protein
I	I-protein
kappa	I-protein
B	I-protein
alpha	I-protein
from	I-protein
NF-kappa	B-protein
B	I-protein
complexes	I-protein
in	I-protein
vivo	O
.	O

Many	O
liberated	O
NF-kappa	B-protein
B	I-protein
dimers	I-protein
reached	O
the	I-protein
nucleus	I-protein
,	O
where	O
increased	I-protein
c-rel	B-protein
,	O
p65	B-protein
and	I-protein
p50	I-protein
were	O
detected	O
by	I-protein
immunoblotting	O
and	I-protein
by	I-protein
DNA	O
binding	I-protein
assays	O
.	O

Some	O
liberated	B-protein
dimers	I-protein
were	O
retained	O
in	I-protein
the	I-protein
cytoplasm	O
,	O
however	O
,	O
through	I-protein
binding	I-protein
to	I-protein
newly	O
synthesized	O
I	I-protein
kappa	I-protein
B	I-protein
alpha	I-protein
,	O
a	I-protein
finding	O
which	O
strongly	O
suggests	O
(	O
i	I-protein
)	O
that	O
the	I-protein
LPS-induced	O
signal	O
causes	O
dissociation	I-protein
of	I-protein
complexes	O
rather	O
than	I-protein
preventing	O
their	O
association	I-protein
and	I-protein
(	O
ii	O
)	O
that	O
dissociation	I-protein
results	O
from	I-protein
modification	I-protein
of	I-protein
I	I-protein
kappa	I-protein
B	I-protein
alpha	I-protein
and	I-protein
not	I-protein
of	I-protein
c-rel	B-protein
or	I-protein
p65	B-protein
.	O

No	I-protein
effect	O
of	I-protein
LPS	B-protein
treatment	O
was	O
detected	O
on	I-protein
p105	I-protein
or	I-protein
p100	B-protein
,	O
which	O
also	O
retain	O
rel	I-protein
family	I-protein
members	I-protein
in	I-protein
the	I-protein
cytoplasm	O
.	O

Quite	O
unexpectedly	O
,	O
we	O
also	O
found	O
that	O
in	I-protein
unstimulated	O
cells	I-protein
there	O
is	O
a	I-protein
constant	I-protein
ongoing	O
process	O
of	I-protein
degradation	I-protein
and	I-protein
replacement	I-protein
of	I-protein
complexed	B-protein
I	I-protein
kappa	I-protein
B	I-protein
alpha	I-protein
.	O

We	O
propose	O
that	O
this	O
turnover	I-protein
results	O
in	I-protein
the	I-protein
low	O
level	I-protein
of	I-protein
active	B-protein
NF-kappa	I-protein
B	I-protein
presumably	O
necessary	O
even	O
in	I-protein
the	I-protein
unstimulated	O
cell	O
,	O
and	I-protein
that	O
the	I-protein
high	O
rate	I-protein
of	I-protein
synthesis	I-protein
of	I-protein
I	I-protein
kappa	I-protein
B	I-protein
alpha	I-protein
provides	O
the	I-protein
ability	O
to	I-protein
turn	O
off	O
NF-kappa	B-protein
B	I-protein
activity	I-protein
rapidly	I-protein
as	O
soon	O
as	O
the	I-protein
activating	O
signal	O
ceases	O
.	O

###MEDLINE:94019342

Identification	O
of	I-protein
a	I-protein
killer	O
cell-specific	I-protein
regulatory	O
element	I-protein
of	I-protein
the	I-protein
mouse	I-protein
perforin	B-protein
gene	O
:	O
an	I-protein
Ets-binding	O
site-homologous	O
motif	I-protein
that	O
interacts	I-protein
with	I-protein
Ets-related	B-protein
proteins	I-protein
.	O

The	O
gene	O
encoding	I-protein
the	I-protein
cytolytic	B-protein
protein	I-protein
perforin	B-protein
is	O
selectively	O
expressed	O
by	I-protein
activated	O
killer	O
lymphocytes	O
.	O

To	O
understand	O
the	I-protein
mechanisms	O
underlying	O
the	I-protein
cell-type-specific	O
expression	I-protein
of	I-protein
this	O
gene	O
,	O
we	O
have	O
characterized	O
the	I-protein
regulatory	O
functions	O
and	I-protein
the	I-protein
DNA-protein	O
interactions	O
of	I-protein
the	I-protein
5'-flanking	O
region	O
of	I-protein
the	I-protein
mouse	I-protein
perforin	B-protein
gene	O
(	O
Pfp	O
)	O
.	O

A	O
region	O
extending	O
from	I-protein
residues	O
+62	O
through	I-protein
-141	O
,	O
which	O
possesses	O
the	I-protein
essential	O
promoter	I-protein
activity	I-protein
,	O
and	I-protein
regions	O
further	O
upstream	O
,	O
which	O
are	O
able	O
to	I-protein
either	O
enhance	O
or	I-protein
suppress	O
gene	O
expression	I-protein
,	O
were	O
identified	I-protein
.	O

The	O
region	O
between	O
residues	O
-411	O
and	I-protein
-566	O
was	O
chosen	O
for	I-protein
further	O
characterization	O
,	O
since	O
it	O
contains	I-protein
an	I-protein
enhancer-like	O
activity	I-protein
.	O

We	O
have	O
identified	I-protein
a	I-protein
32-mer	O
sequence	I-protein
(	O
residues	O
-491	O
to	I-protein
-522	O
)	O
which	O
appeared	O
to	I-protein
be	O
capable	O
of	I-protein
enhancing	I-protein
gene	O
expression	I-protein
in	I-protein
a	I-protein
killer	O
cell-specific	I-protein
manner	O
.	O

Within	O
this	O
segment	I-protein
,	O
a	I-protein
9-mer	O
motif	I-protein
(	O
5'-ACAGGAAGT-3	O
'	O
,	O
residues	O
-505	O
to	I-protein
-497	O
;	O
designated	O
NF-P	O
motif	I-protein
)	O
,	O
which	O
is	O
highly	O
homologous	I-protein
to	I-protein
the	I-protein
Ets	B-protein
proto-oncoprotein-binding	I-protein
site	I-protein
,	O
was	O
found	O
to	I-protein
interact	O
with	I-protein
two	O
proteins	I-protein
,	O
NF-P1	B-protein
and	I-protein
NF-P2	B-protein
.	O

NF-P2	B-protein
appears	O
to	I-protein
be	O
induced	I-protein
by	I-protein
reagents	O
known	O
to	I-protein
up-regulate	O
the	I-protein
perforin	B-protein
message	O
level	I-protein
and	I-protein
is	O
present	O
exclusively	O
in	I-protein
killer	O
cells	I-protein
.	O

Electrophoretic	O
mobility	I-protein
shift	O
assay	O
and	I-protein
UV	O
cross-linking	O
experiments	O
revealed	O
that	O
NF-P1	B-protein
and	I-protein
NF-P2	B-protein
may	O
possess	O
common	I-protein
DNA-binding	B-protein
subunits	I-protein
.	O

However	O
,	O
the	I-protein
larger	O
native	O
molecular	I-protein
mass	I-protein
of	I-protein
NF-P1	B-protein
suggests	O
that	O
NF-P1	B-protein
contains	I-protein
an	I-protein
additional	B-protein
non-DNA-binding	B-protein
subunit	I-protein
(	O
s	I-protein
)	O
.	O

In	O
view	O
of	I-protein
the	I-protein
homology	I-protein
between	O
the	I-protein
NF-P	O
motif	I-protein
and	I-protein
other	O
Ets	O
proto-oncoprotein-binding	O
sites	I-protein
,	O
it	O
is	O
postulated	O
that	O
NF-P1	B-protein
and	I-protein
NF-P2	B-protein
belong	O
to	I-protein
the	I-protein
Ets	B-protein
protein	I-protein
family	I-protein
.	O

Results	O
obtained	O
from	I-protein
the	I-protein
binding	I-protein
competition	O
assay	O
,	O
nevertheless	O
,	O
suggest	O
that	O
NF-P1	B-protein
and	I-protein
NF-P2	B-protein
are	O
related	O
to	I-protein
but	O
distinct	O
from	I-protein
Ets	B-protein
proteins	I-protein
,	O
e.g.	O
,	O
Ets-1	B-protein
,	O
Ets-2	B-protein
,	O
and	I-protein
NF-AT/Elf-1	B-protein
,	O
known	O
to	I-protein
be	O
expressed	O
in	I-protein
T	O
cells	I-protein
.	O

###MEDLINE:94128612

The	O
role	O
of	I-protein
NF-kappa	B-protein
B1	I-protein
(	O
p50/p105	O
)	O
gene	O
expression	I-protein
in	I-protein
activation	I-protein
of	I-protein
human	O
blood	O
T-lymphocytes	O
via	I-protein
CD2	B-protein
and	I-protein
CD28	B-protein
adhesion	I-protein
molecules	I-protein
.	O

Stimulation	O
of	I-protein
primary	O
human	O
T-lymphocytes	O
via	I-protein
CD2	B-protein
and	I-protein
CD28	B-protein
adhesion	I-protein
molecules	I-protein
induces	O
a	I-protein
long-lasting	O
proliferation	I-protein
(	O
>	O
3	O
weeks	O
)	O
.	O

This	O
potent	O
activation	I-protein
does	O
not	I-protein
require	O
accessory	I-protein
cells	I-protein
,	O
such	O
as	O
monocytes	O
,	O
but	O
depends	O
on	I-protein
persistent	I-protein
interleukin	B-protein
2	I-protein
(	O
IL-2	B-protein
)	O
secretion	O
and	I-protein
receptivity	O
,	O
which	O
is	O
associated	I-protein
with	I-protein
high	O
and	I-protein
prolonged	O
expression	I-protein
of	I-protein
the	I-protein
inducible	O
CD25/IL-2	O
receptor	O
alpha	O
(	O
IL-2R	B-protein
alpha	I-protein
)	O
chain	I-protein
gene	O
.	O

The	O
transcription	B-protein
factor	I-protein
NF-kappa	I-protein
B	I-protein
participates	O
in	I-protein
the	I-protein
regulation	I-protein
of	I-protein
both	O
IL-2	B-protein
and	I-protein
IL-2R	O
alpha	O
genes	I-protein
,	O
as	O
well	O
as	O
multiple	O
cellular	O
genes	I-protein
involved	I-protein
in	I-protein
T-cell	O
proliferation	I-protein
.	O

To	O
evaluate	O
the	I-protein
role	O
of	I-protein
NF-kappa	B-protein
B	I-protein
in	I-protein
human	O
peripheral	O
blood	O
T-lymphocytes	O
,	O
we	O
previously	O
analyzed	O
the	I-protein
activation	I-protein
of	I-protein
NF-kappa	B-protein
B-related	I-protein
complexes	I-protein
in	I-protein
response	I-protein
to	I-protein
CD2+CD28	O
costimulation	O
.	O

We	O
demonstrated	O
a	I-protein
long-term	O
induction	I-protein
of	I-protein
p50/p65	B-protein
heterodimer	I-protein
,	O
a	I-protein
putative	B-protein
p65/c-Rel	I-protein
heterodimer	I-protein
,	O
and	I-protein
a	I-protein
constitutive	I-protein
nuclear	O
expression	I-protein
of	I-protein
KBF1/p50	B-protein
homodimers	I-protein
.	O

As	O
the	I-protein
role	O
of	I-protein
p50	B-protein
remains	O
unclear	O
,	O
we	O
focused	O
our	O
present	O
study	O
on	I-protein
NF-kappa	B-protein
B1	I-protein
(	O
p50/p105	O
)	O
gene	O
regulation	I-protein
.	O

Using	O
electrophoretic	O
mobility	I-protein
shift	O
assays	O
and	I-protein
Western	O
and	I-protein
Northern	O
blot	O
analyses	O
,	O
we	O
studied	O
NF-kappa	O
B1	O
gene	O
expression	I-protein
during	I-protein
T-cell	O
stimulation	I-protein
via	I-protein
CD2+CD28	B-protein
.	O

We	O
observed	O
a	I-protein
transient	O
4-	O
to	I-protein
5-fold	O
increase	O
of	I-protein
NF-kappa	O
B1	O
gene	O
expression	I-protein
at	I-protein
both	O
the	I-protein
mRNA	O
and	I-protein
protein	O
levels	I-protein
,	O
lasting	O
for	I-protein
at	I-protein
least	O
24	I-protein
h	I-protein
.	O

p50	O
DNA-binding	O
activity	I-protein
apparently	O
stays	O
highly	O
controlled	O
when	O
p105	I-protein
expression	I-protein
is	O
enhanced	I-protein
by	I-protein
a	I-protein
physiological	O
stimulus	O
of	I-protein
peripheral	O
blood	O
T-cells	I-protein
.	O

Partial	O
inhibition	O
of	I-protein
p50	B-protein
and	I-protein
p105	I-protein
expression	I-protein
by	I-protein
NF-kappa	B-protein
B1	I-protein
antisense	O
oligonucleotides	O
significantly	O
reduced	O
T-cell	O
proliferation	I-protein
and	I-protein
CD25/IL-2R	B-protein
alpha	I-protein
cell	O
surface	O
expression	I-protein
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	I-protein
WORDS	O
)	O

###MEDLINE:94102419

Vitamin	I-protein
D	I-protein
receptor	I-protein
quantitation	O
in	I-protein
human	O
blood	O
mononuclear	O
cells	I-protein
in	I-protein
health	I-protein
and	I-protein
disease	I-protein
.	O

Vitamin	I-protein
D	I-protein
receptor	I-protein
(	O
VDR	B-protein
)	O
concentration	I-protein
was	O
quantitated	O
in	I-protein
human	O
peripheral	O
blood	O
mononuclear	O
cells	I-protein
(	O
PBMC	O
)	O
from	I-protein
patients	O
with	I-protein
absorptive	I-protein
hypercalciuria	O
(	O
AH	I-protein
)	O
and	I-protein
patients	O
with	I-protein
high	O
1	I-protein
,	O
25	I-protein
(	O
OH	O
)	O
2D3	O
due	I-protein
to	I-protein
acquired	O
or	I-protein
transient	O
disease	I-protein
states	O
and	I-protein
the	I-protein
results	O
compared	O
to	I-protein
those	O
in	I-protein
normal	O
subjects	O
.	O

VDR	B-protein
concentration	I-protein
in	I-protein
resting	O
cells	I-protein
was	O
not	I-protein
different	O
between	O
the	I-protein
three	O
groups	O
and	I-protein
represented	O
constitutive	I-protein
receptor	O
expression	I-protein
of	I-protein
monocytes	O
.	O

Following	O
activation	I-protein
with	I-protein
phytohemagglutinin	B-protein
,	O
patients	O
with	I-protein
hypercalcitriolemia	O
demonstrated	O
significantly	O
greater	O
VDR	B-protein
concentrations	O
.	O

Patients	O
with	I-protein
AH	I-protein
demonstrated	O
a	I-protein
normal	O
value	O
for	I-protein
the	I-protein
group	I-protein
,	O
but	O
6	I-protein
patients	O
had	O
significantly	O
greater	O
concentrations	O
of	I-protein
VDR	B-protein
despite	O
normal	O
plasma	O
1	I-protein
,	O
25	I-protein
(	O
OH	O
)	O
2D3	O
in	I-protein
four	O
of	I-protein
the	I-protein
patients	O
.	O

Proliferation	O
,	O
as	O
assessed	O
from	I-protein
[	O
3H	I-protein
]	O
thymidine	B-protein
incorporation	O
was	O
inversely	O
correlated	O
with	I-protein
serum	O
1	I-protein
,	O
25	I-protein
(	O
OH	O
)	O
2D3	O
and	I-protein
was	O
significant	O
(	O
R	I-protein
=	O
-0.299	O
,	O
p	O
=	O
0.048	O
)	O
.	O

Taken	O
together	O
,	O
the	I-protein
results	O
suggest	O
that	O
PBMC	O
provide	O
a	I-protein
useful	O
system	I-protein
for	I-protein
studying	O
VDR	B-protein
status	I-protein
in	I-protein
transient	O
or	I-protein
acquired	O
states	O
of	I-protein
hypercalcitriolemia	O
.	O

Furthermore	O
,	O
the	I-protein
studies	O
in	I-protein
patients	O
with	I-protein
absorptive	I-protein
hypercalciuria	O
disclosed	O
it	O
to	I-protein
be	O
a	I-protein
heterogeneous	O
disorder	I-protein
,	O
characterized	O
by	I-protein
both	O
vitamin	O
D-dependent	O
and	I-protein
D-independent	O
forms	I-protein
of	I-protein
receptor	O
up-regulation	O
.	O

###MEDLINE:93357477

Reactive	O
oxygen	O
intermediates	O
activate	O
NF-kappa	B-protein
B	I-protein
in	I-protein
a	I-protein
tyrosine	O
kinase-dependent	O
mechanism	O
and	I-protein
in	I-protein
combination	O
with	I-protein
vanadate	O
activate	O
the	I-protein
p56lck	B-protein
and	I-protein
p59fyn	I-protein
tyrosine	I-protein
kinases	I-protein
in	I-protein
human	O
lymphocytes	O
.	O

We	O
have	O
previously	O
observed	O
that	O
ionizing	O
radiation	I-protein
induces	O
tyrosine	O
phosphorylation	I-protein
in	I-protein
human	O
B-lymphocyte	O
precursors	O
by	I-protein
stimulation	I-protein
of	I-protein
unidentified	O
tyrosine	B-protein
kinases	I-protein
and	I-protein
this	O
phosphorylation	I-protein
is	O
substantially	O
augmented	O
by	I-protein
vanadate	O
.	O

Ionizing	O
radiation	I-protein
generates	O
reactive	I-protein
oxygen	O
intermediates	O
(	O
ROI	O
)	O
.	O

Because	O
H2O2	O
is	O
a	I-protein
potent	O
ROI	O
generator	O
that	O
readily	O
crosses	O
the	I-protein
plasma	O
membrane	O
,	O
we	O
used	O
H2O2	O
to	I-protein
examine	O
the	I-protein
effects	O
of	I-protein
ROI	O
on	I-protein
signal	O
transduction	I-protein
.	O

We	O
now	O
provide	O
evidence	O
that	O
the	I-protein
tyrosine	O
kinase	O
inhibitor	O
herbimycin	O
A	O
and	I-protein
the	I-protein
free	B-protein
radical	O
scavenger	O
N-acetyl-cysteine	O
inhibit	O
both	O
radiation-induced	I-protein
and	I-protein
H2O2-induced	O
activation	I-protein
of	I-protein
NF-kappa	B-protein
B	I-protein
,	O
indicating	O
that	O
activation	I-protein
triggered	O
by	I-protein
ROI	O
is	O
dependent	I-protein
on	I-protein
tyrosine	O
kinase	O
activity	I-protein
.	O

H2O2	O
was	O
found	O
to	I-protein
stimulate	O
Ins-1	B-protein
,	O
4	I-protein
,	O
5-P3	I-protein
production	I-protein
in	I-protein
a	I-protein
tyrosine	O
kinase-dependent	O
manner	O
and	I-protein
to	I-protein
induce	O
calcium	O
signals	I-protein
that	O
were	O
greatly	O
augmented	O
by	I-protein
vanadate	O
.	O

The	O
synergistic	O
induction	I-protein
of	I-protein
tyrosine	O
phosphorylation	I-protein
by	I-protein
H2O2	O
plus	O
vanadate	O
included	I-protein
physiologically	O
relevant	I-protein
proteins	I-protein
such	O
as	O
PLC	B-protein
gamma	I-protein
1	I-protein
.	O

Although	O
treatment	O
of	I-protein
cells	I-protein
with	I-protein
H2O2	O
alone	O
did	O
not	I-protein
affect	O
the	I-protein
activity	I-protein
of	I-protein
src	B-protein
family	I-protein
kinases	I-protein
,	O
treatment	O
with	I-protein
H2O2	O
plus	O
vanadate	O
led	O
to	I-protein
activation	I-protein
of	I-protein
the	I-protein
p56lck	B-protein
and	I-protein
p59fyn	I-protein
tyrosine	I-protein
kinases	I-protein
.	O

The	O
combined	O
inhibition	O
of	I-protein
phosphatases	B-protein
and	I-protein
activation	I-protein
of	I-protein
kinases	I-protein
provides	O
a	I-protein
potent	O
mechanism	O
for	I-protein
the	I-protein
synergistic	O
effects	O
of	I-protein
H2O2	O
plus	O
vanadate	O
.	O

Induction	O
of	I-protein
tyrosine	O
phosphorylation	I-protein
by	I-protein
ROI	O
may	O
thus	O
lead	O
to	I-protein
many	O
of	I-protein
the	I-protein
pleiotropic	B-protein
effects	O
of	I-protein
ROI	O
in	I-protein
lymphoid	O
cells	I-protein
,	O
including	I-protein
downstream	O
activation	I-protein
of	I-protein
PLC	B-protein
gamma	I-protein
1	I-protein
and	I-protein
NF-kappa	B-protein
B	I-protein

###MEDLINE:81105535

Influence	O
of	I-protein
sex	B-protein
hormone	I-protein
binding	I-protein
globulin	I-protein
and	I-protein
serum	B-protein
albumin	I-protein
on	I-protein
the	I-protein
conversion	I-protein
of	I-protein
androstenedione	O
to	I-protein
testosterone	O
by	I-protein
human	O
erythrocytes	O
.	O

The	O
influence	O
of	I-protein
human	B-protein
serum	I-protein
albumin	I-protein
and	I-protein
sex	B-protein
hormone	I-protein
binding	I-protein
globulin	I-protein
(	O
SHBG	B-protein
)	O
on	I-protein
the	I-protein
enzymic	O
conversion	I-protein
of	I-protein
androstenedione	O
to	I-protein
testosterone	O
in	I-protein
human	O
erythrocytes	O
was	O
investigated	O
in	I-protein
vitro	O
.	O

Total	O
plasma	O
and	I-protein
albumin	B-protein
delayed	O
the	I-protein
conversion	I-protein
rate	I-protein
of	I-protein
androstenedione	O
,	O
while	O
SHBG	B-protein
increased	I-protein
it	O
markedly	O
.	O

The	O
effect	O
of	I-protein
SHBG	B-protein
was	O
largely	O
abolished	O
by	I-protein
heating	O
to	I-protein
60	I-protein
degrees	O
C	O
for	I-protein
1	I-protein
h	I-protein
and	I-protein
by	I-protein
saturating	O
its	O
binding	I-protein
sites	I-protein
by	I-protein
DHT	O
.	O

The	O
effect	O
of	I-protein
both	O
proteins	I-protein
was	O
found	O
to	I-protein
be	O
related	O
to	I-protein
their	O
concentration	I-protein
.	O

It	O
appears	O
that	O
the	I-protein
binding	I-protein
sites	I-protein
of	I-protein
albumin	B-protein
provide	O
a	I-protein
mechanism	O
for	I-protein
retarding	O
androstenedione	O
uptake	I-protein
by	I-protein
the	I-protein
erythrocytes	O
and	I-protein
that	O
the	I-protein
high	O
binding	I-protein
affinity	I-protein
of	I-protein
SHBG	B-protein
for	I-protein
testosterone	O
facilitates	O
the	I-protein
diffusion	O
of	I-protein
this	O
steroid	O
out	O
of	I-protein
the	I-protein
cell	O
and	I-protein
thus	O
,	O
displaces	O
the	I-protein
chemical	O
equilibrium	O
within	B-protein
the	I-protein
cell	O
.	O

###MEDLINE:80161233

Glucocorticoids	O
and	I-protein
lymphocytes	O
.	O

I	I-protein
.	O

Increased	O
glucocorticoid	B-protein
receptor	I-protein
levels	I-protein
in	I-protein
antigen-stimulated	O
lymphocytes	O
.	O

Recently	O
a	I-protein
2-	O
to	I-protein
3-fold	O
increase	O
in	I-protein
the	I-protein
number	I-protein
of	I-protein
glucocorticoid	B-protein
receptors	I-protein
in	I-protein
human	O
peripheral	O
lymphocytes	O
has	O
been	O
noted	O
after	O
in	I-protein
vitro	O
mitogen	O
stimulation	I-protein
.	O

Here	O
,	O
we	O
extend	O
these	O
observations	O
to	I-protein
in	I-protein
vivo	O
immunization	O
.	O

After	O
unilateral	O
immunization	O
of	I-protein
adrenalectomized	O
male	O
rats	O
,	O
a	I-protein
50	I-protein
%	O
increase	O
in	I-protein
glucocorticoid	O
receptor	O
sites	I-protein
per	O
cell	O
,	O
determined	O
by	I-protein
binding	I-protein
of	I-protein
dexamethasone	O
,	O
was	O
observed	O
in	I-protein
cell	O
suspensions	O
of	I-protein
homolateral	O
lymph	O
nodes	O
over	O
those	O
from	I-protein
the	I-protein
contralateral	O
nonimmunized	O
side	O
of	I-protein
the	I-protein
same	O
animal	O
.	O

The	O
association	I-protein
constant	I-protein
for	I-protein
dexamethasone	O
was	O
similar	O
in	I-protein
both	O
groups	O
,	O
as	O
was	O
the	I-protein
stereospecificity	O
for	I-protein
various	O
steroids	O
,	O
the	I-protein
time	O
course	O
of	I-protein
cytoplasmic	O
and	I-protein
nuclear	O
association	I-protein
,	O
and	I-protein
cytoplasmic-to-nuclear	O
translocation	O
.	O

Despite	O
a	I-protein
50	I-protein
%	O
increase	O
in	I-protein
the	I-protein
number	I-protein
of	I-protein
glucocorticoid	B-protein
receptor	I-protein
sites	I-protein
per	O
cell	O
,	O
the	I-protein
cells	I-protein
from	I-protein
the	I-protein
homolateral	O
and	I-protein
controlateral	O
lymph	O
nodes	O
were	O
equally	O
sensitive	I-protein
to	I-protein
the	I-protein
inhibitory	O
effects	O
of	I-protein
dexamethasone	O
,	O
as	O
determined	O
by	I-protein
measurements	O
of	I-protein
the	I-protein
incorporation	O
of	I-protein
radiolabeled	O
precursors	O
of	I-protein
protein	O
,	O
RNA	O
,	O
and	I-protein
DNA	O
,	O
or	I-protein
measurements	O
of	I-protein
in	I-protein
vitro	O
cell	O
survival	B-protein
.	O

###MEDLINE:80032538

Glucocorticoid	B-protein
receptors	I-protein
and	I-protein
actions	O
in	I-protein
rat	I-protein
thymocytes	O
and	I-protein
immunologically	O
stimulated	O
human	O
peripheral	O
lymphocytes	O
.	O

After	O
reviewing	O
briefly	O
our	O
earlier	O
studies	O
on	I-protein
glucocorticoid	B-protein
receptors	I-protein
and	I-protein
mechanisms	O
in	I-protein
thymus	I-protein
cells	I-protein
,	O
we	O
have	O
outlined	O
results	O
from	I-protein
the	I-protein
following	O
two	O
areas	O
of	I-protein
current	I-protein
interest	I-protein
in	I-protein
our	O
laboratories	O
:	O
the	I-protein
``	O
life-cycle	O
''	I-protein
of	I-protein
glucocorticoid	B-protein
receptors	I-protein
and	I-protein
complexes	O
in	I-protein
thymus	I-protein
cells	I-protein
,	O
and	I-protein
the	I-protein
levels	I-protein
of	I-protein
glucocorticoid	B-protein
receptors	I-protein
and	I-protein
sensitivity	I-protein
in	I-protein
immunologically	O
stimulated	O
human	O
peripheral	O
lymphocytes	O
.	O

Several	O
of	I-protein
our	O
results	O
on	I-protein
energetics	O
and	I-protein
kinetics	O
of	I-protein
hormone	I-protein
binding	I-protein
to	I-protein
glucocorticoid	B-protein
receptors	I-protein
in	I-protein
rat	I-protein
thymus	I-protein
cells	I-protein
seem	O
to	I-protein
require	O
extension	O
of	I-protein
the	I-protein
simplest	O
model	I-protein
of	I-protein
hormone-receptor	O
transformations	O
in	I-protein
intact	O
cells	I-protein
.	O

ATP-depletion	O
experiments	O
suggest	O
the	I-protein
existence	O
of	I-protein
a	I-protein
nonbinding	O
form	I-protein
of	I-protein
the	I-protein
receptor	O
;	O
``	O
chase	O
''	I-protein
experiments	O
suggest	O
reaction	I-protein
of	I-protein
hormone	I-protein
directly	O
with	I-protein
nuclear-bound	O
receptor	O
;	O
experiments	O
on	I-protein
depletion	O
and	I-protein
replenishment	O
of	I-protein
cytoplasmic	B-protein
receptor	I-protein
using	O
cortisol	O
and	I-protein
dexamethasone	O
suggest	O
the	I-protein
existence	O
of	I-protein
at	I-protein
least	O
two	O
subpopulations	O
of	I-protein
nuclear-bound	B-protein
hormone-receptor	I-protein
complex	I-protein
.	O

We	O
have	O
found	O
that	O
mitogen	O
or	I-protein
immunologic	O
stimulation	I-protein
of	I-protein
human	O
peripheral	O
lymphocytes	O
in	I-protein
culture	O
leads	O
within	B-protein
24	I-protein
h	I-protein
or	I-protein
so	O
to	I-protein
a	I-protein
striking	O
increase	O
in	I-protein
the	I-protein
number	I-protein
of	I-protein
glucocorticoid	B-protein
receptor	I-protein
sites	I-protein
per	O
cell	O
.	O

We	O
believe	O
this	O
increase	O
may	O
be	O
due	I-protein
to	I-protein
partial	I-protein
synchronization	O
of	I-protein
the	I-protein
cell	O
population	O
in	I-protein
a	I-protein
phase	I-protein
of	I-protein
the	I-protein
cell	O
cycle	I-protein
in	I-protein
which	O
receptor	O
content	O
is	O
high	O
.	O

Contrary	O
to	I-protein
the	I-protein
widely	B-protein
held	O
view	O
that	O
mitogen-stimulated	O
cells	I-protein
become	O
insensitive	O
to	I-protein
glucocorticoids	O
,	O
our	O
experiments	O
show	O
that	O
with	I-protein
respect	O
to	I-protein
inhibition	O
of	I-protein
thymidine	B-protein
and	I-protein
uridine	B-protein
incorporation	O
and	I-protein
glucose	O
uptake	I-protein
,	O
the	I-protein
cells	I-protein
are	O
highly	O
sensitive	I-protein
to	I-protein
dexamethasone	O
at	I-protein
24	I-protein
,	O
48	I-protein
,	O
and	I-protein
72	I-protein
h	I-protein
after	O
stimulation	I-protein
with	I-protein
concanavalin	B-protein
A	I-protein
.	O

###MEDLINE:79064946

Nuclear	I-protein
glucocorticoid	O
binding	I-protein
in	I-protein
chronic	O
lymphatic	B-protein
leukemia	O
lymphocytes	O
.	O

A	O
reliable	O
procedure	O
is	O
described	O
for	I-protein
isolating	O
3H-triamcinolone	B-protein
acetonide	I-protein
(	O
3H-TA	I-protein
)	O
receptor	I-protein
complexes	I-protein
from	I-protein
purified	O
chronic	O
lymphatic	B-protein
leukemia	O
(	O
CLL	O
)	O
lymphocyte	O
nuclei	O
,	O
based	O
on	I-protein
the	I-protein
use	O
of	I-protein
carbobenzoxy-L-phenylalanine	O
(	O
CBZ-L-phe	O
)	O
to	I-protein
prevent	O
breakdown	O
of	I-protein
hormone-receptor	B-protein
complexes	I-protein
during	I-protein
extraction	O
of	I-protein
nuclei	O
with	I-protein
0.6M	O
KCl	O
.	O

Using	O
this	O
method	O
,	O
specific	I-protein
nuclear	O
glucocorticoid	O
binding	I-protein
was	O
demonstrated	O
in	I-protein
14/14	O
patients	O
with	I-protein
untreated	O
CLL	O
.	O

No	I-protein
correlation	O
was	O
found	O
between	O
levels	I-protein
of	I-protein
nuclear-associated	O
3H-TA	O
and	I-protein
peripheral	O
white	I-protein
blood	O
cell	O
count	O
or	I-protein
rosetting	O
ability	O
of	I-protein
circulating	O
lymphocytes	O
.	O

###MEDLINE:94111992

Multiple	B-protein
closely-linked	O
NFAT/octamer	O
and	I-protein
HMG	B-protein
I	I-protein
(	O
Y	O
)	O
binding	I-protein
sites	I-protein
are	O
part	I-protein
of	I-protein
the	I-protein
interleukin-4	I-protein
promoter	I-protein
.	O

We	O
show	O
here	O
that	O
the	I-protein
immediate	B-protein
upstream	O
region	O
(	O
from	I-protein
position	O
-12	O
to	I-protein
-270	O
)	O
of	I-protein
the	I-protein
murine	B-protein
interleukin	I-protein
4	I-protein
(	O
Il-4	B-protein
)	O
gene	O
harbors	O
a	I-protein
strong	O
cell-type	O
specific	I-protein
transcriptional	O
enhancer	O
.	O

In	O
T	O
lymphoma	I-protein
cells	I-protein
,	O
the	I-protein
activity	I-protein
of	I-protein
the	I-protein
Il-4	O
promoter/enhancer	O
is	O
stimulated	O
by	I-protein
phorbol	O
esters	O
,	O
Ca++	I-protein
ionophores	O
and	I-protein
agonists	O
of	I-protein
protein	B-protein
kinase	I-protein
A	I-protein
and	I-protein
inhibited	O
by	I-protein
low	O
doses	O
of	I-protein
the	I-protein
immunosuppressant	O
cyclosporin	O
A	O
.	O

The	O
Il-4	O
promoter/enhancer	O
is	O
transcriptionally	O
inactive	O
in	I-protein
B	O
lymphoma	I-protein
cells	I-protein
and	I-protein
HeLa	O
cells	I-protein
.	O

DNase	I-protein
I	I-protein
footprint	O
protection	I-protein
experiments	O
revealed	O
six	O
sites	I-protein
of	I-protein
the	I-protein
Il-4	O
promoter/enhancer	O
to	I-protein
be	O
bound	I-protein
by	I-protein
nuclear	B-protein
proteins	I-protein
from	I-protein
lymphoid	O
and	I-protein
myeloid	O
cells	I-protein
.	O

Among	O
them	O
are	O
four	O
purine	O
boxes	O
which	O
have	O
been	O
described	O
to	I-protein
be	O
important	O
sequence	I-protein
motifs	I-protein
of	I-protein
the	I-protein
Il-2	O
promoter	I-protein
.	O

They	O
contain	O
the	I-protein
motif	I-protein
GGAAA	O
and	I-protein
are	O
recognized	I-protein
by	I-protein
the	I-protein
inducible	B-protein
and	I-protein
cyclosporin	I-protein
A-sensitive	I-protein
transcription	I-protein
factor	I-protein
NFAT-1	I-protein
.	O

Three	O
of	I-protein
the	I-protein
Il-4	O
NFAT-1	O
sites	I-protein
are	O
closely	O
linked	I-protein
to	I-protein
weak	I-protein
binding	I-protein
sites	I-protein
of	I-protein
Octamer	B-protein
factors	I-protein
.	O

Several	O
purine	O
boxes	O
and	I-protein
an	I-protein
AT-rich	O
protein-binding	I-protein
site	I-protein
of	I-protein
the	I-protein
Il-4	O
promoter	I-protein
are	O
also	O
recognized	I-protein
by	I-protein
the	I-protein
high	B-protein
mobility	I-protein
group	I-protein
protein	I-protein
HMG	I-protein
I	I-protein
(	O
Y	O
)	O
.	O

Whereas	O
the	I-protein
binding	I-protein
of	I-protein
NFAT-1	B-protein
and	I-protein
Octamer	B-protein
factors	I-protein
enhance	O
the	I-protein
activity	I-protein
of	I-protein
the	I-protein
Il-4	O
promoter	I-protein
,	O
the	I-protein
binding	I-protein
of	I-protein
HMG	B-protein
I	I-protein
(	O
Y	O
)	O
suppresses	O
its	O
activity	I-protein
and	I-protein
,	O
therefore	O
,	O
appears	O
to	I-protein
be	O
involved	I-protein
in	I-protein
the	I-protein
suppression	O
of	I-protein
Il-4	B-protein
transcription	O
in	I-protein
resting	O
T	O
lymphocytes	O
.	O

###MEDLINE:94176179

Reversibility	O
of	I-protein
the	I-protein
differentiated	O
state	I-protein
in	I-protein
somatic	I-protein
cells	I-protein
.	O

Analysis	O
of	I-protein
de	I-protein
novo	O
gene	O
activation	I-protein
in	I-protein
multinucleated	O
heterokaryons	O
has	O
shown	O
that	O
the	I-protein
differentiated	O
state	I-protein
,	O
although	O
stable	I-protein
,	O
is	O
not	I-protein
irreversible	O
,	O
and	I-protein
can	O
be	O
reprogrammed	O
in	I-protein
the	I-protein
presence	O
of	I-protein
appropriate	O
combinations	O
of	I-protein
trans-acting	B-protein
regulatory	I-protein
molecules	I-protein
.	O

These	O
properties	O
have	O
been	O
exploited	O
to	I-protein
design	O
strategies	O
for	I-protein
identifying	O
novel	O
regulators	O
of	I-protein
cellular	O
differentiation	I-protein
.	O

###MEDLINE:94016843

Phosphatidylcholine	I-protein
hydrolysis	O
activates	O
NF-kappa	B-protein
B	I-protein
and	I-protein
increases	O
human	O
immunodeficiency	I-protein
virus	I-protein
replication	O
in	I-protein
human	O
monocytes	O
and	I-protein
T	O
lymphocytes	O
.	O

We	O
have	O
tested	O
whether	O
breakdown	O
of	I-protein
phosphatidylcholine	O
(	O
PC	O
)	O
initiated	O
by	I-protein
exogenous	O
addition	O
of	I-protein
a	I-protein
PC-specific	B-protein
phospholipase	I-protein
C	I-protein
(	O
PC-PLC	B-protein
)	O
from	I-protein
Bacillus	O
cereus	O
or	I-protein
by	I-protein
endogenous	O
overexpression	O
of	I-protein
PC-PLC	B-protein
induces	O
functional	O
activation	I-protein
of	I-protein
NF-kappa	B-protein
B	I-protein
and	I-protein
increases	O
human	O
immunodeficiency	I-protein
virus	I-protein
(	O
HIV	I-protein
)	O
enhancer	O
activity	I-protein
.	O

PC-PLC-activated	O
hydrolysis	O
of	I-protein
PC	O
was	O
found	O
to	I-protein
induce	O
bona	O
fide	O
p50/p65	B-protein
NF-kappa	I-protein
B	I-protein
binding	I-protein
activity	I-protein
in	I-protein
three	O
different	O
cell	O
lines	B-protein
of	I-protein
human	O
or	I-protein
murine	O
origin	O
.	O

No	I-protein
significant	O
changes	O
in	I-protein
the	I-protein
turnover	I-protein
of	I-protein
other	O
cellular	O
phospholipids	O
were	O
detected	O
in	I-protein
PC-PLC-treated	O
cells	I-protein
.	O

Induction	O
of	I-protein
NF-kappa	B-protein
B	I-protein
by	I-protein
PC-PLC	B-protein
did	O
not	I-protein
depend	O
on	I-protein
de	I-protein
novo	O
synthesis	I-protein
of	I-protein
proteins	I-protein
or	I-protein
autocrine	B-protein
secretion	O
of	I-protein
either	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
or	I-protein
interleukin	B-protein
1	I-protein
.	O

In	O
human	O
monocytic	I-protein
and	I-protein
lymphoblastoid	O
T-cell	O
lines	B-protein
,	O
induction	I-protein
of	I-protein
NF-kappa	B-protein
B	I-protein
by	I-protein
PC-PLC	B-protein
resulted	O
in	I-protein
clear	I-protein
induction	I-protein
of	I-protein
luciferase	O
expression	I-protein
vectors	O
placed	O
under	O
the	I-protein
control	I-protein
of	I-protein
synthetic	I-protein
kappa	I-protein
B	O
enhancers	O
or	I-protein
wild	O
type	O
,	O
but	O
not	I-protein
kappa	I-protein
B-mutated	O
,	O
HIV	I-protein
long	I-protein
terminal	O
repeat	I-protein
constructs	O
.	O

HIV	I-protein
replication	O
was	O
increased	I-protein
by	I-protein
PC-PLC	B-protein
in	I-protein
chronically	O
infected	O
monocytes	O
and	I-protein
T	O
lymphocytes	O
.	O

NF-kappa	B-protein
B	I-protein
activation	I-protein
promoted	O
by	I-protein
addition	O
of	I-protein
exogenous	B-protein
PC-PLC	I-protein
correlated	O
with	I-protein
an	I-protein
intense	O
production	I-protein
of	I-protein
diacylglycerol	B-protein
.	O

However	O
,	O
addition	O
of	I-protein
a	I-protein
phosphatidylinositol-specific	B-protein
PLC	B-protein
from	I-protein
B.cereus	O
also	O
induced	I-protein
diacylglycerol	B-protein
but	O
did	O
not	I-protein
activate	O
kappa	I-protein
B	I-protein
enhancer-directed	I-protein
vectors	I-protein
.	O

PC-PLC-induced	O
NF-kappa	O
B	O
activation	I-protein
could	O
not	I-protein
be	O
blocked	B-protein
by	I-protein
a	I-protein
specific	I-protein
inhibitor	O
of	I-protein
phorbol	B-protein
ester-inducible	I-protein
protein	I-protein
kinases	I-protein
C	I-protein
.	O

These	O
results	O
indicate	O
that	O
a	I-protein
cellular	O
transduction	I-protein
pathway	I-protein
,	O
dependent	I-protein
on	I-protein
specific	I-protein
PC	O
breakdown	O
,	O
is	O
functional	O
in	I-protein
T	O
lymphocytes	O
and	I-protein
monocytes	O
and	I-protein
may	O
be	O
used	O
by	I-protein
various	O
transmembrane	O
receptors	I-protein
to	I-protein
activate	O
HIV	I-protein
transcription	O
through	I-protein
NF-kappa	O
B-dependent	O
induction	I-protein
of	I-protein
the	I-protein
HIV	I-protein
enhancer	O
.	O

###MEDLINE:94014350

Novel	I-protein
mechanism	O
for	I-protein
inhibition	O
of	I-protein
human	O
T	O
cells	I-protein
by	I-protein
glucocorticoids	O
.	O

Glucocorticoids	O
inhibit	O
signal	O
transduction	I-protein
through	I-protein
IL-2	B-protein
receptor	I-protein
.	O

Interaction	O
of	I-protein
IL-2	B-protein
with	I-protein
its	O
high	B-protein
affinity	I-protein
membrane	I-protein
receptor	I-protein
complex	I-protein
(	O
IL-2R	I-protein
)	O
present	O
on	I-protein
activated	O
T	O
lymphocytes	O
induces	O
cell	O
proliferation	I-protein
and	I-protein
mediates	O
effector	O
functions	O
.	O

Glucocorticoids	O
inhibit	O
IL-2	B-protein
production	I-protein
by	I-protein
inhibiting	I-protein
TCR-mediated	O
signal	O
transduction	I-protein
.	O

We	O
asked	O
whether	O
they	O
also	O
inhibit	O
the	I-protein
action	O
of	I-protein
IL-2	B-protein
by	I-protein
inhibiting	I-protein
signal	O
transduction	I-protein
through	I-protein
IL-2R	B-protein
.	O

Human	O
peripheral	O
blood	O
T	O
cells	I-protein
,	O
stimulated	O
with	I-protein
PMA	O
for	I-protein
48	I-protein
h	I-protein
(	O
PMA	O
blasts	O
)	O
,	O
were	O
incubated	O
with	I-protein
IL-2	B-protein
in	I-protein
the	I-protein
presence	O
of	I-protein
incremental	O
dosages	O
of	I-protein
dexamethasone	O
(	O
Dex	O
;	O
10	I-protein
(	O
-5	O
)	O
-10	O
(	O
-9	O
)	O
M	I-protein
)	O
.	O

Dex	O
inhibited	O
the	I-protein
IL-2-dependent	O
proliferation	I-protein
of	I-protein
PMA	O
blasts	O
in	I-protein
a	I-protein
dose-dependent	O
fashion	O
(	O
IC50	O
,	O
5	O
x	I-protein
10	I-protein
(	O
-8	O
)	O
M	I-protein
)	O
.	O

Cell	I-protein
surface	O
expression	I-protein
of	I-protein
IL-2R	B-protein
alpha-	I-protein
and	I-protein
beta-chains	I-protein
as	O
determined	O
by	I-protein
immunofluorescence	O
analysis	O
was	O
not	I-protein
affected	O
by	I-protein
Dex	O
.	O

In	O
addition	O
,	O
Scatchard	O
plot	O
analysis	O
of	I-protein
125I-labeled	B-protein
IL-2	B-protein
showed	O
that	O
Dex	O
did	O
not	I-protein
affect	O
the	I-protein
binding	I-protein
of	I-protein
IL-2	B-protein
,	O
thus	O
suggesting	O
that	O
inhibition	O
is	O
due	I-protein
to	I-protein
a	I-protein
postreceptor	O
effect	O
.	O

Inhibition	O
of	I-protein
T	O
cell	O
proliferation	I-protein
by	I-protein
Dex	O
was	O
associated	I-protein
with	I-protein
decreased	O
IL-2-dependent	O
tyrosine	O
phosphorylation	I-protein
of	I-protein
several	I-protein
intracellular	I-protein
proteins	I-protein
and	I-protein
decreased	O
phosphorylation	I-protein
of	I-protein
the	I-protein
retinoblastoma	B-protein
gene	I-protein
product	I-protein
Rb	I-protein
,	O
a	I-protein
protein	O
essential	O
for	I-protein
controlling	I-protein
the	I-protein
progression	I-protein
of	I-protein
cells	I-protein
through	I-protein
the	I-protein
cell	O
cycle	I-protein
.	O

IL-2-dependent	O
IL-2R	O
alpha	O
expression	I-protein
in	I-protein
PMA	O
blasts	O
and	I-protein
NF-kB	B-protein
induction	I-protein
in	I-protein
resting	O
human	O
T	O
cells	I-protein
were	O
also	O
inhibited	O
by	I-protein
Dex	O
.	O

These	O
results	O
demonstrate	O
that	O
glucocorticoids	O
inhibit	O
preactivated	O
T	O
cells	I-protein
by	I-protein
down-regulating	O
signal	O
transduction	I-protein
through	I-protein
IL-2R	B-protein
.	O

###MEDLINE:93353597

Chronic	O
human	O
immunodeficiency	I-protein
virus	I-protein
type	O
1	I-protein
infection	I-protein
stimulates	O
distinct	O
NF-kappa	O
B/rel	O
DNA	O
binding	I-protein
activities	O
in	I-protein
myelomonoblastic	O
cells	I-protein
.	O

The	O
relationship	O
between	O
human	O
immunodeficiency	I-protein
virus	I-protein
type	O
1	I-protein
(	O
HIV-1	O
)	O
infection	I-protein
and	I-protein
the	I-protein
induction	I-protein
of	I-protein
NF-kappa	B-protein
B	I-protein
binding	I-protein
activity	I-protein
was	O
examined	O
in	I-protein
a	I-protein
myeloid	O
cell	O
model	I-protein
of	I-protein
HIV-1	O
infection	I-protein
derived	I-protein
from	I-protein
the	I-protein
PLB-985	O
cell	O
line	I-protein
.	O

Chronic	O
infection	I-protein
of	I-protein
PLB-985	O
cells	I-protein
led	O
to	I-protein
increased	I-protein
monocyte-specific	O
surface	O
marker	I-protein
expression	I-protein
,	O
increased	I-protein
c-fms	O
gene	O
transcription	O
,	O
and	I-protein
morphological	O
alterations	O
consistent	O
with	I-protein
differentiation	I-protein
along	O
the	I-protein
monocytic	I-protein
pathway	I-protein
.	O

PLB-IIIB	O
cells	I-protein
displayed	O
a	I-protein
constitutive	I-protein
NF-kappa	O
B-like	I-protein
binding	I-protein
activity	I-protein
that	O
was	O
distinct	O
from	I-protein
that	O
induced	I-protein
by	I-protein
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
or	I-protein
phorbol	O
12-myristate	O
13-acetate	O
treatment	O
of	I-protein
the	I-protein
parental	O
PLB-985	O
cell	O
line	I-protein
.	O

This	O
unique	I-protein
DNA	O
binding	I-protein
activity	I-protein
consisted	O
of	I-protein
proteins	I-protein
of	I-protein
70	I-protein
,	O
90	I-protein
,	O
and	I-protein
100	I-protein
kDa	I-protein
with	I-protein
a	I-protein
high	O
degree	O
of	I-protein
binding	I-protein
specificity	I-protein
for	I-protein
the	I-protein
NF-kappa	B-protein
B	I-protein
site	I-protein
within	B-protein
the	I-protein
PRDII	B-protein
domain	I-protein
of	I-protein
beta	B-protein
interferon	I-protein
.	O

In	O
this	O
report	O
,	O
we	O
characterize	O
the	I-protein
nature	O
of	I-protein
these	O
proteins	I-protein
and	I-protein
demonstrate	O
that	O
binding	I-protein
of	I-protein
these	O
proteins	I-protein
is	O
also	O
induced	I-protein
following	O
Sendai	O
paramyxovirus	O
infection	I-protein
.	O

The	O
70-kDa	B-protein
protein	I-protein
corresponds	O
to	I-protein
the	I-protein
NF-kappa	B-protein
B	I-protein
RelA	I-protein
(	O
p65	I-protein
)	O
subunit	I-protein
,	O
which	O
is	O
activated	O
in	I-protein
response	I-protein
to	I-protein
an	I-protein
acute	O
paramyxovirus	O
infection	I-protein
or	I-protein
a	I-protein
chronic	O
HIV-1	O
infection	I-protein
.	O

Virus	I-protein
infection	I-protein
does	O
not	I-protein
appear	O
to	I-protein
alter	O
the	I-protein
amount	O
of	I-protein
RelA	O
(	O
p65	B-protein
)	O
or	I-protein
NFKB1	B-protein
(	O
p50	O
)	O
but	O
rather	O
affects	O
the	I-protein
capacity	O
of	I-protein
I	I-protein
kappa	I-protein
B	I-protein
alpha	I-protein
to	I-protein
sequester	O
RelA	O
(	O
p65	B-protein
)	O
,	O
therefore	O
leading	O
to	I-protein
constitutive	I-protein
levels	I-protein
of	I-protein
RelA	O
DNA	O
binding	I-protein
activity	I-protein
and	I-protein
to	I-protein
increased	I-protein
levels	I-protein
of	I-protein
NF-kappa	O
B-dependent	O
gene	O
activity	I-protein
.	O

The	O
virally	O
induced	I-protein
90-	B-protein
to	I-protein
100-kDa	I-protein
proteins	I-protein
have	O
a	I-protein
distinct	O
binding	I-protein
specificity	I-protein
for	I-protein
the	I-protein
PRDII	B-protein
domain	I-protein
and	I-protein
an	I-protein
AT-rich	O
sequence	I-protein
but	O
do	O
not	I-protein
cross-react	O
with	I-protein
NF-kappa	O
B	O
subunit-specific	O
antisera	O
directed	I-protein
against	I-protein
NFKB1	B-protein
(	O
p105	I-protein
or	I-protein
p50	B-protein
)	O
,	O
NFKB2	B-protein
(	O
p100	B-protein
or	I-protein
p52	B-protein
)	O
,	O
RelA	O
(	O
p65	B-protein
)	O
,	O
or	I-protein
c-rel	B-protein
.	O

DNA	O
binding	I-protein
of	I-protein
the	I-protein
90-	B-protein
to	I-protein
100-kDa	I-protein
proteins	I-protein
was	O
not	I-protein
inhibited	O
by	I-protein
recombinant	B-protein
I	I-protein
kappa	I-protein
B	I-protein
alpha/MAD-3	I-protein
and	I-protein
was	O
resistant	I-protein
to	I-protein
tryptic	O
digestion	O
,	O
suggesting	O
that	O
these	O
proteins	I-protein
may	O
not	I-protein
be	O
NF-kappa	B-protein
B	I-protein
related	O
.	O

Transient	I-protein
cotransfection	O
experiments	O
demonstrated	O
that	O
RelA	B-protein
and	I-protein
NFKB1	B-protein
expression	I-protein
maximally	O
stimulated	O
HIV-1	O
LTR-	O
and	I-protein
NF-kappa	O
B-dependent	O
reporter	O
genes	I-protein
;	O
differences	O
in	I-protein
NF-kappa	O
B-like	I-protein
binding	I-protein
activity	I-protein
were	O
also	O
reflected	O
in	I-protein
higher	O
constitutive	I-protein
levels	I-protein
of	I-protein
NF-kappa	O
B-regulated	O
gene	O
expression	I-protein
in	I-protein
HIV-1-infected	O
myeloid	O
cells	I-protein
.	O

###MEDLINE:93343972

Presence	O
of	I-protein
estrogen-binding	O
sites	I-protein
on	I-protein
macrophage-like	O
synoviocytes	O
and	I-protein
CD8+	O
,	O
CD29+	O
,	O
CD45RO+	O
T	O
lymphocytes	O
in	I-protein
normal	O
and	I-protein
rheumatoid	O
synovium	O
.	O

OBJECTIVE	O
.	O

To	O
study	O
the	I-protein
presence	O
of	I-protein
estrogen-binding	O
sites	I-protein
(	O
EBS	O
)	O
in	I-protein
the	I-protein
synovial	O
tissues	O
of	I-protein
male	O
and	I-protein
female	I-protein
patients	O
with	I-protein
rheumatoid	O
arthritis	I-protein
(	O
RA	B-protein
)	O
and	I-protein
in	I-protein
age-	O
and	I-protein
sex-matched	O
healthy	O
controls	O
.	O

METHODS	O
.	O

Both	O
type	O
1	I-protein
(	O
high	O
affinity	I-protein
,	O
low	O
binding	I-protein
capacity	O
)	O
and	I-protein
type	O
2	I-protein
(	O
reduced	O
affinity	I-protein
,	O
higher	O
binding	I-protein
capacity	O
)	O
EBS	O
were	O
investigated	O
in	I-protein
both	O
soluble	I-protein
and	I-protein
nuclear	O
fractions	O
of	I-protein
homogenized	O
synovial	O
tissue	O
samples	O
by	I-protein
a	I-protein
dextran-coated	O
charcoal	O
method	O
.	O

To	O
determine	O
what	O
type	O
of	I-protein
synovial	O
cell	O
was	O
positive	I-protein
for	I-protein
EBS	O
,	O
cryosections	O
of	I-protein
synovial	O
tissues	O
were	O
immunostained	O
with	I-protein
a	I-protein
specific	I-protein
monoclonal	I-protein
anti-estrogen	I-protein
receptor	I-protein
antibody	I-protein
(	O
anti-ER	B-protein
MAb	I-protein
)	O
using	O
both	O
immunofluorescence	O
and	I-protein
immunoperoxidase	O
techniques	O
.	O

Double	I-protein
immunostaining	O
with	I-protein
the	I-protein
anti-ER	B-protein
MAb	I-protein
and	I-protein
with	I-protein
specific	I-protein
MAb	I-protein
to	I-protein
detect	O
different	O
macrophage	B-protein
antigens	I-protein
(	O
Ber-MAC3	B-protein
,	O
MAC387	B-protein
,	O
CD68	B-protein
)	O
and	I-protein
CD8+	O
T	O
cell	O
subsets	O
(	O
CD29+	O
,	O
CD45RO+	O
and	I-protein
CD29-	O
,	O
CD45RO-	O
)	O
was	O
performed	O
.	O

RESULTS	O
.	O

Higher	O
affinity	I-protein
EBS	O
were	O
found	O
mostly	O
in	I-protein
nuclear	O
cell	O
fractions	O
of	I-protein
either	O
RA	B-protein
or	I-protein
control	I-protein
synovial	O
tissues	O
(	O
28	I-protein
of	I-protein
the	I-protein
33	I-protein
)	O
.	O

These	O
EBS	O
were	O
present	O
to	I-protein
a	I-protein
lesser	O
extent	O
in	I-protein
soluble	I-protein
cell	O
fractions	O
(	O
11	I-protein
of	I-protein
the	I-protein
33	I-protein
)	O
.	O

Immunostaining	O
showed	O
the	I-protein
estrogen	O
receptor-positive	O
cells	I-protein
to	I-protein
be	O
the	I-protein
macrophage-like	O
synoviocytes	O
and	I-protein
the	I-protein
CD8+	O
,	O
CD29+	O
T	O
cells	I-protein
both	O
in	I-protein
RA	B-protein
and	I-protein
in	I-protein
control	I-protein
synovial	O
tissues	O
.	O

Higher	O
nuclear	O
content	O
of	I-protein
EBS	O
was	O
consistent	O
with	I-protein
more	O
intense	O
nuclear	O
staining	O
of	I-protein
synoviocytes	O
and	I-protein
T	O
cells	I-protein
.	O

CONCLUSION	O
.	O

It	O
is	O
conceivable	O
that	O
the	I-protein
immunomodulatory	O
activity	I-protein
exerted	O
by	I-protein
estrogens	O
is	O
at	I-protein
least	O
partly	O
mediated	I-protein
through	I-protein
their	O
interaction	I-protein
with	I-protein
EBS	O
that	O
are	O
present	O
on	I-protein
macrophage-like	O
synoviocytes	O
,	O
functioning	O
as	O
antigen-processing	O
and	I-protein
antigen-presenting	O
cells	I-protein
,	O
and	I-protein
on	I-protein
antigen-experienced	O
(	O
memory	O
)	O
CD8+	O
T	O
lymphocytes	O
(	O
CD29+	O
,	O
CD45RO+	O
